Trial Id,Protocol #,fmt_Protocol#,Legacy Protocol ID,Product Name,Full Title,Short Title,Protocol Phase ,Protocol Status,Indication,Therapeutic Area,Operational TA,Registry,Pediatric / Non-Pediatric,Study Type,Study Design: Primary Purpose (Interventional),Study Design: Time Perspective (Observational),Study Design: Study Model (Observational),Planned Enrollment,Actual Enrollment,Actual Screened,Actual Rescreened,Actual Screen Failure,Actual Randomized / Dosed,Actual Early Terminated,% Enrollment Completed,Planned Sites,Active Sites,Legacy Company,CRO,COM/CPOM,Primary Contact,Medical Monitor,COPL/POOL,Study Site Engagement,EudraCT#,Expanded Access Availability / Status,Human Subjects Protection Review Board Status,Study Imposed by EMA Flag,Device/Product Not Approved or Cleared by US FDA,Wave,Prioritization,Tier Category,Source CTMS,Planned Primary Study Completion Date,Actual Primary Study Completion Date,Synopsis Planned Date,Synopsis Actual Date,Protocol Planned Date,Protocol Actual Date,First Site Activated Planned Date,First Site Activated Actual Date,FSS Planned Date,FSS Actual Date,FSI Planned Date,FSI Actual Date,FSFV Planned Date,FSFV Actual Date,LSI Planned Date,LSI Actual Date,LSI Avg Tx  Planned Date,LSI Avg Tx Actual Date,LSO Planned Date,LSO Actual Date,LSO 2 Planned Date,LSO 2 Actual Date,LSO 3 Planned Date,LSO 3 Actual Date,LSO 4 Planned Date,LSO 4 Actual Date,LSO Final Planned Date,LSO Final Actual Date,LSLV Planned Date,LSLV Actual Date,DBL Planned Date,DBL Actual Date,DBL 2  Planned Date,DBL 2 Actual Date,DBL 3 Planned Date,DBL 3  Actual Date,DBL 4 Planned Date,DBL 4 Actual Date,DBL Final Planned Date,DBL Final Actual Date,KA/Flash Planned Date,KA/Flash Actual Date,KA 2 10601 Planned Date,KA 2 Actual Date,KA 3 Planned Date,KA 3 Actual Date,KA 4  Planned Date,KA 4 Actual Date,KA Final  Planned Date,KA Final Actual Date,Topline Planned Date,Topline Actual Date,TFL Planned Date,TFL Actual Date,TLF Planned Date,TLF Actual Date,TLF 2 Planned Date,TLF 2 Actual Date,TLF 3 Planned Date,TLF 3 Actual Date,TLF 4 Planned Date,TLF 4 Actual Date,TLF Final Planned Date,TLF Final Actual Date,CSR Planned Date,CSR Actual Date,CSR 2  Planned Date,CSR 2  Actual Date,CSR 3  Planned Date,CSR 3 Actual Date,CSR 4 Planned Date,CSR 4 Actual Date,CSR Final Planned Date,CSR Final Actual Date,OA 1 Planned Date,OA 1 Actual Date,OA 2 Planned Date,OA 2 Actual Date,OA 3 Planned Date,OA 3 Actual Date,Trial Summary Planned Date,Trial Summary Actual Date,Oversight Needs Assessment Planned Date,Oversight Needs Assessment Actual Date,CDO Quality Risk Assessment Planned Date,CDO Quality Risk Assessment Actual Date,Primary Planned Date,Primary Actual Date
1-1ASDLD,TAK-071-1002,'TAK-071-1002,,TAK-071,"A Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, 5-Period Crossover Phase 1b Study To Evaluate The Effects Of Single Oral Administration of TAK-071 On Scopolamine-Induced Cognitive Impairment In Healthy Subjects",POM Scopolamine-induced Cognitive Impairment TAK-0,I,Terminated,(PD) Parkinson's disease,NS,,,,,,,,46,18,183,,165,,12,39.13%,1,1,,PPD,,"Abi Tepede, Betty Katz",,Arthur Simen,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/31/2016,5/31/2016,8/8/2016,8/8/2016,,,11/21/2016,11/21/2016,12/5/2016,12/5/2016,,,6/19/2017,6/19/2017,,,8/8/2017,8/8/2017,,,,,,,,,,,5/24/2018,5/24/2018,,,,,,,,,5/31/2018,5/31/2018,,,,,,,,,,,,,7/2/2018,7/2/2018,,,,,,,,,9/6/2018,9/6/2018,,,,,,,,,,,,,,,9/6/2018,9/6/2018,,,,,,
1-1ASDLN,TAK-828-1002,'TAK-828-1002,,TAK-828,"A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Doses of TAK 828 in Healthy Subjects",Phase 1 MRD,I,Closed,Other,GI,,,,MRD,,,,56,24,93,,69,,9,42.86%,2,,,PPD,Hafizur Choudhury,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BCWTX,TBD-1-1BCWTX,'TBD-1-1BCWTX,,,Single Rising Dose (Healthy and Overweight/Obese)),Single Rising Dose,I,Cancelled,Other,,,,,,,,,56,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BCWUE,TBD-1-1BCWUE,'TBD-1-1BCWUE,,,Phase 1b combination-NSCLC (15pts) (Japan and Asia),,IB,Cancelled,Other,,,,,,,,,15,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BCWUI,TBD-1-1BCWUI,'TBD-1-1BCWUI,,TAK-659,Phase 2 Single Agent Indolent Lymphoma (200 pts),P2 NHL R/R indica2-200pts,II,Cancelled,Heme.Other,Oncology,,,,,,,,200,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BCWUX,TBD-1-1BCWUX,'TBD-1-1BCWUX,,,Phase 1b combination- CRC (15pts) (Japan and Asia),,IB,Cancelled,Other,,,,,,,,,15,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BCWVB,TBD-1-1BCWVB,'TBD-1-1BCWVB,,TAK-659,Phase 2/3 Solid Tumor Nivo Combo  (300 pts),P2/3 Immuno-Onc (300 pts),II/III,Cancelled,Heme.Other,Oncology,,,,,,,,300,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BKVJT,C16014  Korea Continuation,'C16014  Korea Continuation,,Ninlaro,"South Korea Continuation Study - A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma",C16014  Korea Continuation,III,Recruitment Complete,(NDMM) Newly diagnosed multiple myeloma (9Rd),Oncology,Late Oncology,,,,,,,40,41,60,,19,,8,102.50%,11,,,PPD,,"Ai Meng Tan, Lee williams, Fuquan, Kenneth Chen",,Hongmei Li,,,,,,,,,,Medidata CTMS (Pharma),,,,,9/9/2015,9/9/2015,,,,,6/1/2016,6/1/2016,,,4/5/2017,4/5/2017,7/30/2019,7/30/2019,12/2/2019,12/2/2019,,,,,,,5/11/2022,,,,1/22/2020,1/22/2020,,,,,,,,,2/28/2020,2/28/2020,,,,,,,,,,,,,3/26/2020,3/26/2020,,,,,,,,,8/31/2020,8/31/2020,,,,,,,,,,,,,,,5/11/2022,,,,,,,
1-1BKVMB,TBD-1-1BKVMB,'TBD-1-1BKVMB,,TAK-117,Phase 1b Gastric JNA PK/Safety MLN1117 Combo with Paclitaxel,,I,Cancelled,Other,Oncology,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BKVML,C34007,'C34007,,TAK-659,C34007 Phase 1 Asian Lymphoma single agent  (40 pts),C34007 Ph1 Asian,I,Recruitment Complete,(NHL) Non-Hodgkin's lymphoma,Oncology,Early Oncology,,,,,,,22,17,0,,6,11,0,77.27%,5,,,IQVIA,,Sakiko Kaizuka,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/22/2016,9/22/2016,3/21/2017,3/21/2017,,,,,9/7/2017,9/7/2017,,,9/25/2019,9/25/2019,8/17/2020,8/17/2020,8/17/2020,8/17/2020,,,,,,,,,,,10/15/2020,10/15/2020,,,,,,,,,10/22/2020,10/22/2020,,,,,,,,,,,,,11/27/2020,11/27/2020,,,,,,,,,5/10/2021,5/10/2021,,,,,,,,,,,,,,,5/10/2021,5/10/2021,,,,,,
1-1BKVN6,TBD-1-1BKVN6,'TBD-1-1BKVN6,,TAK-117,Phase 1b Gastric JNA PK/Safety MLN1117 Combo with TAK-659,,I,Cancelled,Solid.GI.Gastric,Oncology,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1BP8VZ,TAK-438_115,'TAK-438_115,,vonoprazan,"A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole.",TAK-438 Bismuth Drug interaction study,I,Closed,00002 GERD,GI,,,,DI High Complexity,,,,30,30,211,,181,,,100.00%,1,,,IQVIA,Ippei Nakayama,,,,,,,,,,,,,STARS Inactive,,,1/25/2013,1/25/2013,12/22/2015,12/22/2015,,,9/5/2016,9/5/2016,9/21/2016,9/21/2016,,,3/30/2017,3/30/2017,,,5/11/2017,5/11/2017,,,,,,,,,,,5/17/2017,5/17/2017,,,,,,,,,7/5/2017,7/5/2017,,,,,,,,,,,,,9/25/2017,9/25/2017,,,,,,,,,12/18/2017,12/18/2017,,,,,,,,,,,,,,,12/18/2017,12/18/2017,,,,,,
1-1CG7X7,Vedolizumab-3001,'Vedolizumab-3001,,Entyvio,"An Extension Study to Evaluate The Long-Term Efficacy and Safety of Vedolizumab IV In Patients with Primary Sclerosing Cholangitis, with Underlying Inflammatory Bowel Disease.",3001 P3 PSC Extension (Vedolizumab),III,Cancelled,Other,GI,,,,,,,,215,0,0,,0,,0,0.00%,90,,,,Rosalida Leone,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1CJZ81,TAK-828-1003,'TAK-828-1003,,TAK-828,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of TAK-828 in Patients with Crohn’s Disease (CD)","Phase 1b, MRD in CD Patients",IB,Cancelled,00027 (CD) Crohn's disease,GI,,,,,,,,12,0,0,,0,,0,0.00%,2,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1CJZC7,TAK-438_302,'TAK-438_302,,vonoprazan,"A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter pylori Infection",China IMCT Study-GU,III,Terminated,Cancer (glioma),GI,,,,,,,,830,236,5,,114,1,0,28.43%,68,,,IQVIA,,Sook Koon Michelle Foo,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/6/2012,12/6/2012,5/7/2014,5/7/2014,,,4/17/2017,4/17/2017,6/15/2017,6/15/2017,,,1/22/2020,1/22/2020,,,3/17/2020,3/17/2020,,,,,,,,,,,7/7/2020,7/7/2020,,,,,,,,,7/14/2020,7/14/2020,,,,,,,,,,,,,8/3/2020,8/3/2020,,,,,,,,,10/20/2020,10/20/2020,,,,,,,,,,,,,,,1/29/2021,1/29/2021,,,,,,
1-1CJZCH,TAK-438_304,'TAK-438_304,,vonoprazan,"A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter pylori Infection",China Registration Study,III,All Activities Closed,Cancer (glioma),GI,Early GI,,,Interventional,,,,530,530,3,,248,1,0,100.00%,68,,,IQVIA,,Sook Koon Michelle Foo,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/6/2012,12/6/2012,11/21/2012,11/21/2012,,,4/5/2017,4/5/2017,5/4/2017,5/4/2017,,,1/29/2019,1/29/2019,,,4/12/2019,4/12/2019,,,,,,,,,,,9/5/2019,9/5/2019,,,,,,,,,9/9/2019,9/9/2019,,,,,,,,,,,,,10/9/2019,10/9/2019,,,,,,,,,1/9/2020,1/9/2020,,,,,,,,,,,,,,,3/10/2020,3/10/2020,,,,,,
1-1CJZCS,TAK-935-1005,'TAK-935-1005,,soticlestat (TAK-935),A Phase 1 Bioavailability and Food Effect Study to Compare Tablet versus Solution Formulation and to Assess the Effect of  Food on the Bioavailability of a Single TAK-935 Dose in Healthy Subjects,Rel BA,I,Closed,Other,NS,,,,BA,,,,9,9,21,,12,,,100.00%,1,1,,PPD,Kumudinie Karunaratne,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,4/29/2016,4/29/2016,6/28/2016,6/28/2016,,,9/6/2016,9/6/2016,10/4/2016,10/4/2016,,,10/4/2016,10/4/2016,,,11/9/2016,11/9/2016,,,,,,,,,,,1/11/2017,1/11/2017,,,,,,,,,11/11/2016,11/11/2016,,,,,,,,,,,,,3/22/2017,3/22/2017,,,,,,,,,5/24/2017,5/24/2017,,,,,,,,,,,,,,,5/24/2017,5/24/2017,,,,,,
1-1DC1ZJ,TAK-418-1001,'TAK-418-1001,,TAK-418,"A Randomized, Double-Blind, Placebo-Controlled, Ascending Oral Single Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-418 in Healthy Subjects",SRD/MRD,I,Closed,Other,NS,,,,SRD/FIM,,,,40,40,146,,106,40,2,100.00%,1,1,,PRA,,,,,,,,,,,,,,STARS Inactive,,,8/3/2016,8/3/2016,4/7/2017,4/7/2017,,,6/27/2017,6/27/2017,8/8/2017,8/8/2017,,,11/14/2017,11/14/2017,,,5/12/2018,5/12/2018,,,,,,,,,,,6/7/2018,6/7/2018,,,,,,,,,6/15/2018,6/15/2018,,,,,,,,,,,,,6/29/2018,6/29/2018,,,,,,,,,11/29/2018,11/29/2018,,,,,,,,,,,,,,,11/29/2018,11/29/2018,,,,,,
1-1DC1ZS,TBD-1-1DC1ZS,'TBD-1-1DC1ZS,,TAK-418,PET validation,PET validation,0,Cancelled,Other,NS,,,,EM Phase 0,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1DC1ZT,TBD-1-1DC1ZT,'TBD-1-1DC1ZT,,TAK-418,DDI 1,DDI 1,I,Cancelled,Other,NS,,,,DI Low Complexity,,,,30,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1DC20B,TAK-418-0004,'TAK-418-0004,,TAK-418,"A Study Measuring LSD-1 Occupancy in Healthy Adult Volunteers as a Function of TAK-418 Dose, TAK-418 Plasma Concentration and Liquid Biomarker [18F]MNI-1054",PET occupancy,I,Terminated,Kabuki Syndrome,NS,Early NS,,,,,,,16,7,10,,3,6,1,43.75%,1,,,PRA,,Rhett Behrje,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/4/2019,7/4/2019,12/19/2019,12/19/2019,,,3/5/2020,3/5/2020,1/8/2020,1/8/2020,,,3/3/2020,3/3/2020,,,3/19/2020,3/19/2020,,,,,,,,,,,7/29/2020,7/29/2020,,,,,,,,,,,,,,,,,,,,,,,8/30/2020,8/30/2020,,,,,,,,,11/16/2020,11/16/2020,,,,,,,,,,,,,,,11/16/2020,11/16/2020,,,,,,
1-1DC20E,TAK-418-1004,'TAK-418-1004,,TAK-418,rBA,BA rel,I,Withdrawn,Kabuki Syndrome,NS,,,,,,,,16,,,,,,,,1,,,Celerion,,Eric Henricks,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/21/2019,11/21/2019,2/5/2020,2/5/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/21/2021,,,,,,,
1-1DC217,TAK-828-1004,'TAK-828-1004,,TAK-828,"A Fixed Sequence, Open-Label, 2-Period Crossover Study to Evaluate the Effect of Potent CYP3A4 Inhibitor Itraconazole on the Steady State Pharmacokinetics of TAK-828 in Healthy Adult Subjects",Drug Drug Interaction Study,I,Cancelled,00027 (CD) Crohn's disease,GI,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1DEG3T,TBD-1-1DEG3T,'TBD-1-1DEG3T,,TAK-527,Relative BA Study,TAK-527 Rel BA Study,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1DEG4D,TBD-1-1DEG4D,'TBD-1-1DEG4D,,TAK-527,PET Occupancy Study,TAK-527 PET Receptor Occupancy Study,I,Cancelled,Other,NS,,,,,,,,16,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1DEG44,TBD-1-1DEG44,'TBD-1-1DEG44,,TAK-527,PET Validation Study,TAK-527 PET Tracer Validation Study,I,Cancelled,Other,NS,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1DUG1R,Vedolizumab-3036,'Vedolizumab-3036,,Entyvio,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Vedolizumab in the Treatment of the Grade B-D Acute Intestinal Graft vs Host Disease (GvHD) in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",GvHD Treatment Pivotal,III,Planned,(GvHD SR) Graft versus host disease Steriod Refractory,GI,,,,,,,,460,,,,,,,,100,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1DUG15,Vedolizumab-3035,'Vedolizumab-3035,,Entyvio,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",GvHD Prophylaxis Pivotal,III,Recruitment Complete,Post Operative Recovery,GI,Late GI,,,,Prevention,Prospective,Other,558,343,456,,113,343,154,61.47%,150,113,,PRA,,Mary Traynor,,Johan Jansson,,2018-002141-11,,,,,NA,Advance,,Medidata CTMS (Pharma),,,4/13/2018,4/13/2018,6/15/2018,6/15/2018,,,2/6/2019,2/6/2019,3/26/2019,3/26/2019,,,5/10/2021,5/10/2021,,,11/6/2021,,,,,,,,6/28/2022,,,,2/17/2022,,,,,,,,8/16/2022,,3/10/2022,,,,,,,,8/23/2022,,,,,,3/10/2022,,,,,,,,9/6/2022,,6/23/2022,,,,,,,,12/21/2022,,,,,,,,12/21/2022,,,,,,,
1-1EIATT,Lubiprostone-3001,'Lubiprostone-3001,,Amitiza (lubiprostone),"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation",Lubiprostone CIC Russia,III,Closed,Other,Others,,,,,,,,204,173,0,,13,0,0,84.80%,20,,,IQVIA,Sook Koon Michelle Foo,,,,,,,,,,,,,STARS Inactive,,,,,5/13/2015,5/13/2015,,,2/17/2016,2/17/2016,3/2/2016,3/2/2016,,,12/6/2016,12/6/2016,,,1/23/2017,1/23/2017,,,,,,,,,,,3/21/2017,3/21/2017,,,,,,,,,3/28/2017,3/28/2017,,,,,,,,,,,,,5/4/2017,5/4/2017,,,,,,,,,6/26/2017,6/26/2017,,,,,,,,,,,,,,,6/26/2017,6/26/2017,,,,,,
1-1EIAU4,Lubiprostone-3002,'Lubiprostone-3002,,Amitiza (lubiprostone),"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation",Lubiprostone CIC South Korea,III,Closed,Other,Others,,,,,,,,150,108,0,,17,21,0,72.00%,13,,,IQVIA,Sook Koon Michelle Foo,,,,,,,,,,,,,STARS Inactive,,,,,5/14/2015,5/14/2015,,,4/14/2016,4/14/2016,5/6/2016,5/6/2016,,,1/6/2017,1/6/2017,,,2/17/2017,2/17/2017,,,,,,,,,,,4/21/2017,4/21/2017,,,,,,,,,4/28/2017,4/28/2017,,,,,,,,,,,,,5/26/2017,5/26/2017,,,,,,,,,7/18/2017,7/18/2017,,,,,,,,,,,,,,,5/29/2020,,,,,,,
1-1EIAUN,Lubiprostone-3003,'Lubiprostone-3003,,Amitiza (lubiprostone),"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic, Idiopathic Constipation",Lubiprostone CIC Mexico,III,Closed,Other,Others,,,,,,,,204,172,0,,50,0,0,84.31%,12,,,IQVIA,Jennifer Boynton,,,,,,,,,,,,,STARS Inactive,,,,,5/20/2015,5/20/2015,,,5/11/2016,5/11/2016,5/25/2016,5/25/2016,,,4/28/2017,4/28/2017,,,6/5/2017,6/5/2017,,,,,,,,,,,7/28/2017,7/28/2017,,,,,,,,,8/14/2017,8/14/2017,,,,,,,,,,,,,8/29/2017,8/29/2017,,,,,,,,,11/28/2017,11/28/2017,,,,,,,,,,,,,,,1/15/2019,,,,,,,
1-1EIAVJ,C28003,'C28003,,TAK-580,"An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma",,IB,Closed,Solid.All Comers,Oncology,,,,,,,,106,7,1,,0,0,0,6.60%,15,,,PRA,,,,,,,,,,,,,,STARS Inactive,,,11/17/2015,,1/11/2016,,,,,,7/5/2016,,,,12/18/2017,,5/9/2018,,5/9/2018,,,,,,,,,,,,7/15/2018,,,,,,,,,,9/15/2018,,,,,,,,,,,,,,8/9/2018,,,,,,,,,,1/21/2019,1/21/2019,,,,,,,,,,,,,,,1/21/2019,,,,,,,
1-1EV4LF,TBD-1-1EV4LF,'TBD-1-1EV4LF,,,"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib
Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following
Autologous Stem Cell Transplant",,III,Cancelled,Heme.Multiple Myeloma,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1EV4LQ,C16021CSC,'C16021CSC,,Ninlaro,"China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation",C16021 China Continuation,III,Recruiting,other,Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Case-Crossover,30,19,38,,15,,4,63.33%,14,,,PPD,,"Ai Meng Tan, Jingjing Tan",,Dai Yi,,,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,,,11/2/2016,11/2/2016,,,1/24/2019,1/24/2019,2/21/2019,2/21/2019,,,12/31/2021,,1/24/2024,,1/1/2023,,,,,,,,1/24/2024,,,,1/6/2023,,,,,,,,2/24/2024,,3/16/2023,,,,,,,,3/2/2024,,,,,,4/16/2023,,,,,,,,5/27/2024,,5/10/2023,,,,,,,,8/12/2024,,,,,,,,8/12/2024,,,,,,,
1-1FFWFN,TBD-1-1FFWFN,'TBD-1-1FFWFN,,,PPI partial responder phase 3 study place holder No 1,PPI partial responder phase 3 study place holder N,III,Planned,,,,,,,,,,288,,,,,,,,45,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FFWFY,TBD-1-1FFWFY,'TBD-1-1FFWFY,,,PPI partial responder phase 3 study place holder No 2,PPI partial responder phase 3 study place holder,III,Planned,,,,,,,,,,288,,,,,,,,45,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FFWG7,TBD-1-1FFWG7,'TBD-1-1FFWG7,,,PPI partial responder phase 3 long term open label phase 3 study place holder,PPI partial responder phase 3 long term open label,III,Planned,,,,,,,,,,600,,,,,,,,60,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOIH,TAK-915-1501,'TAK-915-1501,,TAK-915,"Randomized, Double-blind, Placebo-controlled, Parallel, 4-Week, Early Proof of Concept Study of Single Dose Level of TAK-915 as an Add-on Pro-Cognitive Treatment to Second Generation Antipsychotics in Subjects with Stable Schizophrenia",PII POC study,I/II,Cancelled,Other,NS,,,,Other Phase 2,,,,70,0,0,,0,,0,0.00%,10,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOKP,TBD-1-1FQOKP,'TBD-1-1FQOKP,,TAK-418,Autism POC,Autism POC,II,Cancelled,Other,NS,,,,Dose Ranging,,,,240,0,0,,0,,0,0.00%,30,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOKZ,TAK-418-2001,'TAK-418-2001,,TAK-418,Kabuki ePOC,Kabuki POM,II,Cancelled,Kabuki Syndrome,NS,,,,,,,,15,,,,,,,,12,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOLA,TBD-1-1FQOLA,'TBD-1-1FQOLA,,TAK-418,Autism POM,Autism POM,II,Cancelled,Other,NS,,,,Other Phase 2,,,,45,0,0,,0,,0,0.00%,10,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOLK,TBD-1-1FQOLK,'TBD-1-1FQOLK,,TAK-418,Huntington POM,Huntington POM,II,Cancelled,Other,NS,,,,Other Phase 2,,,,60,0,0,,0,,0,0.00%,15,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOM9,TBD-1-1FQOM9,'TBD-1-1FQOM9,,TAK-915,TBD,DDI 1,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOMT,TAK-041-1002,'TAK-041-1002,,TAK-041,"A Phase, Open-Label, Randomized, Positron Emission Tomography Study in Healthy Subjects to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the CNS After Single-Dose Oral Administration",PET,I,Closed,Other,NS,,,,Other Phase 1,,,,12,12,33,,21,,2,100.00%,1,1,,IQVIA,Betty Katz,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,6/1/2016,6/1/2016,7/20/2016,7/20/2016,,,12/26/2016,12/26/2016,1/18/2017,1/18/2017,,,5/29/2017,5/29/2017,,,8/24/2017,8/24/2017,,,,,,,,,,,10/19/2017,10/19/2017,,,,,,,,,7/12/2017,7/12/2017,,,,,,,,,,,,,12/1/2017,12/1/2017,,,,,,,,,4/25/2018,4/25/2018,,,,,,,,,,,,,,,4/25/2018,4/25/2018,,,,,,
1-1FQON4,TBD-1-1FQON4,'TBD-1-1FQON4,,,TBD,POM,IIA,Cancelled,Other,,,,,Other Phase 2,,,,21,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQONC,TBD-1-1FQONC,'TBD-1-1FQONC,,TAK-915,TBD,DDI 2,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQONM,TBD-1-1FQONM,'TBD-1-1FQONM,,TAK-915,TBD,QTC,I,Cancelled,Other,NS,,,,,,,,60,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQORN,TBD-1-1FQORN,'TBD-1-1FQORN,,TAK-071,ADME,ADME,I,Cancelled,00172 Alzheimer's disease,NS,,,,ADME,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQORY,TBD-1-1FQORY,'TBD-1-1FQORY,,TAK-071,QTC,QTC,I,Cancelled,00172 Alzheimer's disease,NS,,,,QTc Interval,,,,60,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOS7,TBD-1-1FQOS7,'TBD-1-1FQOS7,,TAK-071,DDI #1,DDI #1,I,Cancelled,00172 Alzheimer's disease,NS,,,,DI Low Complexity,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOSG,TBD-1-1FQOSG,'TBD-1-1FQOSG,,TAK-071,DDI #2,DDI #2,I,Cancelled,00172 Alzheimer's disease,NS,,,,DI High Complexity,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOU5,TBD-1-1FQOU5,'TBD-1-1FQOU5,,TAK-915,TBD,ADME,I,Cancelled,Other,NS,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FQOV2,TAK-390MR_106,'TAK-390MR_106,,"DEXILANT (dexlansoprazole, MR)","A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Capsules in Healthy Chinese Subjects",Phase 1 China PK _106 Study,I,Closed,Other,GI,,,,China PK,,,,40,40,226,,186,,,100.00%,1,,,Hangzhou Tigermed Consulting,,,,,,,,,,,,,,STARS Inactive,,,8/5/2011,8/5/2011,11/28/2014,11/28/2014,,,11/22/2017,11/22/2017,12/7/2017,12/7/2017,,,1/25/2018,1/25/2018,,,2/8/2018,2/8/2018,,,,,,,,,,,3/23/2018,3/23/2018,,,,,,,,,12/14/2018,12/14/2018,,,,,,,,,,,,,4/27/2018,4/27/2018,,,,,,,,,12/14/2018,12/14/2018,,,,,,,,,,,,,,,1/8/2019,1/8/2019,,,,,,
1-1FQOVB,TAK-390MR_301,'TAK-390MR_301,,"DEXILANT (dexlansoprazole, MR)","A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo",EE Healing and Maintenance China 301 Study,III,Terminated,Erosive esophagitis healing,GI,,,,,,,,450,37,66,,28,,34,8.22%,25,,,Hangzhou Tigermed Consulting,,Yunlong Zheng,,,,,,,,,,,,Medidata CTMS (Pharma),,,8/5/2011,8/5/2011,11/28/2014,11/28/2014,,,12/9/2016,12/9/2016,12/30/2016,12/30/2016,,,8/23/2017,8/23/2017,,,10/30/2017,10/30/2017,,,,,,,,,,,11/30/2017,11/30/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/20/2018,12/20/2018,,,,,,,,,,,,,,,12/20/2018,12/20/2018,,,,,,
1-1FQOVK,TAK-390MR_302,'TAK-390MR_302,,"DEXILANT (dexlansoprazole, MR)",A Phase 3 Double Blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD),GERD China _302  Study,III,Closed,00013 s-GERD (NERD),GI,,,,,,,,200,217,326,,108,,12,108.50%,20,,,Hangzhou Tigermed Consulting,,,,,,,,,,,,,,STARS Inactive,,,8/5/2011,8/5/2011,11/28/2014,11/28/2014,,,12/9/2016,12/9/2016,12/31/2016,12/31/2016,,,2/12/2018,2/12/2018,,,4/10/2018,4/10/2018,,,,,,,,,,,5/11/2018,5/11/2018,,,,,,,,,6/15/2018,6/15/2018,,,,,,,,,,,,,8/31/2018,8/31/2018,,,,,,,,,12/12/2018,12/12/2018,,,,,,,,,,,,,,,12/25/2018,12/25/2018,,,,,,
1-1FY263,TBD-1-1FY263,'TBD-1-1FY263,,,Phase 3 NSCLC Japan MLN1117 Combo with Q3W Docetaxel,,III,Cancelled,Solid.Lung.NSCLC,,,,,,,,,700,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FZFNH,TBD1-1FZFNH,'TBD1-1FZFNH,,TAK-904,Ind. 3 - Second Ph 3 Pivotal (300-400 pts) - Indication 3,TBD1-1FZFNH TAK-904,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FZFNR,TBD-1-1FZFNR,'TBD-1-1FZFNR,,TAK-904,Ind. 2 - First Ph 3 Pivotal (300-400 pts) - Indication 2,Ind. 2 - First Ph 3,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1FZFO2,TBD-1-1FZFO2,'TBD-1-1FZFO2,,TAK-904,Ind. 1 - Second Ph 3 Pivotal (300-400 pts) - Indication 1,Ind. 1 - Second Ph 3,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1G09LJ,TBD-1-1G09LJ,'TBD-1-1G09LJ,,,Phase 2 PD-1 Umbrella study,,II,Cancelled,Solid.Other,,,,,,,,,120,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1G09LU,TBD-1-1G09LU,'TBD-1-1G09LU,,,Phase 3 PD-1 Umbrella study,,III,Cancelled,Solid.Other,,,,,,,,,400,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1GDNNZ,Alogliptin-1002,'Alogliptin-1002,,OSENI (alogliptin and pioglitazone),"A Randomized, Open-Label, Single-Dose, 4-Period Crossover Study to Determine the Bioequivalence of Alogliptin (25 mg) and Pioglitazone (15 and 30 mg) When Administered as Individual Tablets and as Fixed-Dose Combination Tablets to Healthy Russian Subjects",BA and BE of Alogliptin and Pioglitazone FDC in he,I,Closed,Other,CVM,,,,BE,,,,72,72,112,,40,,4,100.00%,1,,,Atlant,Natalie Jones,,,,,,,,,,,,,STARS Inactive,,,1/30/2017,1/30/2017,7/26/2017,7/26/2017,,,5/24/2018,5/24/2018,6/1/2018,6/1/2018,,,6/8/2018,6/8/2018,,,7/13/2018,7/13/2018,,,,,,,,,,,9/12/2018,9/12/2018,,,,,,,,,,,,,,,,,,,,,,,10/10/2018,10/10/2018,,,,,,,,,1/22/2019,1/22/2019,,,,,,,,,,,,,,,8/19/2019,,,,,,,
1-1GGK7H,TBD-1-1GGK7H,'TBD-1-1GGK7H,,,An open-label sequential single dose TAK-272 and multiple doses voriconazole drug drug interaction study single dose TAK-272 and multiple doses voriconazole drug drug interaction study open-label sequential single dose TAK-272 and multiple doses voriconazole drug drug interaction study open-label sequential single dose TAK-272 and multiple doses voriconazole drug drug interaction study,DDI TAK-272 and voriconazole,I,Cancelled,00283 Diabetic nephropathy,,,,,DI High Complexity,,,,16,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1GQ661,C25015,'C25015,,,Phase 3 FL HL (China),Phase 3 FL HL (China),III,Planned,"(HL) Hodgkin lymphoma, 1st line",,,,,,,,,350,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1H5VVF,TAK-041-1003,'TAK-041-1003,,TAK-041,FE,Bioavailability and Food Effect Study,I,Cancelled,Other,NS,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,PRA,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1H5VVZ,TBD-1-1H5VVZ,'TBD-1-1H5VVZ,,,TBD,DDI,I,Cancelled,Other,,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1HVXIV,VedolizumabSC-3030A,'VedolizumabSC-3030A,,Entyvio SC,"A Phase 3, Multi-Center, Open-Label, Randomized, Parallel Group Study in Subjects with Ulcerative Colitis or Crohn’s Disease to Assess Subjects’ Ability to Administer Vedolizumab SC via Needle-safety Device (PFS+NSD) or Autoinjector  (PFS+AI)",SC Home Use sub-study,III,Planned,Support - GI,GI,,,,,,,,80,,,,,,,,25,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1HVXP9,TCV-116CCB_302,'TCV-116CCB_302,,UNISIA (candesartan cilexetil & amlodipine),"A Phase-3 Randomized, Double-Blind, Parallel-Group Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine (8/5 mg) in Chinese Subjects with Mild/Moderate Essential Hypertension, Who do Not Achieve Target Blood Pressure Following Treatment with Amlodipine 5 mg Monotherapy",AML non-responder phase III study,III,Cancelled,00030 Hypertension,CVM,,,,Benchmark Phase 3,,,,370,0,0,,0,,0,0.00%,25,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1HVXPI,TCV-116CCB-1001,'TCV-116CCB-1001,,UNISIA (candesartan cilexetil & amlodipine),"A phase 1, Randomized, Open-label, Single-dose 2 way Crossover Study to Assess the Bioequivalence of TCV-116CCB Tablet and Coadministration of Candesartan Cilexetil Tablet and Amlodipine Tablets in Chinese Healthy Adult Male Subjects",Unisia BE study,I,Cancelled,00030 Hypertension,CVM,,,,BE,,,,56,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1HVXQ3,VedolizumabSC-1017,'VedolizumabSC-1017,,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Pilot Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects",Vedolizumab SC NSD BE Pilot,I,Closed,Other,GI,,,,BE,,,,24,24,47,,23,,,100.00%,1,,,Celerion,,,,,,,,,,,,,,STARS Inactive,,,,,12/17/2017,12/17/2017,,,2/6/2018,2/6/2018,2/26/2018,2/26/2018,,,2/26/2018,2/26/2018,,,8/12/2018,8/12/2018,,,,,,,,,,,9/19/2018,9/19/2018,,,,,,,,,9/28/2018,9/28/2018,,,,,,,,,,,,,10/9/2018,10/9/2018,,,,,,,,,11/8/2018,11/8/2018,,,,,,,,,,,,,,,11/8/2018,11/8/2018,,,,,,
1-1I52NH,TBD-1-1I52NH,'TBD-1-1I52NH,,TAK-659,Phase 2 Combo NHL (160 pts),Ph2 Combo NHL DLBCL,II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1I52V9,TBD-1-1I52V9,'TBD-1-1I52V9,,,Korea Phase 1 PK Study (Vedolizumab),Korea Phase 1 PK Study (Vedolizumab),I,Planned,,,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1J88EV,TAK-041-2002,'TAK-041-2002,,TAK-041,POC in Anhedonia pts,POCC,II,Cancelled,Other,NS,,,,POC,,,,240,0,0,,0,,0,0.00%,50,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1KXHXR,TBD-1-1KXHXR,'TBD-1-1KXHXR,,vonoprazan,DDI Study with Oral contraceptives,DDI Study with Oral contraceptives,I,Planned,ARD (PPI partial responder),GI,,,,,,,,18,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1KXHY2,Esomeprazole-1001,'Esomeprazole-1001,,vonoprazan,"A Phase 1, Randomized, Open-label, 2-way Cross-over Study to Evaluate the Bioequivalence Between a Single Oral Dose of Esomeprazole 40 mg Capsules and Esomeprazole 40 mg Tablets in Healthy Subjects",Esomeprazole Bioequavalence study,I,Closed,00002 GERD,GI,,,,,,,,52,52,110,,58,,2,100.00%,1,,,PRA,,,,,,,,,,,,,,STARS Inactive,,,9/23/2016,9/23/2016,1/31/2017,1/31/2017,,,3/27/2017,3/27/2017,4/22/2017,4/22/2017,,,5/5/2017,5/5/2017,,,5/13/2017,5/13/2017,,,,,,,,,,,6/26/2017,6/26/2017,,,,,,,,,6/26/2017,6/26/2017,,,,,,,,,,,,,8/10/2017,8/10/2017,,,,,,,,,11/21/2017,11/21/2017,,,,,,,,,,,,,,,11/21/2017,,,,,,,
1-1KYU97,TBD-1-1KYU97,'TBD-1-1KYU97,,,"A Phase 2b, Dose finding, double-blind, randomized, placebo-controlled, active reference 6 week study in patients with acutely exacerbated symptoms of schizophrenia",TAK-063 Dose finding US/EEU,II,Cancelled,00149 Schizophrenia,,,,,,,,,480,0,0,,0,,0,0.00%,48,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1KYUHP,TBD-1-1KYUHP,'TBD-1-1KYUHP,,,"A Multi-centre, Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of TAK-242 in Patients with Acute Decompensation of Alcohol-Related Cirrhosis",TAK-242 POC Study in ACLF,II,Cancelled,Other,,,,,POC,,,,80,0,0,,0,,0,0.00%,10,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1L0NQP,Vedolizumab-2004,'Vedolizumab-2004,,Entyvio,"An open-label, dose-finding study of intravenous (IV) vedolizumab for treatment of steroid-refractory graft-versus-host disease (GvHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT)",GvHD Treatment P2a,IIA,Closed,Heme.Other,GI,,,,Dose Ranging,,,,17,17,0,,3,16,0,100.00%,15,,,IQVIA,"Pisita Bolsue-King, Sara Dale",,,,,2016-002985-30,,,,,,,,STARS Inactive,,,5/17/2016,5/17/2016,8/26/2016,8/26/2016,,,4/28/2017,4/28/2017,4/28/2017,4/28/2017,,,2/22/2018,,,,5/9/2018,5/9/2018,,,,,,,,,,,10/10/2018,10/10/2018,,,,,,,,,10/17/2018,10/17/2018,,,,,,,,,,,,,2/28/2019,2/28/2019,,,,,,,,,3/20/2019,3/20/2019,,,,,,,,,,,,,,,3/25/2019,,,,,,,
1-1LEUIX,Vortioxetine-3001,'Vortioxetine-3001,,Trintellix (vortioxetine),Cognition Placeholder,Cognition Placeholder,III,Cancelled,Elderly non-depressed with mild cognitive impairement,NS,,,,,,,,500,,,,,,,,60,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1LU1A3,TBD-1-1LU1A3,'TBD-1-1LU1A3,,TAK-202,TAK-202 arm Phase 3,,III,Cancelled,Solid.Other,Oncology,,,,Benchmark Phase 3,,,,400,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1LU19T,TBD-1-1LU19T,'TBD-1-1LU19T,,TAK-202,TAK-202 arm Phase 2,,II,Cancelled,Solid.Other,Oncology,,,,Benchmark Phase 2,,,,120,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1M2SHB,TBD-1-1M2SHB,'TBD-1-1M2SHB,,,Food Effect Pilot (T3),,I,Cancelled,Solid.Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1M2SHV,C16029,'C16029,,Ninlaro,"A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma",C16029 Ph 2 Id vs Pd,II/III,Recruitment Complete,(MM) Multiple myeloma relapsed/refractory,Oncology,Late Oncology,,,,,,,120,122,195,,73,122,,101.67%,117,30,,PPD,,"Zahir Rajiwate, Gina Gualtiere",,Richard Labotka,,2016-004742-28,,,,,,,,Medidata CTMS (Pharma),,,,,3/29/2017,3/29/2017,,,,,2/22/2018,2/22/2018,,,10/7/2019,10/7/2019,,,3/26/2020,3/26/2020,,,,,,,,,,,9/4/2020,9/4/2020,,,,,,,,,,,,,,,,,,,,,,,10/29/2020,10/29/2020,,,,,,,,,1/15/2021,1/15/2021,,,,,,,,,,,,,,,1/15/2021,,,,,,,
1-1M2SIF,C16027,'C16027,,Ninlaro,"An Open-Label, Rollover Protocol for Patients Previously Enrolled in
Millennium-Sponsored Ixazomib Studies",Ph2 Roll Over Study,II,Recruitment Complete,Support - Oncology,Oncology,Late Oncology,,,,Treatment,Other,Other,42,31,,,,31,,73.81%,15,15,,PPD,,Calvin Gooden,,Catriona Byrne,,2016-001681-28,,,,,,,,Medidata CTMS (Pharma),,,,,6/30/2016,6/30/2016,,,,,12/16/2016,12/16/2016,,,10/15/2021,10/15/2021,9/15/2023,,9/15/2023,,,,,,,,,,,,10/27/2023,,,,,,,,,,11/10/2023,,,,,,,,,,,,,,11/22/2023,,,,,,,,,,3/1/2024,,,,,,,,,,,,,,,,3/1/2024,,,,,,,
1-1MD53K,TBD-1-1MD53K,'TBD-1-1MD53K,,TAK-659,Phase 1b Asian Solid Tumor Single Agent and Combo (200 pts),Ph1b Asian ST SA & Combo,II,Cancelled,Solid.Other,Oncology,,,,,,,,200,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4B4,TBD-1-1MI4B4,'TBD-1-1MI4B4,,TAK-164,Renal Impairment TAK-164,Renal Impairment TAK-164,I,Cancelled,Multiple cancer,Oncology,,,,,,,,60,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4BB,TBD-1-1MI4BB,'TBD-1-1MI4BB,,TAK-164,Human ADME,Human ADME,I,Cancelled,Solid.Other,Oncology,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4CF,TBD-1-1MI4CF,'TBD-1-1MI4CF,,TAK-164,Phase 1b,Phase 1b,Ib,Cancelled,Multiple cancer,Oncology,,,,,,,,50,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4D8,TBD-1-1MI4D8,'TBD-1-1MI4D8,,TAK-164,Ind. 1 Second Ph1b/2 Randomized,Ind. 1 Second Ph1b/2 Randomized,II,Cancelled,Multiple cancer,Oncology,,,,,,,,100,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4DV,TBD-1-1MI4DV,'TBD-1-1MI4DV,,TAK-164,Hepatic Impairment,Hepatic Impairment TAK-164,I,Cancelled,Multiple cancer,Oncology,,,,,,,,70,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4E1,TBD-1-1MI4E1,'TBD-1-1MI4E1,,TAK-164,Ind. 1 Ph 2 Combo Single Arm,Ind. 1 Ph 2 Combo Single Arm,II,Cancelled,Multiple cancer,Oncology,,,,,,,,70,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4EK,TAK-164-1002,'TAK-164-1002,,TAK-164,Ph1 SA Safety/PK - J&A,Ph1 SA Safety/PK - J&A,I,Cancelled,Multiple cancer,Oncology,Early Oncology,,,,,,,30,,,,,,,,1,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/24/2019,6/24/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/24/2019,6/24/2019,,,,,,
1-1MI4EY,TBD-1-1MI4EY,'TBD-1-1MI4EY,,TAK-164,Ind. 2 First Ph1b/2 Randomized,Ind. 2 Second Ph1b/2 Randomized,II,Cancelled,Multiple cancer,Oncology,,,,,,,,100,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4F3,TBD-1-1MI4F3,'TBD-1-1MI4F3,,TAK-164,QT Study,QT Study TAK-164,I,Cancelled,Multiple cancer,Oncology,,,,,,,,40,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4FM,TBD-1-1MI4FM,'TBD-1-1MI4FM,,TAK-164,DDI #1,DDI #1 TAK-164,I,Cancelled,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4G1,TBD-1-1MI4G1,'TBD-1-1MI4G1,,TAK-164,Ind. 2 First Ph1b/2 Randomized,Ind. 2 First Ph1b/2 Randomized,II,Cancelled,Multiple cancer,Oncology,,,,,,,,100,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4GF,TBD-1-1MI4GF,'TBD-1-1MI4GF,,TAK-164,DDI #2,DDI #2 TAK-164,I,Cancelled,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4GO,TBD-1-1MI4GO,'TBD-1-1MI4GO,,TAK-164,Ind. 1 First Ph3,Ind. 1 First Ph3,III,Cancelled,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4H7,TBD-1-1MI4H7,'TBD-1-1MI4H7,,TAK-164,Ind. 1 Second Ph3,Ind. 1 Second Ph3,III,Cancelled,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4I0,TBD-1-1MI4I0,'TBD-1-1MI4I0,,TAK-164,Ind. 2 First Ph3,Ind. 2 First Ph3,III,Cancelled,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4JD,TBD-1-1MI4JD,'TBD-1-1MI4JD,,TAK-164,Ind. 2 Second Ph3,Ind. 2 Second Ph3,III,Cancelled,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4LU,TBD-1-1MI4LU,'TBD-1-1MI4LU,,TAK-164,Ind. 3 First Ph1b/2 Randomized,Ind. 3 First Ph1b/2 Randomized,II,Cancelled,Multiple cancer,Oncology,,,,,,,,100,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4NH,TBD-1-1MI4NH,'TBD-1-1MI4NH,,TAK-164,Ind. 3 Second Ph1b/2 Randomized,Ind. 3 Second Ph1b/2 Randomized,II,Cancelled,Multiple cancer,Oncology,,,,,,,,100,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4OA,TBD-1-1MI4OA,'TBD-1-1MI4OA,,TAK-164,Ind. 3 First Ph3,Ind. 3 First Ph3,III,Cancelled,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI4QC,TBD-1-1MI4QC,'TBD-1-1MI4QC,,TAK-164,Ind. 3 Second Ph3,Ind. 3 Second Ph3,III,Cancelled,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MI48T,TAK-164-1001,'TAK-164-1001,,TAK-164,Ph1 Dose Escalation/Expansion,Ph1 Dose Esc/Exp,I,Reported,Multiple cancer,Oncology,Early Oncology,Non-Registry,,,,,,120,31,40,,9,,12,25.83%,7,,,PRA,,"Lorraine Mehltretter, Katie Kinney",,,,,,,,,,,,Medidata CTMS (Pharma),,,10/6/2017,10/6/2017,11/16/2017,11/16/2017,,,,,5/7/2018,5/7/2018,,,12/3/2019,12/3/2019,4/3/2020,4/3/2020,2/23/2020,2/23/2020,,,,,,,,,,,11/6/2020,,,,,,,,,,,,11/12/2020,,,,,,,,,,,,12/4/2020,,,,,,,,,,4/22/2021,,,,,,,,,,,,,,,,9/3/2021,,,,,,,
1-1MLRR6,TBD-1-1MLRR6,'TBD-1-1MLRR6,,TAK-671,P2 AP POC Trial Place holder (TAK-671),Phase 2a AP All-Comers EPOC (N=140),II,Planned,,GI,Late GI,,,,,,,160,,,,,,,,69,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/12/2020,,12/10/2020,,,,8/22/2021,,8/22/2021,,,,6/24/2022,,8/15/2022,,,,,,,,,,,,,,9/26/2022,,,,,,,,,,10/3/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/19/2022,,,,,,,,12/19/2022,,,,,,,
1-1MLRRP,TBD-1-1MLRRP,'TBD-1-1MLRRP,,TAK-671,P3 AP Trial Placeholder (TAK-671),Phase 3 Pivotal (N=500),III,Planned,,GI,,,,,,,,500,,,,,,,,88,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/17/2022,,4/10/2023,,,,1/7/2024,,2/2/2024,,,,1/17/2027,,3/3/2027,,,,,,,,,,,,,,4/28/2027,,,,,,,,,,5/5/2027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/8/2027,,,,,,,,11/8/2027,,,,,,,
1-1MYTTL,TBD-1-1MYTTL,'TBD-1-1MYTTL,,TAK-671,TAK-671-SRD,SRD,I,Planned,,GI,,,,,,,,48,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/23/2017,11/23/2017,3/29/2018,3/29/2018,,,8/30/2018,8/30/2018,9/18/2018,9/18/2018,,,2/5/2020,2/5/2020,,,4/16/2020,4/16/2020,,,,,,,,,,,6/16/2020,6/16/2020,,,,,,,,,8/6/2020,8/6/2020,,,,,,,,,,,,,8/6/2020,8/6/2020,,,,,,,,,,,,,,,,,10/30/2020,10/30/2020,5/29/2019,5/29/2019,,,,,10/30/2020,10/30/2020,,,,,,
1-1MYTTX,TBD-1-1MYTTX,'TBD-1-1MYTTX,,,TAK-671-MRD,MRD TAK-671,I,Planned,,,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MYTU8,TBD-1-1MYTU8,'TBD-1-1MYTU8,,,P2 ERCP POC Trial Placeholder(TAK-671),POC TAK-671,II,Planned,,,,,,,,,,80,,,,,,,,5,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1MZ2O7,TAK-935-2001,'TAK-935-2001,,soticlestat (TAK-935),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Phase to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies",TAK-935 POM Study (Takeda Study),IIA,Closed,Other,NS,,,,Other Phase 2,,,,18,18,26,,8,,4,100.00%,10,,,PRA,Aparna Sawant,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,10/17/2016,10/17/2016,4/5/2017,4/5/2017,,,6/13/2017,6/13/2017,8/17/2017,8/17/2017,,,6/14/2018,6/14/2018,,,10/12/2018,10/12/2018,,,,,,,,,,,11/2/2018,11/2/2018,,,,,,,,,11/12/2018,11/12/2018,,,,,,,,,,,,,11/20/2018,11/20/2018,,,,,,,,,7/3/2019,7/3/2019,,,,,,,,,,,,,,,7/3/2019,7/3/2019,,,,,,
1-1N4I5Z,TBD-1-1N4I5Z,'TBD-1-1N4I5Z,,TAK-418,CNS target engagement study,CNS target engagement study,I,Cancelled,Other,NS,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1N4I7E,TBD-1-1N4I7E,'TBD-1-1N4I7E,,TAK-418,CNS target engagement biomarkers,CNS target engagement biomarkers,I,Cancelled,Other,NS,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1OTV0B,TAK-828-1006,'TAK-828-1006,,TAK-828,"A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Doses of TAK 828 in Patients with Psoriasis",Proof of mechanism study in psoriasis patients,I,Terminated,00187 Psoriasis,GI,,,,,,,,90,0,0,,0,,0,0.00%,2,,,PPD,Hafizur Choudhury,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1P9TDT,TBD-1-1P9TDT,'TBD-1-1P9TDT,,soticlestat (TAK-935),"Assessment and validation of Plasma Biomarker, 24 Hydroxycholesterol (24 HC), in Epilepsy Syndromes in Children and Adults","Assessment and Validation of Plasma Biomarker, 24",0,Terminated,,NS,,,,,,,,100,,,,,,,,3,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/22/2019,1/22/2019,3/26/2019,3/26/2019,,,6/25/2019,6/25/2019,6/25/2019,6/25/2019,,,12/17/2019,12/17/2019,,,12/25/2019,12/25/2019,,,,,,,,,,,2/19/2020,2/19/2020,,,,,,,,,3/4/2020,3/4/2020,,,,,,,,,,,,,,,,,,,,,,,4/28/2021,4/28/2021,,,,,,,,,,,,,,,4/28/2021,4/28/2021,,,,,,
1-1S6QUZ,TAK-041-2001,'TAK-041-2001,,TAK-041,"A randomized, double-blind, placebo-controlled, three-period cross-over study to evaluate the effects of add-on TAK-041 on motivation and reward in stable patients with Schizophrenia.",TAK-041 Proof of Mechanism Study,II,All Activities Closed,(MDD) Major depressive disorder,NS,Early NS,,,,,,,23,24,86,,62,86,4,104.35%,1,1,,PRA,,"Charlotte Nicklin, Rhett Behrje",,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,3/13/2017,3/13/2017,4/26/2017,4/26/2017,,,3/9/2018,3/9/2018,3/15/2018,3/15/2018,,,8/2/2019,8/2/2019,,,11/8/2019,11/8/2019,,,,,,,,,,,12/12/2019,12/12/2019,,,,,,,,,,,,,,,,,,,,,,,2/14/2020,2/14/2020,,,,,,,,,4/30/2020,4/30/2020,,,,,,,,,,,,,,,4/30/2020,4/30/2020,,,,,,
1-1S6R09,TAK-233-1501,'TAK-233-1501,,,"A randomized, double-blind, single-dose, placebo-controlled, 2-way cross-over phase 1 study to assess the effect of TAK-233 on anorectal function in female healthy volunteers",TAK-233 FI POM,IB,Terminated,00348 Fecal Incontinence,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,Matthew Brown,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1SEYTZ,TBD-1-1SEYTZ,'TBD-1-1SEYTZ,,,Phase 1/2 Renal VEGF Combo  (160pts) BUYUP,Phase 1/2 Renal VEGF Combo,II,Cancelled,Solid.GU.Renal Cell Carcinoma,,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1SJZJJ,TBD-1-1SJZJJ,'TBD-1-1SJZJJ,,sapanisertib,Ph 2 Roll Over Study,Ph 2 Roll Over Study,II,Cancelled,00032 Solid tumor,Oncology,,,,,,,,250,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1TM8YR,Vedolizumab-1019,'Vedolizumab-1019,,Entyvio,PK Study_2nd gen cell line (Vedolizumab),Vedolizumab-1019 MLN0002 - Liquid,I,Completed,Delay the onset of MCI due to Alzheimer's disease,GI,Late GI,,,,,,,190,190,375,,0,0,0,100.00%,1,,,Celerion,,Katie Savage,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,4/17/2019,4/17/2019,10/4/2019,10/4/2019,,,12/2/2019,12/2/2019,12/5/2019,12/5/2019,,,2/18/2020,2/18/2020,,,7/6/2020,7/6/2020,,,,,,,,,,,10/9/2020,10/9/2020,,,,,,,,,10/22/2020,10/22/2020,,,,,,,,,,,,,9/15/2020,9/15/2020,,,,,,,,,4/2/2021,4/2/2021,,,,,,,,,,,,,,,4/2/2021,4/2/2021,,,,,,
1-1UH6R3,TBD-1-1UH6R3,'TBD-1-1UH6R3,,,P2 Open Label extension study to determine long term safety and efficacy of Vedolizumab in peds patients with UC and CD,Vedo peds extension study MLN002,II,Planned,,,,,,,,,,40,,,,,,,,62,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1VADHT,TBD-1-1VADHT,'TBD-1-1VADHT,,sapanisertib,Phase 3 Pivotal mBC ER/PR + Fulvestrant Pre CDK4/6,Phase 3 Pivotal mBC ER/PR + Fulvestrant,III,Cancelled,00056 (BC) Breast cancer,Oncology,,,,,,,,800,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1VADI4,TBD-1-1VADI4,'TBD-1-1VADI4,,sapanisertib,Phase 3 Renal VEGF Combo,Ph 3 Renal VEGF Combo,III,Cancelled,00037 (RCC) Renal cell cancer,Oncology,,,,,,,,600,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1VRDYF,Vedolizumab-2005,'Vedolizumab-2005,,Entyvio,"A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease",Vedo peds extension study,II,Recruitment Complete,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,Late GI,,,,,,,55,59,,,,,21,107.27%,55,24,,PRA,,Jennifer Gillespie,,"Jeffrey Bornstein, William Treem",,2017-002182-21,,,,,NA,Advance,,Medidata CTMS (Pharma),,,8/8/2014,8/8/2014,10/17/2016,10/17/2016,,,7/30/2018,7/30/2018,7/30/2018,7/30/2018,,,5/26/2020,5/26/2020,,,5/26/2025,,,,,,,,,,,,7/22/2025,,,,,,,,,,8/30/2025,,,,,,,,,,,,,,7/29/2025,,,,,,,,,,11/24/2025,,,,,,,,,,,,,,,,11/24/2025,,,,,,,
1-1VZYMN,TAK-954-1005,'TAK-954-1005,,TAK-954,NHV ADME Study,ADME NHV,I,Closed,Other,GI,,,,ADME,,,,6,6,11,,1,6,1,100.00%,1,,,PRA,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,12/13/2017,12/13/2017,3/15/2018,3/15/2018,,,4/27/2018,4/27/2018,5/18/2018,5/18/2018,,,5/18/2018,5/18/2018,,,6/1/2018,6/1/2018,,,,,,,,,,,11/8/2018,11/8/2018,,,,,,,,,12/19/2018,12/19/2018,,,,,,,,,,,,,12/19/2018,12/19/2018,,,,,,,,,8/5/2019,8/5/2019,,,,,,,,,,,,,,,8/5/2019,8/5/2019,,,,,,
1-1VZYNQ,TAK-954-1004,'TAK-954-1004,,TAK-954,"A Fixed Sequence, Open-Label, 2-Period Crossover Trial to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK-954 in Healthy Adult Subjects",CYP3A4 Inhibitor DDI,I,Closed,Other,GI,,,,DI High Complexity,,,,11,10,27,,8,,,90.91%,1,,,PRA,Hafizur Choudhury,,,,,2017-000713-22,,,,,Wave 2,De-Risk,,STARS Inactive,,,12/10/2016,12/10/2016,5/3/2017,5/3/2017,,,6/27/2017,6/27/2017,6/27/2017,6/27/2017,,,6/27/2017,6/27/2017,,,7/24/2017,7/24/2017,,,,,,,,,,,8/28/2017,8/28/2017,,,,,,,,,9/12/2017,9/12/2017,,,,,,,,,,,,,10/9/2017,10/9/2017,,,,,,,,,3/6/2018,3/6/2018,,,,,,,,,,,,,,,3/6/2018,3/6/2018,,,,,,
1-1VZYO4,TBD-1-1VZYO4,'TBD-1-1VZYO4,,TAK-954,Ph3_study #2,3.2 Ph3 Pivotal #2,III,Planned,(POI) Post-Operative Ileus,GI,,,,,,,,600,,,,,,,,100,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,10/17/2022,,10/17/2022,,,,1/9/2023,,1/27/2023,,,,9/6/2024,,,,9/27/2024,,,,,,,,,,,,11/22/2024,,,,,,,,,,11/29/2024,,,,,,,,,,,,,,12/19/2024,,,,,,,,,,3/14/2025,,,,,,,,,,,,,,,,3/14/2025,,,,,,,
1-1VZYOB,TAK-954-1008,'TAK-954-1008,,TAK-954,"A 2-Part, Placebo and Active-Controlled, Randomized Trial to Investigate the Safety and
Pharmacokinetics of Intravenous TAK 954 and to Investigate its Potential for QTc Interval Prolongation in Healthy Adult Subjects",QTc study,I,Cancelled,Elderly non-depressed with mild cognitive impairement,GI,Early GI,,,,,,,36,,,,,,,,1,,,Celerion,,Annette Stevenson,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,4/16/2019,4/16/2019,8/1/2019,8/1/2019,,,5/24/2021,,6/14/2021,,,,9/6/2021,,,,9/20/2021,,,,,,,,,,,,10/18/2021,,,,,,,,,,11/22/2021,,,,,,,,,,,,,,12/13/2021,,,,,,,,,,3/14/2022,,,,,,,,,,,,,,,,3/14/2022,,,,,,,
1-1VZYOK,TAK-954-1007,'TAK-954-1007,,TAK-954,"An Open-Label, Parallel Group Study to Evaluate the Effect of Renal Impairment and dialysis treatment on the Pharmacokinetics (PK) of TAK-954 following a single intravenous dose of TAK-954.",Renal Impairment TAK-954,I,All Activities Closed,(POI) Post-Operative Ileus,GI,Early GI,,,,,,,32,32,55,,22,,1,100.00%,4,4,,PRA,,James Hazel,,Jason Homsy,,2017-000715-16,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/1/2017,6/1/2017,6/29/2017,6/29/2017,,,11/20/2017,11/20/2017,12/1/2017,12/1/2017,,,7/30/2019,7/30/2019,,,8/12/2019,8/12/2019,,,,,,,,,,,9/6/2019,9/6/2019,,,,,,,,,12/4/2019,12/4/2019,,,,,,,,,,,,,1/24/2020,1/24/2020,,,,,,,,,9/25/2020,9/25/2020,,,,,,,,,,,,,,,9/25/2020,9/25/2020,,,,,,
1-1VZYOT,TAK-954-1006,'TAK-954-1006,,TAK-954,"A Phase 1 Non-Randomized, Open-Label Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954",Hepatic Impairment,I,Closed,Other,GI,,,,Hepatic Impairment,,,,24,25,34,,9,,2,104.17%,2,2,,PRA,,,,,,2017-000714-37,,,,,Wave 2,De-Risk,,STARS Inactive,,,4/17/2017,4/17/2017,5/26/2017,5/26/2017,,,11/9/2017,11/9/2017,12/12/2017,12/12/2017,,,8/28/2018,8/28/2018,,,9/10/2018,9/10/2018,,,,,,,,,,,10/15/2018,10/15/2018,,,,,,,,,2/22/2019,2/22/2019,,,,,,,,,,,,,2/22/2019,2/22/2019,,,,,,,,,5/28/2019,5/28/2019,,,,,,,,,,,,,,,9/9/2019,9/9/2019,,,,,,
1-1VZYOX,TBD-1-1VZYOX,'TBD-1-1VZYOX,,TAK-954,Ph3_study #1,3.1 Ph3 Pivotal #1,III,Planned,(POI) Post-Operative Ileus,GI,,,,,,,,600,,,,,,,,100,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,10/17/2022,,,,1/9/2023,,1/27/2023,,,,9/6/2024,,,,9/27/2024,,,,,,,,,,,,11/22/2024,,,,,,,,,,11/29/2024,,,,,,,,,,,,,,12/19/2024,,,,,,,,,,3/14/2025,,,,,,,,,,,,,,,,3/14/2025,,,,,,,
1-1W19RS,TBD-1-1W19RS,'TBD-1-1W19RS,,TAK-954,Ph1 Japan PK,Phase 1 Japan PK,I,Planned,(POI) Post-Operative Ileus,GI,,,,,,,,36,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,1/10/2025,,3/14/2025,,,,,,5/30/2025,,,,7/18/2025,,,,8/14/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/12/2026,,,,,,,,,,,,,,,,2/12/2026,,,,,,,
1-1W19RW,TAK-954-2002,'TAK-954-2002,,TAK-954,"A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance",Phase 2b ICU EFI study,IIb,Terminated,"DU,GU,GERD",GI,,,,,,,,200,1,3,,2,,1,0.50%,40,,,PRA,,Rudi Taljaard,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/20/2017,11/20/2017,1/19/2018,1/19/2018,,,8/25/2018,8/25/2018,8/25/2018,8/25/2018,,,8/25/2018,8/25/2018,,,8/29/2018,8/29/2018,,,,,,,,,,,2/1/2019,2/1/2019,,,,,,,,,12/20/2019,12/20/2019,,,,,,,,,,,,,12/20/2019,12/20/2019,,,,,,,,,7/9/2019,7/9/2019,,,,,,,,,,,,,,,,,,,,,,
1-1W19SB,TBD-1-1W19SB,'TBD-1-1W19SB,,TAK-954,Ph1 Age & Gender study,Phase 1.7 DDI: CYP/ Transporter inhibitor II (plac,I,Planned,(POI) Post-Operative Ileus,GI,,,,,,,,24,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/28/2022,,9/29/2022,,,,12/30/2022,,1/27/2023,,,,1/27/2023,,,,3/15/2023,,,,,,,,,,,,4/12/2023,,,,,,,,,,4/19/2023,,,,,,,,,,,,,,5/9/2023,,,,,,,,,,8/2/2023,,,,,,,,,,,,,,,,8/2/2023,,,,,,,
1-1W19SP,TBD-1-1W19SP,'TBD-1-1W19SP,,TAK-954,Mechanism-based DDI,Mechanism based DDI,I,Planned,(POI) Post-Operative Ileus,GI,,,,,,,,24,,,,,,,,1,,,Celerion,,,,Oluwakemi Bankole,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/5/2022,,10/7/2022,,,,1/27/2023,,2/24/2023,,,,2/24/2023,,,,3/20/2023,,,,,,,,,,,,4/17/2023,,,,,,,,,,4/24/2023,,,,,,,,,,,,,,5/12/2023,,,,,,,,,,8/7/2023,,,,,,,,,,,,,,,,8/7/2023,,,,,,,
1-1W19SY,TBD-1-1W19SY,'TBD-1-1W19SY,,TAK-954,DDI_3,Phase 1.10 DDI: Interaction with SOC drugs (placeh,I,Planned,(POI) Post-Operative Ileus,GI,,,,,,,,48,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/5/2022,,10/7/2022,,,,1/27/2023,,2/24/2023,,,,2/24/2023,,,,3/10/2023,,,,,,,,,,,,3/20/2023,,,,,,,,,,3/27/2023,,,,,,,,,,,,,,4/14/2023,,,,,,,,,,7/10/2023,,,,,,,,,,,,,,,,7/10/2023,,,,,,,
1-1WDABJ,Dup- Pevonedistat-3001,'Dup- Pevonedistat-3001,,,"A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia",,III,Cancelled,Other,,,,,,,,,450,0,0,,0,,0,0.00%,1,,,,Jacqueline Roy Hazel,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1WDAE1,Vedolizumab-2006,'Vedolizumab-2006,,Entyvio,"Vedolizumab-2006: A Randomized, Open Label Phase 2 Study to Assess Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Exploratory Efficacy of Vedolizumab Process C compared to Process D  in Subjects with Moderately to Severely Active Ulcerative Colitis",6-Month Clinical Immunogenicity Study,II,Planned,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,,,,,,,,160,,,,,,,,100,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,2/21/2023,,,,,,6/14/2023,,,,8/19/2024,,,,2/17/2025,,,,,,,,,,,,4/14/2025,,,,,,,,,,5/5/2025,,,,,,,,,,,,,,6/9/2025,,,,,,,,,,11/13/2025,,,,,,,,,,,,,,,,11/13/2025,,,,,,,
1-1X3FHR,TBD-1-1X3FHR,'TBD-1-1X3FHR,,TAK-202,Phase 2/3 PD-1 Combo Pivotal,Ph 2/3 PD-1 Combo Pivotal,III,Planned,Metastatic Melanoma,Oncology,,,,,,,,600,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1X3FRR,TAK-831-2001,'TAK-831-2001,,TAK-831,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects,  Safety, Tolerability and Pharmacokinetics of Multiple Doses of  Oral TAK-831 in Adult Patients with Schizophrenia",POM SCH (Biomarker),II,Completed,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Early NS,,,,,,,40,31,52,,21,31,6,77.50%,3,2,,PRA,,"Rhett Behrje, Nancy Goodman",,"John Dunlop, Nick Demartinis",,2017-001739-38,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,3/21/2017,3/21/2017,5/3/2017,5/3/2017,,,1/4/2018,1/4/2018,3/20/2018,3/20/2018,,,11/11/2020,11/11/2020,,,12/21/2020,12/21/2020,,,,,,,,,,,2/15/2021,2/15/2021,,,,,,,,,3/2/2021,3/2/2021,,,,,,,,,,,,,4/13/2021,4/13/2021,,,,,,,,,6/21/2021,6/21/2021,,,,,,,,,,,,,,,6/21/2021,6/21/2021,,,,,,
1-1Y6NED,Alofisel-4001,'Alofisel-4001,,Alofisel,Post-Authorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula,Postauthorization Safety Study of Darvadstrocel Re,IV,Recruiting,Disease-modifying in epilepsy,GI,Late GI,,Non-pediatric only (>18 yr),Interventional,Treatment,,Other,50,3,4,,2,,,6.00%,29,,,Parexel,,Beth Hudgins,,,,2017-002491-10,,,,,NA,Advance,,Medidata CTMS (Pharma),,,6/29/2018,6/29/2018,7/3/2020,7/3/2020,,,12/22/2020,12/22/2020,3/3/2021,3/3/2021,,,2/28/2023,,,,2/26/2026,,,,,,,,,,,,4/23/2026,,,,,,,,,,4/30/2026,,,,,,,,,,,,,,5/21/2026,,,,,,,,,,8/13/2026,,,,,,,,,,,,,,,,4/22/2027,,,,,,,
1-1Y6NEO,Darvadstrocel-3003,'Darvadstrocel-3003,,Alofisel,Darvadstrocel Long-term Extension of ADMIRE II,Long-term Follow-up Study to ADMIRE-CD II,III,Recruiting,Disease-modifying in epilepsy,GI,Late GI,Non-Registry,,Interventional,,,,150,107,107,,,,5,71.33%,110,,,Parexel,,Manuel Luque,,,,2019-000333-39,,,,,NA,Advance,,Medidata CTMS (Pharma),,,7/19/2018,7/19/2018,3/30/2019,3/30/2019,,,9/16/2019,9/16/2019,11/4/2019,11/4/2019,,,2/18/2022,,,,2/16/2024,,,,,,,,,,,,4/15/2024,,,,,,,,,,4/22/2024,,,,,,,,,,,,,,5/13/2024,,,,,,,,,,8/10/2024,,,,,,,,,,,,,,,,2/14/2025,,,,,,,
1-1Y6NEZ,Cx611-0204,'Cx611-0204,,Alofisel,SEPCELL,SEPCELL,I/II,Completed,Disease-modifying in epilepsy,GI,Late GI,,Non-pediatric only (>18 yr),,Supportive Care,Prospective,Cohort,80,84,90,,6,,,105.00%,27,,,TFS,,Jennifer Boynton,,,,2015-002994-39,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,1/31/2017,1/31/2017,1/31/2017,1/31/2017,,,1/31/2017,1/31/2017,1/31/2017,1/31/2017,,,12/17/2019,12/17/2019,,,7/31/2020,7/31/2020,,,,,,,12/14/2021,,,,10/15/2020,10/15/2020,,,,,,,2/8/2022,,10/28/2020,10/28/2020,,,,,,,2/22/2022,,,,,,12/3/2020,12/3/2020,,,,,,,4/19/2022,,6/30/2021,6/30/2021,,,,,,,6/21/2022,,,,,,,,6/21/2022,,,,,,,
1-1Y6NF8,Cx601-0303,'Cx601-0303,,Alofisel,ADMIRE 2,ADMIRE 2,III,Recruiting,Disease-modifying in epilepsy,GI,Late GI,Non-Registry,,Interventional,,,,554,407,606,,190,,36,73.47%,140,,,Parexel,,Manuel Luque,,,,2017-000725-12,,,,,NA,Advance,TAU Choice,Medidata CTMS (Pharma),,,2/17/2017,2/17/2017,4/28/2017,4/28/2017,,,8/30/2017,8/30/2017,11/30/2017,11/30/2017,,,2/28/2022,,,,8/15/2022,,,,,,,,2/27/2023,,,,10/20/2022,,,,,,,,4/26/2023,,11/1/2022,,,,,,,,5/8/2023,,,,,,11/21/2022,,,,,,,,5/26/2023,,2/17/2023,,,,,,,,8/24/2023,,,,,,,,2/26/2024,,,,,,,
1-1YQUIR,C34008,'C34008,,TAK-659,Phase 1b Venetoclax Combo NHL (56 pts,C34008 Phase 1b Venetoclax Combo NHL (56 pts),Ib,Recruitment Complete,(NHL) Non-Hodgkin's lymphoma,Oncology,Early Oncology,,,,,,,53,43,62,,19,,42,81.13%,20,2,,PRA,,"Sarah Noah, Michelle Thompson",,,,,,,,,,,,Medidata CTMS (Pharma),,,4/13/2017,4/13/2017,8/30/2017,8/30/2017,,,,,3/2/2018,3/2/2018,,,9/30/2019,9/30/2019,9/19/2021,,9/19/2021,,,,,,,,,,,,10/26/2021,,,,,,,,,,,,,,,,,,,,,,,,11/24/2021,,,,,,,,,,4/6/2022,,,,,,,,10/5/2022,,,,,,,,10/14/2022,,,,,,,
1-1ZTG51,TAK-906-1002,'TAK-906-1002,,TAK-906,"A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled  Trial to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Subjects with Diabetes Mellitus with Gastroparesis (DG) or Idiopathic Gastroparesis (IG)",Phase 2a PK/PD DG&IG,IIA,Closed,Solid.Other,GI,,,,,,,,48,51,76,,25,,3,106.25%,9,,,PRA,Deborah Keeter,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,12/13/2016,12/13/2016,5/24/2017,5/24/2017,,,9/25/2017,9/25/2017,10/4/2017,10/4/2017,,,2/20/2018,2/20/2018,,,3/11/2018,3/11/2018,,,,,,,,,,,7/19/2018,7/19/2018,,,,,,,,,8/1/2018,8/1/2018,,,,,,,,,,,,,8/31/2018,8/31/2018,,,,,,,,,1/4/2019,1/4/2019,,,,,,,,,,,,,,,1/4/2019,,,,,,,
1-2A2A6L,TBD-1-2A2A6L,'TBD-1-2A2A6L,,,Phase 1b MBC 522+Herceptin+Perjeta,Ph1b MBC 522+Herceptin+Perjeta,IB,Cancelled,Other,,,,,,,,,30,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2A2A6W,TBD-1-2A2A6W,'TBD-1-2A2A6W,,,Phase 3 MBC Pivotal vs Taxane,Ph3 MBC Pivotal vs Taxane,III,Cancelled,Other,,,,,,,,,520,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2A2A7E,TBD-1-2A2A7E,'TBD-1-2A2A7E,,,Phase 1b NSCLC 522+P (40 pts),Ph1b NSCLC 522+P (40 pts),IIB,Cancelled,Other,,,,,,,,,40,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2A2A7N,TBD-1-2A2A7N,'TBD-1-2A2A7N,,,Phase 2 NSCLC Gaiting 522 vs P Doublet,Ph2 NSCLC Gaiting 522 vs P Doublet,II,Cancelled,Other,,,,,,,,,90,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2A2A75,TBD-1-2A2A75,'TBD-1-2A2A75,,,Phase 2/3 NSCLC Pivotal vs P Doublet - 3 Arms,Ph2/3 NSCLC Pivotal vs P Doublet,III,Cancelled,Other,,,,,,,,,"1,308",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2A2AAR,TBD-1-2A2AAR,'TBD-1-2A2AAR,,,Phase 2/3 Gastric Pivotal Her2HIGH 522 vs SA cytotoxic,Ph2/3 Gastric Her2HIGH 522 vs SA cytotoxic,III,Cancelled,Other,,,,,,,,,250,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2A2AC6,TBD-1-2A2AC6,'TBD-1-2A2AC6,,,Phase 2/3 Gastric Pivotal Her2LOW 522 vs SA cytotoxic,Ph2/3 Gastric Her2LOW 522 vs SA cytotoxic,III,Cancelled,Other,,,,,,,,,670,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2DAR45,TAK-653-1002,'TAK-653-1002,,TAK-653,"A randomized, double blind, placebo controlled, four-period cross-over study to evaluate the effects of TAK-653 on attenuating cognitive, EEGc, and MRI changes induced by ketamine administration in healthy male volunteers",MRI Cognition after Ketamine,I,Withdrawn,(TRD) Treatment Resistance to Depression,NS,,,,,,,,36,,,,,,,,1,,,PRA,,,,Rolando Gutierrez-Esteinou,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2DYWC1,TBD-1-2DYWC1,'TBD-1-2DYWC1,,,"A Phase 1 Drug-Drug Interaction Study between Brigatinib and the CYP3A Substrate, Midazolam, in Patients with ALK-Positive or ROS1-Positive Solid Tumors",TBD-1-2DYWC1 Brigatinib,I,Planned,,,,,,,,,,20,,,,,,,,3,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2FHCAF,TAK-079-1501,'TAK-079-1501,,Mezagitamab (TAK-079),"A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma",Phase 1/2a MM CLL,I/II,Recruitment Complete,Lower back pain,RGH,Others,,,Interventional,,,,52,51,66,,15,,44,98.08%,9,7,,PPD,,Rachel McComb,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/1/2017,,10/12/2017,10/12/2017,,,,,5/8/2018,5/8/2018,,,2/28/2021,,9/27/2021,,12/30/2021,,,,,,,,,,,,12/27/2022,,,,,,,,,,1/25/2023,,,,,,,,,,,,,,1/25/2023,,,,,,,,,,4/30/2023,,,,,,,,,,,,,,,,4/30/2023,,,,,,,
1-2GG2AA,TAK-925-1002,'TAK-925-1002,,TAK-925,"A Phase 1b, 4-Period Crossover, Placebo-Controlled, Randomized, Single Dose Study to
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in
Sleep-Deprived Healthy Adults Utilizing Modafinil as an Active Comparator",TAK-925 NHV Sleep Deprived,IB,Closed,Other,NS,,,,,,,,20,20,77,,57,20,2,100.00%,1,,,PRA,,,,,,,,,,,Wave 1,Accelerate,,STARS Inactive,,,1/31/2018,1/31/2018,3/8/2018,3/8/2018,,,5/4/2018,5/4/2018,5/30/2018,5/30/2018,,,9/18/2018,9/18/2018,,,11/7/2018,11/7/2018,,,,,,,,,,,12/11/2018,12/11/2018,,,,,,,,,12/21/2018,12/21/2018,,,,,,,,,,,,,1/24/2019,1/24/2019,,,,,,,,,4/24/2019,4/24/2019,,,,,,,,,,,,,,,11/5/2019,11/5/2019,,,,,,
1-2H721I,Brigatinib-2002,'Brigatinib-2002,,Alunbrig,"Brigatinib in Patients with Anaplastic Lymphoma Kinase (ALK)-positive, Advanced Non-small Cell Lung Cancer (NSCLC) progressed with Alectinib or Ceritinib)",Brigatinib-2002,II,Recruitment Complete,Hemostasis and tissue sealing in GI Anastomosis,Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,,,,103,104,123,,19,,103,100.97%,89,61,,TBD,,"Kate Danis, Brittany Demers",,,,2018-000635-27,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,10/6/2018,10/6/2018,,,,,2/12/2019,2/12/2019,,,12/30/2019,12/30/2019,4/30/2021,,9/30/2020,9/30/2020,5/13/2021,,,,,,10/30/2022,,,,11/26/2020,11/26/2020,7/1/2021,,,,,,12/30/2022,,12/1/2020,12/1/2020,7/7/2021,,,,,,1/7/2023,,,,,,12/24/2020,12/24/2020,7/28/2021,,,,,,1/27/2023,,6/2/2021,,11/3/2021,,,,,,5/3/2023,,,,,,,,5/3/2023,,,,,,,
1-2H721R,TAK-418-1003,'TAK-418-1003,,TAK-418,"TAK-418 ,MRD",TAK-418 MRD,I,Closed,Other,NS,,,,MRD,,,,48,24,,,,,,50.00%,2,,,PRA,,,,,,,,,,,,,,STARS Inactive,,,2/5/2018,2/5/2018,3/23/2018,3/23/2018,,,5/28/2018,5/28/2018,7/10/2018,7/10/2018,,,,,,,1/18/2019,1/18/2019,,,,,,,,,,,2/12/2019,2/12/2019,,,,,,,,,3/1/2019,3/1/2019,,,,,,,,,,,,,3/25/2019,3/25/2019,,,,,,,,,7/30/2019,7/30/2019,,,,,,,,,,,,,,,7/30/2019,7/30/2019,,,,,,
1-2H7217,Brigatinib-3001,'Brigatinib-3001,,Alunbrig,A Phase 3 randomized study of brigatinib vs. alectinib in advanced ALK+ NSCLC patients previously treated with crizotinib,Piv H2H Alectinib Post Crizotinib,III,Recruiting,(NSCLC) Non-small cell lung cancer,Oncology,Late Oncology,,,,,,,246,255,315,,60,255,89,103.66%,120,112,,PRA,,Kate Danis,,,,2018-001957-29,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,5/15/2018,5/15/2018,,,,,5/7/2019,5/7/2019,,,6/16/2021,,8/10/2022,,3/29/2022,,3/15/2023,,,,,,6/15/2023,,,,5/28/2022,,5/15/2023,,,,,,8/16/2023,,6/1/2022,,5/20/2023,,,,,,8/22/2023,,,,,,6/29/2022,,6/14/2023,,,,,,9/15/2023,,9/10/2022,,8/29/2023,,,,,,11/20/2023,,,,,,,,11/20/2023,,,,,,,
1-2IFHJV,VedolizumabSC-1021,'VedolizumabSC-1021,,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Pilot Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects",Vedolizumab SC AI BE Pilot,I,Closed,00020 (UC) Ulcerative colitis,GI,,,,,,,,24,24,58,,34,,,100.00%,2,,,Celerion,,,,,,,,,,,,,,STARS Inactive,,,,,12/18/2017,12/18/2017,,,2/22/2018,2/22/2018,3/10/2018,3/10/2018,,,3/10/2018,3/10/2018,,,8/24/2018,8/24/2018,,,,,,,,,,,10/5/2018,10/5/2018,,,,,,,,,,,,,,,,,,,,,,,10/17/2018,10/17/2018,,,,,,,,,11/27/2018,11/27/2018,,,,,,,,,,,,,,,11/27/2018,11/27/2018,,,,,,
1-2IFHK7,VedolizumabSC-1022,'VedolizumabSC-1022,,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects",Vedolizumab SC AI BE Study,I,Closed,00020 (UC) Ulcerative colitis,GI,,,,Interventional,,,,204,204,369,,165,,3,100.00%,2,,,Celerion,,,,,,,,,,,,,,STARS Inactive,,,,,12/18/2017,12/18/2017,,,3/12/2018,3/12/2018,3/24/2018,3/24/2018,,,6/10/2018,6/10/2018,,,11/21/2018,11/21/2018,,,,,,,,,,,12/11/2018,12/11/2018,,,,,,,,,,,,,,,,,,,,,,,12/21/2018,12/21/2018,,,,,,,,,2/1/2019,2/1/2019,,,,,,,,,,,,,,,2/1/2019,2/1/2019,,,,,,
1-2J1GSP,TAK-788-1001,'TAK-788-1001,,Mobocertinib (TAK-788),Ph1 SRD NHV/Pilot Food Effect,Ph1 SRD NHV/Food Effect,I,All Activities Closed,Support - Oncology,Oncology,Late Oncology,,,,,,,68,68,161,,97,,,100.00%,1,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/5/2017,12/5/2017,2/8/2018,2/8/2018,,,3/28/2018,3/28/2018,4/18/2018,4/18/2018,,,12/12/2018,12/12/2018,1/18/2019,1/18/2019,1/18/2019,1/18/2019,,,,,,,,,,,5/22/2019,5/22/2019,,,,,,,,,6/19/2019,6/19/2019,,,,,,,,,,,,,6/19/2019,6/19/2019,,,,,,,,,1/7/2020,1/7/2020,,,,,,,,,,,,,,,1/7/2020,1/7/2020,,,,,,
1-2J1GT0,TBD-1-2J1GT0,'TBD-1-2J1GT0,,,Phase 1 Prelim Food Effect,Ph1 Prelim Food Effect,I,Cancelled,Solid.Lung.NSCLC,,,,,,,,,20,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2J1GT9,TBD-1-2J1GT9,'TBD-1-2J1GT9,,,Ph2 HER2 exon 20ins Single Arm,Ph2 HER2 exon 20 Single Arm,II,Cancelled,Solid.Lung.NSCLC,,,,,,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2J1GTI,TBD-1-2J1GTI,'TBD-1-2J1GTI,,,Phase 3 HER2 exon20,Ph3 HER2 exon20,III,Cancelled,Solid.Lung.NSCLC,,,,,,,,,250,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2J1GTR,TBD-1-2J1GTR,'TBD-1-2J1GTR,,,Phase 2 EGFR/HER2 exon20 + Brain Mets,Ph2 EGFR/HER2 exon20+Brain Mets,II,Cancelled,Solid.Lung.NSCLC,,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2K0ADV,TBD-1-2K0ADV,'TBD-1-2K0ADV,,,Phase 3 randomized study of TAK-906 vs. Metoclopramide in Patients with Diabetic Gastroparesis,TAK-906 vs MTCL in DG pts,III,Cancelled,Other,,,,,,,,,"1,550",0,0,,0,,0,0.00%,200,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2K0AE6,Vedolizumab-4003,'Vedolizumab-4003,,Entyvio,Vedolizumab-4003 Fistulizing CD,ENTERPRISE:Fistulizing CD,IV,Not Yet Recruiting,,GI,Real World Evidence,,Non-pediatric only (>18 yr),Interventional,Treatment,,,100,,,,,,,,40,,,TBD,,Brittney Thompson,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,8/10/2016,8/10/2016,9/7/2016,9/7/2016,,,3/7/2018,3/7/2018,,,11/14/2018,11/14/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/14/2018,11/14/2018,,,,,,
1-2K0AEF,Vedolizumab-4004,'Vedolizumab-4004,,Entyvio,Vedolizumab-4004 Chronic Pouchitis,EARNEST-Chronic Pouchitis,IV,Reported,,GI,Real World Evidence,,Non-pediatric only (>18 yr),Interventional,Treatment,,,110,102,102,,,102,35,92.73%,40,,,Alimentiv,,Brittney Thompson,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,10/12/2016,10/12/2016,11/2/2016,11/2/2016,,,2/28/2019,,,,2/6/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/6/2020,,,,,,,
1-2K0AEO,Vedolizumab - EMERGE,'Vedolizumab - EMERGE,,,Vedolizumab - EMERGE Induction,EMERGE Induction,IV,Not Yet Recruiting,,,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2K0AEX,Vedolizumab-4013,'Vedolizumab-4013,,,Vedolizumab-4013 Extended Access Program in UC/CD,Entyvio - XAP,IIIb,Recruiting,,,Real World Evidence,,,,,,,335,338,,,,,86,100.90%,83,,,PPD,,"Brittney Thompson, Jeff Back",,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2LTMMZ,TBD-1-2LTMMZ,'TBD-1-2LTMMZ,,TAK-831,ADME Radiolabel,Radiolabeled AME,I,Cancelled,Schizophrenia,NS,,,,,,,,6,,,,,,,,1,,,Celerion,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2LTMNA,TBD-1-2LTMNA,'TBD-1-2LTMNA,,TAK-831,TQT,TQT TAK-831,I,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,40,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2LTMNJ,TBD-1-2LTMNJ,'TBD-1-2LTMNJ,,TAK-831,Renal Impairment,Renal Impairment TAK-831,I,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,32,,,,,,,,2,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2LTMNS,TBD-1-2LTMNS,'TBD-1-2LTMNS,,TAK-831,Hepatic Impairment,Hepatic Impairment TAK-831,I,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,48,,,,,,,,2,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2LTMO1,TBD-1-2LTMO1,'TBD-1-2LTMO1,,TAK-831,Asian Bridging PK in Japan,Asian Bridging PK in Japan,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2N9K5H,TAK-101-2001,'TAK-101-2001,,TAK-101,"Double-blind, randomized, placebo controlled, dose-ranging study in symptomatic patients on a gluten free diet",TIMP-Glia Ph 2b Dose Ranging related to PRO,IIb,Not Yet Recruiting,Celiac,GI,Gastroenterology,,,,,,,108,,,,,,,,34,14,,IQVIA,,Natalie Jones,,,,,,,,,Wave 2,Advance,TAU Choice,Medidata CTMS (Pharma),,,12/17/2019,12/17/2019,6/11/2020,6/11/2020,,,9/14/2022,,10/26/2022,,,,3/4/2024,,,,7/29/2024,,,,,,,,,,,,9/23/2024,,,,,,,,,,10/7/2024,,,,,,,,,,,,,,10/28/2024,,,,,,,,,,3/20/2025,,,,,,,,,,,,,,,,3/20/2025,,,,,,,
1-2N9K5S,TBD-1-2N9K5S,'TBD-1-2N9K5S,,TAK-101,"A randomized, double-blind, placebo-controlled dose-ranging investigations of efficacy and safety",TIMP-Glia Ph 3 Pivotal TBD-1-2N9K5S,III,Planned,Celiac,GI,Early GI,,,,,,,400,,,,,,,,100,,,TBD,,,,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,10/7/2024,,12/2/2024,,,,3/24/2025,,5/19/2025,,,,10/22/2026,,,,1/15/2026,,,,,,,,4/8/2027,,,,3/12/2026,,,,,,,,6/3/2027,,3/26/2026,,,,,,,,6/17/2027,,,,,,4/9/2026,,,,,,,,7/1/2027,,9/23/2027,,,,,,,,,,,,,,,,9/23/2027,,,,,,,
1-2N9K61,TBD-1-2N9K61,'TBD-1-2N9K61,,TAK-101,"A randomized, double-blind, placebo-controlled dose-ranging investigations of efficacy and safety",TIMP-Glia Ph 3 Pivotal TBD-1-2N9K61,III,Planned,Celiac,GI,,,,,,,,400,,,,,,,,100,,,TBD,,,,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,2/20/2026,,4/16/2026,,,,8/6/2026,,10/1/2026,,,,10/1/2027,,3/17/2028,,,,,,,,,,,,,,5/12/2028,,,,,,,,,,5/26/2028,,,,,,,,,,,,,,6/9/2028,,,,,,,,,,9/1/2028,,,,,,,,,,,,,,,,3/16/2029,,,,,,,
1-2NGAXM,TBD-1-2NGAXM,'TBD-1-2NGAXM,,TAK-062,A randomized double-blind placebo controlled ascending gluten dose study to evaluate Kuma062,Kuma062 Ph 2a Dose Ranging,IIA,Cancelled,Other,GI,,,,,,,,50,0,0,,0,,0,0.00%,10,,,,,,,,,,,,,,Wave 2,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2NGAXV,TAK-062-2001,'TAK-062-2001,,TAK-062,A randomized double-blind placebo control study to assess symptom improvement in Non-Responsive Celiac Disease with Kuma062,Kuma062 Ph 2b Dose Ranging,IIb,Planned,Diabetic Macular Edema (DME),GI,Late GI,,,Interventional,Treatment,,,350,,,,,,,,88,,,IQVIA,,"Lisa Oloughlin, Brian Sontag",,,,,,,,,Wave 2,Advance,TAU Choice,Medidata CTMS (Pharma),,,8/20/2019,8/20/2019,2/25/2022,,,,6/28/2022,,8/23/2022,,,,12/31/2024,,,,,,,,,,,,6/17/2025,,,,,,,,,,,,8/12/2025,,9/19/2023,,,,,,,,8/26/2025,,,,,,,,,,,,,,9/9/2025,,12/2/2025,,,,,,,,,,,,,,,,6/16/2026,,,,,,,
1-2NGAY4,TBD-1-2NGAY4,'TBD-1-2NGAY4,,TAK-062,"A randomized, double-blind, placebo controlled study to assess the change in Symptoms and Mucosal Morphometry in Celiac Patients on a Gluten-Free Diet",TBD-1-2NGAY4 Kuma062 Ph 3 Pivotal,III,Planned,Celiac,GI,,,,,,,,400,,,,,,,,100,,,TBD,,,,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,10/10/2025,,12/5/2025,,,,3/27/2026,,5/22/2026,,,,5/22/2027,,11/6/2027,,,,,,,,,,,,,,12/31/2027,,,,,,,,,,1/14/2028,,,,,,,,,,,,,,1/28/2028,,,,,,,,,,4/21/2028,,,,,,,,,,,,,,,,11/3/2028,,,,,,,
1-2NGAYD,TBD-1-2NGAYD,'TBD-1-2NGAYD,,TAK-062,"A randomized, double-blind, placebo controlled study to assess the change in Symptoms and Mucosal Morphometry in Celiac Patients on a Gluten-Free Diet",Kuma062 Ph 3 Pivotal Kuma062,III,Planned,Celiac,GI,,,,,,,,400,,,,,,,,100,,,TBD,,,,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,10/10/2025,,12/5/2025,,,,3/27/2026,,5/22/2026,,,,5/22/2027,,11/6/2027,,,,,,,,,,,,,,12/31/2027,,,,,,,,,,1/14/2028,,,,,,,,,,,,,,1/28/2028,,,,,,,,,,4/21/2028,,,,,,,,,,,,,,,,11/3/2028,,,,,,,
1-2NGAYV,Vonoprazan-3002,'Vonoprazan-3002,,vonoprazan,"A Randomized Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of bismuth-containing quadruple therapy with Oral TAK-438 20 mg Compared to Esomeprazole 20mg Twice-Daily in  Subjects With Helicobacter pylori Infection",China Registration; HP,III,Recruiting,Prophylaxis and Treatment of Gout Flares in adult,GI,Late GI,,,,Treatment,,,510,438,700,,251,439,12,85.88%,30,29,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,10/17/2017,10/17/2017,10/3/2018,10/3/2018,,,4/24/2020,4/24/2020,4/30/2020,4/30/2020,,,10/22/2021,,,,12/8/2021,,,,,,,,,,,,2/9/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/25/2022,,,,,,,,,,,,,,,,7/8/2022,,,,,,,
1-2OW4JS,Cancelled TAK-164-1001,'Cancelled TAK-164-1001,,,"An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients with Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C",,I,Cancelled,00018 (GC) Gastric cancer,,,,,,,,,95,0,0,,0,,0,0.00%,8,,,PRA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2PJ2CV,TBD-1-2PJ2CV,'TBD-1-2PJ2CV,,Alunbrig,Ph1b/2 Brig + MEK Combo in NSCLC,Ph1b/2 Brig + MEK Combo,II,Cancelled,Other,Oncology,,,,,,,,50,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2PJ2D6,TBD-1-2PJ2D6,'TBD-1-2PJ2D6,,Alunbrig,Ph2 1L ROS1+ NSCLC,Ph2 1L ROS1+,II,Cancelled,Other,Oncology,,,,,,,,50,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2PJ2DG,TBD-1-2PJ2DG,'TBD-1-2PJ2DG,,Alunbrig,Phase 2 non-ALK Indication,Phase 2 non-ALK Indication,II,Planned,(NSCLC) Non-small cell lung cancer,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2PJ2LB,TAK-079-2001,'TAK-079-2001,,Mezagitamab (TAK-079),"A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus",SLE,Ib,Recruiting,(SLE) Systemic lupus erythematosus,RGH,Others,,,,,,,16,22,58,,35,23,5,137.50%,20,19,,PPD,,"Rebecca Liguori, Ashley Antoine",,,,,,,,,,,,Medidata CTMS (Pharma),,,6/8/2018,6/8/2018,8/1/2018,8/1/2018,,,,,12/13/2018,12/13/2018,,,5/10/2021,5/10/2021,11/4/2021,,11/4/2021,,,,,,,,,,,,12/3/2021,,,,,,,,,,12/10/2021,,,,,,,,,,,,,,12/23/2021,,,,,,,,,,3/28/2022,,,,,,,,,,,,,,,,3/28/2022,,,,,,,
1-2PZXG5,TAK-935-2003,'TAK-935-2003,,soticlestat (TAK-935),"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as Adjunctive Therapy in Adult Patients with Chronic Complex Regional Pain Syndrome (CRPS)",CRPS Study,II,Cancelled,Other,NS,,,,Other Phase 2,,,,24,0,0,,0,,0,0.00%,2,,,PRA,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2QRQG9,TAK-418-2002,'TAK-418-2002,,,SCZ KM2DF mutation ePOC,,II,Cancelled,00149 Schizophrenia,,,,,,,,,20,0,0,,0,,0,0.00%,9,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2RLYB1,TAK-935-2006,'TAK-935-2006,,soticlestat (TAK-935),"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Pediatric Patients with Developmental and/or Epileptic Encephalopathies",Pediatric POC – ELEKTRA (Ovid study),II,Completed,Adjunctive treatment in focal epilepsy,NS,Late NS,,,Interventional,,,,124,141,173,,32,,15,113.71%,45,,,PPD,,Siew Tin Gan,,Hitoshi Imakagura,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,2/20/2018,2/20/2018,,,8/8/2018,8/8/2018,9/19/2018,9/19/2018,,,1/23/2020,1/23/2020,,,6/9/2020,6/9/2020,,,,,,,,,,,7/20/2020,7/20/2020,,,,,,,,,7/31/2020,7/31/2020,,,,,,,7/31/2020,7/31/2020,,,,,9/30/2020,9/30/2020,,,,,,,,,8/31/2021,,,,,,,,,,,,,,,,8/31/2021,,,,,,,
1-2RLYPR,TAK-935-2005,'TAK-935-2005,,soticlestat (TAK-935),"Open label, extension study to assess safety and tolerability of TAk-935 in patients with rare epilepsy; TAK-935-18-001",Open label extension study - ENDYMION (Ovid Study),II,Recruitment Complete,Adjunctive treatment in focal epilepsy,NS,Late NS,,,Interventional,,,,490,156,156,,,,61,31.84%,220,,,PPD,,"Siew Tin Gan, Hendriks Eric",,Dimitrios Arkilo,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,1/17/2018,1/17/2018,4/16/2018,4/16/2018,,,7/19/2018,7/19/2018,8/16/2018,8/16/2018,,,7/13/2020,7/13/2020,,,10/31/2022,,,,,,,,6/10/2025,,,,11/28/2022,,,,,,,,7/8/2025,,12/5/2022,,,,,,,,7/15/2025,,,,,,1/3/2023,,,,,,,,8/13/2025,,3/28/2023,,,,,,,,11/17/2025,,,,,,,,11/17/2025,,,,,,,
1-2SYQ42,Risperidone-0001,'Risperidone-0001,,,"A PILOT STUDY EXPLORING THE REPRODUCIBILITY AND SUITABILITY FOR
MULTI-CENTER CLINICAL TRIALS OF fMRI BOLD SIGNAL DURING A MONETARY
INCENTIVE DELAY TASK AND ARTERIAL SPIN LABELING WITH AND WITHOUT
PRIOR ADMINISTRATION OF RISPERIDONE",,0,Closed,Other,,,,,,,,,5,5,11,,6,,,100.00%,1,,,PRA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2TFPVE,TBD-1-2TFPVE,'TBD-1-2TFPVE,,,"A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL) A Phase 3, Randomized, Open-label, Multicenter Study Compari",TBD-1-2TFPVE Ponatinib,III,Planned,,,,,,,,,,320,,,,,,,,80,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2TFPVR,TAK-951-1001,'TAK-951-1001,,TAK-951,TAK-951 FIH,FIH study,I,Completed,Dyslipidemia,GI,Early GI,,,Interventional,,,,128,124,124,,,,,96.88%,1,,,PRA,,"Holly Oakley, James Hazel",,Cristina Almansa,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,10/5/2018,10/5/2018,1/4/2019,1/4/2019,,,2/26/2019,2/26/2019,3/25/2019,3/25/2019,,,9/23/2020,9/23/2020,,,11/2/2020,11/2/2020,,,,,,,,,,,2/26/2021,2/26/2021,,,,,,,,,,,,,,,,,,,,,,,4/29/2021,4/29/2021,,,,,,,,,7/21/2021,,,,,,,,,,,,,,,,7/21/2021,,,,,,,
1-2TFPW0,TBD-1-2TFPW0,'TBD-1-2TFPW0,,TAK-951,TAK-951 CVS PoC,CVS POC,IIa,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,Early GI,,,,,,,90,,,,,,,,1,,,TBD,,Holly Oakley,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,2/28/2023,,6/27/2023,,,,10/3/2023,,10/31/2023,,,,6/25/2024,,,,12/10/2024,,,,,,,,,,,,2/4/2025,,,,,,,,,,2/11/2025,,,,,,,,,,,,,,3/4/2025,,,,,,,,,,6/24/2025,,,,,,,,,,,,,,,,6/24/2025,,,,,,,
1-2TFQBD,TAK-418-0001,'TAK-418-0001,,TAK-418,A Study to Evaluate Cognitive Performance and Biomarkers in Subjects with Kabuki Syndrome,Kabuki Biomarker Study,0,Cancelled,Kabuki Syndrome,NS,,,,,,,,60,,,,,,,,10,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2TM0AN,TAK-981-1002,'TAK-981-1002,,TAK-981,"An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies",Phase 1/2 Dose Escalation/Expansion,I/II,Recruiting,Multiple cancer,Oncology,Early Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,,,216,83,106,,22,,72,38.43%,60,32,,PPD,,"Dana Atkinson, Katie Kinney","Alejandro Gomez, Igor Proscurshim",Tomoko Yanai,,2020-003947-27,,Approved,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,,,5/7/2018,5/7/2018,,,,,10/22/2018,10/22/2018,,,9/8/2022,,12/1/2022,,12/7/2022,,,,,,,,5/4/2023,,,,2/5/2023,,,,,,,,6/1/2023,,2/10/2023,,,,,,,,,,,,,,3/5/2023,,,,,,,,6/29/2023,,5/28/2023,,,,,,,,10/1/2023,,,,,,,,10/1/2023,,,,,,,
1-2U8J3J,TBD-1-2U8J3J,'TBD-1-2U8J3J,,TAK-831,China POC,China POC,II,Cancelled,Schizophrenia,NS,,,,,,,,70,,,,,,,,7,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2U8JCF,TBD-1-2U8JCF,'TBD-1-2U8JCF,,Mobocertinib (TAK-788),Ph2 Pivotal EGFR uncommon mutations (100 pts),Ph2 EGFR uncommon mut,II,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2UGJFT,TBD-1-2UGJFT,'TBD-1-2UGJFT,,TAK-071,Pivotal in PD,TBD-1-2UGJFT ePOC PD Gait TAK-071,III,Planned,(PD) Parkinson's disease,NS,,,,,,,,400,,,,,,,,60,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/22/2023,,5/22/2023,,,,4/4/2024,,11/13/2024,,,,5/26/2027,,,,1/27/2028,,,,,,,,,,,,4/24/2028,,,,,,,,,,5/8/2028,,,,,,,,,,,,,,6/5/2028,,,,,,,,,,11/2/2028,,,,,,,,,,,,,,,,11/2/2028,,,,,,,
1-2UGJGD,TAK-954-2004,'TAK-954-2004,,TAK-954,"A Randomized, Double-Blind, Placebo-Controlled,   Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large– and Small–bowel Resection",TAK-954 POC in POGD,IIb,Recruiting,(POI) Post-Operative Ileus,GI,Late GI,,,,,,,180,147,187,,40,147,30,81.67%,30,22,,PRA,,Terry White,,,,2018-003318-42,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/6/2018,8/6/2018,10/15/2018,10/15/2018,,,3/7/2019,3/7/2019,3/18/2019,3/18/2019,,,12/31/2021,,,,4/11/2022,,,,,,,,,,,,5/9/2022,,,,,,,,,,5/16/2022,,,,,,,,,,,,,,6/6/2022,,,,,,,,,,8/29/2022,,,,,,,,,,1/20/2021,1/20/2021,,,,,8/29/2022,,,,,,,
1-2UGJKJ,TAK-071-1003,'TAK-071-1003,,TAK-071,DDI,DDI #1 TAK-071,I,Suspended,(PD) Parkinson's disease,NS,Late NS,,,,,,,40,,,,,,,,1,,,PRA,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/29/2022,,8/17/2022,,,,10/5/2022,,12/28/2022,,,,12/28/2022,,,,2/8/2023,,,,,,,,,,,,3/8/2023,,,,,,,,,,,,,,,,,,,,,,,,5/2/2023,,,,,,,,,,8/22/2023,,,,,,,,,,,,,,,,8/22/2023,,,,,,,
1-2UGJKW,TAK-041-1005,'TAK-041-1005,,TAK-041,DDI TAK-041,DDI TAK-041,I,Suspended,(MDD) Major depressive disorder,NS,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2UGJL5,TAK-041-1004,'TAK-041-1004,,TAK-041,hADME,hADME,I,Suspended,(MDD) Major depressive disorder,NS,,,,,,,,8,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2UGJLN,Ponatinib-1501,'Ponatinib-1501,,Iclusig,"A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation",Pediatric R/R Ph+ ALL Chemo Combo,I/II,Recruiting,Prevention of arteriovenous shunt (hemodialysis) failure,Oncology,Late Oncology,,Both pediatric and non-pediatric,Interventional,Treatment,Prospective,,74,2,2,,,2,,2.70%,74,47,,PPD,,"Deborah Bruce, Fuquan, Kenneth Chen, Deborah Scarcella",,"E. Jane Leonard, Joe Matloub, Shouryadeep Srivastava",,2019-002549-39,,Approved,,,,,,Medidata CTMS (Pharma),,,3/5/2019,3/5/2019,7/25/2019,7/25/2019,,,,,3/5/2021,3/5/2021,,,8/27/2024,,2/27/2025,,2/27/2025,,,,,,,,8/27/2027,,,,4/24/2025,,,,,,,,10/21/2027,,4/30/2025,,,,,,,,10/28/2027,,,,,,5/24/2025,,,,,,,,10/31/2027,,8/16/2025,,,,,,,,12/16/2027,,,,,,,,12/16/2027,,,,,,,
1-2UGJLX,TBD-1-2UGJLX,'TBD-1-2UGJLX,,,Iclusig Relative BA Pediatric Formulation study in NHV,Rel BA Pediatric Formulation,I,Cancelled,Other,,,,,,,,,20,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2UGK0D,TAK-418-0002,'TAK-418-0002,,TAK-418,"An open-label, brain positron emission tomography, Phase 0 study of [18F]MNI-1054 as a marker for Lysine-specific histone demethylase 1A (LSD1) Human Validation Study",TAK-418 PET Occupancy Study,0,Closed,Other,NS,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,7/13/2018,7/13/2018,7/16/2018,7/16/2018,,,8/27/2018,8/27/2018,9/14/2018,9/14/2018,,,10/12/2018,10/12/2018,,,11/6/2018,11/6/2018,,,,,,,,,,,11/7/2018,11/7/2018,,,,,,,,,11/30/2018,11/30/2018,,,,,,,,,,,,,,,,,,,,,,,3/19/2019,3/19/2019,,,,,,,,,,,,,,,3/19/2019,3/19/2019,,,,,,
1-2V644J,TBD-1-2V644J,'TBD-1-2V644J,,TAK-101,"Double-Blind, Randomized, Placebo-controlled dose ranging study in well controlled celiac disease patients on a Gluten Free Diet",TIMP-Glia P2b part 1: dose response related to T c,IIB,Cancelled,Other,GI,,,,,,,,60,0,0,,0,,0,0.00%,7,,,,,,,,,,,,,,Wave 2,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2X77JU,SCZD-0001,'SCZD-0001,,Other Compounds - CNS,A Pilot Study of Digital Health Technology Assessments in Schizophrenia,SCZD DHTA,0,All Activities Closed,Support,NS,Late NS,,,,,,,44,48,76,,28,,2,109.09%,6,,,PRA,,Michael Stieber,,"Nick Demartinis, Robert Alexander, Venkatesha Murthy",,,,,,,,,,Medidata CTMS (Pharma),,,8/20/2018,8/20/2018,9/7/2018,9/7/2018,,,12/6/2018,12/6/2018,12/19/2018,12/19/2018,,,4/5/2019,4/5/2019,,,7/30/2019,7/30/2019,,,,,,,,,,,10/17/2019,,,,,,,,,,10/31/2019,,,,,,,,,,,,,,,,,,,,,,,,3/12/2020,,,,,,,,,,,,,,,,3/12/2020,,,,,,,
1-2XTQIM,TAK-418-0003,'TAK-418-0003,,TAK-418,BCH ASD prospective BM,Phase 0 Biomarker and Cognition Study,0,Cancelled,Kabuki Syndrome,NS,,,,,,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2YDS7R,TAK-935-2007,'TAK-935-2007,,soticlestat (TAK-935),"A Phase-2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Tolerability and Safety of TAK-935 as Monotherapy for Prophylaxis in Adult Patients with Episodic Migraine with and/or without Aura",Episodic Migraine with and/or without Aura,II,Cancelled,Other,NS,,,,POC,,,,52,0,0,,0,,0,0.00%,5,,,PRA,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2YLIZL,TAK-935-2004,'TAK-935-2004,,soticlestat (TAK-935),"A MULTICENTER, OPEN-LABEL, PILOT STUDY OF TAK-935 IN PATIENTS WITH 15Q DUPLICATION SYNDROME OR CDKL5 DEFICIENCY DISORDER",Ultra-rare open label study - ARCADE (Ovid study),II,Completed,Adjunctive treatment in focal epilepsy,NS,Late NS,,,Interventional,,,,30,20,28,,8,,2,66.67%,3,,,PPD,,"Kraig Keeter, Siew Tin Gan",,Dimitrios Arkilo,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,3/9/2018,3/9/2018,5/22/2018,5/22/2018,,,9/10/2018,9/10/2018,10/8/2018,10/8/2018,,,6/19/2020,6/19/2020,,,7/13/2020,7/13/2020,,,,,,,,,,,7/31/2020,7/31/2020,,,,,,,,,8/14/2020,8/14/2020,,,,,,,,,,,,,8/31/2020,8/31/2020,,,,,,,,,8/31/2021,,,,,,,,,,,,,,,,8/31/2021,,,,,,,
1-2Z01LH,TBD-1-2Z01LH,'TBD-1-2Z01LH,,TAK-906,Phase 3 randomized efficacy study of TAK-906 vs. Placebo with withdrawal period in Patients with Diabetic Gastroparesis,P3 study with WD pd in DG,III,Terminated,Other,GI,,,,,,,,540,0,0,,0,,0,0.00%,100,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2Z01LT,TBD-1-2Z01LT,'TBD-1-2Z01LT,,TAK-906,Phase 3 randomized efficacy study of TAK-906 vs. Placebo with withdrawal period in Patients with Idiopathic Gastroparesis,TBD-1-2Z01LT TAK-906,III,Planned,(GP) Gastroparesis,GI,Late GI,,,,,,,540,,,,,,,,100,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3A58OZ,TAK-925-2002,'TAK-925-2002,,TAK-925,"A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia",Idiopathic Hypersomnia (IH) Study,Ib,Completed,IH (Idiopathic Hypersomnia),NS,Late NS,,Non-pediatric only (>18 yr),Interventional,Treatment,,Other,40,28,0,,41,28,,70.00%,10,,,IQVIA,,Beth Hudgins,,,,,,,,,,,Wave 1,Medidata CTMS (Pharma),,,6/13/2019,6/13/2019,8/6/2019,8/6/2019,,,1/26/2020,1/26/2020,3/10/2020,3/10/2020,,,11/17/2020,11/17/2020,,,11/25/2020,11/25/2020,,,,,,,,,,,1/21/2021,1/21/2021,,,,,,,,,1/28/2021,1/28/2021,,,,,,,,,,,,,5/20/2021,5/20/2021,,,,,,,,,7/7/2021,,,,,,,,,,,,,,,,11/24/2021,,,,,,,
1-3A58P8,TAK-925-2001,'TAK-925-2001,,TAK-925,"A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP",TAK-925-2001 - EDS in Obstructive Sleep Apnea (OSA,II,All Activities Closed,OSA (Obstructive Sleep Apnea),NS,Late NS,,,,,,,42,25,119,,94,25,2,59.52%,18,,,IQVIA,,Beth Hudgins,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/15/2019,7/15/2019,8/6/2019,8/6/2019,,,11/19/2019,11/19/2019,12/1/2019,12/1/2019,,,3/22/2020,3/22/2020,,,4/2/2020,4/2/2020,,,,,,,,,,,6/18/2020,6/18/2020,,,,,,,,,6/29/2020,6/29/2020,,,,,,,,,,,,,9/7/2020,9/7/2020,,,,,,,,,10/29/2020,10/29/2020,,,,,,,,,,,,,,,3/31/2021,,,,,,11/19/2019,11/19/2019
1-3BD3YR,TAK-906-1009,'TAK-906-1009,,TAK-906,"A OPEN-LABEL, 2-PERIOD, CROSSOVER STUDY TO EVALUATE THE EFFECT OF OATP1B1 AND OATP1B3 INHIBITOR ON THE PHARMACOKINETICS OF ORAL TAK-906 IN HEALTHY ADULT SUBJECTS",Phase 1.2: DDI: Inhibitor (OATP1B1/ 1B3) (TAK-906-,I,All Activities Closed,(GP) Gastroparesis,GI,Early GI,,,,,,,12,12,34,,0,0,0,100.00%,1,,,Celerion,,Katie Savage,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/10/2019,7/10/2019,9/20/2019,9/20/2019,,,10/12/2019,10/12/2019,10/25/2019,10/25/2019,,,10/25/2019,10/25/2019,,,11/12/2019,11/12/2019,,,,,,,,,,,1/6/2020,1/6/2020,,,,,,,,,,,,,,,,,,,,,,,5/4/2020,5/4/2020,,,,,,,,,5/26/2020,5/26/2020,,,,,,,,,,,,,,,5/26/2020,5/26/2020,,,,,,
1-3BD4A3,TBD-1-3BD4A3,'TBD-1-3BD4A3,,TAK-418,ASD POC (TAK-418),POC,II,Cancelled,Other,NS,,,,,,,,100,0,0,,0,,0,0.00%,15,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD4AC,TBD-1-3BD4AC,'TBD-1-3BD4AC,,TAK-418,Pivotal KS,Pivotal KS,II/III,Cancelled,Kabuki Syndrome,NS,,,,,,,,300,,,,,,,,36,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD4AL,TBD-1-3BD4AL,'TBD-1-3BD4AL,,TAK-418,Pivotal ASD,Pivotal ASD,II/III,Planned,(ASD) Autism Spectrum Disorder,NS,,,,,,,,300,,,,,,,,60,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD4B4,TBD-1-38D4B4,'TBD-1-38D4B4,,TAK-653,Dose Ranging,Dose Ranging,II,Cancelled,(TRD) Treatment Resistance to Depression,NS,,,,,,,,300,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD4BD,TBD-1-38D4BD,'TBD-1-38D4BD,,TAK-653,Pivotal 1,Pivotal 1 TAK-653,III,Planned,(TRD) Treatment Resistance to Depression,NS,,,,,,,,300,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/27/2023,,9/4/2023,,,,,,12/11/2023,,,,5/14/2025,,,,8/6/2025,,,,,,,,,,,,10/15/2025,,,,,,,,,,10/24/2025,,,,,,,,,,,,,,,,,,,,,,,,2/4/2026,,,,,,,,,,,,,,,,2/4/2026,,,,,,,
1-3BD4BM,TBD-1-38D4BM,'TBD-1-38D4BM,,TAK-653,Open Label,Open Label,III,Planned,(TRD) Treatment Resistance to Depression,NS,,,,,,,,500,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD4BW,TBD-1-38D4BW,'TBD-1-38D4BW,,TAK-831,Pivotal 1,Pivotal 1 TAK-831,III,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,600,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/6/2023,,8/17/2023,,,,5/9/2024,,7/4/2024,,,,11/13/2026,,,,5/14/2027,,,,,,,,,,,,7/9/2027,,,,,,,,,,8/16/2027,,,,,,,,,,,,,,8/6/2027,,,,,,,,,,10/29/2027,,,,,,,,,,,,,,,,10/29/2027,,,,,,,
1-3BD4CB,TBD-1-38D4CB,'TBD-1-38D4CB,,TAK-831,Pivotal 2,Pivotal 2 TAK-831,III,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,600,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD4CL,TBD-1-38D4CL,'TBD-1-38D4CL,,TAK-653,Pivotal 2,Pivotal 2 TAK-653,III,Planned,(TRD) Treatment Resistance to Depression,NS,,,,,,,,300,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD42G,TBD-1-3BD42G,'TBD-1-3BD42G,,TAK-041,PIII 1st Pivotal Anhedonia,Pivotal,III,Planned,(MDD) Major depressive disorder,NS,,,,,,,,600,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD42Q,TBD-1-3BD42Q,'TBD-1-3BD42Q,,TAK-041,PIII 2nd Pivotal trial,OL,III,Planned,(MDD) Major depressive disorder,NS,,,,,,,,600,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3BD47R,TBD-1-3BD47R,'TBD-1-3BD47R,,TAK-341,OL PD & MSA,OL PD & MSA,III,Planned,(PD) Parkinson's disease,NS,,,,,,,,550,,,,,,,,80,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/14/2023,,10/23/2023,,,,,,2/22/2024,,,,5/14/2026,,,,4/15/2027,,,,,,,,,,,,6/10/2027,,,,,,,,,,6/24/2027,,,,,,,,,,,,,,,,,,,,,,,,12/21/2027,,,,,,,,,,,,,,,,4/13/2028,,,,,,,
1-3BD48A,TBD-1-3BD48A,'TBD-1-3BD48A,,TAK-341,POC MSA,POC MSA,II/III,Planned,Multiple System Atrophy,NS,,,,,,,,588,,,,,,,,50,,,TBD,,,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,7/1/2022,,9/2/2022,,,,3/13/2023,,3/13/2023,,,,12/16/2024,,,,11/17/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/28/2026,,,,,,,,,,,,,,,,11/16/2026,,,,,,,
1-3BD48K,TBD-1-3BD48K,'TBD-1-3BD48K,,TAK-341,Pivotal PD,Pivotal PD,III,Planned,(PD) Parkinson's disease,NS,,,,,,,,450,,,,,,,,80,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,2/15/2023,,4/19/2023,,,,8/2/2023,,8/30/2023,,,,8/28/2024,,,,7/30/2025,,,,,,,,,,,,1/12/2026,,,,,,,,,,1/26/2026,,,,,,,,,,,,,,,,,,,,,,,,7/23/2026,,,,,,,,,,,,,,,,11/16/2026,,,,,,,
1-3BD481,TBD-1-3BD481,'TBD-1-3BD481,,TAK-341,POC PD,POC PD,II/III,Planned,(PD) Parkinson's disease,NS,Late NS,,,,,,,450,,,,,,,,80,,,TBD,,Michael Stieber,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,10/10/2022,,12/19/2022,,,,5/18/2023,,5/18/2023,,,,10/31/2024,,,,10/31/2024,,,,,,,,,,,,12/26/2024,,,,,,,,,,1/9/2025,,,,,,,,,,,,,,,,,,,,,,,,7/31/2025,,,,,,,,,,,,,,,,10/30/2025,,,,,,,
1-3CYXMQ,TBD-1-3CYXMQ,'TBD-1-3CYXMQ,,TAK-041,DDI OC,DDI OC,I,Planned,(MDD) Major depressive disorder,NS,,,,,,,,40,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXN0,TBD-1-3CYXN0,'TBD-1-3CYXN0,,TAK-041,Hepatic Impairment TAK-041,Hepatic Impairment TAK-041,I,Suspended,(MDD) Major depressive disorder,NS,Early NS,,,,,,,36,,,,,,,,2,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXN9,TBD-1-3CYXN9,'TBD-1-3CYXN9,,TAK-041,Renal Impairment TAK-041,Renal Impairment TAK-041,I,Planned,(MDD) Major depressive disorder,NS,,,,,,,,36,,,,,,,,3,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXNM,TBD-1-3CYXNM,'TBD-1-3CYXNM,,TAK-478,TAK-478 Relative BA Suspencion to Tablet,TAK-478 Relative BA,I,Cancelled,(TRD) Treatment Resistance to Depression,NS,Early NS,,,,,,,8,,,,,,,,1,,,Celerion,,Michael Stieber,,,,,,,,,,,,Medidata CTMS (Pharma),,,4/14/2020,,4/28/2020,,,,6/23/2020,,6/23/2020,,,,6/24/2020,,,,7/14/2020,,,,,,,,,,,,8/11/2020,,,,,,,,,,8/18/2020,,,,,,,,,,,,,,,,,,,,,,,,1/19/2021,,,,,,,,,,,,,,,,4/11/2025,,,,,,,
1-3CYXO2,TBD-1-3CYXO2,'TBD-1-3CYXO2,,TAK-041,rBA,rBA,I,Suspended,(MDD) Major depressive disorder,NS,Early NS,,,,,,,36,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXOB,TBD-1-3CYXOB,'TBD-1-3CYXOB,,TAK-041,Asian Bridging,Asian Bridging,I,Suspended,(MDD) Major depressive disorder,NS,Early NS,,,,,,,20,,,,,,,,1,,,Celerion,,Michael Stieber,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXOF,TBD-1-3CYXOF,'TBD-1-3CYXOF,,TAK-478,TAK-478 Ph. 2-3 tablet,TAK-478 Relative BA  2-3 tablet,I,Cancelled,(TRD) Treatment Resistance to Depression,NS,,,,,,,,96,,,,,,,,1,,,Celerion,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/12/2024,,1/26/2024,,,,3/22/2024,,3/22/2024,,,,3/25/2024,,,,4/12/2024,,,,,,,,,,,,5/10/2024,,,,,,,,,,5/17/2024,,,,,,,,,,,,,,,,,,,,,,,,10/18/2024,,,,,,,,,,,,,,,,4/11/2025,,,,,,,
1-3CYXOO,TBD-1-3CYXOO,'TBD-1-3CYXOO,,TAK-478,TAK-478 ePoC in TRD 1,TAK-478 ePoC in TRD 1,II,Cancelled,(TRD) Treatment Resistance to Depression,NS,,,,,,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/23/2020,,2/17/2021,,,,6/9/2021,,6/29/2021,,,,12/14/2021,,,,3/8/2022,,,,,,,,,,,,5/3/2022,,,,,,,,,,5/10/2022,,,,,,,,,,,,,,,,,,,,,,,,3/7/2023,,,,,,,,,,,,,,,,3/7/2023,,,,,,,
1-3CYXOY,TBD-1-3CYXOY,'TBD-1-3CYXOY,,TAK-478,TAK-478 ePoC in TRD 2,TAK-478 ePoC in TRD 2,II,Cancelled,(TRD) Treatment Resistance to Depression,NS,,,,,,,,300,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/7/2022,,6/21/2022,,,,10/11/2022,,10/11/2022,,,,4/11/2023,,,,10/10/2023,,,,,,,,,,,,12/5/2023,,,,,,,,,,12/12/2023,,,,,,,,,,,,,,,,,,,,,,,,6/25/2024,,,,,,,,,,,,,,,,10/8/2024,,,,,,,
1-3CYXP4,TBD-1-3CYXP4,'TBD-1-3CYXP4,,TAK-041,BE,BE,I,Suspended,(MDD) Major depressive disorder,NS,Early NS,,,,,,,20,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXPI,TBD-1-3CYXPI,'TBD-1-3CYXPI,,TAK-478,TAK-478 TRD,TAK-478 TRD,III,Cancelled,(TRD) Treatment Resistance to Depression,NS,,,,,,,,"1,000",,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/23/2024,,4/30/2024,,,,7/23/2024,,8/20/2024,,,,4/1/2025,,,,9/30/2025,,,,,,,,,,,,11/25/2025,,,,,,,,,,12/2/2025,,,,,,,,,,,,,,,,,,,,,,,,3/17/2026,,,,,,,,,,,,,,,,9/29/2026,,,,,,,
1-3CYXPN,TBD-1-3CYXPN,'TBD-1-3CYXPN,,TAK-041,TQT,TQT,I,Suspended,(MDD) Major depressive disorder,NS,Early NS,,,,,,,20,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXQ4,TBD-1-3CYXQ4,'TBD-1-3CYXQ4,,TAK-478,TAK-478 14 C Label,TAK-478 14 C Label,I,Cancelled,(TRD) Treatment Resistance to Depression,NS,Early NS,,,,,,,1,,,,,,,,1,,,Celerion,,Michael Stieber,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/14/2022,,7/28/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/23/2023,,,,,,,
1-3CYXQD,TBD-1-3CYXQD,'TBD-1-3CYXQD,,TAK-478,TAK-478 ADME,TAK-478 ADME,I,Cancelled,(TRD) Treatment Resistance to Depression,NS,,,,,,,,6,,,,,,,,1,,,Celerion,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/14/2023,,3/28/2023,,,,5/23/2023,,5/23/2023,,,,5/24/2023,,,,6/13/2023,,,,,,,,,,,,7/11/2023,,,,,,,,,,7/18/2023,,,,,,,,,,,,,,,,,,,,,,,,12/19/2023,,,,,,,,,,,,,,,,6/11/2024,,,,,,,
1-3CYXQQ,TBD-1-3CYXQQ,'TBD-1-3CYXQQ,,TAK-041,Opioid - Safety,Opioid - Safety,I,Planned,(MDD) Major depressive disorder,NS,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXQX,TBD-1-3CYXQX,'TBD-1-3CYXQX,,TAK-478,TAK-478 OLE Safety Study,TAK-478 OLE Safety Study,I,Cancelled,(TRD) Treatment Resistance to Depression,NS,,,,,,,,500,,,,,,,,1,,,Celerion,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/9/2024,,6/11/2024,,,,,,2/18/2025,,,,12/9/2025,,,,9/15/2026,,,,,,,,,,,,11/10/2026,,,,,,,,,,11/17/2026,,,,,,,,,,,,,,,,,,,,,,,,8/20/2027,,,,,,,,,,,,,,,,9/14/2027,,,,,,,
1-3CYXR6,TBD-1-3CYXR6,'TBD-1-3CYXR6,,TAK-653,ADME,TAK-653:  ADME,I,Cancelled,"(LN) Class III and IV, Lupus Nephritis",NS,Late NS,,,,,,,6,,,,,,,,1,,,TBD,,Michael Stieber,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,9/24/2021,,11/5/2021,,,,,,2/7/2022,,,,5/2/2022,,,,7/25/2022,,,,,,,,,,,,8/29/2022,,,,,,,,,,9/12/2022,,,,,,,,,,,,,,,,,,,,,,,,3/9/2023,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXR9,TBD-1-3CYXR9,'TBD-1-3CYXR9,,TAK-041,Opioid - PD 1,Opioid - PD 1,I,Planned,(MDD) Major depressive disorder,NS,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXS0,TBD-1-3CYXS0,'TBD-1-3CYXS0,,TAK-653,TAK-653-DDI,TAK-653-DDI,I,Cancelled,Normal Healthy Volunteer,NS,,,,,,,,16,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXS2,TBD-1-3CYXS2,'TBD-1-3CYXS2,,TAK-041,Opioid - PD 2,Opioid - PD 2,I,Planned,(MDD) Major depressive disorder,NS,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXSK,TBD-1-3CYXSK,'TBD-1-3CYXSK,,TAK-653,JPN,TAK-653-JPN,I,Planned,(TRD) Treatment Resistance to Depression,NS,Late NS,,,,,,,24,,,,,,,,1,,,TBD,,Michael Stieber,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/5/2017,,,,,,,
1-3CYXSL,TBD-1-3CYXSL,'TBD-1-3CYXSL,,TAK-071,DDI,DDI #2 OC TAK-071,I,Planned,(PD) Parkinson's disease,NS,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/29/2022,,8/17/2022,,,,10/5/2022,,12/28/2022,,,,2/8/2023,,,,3/8/2023,,,,,,,,,,,,4/5/2023,,,,,,,,,,4/5/2023,,,,,,,,,,,,,,5/30/2023,,,,,,,,,,8/22/2023,,,,,,,,,,,,,,,,10/5/2022,,,,,,,
1-3CYXSU,TBD-1-3CYXSU,'TBD-1-3CYXSU,,TAK-071,Hepatic Impairment,Hepatic Impairment TAK-071,I,Planned,(PD) Parkinson's disease,NS,Early NS,,,,,,,36,,,,,,,,2,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/11/2023,,8/1/2023,,,,9/12/2023,,10/10/2023,,,,10/17/2023,,,,11/28/2023,,,,,,,,,,,,1/2/2024,,,,,,,,,,1/23/2024,,,,,,,,,,,,,,1/29/2024,,,,,,,,,,7/12/2024,,,,,,,,,,,,,,,,7/12/2024,,,,,,,
1-3CYXT3,TBD-1-3CYXT3,'TBD-1-3CYXT3,,TAK-653,CHN,TAK-653-CHN,I,Planned,(TRD) Treatment Resistance to Depression,NS,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXTC,TBD-1-3CYXTC,'TBD-1-3CYXTC,,TAK-653,Bioequivalent,TAK-653 Bioequivalent,I,Planned,(TRD) Treatment Resistance to Depression,NS,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXTV,TBD-1-3CYXTV,'TBD-1-3CYXTV,,TAK-653,Hepatic Impairment,TAK-653 Hepatic Impairment,I,Cancelled,"(LN) Class III and IV, Lupus Nephritis",NS,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXU4,TBD-1-3CYXU4,'TBD-1-3CYXU4,,TAK-653,Renal Impairment,TAK-653 Renal Impairment,I,Cancelled,"(LN) Class III and IV, Lupus Nephritis",NS,,,,,,,,32,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXU9,TBD-1-3CYXU9,'TBD-1-3CYXU9,,TAK-071,Renal Impairment,Renal Impairment TAK-071,I,Planned,(PD) Parkinson's disease,NS,Early NS,,,,,,,36,,,,,,,,3,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/11/2023,,8/1/2023,,,,9/12/2023,,10/10/2023,,,,10/17/2023,,,,11/28/2023,,,,,,,,,,,,1/2/2024,,,,,,,,,,1/23/2024,,,,,,,,,,,,,,,,,,,,,,,,7/12/2024,,,,,,,,,,,,,,,,7/12/2024,,,,,,,
1-3CYXUI,TBD-1-3CYXUI,'TBD-1-3CYXUI,,TAK-071,rBA,rBA TAK-071,I,Planned,(PD) Parkinson's disease,NS,Early NS,,,,,,,36,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/11/2023,,8/1/2023,,,,9/12/2023,,10/10/2023,,,,10/17/2023,,,,11/5/2023,,,,,,,,,,,,12/8/2023,,,,,,,,,,12/29/2023,,,,,,,,,,,,,,,,,,,,,,,,6/19/2024,,,,,,,,,,,,,,,,6/19/2024,,,,,,,
1-3CYXUN,TBD-1-3CYXUN,'TBD-1-3CYXUN,,TAK-653,Bioequivalent - commercial study,TAK-653 Bioequivalent - commercial study,I,Cancelled,"(LN) Class III and IV, Lupus Nephritis",NS,,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXUW,TBD-1-3CYXUW,'TBD-1-3CYXUW,,TAK-653,TAK-653 TQT,TAK-653 TQT,I,Planned,(TRD) Treatment Resistance to Depression,NS,,,,,,,,48,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXVN,TBD-1-3CYXVN,'TBD-1-3CYXVN,,TAK-071,Asian Bridging,Asian Bridging TAK-071,I,Planned,(PD) Parkinson's disease,NS,,,,,,,,20,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/11/2023,,8/1/2023,,,,9/12/2023,,10/10/2023,,,,10/17/2023,,,,11/28/2023,,,,,,,,,,,,1/2/2024,,,,,,,,,,1/23/2024,,,,,,,,,,,,,,1/29/2024,,,,,,,,,,7/12/2024,,,,,,,,,,,,,,,,7/12/2024,,,,,,,
1-3CYXVW,TBD-1-3CYXVW,'TBD-1-3CYXVW,,TAK-071,BE,BE TAK-071,I,Planned,(PD) Parkinson's disease,NS,Early NS,,,,,,,20,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/11/2023,,8/1/2023,,,,9/12/2023,,10/10/2023,,,,10/17/2023,,,,11/28/2023,,,,,,,,,,,,1/2/2024,,,,,,,,,,1/23/2024,,,,,,,,,,,,,,1/29/2024,,,,,,,,,,7/12/2024,,,,,,,,,,,,,,,,7/12/2024,,,,,,,
1-3CYXW1,TBD-1-3CYXW1,'TBD-1-3CYXW1,,,TAK-906,TAK-906 TQT,I,Planned,,,,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXWF,TBD-1-3CYXWF,'TBD-1-3CYXWF,,TAK-071,TQT,TQT TAK-071,I,Planned,(PD) Parkinson's disease,NS,Early NS,,,,,,,20,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/9/2023,,8/11/2023,,,,11/14/2023,,12/14/2023,,,,12/28/2023,,,,2/8/2024,,,,,,,,,,,,3/14/2024,,,,,,,,,,4/4/2024,,,,,,,,,,,,,,4/10/2024,,,,,,,,,,9/24/2024,,,,,,,,,,,,,,,,9/24/2024,,,,,,,
1-3CYXWK,TAK-478-1001,'TAK-478-1001,,TAK-478,"A Randomized Double-Blind Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of Oral TAK-478 in Healthy Subjects",TAK-478 HVT SRD/MRD & TMS,I,Cancelled,(TRD) Treatment Resistance to Depression,NS,Early NS,,,,,,,96,,,,,,,,1,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,8/14/2019,8/14/2019,10/16/2019,,,,1/22/2020,,2/5/2020,,,,7/7/2020,,,,8/12/2020,,,,,,,,,,,,9/9/2020,,,,,,,,,,9/30/2020,,,,,,,,,,,,,,,,,,,,,,,,2/17/2021,,,,,,,,,,,,,,,,4/11/2025,,,,,,,
1-3CYXWY,TBD-1-3CYXWY,'TBD-1-3CYXWY,,TAK-071,hADME,hADME TAK-071,I,Planned,(PD) Parkinson's disease,NS,Early NS,,,,,,,40,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/3/2023,,7/5/2023,,,,10/6/2023,,11/7/2023,,,,11/7/2023,,,,12/19/2023,,,,,,,,,,,,1/23/2024,,,,,,,,,,2/13/2024,,,,,,,,,,,,,,2/19/2024,,,,,,,,,,8/2/2024,,,,,,,,,,,,,,,,8/2/2024,,,,,,,
1-3CYXX7,TBD-1-3CYXX7,'TBD-1-3CYXX7,,soticlestat (TAK-935),ADME Radiolabel,Radiolabeled AME,I,Cancelled,Other,NS,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXXD,TAK-935-1008,'TAK-935-1008,,soticlestat (TAK-935),ADME/ABA (TAK-935),ADME/ABA (TAK-935),I,Planned,(GvHD) Graft versus host disease,NS,Late NS,,,,,,,16,16,,,,,,100.00%,1,,,Celerion,,"Annette Stevenson, Siew Tin Gan",,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,2/24/2020,2/24/2020,6/8/2020,6/8/2020,,,7/7/2020,7/7/2020,7/9/2020,7/9/2020,,,7/17/2020,7/17/2020,,,8/16/2020,8/16/2020,,,,,,,,,,,9/18/2020,9/18/2020,,,,,,,,,10/16/2020,10/16/2020,,,,,,,,,,,,,,,,,,,,,,,9/22/2021,,,,,,,,,,,,,,,,9/22/2021,,,,,,,
1-3CYXXM,TAK-935-1007,'TAK-935-1007,,soticlestat (TAK-935),DDI (inhibition) TAK-935,DDI (inhibition) TAK-935,I,Planned,(GvHD) Graft versus host disease,NS,Early NS,,,Interventional,,,,28,,,,,,,,1,,,Celerion,,Annette Stevenson,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,6/14/2021,6/14/2021,8/25/2021,,,,9/27/2021,,10/25/2021,,,,11/10/2021,,,,11/30/2021,,,,,,,,,,,,1/10/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/19/2022,,,,,,,,,,,,,,,,4/19/2022,,,,,,,
1-3CYXY3,TBD-1-3CYXY3,'TBD-1-3CYXY3,,TAK-071,Pivotal in PD,TBD-1-3CYXY3 ePOC PD Gait TAK-071,III,Planned,(PD) Parkinson's disease,NS,,,,,,,,400,,,,,,,,60,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/22/2023,,5/22/2023,,,,4/4/2024,,11/13/2024,,,,5/26/2027,,,,1/27/2028,,,,,,,,,,,,4/24/2028,,,,,,,,,,5/8/2028,,,,,,,,,,,,,,6/5/2028,,,,,,,,,,11/2/2028,,,,,,,,,,,,,,,,11/2/2028,,,,,,,
1-3CYXY6,TBD-1-3CYXY6,'TBD-1-3CYXY6,,soticlestat (TAK-935),tQT (if waiver not approved) TAK-935,tQT (if waiver not approved) TAK-935,I,Planned,Adjunctive treatment in focal epilepsy,NS,Late NS,,,,,,,50,,,,,,,,2,,,TBD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,10/18/2021,,12/20/2021,,,,,,3/21/2022,,,,9/5/2022,,,,10/5/2022,,,,,,,,,,,,11/9/2022,,,,,,,,,,11/30/2022,,,,,,,,,,,,,,,,,,,,,,,,5/22/2023,,,,,,,,,,,,,,,,5/22/2023,,,,,,,
1-3CYXYF,TAK-935-1013,'TAK-935-1013,,soticlestat (TAK-935),renal impairment TAK-935,renal impairment TAK-935,I,Planned,Adjunctive treatment in focal epilepsy,NS,Late NS,,,,,,,40,,,,,,,,2,,,TBD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,2/15/2023,,4/19/2023,,,,7/13/2023,,8/14/2023,,,,11/18/2024,,,,11/21/2024,,,,,,,,,,,,1/10/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/24/2025,,,,,,,,,,,,,,,,6/24/2025,,,,,,,
1-3CYXYO,TBD-1-3CYXYO,'TBD-1-3CYXYO,,soticlestat (TAK-935),hepatic impairment TAK-935,hepatic impairment TAK-935,I,Planned,Adjunctive treatment in focal epilepsy,NS,Late NS,,,,,,,48,,,,,,,,2,,,TBD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,7/20/2021,,8/27/2021,,,,,,11/10/2021,,,,6/10/2022,,,,7/11/2022,,,,,,,,,,,,7/11/2022,,,,,,,,,,7/25/2022,,,,,,,,,,,,,,,,,,,,,,,,11/14/2022,,,,,,,,,,,,,,,,11/14/2022,,,,,,,
1-3CYXYY,TAK-935-1014,'TAK-935-1014,,soticlestat (TAK-935),BE TAK-935,BE TAK-935,I,Planned,Adjunctive treatment in focal epilepsy,NS,Late NS,,,,,,,40,,,,,,,,1,,,TBD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,11/16/2021,,1/18/2022,,,,,,3/28/2022,,,,5/30/2022,,,,6/29/2022,,,,,,,,,,,,8/3/2022,,,,,,,,,,8/24/2022,,,,,,,,,,,,,,,,,,,,,,,,2/13/2023,,,,,,,,,,,,,,,,2/13/2023,,,,,,,
1-3CYXZ7,TBD-1-3CYXZ7,'TBD-1-3CYXZ7,,soticlestat (TAK-935),Dup15q TAK-935,Dup15q TAK-935,III,Cancelled,Other,NS,,,,,,,,48,0,0,,0,,0,0.00%,2,,,,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXZG,TBD-1-3CYXZG,'TBD-1-3CYXZG,,soticlestat (TAK-935),CDD TAK-935,CDD TAK-935,III,Planned,Adjunctive treatment in focal epilepsy,NS,Late NS,,,,,,,48,,,,,,,,2,,,TBD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYXZP,TAK-935-3001,'TAK-935-3001,,soticlestat (TAK-935),DS TAK-935,Ph3 study in DS (Ovid study),III,Not Yet Recruiting,(GvHD) Graft versus host disease,NS,Late NS,,,,,,,142,,,,,,,,70,,,PPD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,,,3/23/2021,3/23/2021,,,8/2/2021,,8/31/2021,,,,10/19/2022,,,,3/1/2023,,,,,,,,,,,,3/22/2023,,,,,,,,,,3/29/2023,,,,,,,,,,,,,,4/12/2023,,,,,,,,,,6/28/2023,,,,,,,,,,,,,,,,6/28/2023,,,,,,,
1-3CYXZZ,TAK-935-3002,'TAK-935-3002,,soticlestat (TAK-935),LGS TAK-935,Ph3 study in LGS (Ovid study),III,Not Yet Recruiting,(GvHD) Graft versus host disease,NS,Late NS,,,,,,,228,,,,,,,,95,,,PPD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,,,3/24/2021,3/24/2021,,,8/2/2021,,8/31/2021,,,,10/19/2022,,,,3/1/2023,,,,,,,,,,,,3/22/2023,,,,,,,,,,3/29/2023,,,,,,,,,,,,,,4/12/2023,,,,,,,,,,6/28/2023,,,,,,,,,,,,,,,,6/28/2023,,,,,,,
1-3CYY0K,TBD-1-3CYY0K,'TBD-1-3CYY0K,,TAK-071,OL in PD,TBD-1-3CYY0K ePOC PD Gait TAK-071,III,Planned,(PD) Parkinson's disease,NS,,,,,,,,450,,,,,,,,60,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,10/12/2023,,11/2/2023,,,,5/14/2025,,5/14/2025,,,,6/27/2028,,,,7/2/2029,,,,,,,,,,,,8/27/2029,,,,,,,,,,9/10/2029,,,,,,,,,,,,,,10/8/2029,,,,,,,,,,3/7/2030,,,,,,,,,,,,,,,,3/7/2030,,,,,,,
1-3CYY0U,TBD-1-3CYY0U,'TBD-1-3CYY0U,,TAK-831,DDI,DDI #2 OC TAK-831,I,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,40,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYY1G,TAK-925-1011,'TAK-925-1011,,TAK-925,Bioavailability Study for TAK-925 Phase 2 Sustained Release Patches,Bioavailability: TAK-925 Sustained Release Patches,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,16,,,,,,,,1,,,TBD,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,11/4/2022,,12/2/2022,,,,1/13/2023,,2/12/2023,,,,3/17/2023,,,,4/6/2023,,,,,,,,,,,,5/4/2023,,,,,,,,,,5/25/2023,,,,,,,,,,,,,,7/13/2023,,,,,,,,,,11/14/2023,,,,,,,,,,,,,,,,4/4/2024,,,,,,,
1-3CYY1Z,TBD-1-3CYY1Z,'TBD-1-3CYY1Z,,TAK-925,"A Phase 1 , Open Label, Absorption, Distribution, Metabolism and Elimination Study of TAK-925 in Health Adult Subjects",TAK-925 ADME study,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,16,,,,,,,,1,,,TBD,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,8/30/2021,,11/8/2021,,,,1/7/2022,,1/10/2022,,,,6/10/2022,,,,8/17/2022,,,,,,,,,,,,10/12/2022,,,,,,,,,,1/31/2024,,,,,,,,,,,,,,6/13/2028,,,,,,,,,,10/13/2028,,,,,,,,,,,,,,,,10/13/2028,,,,,,,
1-3CYY2R,TBD-1-3CYY2R,'TBD-1-3CYY2R,,TAK-925,"A Phase 1 , Thorough QT (TQT) Study of TAK-925 in Health Adult Subjects",TAK-925 TQT study,I,Planned,Sleep Disorders,NS,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,7/29/2021,,9/30/2021,,,,12/1/2021,,1/11/2022,,,,4/4/2022,,,,4/18/2022,,,,,,,,,,,,6/13/2022,,,,,,,,,,7/4/2022,,,,,,,,,,,,,,8/22/2022,,,,,,,,,,12/22/2022,,,,,,,,,,,,,,,,4/17/2023,,,,,,,
1-3CYY3I,TBD-1-3CYY3I,'TBD-1-3CYY3I,,,"A Phase 2a , TAK-925 Randomized Double Blind Placebo Controlled Study in Type 1 Narcoleptic Patients",TAK-925 NT1 POC study,IIA,Cancelled,Other,,,,,,,,,42,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYY3R,TBD-1-3CYY3R,'TBD-1-3CYY3R,,TAK-925,A Phase 3 Safety and Efficacy Study of TAK-925 in Type 1 Narcoleptic Patients,TAK-925 P3 Study in Type 1 Narcolepsy Patients 1,III,Planned,Sleep Disorders,NS,,,,,,,,150,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,8/6/2024,,8/6/2024,,,,8/7/2024,,10/8/2024,,,,9/9/2026,,,,11/4/2026,,,,,,,,,,,,12/30/2026,,,,,,,,,,1/14/2027,,,,,,,,,,,,,,,,,,,,,,,,6/2/2027,,,,,,,,,,,,,,,,11/3/2027,,,,,,,
1-3CYY4C,TBD-1-3CYY4C,'TBD-1-3CYY4C,,TAK-925,A Phase 3 Long Term Safety Study of TAK-925 in Type 1 Narcoleptic Patients​,TAK-925 P3  LT Safety in Type1 Narcolepsy Patients,III,Planned,,NS,,,,,,,,300,,,,,,,,50,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/29/2022,,7/5/2023,,,,,,12/31/2024,,,,11/4/2026,,,,11/3/2027,,,,,,,,,,,,12/29/2027,,,,,,,,,,1/12/2028,,,,,,,,,,,,,,,,,,,,,,,,7/10/2028,,,,,,,,,,,,,,,,11/2/2028,,,,,,,
1-3CYY13,TBD-1-3CYY13,'TBD-1-3CYY13,,TAK-831,BE,BE TAK-831,I,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,40,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3CYY28,TBD-1-3CYY28,'TBD-1-3CYY28,,TAK-925,"A Phase 1 , Renal and Hepatic Impairment Study of TAK-925 in Health Adult Subjects",TAK-925 Renal and Hepatic Impairment study,I,Planned,Sleep Disorders,NS,,,,,,,,32,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,4/28/2023,,6/30/2023,,,,8/31/2023,,9/1/2023,,,,1/29/2024,,,,2/12/2024,,,,,,,,,,,,4/8/2024,,,,,,,,,,4/29/2024,,,,,,,,,,,,,,6/17/2024,,,,,,,,,,10/17/2024,,,,,,,,,,,,,,,,2/10/2025,,,,,,,
1-3CYY30,TBD-1-3CYY30,'TBD-1-3CYY30,,TAK-925,A Phase 1 Human Abuse Liability Study of TAK-925 in Health Adult Subjects,TAK-925 Human Abuse Liability  study​,I,Planned,Sleep Disorders,NS,,,,,,,,32,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,6/8/2022,,8/10/2022,,,,10/11/2022,,10/12/2022,,,,2/7/2023,,,,1/24/2023,,,,,,,,,,,,3/21/2023,,,,,,,,,,4/11/2023,,,,,,,,,,,,,,5/30/2023,,,,,,,,,,,,,,,,,,,,,,,,,,1/23/2024,,,,,,,
1-3CYY39,TBD-1-3CYY39,'TBD-1-3CYY39,,TAK-925,"A Phase 1 Patch Adhesion, Irritation and Sensitization Study of TAK-925 in Health Adult Subjects",TAK-925 Patch Study,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,16,,,,,,,,1,,,TBD,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,4/26/2023,,5/17/2023,,,,6/28/2023,,7/28/2023,,,,11/29/2023,,,,12/13/2023,,,,,,,,,,,,1/19/2024,,,,,,,,,,2/9/2024,,,,,,,,,,,,,,3/29/2024,,,,,,,,,,7/31/2024,,,,,,,,,,,,,,,,12/11/2024,,,,,,,
1-3CYY41,TBD-1-3CYY41,'TBD-1-3CYY41,,TAK-925,A Phase 3 Safety and Efficacy Study of TAK-925 in Type 1 Narcoleptic Patients,TAK-925 P3 Study in Type 1 Narcolepsy Patients 2,III,Planned,Sleep Disorders,NS,,,,,,,,150,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,12/30/2022,,2/13/2023,,,,4/24/2023,,5/12/2023,,,,5/14/2024,,,,7/9/2024,,,,,,,,,,,,9/3/2024,,,,,,,,,,9/18/2024,,,,,,,,,,,,,,,,,,,,,,,,2/4/2025,,,,,,,,,,,,,,,,7/8/2025,,,,,,,
1-3D8NXB,PvP-102-01,'PvP-102-01,,TAK-062,A Ph1 Healthy Volunteer study to test new oral formulation,KUMA062 Forumulation Bridging,I,Completed,Celiac,GI,Early GI,,,Interventional,,,,42,42,,,,,,100.00%,1,,,Precision for Medicine,,Natalie Jones,,,,,,,,,Wave 2,Advance,TAU Choice,Medidata CTMS (Pharma),,,11/11/2019,11/11/2019,12/9/2019,12/9/2019,,,3/2/2020,3/2/2020,3/16/2020,3/16/2020,,,1/26/2021,1/26/2021,,,3/3/2021,3/3/2021,,,,,,,,,,,8/20/2021,,,,,,,,,,9/3/2021,,,,,,,,,,,,,,9/22/2021,,,,,,,,,,1/14/2022,,,,,,,,,,,,,,,,1/14/2022,,,,,,,
1-3D8NXM,TAK-079-1005,'TAK-079-1005,,Mezagitamab (TAK-079),"A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients with Generalized Myasthenia Gravis.",TAK-079-1005 TAK-079,II,Recruiting,(MG) Myasthenia Gravis,RGH,Others,,,,,,,36,24,52,,28,24,,66.67%,49,41,,PPD,,Lauren Dinsmore,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,2/1/2019,2/1/2019,9/12/2019,9/12/2019,,,,,11/10/2020,11/10/2020,,,8/16/2021,,3/30/2022,,3/30/2022,,,,,,,,,,,,4/25/2022,,,,,,,,,,5/2/2022,,,,,,,,,,,,,,5/23/2022,,,,,,,,,,8/15/2022,,,,,,,,,,,,,,,,8/15/2022,,,,,,,
1-3D8O4J,TBD-1-3D8O4J,'TBD-1-3D8O4J,,TAK-925,"A Phase 1, Human Drug Drug Interaction Study of TAK-925 in Normal Healthy Volunteers",TBD-1-3D8O4J TAK-925,I,Planned,Sleep Disorders,NS,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3D8O4U,TBD-1-3D8O4U,'TBD-1-3D8O4U,,,Ph2/3 Pivotal SqNSCLC,,II,Cancelled,Other,,,,,,,,,120,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3D8O5D,TBD-1-3D8O5D,'TBD-1-3D8O5D,,TAK-925,"A Phase 1B, Night Time Threshold Study of TAK-925 in Healthy Normal Volunteers and Type 1 Narcoleptic Patients",TBD-1-3D8O5D TAK-925,Ib,Planned,Sleep Disorders,NS,,,,,,,,28,,,,,,,,5,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3D8O5O,TAK-925-1010,'TAK-925-1010,,TAK-925,"A Phase 1, Human Drug Drug Interaction Study of TAK-925 in Normal Healthy Volunteers",TAK-925 TYBOST Phase 1 DDI -TBD,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,16,,,,,,,,1,,,TBD,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,3/3/2022,,5/5/2022,,,,7/6/2022,,7/7/2022,,,,7/26/2022,,,,8/10/2022,,,,,,,,,,,,10/4/2022,,,,,,,,,,10/25/2022,,,,,,,,,,,,,,12/13/2022,,,,,,,,,,4/14/2023,,,,,,,,,,,,,,,,8/8/2023,,,,,,,
1-3D8O5X,TAK-418-0005,'TAK-418-0005,,TAK-418,"A Non-Interventional, Naturalistic Autism Spectrum Disorder Biomarker Study in Pediatric Autism Patients",,0,Cancelled,Other,NS,,,,,,,,90,0,0,,0,,0,0.00%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3D8O53,TBD-1-3D8O53,'TBD-1-3D8O53,,,Ph3 Pivotal/Confirmatory SqNSCLC,TBD-1-3D8O53 + INK128,III,Planned,,,,,,,,,,350,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3DYC4G,TAK-994-1004,'TAK-994-1004,,TAK-994,"A Phase 1 Study to Assess Absolute Bioavailability of TAK-994 and to Characterize Mass Balance, Pharmacokinetics, Absorption, Metabolism, and Excretion of [14C]TAK-994 in Male Healthy Subjects",TAK-994 ADME study,I,Planned,Sleep Disorders,NS,Early NS,,Non-pediatric only (>18 yr),Interventional,,,,6,6,17,,0,0,0,100.00%,1,,,Celerion,,Erin Hefner,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,1/12/2021,1/12/2021,3/9/2021,3/9/2021,,,4/14/2021,4/14/2021,4/22/2021,4/22/2021,,,5/13/2021,5/13/2021,,,6/20/2021,6/20/2021,,,,,,,,,,,7/23/2021,,,,,,,,,,8/13/2021,,,,,,,,,,,,,,8/19/2021,,,,,,,,,,4/21/2022,,,,,,,,,,,,,,,,6/17/2022,,,,,,,
1-3DYC4P,TAK-994-1007,'TAK-994-1007,,TAK-994,"A Phase 1, Human Drug Drug Interaction Study of TAK-994 and Modafinil in Normal Healthy Volunteers",TAK-994 DDI study,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,3/21/2022,,4/18/2022,,,,6/13/2022,,7/11/2022,,,,8/10/2022,,,,8/24/2022,,,,,,,,,,,,10/19/2022,,,,,,,,,,11/2/2022,,,,,,,,,,,,,,11/15/2022,,,,,,,,,,2/7/2023,,,,,,,,,,,,,,,,8/23/2023,,,,,,,
1-3DYC4Y,TAK-994-1006,'TAK-994-1006,,TAK-994,"A Phase 1, Relative Bio-Availability Study of TAK-994 in Normal Healthy Volunteers",TAK-994 BA study,I,Recruitment Complete,Sleep Disorders,NS,Early NS,,Non-pediatric only (>18 yr),Interventional,Treatment,,,54,54,119,,0,0,0,100.00%,2,,,Celerion,,Erin Hefner,,,,,,,,,Wave 1,Accelerate,Wave 1,Medidata CTMS (Pharma),,,10/15/2020,10/15/2020,12/17/2020,12/17/2020,,,2/16/2021,2/16/2021,3/2/2021,3/2/2021,,,3/12/2021,3/12/2021,,,4/5/2021,4/5/2021,,,,,,,,,,,5/7/2021,5/7/2021,,,,,,,,,5/18/2021,5/18/2021,,,,,,,,,,,,,7/20/2021,,,,,,,,,,9/29/2021,,,,,,,,,,,,,,,,4/1/2022,,,,,,,
1-3DYC5G,TAK-994-1009,'TAK-994-1009,,TAK-994,"A Phase 1, TAK-994 Pharmacokinetic Study In Renal Impaired Patients",TAK-994  PK Study in Renal Impaired Pt,I,Planned,"(MCL) Mantle cell lymphoma, 1st line",NS,Early NS,,Non-pediatric only (>18 yr),Interventional,,,,72,,,,,,,,1,,,Celerion,,Veronique Copalu,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,7/9/2021,7/9/2021,9/10/2021,,,,11/4/2021,,12/2/2021,,,,5/31/2022,,,,6/14/2022,,,,,,,,,,,,8/9/2022,,,,,,,,,,8/30/2022,,,,,,,,,,,,,,9/5/2022,,,,,,,,,,11/28/2022,,,,,,,,,,,,,,,,6/13/2023,,,,,,,
1-3DYC5P,TAK-994-3002,'TAK-994-3002,,TAK-994,A Phase 3 Safety and Efficacy Study of TAK-994 vs. Active Comparator in Type 1 Narcoleptic Patients,TBD-1-3DYC5P Type 1 Narcolepsy Patients TAK-994,III,Planned,Sleep Disorders,NS,Late NS,,,,,,,180,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,9/10/2021,,10/15/2021,,,,9/12/2022,,10/24/2022,,,,9/19/2023,,,,11/14/2023,,,,,,,,,,,,12/12/2023,,,,,,,,,,12/19/2023,,,,,,,,,,,,,,,,,,,,,,,,4/1/2024,,,,,,,,,,,,,,,,11/12/2024,,,,,,,
1-3DYC5Y,TAK-994-3003,'TAK-994-3003,,TAK-994,A Phase 3 Open Label Extenstion Study of TAK-994 in Type 1 Narcoleptic Patients,TAK-994 Open Label Extention Study,III,Planned,Sleep Disorders,NS,Late NS,,,,,,,400,,,,,,,,100,,,TBD,,Marilyn Swick,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,6/21/2021,6/21/2021,9/17/2021,,,,10/28/2021,,10/28/2021,,,,11/22/2023,,,,10/23/2024,,,,,,,,,,,,11/25/2024,,,,,,,,,,12/2/2024,,,,,,,,,,,,,,,,,,,,,,,,4/1/2025,,,,,,,,,,,,,,,,10/22/2025,,,,,,,
1-3DYC45,TAK-994-1005,'TAK-994-1005,,TAK-994,"A Phase 1, Human Abuse Liability Study of TAK-994 in Normal Healthy Volunteers",TAK-994 Abuse Liability Study,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,6/10/2022,,8/12/2022,,,,10/21/2022,,11/18/2022,,,,3/27/2023,,,,4/10/2023,,,,,,,,,,,,6/5/2023,,,,,,,,,,6/26/2023,,,,,,,,,,,,,,6/30/2023,,,,,,,,,,9/22/2023,,,,,,,,,,,,,,,,4/8/2024,,,,,,,
1-3DYC57,TAK-994-1008,'TAK-994-1008,,TAK-994,"A Phase 1, Thorough QT (TQT) Study of TAK-994 in Normal Healthy Volunteers",TAK-994 TQT study,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,11/2/2021,,1/4/2022,,,,3/9/2022,,3/23/2022,,,,7/21/2022,,,,8/14/2022,,,,,,,,,,,,1/5/2023,,,,,,,,,,1/26/2023,,,,,,,,,,,,,,7/4/2023,,,,,,,,,,9/26/2023,,,,,,,,,,,,,,,,9/26/2023,,,,,,,
1-3DYC68,TAK-994-3001,'TAK-994-3001,,TAK-994,A Phase 3 Safety and Efficacy Study of TAK-994 in Type 1 Narcoleptic Patients,P3 Study in Type 1 Narcolepsy Patients TAK-994,III,Planned,Sleep Disorders,NS,Late NS,,,,,,,120,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,11/17/2021,,4/14/2022,,,,5/26/2022,,6/17/2022,,,,6/12/2023,,,,8/7/2023,,,,,,,,,,,,9/1/2023,,,,,,,,,,9/18/2023,,,,,,,,,,,,,,9/28/2023,,,,,,,,,,12/21/2023,,,,,,,,,,,,,,,,8/2/2024,,,,,,,
1-3DYCDB,TAK-951-0001,'TAK-951-0001,,TAK-951,A Ph0 natural history study in CVS patients,NH trial in CVS pts track digital prodromal BM,0,Recruiting,Cyclic Vomiting Syndrome-Prodrome,GI,Early GI,,,,,,,100,64,80,,10,,11,64.00%,1,,,Cambridge Cognition,,Rhett Behrje,,,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,10/4/2019,10/4/2019,4/24/2020,4/24/2020,,,2/8/2021,2/8/2021,2/15/2021,2/15/2021,,,8/30/2021,,,,2/28/2022,,,,,,,,,,,,3/31/2022,,,,,,,,,,4/14/2022,,,,,,,,,,,,,,4/28/2022,,,,,,,,,,9/8/2022,,,,,,,,,,,,,,,,9/8/2022,,,,,,,
1-3DYCDM,TAK-951-1004,'TAK-951-1004,,TAK-951,A Ph1 IV PK profiling study in healthy volunteers,TAK951 Ph1 IV PK Profiling Study,I,Completed,Dyslipidemia,GI,Early GI,,,Interventional,,,,40,32,112,,0,0,0,80.00%,1,,,Celerion,,Veronique Copalu,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,2/14/2020,2/14/2020,5/11/2020,5/11/2020,,,7/7/2020,7/7/2020,10/9/2020,10/9/2020,,,4/18/2021,4/18/2021,,,5/16/2021,5/16/2021,,,,,,,,,,,6/14/2021,6/14/2021,,,,,,,,,,,,,,,,,,,,,,,8/30/2021,,,,,,,,,,10/7/2021,,,,,,,,,,,,,,,,10/7/2021,,,,,,,
1-3DYCHR,TBD-1-3DYCHR,'TBD-1-3DYCHR,,,Naturalistic Registry Study of Type 1 Narcoleptic Patients,TBD-1-3DYCHR TAK-994,0,Planned,,,,,,,,,,40,,,,,,,,5,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3DYCIB,TBD-1-3DYCIB,'TBD-1-3DYCIB,,TAK-994,A Phase 3 Safety and Efficacy Study of TAK-994 and an Active Comparator in Type 1 Narcoleptic Patients,TAK-994-TBD Phase 3 Active Comparator Study (for E,III,Planned,"(MCL) Mantle cell lymphoma, 1st line",NS,Late NS,,,,,,,180,,,,,,,,30,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,12/31/2021,,5/20/2022,,,,8/5/2022,,12/30/2022,,,,2/23/2024,,,,5/17/2024,,,,,,,,,,,,6/27/2024,,,,,,,,,,7/11/2024,,,,,,,,,,,,,,7/24/2024,,,,,,,,,,10/16/2024,,,,,,,,,,,,,,,,5/15/2025,,,,,,,
1-3DYCL9,TAK-079-1004,'TAK-079-1004,,Mezagitamab (TAK-079),"A Randomized, Double-blind, Placebo-Controlled Phase II study of Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune Thrombocytopenic Purpura",TAK-079-1004 TAK-079,II,Recruiting,(ITP) Immune Thrombocytopenic Purpura,RGH,Others,,,,,,,54,12,33,,20,12,1,22.22%,33,30,,PPD,,Lauren Dinsmore,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/6/2019,8/6/2019,11/6/2019,11/6/2019,,,,,11/25/2020,11/25/2020,,,3/15/2023,,3/11/2024,,3/11/2024,,,,,,,,,,,,4/8/2024,,,,,,,,,,4/4/2024,,,,,,,,,,,,,,4/29/2024,,,,,,,,,,7/29/2024,,,,,,,,,,,,,,,,7/29/2024,,,,,,,
1-3DYCND,TBD-1-3DYCND,'TBD-1-3DYCND,,TAK-635,A Phase 1 DDI study to support Ph2 development,Ph1 DDI study,I,Cancelled,Irritable bowel syndrome,GI,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,10/2/2020,,,,10/30/2020,,11/27/2020,,,,12/14/2020,,,,12/18/2020,,,,,,,,,,,,1/15/2021,,,,,,,,,,1/22/2021,,,,,,,,,,,,,,,,,,,,,,,,6/25/2021,,,,,,,,,,,,,,,,12/17/2021,,,,,,,
1-3DYCNO,TBD-1-3DYCNO,'TBD-1-3DYCNO,,TAK-635,A Phase 1 FIH SAD/MAD study with formulation and food effect evaluation,Ph1 FIH SAD/MAD/Formulation Food Effect,I,Cancelled,Irritable bowel syndrome,GI,,,,,,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/27/2019,9/27/2019,2/6/2020,,,,5/1/2020,,5/29/2020,,,,12/18/2020,,,,12/18/2020,,,,,,,,,,,,1/15/2021,,,,,,,,,,1/22/2021,,,,,,,,,,,,,,,,,,,,,,,,6/25/2021,,,,,,,,,,,,,,,,12/17/2021,,,,,,,
1-3DYCO1,TBD-1-3DYCO1,'TBD-1-3DYCO1,,TAK-635,A Phase 1 JP ethnic PK study to enable Japan to join the phase 2/global program in IBD,Ph1 Japanese PK study,I,Cancelled,Irritable bowel syndrome,GI,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,5/17/2022,,,,6/14/2022,,7/12/2022,,,,8/10/2022,,,,8/23/2022,,,,,,,,,,,,9/20/2022,,,,,,,,,,9/27/2022,,,,,,,,,,,,,,,,,,,,,,,,2/28/2023,,,,,,,,,,,,,,,,8/22/2023,,,,,,,
1-3DYCOA,TBD-1-3DYCOA,'TBD-1-3DYCOA,,TAK-635,A Phase 1 Human ADME study,Ph 1 Human ADME study,I,Cancelled,Dental pain,GI,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,6/13/2023,,,,8/8/2023,,9/5/2023,,,,9/26/2023,,,,10/13/2023,,,,,,,,,,,,11/10/2023,,,,,,,,,,11/17/2023,,,,,,,,,,,,,,,,,,,,,,,,4/19/2024,,,,,,,,,,,,,,,,10/11/2024,,,,,,,
1-3DYCOJ,TBD-1-3DYCOJ,'TBD-1-3DYCOJ,,TAK-635,A Phase 2a proof of concept study in IBD patients,Ph2a ePoC study in IBD patients,IIa,Cancelled,Irritable bowel syndrome,GI,,,,,,,,60,,,,,,,,15,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/6/2020,,12/29/2020,,,,4/20/2021,,4/20/2021,,,,7/20/2023,,,,10/12/2023,,,,,,,,,,,,12/7/2023,,,,,,,,,,12/14/2023,,,,,,,,,,,,,,,,,,,,,,,,10/10/2024,,,,,,,,,,,,,,,,10/10/2024,,,,,,,
1-3ELU4K,TAK-925-1016,'TAK-925-1016,,TAK-925,"A Phase 1, of TAK-925 and Cobicistat FDC Tablets in Normal Healthy Volunteers",TAK-925 1016 TYBOST Combination Repeat Dose clinic,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,32,,,,,,,,1,,,"Celerion, Inc",,Erin Hefner,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,10/16/2020,10/16/2020,11/20/2020,11/20/2020,,,8/16/2021,,8/16/2021,,,,11/8/2021,,,,11/26/2021,,,,,,,,,,,,1/21/2022,,,,,,,,,,2/11/2022,,,,,,,,,,,,,,4/1/2022,,,,,,,,,,8/3/2022,,,,,,,,,,,,,,,,11/25/2022,,,,,,,
1-3ELU4T,TBD-1-3ELU4T,'TBD-1-3ELU4T,,TAK-925,A Phase 1 Study of TAK-925  Buccal/Sublingual Film & Sublingual Tablet in Healthy Volunteers,TBD-1-3ELU4T TAK-925,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,24,,,,,,,,1,,,TBD,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3ELU5B,TAK-925-1012,'TAK-925-1012,,TAK-925,A Phase 1 Study of TAK-925 Continuous Subcutaneous Infusion in Normal Healthy Volunteers,TAK-925-1012 SubQ continuous infusion single dose,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,24,,,,,,,,1,,,PRA,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,5/19/2022,,6/30/2022,,,,8/31/2022,,9/1/2022,,,,9/14/2022,,,,9/20/2022,,,,,,,,,,,,11/15/2022,,,,,,,,,,12/6/2022,,,,,,,,,,,,,,1/24/2023,,,,,,,,,,5/26/2023,,,,,,,,,,,,,,,,9/19/2023,,,,,,,
1-3ELU5K,TBD-1-3ELU5K,'TBD-1-3ELU5K,,TAK-994,A Phase II POC NT2 Patients,Phase 2 NT2 POC Study,I,Planned,Sleep Disorders,NS,Late NS,,,,,,,72,,,,,,,,20,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,11/15/2021,,1/17/2022,,,,3/28/2022,,4/25/2022,,,,6/15/2023,,,,7/13/2023,,,,,,,,,,,,9/7/2023,,,,,,,,,,9/28/2023,,,,,,,,,,,,,,10/19/2023,,,,,,,,,,1/11/2024,,,,,,,,,,,,,,,,7/11/2024,,,,,,,
1-3ELU5T,TBD-1-3ELU5T,'TBD-1-3ELU5T,,,A Phase 2 TAK-994 Study of Attention-Deficit/Hyperactivity Disorder Patients with Excessive Daytime Sleepiness,TBD-1-3ELU5T TAK-994,I,Planned,,,,,,,,,,80,,,,,,,,25,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3ELU9B,TBD-1-3ELU9B,'TBD-1-3ELU9B,,,A Phase 2 TAK-994 Study of Atypical Depression Patients with Excessive Day Sleepiness,TBD-1-3ELU9B TAK-994,I,Planned,,,,,,,,,,70,,,,,,,,20,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3ELU9L,TBD1-3ELU9L,'TBD1-3ELU9L,,,A Phase 1b TAK-994 Study of Hallucinations in Patients with Dementia With Lewy Bodies (DLB),TBD1-3ELU9L TAK-994,Ib,Planned,,,,,,,,,,40,,,,,,,,15,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3ELU9U,TBD-1-3ELU9U,'TBD-1-3ELU9U,,,A Phase 1b Biomarker Study of Digital Wearable Devices in Type 1 Narcoleptic Patients in China,TBD-1-3ELU9U TAK-994,Ib,Planned,,,,,,,,,,40,,,,,,,,3,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3ELU49,TAK-925-1013,'TAK-925-1013,,TAK-925,PK study - TAK-925 and Cobicistat,TAK-925-1013 TAK-925,I,All Activities Closed,Sleep Disorders,NS,Early NS,,,,,,,16,16,37,,0,0,0,100.00%,1,,,Celerion,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,11/25/2019,11/25/2019,1/24/2020,1/24/2020,,,2/11/2020,2/11/2020,2/25/2020,2/25/2020,,,2/26/2020,2/26/2020,,,3/13/2020,3/13/2020,,,,,,,,,,,4/24/2020,4/24/2020,,,,,,,,,4/21/2020,4/21/2020,,,,,,,,,,,,,8/24/2020,8/24/2020,,,,,,,,,12/11/2020,12/11/2020,,,,,,,,,,,,,,,3/11/2021,3/11/2021,,,,,,
1-3ELU52,TAK-925-1014,'TAK-925-1014,,TAK-925,A Phase 1 Study of TAK-925 Transdermal Liquid Reservoir Patch in Normal Healthy Volunteers,TAK-925-1014 Repeat dose Patch Safety and Tolerabi,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,24,,,,,,,,1,,,TBD,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,12/28/2021,,2/8/2022,,,,4/11/2022,,4/12/2022,,,,5/13/2022,,,,5/20/2022,,,,,,,,,,,,7/8/2022,,,,,,,,,,7/29/2022,,,,,,,,,,,,,,9/16/2022,,,,,,,,,,1/18/2023,,,,,,,,,,,,,,,,5/19/2023,,,,,,,
1-3ELUA3,TAK-994-1502,'TAK-994-1502,,,"A Phase 1B, Night Time Threshold Study of TAK-994 in Healthy Normal Volunteers and Type 1 Narcoleptic Patients",,IB,Cancelled,Other,,,,,,,,,30,0,0,,0,,0,0.00%,5,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3F2E80,TBD-1-3F2E80,'TBD-1-3F2E80,,,TAK-102 TBD,TAK-102 Cell Therapies,I,Planned,,,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3G1MUN,TAK-994-0001,'TAK-994-0001,,TAK-994,A Phase 0 Biomarker Study to Assess Night-to-Night Variance in Sleep Electroencephalography (EEG) in Patients with type 1 narcolepsy (NT1) Compared to Healthy Controls,TAK-994-0001 TAK-994,0,Completed,Sleep Disorders,NS,Late NS,,,,,,,32,33,0,,13,0,,103.13%,12,5,,IQVIA,,Marilyn Swick,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,12/19/2019,12/19/2019,2/20/2020,2/20/2020,,,6/30/2020,6/30/2020,8/3/2020,8/3/2020,,,4/26/2021,4/26/2021,,,5/4/2021,5/4/2021,,,,,,,,,,,7/30/2021,,,,,,,,,,8/11/2021,,,,,,,,,,,,,,8/19/2021,,,,,,,,,,8/31/2021,,,,,,,,,,,,,,,,5/2/2022,,,,,,,
1-3GVQ8W,TAK-102-1501,'TAK-102-1501,,TAK-102,"An Open-Label, Dose Escalation, Phase 1/2, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing, Relapsed/Refractory Solid Tumors",TAK-102-1501,I/II,Not Yet Recruiting,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,,14,7,0,,0,0,0,50.00%,3,2,,TBD,,Ippei Nakayama,,,,,,Approved,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3HUR3B,Darvadstrocel-3005,'Darvadstrocel-3005,,Alofisel,"A Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of complex cryptoglandular fistula",CCF Ph3 safety and efficacy,III,Cancelled,Other,GI,,,,,,,,200,0,0,,0,,0,0.00%,100,,,IQVIA,,,,,,,,,,,NA,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3HUR3S,Darvadstrocel-3006,'Darvadstrocel-3006,,Alofisel,"A Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of darvadstrocel in the Treatment of Rectovaginal Fistula in Crohn’s Disease Patients.",RVF Ph3 safety and efficacy,III,Cancelled,Other,GI,,,,,,,,256,0,0,,0,,0,0.00%,150,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3HUR41,Darvadstrocel-1001,'Darvadstrocel-1001,,Alofisel,An open label Phase 1 Study to Evaluate an optimal surgical technique for administration of darvadstrocel for the Treatment of Rectovaginal Fistula in Crohn’s Disease Patients.,RVF Surgical Optimzation,I,Planned,Complex Perianal Fistulas,GI,,,,,,,,35,,,,,,,,10,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3ILKVN,TAK-981-1502,'TAK-981-1502,,TAK-981,"A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors",PD1,Ib,Recruiting,Multiple cancer,Oncology,Early Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,,,228,31,38,,6,,23,13.60%,60,35,,PPD,,"Dana Atkinson, Linda Nadrowski",,,,2020-004325-23,,Approved,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,,,2/19/2020,2/19/2020,,,,,8/24/2020,8/24/2020,,,11/2/2022,,5/1/2023,,12/2/2022,,,,,,,,5/25/2024,,,,12/9/2022,,,,,,,,6/8/2024,,12/16/2022,,,,,,,,,,,,,,12/23/2022,,,,,,,,7/6/2024,,3/17/2023,,,,,,,,10/26/2024,,,,,,,,3/12/2025,,,,,,,
1-3JM5ZT,TBD-1-3JM5ZT,'TBD-1-3JM5ZT,,TAK-252,Ph2 Registration (TBD),Ph2 Registration,II,Planned,Multiple cancer,Oncology,Late Oncology,,,,,,,150,,,,,,,,20,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/10/2022,,7/5/2022,,,,,,10/24/2022,,,,2/10/2025,,5/6/2026,,5/6/2026,,,,,,,,,,,,7/1/2026,,,,,,,,,,7/8/2026,,,,,,,,,,,,,,7/29/2026,,,,,,,,,,12/9/2026,,,,,,,,,,8/9/2025,,,,,,12/9/2026,,,,,,,
1-3KNU5B,TBD-1-3KNU5B,'TBD-1-3KNU5B,,TAK-994,OSA PH II POC,TBD-1-3KNU5B ePOC TAK-994,II,Cancelled,,NS,Late NS,,,,,,,50,,,,,,,,20,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/1/2021,,4/1/2021,,,,8/2/2021,,8/2/2021,,,,6/7/2022,,,,6/27/2022,,,,,,,,,,,,7/25/2022,,,,,,,,,,8/1/2022,,,,,,,,,,,,,,9/12/2022,,,,,,,,,,12/16/2022,,,,,,,,,,,,,,,,6/26/2023,,,,,,,
1-3KNU5L,TBD-1-3KNU5L,'TBD-1-3KNU5L,,TAK-994,IH PH II POC,TBD-1-3KNU5L ePOC TAK-994,II,Planned,IH (Idiopathic Hypersomnia),NS,Late NS,,,,,,,50,,,,,,,,20,,,IQVIA,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,10/6/2021,,12/8/2021,,,,4/4/2022,,4/4/2022,,,,7/14/2023,,,,8/11/2023,,,,,,,,,,,,9/11/2023,,,,,,,,,,9/18/2023,,,,,,,,,,,,,,11/6/2023,,,,,,,,,,8/9/2024,,,,,,,,,,,,,,,,8/9/2024,,,,,,,
1-3LQ3WV,TBD-1-3LQ3WV,'TBD-1-3LQ3WV,,soticlestat (TAK-935),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 in Adult Subjects With Chronic Complex Regional Pain Syndrome",A Ph 3 study on Eff. and Safety of TAK-935 on CRPS,III,Planned,(Ph+ ALL) Philadelphia chromosome-positive acute lymphoblastic leukemia,NS,Late NS,,,,,,,200,,,,,,,,20,,,TBD,,Siew Tin Gan,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3LQ3X7,TBD-1-3LQ3X7,'TBD-1-3LQ3X7,,soticlestat (TAK-935),"An open-label, multi-site extension study to assess the long term safety and tolerability of TAK-935 in adult subjects with Chronic Complex Regional Pain Syndrome (CRPS)",An OLE study of TAK-935 in CRPS,III,Planned,,NS,Late NS,,,,,,,224,,,,,,,,25,,,TBD,,Siew Tin Gan,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3LQ3XP,TAK-341-1001,'TAK-341-1001,,TAK-341,MSA MAD,MSA MAD,I,Planned,Multiple System Atrophy,NS,Late NS,,,,,,,60,,,,,,,,20,,,PPD,,Jamie Jay Rothstein,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,8/9/2021,,1/31/2022,,,,2/25/2022,,8/5/2022,,,,9/15/2022,,,,9/15/2023,,,,,,,,,,,,7/1/2022,,,,,,,,,,2/2/2023,,,,,,,,,,,,,,,,,,,,,,,,2/15/2024,,,,,,,,,,,,,,,,2/15/2024,,,,,,,
1-3LQ3Y0,TBD-1-3LQ3Y0,'TBD-1-3LQ3Y0,,,ePOC Other 1,ePOC Other 1,I,Cancelled,Other,,,,,,,,,30,0,0,,0,,0,0.00%,15,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3LQ3Y9,TBD-1-3LQ3Y9,'TBD-1-3LQ3Y9,,TAK-994,ePOC Other Prader Willi Syndrome,ePOC Other 2,I,Cancelled,Support,NS,Late NS,,,,,,,30,,,,,,,,15,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,11/12/2021,,1/14/2022,,,,3/25/2022,,4/22/2022,,,,12/30/2022,,,,1/27/2023,,,,,,,,,,,,3/24/2023,,,,,,,,,,4/14/2023,,,,,,,,,,,,,,9/20/2023,,,,,,,,,,12/13/2023,,,,,,,,,,,,,,,,1/26/2024,,,,,,,
1-3LQ3YI,TBD-1-3LQ3YI,'TBD-1-3LQ3YI,,TAK-994,OSA PH III,OSA PH III,I,Planned,OSA (Obstructive Sleep Apnea),NS,Late NS,,,,,,,360,,,,,,,,40,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,3/10/2025,,5/12/2025,,,,8/4/2025,,9/1/2025,,,,7/28/2026,,,,10/20/2026,,,,,,,,,,,,11/17/2026,,,,,,,,,,12/1/2026,,,,,,,,,,,,,,,,,,,,,,,,3/8/2027,,,,,,,,,,,,,,,,10/19/2027,,,,,,,
1-3LQ3YR,TBD-1-3LQ3YR,'TBD-1-3LQ3YR,,TAK-994,OSA PH III Comp,OSA PH II Comp,I,Planned,OSA (Obstructive Sleep Apnea),NS,Late NS,,,,,,,480,,,,,,,,60,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,3/10/2025,,5/12/2025,,,,8/4/2025,,9/1/2025,,,,7/28/2026,,,,10/20/2026,,,,,,,,,,,,11/17/2026,,,,,,,,,,12/1/2026,,,,,,,,,,,,,,,,,,,,,,,,3/8/2027,,,,,,,,,,,,,,,,10/19/2027,,,,,,,
1-3LQ3Z0,TBD-1-3LQ3Z0,'TBD-1-3LQ3Z0,,TAK-994,OSA PH III OLE,OSA PH III OLE,I,Planned,OSA (Obstructive Sleep Apnea),NS,,,,,,,,300,,,,,,,,60,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,12/12/2022,,5/15/2023,,,,1/3/2024,,1/3/2024,,,,4/15/2025,,,,8/1/2026,,,,,,,,,,,,5/14/2025,,,,,,,,,,5/21/2025,,,,,,,,,,,,,,7/9/2025,,,,,,,,,,4/14/2026,,,,,,,,,,,,,,,,2/8/2027,,,,,,,
1-3LQ3Z9,TAK-994-3006,'TAK-994-3006,,TAK-994,IH PH III,IH PH III,I,Planned,(MM) Multiple myeloma relapsed/refractory Lower Costs,NS,,,,,,,,240,,,,,,,,40,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/7/2023,,1/29/2024,,,,4/22/2024,,5/20/2024,,,,1/10/2026,,,,4/3/2026,,,,,,,,,,,,5/1/2026,,,,,,,,,,5/15/2026,,,,,,,,,,,,,,,,,,,,,,,,8/20/2026,,,,,,,,,,,,,,,,8/20/2026,,,,,,,
1-3LQ3Z9,TBD-1-3LQ3Z9,'TBD-1-3LQ3Z9,,TAK-994,IH PH III,IH PH III,I,Planned,IH (Idiopathic Hypersomnia),NS,,,,,,,,240,,,,,,,,40,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,11/7/2023,,1/29/2024,,,,4/22/2024,,5/20/2024,,,,1/10/2026,,,,4/3/2026,,,,,,,,,,,,5/1/2026,,,,,,,,,,5/15/2026,,,,,,,,,,,,,,,,,,,,,,,,8/20/2026,,,,,,,,,,,,,,,,8/20/2026,,,,,,,
1-3LQ4C5,TAK-676-1002,'TAK-676-1002,,TAK-676,"An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors",TAK-676 as Single Agent and in Combination With Pe,I,Recruiting,Multiple cancer,Oncology,Early Oncology,,,,Treatment,,,76,26,30,,3,,21,34.21%,8,9,,PRA,,Laurie Lobue,,,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,11/20/2019,11/20/2019,1/17/2020,1/17/2020,,,,,8/4/2020,8/4/2020,,,5/9/2022,,1/4/2023,,1/4/2023,,,,,,,,,,,,3/1/2023,,,,,,,,,,3/8/2023,,,,,,,,,,,,,,3/15/2023,,,,,,,,,,6/7/2023,,,,,,,,,,,,,,,,6/7/2023,,,,,,,
1-3LQ45H,Pevonedistat-3001CCC,'Pevonedistat-3001CCC,,pevonedistat (TAK-924),"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia",Pevonedistat-3001CCC,III,Recruiting,Blood cancer,Oncology,Late Oncology,,,,,,,48,13,15,,2,,,27.08%,12,,,PPD,,"Tracy CHEN, Lydia Liu",,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,8/11/2020,8/11/2020,,,,,12/6/2020,12/6/2020,,,7/31/2022,,7/25/2023,,4/30/2023,,,,,,,,1/15/2025,,,,6/25/2023,,,,,,,,3/12/2025,,7/2/2023,,,,,,,,3/19/2025,,,,,,7/23/2023,,,,,,,,4/9/2025,,8/31/2023,,,,,,,,7/16/2025,,,,,,,,7/16/2025,,,,,,,
1-3LQ411,TAK-935-1004,'TAK-935-1004,,soticlestat (TAK-935),A phase 1 study to characterize the safety and tolerability profile of TAK-935 following single and multiple dose with titration in healthy Japanese adults subjects.,A phase 1 SRD/MRD study in Japanese healthy adult,I,Reported,(GvHD) Graft versus host disease,NS,,,,,,,,32,0,,,,,,0.00%,1,,,PRA,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,3/5/2020,3/5/2020,5/11/2020,5/11/2020,,,8/13/2020,8/13/2020,8/24/2020,8/24/2020,,,10/21/2020,10/21/2020,,,11/14/2020,11/14/2020,,,,,,,,,,,3/18/2021,3/18/2021,,,,,,,,,3/24/2021,3/24/2021,,,,,,,,,,,,,4/8/2021,4/8/2021,,,,,,,,,4/22/2021,4/22/2021,,,,,,,,,,,,,,,4/22/2021,4/22/2021,,,,,,
1-3MH6AD,TBD-1-3MH6AD,'TBD-1-3MH6AD,,,A Phase 1 TAK-925 Transdermal Liquid Reservoir Patch Study Evaluating PK At Multiple Sites in Normal Health Volunteers,TAK-925 Multiple Site PK Patch Study,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3MH6AO,TBD-1-3MH6AO,'TBD-1-3MH6AO,,,A Phase 1 TAK-925 Transdermal Liquid Reservoir Patch Study Evaluating PK in Aged Skin in an Elderly Population,TAK-925 Aged Skin PK Patch Study,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3MH6AX,TBD-1-3MH6AX,'TBD-1-3MH6AX,,,A Phase I Relative BA Study in Healthy Normal Subjects Evaluating TAK-925 Buccal  Formulation,TAK-925 Buccal rBA Study,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3NFFME,TAK-788-2001,'TAK-788-2001,,Mobocertinib (TAK-788),A Phase 2 Multicenter Open-label expansion Study to Evaluate the Safety profile and Patient-Reported Outcomes of TAK-788 in Patients with Non-Small Cell Lung Cancer With EGFR or HER2 Mutations,TAK-788 AE Management Study,II,Withdrawn,Support - Oncology,Oncology,Late Oncology,,,,,,,60,,,,,,,,30,,,PPD,,Calvin Gooden,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/16/2020,3/16/2020,7/21/2020,7/21/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/21/2020,7/21/2020,,,,,,
1-3NFG0L,TAK-925-1017,'TAK-925-1017,,TAK-925,A Phase I Relative BA Study in Healthy Normal Subjects Evaluating TAK-925 Tablet  Formulation,TAK-925 rBA TAK-925 tablet,I,Cancelled,"(MCL) Mantle cell lymphoma, 1st line",NS,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,11/18/2021,,1/20/2022,,,,3/23/2022,,3/24/2022,,,,4/22/2022,,,,5/12/2022,,,,,,,,,,,,7/7/2022,,,,,,,,,,7/28/2022,,,,,,,,,,,,,,8/4/2022,,,,,,,,,,10/27/2022,,,,,,,,,,,,,,,,5/11/2023,,,,,,,
1-3NFG0V,TBD-1-3NFG0V,'TBD-1-3NFG0V,,,A Phase I multiple dose Study in Healthy Normal Subjects Evaluating TAK-925 sublingual Film Formulation,TAK-925 - sublingual film repeat dose PK study,I,Planned,,,,,,,,,,8,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3NFG1I,TBD-1-3NFG1I,'TBD-1-3NFG1I,,,A Phase I relative BA Study in Healthy Normal Subjects Evaluating single dose TAK-925 subcutaneous bolus injection Formulation,TAK-925 - rBA Sub Q single bolus injection,I,Planned,,,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3NFG1V,TBD-1-3NFG1V,'TBD-1-3NFG1V,,TAK-925,A Phase I multiple dose Study in Healthy Normal Subjects Evaluating TAK-925 subcutaneous infusion Formulation,TAK-925 -Sub Q continuous infusion multiple dose P,I,Planned,,NS,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/15/2023,,3/29/2023,,,,5/30/2023,,5/31/2023,,,,7/18/2023,,,,8/28/2023,,,,,,,,,,,,10/23/2023,,,,,,,,,,11/13/2023,,,,,,,,,,,,,,11/20/2023,,,,,,,,,,2/12/2024,,,,,,,,,,,,,,,,8/26/2024,,,,,,,
1-3NFG09,TBD-1-3NFG09,'TBD-1-3NFG09,,,A Phase I multiple dose Study in Healthy Normal Subjects Evaluating TAK-925 Buccal Film Formulation,TAK-925 Buccal Film multiple dose PK,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3NFG14,TBD-1-3NFG14,'TBD-1-3NFG14,,,A Phase I multiple dose Study in Healthy Normal Subjects Evaluating TAK-925 sublingual solution Formulation,TAK-925 - sublingual solution repeat dose,I,Planned,,,,,,,,,,8,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3NFG24,TAK-1-3NFG24,'TAK-1-3NFG24,,,A Phase I multiple dose Study in Healthy Normal Subjects Evaluating TAK-925 bolus injection Formulation,TAK-925-  Sub Q single bolus injection multiple,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3OWCJQ,TBD-1-3OWCJQ,'TBD-1-3OWCJQ,,TAK-605 TBio-6517,Ph 1/2a IV Solid Tumor - IV SA,Ph 1/2a Solid Tumor - IV SA,I/II,Planned,,Oncology,Late Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/8/2021,,7/29/2021,,,,,,10/21/2021,,,,9/16/2022,,2/13/2023,,2/13/2023,,,,,,,,,,,,4/7/2023,,,,,,,,,,4/14/2023,,,,,,,,,,,,,,5/5/2023,,,,,,,,,,9/15/2023,,,,,,,,,,,,,,,,9/15/2023,,,,,,,
1-3OWCKE,TBD-1-3OWCKE,'TBD-1-3OWCKE,,TAK-605 TBio-6517,Ph 1/2a IV Solid Tumor - IV + PD-1,Ph 1/2a IV Solid Tumor - IV + PD-1,I/II,Planned,,Oncology,Late Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/2/2022,,6/27/2022,,,,,,10/16/2022,,,,9/11/2023,,12/4/2024,,12/4/2024,,,,,,,,,,,,1/28/2025,,,,,,,,,,2/4/2025,,,,,,,,,,,,,,2/25/2025,,,,,,,,,,7/8/2025,,,,,,,,,,,,,,,,7/8/2025,,,,,,,
1-3OWCKO,TBD-1-3OWCKO,'TBD-1-3OWCKO,,TAK-605 TBio-6517,Ph 1 IV Solid Tumor - IV + Chemo,Ph 1 IV Solid Tumor - IV + Chemo,I,Planned,,Oncology,Late Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/2/2022,,6/27/2022,,,,,,10/16/2022,,,,7/13/2023,,4/8/2024,,4/8/2024,,,,,,,,,,,,5/31/2024,,,,,,,,,,6/7/2024,,,,,,,,,,,,,,6/28/2024,,,,,,,,,,11/8/2024,,,,,,,,,,,,,,,,11/8/2024,,,,,,,
1-3OWCL4,TBD-1-3OWCL4,'TBD-1-3OWCL4,,TAK-605 TBio-6517,Ph 1 CD20+ NHL - IT SA,Ph 1 CD20+ NHL - IT SA,I,Planned,,Oncology,Late Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,10/20/2021,,12/15/2021,,,,,,4/5/2022,,,,7/4/2022,,12/1/2022,,12/1/2022,,,,,,,,,,,,1/26/2023,,,,,,,,,,2/2/2023,,,,,,,,,,,,,,2/23/2023,,,,,,,,,,7/6/2023,,,,,,,,,,,,,,,,7/6/2023,,,,,,,
1-3OWCLD,TBD-1-3OWCLD,'TBD-1-3OWCLD,,TAK-605 TBio-6517,Ph 2/3 Randomized Confirmatory Study,Ph 2/3 Randomized Confirmatory Study,II/III,Planned,,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/9/2024,,9/3/2024,,,,,,12/23/2024,,,,5/7/2025,,1/2/2026,,1/2/2026,,,,,,,,,,,,2/27/2026,,,,,,,,,,3/6/2026,,,,,,,,,,,,,,3/27/2026,,,,,,,,,,6/19/2026,,,,,,,,,,,,,,,,6/19/2026,,,,,,,
1-3OWCLM,TBD-1-3OWCLM,'TBD-1-3OWCLM,,TAK-605 TBio-6517,Ph 1 CD20+ NHL - IT + Rituximab,Ph 1 CD20+ NHL - IT + Rituximab,I,Planned,,Oncology,Late Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/18/2022,,3/15/2022,,,,,,7/4/2022,,,,9/17/2022,,2/14/2023,,2/14/2023,,,,,,,,,,,,4/11/2023,,,,,,,,,,4/18/2023,,,,,,,,,,,,,,5/9/2023,,,,,,,,,,9/19/2023,,,,,,,,,,,,,,,,9/19/2023,,,,,,,
1-3OWCLV,TBD-1-3OWCLV,'TBD-1-3OWCLV,,TAK-605 TBio-6517,Ph 1 CD20+ NHL - IV + Rituximab,Ph 1 CD20+ NHL - IV + Rituximab,I,Planned,,Oncology,Late Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/7/2022,,9/12/2022,,,,,,12/31/2022,,,,3/16/2023,,8/13/2023,,8/13/2023,,,,,,,,,,,,10/6/2023,,,,,,,,,,10/13/2023,,,,,,,,,,,,,,11/3/2023,,,,,,,,,,3/15/2024,,,,,,,,,,,,,,,,3/15/2024,,,,,,,
1-3OWCM9,TBD-1-3OWCM9,'TBD-1-3OWCM9,,TAK-605 TBio-6517,Ph 1 CD20+ NHL + Rituximab (Expansion),Ph 1 CD20+ NHL + Rituximab (Expansion),I,Planned,,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,8/11/2023,,10/6/2023,,,,,,1/25/2024,,,,4/9/2024,,9/6/2024,,9/6/2024,,,,,,,,,,,,11/1/2024,,,,,,,,,,11/8/2024,,,,,,,,,,,,,,11/29/2024,,,,,,,,,,4/11/2025,,,,,,,,,,,,,,,,4/11/2025,,,,,,,
1-3OWCQQ,TAK-007-2001,'TAK-007-2001,,TAK-007,Ph 2 Pivotal r/r DLBCL & Indolent NHL 3L,TAK-007-2001_1-3OWCQQ_Ph 2 Part 1 r/r LBCL and iNHL,II,Not Yet Recruiting,Hypertension,Oncology,Cell Therapy,,,,,,,268,,,,,,,,71,,,TBD,,"Stephen Curwen, Carissa winegar",,,,,,,,,,,Wave 1,Medidata CTMS (Pharma),,,10/15/2020,10/15/2020,5/5/2021,5/5/2021,,,,,11/30/2021,,,,6/13/2024,,7/15/2024,,9/11/2024,,,,,,,,5/18/2029,,,,,,,,,,,,7/13/2029,,,,,,,,,,7/27/2029,,,,,,,,,,,,,,8/10/2029,,,,,,,,,,11/30/2029,,,,,,,,11/30/2029,,,,,,,
1-3OWCR4,TBD-1-3OWCR4,'TBD-1-3OWCR4,,,Post-Marketing LCM,Post-Marketing LCM,IV,Planned,,,Cell Therapy,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3OWCRF,TBD-1-3OWCRF,'TBD-1-3OWCRF,,TAK-007,Ph 2 Pivotal r/r Indolent NHL 3L,Ph 2 Pivotal r/r Indolent NHL 3L,II,Cancelled,"(NHL) Non Hodgkin's Lymphoma, relapsed/refractory",Oncology,Early Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3OWCRP,TBD-1-3OWCRP,'TBD-1-3OWCRP,,,Pediatric Program B,Pediatric Program B,I,Cancelled,,,Cell Therapy,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3OWCRY,TAK-007-2002,'TAK-007-2002,,TAK-007,Ph 2 Pivotal r/r CLL >2L,Ph 2 Pivotal r/r CLL >2L,II,Planned,NSAIDs-induced ulcer,Oncology,Cell Therapy,,,,,,,145,,,,,,,,65,,,PPD,,Dinah Eke,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,6/29/2023,,,,,,8/28/2023,,,,9/15/2025,,10/15/2025,,3/16/2026,,,,,,,,9/4/2030,,,,5/11/2026,,,,,,,,10/30/2030,,5/25/2026,,,,,,,,11/6/2030,,,,,,6/8/2026,,,,,,,,11/27/2030,,10/19/2026,,,,,,,,4/9/2031,,,,,,,,4/9/2031,,,,,,,
1-3PJZCR,NSMM-5001,'NSMM-5001,,,"A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study",NSMM-5001 MLN9708 - IIS,II,Recruiting,,,,,,,,,,1,"4,638",0,,0,0,3983,463800.00%,1,84,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3QKR69,TBD-1-3QKR69,'TBD-1-3QKR69,,soticlestat (TAK-935),"A Phase 3, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and tolerability of 3 doses of TAK-935  as an adjunct therapy in adult participants with Complex Regional Pain Syndrome",Dose-ranging study of TAK-935 as an adjunct therap,III,Planned,,NS,,,,,,,,240,,,,,,,,50,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3QKR78,TAK-788-3002,'TAK-788-3002,,Mobocertinib (TAK-788),A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 + Platinum-Based Chemotherapy Combination as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations,Phase 3 RCT TAK-788 Chemo,III,Cancelled,(NSCLC) Non-small cell lung cancer,Oncology,Late Oncology,,,,,,,273,,,,,,,,250,,,PPD,,,,,,2021-000505-25,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,1/7/2021,1/7/2021,4/30/2021,,,,,,8/31/2021,,,,1/31/2023,,10/30/2023,,2/28/2023,,,,,,,,1/30/2026,,,,4/25/2023,,,,,,,,3/27/2026,,5/2/2023,,,,,,,,4/3/2026,,,,,,5/23/2023,,,,,,,,4/24/2026,,8/15/2023,,,,,,,,7/17/2026,,,,,,,,7/17/2026,,,,,,,
1-3RHGXL,TAK-981-1003,'TAK-981-1003,,,A Study to Evaluate the Safety and Antiviral Activity of TAK-981 in Patients with Mild or Moderate Coronavirus Disease 2019,TAK-981-1003 TAK-981,I/II,Suspended,,,,,,,,,,800,,,,,,,,100,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3S3ANZ,TBD-1-3S3ANZ,'TBD-1-3S3ANZ,,TAK-007,Ph 1/2 Dose Escalation and Expansion,Ph 1/2 Dose Escalation and Expansion,II,Planned,Support - Oncology,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3S3AWP,TAK-671-1501,'TAK-671-1501,,TAK-671,"A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 1B Study to Evaluate the Safety and Tolerability of Different Doses of TAK-671 Administered as a Single Intravenous Dose in Adult and Elderly Populations for the Treatment of COVID-19",P1B Study in COVID-19 Patients,Ib,Withdrawn,RA/SLE,GI,,,,,,,,40,,,,,,,,15,,,PPD,,James Hazel,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/19/2020,5/19/2020,5/28/2020,5/28/2020,,,9/10/2020,,9/11/2020,,,,12/22/2020,,,,11/27/2020,,1/19/2021,,,,,,,,,,,,,,,,,,2/19/2021,,11/13/2020,,,,,,,,2/24/2021,,,,,,,,,,,,,,3/22/2021,,4/30/2021,,,,,,,,,,,,,,,,11/26/2021,,,,,,,
1-3S3AX3,TBD-1-3S3AX3,'TBD-1-3S3AX3,,,"A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 1B Study to Evaluate the Safety and Tolerability of Different Doses of TAK-671 Administered as a Single Intravenous Dose in Adult and Elderly Populations for the Treatment of COVID-19",P1B Study in COVID-19 Patients,IB,Planned,Other,,,,,Age/Gender/Race,,,,40,0,0,,0,,0,0.00%,13,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3SDL3H,TAK-994-2001,'TAK-994-2001,,TAK-994,"Randomized, Double-blind, Placebo-controlled Cross-over Study of TAK-994 in Patients with Parkinson’s Disease Who Are Experiencing Excessive Daytime Sleepiness",TBD-1-3SDL3H ePOC TAK-994,II,Cancelled,Support,NS,,,,,,,,40,,,,,,,,10,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,12/8/2021,,2/2/2022,,,,6/16/2022,,7/7/2022,,,,6/8/2023,,,,8/22/2023,,,,,,,,,,,,9/19/2023,,,,,,,,,,9/26/2023,,,,,,,,,,,,,,10/17/2023,,,,,,,,,,1/9/2024,,,,,,,,,,,,,,,,2/27/2025,,,,,,,
1-3SDL3V,TAK-994-3005,'TAK-994-3005,,TAK-994,NT2 PH III,TBD-1-3SDL3V ePOC TAK-994,II,Planned,"(MCL) Mantle cell lymphoma, 1st line",NS,,,,,,,,130,,,,,,,,35,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/7/2023,,1/29/2024,,,,4/22/2024,,5/20/2024,,,,1/10/2026,,,,4/3/2026,,,,,,,,,,,,5/1/2026,,,,,,,,,,5/15/2026,,,,,,,,,,,,,,,,,,,,,,,,8/20/2026,,,,,,,,,,,,,,,,8/20/2026,,,,,,,
1-3SDL3V,TBD-1-3SDL3V,'TBD-1-3SDL3V,,TAK-994,NT2 PH III,TBD-1-3SDL3V ePOC TAK-994,II,Planned,Sleep Disorders,NS,,,,,,,,130,,,,,,,,35,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,12/7/2023,,1/29/2024,,,,4/22/2024,,5/20/2024,,,,1/10/2026,,,,4/3/2026,,,,,,,,,,,,5/1/2026,,,,,,,,,,5/15/2026,,,,,,,,,,,,,,,,,,,,,,,,8/20/2026,,,,,,,,,,,,,,,,8/20/2026,,,,,,,
1-3SDL33,TAK-994-1503,'TAK-994-1503,,TAK-994,"A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Oral TAK 994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Subjects",Acute sleep phase delayed HVs,I,Reported,Sleep Disorders,NS,Early NS,,Non-pediatric only (>18 yr),Interventional,Treatment,,,18,19,50,,31,19,5,105.56%,1,1,,PRA,,Erin Hefner,,,,,,Approved,,,Wave 2,Accelerate,Wave 1,Medidata CTMS (Pharma),,,6/1/2020,6/1/2020,8/10/2020,8/10/2020,,,9/23/2020,9/23/2020,10/14/2020,10/14/2020,,,12/3/2020,12/3/2020,,,12/30/2020,12/30/2020,,,,,,,,,,,1/28/2021,1/28/2021,,,,,,,,,2/18/2021,2/18/2021,,,,,,,,,,,,,3/5/2021,3/5/2021,,,,,,,,,5/27/2021,5/27/2021,,,,,,,,,,,,,,,12/28/2021,,,,,,,
1-3SG5JF,TBD-1-3SG5JF,'TBD-1-3SG5JF,,TAK-994,"A Phase 1, Human Drug Drug Interaction Study of TAK-994 and Sodium Oxybate in Normal Healthy Volunteers",Modified release for PK vs. drug drug interaction,I,Planned,Sleep Disorders,NS,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,4/5/2022,,5/3/2022,,,,6/28/2022,,7/26/2022,,,,8/25/2022,,,,9/8/2022,,,,,,,,,,,,11/3/2022,,,,,,,,,,11/17/2022,,,,,,,,,,,,,,11/30/2022,,,,,,,,,,2/22/2023,,,,,,,,,,,,,,,,9/7/2023,,,,,,,
1-3SG5K1,TAK-994-1013,'TAK-994-1013,,TAK-994,"A Phase 1, TAK-994 Pharmacokinetic Study In Hepatic Impaired Patients",TAK-994  PK Study in Hepatic Impaired Pt,I,Planned,"(MCL) Mantle cell lymphoma, 1st line",NS,,,,,,,,48,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,7/9/2021,7/9/2021,9/10/2021,,,,10/27/2021,,11/24/2021,,,,5/23/2022,,,,6/6/2022,,,,,,,,,,,,8/1/2022,,,,,,,,,,8/22/2022,,,,,,,,,,,,,,8/26/2022,,,,,,,,,,11/18/2022,,,,,,,,,,,,,,,,6/5/2023,,,,,,,
1-3SG5KG,TAK-925-1015,'TAK-925-1015,,TAK-925,"A Phase 1b, Randomized, Placebo-Controlled, Safety, Toelrability and PK Study of TAK-925 and Cobicistat in Patients with Narcolepsy with Cataplexy (NT1)",Phase 1b TAK-925/Cobi in NT1 Subjects,Ib,Planned,Sleep Disorders,NS,Late NS,,,,,,,24,,,,,,,,8,,,TBD,,Marilyn Swick,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,2/8/2022,,4/19/2022,,,,8/24/2022,,8/24/2022,,,,2/8/2023,,,,3/8/2023,,,,,,,,,,,,5/3/2023,,,,,,,,,,5/17/2023,,,,,,,,,,,,,,,,,,,,,,,,8/23/2023,,,,,,,,,,,,,,,,3/7/2024,,,,,,,
1-3T42UX,TBD-1-3T42UX,'TBD-1-3T42UX,,TAK-925,Disorder of Consciousness,ePOC TAK-925,Ib,Planned,,NS,,,,,,,,200,,,,,,,,40,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,10/8/2021,,12/10/2021,,,,3/18/2022,,4/6/2022,,,,1/11/2023,,,,1/25/2023,,,,,,,,,,,,2/22/2023,,,,,,,,,,3/1/2023,,,,,,,,,,,,,,3/29/2023,,,,,,,,,,6/21/2023,,,,,,,,,,,,,,,,1/24/2024,,,,,,,
1-3T42V8,TAK-925-1501,'TAK-925-1501,,TAK-925,Post-Op recovery,Post-Op Recovery - Orexin,Ib,Planned,Sleep Disorders,NS,Late NS,,,,,,,100,,,,,,,,35,,,PPD,,Jamie Jay Rothstein,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,1/10/2022,,3/1/2022,,,,9/16/2022,,10/17/2022,,,,4/28/2023,,,,11/15/2023,,,,,,,,,,,,12/20/2023,,,,,,,,,,1/3/2024,,,,,,,,,,,,,,1/31/2024,,,,,,,,,,4/24/2024,,,,,,,,,,,,,,,,11/13/2024,,,,,,,
1-3T42VR,TBD-1-3T42VR,'TBD-1-3T42VR,,TAK-994,NT2 OLE,OLE,II,Planned,Sleep Disorders,NS,,,,,,,,350,,,,,,,,35,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,12/8/2021,,2/15/2022,,,,5/10/2022,,6/7/2022,,,,9/9/2027,,,,12/2/2027,,,,,,,,,,,,12/30/2027,,,,,,,,,,1/6/2028,,,,,,,,,,,,,,,,,,,,,,,,4/20/2028,,,,,,,,,,,,,,,,4/20/2028,,,,,,,
1-3T42W0,TBD-1-3T42W0,'TBD-1-3T42W0,,,EDS in OSA,MR form,I,Planned,,,,,,,,,,100,,,,,,,,30,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3T42Y7,TBD-1-3T42Y7,'TBD-1-3T42Y7,,,TAK-925/Cobi vs. Comparator in NT1 patients,H2H,III,Planned,,,,,,,,,,180,,,,,,,,60,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3T42ZN,TBD-1-3T42ZN,'TBD-1-3T42ZN,,TAK-981,TAK-981/Chemo-radiation study,TAK-981/Chemo-radiation study,I/II,Planned,Multiple cancer,Oncology,,,,,,,,24,,,,,,,,6,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,12/15/2021,,,,,,3/15/2022,,,,9/6/2023,,3/4/2024,,,,,,,,,,,,,,,,,,,,,,8/31/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/29/2024,,,,,,,,11/29/2024,,,,,,,
1-3T433K,Vonoprazan-1001,'Vonoprazan-1001,,vonoprazan,"A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With Vonoprazan Versus Quadruple Therapy with Esomeprazole",TAK438-DDI (China) Study,I,Recruiting,Prophylaxis and Treatment of Gout Flares in adult,GI,,,Non-pediatric only (>18 yr),Interventional,Treatment,,,42,30,160,,130,,7,71.43%,1,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/10/2020,2/10/2020,8/21/2020,8/21/2020,,,4/6/2021,4/6/2021,4/26/2021,4/26/2021,,,7/30/2021,,,,9/10/2021,,,,,,,,,,,,10/19/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/3/2022,,,,,,,,,,,,,,,,3/9/2022,,,,,,,
1-3T434M,TAK-861-1001,'TAK-861-1001,,TAK-861,SRD NHV/MRD NHV/NT1,FIH TAK-861-1001,I,Recruiting,Sleep Disorders,NS,Late NS,,,,,,,196,24,83,,52,24,,12.24%,15,,,IQVIA,,Shunsuke Tuono,,,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,9/28/2020,9/28/2020,12/15/2020,12/15/2020,,,4/2/2021,4/2/2021,4/21/2021,4/21/2021,,,2/11/2022,,,,3/3/2022,,,,,,,,,,,,3/31/2022,,,,,,,,,,4/7/2022,,,,,,,,,,,,,,,,,,,,,,,,8/3/2022,,,,,,,,,,,,,,,,9/22/2023,,,,,,,
1-3T434V,TBD-1-3T434V,'TBD-1-3T434V,,TAK-861,NT1 Dose Ranging,POC,II,Planned,Sleep Disorders,NS,,,,,,,,112,,,,,,,,40,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,11/18/2021,,1/13/2022,,,,5/5/2022,,5/11/2022,,,,12/6/2022,,,,2/28/2023,,,,,,,,,,,,4/25/2023,,,,,,,,,,5/2/2023,,,,,,,,,,,,,,,,,,,,,,,,2/27/2024,,,,,,,,,,,,,,,,2/27/2024,,,,,,,
1-3T435H,TBD-1-3T435H,'TBD-1-3T435H,,,Prader Willi,POC TAK-994,I,Planned,,,,,,,,,,80,,,,,,,,40,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3T435S,TBD-1-3T435S,'TBD-1-3T435S,,TAK-994,IH OLE,PH II III Combo,II/III,Planned,IH (Idiopathic Hypersomnia),NS,,,,,,,,220,,,,,,,,35,,,IQVIA,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,11/8/2021,,1/14/2022,,,,8/5/2022,,8/19/2022,,,,8/15/2025,,,,6/19/2026,,,,,,,,,,,,7/17/2026,,,,,,,,,,7/24/2026,,,,,,,,,,,,,,,,,,,,,,,,11/6/2026,,,,,,,,,,,,,,,,11/6/2026,,,,,,,
1-3T436O,TAK-510-1001,'TAK-510-1001,,TAK-510,FIH study,FIH study TAK-510,I,Recruiting,Dyslipidemia,GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,Other,Cohort,160,16,0,,0,0,0,10.00%,2,2,,PPD,,"Debra Ennis, Kelly Hanna",,,,,,Approved,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,9/4/2020,9/4/2020,12/2/2020,12/2/2020,,,2/3/2021,2/3/2021,2/25/2021,2/25/2021,,,1/13/2022,,,,2/10/2022,,,,,,,,,,,,3/10/2022,,,,,,,,,,3/30/2022,,,,,,,,,,,,,,,,,,,,,,,,5/16/2022,,,,,,,,,,,,,,,,2/9/2023,,,,,,,
1-3T436Z,TBD-1-3T436Z,'TBD-1-3T436Z,,TAK-510,IV PK study,IV PK study TAK-510,I,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,,,,,,,,25,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,2/24/2022,,4/7/2022,,,,6/30/2022,,7/28/2022,,,,10/21/2022,,,,11/11/2022,,,,,,,,,,,,12/9/2022,,,,,,,,,,12/16/2022,,,,,,,,,,,,,,,,,,,,,,,,5/19/2023,,,,,,,,,,,,,,,,11/10/2023,,,,,,,
1-3T437A,TBD-1-3T437A,'TBD-1-3T437A,,TAK-510,Japan PK study TAK-510,Japan PK study TAK-510,I,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,,,,,,,,25,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3T437X,TBD-1-3T437X,'TBD-1-3T437X,,TAK-510,ePoC study TAK-510,ePoC study TAK-510,II,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,,,,Interventional,,,,100,,,,,,,,10,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3T438J,TBD-1-3T438J,'TBD-1-3T438J,,TAK-105,IV PK study,IV PK study TAK-105,I,Planned,Chemotherapy Induced Nausea Vomiting (CINV),GI,,,,,,,,25,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,2/22/2023,,4/5/2023,,,,6/14/2023,,7/12/2023,,,,11/2/2023,,,,11/29/2023,,,,,,,,,,,,12/27/2023,,,,,,,,,,1/3/2024,,,,,,,,,,,,,,,,,,,,,,,,6/5/2024,,,,,,,,,,,,,,,,11/27/2024,,,,,,,
1-3T439G,TBD-1-3T439G,'TBD-1-3T439G,,TAK-105,"Phase 2b, 3 month CVS Prophy DRF Study","Phase 2b, 3 month CVS Prophy DRF study",II,Planned,Erosive esophagitis healing,GI,,,,,,,,100,,,,,,,,10,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,6/1/2022,,10/26/2022,,,,4/3/2023,,4/3/2023,,,,3/4/2024,,,,6/24/2024,,,,,,,,,,,,8/19/2024,,,,,,,,,,8/26/2024,,,,,,,,,,,,,,,,,,,,,,,,3/10/2025,,,,,,,,,,,,,,,,6/23/2025,,,,,,,
1-3T4300,TAK-981-1503,'TAK-981-1503,,TAK-981,TAK-981/Anti-CD38 mAb study,TAK-981-1503,I/II,Recruiting,Multiple cancer,Oncology,Early Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,,,81,1,1,,,,,1.23%,15,6,,TBD,,Brittany Demers,,,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,,,11/5/2020,11/5/2020,,,,,5/11/2021,5/11/2021,,,8/26/2023,,2/10/2024,,,,,,,,,,2/10/2025,,,,,,,,,,,,3/24/2025,,,,,,,,,,3/31/2025,,,,,,,,,,,,,,4/21/2025,,,,,,,,,,6/24/2025,,,,,,,,6/24/2025,,,,,,,
1-3T4354,TAK-861-1002,'TAK-861-1002,,TAK-861,NHV Sleep Deprivation,HV Sleep Deprived,I,Planned,Sleep Disorders,NS,Late NS,,,,,,,18,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,8/31/2021,,3/8/2022,,,,4/7/2022,,4/7/2022,,,,9/1/2022,,,,9/23/2022,,,,,,,,,,,,10/21/2022,,,,,,,,,,10/28/2022,,,,,,,,,,,,,,,,,,,,,,,,2/22/2023,,,,,,,,,,,,,,,,9/22/2023,,,,,,,
1-3T4388,TAK-105-1001,'TAK-105-1001,,TAK-105,FIH study TAK-105,FIH study TAK-105,I,Not Yet Recruiting,Chemotherapy Induced Nausea Vomiting (CINV),GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,Other,Cohort,216,,,,,,,,2,1,,PPD,,Kelly Hanna,,,,,,,,,NA,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,2/25/2021,2/25/2021,6/1/2021,6/1/2021,,,7/19/2021,,8/11/2021,,,,10/21/2022,,,,1/11/2023,,,,,,,,,,,,2/28/2023,,,,,,,,,,3/15/2023,,,,,,,,,,,,,,,,,,,,,,,,8/8/2023,,,,,,,,,,,,,,,,1/10/2024,,,,,,,
1-3T4393,TBD-1-3T4393,'TBD-1-3T4393,,TAK-105,Japan PK study,Japan PK study,I,Planned,Chemotherapy Induced Nausea Vomiting (CINV),GI,,,,,,,,25,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,2/22/2023,,4/5/2023,,,,6/14/2023,,7/12/2023,,,,11/2/2023,,,,11/29/2023,,,,,,,,,,,,12/27/2023,,,,,,,,,,1/3/2024,,,,,,,,,,,,,,,,,,,,,,,,6/5/2024,,,,,,,,,,,,,,,,11/27/2024,,,,,,,
1-3TL6IT,TAK-906-1011,'TAK-906-1011,,TAK-906,"Phase 1 Randomized, Placebo Controlled study Evaluating Safety, Tolerability and PK of Single Ascending Doses of Oral TAK-906 formulation",Phase 1 SRD,I,Planned,(GP) Gastroparesis,GI,Early GI,,,,,,,40,,,,,,,,1,,,TBD,,Anne Crissey,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/12/2022,,7/18/2022,,,,10/18/2022,,11/15/2022,,,,11/15/2022,,,,1/23/2023,,,,,,,,,,,,2/20/2023,,,,,,,,,,2/27/2023,,,,,,,,,,,,,,3/17/2023,,,,,,,,,,5/29/2023,,,,,,,,,,,,,,,,5/29/2023,,,,,,,
1-3TL6U7,TBD-1-3TL6U7,'TBD-1-3TL6U7,,,"A Phase 3, TAK-994 in NT1 Patients Enriched for Cataplexy",TAK-994 WCR Study,III,Cancelled,,,,,,,,,,180,,,,,,,,6,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3TTO2D,TBD-1-3TTO2D,'TBD-1-3TTO2D,,,"A Phase I, Absorption, Distribution, Metabolic and Excretion Study of TAK-861 in Normal Healthy Volunteers",TAK-861 Human ADME study,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3TTO2M,TBD-1-3TTO2M,'TBD-1-3TTO2M,,,"A Phase I, Relative Bio-Availability Study in TAK-861 in Normal Healthy Volunteers",TAK-861 rBA Study,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3TTO2V,TBD-1-3TTO2V,'TBD-1-3TTO2V,,,"A Phase I, Human Drug Drug Interaction + Time Dependent Inhibition Study of TAK-861 and Modafinil in Normal Healthy Volunteers",TAK-861 DDI + TDI Assessment Study,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3TTO34,TBD-1-3TTO34,'TBD-1-3TTO34,,,"A Phase I, Human Drug Drug Interaction Study with TAK-861 and Sodium Oxybate in Normal Healthy Volunteers",TAK-861,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3TUZC7,TBD-1-3TUZC7,'TBD-1-3TUZC7,,,Wakefullness,IH/NT2,II,Planned,,,,,,,,,,20,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3TUZGV,TAK-059-1001,'TAK-059-1001,,,"A Phase 1, Placebo Controlled Randomized, Single Ascending Dose and Multiple Ascending Dose Study of TAK-059 in Normal Healthy Volunteers",FIH SRD/MRD Study,I,Planned,,,,,,Interventional,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3TUZIB,TBD-1-3TUZIB,'TBD-1-3TUZIB,,,rEDS PD,rEDS PD,II,Planned,,,,,,,,,,80,,,,,,,,10,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3UJWK7,TAK-039-1501,'TAK-039-1501,,TAK-039,"A Randomized, Open-label, Parallel Group, Multicenter, Phase 1b Study to Evaluate the Engraftment, Safety, and Tolerability of Oral TAK-039 in Adult Subjects With Liver Cirrhosis who are at Risk for Developing Hepatic Encephalopathy.",TAK-039  Phase 1b Study to Evaluate the Engraftmen,Ib,Planned,Hepatic Encephalopathy (HE),GI,Early GI,,,,,,,30,,,,,,,,6,,,TBD,,Natalie Jones,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,3/23/2021,3/23/2021,11/26/2021,,,,2/24/2022,,3/6/2022,,,,10/14/2022,,,,1/12/2023,,,,,,,,,,,,2/9/2023,,,,,,,,,,2/23/2023,,,,,,,,,,,,,,,,,,,,,,,,6/30/2023,,,,,,,,,,,,,,,,6/30/2023,,,,,,,
1-3VR43D,TBD-1-3VR43D,'TBD-1-3VR43D,,TAK-981,TAK-981/HER2 mAb combo study,TAK-981/HER2 mAb combo study,I/II,Planned,Multiple cancer,Oncology,,,,,,,,65,,,,,,,,60,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,11/30/2021,,,,,,3/30/2022,,,,4/18/2024,,10/15/2024,,,,,,,,,,8/11/2025,,,,,,,,,,,,10/6/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/29/2025,,,,,,,,12/29/2025,,,,,,,
1-3WIIYH,TBD-1-3WIIYH,'TBD-1-3WIIYH,,TAK-994,"A Phase 1, TAK-994 in NT1 Pediatric Study",TAK-994 Pediatric Study,I,Planned,,NS,,,,,,,,16,,,,,,,,25,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,7/6/2022,,12/7/2022,,,,4/1/2023,,4/5/2023,,,,3/6/2024,,,,4/5/2024,,,,,,,,,,,,5/30/2024,,,,,,,,,,6/14/2024,,,,,,,,,,,,,,6/27/2024,,,,,,,,,,9/30/2024,,,,,,,,,,,,,,,,4/4/2025,,,,,,,
1-3X9D1N,TAK-951-1005,'TAK-951-1005,,TAK-951,CV Study 1 - MRI with echo,CV Study 1 - MRI with echo,I,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,Early GI,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,4/6/2021,4/6/2021,1/14/2022,,,,3/17/2022,,3/17/2022,,,,5/3/2022,,,,5/28/2022,,,,,,,,,,,,8/5/2022,,,,,,,,,,8/12/2022,,,,,,,,,,,,,,9/2/2022,,,,,,,,,,11/25/2022,,,,,,,,,,,,,,,,11/25/2022,,,,,,,
1-3X9D1Z,TBD-1-3X9D1Z,'TBD-1-3X9D1Z,,,CV Study 2 - Alpha-1 agonist/TAK-951 PD,CV Study 2 - Alpha-1 agonist/TAK-951 PD,I,Cancelled,Other,,,,,,,,,50,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3X9D2A,TAK-951-2002,'TAK-951-2002,,TAK-951,PONV Dose Range Finding,PONV Dose Range Finding,II,Planned,Post-operative Nausea Vomiting (PONV),GI,,,,,,,,100,,,,,,,,4,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3X9D2L,TAK-951-2003,'TAK-951-2003,,TAK-951,PONV Rescue PoC,PONV Rescue PoC,II,Planned,Post-operative Nausea Vomiting (PONV),GI,,,,,,,,100,,,,,,,,4,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3X9D2U,TBD-1-3X9D2U,'TBD-1-3X9D2U,,,Phase 1 IV PK Study,IV PK,I,Cancelled,Other,,,,,,,,,50,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3X9D3J,TBD-1-3X9D3J,'TBD-1-3X9D3J,,,Japanese Ethnic PK,Japanese Ethnic PK,I,Cancelled,Other,,,,,,,,,50,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3X9D3U,TBD-1-3X9D3U,'TBD-1-3X9D3U,,,Phase 1 IV PK Study,IV PK Study,I,Cancelled,Other,,,,,,,,,50,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3X9D38,TBD-1-3X9D38,'TBD-1-3X9D38,,,Phase 2a ePoC study,ePoC study,IIA,Cancelled,Other,,,,,,,,,100,0,0,,0,,0,0.00%,4,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3X9D45,TBD-1-3X9D45,'TBD-1-3X9D45,,,Phase 2a ePoC study,ePoC study,II,Cancelled,Other,,,,,,,,,100,0,0,,0,,0,0.00%,4,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3XSJOP,TAK-951-1501,'TAK-951-1501,,TAK-951,Phase 1b CVS pilot study,CVS pilot study,Ib,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,Early GI,,,Interventional,,,,20,,,,,,,,4,,,TBD,,Anne Crissey,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,2/19/2021,2/19/2021,7/20/2021,,,,1/14/2022,,2/15/2022,,,,6/21/2022,,,,2/21/2023,,,,,,,,,,,,3/21/2023,,,,,,,,,,3/28/2023,,,,,,,,,,,,,,4/18/2023,,,,,,,,,,8/8/2023,,,,,,,,,,,,,,,,8/8/2023,,,,,,,
1-3XSJQX,TAK-951-1007,'TAK-951-1007,,TAK-951,Phase 1 Anti-Nausea PoC study,Anti-Nausea PoC,I,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,Early GI,,,,,,,50,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,10/1/2021,,1/14/2022,,,,2/11/2022,,3/18/2022,,,,7/22/2022,,,,8/11/2022,,,,,,,,,,,,9/8/2022,,,,,,,,,,9/15/2022,,,,,,,,,,,,,,10/6/2022,,,,,,,,,,1/26/2023,,,,,,,,,,,,,,,,1/26/2023,,,,,,,
1-3Y0MJX,TBD-1-3Y0MJX,'TBD-1-3Y0MJX,,TAK-999,P3 Adult F2-F3,P3 Adult F2-F3,III,Planned,Alpha1-Antitrypsin Deficient Emphysema,GI,,,,,,,,130,,,,,,,,50,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,11/30/2021,,,,3/22/2022,,4/18/2022,,,,11/26/2023,,,,11/26/2025,,,,,,,,,,,,1/22/2026,,,,,,,,,,1/29/2026,,,,,,,,,,,,,,2/19/2026,,,,,,,,,,5/14/2026,,,,,,,,,,,,,,,,5/14/2026,,,,,,,
1-3Y0MK8,TBD-1-3Y0MK8,'TBD-1-3Y0MK8,,TAK-999,P3 Adult F4,P3 Adult F4,III,Planned,Alpha1-Antitrypsin Deficient Emphysema,GI,,,,,,,,154,,,,,,,,50,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,11/30/2021,,,,,,4/18/2022,,,,3/8/2024,,,,2/26/2026,,,,,,,,,,,,3/26/2026,,,,,,,,,,4/2/2026,,,,,,,,,,,,,,4/23/2026,,,,,,,,,,7/16/2026,,,,,,,,,,,,,,,,7/16/2026,,,,,,,
1-3Y0MKK,TAK-999-1001,'TAK-999-1001,,TAK-999,Hepatic Impairment,Hepatic Impairment TAK-999,I,Planned,Alpha1-Antitrypsin Deficient Emphysema,GI,Early GI,,,,,,,24,,,,,,,,15,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,11/30/2021,,,,11/30/2021,,5/4/2022,,,,10/31/2022,,,,1/17/2023,,,,,,,,,,,,2/28/2023,,,,,,,,,,3/7/2023,,,,,,,,,,,,,,3/27/2023,,,,,,,,,,6/20/2023,,,,,,,,,,,,,,,,6/20/2023,,,,,,,
1-3Y0MKV,TBD-1-3Y0MKV,'TBD-1-3Y0MKV,,TAK-999,Pediatric (3-48m),Pediatric (3-48m),III,Planned,Alpha1-Antitrypsin Deficient Emphysema,GI,,,,,,,,130,,,,,,,,50,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,5/30/2024,,,,6/27/2024,,2/12/2025,,,,11/18/2026,,,,5/17/2028,,,,,,,,,,,,7/12/2028,,,,,,,,,,7/19/2028,,,,,,,,,,,,,,8/9/2028,,,,,,,,,,11/1/2028,,,,,,,,,,,,,,,,11/1/2028,,,,,,,
1-3Y0ML6,TBD-1-3Y0ML6,'TBD-1-3Y0ML6,,TAK-999,Pediatric (4-17yrs),Pediatric (4-17yrs),III,Planned,Alpha1-Antitrypsin Deficient Emphysema,GI,,,,,,,,40,,,,,,,,25,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,5/20/2022,,,,12/30/2022,,1/30/2023,,,,5/4/2024,,,,11/3/2024,,,,,,,,,,,,12/27/2024,,,,,,,,,,1/10/2025,,,,,,,,,,,,,,1/24/2025,,,,,,,,,,4/18/2025,,,,,,,,,,,,,,,,4/18/2025,,,,,,,
1-3Y0MLH,TBD-1-3Y0MLH,'TBD-1-3Y0MLH,,TAK-999,P2 & P3 OLE,P2 & P3 OLE,III,Planned,Alpha1-Antitrypsin Deficient Emphysema,GI,,,,,,,,150,,,,,,,,50,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,10/27/2021,,,,,,3/15/2022,,,,5/17/2028,,,,1/24/2029,,,,,,,,,,,,3/21/2029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/13/2029,,,,,,,,,,,,,,,,6/13/2029,,,,,,,
1-3Y0MLS,TBD-1-3Y0MLS,'TBD-1-3Y0MLS,,TAK-999,36 m Clinical Outcomes,36 m Clinical Outcomes,IV,Planned,Alpha1-Antitrypsin Deficient Emphysema,GI,,,,,,,,300,,,,,,,,50,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,5/16/2022,,,,,,2/27/2024,,,,2/27/2026,,,,11/2/2028,,,,,,,,,,,,12/28/2028,,,,,,,,,,1/4/2029,,,,,,,,,,,,,,1/25/2029,,,,,,,,,,4/19/2029,,,,,,,,,,,,,,,,4/19/2029,,,,,,,
1-3Y0MM5,TAK-039-2001,'TAK-039-2001,,TAK-039,Phase 2a ePoC study,Ph2a HE PoC study TAK-039,IIa,Planned,Hepatic Encephalopathy (HE),GI,,,,,,,,100,,,,,,,,30,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,2/23/2023,,3/23/2023,,,,6/15/2023,,8/10/2023,,,,10/31/2024,,,,4/17/2025,,,,,,,,,,,,5/15/2025,,,,,,,,,,5/29/2025,,,,,,,,,,,,,,,,,,,,,,,,10/3/2025,,,,,,,,,,,,,,,,4/16/2026,,,,,,,
1-3Y9HCB,TBD-1-3Y9HCB,'TBD-1-3Y9HCB,,TAK-062,A Phase I Study in Healthy Subjects to compare two different formulations of TAK-062,Formulation comparability study,I,Planned,Celiac,GI,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,11/11/2022,,1/6/2023,,,,3/6/2023,,3/6/2023,,,,5/1/2023,,6/12/2023,,,,,,,,,,,,,,7/10/2023,,,,,,,,,,7/24/2023,,,,,,,,,,,,,,8/7/2023,,,,,,,,,,10/30/2023,,,,,,,,,,,,,,,,10/30/2023,,,,,,,
1-3Y9HD9,TBD-1-3Y9HD9,'TBD-1-3Y9HD9,,ADCETRIS,TBC,"Adult Phase 2 FL PTCL, China only single arm Study",II,Planned,,Oncology,,,,,,,,52,,,,,,,,15,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3Y9HEY,TAK-500-1001,'TAK-500-1001,,TAK-500,"An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500 as a Single Agent and in Combination With an Anti-PD-1/Anti-PD-L1 in Adult Patients With Advanced or Metastatic Solid Tumors",TAK-500 First in Human,I,Planned,Solid tumor,Oncology,Early Oncology,,,,,,,65,,,,,,,,10,,,PPD,,Katie Kinney,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,9/30/2021,,9/30/2021,,,,,,12/8/2021,,,,5/26/2024,,11/22/2024,,11/22/2024,,,,,,,,,,,,1/17/2025,,,,,,,,,,1/24/2025,,,,,,,,,,,,,,2/14/2025,,,,,,,,,,6/27/2025,,,,,,,,,,,,,,,,6/27/2025,,,,,,,
1-3Y9NDT,TBD-1-3Y9NDT,'TBD-1-3Y9NDT,,TAK-500,Phase 1b/2 Expansion,Phase 1b/2 Expansion,II,Cancelled,Friedreich's ataxia,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,1/29/2025,,3/25/2025,,,,,,7/23/2025,,,,6/18/2026,,12/15/2026,,12/15/2026,,,,,,,,,,,,2/9/2027,,,,,,,,,,2/16/2027,,,,,,,,,,,,,,3/9/2027,,,,,,,,,,7/20/2027,,,,,,,,,,,,,,,,7/20/2027,,,,,,,
1-3Y9NE6,TBD-1-3Y9NE6,'TBD-1-3Y9NE6,,TAK-500,Phase 2/3 Registration Study,Phase 2/3 Registration Study,III,Planned,Solid tumor,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,3/24/2025,,6/2/2025,,,,,,9/21/2025,,,,9/16/2026,,6/2/2029,,3/15/2027,,,,,,,,6/2/2029,,,,5/10/2027,,,,,,,,7/27/2029,,5/17/2027,,,,,,,,8/3/2029,,,,,,6/7/2027,,,,,,,,8/24/2029,,8/30/2027,,,,,,,,11/16/2029,,,,,,,,11/16/2029,,,,,,,
1-3Y9NEF,TBD-1-3Y9NEF,'TBD-1-3Y9NEF,,TAK-500,Human ADME,Human ADME TAK-500,I,Planned,Solid tumor,Oncology,,,,,,,,6,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,7/7/2025,,9/1/2025,,,,,,12/20/2025,,,,6/18/2026,,3/15/2027,,3/15/2027,,,,,,,,,,,,5/10/2027,,,,,,,,,,5/17/2027,,,,,,,,,,,,,,6/7/2027,,,,,,,,,,10/18/2027,,,,,,,,,,,,,,,,10/18/2027,,,,,,,
1-3Y9NEO,TBD-1-3Y9NEO,'TBD-1-3Y9NEO,,TAK-500,Phase 1 Definitive Food Effect,Phase 1 Definitive Food Effect,I,Planned,Solid tumor,Oncology,,,,,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,1/2/2026,,2/27/2026,,,,,,6/18/2026,,,,11/15/2026,,2/13/2027,,2/13/2027,,,,,,,,,,,,4/9/2027,,,,,,,,,,4/16/2027,,,,,,,,,,,,,,5/7/2027,,,,,,,,,,9/17/2027,,,,,,,,,,,,,,,,9/17/2027,,,,,,,
1-3Y9NEX,TBD-1-3Y9NEX,'TBD-1-3Y9NEX,,TAK-500,Phase 3 Pivotal Confirmatory,Ph 3 Pivotal Confirmatory,III,Planned,Solid tumor,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,1/12/2027,,3/24/2027,,,,,,7/13/2027,,,,7/2/2029,,3/18/2032,,3/29/2030,,,,,,,,3/18/2032,,,,5/24/2030,,,,,,,,5/13/2032,,5/31/2030,,,,,,,,5/20/2032,,,,,,6/21/2030,,,,,,,,6/10/2032,,9/13/2030,,,,,,,,,,,,,,,,9/2/2032,,,,,,,
1-3Y30BF,TBD-1-3Y30BF,'TBD-1-3Y30BF,,Sibofimloc (TAK-018),POC in Ileitis: Ph2b in Moderate to several luminal CD,POC in Ileitis,II,Planned,(CD) Crohn's disease,GI,,,,,,,,180,,,,,,,,40,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,11/30/2021,,1/6/2023,,,,4/28/2023,,4/28/2023,,,,4/26/2024,,,,1/3/2025,,,,,,,,,,,,2/28/2025,,,,,,,,,,3/7/2025,,,,,,,,,,,,,,,,,,,,,,,,1/2/2026,,,,,,,,,,,,,,,,1/2/2026,,,,,,,
1-3Y30BQ,TBD-1-3Y30BQ,'TBD-1-3Y30BQ,,Sibofimloc (TAK-018),Dose Range Finding in POCD: Ph2b dose range study for maintenance of remission in POCD patients,Dose Range Finding in POCD,II,Suspended,(CD) Crohn's disease,GI,,,,,,,,135,,,,,,,,40,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3Y30D6,TBD-1-3Y30D6,'TBD-1-3Y30D6,,,"A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation",Ponatinib With Chemotherapy in Pediatric Patients,I/II,Not Yet Recruiting,,,,,,,,,,74,,,,,,,,74,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3YIB1T,TBD-1-3YIB1T,'TBD-1-3YIB1T,,TAK-062,TBD,TBD,0,Planned,Complex Perianal Fistulas,GI,,,,,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,1/16/2023,,3/13/2023,,,,7/3/2023,,8/28/2023,,,,4/24/2024,,7/17/2024,,,,,,,,,,,,,,9/11/2024,,,,,,,,,,9/25/2024,,,,,,,,,,,,,,10/9/2024,,,,,,,,,,1/1/2025,,,,,,,,,,,,,,,,1/1/2025,,,,,,,
1-3YIB3H,TAK-925-1018,'TAK-925-1018,,,Open-Label PK Pharmacokinetics Particle Size Study,TAK-925  PK Particle Size Study,I,Planned,,,,,,,,,,16,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3YIB5I,TAK-039-3001,'TAK-039-3001,,TAK-039,Phase 3 HE Study - Pivotal 1,Ph3 - Pivotal Study 1,III,Planned,Hepatic Encephalopathy (HE),GI,,,,,,,,500,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/11/2025,,8/8/2025,,,,12/10/2025,,10/3/2025,,,,1/21/2028,,,,3/17/2028,,,,,,,,,,,,4/14/2028,,,,,,,,,,4/28/2028,,,,,,,,,,,,,,,,,,,,,,,,9/1/2028,,,,,,,,,,,,,,,,3/16/2029,,,,,,,
1-3YIB5V,TBD-1-3YIB5V,'TBD-1-3YIB5V,,,Phase 3 HE Study - Pivotal 2,Ph3 - Pivotal Study 2,III,Suspended,,,,,,,,,,50,,,,,,,,10,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3YIB6J,TBD-1-3YIB6J,'TBD-1-3YIB6J,,Entyvio SC,P3 Pediatric SC UC/CD,P3 Pediatric SC UC/CD,III,Planned,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,,,,,,,,100,,,,,,,,80,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,1/31/2022,,6/30/2022,,,,9/29/2022,,11/28/2022,,,,11/12/2025,,,,11/25/2026,,,,,,,,,,,,1/19/2027,,,,,,,,,,1/26/2027,,,,,,,,,,,,,,2/23/2027,,,,,,,,,,5/18/2027,,,,,,,,,,,,,,,,11/23/2027,,,,,,,
1-3YIB6W,TBD-1-3YIB6W,'TBD-1-3YIB6W,,Entyvio SC,P3 Pediatric SC OLE,P3 Pediatric SC OLE,III,Planned,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,,,,,,,,50,,,,,,,,80,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,10/12/2022,,12/21/2022,,,,,,11/28/2023,,,,11/25/2026,,,,11/9/2029,,,,,,,,,,,,1/3/2030,,,,,,,,,,1/10/2030,,,,,,,,,,,,,,1/31/2030,,,,,,,,,,4/25/2030,,,,,,,,,,,,,,,,11/7/2030,,,,,,,
1-3YIB55,TAK-039-2002,'TAK-039-2002,,TAK-039,Phase 2a ePoC study,Ph2a HE PoC study TAK-039 TBD-1-3YIB55,II,Planned,Hepatic Encephalopathy (HE),GI,,,,,,,,100,,,,,,,,30,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,4/12/2022,,6/7/2022,,,,9/27/2022,,9/27/2022,,,,2/13/2024,,,,7/30/2024,,,,,,,,,,,,9/24/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/18/2025,,,,,,,,,,,,,,,,2/18/2025,,,,,,,
1-3YIIRV,TBD-1-3YIIRV,'TBD-1-3YIIRV,,Sibofimloc (TAK-018),TAK-018 P3 pivotal POCD,TAK-018 P3 pivotal POCD,III,Planned,(CD) Crohn's disease,GI,,,,,,,,350,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,2/22/2023,,6/23/2023,,,,7/19/2024,,8/16/2024,,,,8/1/2025,,,,12/25/2026,,,,,,,,,,,,2/19/2027,,,,,,,,,,2/26/2027,,,,,,,,,,,,,,,,,,,,,,,,6/11/2027,,,,,,,,,,,,,,,,12/24/2027,,,,,,,
1-3YIIS7,TBD-1-3YIIS7,'TBD-1-3YIIS7,,Sibofimloc (TAK-018),TAK-018 P3 induction 1 for mod to sev Luminal CD,TAK-018 P3 induction 1 Luminal CD,III,Planned,(CD) Crohn's disease,GI,,,,,,,,440,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/7/2025,,9/5/2025,,,,12/26/2025,,1/23/2026,,,,7/24/2026,,,,12/17/2027,,,,,,,,,,,,2/11/2028,,,,,,,,,,2/18/2028,,,,,,,,,,,,,,,,,,,,,,,,6/2/2028,,,,,,,,,,,,,,,,12/15/2028,,,,,,,
1-3YIISG,TBD-1-3YIISG,'TBD-1-3YIISG,,Sibofimloc (TAK-018),TAK-018 P3 induction 2 for mod to sev Luminal CD,TAK-018 P3 induction 2  Luminal CD,III,Planned,(CD) Crohn's disease,GI,,,,,,,,440,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/7/2025,,9/5/2025,,,,12/26/2025,,1/23/2026,,,,7/24/2026,,,,1/22/2027,,,,,,,,,,,,3/19/2027,,,,,,,,,,3/26/2027,,,,,,,,,,,,,,,,,,,,,,,,7/9/2027,,,,,,,,,,,,,,,,1/21/2028,,,,,,,
1-3YIISP,TBD-1-3YIISP,'TBD-1-3YIISP,,Sibofimloc (TAK-018),TAK-018 P3 maintenance for mod to sev Luminal CD,TAK-018 P3 maintenance Luminal CD,III,Planned,(CD) Crohn's disease,GI,,,,,,,,350,,,,,,,,50,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,5/7/2025,,9/5/2025,,,,,,7/24/2026,,,,7/23/2027,,,,7/21/2028,,,,,,,,,,,,9/15/2028,,,,,,,,,,9/22/2028,,,,,,,,,,,,,,,,,,,,,,,,1/5/2029,,,,,,,,,,,,,,,,7/20/2029,,,,,,,
1-3YZTGT,TAK-994-1504,'TAK-994-1504,,TAK-994,A Phase 2 Long Term Extension Study for Subjects from TAK-994-1501,TAK-994-1501 Open Label Extension,II,Planned,Sleep Disorders,NS,,,,,,,,112,7,7,,,7,,6.25%,70,,,IQVIA,,Marilyn Swick,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,12/1/2020,12/1/2020,2/3/2021,2/3/2021,,,4/29/2021,4/29/2021,4/30/2021,4/30/2021,,,1/31/2022,,,,6/30/2022,,,,,,,,,,,,8/30/2022,,,,,,,,,,9/7/2022,,,,,,,,,,,,,,,,,,,,,,,,12/30/2022,,,,,,,,,,,,,,,,4/4/2025,,,,,,,
1-3YZTI6,Darvadstrocel-2001,'Darvadstrocel-2001,,Alofisel,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Subjects With Complex Cryptoglandular Fistula(s) Over a Period of 52 Weeks.",CCF Phase 2 Safety & Efficacy,II,Cancelled,Other,GI,,,,,,,,80,0,0,,0,,0,0.00%,60,,,IQVIA,,,,,,,,,,,NA,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3YZTO1,TBD-1-3YZTO1,'TBD-1-3YZTO1,,Mezagitamab (TAK-079),Ph1b MAD in UC,Ph1b MAD in UC,I,Planned,(UC) Ulcerative colitis,RGH,,,,,,,,48,,,,,,,,20,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/26/2021,,11/3/2021,,,,3/7/2022,,3/7/2022,,,,12/5/2022,,,,2/27/2023,,,,,,,,2/25/2025,,,,,,,,,,,,4/21/2025,,4/24/2023,,,,,,,,4/28/2025,,,,,,,,,,,,,,5/19/2025,,,,,,,,,,9/8/2025,,,,,,,,9/8/2025,,,,,,,
1-3YZTOE,TBD-1-3YZTOE,'TBD-1-3YZTOE,,Mezagitamab (TAK-079),Ph2 Safety/Efficacy in UC,Ph2 Safety/Efficacy in UC,II,Planned,(UC) Ulcerative colitis,GI,,,,,,,,150,,,,,,,,50,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3ZGBTN,TBD-1-3ZGBTN,'TBD-1-3ZGBTN,,TAK-186,Phase 3 mCRC Study,Ph3 mCRC,III,Planned,,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/22/2023,,12/1/2023,,,,,,3/22/2024,,,,3/8/2026,,8/5/2026,,7/8/2026,,,,,,,,,,,,9/22/2026,,,,,,,,,,9/29/2026,,,,,,,,,,,,,,10/20/2026,,,,,,,,,,1/12/2027,,,,,,,,,,,,,,,,1/12/2027,,,,,,,
1-3ZGBTW,TBD-1-3ZGBTW,'TBD-1-3ZGBTW,,TAK-186,Phase 3 mNSCLC Study,Ph3 mNSCLC,III,Planned,,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/20/2024,,5/29/2024,,,,,,9/18/2024,,,,9/8/2026,,2/5/2027,,2/5/2027,,,,,,,,,,,,4/2/2027,,,,,,,,,,4/9/2027,,,,,,,,,,,,,,4/30/2027,,,,,,,,,,7/23/2027,,,,,,,,,,,,,,,,7/23/2027,,,,,,,
1-3ZP5IZ,TBD-1-3ZP5IZ,'TBD-1-3ZP5IZ,,pevonedistat (TAK-924),Ph 1b/2 Pevonedistat/MBG453/Aza combination in 1L HR MDS,Ph 1b/2 Pevonedistat/MBG453/Aza combination in 1L,I/II,Planned,Blood cancer,Oncology,,,,,,,,70,,,,,,,,35,,,TBD,,Sarah Farooq,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,9/30/2021,,,,,,1/28/2022,,,,9/30/2023,,6/29/2024,,1/3/2024,,,,,,,,6/30/2026,,,,2/14/2024,,,,,,,,8/25/2026,,2/18/2024,,,,,,,,,,,,,,3/13/2024,,,,,,,,,,3/31/2024,,,,,,,,9/30/2026,,,,,,,,12/6/2006,,,,,,,
1-3ZP5JT,TBD-1-3ZP5JT,'TBD-1-3ZP5JT,,pevonedistat (TAK-924),Ph 1b/2 Pevonedistat/Venetoclax/Aza combination in 1L HR MDS,Ph 1b/2 Pevonedistat/Venetoclax/Aza combination in,I/II,Planned,Blood cancer,Oncology,,,,,,,,70,,,,,,,,35,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,9/30/2021,,,,,,1/28/2022,,,,1/28/2023,,10/28/2023,,,,,,,,,,10/28/2025,,,,,,,,,,,,12/23/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/28/2026,,,,,,,,1/28/2026,,,,,,,
1-3ZP5KE,Pevonedistat-1501,'Pevonedistat-1501,,pevonedistat (TAK-924),Ph 1b/2 Pevonedistat/Aza combincation in 1L unfit AML- Japan Bridging study,Ph 1b/2 Pevonedistat/Aza combincation in 1L unfit,I/II,Planned,(AML) Acute myeloid leukemia,Oncology,,,,,,,,36,,,,,,,,26,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,9/14/2021,,,,,,12/12/2021,,,,4/12/2023,,12/18/2023,,,,,,,,,,12/6/2006,,,,,,,,,,,,1/31/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/6/2007,,,,,,,,12/18/2023,,,,,,,
1-3ZP9CZ,TBD-1-3ZP9CZ,'TBD-1-3ZP9CZ,,TAK-186,Phase 3 mSCCHN Study,Ph3 mSCCHN,III,Planned,,Oncology,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/16/2024,,11/25/2024,,,,,,3/17/2025,,,,3/7/2027,,8/4/2027,,8/4/2027,,,,,,,,,,,,9/29/2027,,,,,,,,,,10/6/2027,,,,,,,,,,,,,,10/27/2027,,,,,,,,,,1/19/2028,,,,,,,,,,,,,,,,1/19/2028,,,,,,,
1-3ZX32Z,TAK-994-1011,'TAK-994-1011,,TAK-994,TAK-994 HV DDI with CYP3A4 Inducer,TAK-994 HV DDI with CYP3A$ inhibitor Or inducer,I,Planned,"(MCL) Mantle cell lymphoma, 1st line",NS,,,,,,,,10,,,,,,,,1,,,Celerion,,Annette Stevenson,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,5/6/2021,5/6/2021,7/8/2021,7/8/2021,,,9/2/2021,,9/24/2021,,,,9/24/2021,,,,10/24/2021,,,,,,,,,,,,11/23/2021,,,,,,,,,,12/7/2021,,,,,,,,,,,,,,12/20/2021,,,,,,,,,,3/14/2022,,,,,,,,,,,,,,,,10/21/2022,,,,,,,
1-3ZX33V,TAK-994-1012,'TAK-994-1012,,TAK-994,Healthy Volunteers Drug Interaction with CYP3A4 (induction) or OATP (inhibition) substrate,TAK-994 HV DDI with CYP3A4 or OATP substrate,I,Planned,"(MCL) Mantle cell lymphoma, 1st line",NS,Early NS,,Non-pediatric only (>18 yr),Interventional,,,,24,,,,,,,,1,,,Celerion,,Erin Hefner,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,5/7/2021,5/7/2021,6/16/2021,6/16/2021,,,7/20/2021,,8/17/2021,,,,9/16/2021,,,,9/30/2021,,,,,,,,,,,,11/25/2021,,,,,,,,,,12/9/2021,,,,,,,,,,,,,,12/22/2021,,,,,,,,,,3/16/2022,,,,,,,,,,,,,,,,9/29/2022,,,,,,,
1-3ZX307,TAK-925-1019,'TAK-925-1019,,TAK-925,Healthy Volunteers Anesthetized Study with TAK-925 for Post Op Recovery,TAK-925  HV Anesthetized Study,I,Planned,,NS,Early NS,,,,,,,20,,,,,,,,2,,,TBD,,Jamie Jay Rothstein,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,7/6/2021,7/6/2021,,,,,9/16/2021,,,,2/7/2022,,,,2/15/2022,,,,,,,,,,,,,,,,,,,,,,3/30/2022,,,,,,,,,,,,,,4/12/2022,,,,,,,,,,6/2/2022,,,,,,,,,,,,,,,,6/2/2022,,,,,,,
1-3ZX345,TAK-994-1010,'TAK-994-1010,,,Healthy Volunteers Phase 1 Single Dose PK Study with Modified Release Formulation,TAK-994 HV PK Single Dose Modified Release,I,Planned,,,,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-6RQWZ,C14011,'C14011,,Alisertib,"A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine",Ph 1 B-cell lymphoma,I/II,Closed,Heme.Lymphoma.DLBCL,Oncology,,,,,,,,45,41,0,,4,0,0,91.11%,12,,,IQVIA,Mary-Anne McKenna,,,,,,,,,,,,,STARS Inactive,,,,,2/22/2011,2/22/2011,,,,,8/9/2011,8/9/2011,,,1/14/2014,1/14/2014,2/26/2015,2/26/2015,,,,,,,,,,,,,6/8/2015,6/8/2015,,,,,,,,,7/30/2015,7/30/2015,,,,,,,,,,,,,,,,,,,,,,,2/2/2016,2/2/2016,,,,,,,10/18/2016,10/18/2016,,,,,,,12/1/2016,12/1/2016,,,,,,
1-6RR4S,C16009,'C16009,,Ninlaro,"Phase 1 Study of Oral MLN9708 to Assess Relative Bioavailability; Food Effect; Drug-Drug Interaction With Ketoconazole, Clarithromycin, or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma","Ph1 BA, FE, DDI Multiarm",I,Closed,Solid.All Comers,Oncology,,,,,,,,125,112,149,,37,,36,89.60%,6,1,,ICON,Jonathan Young,,,,,,,,,,,,,STARS Inactive,,,,,8/4/2011,8/4/2011,,,,,11/11/2011,11/11/2011,,,3/9/2015,3/9/2015,7/21/2015,7/21/2015,12/31/2016,12/31/2016,,,,,,,12/31/2016,12/31/2016,,,5/27/2015,5/27/2015,,,,,,,8/17/2016,8/17/2016,6/5/2015,6/5/2015,,,,,,,,,,,,,,,,,,,,,,,6/19/2015,6/19/2015,,,,,,,3/24/2017,3/24/2017,,,,,,,3/24/2017,3/24/2017,,,,,,
1-6S9B1,C21008,'C21008,,,"A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [C]-Orteronel (TAK-700) Following a Single Oral Administration in Healthy Subjects",,I,Closed,Solid.GU.Prostate,,,,,,,,,6,6,0,,0,,0,100.00%,1,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-6S9EN,C21009,'C21009,,,"A Phase 1 , Randomized, Single-Dose Crossover Study of the Bioequivalence of Two Formulations of Orteronel (TAK-700) in Healthy Males",,I,Closed,Solid.GU.Prostate,,,,,,,,,52,54,0,,0,,54,103.85%,1,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-6SLSD,C13009,'C13009,,,"A Phase 1 Single Dose Study to Determine the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Lyophilized Formulation (Process C Drug Product) of MLN0002 in Healthy Subjects",,I,Closed,Other,,,,,,,,,1,87,0,,0,,21,8700.00%,70,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-6SM1F,C13010,'C13010,,,A Phase 1 Study of the Bioavailability of MLN0002 Administered by Subcutaneous and Intramuscular Injection to Healthy Male Subjects,,I,Closed,Other,,,,,,,,,42,42,0,,0,,2,100.00%,1,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-7L1EP,C14007PH2,'C14007PH2,,,"A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematologica Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies",,I/II,Closed,Solid.Other,,,,,,,,,249,252,330,,78,,146,101.20%,1,6,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-7L1FK,C14008PH2,'C14008PH2,,,"Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer",Ph 2 Ovarian,I/II,Closed,Solid.Gyn.Ovarian,,,,,,,,,172,39,0,,10,0,0,22.67%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-7L1FU,C16005PH2,'C16005PH2,,,"An Open-Label, Dose-Escalation Phase 1/2 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, Administered in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment",,I/II,Closed,Heme.Multiple Myeloma,,,,,,,,,1,0,0,,8,0,0,0.00%,1,,,PPD,Cathy O'Connell,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8NPF,C21004,'C21004,,TAK-700,"A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK 700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy Naïve Metastatic Castration-Resistant Prostate Cancer",elm.pc,III,Closed,Solid.GU.Prostate,Oncology,,,,,,,,"1,454","1,560",,,,,,107.29%,395,104,,PPD,,,,,,2010-018661-35,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8NQJ,C05009 UPFRONT,'C05009 UPFRONT,,VELCADE (Bortezomib),"Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation:  VELCADE® (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE® and Dexamethasone (VD) versus VELCADE®, Melphalan, and Prednisone (VMP)",UPFRONT,IIIB,Closed,Heme.Multiple Myeloma,Marketed Products,,,,,,,,500,502,565,,62,,357,100.40%,270,2,,,,,,,,,,,,,,,,STARS Inactive,,,,,4/5/2007,4/5/2007,,,,,6/26/2007,6/26/2007,,,3/31/2010,3/31/2010,3/29/2013,3/29/2013,,,,,,,,,,,,,,,,,,,,,,,5/31/2013,5/31/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/31/2013,5/31/2013,,,,,,
1-8NRV,C05011 VERTICAL,'C05011 VERTICAL,,VELCADE (Bortezomib),A Phase 2 Study of VELCADE® (bortezomib) in Combination with Bendamustine and Rituximab in Subjects with Relapsed or Refractory Follicular Lymphoma,VERTICAL,II,Closed,Heme.Lymphoma.Follicular,Marketed Products,,,,,,,,71,73,79,,7,,33,102.82%,30,1,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,10/31/2007,10/31/2007,,,,,2/14/2008,2/14/2008,,,6/29/2009,6/29/2009,5/7/2010,5/7/2010,,,,,,,,,,,,,,,,,,,,,,,6/2/2010,6/2/2010,,,,,,,,,,,,,,,,,,,,,,,10/28/2010,10/28/2010,,,,,,,10/28/2010,10/28/2010,,,,,,,10/28/2010,10/28/2010,,,,,,
1-8O1D,C21005,'C21005,,TAK-700,"A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK 700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy",elm.pc,III,Closed,Solid.GU.Prostate,Oncology,,,,,,,,"1,083","1,099",,,,,,101.48%,358,46,,PPD,,,,,,2010-018662-23,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8O2F,C21007,'C21007,,,"A Phase 1, Randomized, Single-Dose Crossover Study of the Effect of Food on Absorption of Orteronel (TAK-700) in Healthy Males",,I,Closed,Solid.GU.Prostate,,,,,,,,,42,42,57,,0,,3,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8P8P,C21001,'C21001,,TAK-700,"A Phase 2, Multicenter  Open-Label Study Evaluating the Safety and Efficacy of TAK-700 in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (CRPC) and a Rising Prostate-Specific Androgen (PSA)",,II,Closed,Solid.GU.Prostate,Oncology,,,,,,,,42,39,73,,39,,14,92.86%,9,1,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8PC5,C21002,'C21002,,,A Phase 1 Study of the Relative Bioavailability of Two Formulations of TAK-700 in Healthy Male Subjects,,I,Closed,Solid.GU.Prostate,,,,,,,,,24,48,72,,0,,1,200.00%,1,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8PHK,C21003,'C21003,,TAK-700,An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer,,I/II,Closed,Solid.GU.Prostate,Oncology,,,,,,,,40,38,51,,14,,13,95.00%,9,2,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8PNQ,C23001,'C23001,,MEPACT (mifamurtide),"An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Liposomal Muramyltripeptide Phosphatidylethanolamine (L-MTP-PE) in Subjects with Mild or Moderate Chronic Renal Insufficiency Compared to Healthy, Adult Subjects",,I,Closed,Solid.Bone.Osteosarcoma,Marketed Products,,,,,,,,32,33,53,,20,,1,103.13%,3,,,PPD,,,,,,2009-017204-89,,,,,,,,STARS Inactive,,,,,4/21/2010,4/21/2010,,,,,9/9/2010,9/9/2010,,,6/14/2011,6/14/2011,6/22/2011,6/22/2011,,,,,,,,,,,,,,,,,,,,,,,11/15/2011,11/15/2011,,,,,,,,,,,,,,,,,,,,,,,4/28/2012,4/28/2012,,,,,,,4/28/2012,4/28/2012,,,,,,,4/28/2012,4/28/2012,,,,,,
1-8POT,C22001,'C22001,,,"A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, A Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematalogic Malignancies",,I,Closed,Solid.All Comers,,,,,,,,,84,32,38,,6,,2,38.10%,3,3,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8PQG,C23002,'C23002,,MEPACT (mifamurtide),"An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Liposomal Muramyltripeptide Phosphatidylethanolamine (L-MTP-PE) in Subjects With Mild or Moderate Chronic Hepatic Impairment Compared to Healthy, Adult Subjects",,I,Closed,Solid.Bone.Osteosarcoma,Marketed Products,,,,,,,,32,37,48,,11,,1,115.63%,3,,,PPD,,,,,,2009-017204-89,,,,,,,,STARS Inactive,,,,,4/21/2010,4/21/2010,,,,,9/13/2010,9/13/2010,,,6/27/2011,6/27/2011,7/7/2011,7/7/2011,,,,,,,,,,,,,,,,,,,,,,,11/30/2011,11/30/2011,,,,,,,,,,,,,,,,,,,,,,,4/28/2012,4/28/2012,,,,,,,4/28/2012,4/28/2012,,,,,,,4/28/2012,4/28/2012,,,,,,
1-8QJ0,C23003,'C23003,,MEPACT (mifamurtide),"Mifamurtide Observational, Noninterventional Surveillance Study of Patients With Newly Diagnosed Osteosarcoma",,IV,Closed,Solid.Bone.Osteosarcoma,Marketed Products,,,,,,,,300,25,0,,0,,12,8.33%,50,1,,PPD,,,,,,2009-017204-89,,,,,,,,STARS Inactive,,,,,4/20/2010,4/20/2010,,,,,12/26/2011,12/26/2011,,,12/6/2013,12/6/2013,12/17/2013,12/17/2013,,,,,,,,,,,,,,,,,,,,,,,3/7/2014,3/7/2014,,,,,,,,,,,,,,,,,,,,,,,5/2/2014,5/2/2014,,,,,,,5/2/2014,5/2/2014,,,,,,,5/2/2014,5/2/2014,,,,,,
1-8QJH,GLOBAL_PROTOCOL,'GLOBAL_PROTOCOL,,,Global Protocol,,I,Closed,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8R5P,C13006,'C13006,,,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis",GEMINI: UC Study,III,Closed,Other,,,,,,,,,876,895,1406,,509,,524,102.17%,305,1,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8R6Z,C13007,'C13007,,,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn’s Disease",GEMINI: CD Study,III,Closed,Other,,,,,,,,,"1,109","1,116",1920,,804,,696,100.63%,462,1,,IQVIA,,,,,,2008-002783-33,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8R8L,C13008,'C13008,,Entyvio,"A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn’s Disease",GEMINI: LTS,III,Closed,00020 (UC) Ulcerative colitis,GI,,,,Long Term Safety,,,,"2,200","2,244",,,,,1502,102.00%,462,1,,IQVIA,Faisal Khan,,,,,2008-002784-14,,,,,,,,STARS Inactive,,,,,6/26/2008,6/26/2008,,,,,5/22/2009,5/22/2009,,,10/3/2012,10/3/2012,,,10/31/2017,10/31/2017,,,,,,,,,,,1/29/2018,1/29/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/16/2018,7/16/2018,,,,,,,,,,,,,,,7/16/2018,,,,,,,
1-8R51,C05013,'C05013,,VELCADE (Bortezomib),"An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma",Ph2 DLBCL Pyramid,II,Closed,Heme.Lymphoma.DLBCL,Marketed Products,,,,,,,,190,29,0,,33,0,0,15.26%,76,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,5/15/2009,5/15/2009,,,,,10/1/2009,10/1/2009,,,7/10/2013,7/10/2013,7/30/2015,7/30/2015,,,,,,,,,,,,,9/24/2015,9/24/2015,,,,,,,,,10/27/2015,10/27/2015,,,,,,,,,,,,,,,,,,,,,,,2/15/2016,2/15/2016,,,,,,,2/15/2016,2/15/2016,,,,,,,2/15/2016,2/15/2016,,,,,,
1-8UE2,C13011,'C13011,,,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease",GEMINI: CD safety,III,Closed,Other,,,,,,,,,396,416,660,,243,,28,105.05%,150,1,,IQVIA,,,,,,2009-016488-12,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8UEJ,C13012,'C13012,,,A Phase 1 Single-Arm Study to Evaluate the Effects of a Single Intravenous Dose of Vedolizumab (MLN0002) on the CD4+:CD8+ Lymphocyte Ratio in the Cerebrospinal Fluid of Healthy Subjects,CSF Study,I,Closed,Normal Healthy Volunteer,,,,,,,,,22,14,37,,23,,1,63.64%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8UFN,C13013,'C13013,,,"A Phase 1 Randomized, Blinded, Placebo-controlled Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Gut Antigenic Challenge in the Presence of Vedolizumab",Vaccine Study,I,Closed,Normal Healthy Volunteer,,,,,,,,,125,127,332,,205,,2,101.60%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-8UG5,C14004,'C14004,,Alisertib,"A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Aggressive Non-Hodgkin's Lymphoma",,II,Closed,Heme.Lymphoma.All Comers,Oncology,,,,,,,,44,48,56,,8,,46,109.09%,16,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,11/3/2008,11/3/2008,,,,,2/10/2009,2/10/2009,,,8/31/2010,8/31/2010,1/4/2011,1/4/2011,,,,,,,,,,,,,4/29/2011,4/29/2011,,,,,,,,,6/27/2011,6/27/2011,,,,,,,,,,,,,,,,,,,,,,,11/29/2012,11/29/2012,,,,,,,11/29/2012,11/29/2012,,,,,,,11/29/2012,11/29/2012,,,,,,
1-8UGS,C14005,'C14005,,Alisertib,"A Phase 2 Trial of MLN8237, an Oral Aurora A kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodyspastic Syndrome",,II,Closed,Heme.Leukemia,Oncology,,,,,,,,44,57,63,,8,,56,129.55%,45,,,,,,,,,,,,,,,,,STARS Inactive,,,,,12/4/2008,12/4/2008,,,,,2/16/2009,2/16/2009,,,12/22/2009,12/22/2009,8/15/2011,8/15/2011,,,,,,,,,,,,,9/14/2011,9/14/2011,,,,,,,,,7/15/2010,7/15/2010,,,,,,,,,,,,,,,,,,,,,,,5/16/2012,5/16/2012,,,,,,,5/16/2012,5/16/2012,,,,,,,5/16/2012,5/16/2012,,,,,,
1-8UHP,C14006,'C14006,,Alisertib,"A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum- Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",,II,Closed,Solid.Gyn.Ovarian,Oncology,,,,,,,,56,31,34,,3,,30,55.36%,28,3,,,,,,,,,,,,,,,,STARS Inactive,,,,,12/4/2008,12/4/2008,,,,,3/25/2009,3/25/2009,,,8/3/2009,8/3/2009,4/12/2010,4/12/2010,,,,,,,,,,,,,2/10/2011,2/10/2011,,,,,,,,,3/12/2011,3/12/2011,,,,,,,,,,,,,,,,,,,,,,,7/11/2011,7/11/2011,,,,,,,7/10/2011,7/10/2011,,,,,,,7/11/2011,7/11/2011,,,,,,
1-8UIE,C14007,'C14007,,Alisertib,"A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematologica Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies",,I/II,Closed,Solid.Other,Oncology,,,,,,,,270,273,352,,0,,88,101.11%,52,1,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,10/23/2009,10/23/2009,,,,,2/16/2010,2/16/2010,,,9/24/2012,9/24/2012,5/3/2013,5/3/2013,,,,,,,,,,,,,5/30/2013,5/30/2013,,,,,,,,,6/28/2013,6/28/2013,,,,,,,,,,,,,,,,,,,,,,,1/6/2014,1/6/2014,,,,,,,1/6/2014,1/6/2014,,,,,,,1/6/2014,1/6/2014,,,,,,
1-8UJL,C14008,'C14008,,Alisertib,"Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer",Ph 1/2 Ovarian,I/II,Closed,Solid.Gyn.Ovarian,Oncology,,,,,,,,172,1,0,,6,0,0,0.58%,43,,,IQVIA,Robyn Horrigan,,,,,,,,,,,,,STARS Inactive,,,,,12/15/2009,12/15/2009,,,,,5/3/2010,5/3/2010,,,8/13/2013,8/13/2013,12/31/2014,12/31/2014,,,,,,,,,,,,,8/12/2014,8/12/2014,,,,,,,,,11/19/2014,11/19/2014,,,,,,,,,,,,,,,,,,,,,,,1/19/2016,1/19/2016,,,,,,,7/19/2017,7/19/2017,,,,,,,8/28/2017,8/28/2017,,,,,,
1-8UKX,C14009,'C14009,,Alisertib,"A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving A Standard Docetaxel Regimen",Ph 1 Solid tumors,I,Closed,Solid.GU.Prostate,Oncology,,,,,,,,40,3,0,,7,0,0,7.50%,4,,,IQVIA,Mary-Anne McKenna,,,,,,,,,,,,,STARS Inactive,,,,,12/16/2009,12/16/2009,,,,,9/13/2010,9/13/2010,,,9/11/2013,9/11/2013,1/31/2014,1/31/2014,,,,,,,,,,,,,1/27/2017,1/27/2017,,,,,,,,,6/12/2014,6/12/2014,,,,,,,,,,,,,,,,,,,,,,,4/6/2015,4/6/2015,,,,,,,1/4/2017,1/4/2017,,,,,,,1/27/2017,,,,,,,
1-8ULC,C14010,'C14010,,Alisertib,"An Open-Label, Phase 1 Study of the Relative Bioavailability, Food Effect, Safety and Tolerability of an Oral Solution Formulation of MLN8237 in Patients with Advanced Solid Tumors",,I,Closed,Solid.All Comers,Oncology,,,,,,,,60,5,0,,0,0,0,8.33%,3,,,IQVIA,Patty Grier,,,,,,,,,,,,,STARS Inactive,,,,,6/26/2009,6/26/2009,,,,,9/28/2009,9/28/2009,,,11/2/2011,11/2/2011,12/28/2011,12/28/2011,,,,,,,,,,,,,4/12/2012,4/12/2012,,,,,,,,,5/18/2012,5/18/2012,,,,,,,,,,,,,,,,,,,,,,,10/18/2012,10/18/2012,,,,,,,10/18/2012,10/18/2012,,,,,,,10/18/2012,10/18/2012,,,,,,
1-8ULV,C16003,'C16003,,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and/or Refractory Multiple Myeloma",Ph1 RRMM,I,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,63,0,0,,2,0,0,0.00%,7,,,IQVIA,Kalpana Sawant,,,,,,,,,,,,,STARS Inactive,,,,,5/18/2009,5/18/2009,,,,,10/12/2009,10/12/2009,,,6/18/2012,6/18/2012,,,10/22/2012,10/22/2012,,,,,,,5/23/2017,5/23/2017,,,3/25/2013,3/25/2013,,,,,,,6/30/2017,6/30/2017,1/18/2013,1/18/2013,,,,,,,,,,,,,,,,,,,,,7/31/2017,7/31/2017,11/8/2013,11/8/2013,,,,,,,12/8/2017,12/8/2017,,,,,,,12/8/2017,,,,,,,
1-8UMA,C16004,'C16004,,Ninlaro,"An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma",Ph1 RRMM weekly dosing,I,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,70,1,0,,1,0,0,1.43%,6,,,,Greg Wright,,,,,,,,,,,,,STARS Inactive,,,,,6/22/2009,6/22/2009,,,,,11/30/2009,11/30/2009,,,9/24/2012,9/24/2012,1/30/2014,1/30/2014,9/20/2014,9/20/2014,,,,,,,9/20/2014,9/20/2014,,,6/10/2013,6/10/2013,,,,,,,4/20/2014,4/20/2014,,,,,,,,,,,,,,,,,,,,,,,,,1/27/2014,1/27/2014,,,,,,,8/31/2017,8/31/2017,,,,,,,8/31/2017,8/31/2017,,,,,,
1-8UMZ,C16005,'C16005,,Ninlaro,"An Open-Label, Dose-Escalation Phase 1/2 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, Administered in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment",Ph 1/2 IRD NDMM,I/II,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,61,65,0,,0,0,64,106.56%,16,,,PPD,Kalpana Sawant,,,,,,,,,,,,,STARS Inactive,,,,,5/26/2010,5/26/2010,,,,,11/22/2010,11/22/2010,,,2/28/2012,2/28/2012,10/20/2013,10/20/2013,10/20/2013,10/20/2013,,,,,,,2/1/2018,2/1/2018,,,4/7/2014,4/7/2014,,,,,,,3/2/2018,3/2/2018,4/29/2014,4/29/2014,,,,,,,3/23/2018,3/23/2018,,,,,,,,,,,,,3/23/2018,3/23/2018,7/15/2014,7/15/2014,,,,,,,5/10/2018,5/10/2018,,,,,,,5/10/2018,,,,,,,
1-8UNO,C16006,'C16006,,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a  Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard  Care Regimen  of Melphalan and Prednisone in Patients With Newly Diagnosed  Multiple Myeloma Requiring Systemic Treatment",Ph 1/2 IMP NDMM,I/II,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,61,61,0,,0,0,27,100.00%,31,,,PPD,Eric Hoberman,,,,,,,,,,,,,STARS Inactive,,,,,12/22/2010,12/22/2010,,,,,6/27/2011,6/27/2011,,,5/19/2014,5/19/2014,10/19/2015,10/19/2015,12/29/2016,12/29/2016,,,,,,,,,,,5/3/2017,5/3/2017,,,,,,,,,5/12/2017,5/12/2017,,,,,,,,,,,,,,,,,,,,,,,10/27/2017,10/27/2017,,,,,,,,,,,,,,,10/27/2017,,,,,,,
1-8UOZ,C16007,'C16007,,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment",Ph1 amyloid,I,Closed,Heme.Amyloidosis,Oncology,,,,Interventional,,,,32,27,41,,14,0,0,84.38%,10,,,ICON,Cathy O'Connell,,,,,,,,,,,,,STARS Inactive,,,,,8/31/2010,8/31/2010,,,,,5/19/2011,5/19/2011,,,12/6/2012,12/6/2012,8/1/2013,8/1/2013,12/6/2013,12/6/2013,,,,,,,11/13/2018,11/13/2018,,,2/12/2014,2/12/2014,,,,,,,12/6/2018,12/6/2018,,,,,,,,,12/17/2018,12/17/2018,,,,,,,,,,,,,12/17/2018,12/17/2018,8/6/2014,8/6/2014,,,,,,,3/27/2019,3/27/2019,,,,,,,3/27/2019,,,,,,,
1-8UPO,C16008,'C16008,,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment",Ph 1/2 I(2w)+RD NDMM,I/II,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,60,64,0,,0,0,54,106.67%,19,,,PPD,"Cathy O'Connell, Kalpana Sawant",,,,,,,,,,,,,STARS Inactive,,,,,2/28/2011,2/28/2011,,,,,11/7/2011,11/7/2011,,,10/15/2012,10/15/2012,10/14/2013,10/14/2013,10/14/2013,10/14/2013,,,,,,,11/27/2017,11/27/2017,,,2/28/2014,2/28/2014,,,,,,,12/19/2017,12/19/2017,8/28/2014,8/28/2014,,,,,,,1/25/2018,1/25/2018,,,,,,,,,,,,,1/25/2018,1/25/2018,4/6/2015,4/6/2015,,,,,,,3/14/2018,3/14/2018,,,,,,,3/14/2018,,,,,,,
1-8VE8X,C15002,'C15002,,pevonedistat (TAK-924),"An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Lymphoma or Multiple Myeloma",,I,Closed,Heme.Lymphoma.All Comers,Oncology,,,,,,,,99,56,58,,1,,0,56.57%,14,1,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,2/5/2008,2/5/2008,,,,,6/30/2008,6/30/2008,,,4/2/2013,4/2/2013,7/15/2013,7/15/2013,7/15/2013,7/15/2013,,,,,,,,,,,9/30/2013,9/30/2013,,,,,,,,,10/29/2013,10/29/2013,,,,,,,,,,,,,,,,,,,,,,,4/29/2014,4/29/2014,,,,,,,,,,,,,,,4/29/2014,4/29/2014,,,,,,
1-8VE85,C15001,'C15001,,pevonedistat (TAK-924),"An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Nonhematologic Malignancies",,I,Closed,Solid.All Comers,Oncology,,,,,,,,89,62,62,,0,,1,69.66%,6,1,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,12/11/2007,12/11/2007,,,,,4/28/2008,4/28/2008,,,11/16/2011,11/16/2011,2/15/2012,2/15/2012,2/15/2012,2/15/2012,,,,,,,,,,,3/16/2012,3/16/2012,,,,,,,,,4/12/2012,4/12/2012,,,,,,,,,,,,,,,,,,,,,,,8/2/2012,8/2/2012,,,,,,,,,,,,,,,8/2/2012,8/2/2012,,,,,,
1-8VEAE,C15003,'C15003,,pevonedistat (TAK-924),"An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia",,I,Closed,Heme.Leukemia.Acute,Oncology,,,,,,,,72,72,79,,7,,3,100.00%,10,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,4/13/2009,4/13/2009,,,,,7/27/2009,7/27/2009,,,2/21/2013,2/21/2013,8/25/2013,8/25/2013,8/25/2013,8/25/2013,,,,,,,,,,,10/28/2013,10/28/2013,,,,,,,,,11/25/2013,11/25/2013,,,,,,,,,,,,,,,,,,,,,,,4/23/2014,4/23/2014,,,,,,,,,,,,,,,4/23/2014,4/23/2014,,,,,,
1-8VEAZ,C15005,'C15005,,pevonedistat (TAK-924),"A Phase 1 , Open-Label, Dose- Escalation Study of MLN4924, a Novel Inhibiotr of Nedd8-Activating Enzyme, in Adult Patients with Melanoma",,I,Closed,Solid.Skin.Melanoma,Oncology,,,,,,,,66,37,37,,0,,3,56.06%,3,1,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,9/15/2009,9/15/2009,,,,,12/7/2009,12/7/2009,,,1/31/2012,1/31/2012,5/22/2012,5/22/2012,5/22/2012,5/22/2012,,,,,,,,,,,8/17/2012,8/17/2012,,,,,,,,,9/17/2012,9/17/2012,,,,,,,,,,,,,,,,,,,,,,,8/19/2013,8/19/2013,,,,,,,,,,,,,,,8/19/2013,8/19/2013,,,,,,
1-9CJO7,C15007,'C15007,,,"A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of MLN4924 Plus Azacitidine Versus Single-Agent Azacitidine in Elderly, Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML)",,III,Cancelled,Heme.Leukemia.Acute,,,,,,,,,694,0,0,,0,,0,0.00%,140,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-9GFC9,C20002,'C20002,,,"A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies",,I,Cancelled,Solid.All Comers,,,,,,,,,161,0,1,,0,,0,0.00%,15,3,,ICON,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-9GYS5,C25002,'C25002,,ADCETRIS,A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma,Phase 1/2 Pediatric r/r HL & ALCL,I/II,Closed,Heme.Other,Oncology,,,,,,,,42,36,40,,5,0,0,85.71%,24,5,,ICON,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,7/11/2011,7/11/2011,,,,,4/16/2012,4/16/2012,,,4/12/2016,4/12/2016,10/12/2016,10/12/2016,10/12/2016,10/12/2016,,,,,,,4/12/2018,4/12/2018,,,12/3/2016,12/3/2016,,,,,,,5/2/2018,5/2/2018,12/9/2016,12/9/2016,,,,,,,6/7/2018,6/7/2018,,,,,2/2/2017,2/2/2017,,,,,,,5/30/2018,5/30/2018,3/29/2017,3/29/2017,,,,,,,7/26/2018,7/26/2018,,,,,,,7/26/2018,7/26/2018,,,,,,
1-9GYT5,C15006,'C15006,,,"A Phase 1B, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients with Acute Myelogenous Leukemia (AML)",,I,Cancelled,Heme.Other,,,,,,,,,21,0,0,,0,,0,0.00%,5,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-9H2OY,C16012,'C16012,,,"An Open-label, Phase 2 Study of MLN9708 Oral Formulation in Adult Patients With Advanced Nonhematologic Malignancies Expressing Elevated Cytoplasmic p65/NFkB",,II,Cancelled,Solid.All Comers,,,,,,,,,77,0,0,,0,,0,0.00%,25,5,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-9H2R5,C21010,'C21010,,TAK-700,"A Phase 1, Single-Dose Study of the Safety and Pharmacokinetics of Orteronel in Subjects With Varying Degrees of Renal Impairment",,I,Closed,Solid.GU.Prostate,Oncology,,,,,,,,32,32,68,,36,,0,100.00%,4,5,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-9H28T,C25003,'C25003,,ADCETRIS,"A Randomized, Open-label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma",Phase 3 FL HL,III,Recruitment Complete,Metastatic melanoma with B-raf and N-ras mutations,Oncology,Late Oncology,,,Interventional,Treatment,Prospective,Other,23,"1,309",1546,,236,0,0,5691.30%,258,223,,ICON,,"Clarida Martinez, Jodi Pappas, Sakiko Kaizuka, Vijay Maharaj, Yuko Shimada, Zahir Rajiwate, Calvin Gooden",,"Akiko Kimura, Dirk Huebner, Jessica Sachs, Takafumi Matsushima, Takayuki Asato",,2011-005450-60,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,8/3/2012,8/3/2012,,,,,11/19/2012,11/19/2012,,,1/13/2016,1/13/2016,7/14/2016,7/14/2016,9/13/2021,4/20/2017,,,,,,,1/15/2026,,,,12/26/2021,6/12/2017,,,,,,,3/12/2026,,6/23/2017,6/23/2017,1/2/2022,,,,,,4/9/2026,,,,,,6/28/2017,6/28/2017,1/22/2022,,,,,,5/7/2026,,8/18/2017,8/18/2017,5/29/2022,,,,,,8/27/2026,,,,,,,,8/27/2026,,,,,,,
1-9HF2D,C16010,'C16010,,Ninlaro,"A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma",Ph3 IRD RRMM,III,Recruitment Complete,(MM) Multiple myeloma relapsed/refractory,Oncology,Late Oncology,,,,,,,41,838,1066,,228,838,,2043.90%,150,114,,PPD,,"Fuquan, Kenneth Chen, Kacy Gillis, Sally Buelta, Tomoko Ohta, Lee williams",,"Andreas Muehler, Hui Wang, Richard Labotka",,2011-005496-17,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,2/21/2012,2/21/2012,,,8/13/2012,8/13/2012,8/28/2012,8/28/2012,,,5/27/2014,5/27/2014,12/27/2015,12/27/2015,10/30/2014,10/30/2014,11/13/2017,11/13/2017,9/28/2020,9/28/2020,12/31/2021,,,,,,1/15/2015,1/15/2015,1/14/2018,1/14/2018,11/6/2020,11/6/2020,,,,,3/6/2015,3/6/2015,,,,,,,,,,,,,,,,,11/24/2020,11/24/2020,,,,,6/21/2015,6/21/2015,,,4/15/2021,4/15/2021,5/31/2022,,,,1/7/2015,1/7/2015,5/13/2015,,2/13/2018,2/13/2018,5/31/2022,,,,,,,
1-9HFAI,C21011,'C21011,,,"A Phase 1, Randomized, Double-Blind, Crossover Placeboand Positive-Controlled Study to Investigate the Electrophysiological Effects of a Single Oral Dose of TAK-700 on QT Intervals in Healthy Male Subjects",,I,Terminated,Solid.GU.Prostate,,,,,,,,,1,0,0,,0,,0,0.00%,1,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-9I7GV,C14012,'C14012,,Alisertib,"A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma",Ph 3 PTCL,III,Closed,Heme.Lymphoma.T-Cell,Oncology,,,,,,,,354,155,3,,62,274,0,43.79%,180,1,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,7/25/2011,7/25/2011,,,,,6/11/2012,6/11/2012,,,11/5/2014,11/5/2014,6/30/2015,6/30/2015,6/30/2015,6/30/2015,,,,,,,12/15/2017,,,,9/15/2015,9/15/2015,,,,,,,2/5/2018,,10/30/2015,10/30/2015,,,,,,,,,,,,,10/9/2015,10/9/2015,,,,,,,3/2/2018,,7/27/2016,7/27/2016,,,,,,,,,,,,,,,3/2/2018,,,,,,,
1-9K2F,C14001,'C14001,,Alisertib,"An Open-Label, Dose Escalation Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, In patients with advanced solid tumors",,I,Closed,Solid.All Comers,Oncology,,,,,,,,118,87,0,,0,,87,73.73%,3,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,2/14/2007,2/14/2007,,,,,5/15/2007,5/15/2007,,,6/18/2010,6/18/2010,8/9/2010,8/9/2010,,,,,,,,,,,,,11/23/2010,11/23/2010,,,,,,,,,12/2/2010,12/2/2010,,,,,,,,,,,,,,,,,,,,,,,4/19/2011,4/19/2011,,,,,,,4/19/2011,4/19/2011,,,,,,,4/19/2011,4/19/2011,,,,,,
1-9K2Y,C14002,'C14002,,Alisertib,"A Phase 1 Clinical and Pharmacodynamic Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Malignancies",,I,Closed,Solid.Other,Oncology,,,,,,,,67,59,0,,0,,59,88.06%,2,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,2/14/2007,2/14/2007,,,,,10/22/2007,10/22/2007,,,7/20/2010,7/20/2010,9/30/2010,9/30/2010,,,,,,,,,,,,,1/14/2011,1/14/2011,,,,,,,,,1/27/2011,1/27/2011,,,,,,,,,,,,,,,,,,,,,,,11/30/2011,11/30/2011,,,,,,,11/30/2011,11/30/2011,,,,,,,11/30/2011,11/30/2011,,,,,,
1-9K3D,C14003,'C14003,,Alisertib,"An Open-Label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies",Ph 1 Heme,I,Closed,Heme.All Comers,Oncology,,,,,,,,97,58,81,,23,,1,59.79%,10,2,,In-House,Mary-Anne McKenna,,,,,,,,,,,,,STARS Inactive,,,,,3/26/2008,3/26/2008,,,,,7/17/2008,7/17/2008,,,11/15/2011,11/15/2011,6/29/2012,6/29/2012,,,,,,,,,,,,,12/19/2016,12/19/2016,,,,,,,,,7/6/2012,7/6/2012,,,,,,,,,,,,,,,,,,,,,,,11/29/2012,11/29/2012,,,,,,,11/29/2012,11/29/2012,,,,,,,12/19/2016,12/19/2016,,,,,,
1-9KB55,C27001,'C27001,,relugolix,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose, Inpatient and Outpatient Study in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy for Testosterone Lowering of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist",,I,Closed,Solid.GU.Prostate,Oncology,,,,,,,,218,176,0,,0,,5,80.73%,2,,,Hammersmith Medicines Research,,,,,,,,,,,,,,STARS Inactive,,,,,9/29/2011,9/29/2011,,,,,10/17/2011,10/17/2011,,,9/28/2012,9/28/2012,12/18/2012,12/18/2012,12/18/2012,12/18/2012,,,,,,,,,,,1/17/2013,1/17/2013,,,,,,,,,2/16/2013,2/16/2013,,,,,,,,,,,,,,,,,,,,,,,6/26/2013,6/26/2013,,,,,,,,,,,,,,,6/26/2013,6/26/2013,,,,,,
1-10E05V,TAK-390MR_206,'TAK-390MR_206,,,"A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease",Peds 12-17yo GERD (Delayed Release),II,Closed,Other,,,,,Pediatric Safety/Efficacy,,,,104,0,0,,0,,0,0.00%,56,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,6/6/2011,6/6/2011,2/9/2012,2/9/2012,,,,,7/27/2012,7/27/2012,,,12/10/2013,12/10/2013,,,1/21/2014,1/21/2014,,,,,,,,,,,3/13/2014,3/13/2014,,,,,,,,,4/10/2014,4/10/2014,,,,,,,,,,,,,,,,,,,,,,,8/14/2014,8/14/2014,,,,,,,,,,,,,,,8/14/2014,8/14/2014,,,,,,
1-10ELBQ,TBD-18785,'TBD-18785,,TAK-243,Study #1,Study #1,I/II,Cancelled,Other,Oncology,,,,,,,,80,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELCL,TBD-18786,'TBD-18786,,TAK-243,Study #2,Study #2,I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELD0,TBD-18790,'TBD-18790,,TAK-243,Study Indication #3,Study Indication #3,I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELDC,TBD-18791,'TBD-18791,,TAK-243,Study,Study,I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELDL,TBD-18792,'TBD-18792,,TAK-243,Study,Study,II,Cancelled,Other,Oncology,,,,,,,,200,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELDU,TBD-18793,'TBD-18793,,TAK-243,Multi-Dz SA,Multi-Dz SA,II,Cancelled,Other,Oncology,,,,,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELE3,TBD-18794,'TBD-18794,,TAK-243,Human ADME,Human ADME,I,Cancelled,Other,Oncology,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELEC,TBD-18795,'TBD-18795,,TAK-243,DDI #1,DDI #1,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELEL,TBD-18796,'TBD-18796,,TAK-243,DDI #2,DDI #2,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELEU,TBD-18797,'TBD-18797,,TAK-243,Study #1,Study #1,III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELFX,TBD-18798,'TBD-18798,,TAK-243,Study #2,Study #2,III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELG6,TBD-18799,'TBD-18799,,TAK-243,Study #3,Study #3,III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELGF,TBD-18800,'TBD-18800,,TAK-243,QT Study,QT Study,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELGO,TBD-18801,'TBD-18801,,TAK-243,Pediatric,Pediatric,I,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELH7,TBD-18802,'TBD-18802,,TAK-243,BA Study,BA Study,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELHW,TBD-18803,'TBD-18803,,TAK-243,Bridging Study,Bridging Study,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELI5,TBD-18804,'TBD-18804,,TAK-243,Hepatic Impairment,Hepatic Impairment,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELIO,TBD-18805,'TBD-18805,,TAK-243,Renal Impairment,Renal Impairment,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELIX,TBD-18806,'TBD-18806,,TAK-243,w/ Food Effect-Heme,w/ Food Effect-Heme,I,Cancelled,Other,Oncology,,,,,,,,80,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELJ6,TBD-18825,'TBD-18825,,relugolix,Human ADME,Human ADME,I,Cancelled,Other,Oncology,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELJS,TBD-18831,'TBD-18831,,relugolix,BA Study,BA Study,I,Terminated,,Oncology,,,,,,,,50,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,1/22/2015,1/22/2015,,,,,3/24/2015,3/24/2015,,,3/24/2015,3/24/2015,5/17/2015,5/17/2015,5/17/2015,5/17/2015,,,,,,,,,,,6/15/2015,6/15/2015,,,,,,,,,7/15/2015,7/15/2015,,,,,,,,,,,,,,,,,,,,,,,11/4/2015,11/4/2015,,,,,,,,,,,,,,,11/4/2015,11/4/2015,,,,,,
1-10ELKC,TBD-18832,'TBD-18832,,relugolix,Renal Impairment,Renal Impairment,I,Cancelled,Other,Oncology,,,,,,,,16,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELKL,TBD-18833,'TBD-18833,,relugolix,Hepatic Impairment,Hepatic Impairment,I,Cancelled,Other,Oncology,,,,,,,,32,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELKU,TBD-18955,'TBD-18955,,,Phase 3 Renal (600pts),Phase 3 Renal (600pts),III,Cancelled,Other,,,,,,,,,600,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELL3,TBD-19226,'TBD-19226,,sapanisertib,3 Pivotal Endometrial MLN0128 co,3 Pivotal Endometrial MLN0128 co,III,Cancelled,Pouchitis,Oncology,,,,,,,,600,,,,,,,,1,,,TBD,,,,,,,,,,,NA,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELLF,TBD-19234,'TBD-19234,,relugolix,#1 ADT for advanced PC-China/Kor,Ph 1b/2 Heme IO co#1 ADT for advanced PC-China/Kor,III,Cancelled,Other,Oncology,,,,,,,,360,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELLW,TBD-19235,'TBD-19235,,relugolix,BE/FE Commercial Tab/S-D,BE/FE Commercial Tab/S-D,I,Cancelled,Other,Oncology,,,,,,,,40,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELMH,TBD-19293,'TBD-19293,,TAK-264,Gastric,Gastric,III,Cancelled,Other,Oncology,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELMT,TBD-19294,'TBD-19294,,TAK-264,Pancreatic,Pancreatic,III,Cancelled,Other,Oncology,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELNE,TBD-19297,'TBD-19297,,relugolix,DDI w/CYP2A Inducer,DDI w/CYP2A Inducer,I,Cancelled,Other,Oncology,,,,,,,,40,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELNX,TBD-19305,'TBD-19305,,TAK-580,Phase 2/3 Registration Combo #1,Phase 2/3 Registration Combo #1,II/III,Cancelled,Other,Oncology,,,,,,,,600,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELOA,TBD-19306,'TBD-19306,,TAK-580,Food effect Pilot T2,Food Effect Study Ph2 CTM,I,Cancelled,Other,Oncology,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELOL,TAK-931-1002,'TAK-931-1002,,TAK-931,"An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 (CDC7) Inhibitor, in Adult Patients With Advanced Nonhematologic Tumors",Single Agent,I,All Activities Closed,Multiple cancer,Oncology,Early Oncology,,,,,,,80,80,100,,20,,80,100.00%,2,,,PPD,,,,"Hongmei Li, Li Hongmei, Nachos Garcia-Ribas, Takayuki Asato",,,,,,,NA,,,Medidata CTMS (Pharma),,,11/17/2015,11/17/2015,12/14/2015,12/14/2015,,,,,3/30/2016,3/30/2016,,,8/6/2019,8/6/2019,12/21/2019,12/21/2019,12/20/2019,12/20/2019,,,,,,,,,,,4/6/2020,4/6/2020,,,,,,,,,4/10/2020,4/10/2020,,,,,,,,,,,,,5/19/2020,5/19/2020,,,,,,,,,10/27/2020,10/27/2020,,,,,,,,,,,,,,,10/27/2020,10/27/2020,,,,,,
1-10ELPN,TAK-931-1003,'TAK-931-1003,,TAK-931,TAK-931-1003 RBA-FE-PPI,Phase 1 rBA-Food Effect-PPI (60 pts),I,All Activities Closed,Multiple cancer,Oncology,Early Oncology,,,,,,,44,21,31,,10,21,21,47.73%,4,,,PRA,,Michelle Thompson,,,,,,,,,NA,,,Medidata CTMS (Pharma),,,5/7/2018,5/7/2018,6/27/2018,6/27/2018,,,,,4/10/2019,4/10/2019,,,8/5/2019,8/5/2019,12/3/2019,12/3/2019,12/3/2019,12/3/2019,,,,,,,,,,,4/7/2020,4/7/2020,,,,,,,,,4/13/2020,4/13/2020,,,,,,,,,,,,,8/17/2020,8/17/2020,,,,,,,,,9/25/2020,9/25/2020,,,,,,,,,,,,,,,9/25/2020,9/25/2020,,,,,,
1-10ELQ6,TAK-931-2001,'TAK-931-2001,,TAK-931,Phase 2 Single Agent (88 pts),Phase 2 Single Agent (88 pts),I/II,Reported,Multiple cancer,Oncology,Early Oncology,,,,,,,142,101,126,,25,,101,71.13%,15,,,PRA,,"Yumi Oomuku, Michelle Thompson",,,,,,,,,NA,,,Medidata CTMS (Pharma),,,3/16/2017,3/16/2017,7/14/2017,7/14/2017,,,,,11/1/2017,11/1/2017,,,10/9/2019,10/9/2019,8/24/2020,8/24/2020,8/24/2020,8/24/2020,,,,,,,,,,,11/6/2020,11/6/2020,,,,,,,,,,,,,,,,,,,,,,,1/21/2021,1/21/2021,,,,,,,,,5/5/2021,5/5/2021,,,,,,,,,,,,,,,5/5/2021,5/5/2021,,,,,,
1-10ELQF,TBD-19415,'TBD-19415,,TAK-931,Phase 1b/2 Combination (160pts),Phase 1b/2 Combination (160pts),I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELQO,TBD-19416,'TBD-19416,,TAK-931,Pivotal,Pivotal,II,Cancelled,Other,Oncology,,,,,,,,200,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELQX,TBD-19418,'TBD-19418,,TAK-931,Multi Dz SA,Multi Dz SA,II,Cancelled,Other,Oncology,,,,,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELR6,TBD-19419,'TBD-19419,,TAK-931,Indication #2,Indication #2,I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELRF,TBD-19420,'TBD-19420,,TAK-931,DDI #1,DDI #1,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELRQ,TBD-19421,'TBD-19421,,TAK-931,DDI #2,DDI #2,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELS9,TBD-19422,'TBD-19422,,TAK-931,Indication #3,Indication #3,I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELSI,TBD-19423,'TBD-19423,,TAK-931,Indication #1,Indication #1,III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELSR,TBD-19424,'TBD-19424,,TAK-931,Indication #2,Indication #2,III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELT0,TBD-19425,'TBD-19425,,TAK-931,Indication #3,Indication #3,III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELT9,TBD-19630,'TBD-19630,,,Renal SA vs,Renal SA vs,II,Planned,,,,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELTV,TBD-19633,'TBD-19633,,TAK-264,Pancreatic Combo,Pancreatic Combo,III,Cancelled,Other,Oncology,,,,,,,,700,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELU7,TBD-19634,'TBD-19634,,TAK-264,Gastric Combo,Gastric Combo,III,Cancelled,Other,Oncology,,,,,,,,700,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELUG,TBD-19635,'TBD-19635,,TAK-580,Phase 2 NSCLC,Phase 2 NSCLC,II,Cancelled,Other,Oncology,,,,,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELUS,TBD-19654,'TBD-19654,,,PD-1 with MLN2480 combo,PD-1 with MLN2480 combo,IB,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELV2,TBD-19696,'TBD-19696,,ADCETRIS,Combo w/ MLN0128,PD-1 Combo,Ib,Planned,"(HL) Hodgkin lymphoma, relapsed/refractory",Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELXD,C16047,'C16047,,Ninlaro,Ph 2 I-Dara Maintenance,Ph 2 I-Dara Maintenance,II,Recruitment Complete,MM DN Dara,Oncology,Late Oncology,,,,,,,60,61,97,,36,,43,101.67%,25,35,,PRA,,"Emma Rouse, Zahir Rajiwate, Laurie Lobue, Kate Danis",,Debbie Berg,,2017-003977-32,,,,,NA,Advance,,Medidata CTMS (Pharma),,,9/15/2017,9/15/2017,11/30/2017,11/30/2017,,,,,8/3/2018,8/3/2018,,,7/31/2019,7/31/2019,1/31/2020,1/31/2020,1/31/2020,1/31/2020,,,1/31/2022,,,,6/26/2022,,,,3/17/2020,3/17/2020,,,,,,,7/25/2022,,3/24/2020,3/24/2020,,,,,,,8/15/2022,,,,,,8/8/2020,8/8/2020,,,,,,,,,,,,,,,,,11/14/2022,,,,,,,,11/14/2022,,,,,,,
1-10ELY9,TBD-19709,'TBD-19709,,TAK-117,Gastric Multi Arm Combo Docet,Gastric Multi Arm Combo Docet,I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELYI,TBD-19710,'TBD-19710,,TAK-117,BA Study Ph 3 formulation 3 way cross,BA Study Ph 3 formulation 3 way cross,III,Cancelled,Other,Oncology,,,,,,,,20,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELYU,TBD-19711,'TBD-19711,,TAK-117,Gastric R/R,Gastric R/R,III,Cancelled,Other,Oncology,,,,,,,,500,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELZ3,TBD-19718,'TBD-19718,,TAK-117,BA Study Ph3 formulation 3 way cross,BA Study Ph3 formulation 3 way cross,III,Cancelled,Other,Oncology,,,,,,,,20,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10ELZC,C31008,'C31008,,sapanisertib,JNA PK/Safety SA and Combo w,JNA PK/Safety SA and Combo w,I,Reported,(BC) Breast cancer,Oncology,Late Oncology,,,,,,,46,28,0,,6,0,0,60.87%,4,,,IQVIA,,"Chie Kawahara, Sakiko Kaizuka",,"Farhad Sedarati, Tomoko Yanai",,,,,,,,,,Medidata CTMS (Pharma),,,4/6/2017,4/6/2017,8/2/2017,8/2/2017,,,,,1/31/2018,1/31/2018,,,4/19/2019,4/19/2019,8/28/2019,8/28/2019,8/28/2019,8/28/2019,,,,,,,,,,,10/24/2019,10/24/2019,,,,,,,,,11/25/2019,11/25/2019,,,,,,,,,,,,,11/25/2019,11/25/2019,,,,,,,,,3/5/2020,3/5/2020,,,,,,,,,,,,,,,3/5/2020,,,,,,,
1-10EM06,TBD-18772,'TBD-18772,,TAK-659,Phase 3 Solid (1000 pts),P3 Heme/Solid #3 (1000pts),III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGW6,TBD-18771,'TBD-18771,,TAK-659,Phase 3 Heme (1000 pts),P3 Heme AML Combo 1000pts,III,Cancelled,Other,Oncology,,,,,,,,"1,000",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGWP,TBD-18770,'TBD-18770,,TAK-659,Phase 2/3 DLBCL Combo - BR+/- TAK-659 (500 pts),P3 Heme DLBCLCombo 1000pt,III,Cancelled,Other,Oncology,,,,,,,,300,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGX3,C34004,'C34004,,TAK-659,C34004 Phase 2 Single Agent (R/R DLBCL) (82 pts),C34004 Phase 2 Single Agent (R/R DLBCL) (82 pts),II,Completed,Hunter syndrome treatment of CNS Symptoms,Oncology,Early Oncology,,,,,,,122,49,84,,35,,45,40.16%,50,,,PRA,,"Rachel Margulis, Sarah Noah, Michelle Thompson",,,,2016-003716-12,,,,,,,,Medidata CTMS (Pharma),,,3/18/2016,3/18/2016,3/1/2017,3/1/2017,,,,,10/23/2017,10/23/2017,,,8/2/2018,8/2/2018,1/31/2019,1/31/2019,1/31/2019,1/31/2019,,,,,,,3/20/2020,3/20/2020,,,4/11/2019,4/11/2019,,,,,,,4/21/2020,4/21/2020,4/18/2019,4/18/2019,,,,,,,,,,,,,5/21/2019,5/21/2019,,,,,,,,,11/15/2019,11/15/2019,,,,,,,7/9/2020,7/9/2020,,,,,,,7/9/2020,7/9/2020,,,,,,
1-10FGXC,TBD-18768,'TBD-18768,,TAK-659,TBD,P2/3 AML S.Agent (200pts),II/III,Cancelled,Other,Oncology,,,,,,,,200,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGXL,C34003,'C34003,,TAK-659,A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors,P1b Immuno-Onc (200pts),IB,Closed,Other,Oncology,,,,,,,,48,41,64,,23,,41,85.42%,25,1,,PRA,,,,,,,,,,,,,,STARS Inactive,,,12/14/2015,12/14/2015,4/6/2016,4/6/2016,,,,,8/25/2016,8/25/2016,,,7/25/2018,7/25/2018,10/15/2018,10/15/2018,10/15/2018,10/15/2018,,,,,,,,,,,5/7/2019,5/7/2019,,,,,,,,,5/21/2019,5/21/2019,,,,,,,,,,,,,7/1/2019,7/1/2019,,,,,,,,,10/1/2019,10/1/2019,,,,,,,,,,,,,,,10/1/2019,10/1/2019,,,,,,
1-10FGXU,C34005,'C34005,,TAK-659,C34005 Phase 1b Multi-Arm Combo study (100pts),C34005 Phase 1b Multi-Arm Combo study (100pts),Ib,Recruitment Complete,(NHL) Non-Hodgkin's lymphoma,Oncology,Early Oncology,,,,,,,55,43,70,,27,,,78.18%,15,,,PRA,,"Laurie Lobue, Sarah Noah, Michelle Thompson",,Benjamin Lee,,,,,,,,,,Medidata CTMS (Pharma),,,3/31/2016,3/31/2016,6/7/2016,6/7/2016,,,,,6/15/2017,6/15/2017,,,11/20/2018,11/20/2018,7/27/2020,7/27/2020,7/27/2020,7/27/2020,,,,,,,,,,,9/4/2020,9/4/2020,,,,,,,,,9/4/2020,9/4/2020,,,,,,,,,,,,,10/9/2020,10/9/2020,,,,,,,,,12/22/2020,12/22/2020,,,,,,,,,,,,,,,12/22/2020,12/22/2020,,,,,,
1-10FGY3,TBD-18764,'TBD-18764,,TAK-659,Phase 2/3 AML combo,Phase 2/3 AML combo,I/II,Cancelled,Other,Oncology,,,,,,,,160,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGYC,TBD-18763,'TBD-18763,,TAK-659,Phase 1b/2 Indolent NHL Combo (280 pts),P1b/2 NHL Combo2-280 pts,I/II,Cancelled,Other,Oncology,,,,,,,,280,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGYL,TBD-18761,'TBD-18761,,TAK-659,TBD,Renal Impairment (70pts),I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGYU,TBD-18760,'TBD-18760,,TAK-659,TBD,QT Study (45pts),I,Cancelled,Other,Oncology,,,,,,,,45,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGZ3,TBD-18759,'TBD-18759,,TAK-659,TBD,Pediatrics (100pts),I,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGZM,C34010,'C34010,,TAK-659,C34010 Human ADME (12 pts),C34010 Human ADME (12 pts),I,Cancelled,Other,Oncology,,,,,,,,6,0,0,,0,,0,0.00%,1,,,PRA,Melinda Snyder,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FGZV,TBD-18757,'TBD-18757,,TAK-659,TBD,Hepatic Impairment (70pt),I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH0N,TBD-18755,'TBD-18755,,TAK-659,TBD,DDI #1 (25pts),I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH0W,TBD-18751,'TBD-18751,,,Bridging Study,Bridging Study,I,Cancelled,Other,,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH3N,TBD-18742,'TBD-18742,,sapanisertib,Renal Impairment,Renal Impairment,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH3W,TBD-18741,'TBD-18741,,sapanisertib,Hepatic Impairment INK128,Hepatic Impairment INK128,I,Planned,Support - Oncology,Oncology,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH4O,TBD-18739,'TBD-18739,,sapanisertib,Pediatrics,Pediatrics,I,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH4Z,TBD-18738,'TBD-18738,,sapanisertib,Bridging Study,Bridging Study,I,Cancelled,Other,Oncology,,,,,,,,32,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH5H,TBD-18733,'TBD-18733,,sapanisertib,DDI #2 Study,DDI #2 Study,I,Planned,Support - Oncology,Oncology,,,,,,,,25,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH8G,TBD-18694,'TBD-18694,,TAK-117,QTc Study,QTc Study,I,Cancelled,Other,Oncology,,,,,,,,40,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH04,TBD-18756,'TBD-18756,,TAK-659,DDI #2 (25 pts),DDI #2 (25pts),I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH15,TBD-18750,'TBD-18750,,,BA Study,BA Study,I,Cancelled,Other,,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH45,TBD-18740,'TBD-18740,,sapanisertib,Human ADME,Human ADME,I,Cancelled,Other,Oncology,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH58,TBD-18735,'TBD-18735,,sapanisertib,mBC ER/PR+ Post AI,mBC ER/PR+ Post AI,III,Cancelled,Other,Oncology,,,,,,,,800,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FH60,TBD-18732,'TBD-18732,,sapanisertib,DDI #1 Study,DDI #1 Study,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FHKN,C25010,'C25010,,ADCETRIS,"A Phase 2, Single-Arm, Open-label
Study of Brentuximab Vedotin in Chinese Patients With
Relapsed/Refractory CD30-Positive Hodgkin Lymphoma
(HL) or Systemic Anaplastic Large Cell Lymphoma
(sALCL)",China Local Study w/PK,II,Reported,Maintenance of healed erosive esophagitis,Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,30,39,43,,4,39,39,130.00%,9,,,IQVIA,,"Shu Zhang, Jingjing Tan",,,,,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,,,4/21/2016,4/21/2016,,,11/7/2016,11/7/2016,11/23/2016,11/23/2016,,,7/25/2017,7/25/2017,7/3/2018,7/3/2018,8/2/2018,8/2/2018,,,,,,,2/3/2020,2/3/2020,,,9/12/2018,9/12/2018,,,,,,,6/26/2020,6/26/2020,9/21/2018,9/21/2018,,,,,,,7/3/2020,7/3/2020,,,,,11/2/2018,11/2/2018,,,,,,,7/13/2020,7/13/2020,12/21/2018,12/21/2018,,,,,,,9/4/2020,9/4/2020,,,,,,,9/4/2020,9/4/2020,,,,,,
1-10FL2J,TBD-17701,'TBD-17701,,TAK-264,Gastric Chemo Combo,Gastric Chemo Combo,I/II,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL3D,TBD-17702,'TBD-17702,,TAK-264,Pancreatic Chemo Combo,Pancreatic Chemo Combo,I/II,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL3M,TBD-17709,'TBD-17709,,TAK-264,DDI #1,DDI #1,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL4E,TBD-17712,'TBD-17712,,TAK-264,BA Study,BA Study,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL4N,TBD-17713,'TBD-17713,,TAK-264,Renal Impaired,Renal Impaired,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL5G,TBD-17715,'TBD-17715,,TAK-264,Human ADME,Human ADME,I,Cancelled,Other,Oncology,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL5P,TBD-17716,'TBD-17716,,TAK-264,Bridging Study,Bridging Study,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL6M,TBD-18143,'TBD-18143,,TAK-580,Phase 2 CRC - Solid,Phase 2 NSCLC non-v600e (150 pts),II,Cancelled,Other,Oncology,,,,,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL7P,TBD-18146,'TBD-18146,,TAK-580,DDI #1 CYP2C/3A inducer,DDI #1 CYP2C/3A inducer,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL8H,TBD-18150,'TBD-18150,,TAK-580,Phase 3 NSCLC - Solid Tumor,Phase 3 NSCLC - Solid Tumor,III,Cancelled,Other,Oncology,,,,,,,,500,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL8Q,TBD-18151,'TBD-18151,,TAK-580,Phase 3 CRC,Phase 3 CRC,III,Cancelled,Other,Oncology,,,,,,,,500,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL8Z,TBD-18153,'TBD-18153,,TAK-580,Phase 2 Registration Enabling Pediatrics,Phase 2 Registration Enabling Pediatrics,I,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL45,TBD-17710,'TBD-17710,,TAK-264,DDI #2,DDI #2,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL56,TBD-17714,'TBD-17714,,TAK-264,QT Study,QT Study,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL68,TBD-17717,'TBD-17717,,TAK-264,Hepatic Impaired,Hepatic Impaired,I,Cancelled,Other,Oncology,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FL88,TBD-18147,'TBD-18147,,TAK-580,DDI #2 CYP2C8 inhibitor,DDI #2 CYP2C8 inhibitor,I,Cancelled,Other,Oncology,,,,,,,,25,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLBP,TBD-18155,'TBD-18155,,TAK-580,Human ADME,Human ADME,I,Cancelled,Other,Oncology,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLBY,TBD-18156,'TBD-18156,,TAK-580,QT Study,QT Study,I,Cancelled,Other,Oncology,,,,,,,,45,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLC7,TBD-18157,'TBD-18157,,TAK-580,Relative BA,Relative BA,I,Cancelled,Other,Oncology,,,,,,,,52,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLCG,TBD-18158,'TBD-18158,,TAK-580,Renal Impairment,Renal Impairment,I,Cancelled,Other,Oncology,,,,,,,,18,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLCP,TBD-18159,'TBD-18159,,TAK-580,Hepatic Impairment,Hepatic Impairment,I,Cancelled,Other,Oncology,,,,,,,,32,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLDS,TBD-17382,'TBD-17382,,pevonedistat (TAK-924),NSCLC Combo,NSCLC Combo,II,Cancelled,Other,Oncology,,,,,,,,106,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLE4,Pevonedistat-3001,'Pevonedistat-3001,,pevonedistat (TAK-924),"A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia",Ph 3 HR-MDS,III,Recruitment Complete,"Follicular B-cell Non-Hodgkin's lymphoma, relapsed/refractory, combination with rituximab",Oncology,Late Oncology,,,Interventional,,,,450,560,0,,0,0,56,124.44%,136,140,,PPD,,"Heather Knowles, Kaori Oneda, Lydia Liu, Stephen Curwen, Tara Sadowski",,,,2017-000318-40,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,,,8/4/2017,8/4/2017,,,,,12/18/2017,12/18/2017,,,12/2/2019,12/2/2019,11/26/2020,11/26/2020,5/28/2021,5/28/2021,,,,,,,3/31/2023,,,,8/19/2021,,,,,,,,5/25/2023,,8/25/2021,,,,,,,,,,,,,,9/24/2021,,,,,,,,6/22/2023,,11/1/2021,,,,,,,,10/12/2023,,,,,,,,10/12/2023,,,,,,,
1-10FLEN,Pevonedistat-1016,'Pevonedistat-1016,,pevonedistat (TAK-924),Organ Impairment,Organ Impairment,I,Recruiting,Support - Oncology,Oncology,Late Oncology,,,Interventional,,,,42,19,0,,0,0,1,45.24%,15,14,,PPD,,"Douglas Faller, Tara Sadowski, Elizabeth Halter, Sarah Farooq",,Farhad Sedarati,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/7/2018,11/7/2018,,,,,7/22/2019,7/22/2019,,,4/7/2022,,9/22/2022,,5/4/2022,,,,,,,,9/22/2022,,,,6/29/2022,,,,,,,,11/17/2022,,7/6/2022,,,,,,,,,,,,,,7/27/2022,,,,,,,,12/15/2022,,12/7/2022,,,,,,,,3/30/2023,,,,,,,,3/30/2023,,,,,,,
1-10FLEX,TBD-17657,'TBD-17657,,pevonedistat (TAK-924),Hepatic Impairment,Hepatic Impairment MLN4924 - Liquid,I,Cancelled,Support - Oncology,Oncology,,,,,,,,60,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLF6,TBD-17834,'TBD-17834,,,Combo Lung,Combo Lung,III,Cancelled,Other,,,,,,,,,680,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLFG,Pevonedistat-1014,'Pevonedistat-1014,,pevonedistat (TAK-924),Evaluation of Effects of Pevonedistat on the QTc Interval in Patients with Advanced Solid Tumors,QT Study,I,Recruitment Complete,Support - Oncology,Oncology,Late Oncology,,,,,,,45,44,68,,24,0,3,97.78%,8,6,,PRA,,"Cynthia Knight, Heather Cameron, Melinda Snyder, Elizabeth Halter, Gabriel Berman",,Vivek Samnotra,,2017-002610-31,,,,,,,,Medidata CTMS (Pharma),,,,,6/29/2017,6/29/2017,,,,,3/13/2018,3/13/2018,,,12/17/2018,12/17/2018,5/16/2019,5/16/2019,1/7/2019,1/7/2019,,,,,,,6/21/2021,6/21/2021,,,5/6/2019,5/6/2019,,,,,,,8/25/2021,,,,,,,,,,,,,,,,8/22/2019,8/22/2019,,,,,,,9/16/2021,,12/31/2019,12/31/2019,,,,,,,1/6/2022,,,,,,,,1/6/2022,,,,,,,
1-10FLFP,TBD-17913,'TBD-17913,,pevonedistat (TAK-924),NSCLC +/- Docetaxel,NSCLC +/- Docetaxel,II,Cancelled,Other,Oncology,,,,,,,,138,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLFY,TBD-18186,'TBD-18186,,pevonedistat (TAK-924),Pediatric Study,Pediatric Study,I,Planned,Support - Oncology,Oncology,,,,,,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FLG7,Pevonedistat-1013,'Pevonedistat-1013,,pevonedistat (TAK-924),Human ADME Study,Human ADME Study,I,Closed,Other,Oncology,,,,Interventional,,,,8,8,13,,5,,1,100.00%,2,,,PRA,Melinda Snyder,,,,,,,,,,,,,STARS Inactive,,,,,11/29/2016,11/29/2016,,,,,5/25/2017,5/25/2017,,,2/1/2018,2/1/2018,7/2/2018,7/2/2018,2/9/2018,2/9/2018,,,,,,,11/5/2018,11/5/2018,,,4/9/2018,4/9/2018,,,,,,,12/10/2018,12/10/2018,4/16/2018,4/16/2018,,,,,,,,,,,,,7/31/2018,7/31/2018,,,,,,,1/17/2019,1/17/2019,10/22/2018,10/22/2018,,,,,,,5/14/2019,5/14/2019,,,,,,,5/14/2019,,,,,,,
1-10FLGJ,TBD-18687,'TBD-18687,,TAK-117,DDI Keto,DDI Keto,I,Cancelled,Other,Oncology,,,,,,,,32,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FN2A,TBD-18691,'TBD-18691,,TAK-117,NSCLC Squamous,NSCLC Squamous,III,Cancelled,Other,Oncology,,,,,,,,715,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FN2J,TBD-18692,'TBD-18692,,TAK-117,Renal Impairment,Renal Impairment,I,Cancelled,Other,Oncology,,,,,,,,40,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FN2S,TBD-18693,'TBD-18693,,TAK-117,Hepatic Impairment,Hepatic Impairment,I,Cancelled,Other,Oncology,,,,,,,,40,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FN3J,TBD-18743,'TBD-18743,,TAK-117,DDI #2,DDI #2,I,Cancelled,Other,Oncology,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FN3S,TBD-18746,'TBD-18746,,TAK-117,Pediatrics,Pediatrics,I,Cancelled,Other,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FN4K,TBD-17718,'TBD-17718,,,SCLC,SCLC,III,Cancelled,Other,,,,,,,,,422,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FN4T,TBD-18291,'TBD-18291,,,PTCL Asia Bridging Study,PTCL Asia Bridging Study,II,Cancelled,Other,,,,,,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FNMZ,TBD-17391,'TBD-17391,,Ninlaro,2 Combo Sub Type #1,2 Combo Sub Type #1,I/II,Cancelled,Other,Oncology,,,,,,,,75,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FNNC,TBD-17803,'TBD-17803,,Ninlaro,Ph 3 Pediatrics,Pediatrics Study,III,Planned,Support - Oncology,Oncology,,,,,,,,186,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,10/28/2026,,,,,,3/30/2027,,,,4/14/2029,,4/14/2031,,4/14/2031,,,,,,,,,,,,5/29/2031,,,,,,,,,,7/7/2031,,,,,,,,,,,,,,8/18/2031,,,,,,,,,,11/16/2031,,,,,,,,,,,,,,,,11/16/2031,,,,,,,
1-10FNNN,TBD-17848,'TBD-17848,,Ninlaro,NHL,NHL,III,Cancelled,Other,Oncology,,,,,,,,500,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10FNNY,T2017-002,'T2017-002,,Ninlaro,Ph 1/2 Pediatrics,Ph 1 Pediatrics - 40 pts,I,Planned,,Oncology,Late Oncology,,,,,,,36,,,,,,,,1,,,TBD,,,,,,2019-001947-28,,,,,,,,Medidata CTMS (Pharma),,,,,10/16/2018,10/16/2018,,,,,2/13/2019,2/13/2019,,,1/27/2021,,2/18/2023,,2/18/2023,,,,,,,,,,,,4/4/2023,,,,,,,,,,5/13/2023,,,,,,,,,,,,,,6/24/2023,,,,,,,,,,9/22/2023,,,,,,,,,,,,,,,,9/22/2023,,,,,,,
1-10GMSH,TBD-18695,'TBD-18695,,TAK-117,Human ADME,Human ADME,I,Cancelled,Other,Oncology,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-10XM9M,Leuprorelin-4001,'Leuprorelin-4001,,LEUPLIN (leuprorelin acetate),"An Open label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Preccocious Puberty",Prospective ph4,IV,Closed,Other,Others,,,,Other Phase IV,,,,300,307,340,,33,,23,102.33%,12,,,Hangzhou Tigermed Consulting,Winston Wang,,,,,,,,,,,,,STARS Inactive,,,1/6/2015,1/6/2015,11/3/2014,11/3/2014,,,7/28/2015,7/28/2015,8/11/2015,8/11/2015,,,12/30/2016,12/30/2016,,,11/19/2018,11/19/2018,,,,,,,,,,,1/17/2019,1/17/2019,,,,,,,,,1/28/2019,1/28/2019,,,,,,,,,,,,,1/28/2019,1/28/2019,,,,,,,,,4/18/2019,4/18/2019,,,,,,,,,,,,,,,4/19/2019,4/19/2019,,,,,,
1-12LDAB,TAK-390MR-1001,'TAK-390MR-1001,,"DEXILANT (dexlansoprazole, MR)","A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two Part Crossover Study to Compare the Bioavailability of Dexlansoprazole from Dexlansoprazole Delayed Release Capsules 30 mg and 60 mg Manufactured by Takeda Oranienburg Relative to Reference Dexlansoprazole Delayed Release Capsules 30 mg and 60 mg Manufactured by Takeda Osaka in Healthy Subjects",Oranienburg BE study (Fasted),I,Closed,00002 GERD,Others,,,,BE,,,,104,116,218,,100,,16,111.54%,1,,,PRA,Kumudinie Karunaratne,,,,,,,,,,,,,STARS Inactive,,,3/16/2016,3/16/2016,10/31/2016,10/31/2016,,,4/24/2017,4/24/2017,5/20/2017,5/20/2017,,,6/24/2017,6/24/2017,,,7/14/2017,7/14/2017,,,,,,,,,,,8/16/2017,8/16/2017,,,,,,,,,,,,,,,,,,,,,,,10/5/2017,10/5/2017,,,,,,,,,11/1/2017,11/1/2017,,,,,,,,,,,,,,,11/1/2017,11/1/2017,,,,,,
1-12LDAM,TAK-448-1005,'TAK-448-1005,,TAK-448,A Phase 1 Bioavailability study in Healthy Subjects to Evaluate the Pharmacokinetic Profile of TAK-448 Prototype Oral Formulations,"Phase 1, bioavailability study",I,Cancelled,Other,CVM,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,Karen Watkins,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12MTGF,Vedolizumab-5001,'Vedolizumab-5001,,Entyvio,Study title: OTIS Entyvio Pregnancy exposure registry,Pregnancy registry,IV,Recruitment Complete,facilitation of non-invasive ventilation in neonates,GI,Late GI,,,,Other,Prospective,Other,300,304,357,,54,,,101.33%,1,,,Univ. California San Diego,,,,Paul Dolin,,,,,,,,,,Medidata CTMS (Pharma),,,,,10/5/2015,10/5/2015,,,12/10/2015,12/10/2015,12/10/2015,12/10/2015,,,10/20/2020,10/20/2020,,,7/1/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/31/2023,,,,,,,,,,,,,,,,5/31/2023,,,,,,,
1-12MXFG,TBD-1-12MXFG,'TBD-1-12MXFG,,TAK-041,"An exploratory, open-label, Phase 0 study to evaluate task reinforcement learning coupled with the fMRI BOLD in health volunteers","Phase 0, Exploratory study",0,Cancelled,00149 Schizophrenia,NS,,,,,,,,20,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12MXSR,TAK-041-1001,'TAK-041-1001,,TAK-041,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects","Phase 1, SRD/MRD",I,All Activities Closed,(MDD) Major depressive disorder,NS,Early NS,,,,,,,114,114,380,,276,,3,100.00%,1,1,,PPD,,"Alexandra Minn, Rhett Behrje",,Tolga Uz,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,10/31/2016,10/31/2016,4/1/2016,4/1/2016,,,5/9/2016,5/9/2016,6/27/2016,6/27/2016,,,7/9/2019,7/9/2019,,,9/22/2019,9/22/2019,,,,,,,,,,,11/14/2019,11/14/2019,,,,,,,,,10/17/2019,10/17/2019,,,,,,,,,,,,,12/20/2019,12/20/2019,,,,,,,,,4/30/2020,4/30/2020,,,,,,,,,,,,,,,4/30/2020,4/30/2020,,,,,,
1-13KZE5,TBD-1-13KZE5,'TBD-1-13KZE5,,,Phase 1 Combo with Ixazomib,Phase 1 Combo with Ixazomib,I,Planned,,,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-13KZEE,TBD-1-13KZEE,'TBD-1-13KZEE,,,Phase 3 Early Stage HL,Phase 3 Early Stage HL,III,Planned,,,,,,,,,,"1,500",,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-13KZLB,TBD-1-13KZLB,'TBD-1-13KZLB,,,Phase 3 BLBCL FL CD30 +,Phase 3 BLBCL FL,III,Planned,,,,,,,,,,536,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-13KZLX,C31006,'C31006,,sapanisertib,An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy,Phase 2 POC mBC (ER+/HER-) Post AI Combo with Fulv,II,Recruitment Complete,Hemophilia A and Hemophilia B with inhibitors,Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,,141,141,191,,50,,141,100.00%,55,,,GEICAM,,"Deborah Bruce, Heather Davidson, Sally Buelta, Tara Sadowski, Deborah Scarcella",,"E. Jane Leonard, Michelle Kneissl",,2015-003612-20,,Approved,,,,,,Medidata CTMS (Pharma),,,7/22/2015,7/22/2015,2/10/2016,2/10/2016,,,,,8/12/2016,8/12/2016,,,5/14/2018,5/14/2018,1/31/2019,1/31/2019,11/29/2019,11/29/2019,,,,,,,,,,,4/6/2020,4/6/2020,,,,,,,,,5/13/2020,5/13/2020,,,,,,,,,,,,,5/13/2020,5/13/2020,,,,,,,,,9/10/2020,9/10/2020,,,,,,,,,,,,,,,9/10/2020,,,,,,,
1-13KZMH,Vortioxetine-4001,'Vortioxetine-4001,,Trintellix (vortioxetine),"A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/day vs. Paroxetine 20 mg/day on Sexual Functioning in Healthy Subjects",TESD Healthy Volunteer Study,IV,Closed,Other,NS,,,,,,,,352,361,591,,230,,67,102.56%,16,,,IQVIA,Ann Haas,,,,,,,,,,,,,STARS Inactive,,,2/16/2016,2/16/2016,7/13/2016,7/13/2016,,,11/21/2016,11/21/2016,12/6/2016,12/6/2016,,,4/24/2017,4/24/2017,,,6/9/2017,6/9/2017,,,,,,,,,,,7/31/2017,7/31/2017,,,,,,,,,8/10/2017,8/10/2017,,,,,,,,,,,,,8/30/2017,8/30/2017,,,,,,,,,12/7/2017,12/7/2017,,,,,,,,,,,,,,,12/7/2017,12/7/2017,,,,,,
1-13NNMT,C34009,'C34009,,TAK-659,"An Open-label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies",C34009 Phase 1 Human Food Effect (15 pts),I,Terminated,Other,Oncology,,,,Food Effect,,,,1,0,0,,0,,0,0.00%,1,,,PRA,Zane O'Keefe,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-13PAC6,TAK-154-0001,'TAK-154-0001,,TAK-154,An Exploratory Biomarker Study to Investigate Melatonin Levels in Healthy Volunteers and Type 2 Diabetes Mellitus Subjects With and Without Sleep Disorder,TAK-154 Melatonin Biomarker Ph0,0,Cancelled,00050 Type 2 diabetes,CVM,,,,,,,,30,0,0,,0,,0,0.00%,1,,,In-House,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-14MLFD,TBD-1-14MLFD,'TBD-1-14MLFD,,TAK-020,A Phase 1 study to evaluate the Relative Bioavailability of TAK-020,"Phase 1, Relative BA #2",I,Cancelled,(RA) Rheumatoid arthritis,Immunology,,,,,,,,40,,,,,,,,1,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/6/2017,,3/10/2017,,,,6/5/2017,,7/5/2017,,,,7/7/2017,,,,9/29/2017,,,,,,,,,,,,11/20/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/2/2018,,,,,,,,,,,,,,,,5/2/2018,,,,,,,
1-15KY83,C16022,'C16022,,,"A Randomized, Open-label Phase 3 Study of Oral Ixazomib, Oral Cyclophosphamide, and dexamethasone (ICd) for 12 cycles followed by Ixazomib, dexamethasone (Id) Treated to Disease Progression vs Subcutaneous Bortezomib and dexamethasone (Vd) Treated to Disease Progression in Adult Patients with Relapsed and/or Refractory Multiple Myeloma",,III,Cancelled,Heme.Multiple Myeloma,,,,,Benchmark Phase 3,,,,500,0,0,,0,,0,0.00%,150,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-16RMAP,NaltrexBuprop-1007,'NaltrexBuprop-1007,,Contrave,A Phase 1 BE study to support the TOB site transfer,BE Study TOB Site Transfer,I,Cancelled,00078 Obesity,Marketed Products,,,,,,,,104,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-16RMAZ,NaltrexBuprop-1008,'NaltrexBuprop-1008,,Contrave,: A Phase 1 BA/BE study to support the pediatric 0.5 and 1.0X formulation,,I,Cancelled,Other,Marketed Products,,,,,,,,116,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-17J3FB,TAK-653-2001,'TAK-653-2001,,TAK-653,"A randomised, double-blind, placebo-controlled, 2-part, adaptive design study to evaluate the efficacy and safety of TAK-653 in the treatment of subjects with major depressive disorder",Experimental Medicine Study,IIa,Withdrawn,(TRD) Treatment Resistance to Depression,NS,,,,,,,,90,,,,,,,,20,,,PRA,,Theresa Walls,,"Amir Inamdar, Rolando Gutierrez-Esteinou",,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-17VBPI,TAK-828-1001,'TAK-828-1001,,TAK-828,"A Randomized, Double-Blind (Sponsor Open), Placebo-Controlled, Phase 1, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK 828 in Healthy Non-Japanese and Japanese Subjects",Phase 1 SRD,I,Closed,Other,GI,,,,SRD/FIM,,,,36,36,85,,49,,7,100.00%,2,1,,PPD,Hafizur Choudhury,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-17VBPS,Vedolizumab-1015,'Vedolizumab-1015,,Entyvio,"An open-label, dose-finding study of vedolizumab intravenous (IV) vedolizumab plus standard of care for graft-versus-host disease (GvHD) prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)",GvHD Prophylaxis P1b,IB,Closed,Heme.Other,GI,,,,Dose Ranging,,,,24,24,31,,7,,6,100.00%,4,,,PRA,,,,,,,,,,,NA,Advance,,STARS Inactive,,,10/6/2015,10/6/2015,12/9/2015,12/9/2015,,,,,6/29/2016,6/29/2016,,,6/22/2017,6/22/2017,,,7/10/2018,7/10/2018,,,,,,,,,,,8/29/2018,8/29/2018,,,,,,,,,9/6/2018,9/6/2018,,,,,,,,,,,,,11/30/2018,11/30/2018,,,,,,,,,1/16/2019,1/16/2019,,,,,,,,,,,,,,,1/16/2019,,,,,,,
1-17X9H9,Vedolizumab-1014,'Vedolizumab-1014,,Entyvio,"Open-Label, Single-Center, Phase 1 Study to Determine the Pharmacokinetics of Single Intravenous Dose of Vedolizumab 300 mg in Healthy Adult Chinese Subjects",China Ph1 PK,I,Closed,Other,GI,,,,Interventional,,,,16,16,92,,76,,,100.00%,1,,,PRA,"Tomoka Tsukada, Winston Wang",,,,,,,,,,NA,Advance,,STARS Inactive,,,3/20/2015,3/20/2015,7/10/2015,7/10/2015,,,3/5/2018,3/5/2018,3/20/2018,3/20/2018,,,3/22/2018,3/22/2018,,,7/26/2018,7/26/2018,,,,,,,,,,,11/14/2018,11/14/2018,,,,,,,,,11/21/2018,11/21/2018,,,,,,,,,,,,,11/21/2018,11/21/2018,,,,,,,,,4/10/2019,4/10/2019,,,,,,,,,,,,,,,4/10/2019,4/10/2019,,,,,,
1-17X9HR,Vedolizumab-3033,'Vedolizumab-3033,,Entyvio,Phase 3 Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Patients with Moderately to Severely Active Ulcerative Colitis,China Ulcerative Colitis,III,Recruiting,"Cancer (HDPC, 2nd line)",GI,Late GI,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,302,290,468,,176,290,110,96.03%,34,32,,IQVIA,,"Terry Gu, Tomoka Tsukada, Lara Grace Marzo",,Wen Zhou,,,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,3/19/2015,3/19/2015,7/8/2015,7/8/2015,,,8/3/2017,8/3/2017,8/22/2017,8/22/2017,,,10/29/2021,,,,,,,,,,,,4/24/2023,,,,6/8/2022,,,,,,,,6/23/2023,,8/5/2020,,,,,,,,7/7/2023,,,,,,8/20/2020,,,,,,,,7/21/2023,,8/3/2017,,,,,,,,10/13/2023,,,,,,,,3/22/2022,,,,,,,
1-17X9I5,Vedolizumab-3034,'Vedolizumab-3034,,Entyvio,A Phase 3 Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Patients with Moderately to Severely Active Crohn’s Disease Protocol,China Crohn's Disease,III,Recruitment Complete,Delay the onset of MCI due to Alzheimer's disease,GI,Late GI,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,204,215,346,,131,215,108,105.39%,30,,,IQVIA,,"Terry Gu, Tomoka Tsukada, Lara Grace Marzo",,Wen Zhou,,,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,3/19/2015,3/19/2015,7/8/2015,7/8/2015,,,8/3/2017,8/3/2017,8/24/2017,8/24/2017,,,12/20/2018,12/20/2018,,,2/28/2019,2/28/2019,,,,,,,9/3/2020,,,,6/13/2019,6/13/2019,,,,,,,1/30/2021,,6/27/2019,6/27/2019,,,,,,,1/15/2021,,,,,,7/11/2019,7/11/2019,,,,,,,1/29/2021,,11/28/2019,11/28/2019,,,,,,,6/18/2021,,,,,,,,3/4/2021,,,,,,,
1-17X9JR,TAK-527-1001,'TAK-527-1001,,TAK-527,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-527 in Healthy Subjects",TAK-527 SRD Study,I,Cancelled,Other,NS,,,,,,,,80,0,0,,0,,0,0.00%,1,,,PPD,Natalie Jones,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-17X9K0,TBD-1-17NY,'TBD-1-17NY,,TAK-527,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Doses of TAK-527 in Healthy Subjects",TAK-527 MRD Study,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-18NLQH,TAK-071-1001,'TAK-071-1001,,TAK-071,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",TAK-071 SRD and MRD,I,Terminated,(PD) Parkinson's disease,NS,,,,,,,,186,177,363,,184,,1,95.16%,1,1,,PPD,,Kumudinie Karunaratne,,"Arthur Simen, Ferenc Martenyi",,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,11/30/2015,11/30/2015,4/6/2016,4/6/2016,,,5/5/2016,5/5/2016,5/18/2016,5/18/2016,,,5/24/2017,5/24/2017,,,6/8/2017,6/8/2017,,,,,,,,,,,8/14/2017,8/14/2017,,,,,,,,,8/22/2017,8/22/2017,,,,,,,,,,,,,4/10/2018,4/10/2018,,,,,,,,,6/14/2018,6/14/2018,,,,,,,,,,,,,,,6/14/2018,6/14/2018,,,,,,
1-19NQK7,TAK-071-0001,'TAK-071-0001,,TAK-071,Phase 0 Scopolamine Validation Study in healthy volunteers,"Phase 0, Scopolamine Validation",0,Cancelled,00172 Alzheimer's disease,NS,,,,EM Phase 0,,,,48,0,0,,0,,0,0.00%,1,,,PPD,Ellen Rhodes,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-19NQKS,TAK-071-2001,'TAK-071-2001,,TAK-071,Phase 2 POCC Study in Patients with DLB,"Phase 2, POCC in DLB",II,Cancelled,(PD) Parkinson's disease,NS,,,,,,,,240,,,,,,,,30,,,PRA,,,,Ferenc Martenyi,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-19QO8J,TBD-1-19QO8J,'TBD-1-19QO8J,,TAK-117,Phase 2 NSCLC Japan MLN1117 Combo with Q3W Docetaxel (60pts),,II,Cancelled,Solid.Other,Oncology,,,,Benchmark Phase 2,,,,60,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-19ZQ0F,TBD-1-19ZQ0F,'TBD-1-19ZQ0F,,,Phase 1b Gastric J & A PK/Safety MLN1117 Combo with TAK-659 (12pts),,I,Cancelled,00018 (GC) Gastric cancer,,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-19ZQ05,TBD-1-19ZQ05,'TBD-1-19ZQ05,,,Phase 1b Gastric J & A PK/Safety MLN1117 Combo with Paclitaxel (12pts),,I,Cancelled,00018 (GC) Gastric cancer,,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-21HO75,TAK-906-1003,'TAK-906-1003,,TAK-906,"A Fixed Sequence, Open-Label, 2-Period, Crossover Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral TAK 906 in Healthy Adult Subjects.",Itraconazole DDI NHV,I,Closed,Other,GI,,,,,,,,12,12,39,,23,,1,100.00%,1,,,PRA,"Angela Gamble, Jeanette Chen",,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,2/22/2017,2/22/2017,3/21/2017,3/21/2017,,,6/5/2017,6/5/2017,6/23/2017,6/23/2017,,,6/23/2017,6/23/2017,,,7/11/2017,7/11/2017,,,,,,,,,,,8/18/2017,8/18/2017,,,,,,,,,9/1/2017,9/1/2017,,,,,,,,,,,,,10/6/2017,10/6/2017,,,,,,,,,2/23/2018,2/23/2018,,,,,,,,,,,,,,,2/23/2018,2/23/2018,,,,,,
1-22AXI5,TAK-573-1501,'TAK-573-1501,,TAK-573,Phase 1 SA Safety/PK,Phase 1 SA Safety/PK,I,Recruiting,Multiple cancer,Oncology,Early Oncology,,,,,,,117,87,112,,24,,71,74.36%,9,10,,PRA,,Lorraine Mehltretter,,Nachos Garcia-Ribas,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,4/6/2017,4/6/2017,,,,,10/9/2017,10/9/2017,,,4/30/2022,,10/31/2022,,5/26/2023,,,,,,,,,,,,7/27/2023,,,,,,,,,,8/3/2023,,,,,,,,,,,,,,8/24/2023,,,,,,,,,,9/29/2023,,,,,,,,,,,,,,,,9/29/2023,,,,,,,
1-22IBXF,Pevonedistat-1015,'Pevonedistat-1015,,pevonedistat (TAK-924),DDI Study,DDI Study,I,Reported,Support - Oncology,Oncology,Late Oncology,,,Observational,,,,20,20,26,,6,,20,100.00%,4,,,PRA,,"Elizabeth Halter, Kimberly Phillips",,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/29/2017,11/29/2017,,,,,8/27/2018,8/27/2018,,,4/29/2019,4/29/2019,8/31/2019,,5/10/2019,5/10/2019,,,,,,,4/29/2020,4/29/2020,,,7/16/2019,7/16/2019,,,,,,,9/4/2020,9/4/2020,,,,,,,,,,,,,,,8/12/2019,8/12/2019,,,,,,,10/14/2020,10/14/2020,12/9/2019,12/9/2019,,,,,,,2/22/2021,2/22/2021,,,,,,,2/22/2021,,,,,,,
1-23H32V,TBD-1-23H32V,'TBD-1-23H32V,,TAK-906,"A Multicenter, Open-label Phase 3 Study to Evaluate the Long Term Safety of Twice-Daily Oral Administration of a Peripherally Selective Dopamine Receptor D2/D3 antagonist, TAK-906, for the Treatment of Adult Subjects With Symptomatic Idiopathic and Diabetic Gastroparesis",Phase 3 OLE in DG & IG,III,Planned,(GP) Gastroparesis,GI,Late GI,,,,,,,"1,500",,,,,,,,200,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,12/27/2021,,5/30/2022,,,,,,9/19/2023,,,,3/12/2025,,,,8/11/2026,,,,,,,,,,,,10/6/2026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/29/2026,,,,,,,,,,,,,,,,12/29/2026,,,,,,,
1-23H33H,TBD- 1-23H33H,'TBD- 1-23H33H,,TAK-906,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administrations of  a Peripherally Selective Dopamine Receptor D2/D3 Antagonist, TAK-906, for the Treatment of Adult Subjects With Symptomatic Idiopathic Gastroparesis.",Phase 3 Study in IG pts.,III,Planned,(GP) Gastroparesis,GI,Late GI,,,,,,,750,,,,,,,,200,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,12/27/2021,,5/30/2022,,,,9/19/2022,,10/18/2022,,,,4/10/2024,,,,3/12/2025,,,,,,,,,,,,5/7/2025,,,,,,,,,,5/14/2025,,,,,,,,,,,,,,6/3/2025,,,,,,,,,,8/27/2025,,,,,,,,,,,,,,,,8/27/2025,,,,,,,
1-23H33O,TBD-1-23H33O,'TBD-1-23H33O,,TAK-906,Renal Impairment Study of TAK-906,TAK-906 renal impairment,I,Planned,(GP) Gastroparesis,GI,Early GI,,,,,,,24,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/21/2022,,8/15/2022,,,,8/30/2022,,12/13/2022,,,,4/11/2023,,,,5/11/2023,,,,,,,,,,,,6/8/2023,,,,,,,,,,6/15/2023,,,,,,,,,,,,,,7/5/2023,,,,,,,,,,9/28/2023,,,,,,,,,,,,,,,,9/28/2023,,,,,,,
1-23H34G,TAK-906-1007,'TAK-906-1007,,TAK-906,ADME Study of TAK-906,ADME Study of TAK-906,I,Completed,Dry Eye Disease,GI,Late GI,,,Interventional,,,,6,6,19,,0,0,0,100.00%,1,,,Celerion,,Veronique Copalu,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,3/9/2020,3/9/2020,4/3/2020,4/3/2020,,,6/17/2020,6/17/2020,7/30/2020,7/30/2020,,,9/1/2020,9/1/2020,,,9/29/2020,9/29/2020,,,,,,,,,,,10/30/2020,10/30/2020,,,,,,,,,6/11/2021,6/11/2021,,,,,,,,,,,,,7/14/2021,7/14/2021,,,,,,,,,10/8/2021,,,,,,,,,,,,,,,,10/8/2021,,,,,,,
1-23H34P,TBD-1-23H34P,'TBD-1-23H34P,,TAK-906,CNS distribution Study of TAK-906,CNS study of TAK-906,I,Planned,(GP) Gastroparesis,GI,,,,,,,,24,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-23H34T,TAK-906-1008,'TAK-906-1008,,TAK-906,Oral Contraceptive  Study of TAK-906,Oral Contraceptive study,I,Planned,(GP) Gastroparesis,GI,Early GI,,,,,,,24,,,,,,,,1,,,Celerion,,Katie Savage,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/17/2022,,8/12/2022,,,,11/4/2022,,12/13/2022,,,,1/10/2023,,,,1/24/2023,,,,,,,,,,,,2/21/2023,,,,,,,,,,2/28/2023,,,,,,,,,,,,,,3/20/2023,,,,,,,,,,6/13/2023,,,,,,,,,,,,,,,,6/13/2023,,,,,,,
1-23H35C,TBD-1-23H35C,'TBD-1-23H35C,,TAK-906,Definitive Food Effect study with commercial formulation,,I,Cancelled,Other,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-23H35R,TAK-906-1005,'TAK-906-1005,,TAK-906,Bioequiavelance Study of TAK-906,BE study of TAK-906,I,Planned,(GP) Gastroparesis,GI,Early GI,,,,,,,24,0,39,,0,0,0,0.00%,1,,,Celerion,,"Katie Savage, Debra Ennis",,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,2/11/2021,2/11/2021,3/17/2021,3/17/2021,,,12/2/2021,,1/28/2022,,,,1/28/2022,,,,2/23/2022,,,,,,,,,,,,3/31/2022,,,,,,,,,,4/7/2022,,,,,,,,,,,,,,6/2/2022,,,,,,,,,,6/30/2022,,,,,,,,,,,,,,,,6/30/2022,,,,,,,
1-23H333,TBD-1-23H333,'TBD-1-23H333,,TAK-906,Hepatic Impairment Study of TAK-906,TAK-906 hepatic impairment,I,Planned,(GP) Gastroparesis,GI,Early GI,,,,,,,24,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/12/2022,,8/25/2022,,,,9/27/2022,,12/13/2022,,,,7/6/2023,,,,8/7/2023,,,,,,,,,,,,9/4/2023,,,,,,,,,,9/11/2023,,,,,,,,,,,,,,9/29/2023,,,,,,,,,,12/25/2023,,,,,,,,,,,,,,,,12/25/2023,,,,,,,
1-23H340,TBD-1-23H340,'TBD-1-23H340,,TAK-906,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administrations of  a Peripherally Selective Dopamine Receptor D2/D3 Antagonist, TAK-906, for the Treatment of Adult Subjects With Symptomatic Diabetic Gastroparesis",Phase 3 Study in DG pts.,III,Planned,(GP) Gastroparesis,GI,Late GI,,,,,,,750,,,,,,,,200,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,12/27/2021,,5/30/2022,,,,9/19/2022,,10/18/2022,,,,4/10/2024,,,,3/12/2025,,,,,,,,,,,,5/7/2025,,,,,,,,,,5/14/2025,,,,,,,,,,,,,,6/3/2025,,,,,,,,,,8/27/2025,,,,,,,,,,,,,,,,8/27/2025,,,,,,,
1-23H347,TAK-906-1006,'TAK-906-1006,,TAK-906,Phase 1.6 DDI PPI,DDI TAK-906 SOC,I,Closed,Other,GI,,,,,,,,12,12,12,,,,,100.00%,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,12/13/2018,12/13/2018,2/7/2019,2/7/2019,,,2/27/2019,2/27/2019,3/13/2019,3/13/2019,,,3/20/2019,3/20/2019,,,3/30/2019,3/30/2019,,,,,,,,,,,5/4/2019,5/4/2019,,,,,,,,,5/28/2019,5/28/2019,,,,,,,,,,,,,5/28/2019,5/28/2019,,,,,,,,,7/29/2019,7/29/2019,,,,,,,,,,,,,,,7/29/2019,7/29/2019,,,,,,
1-23H358,TAK-906-1010,'TAK-906-1010,,TAK-906,Thorough Qt Study of TAK-906,TQt Study of TAK-906,I,Planned,(GP) Gastroparesis,GI,Early GI,,,,,,,24,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/12/2022,,7/18/2022,,,,10/18/2022,,11/15/2022,,,,12/13/2022,,,,2/10/2023,,,,,,,,,,,,3/10/2023,,,,,,,,,,3/17/2023,,,,,,,,,,,,,,4/6/2023,,,,,,,,,,6/30/2023,,,,,,,,,,,,,,,,6/30/2023,,,,,,,
1-23RG7D,Vedolizumab-2007,'Vedolizumab-2007,,Entyvio,"A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease",Efficacy and Safety of Vedolizumab IV in the Treat,II,Cancelled,Other,GI,,,,DI High Complexity,,,,75,0,0,,0,,0,0.00%,30,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-24RE13,TAK-954-2003,'TAK-954-2003,,TAK-954,"Effect of TAK-954, a selective 5-HT4 receptor agonist on gastrointestinal and colonic transit and pharmacokinetics in patients with diabetic or idiopathic gastroparesis and previously documented delay in stomach emptying.",Phase 2a colonic transit,IIA,Closed,Other,GI,,,,,,,,48,36,44,,9,37,2,75.00%,1,,,PRA,Eleonora Uberti Foppa,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,4/28/2017,4/28/2017,8/2/2017,8/2/2017,,,1/2/2018,1/2/2018,1/6/2018,1/6/2018,,,6/4/2019,6/4/2019,,,7/12/2019,7/12/2019,,,,,,,,,,,8/27/2019,8/27/2019,,,,,,,,,9/11/2019,9/11/2019,,,,,,,,,,,,,10/11/2019,10/11/2019,,,,,,,,,12/18/2019,12/18/2019,,,,,,,,,11/16/2018,11/16/2018,,,,,12/18/2019,12/18/2019,,,,,,
1-24REKY,AP26113-11-101,'AP26113-11-101,,Alunbrig,"101 Ph1/2 Safety, PK, Tolerability",AP26113-11-101,I/II,All Activities Closed,,Oncology,Late Oncology,,,,,,,137,137,171,,34,,45,100.00%,10,,,TBD,,Brittany Demers,,,,2011-005718-12,,,,,,,,Medidata CTMS (Pharma),,,,,6/27/2011,6/27/2011,,,,,9/20/2011,9/20/2011,,,7/8/2014,7/8/2014,6/12/2019,6/12/2019,2/11/2020,2/11/2020,,,,,,,,,,,7/29/2020,7/29/2020,,,,,,,,,,,,,,,,,,,,,,,8/27/2020,8/27/2020,,,,,,,,,11/17/2020,11/17/2020,,,,,,,,,,,,,,,11/17/2020,11/17/2020,,,,,,
1-24RELR,AP26113-13-201,'AP26113-13-201,,Alunbrig,"ALTA Ph2 Multicenter, Randomized Study","ALTA Ph2 Multicenter, Randomized",II,Closed,Solid.Lung.NSCLC,Oncology,,,,,,,,222,222,269,,47,,167,100.00%,80,,,PRA,,,,,,2013-002134-21,,,,,NA,Advance,,STARS Inactive,,,6/27/2013,6/27/2013,6/27/2013,6/27/2013,,,,,6/9/2014,6/9/2014,,,9/21/2015,9/21/2015,2/6/2017,,11/14/2016,11/14/2016,,,,,,,2/27/2020,2/27/2020,,,12/23/2016,12/23/2016,,,,,,,6/5/2020,6/5/2020,1/23/2017,1/23/2017,,,,,,,6/9/2020,6/9/2020,,,,,1/23/2017,1/23/2017,,,,,,,7/17/2020,7/17/2020,4/16/2017,4/16/2017,,,,,,,9/21/2020,9/21/2020,,,,,,,9/21/2020,,,,,,,
1-24RELX,AP32788-15-101,'AP32788-15-101,,Mobocertinib (TAK-788),Ph 1/2 Safety/PK,Ph 1/2 Safety/PK TBD-1-24RELX,I/II,Recruiting,(NSCLC) Non-small cell lung cancer,Oncology,Late Oncology,,,,,,,336,226,276,,51,186,183,67.26%,95,28,,PRA,,Sally Buelta,,,,2016-001271-68,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,,,11/21/2015,11/21/2015,,,,,6/16/2016,6/16/2016,,,8/31/2021,,5/31/2022,,5/29/2020,5/29/2020,11/1/2020,11/1/2020,,,,,3/13/2023,,,,9/4/2020,9/4/2020,1/8/2021,1/8/2021,,,,,5/8/2023,,9/18/2020,9/18/2020,1/15/2021,1/15/2021,,,,,5/15/2023,,,,,,10/8/2020,10/8/2020,2/5/2021,2/5/2021,,,,,6/5/2023,,1/19/2021,1/19/2021,,,,,,,10/16/2023,,,,,,,,8/10/2025,,,,,,,
1-24REM6,TBD-1-24REM6,'TBD-1-24REM6,,Mobocertinib (TAK-788),Ph 2 Pivotal Study,Ph 2 Pivotal Study,II,Cancelled,Other,Oncology,,,,,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-24REMA,AP26113-15-107,'AP26113-15-107,,Alunbrig,107 Hepatic Impairment,107 Hepatic Impairment,I,Closed,Solid.Lung.NSCLC,Oncology,,,,,,,,1,0,0,,0,,0,0.00%,1,,,INC Research,,,,,,,,,,,,,,STARS Inactive,,,,,2/27/2016,2/27/2016,,,,,5/19/2016,5/19/2016,,,11/26/2016,11/26/2016,12/4/2016,12/4/2016,12/4/2016,12/4/2016,,,,,,,,,,,6/26/2017,6/26/2017,,,,,,,,,8/4/2017,8/4/2017,,,,,,,,,,,,,8/29/2017,8/29/2017,,,,,,,,,9/19/2017,9/19/2017,,,,,,,,,,,,,,,9/19/2017,9/19/2017,,,,,,
1-24REMP,TAK-788-3001,'TAK-788-3001,,Mobocertinib (TAK-788),A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations,Phase 3 Study,III,Recruiting,Hemostasis and tissue sealing in GI Anastomosis,Oncology,Late Oncology,Non-Registry,Non-pediatric only (>18 yr),Interventional,Treatment,,,318,140,195,,55,140,60,44.03%,168,153,,PPD,,"Chris Daly, Sally Buelta",,,,2019-001845-42,,Approved,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,2/28/2019,2/28/2019,8/8/2019,8/8/2019,,,1/6/2020,1/6/2020,1/10/2020,1/10/2020,,,5/31/2022,,3/31/2023,,5/31/2022,,,,,,,,5/31/2025,,,,7/26/2022,,,,,,,,7/26/2025,,8/2/2022,,,,,,,,8/2/2025,,,,,,8/23/2022,,,,,,,,8/23/2025,,11/15/2022,,,,,,,,11/15/2025,,,,,,,,11/15/2025,,,,,,,
1-24REMU,AP26113-15-108,'AP26113-15-108,,Alunbrig,108 Renal Impairment,108 Renal Impairment,I,Closed,Solid.Lung.NSCLC,Oncology,,,,,,,,1,0,0,,0,,0,0.00%,1,,,INC Research,,,,,,,,,,,,,,STARS Inactive,,,,,2/27/2016,2/27/2016,,,,,5/26/2016,5/26/2016,,,10/27/2016,10/27/2016,11/3/2016,11/3/2016,11/3/2016,11/3/2016,,,,,,,,,,,6/26/2017,6/26/2017,,,,,,,,,10/12/2017,10/12/2017,,,,,,,,,,,,,10/18/2017,10/18/2017,,,,,,,,,11/28/2017,11/28/2017,,,,,,,,,,,,,,,11/28/2017,11/28/2017,,,,,,
1-24REN3,AP26113-13-301,'AP26113-13-301,,Alunbrig,ALTA-1L Ph3 Brigatinib vs Crizotinib,AP26113-13-301 (ALTA-1L),III,Completed,Hepatic Encephalopathy (HE),Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,,,270,275,311,,36,45,126,101.85%,150,18,,PRA Health Sciences,,"Chris Daly, Katie Chong, Brittany Demers",,"Barbara Wamil, Pingkuan Zhang",,2015-003447-19,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,10/22/2015,10/22/2015,,,,,6/9/2016,6/9/2016,,,8/15/2017,8/15/2017,5/19/2020,5/19/2020,2/19/2018,2/19/2018,6/28/2019,6/28/2019,,,,,12/21/2020,12/21/2020,,,6/21/2018,6/21/2018,9/21/2019,9/21/2019,,,,,3/2/2021,3/2/2021,6/29/2018,6/29/2018,10/4/2019,10/4/2019,,,,,,,,,,,7/18/2018,7/18/2018,10/25/2019,10/25/2019,,,,,3/30/2021,3/30/2021,9/16/2018,9/16/2018,12/12/2019,12/12/2019,,,,,6/16/2021,,,,,,,,6/16/2021,,,,,,,
1-24RENC,Brigatinib-2001,'Brigatinib-2001,,Alunbrig,"A Single-arm, Multi-center, Phase 2 Study of Brigatinib in Japanese  Patients with ALK-positive, Non-Small Cell Lung Cancer (NSCLC)",Ph2 Japan 2nd Line,II,Reported,(NSCLC) Non-small cell lung cancer,Oncology,Late Oncology,,,,,,,80,72,79,,7,,45,90.00%,1,,,TBD,,Kyeongeun Park,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,6/23/2017,6/23/2017,11/2/2017,11/2/2017,,,,,2/21/2018,2/21/2018,,,4/12/2019,4/12/2019,3/16/2020,,9/3/2019,9/3/2019,,,,,,,7/31/2021,,,,11/12/2019,11/12/2019,,,,,,,8/4/2021,,11/14/2019,11/14/2019,,,,,,,,,,,,,12/10/2019,12/10/2019,,,,,,,8/25/2021,,1/15/2020,1/15/2020,,,,,,,12/17/2021,,,,,,,,12/17/2021,,,,,,,
1-25CUNJ,TBD-1-25CUNJ,'TBD-1-25CUNJ,,,P2/3 immuno-oncology placeholder,P2 immuno-oncology placeholder,II,Planned,,,,,,,,,,250,,,,,,,,50,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-25CUNT,TAK-906-2002,'TAK-906-2002,,TAK-906,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a peripherally selective Dopamine receptor D2/D3 antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis",P2 12 week DG/IG pts,IIb,Recruitment Complete,(GP) Gastroparesis,GI,Late GI,,,,,,,205,242,859,,617,242,51,118.05%,106,85,,PRA,,Terry White,,,,2018-001275-21,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/20/2017,6/20/2017,3/23/2018,3/23/2018,,,10/17/2018,10/17/2018,12/13/2018,12/13/2018,,,3/19/2021,3/19/2021,,,7/12/2021,7/12/2021,,,,,,,,,,,8/24/2021,,,,,,,,,,8/31/2021,,,,,,,,,,,,,,9/21/2021,,,,,,,,,,12/22/2021,,,,,,,,,,,,,,,,12/22/2021,,,,,,,
1-25CUP8,TBD-1-25CUP8,'TBD-1-25CUP8,,TAK-906,Asia bridging study,Asian NHV PK study,I,Planned,(GP) Gastroparesis,GI,,,,,,,,24,,,,,,,,1,,,PRA,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/27/2022,,8/22/2022,,,,11/14/2022,,12/13/2022,,,,2/7/2023,,,,2/21/2023,,,,,,,,,,,,3/21/2023,,,,,,,,,,3/28/2023,,,,,,,,,,,,,,4/17/2023,,,,,,,,,,7/11/2023,,,,,,,,,,,,,,,,7/11/2023,,,,,,,
1-25CUQB,TBD-1-25CUQB,'TBD-1-25CUQB,,TAK-906,TAK,SOC-Japan,I,Planned,,GI,Early GI,,,,,,,138,,,,,,,,1,,,TBD,,"Chie Kawahara, Ippei Nakayama",,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/20/2022,,8/15/2022,,,,11/15/2022,,12/13/2022,,,,4/11/2023,,,,5/3/2023,,,,,,,,,,,,5/31/2023,,,,,,,,,,6/7/2023,,,,,,,,,,,,,,6/27/2023,,,,,,,,,,9/20/2023,,,,,,,,,,,,,,,,9/20/2023,,,,,,,
1-25CUUR,TAK-831-1005,'TAK-831-1005,,TAK-831,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects",MRD2/CSF study,I,Closed,00149 Schizophrenia,NS,,,,MRD,,,,48,50,126,,76,50,3,104.17%,1,,,PRA,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,5/31/2017,5/31/2017,6/8/2017,6/8/2017,,,8/3/2017,8/3/2017,8/3/2017,8/3/2017,,,7/13/2018,7/13/2018,,,9/9/2018,9/9/2018,,,,,,,,,,,10/2/2018,10/2/2018,,,,,,,,,9/11/2018,9/11/2018,,,,,,,,,,,,,11/16/2018,11/16/2018,,,,,,,,,5/2/2019,5/2/2019,,,,,,,,,,,,,,,9/6/2019,9/6/2019,,,,,,
1-25FRSE,Actovegin-3001,'Actovegin-3001,,Actovegin (deproteinized hemoderivative of calf blood),"A Randomized, Multi-center, Parallel Group, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects with Peripheral Arterial Occlusive Disease Fontaine Stage IIB",PAOD LOC RIC,IIIb,All Activities Closed,,Others,Marketed Products,,,,Treatment,,,366,366,387,,21,,3,100.00%,20,,,Atlant,,Olga Orlova,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/18/2017,1/18/2017,12/21/2017,12/21/2017,,,4/30/2018,4/30/2018,8/3/2018,8/3/2018,,,3/5/2019,3/5/2019,,,8/20/2019,8/20/2019,,,,,,,,,,,11/22/2019,11/22/2019,,,,,,,,,12/6/2019,12/6/2019,,,,,,,,,,,,,1/24/2020,1/24/2020,,,,,,,,,4/24/2020,4/24/2020,,,,,,,,,,,,,,,6/19/2020,6/19/2020,,,,,,
1-26JYIY,VedolizumabSC-1018,'VedolizumabSC-1018,,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects",Vedolizumab SC NSD BE Study,I,Closed,Other,GI,,,,BE,,,,102,102,210,,108,,1,100.00%,1,,,Celerion,,,,,,,,,,,,,,STARS Inactive,,,,,12/18/2017,12/18/2017,,,2/18/2018,2/18/2018,3/16/2018,3/16/2018,,,4/10/2018,4/10/2018,,,9/21/2018,9/21/2018,,,,,,,,,,,10/5/2018,10/5/2018,,,,,,,,,,,,,,,,,,,,,,,10/31/2018,10/31/2018,,,,,,,,,12/13/2018,12/13/2018,,,,,,,,,,,,,,,12/13/2018,12/13/2018,,,,,,
1-26JYJ8,Brigatinib-1001,'Brigatinib-1001,,Alunbrig,"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam
in Patients With ALK-Positive or ROS1-Positive Solid Tumors",DDI Study with Midazolam,I,Recruitment Complete,Support - Oncology,Oncology,Late Oncology,,,,,,,20,24,32,,8,,24,120.00%,14,14,,PRA,,Kate Danis,,,,2018-001624-19,,,,,,,,Medidata CTMS (Pharma),,,9/20/2017,9/20/2017,11/14/2017,11/14/2017,,,,,7/4/2019,7/4/2019,,,2/25/2020,2/25/2020,3/25/2020,3/25/2020,3/25/2020,3/25/2020,,,,,,,4/29/2021,,,,10/12/2020,10/12/2020,,,,,,,6/22/2021,,11/3/2020,11/3/2020,,,,,,,8/26/2021,,,,,,11/18/2020,11/18/2020,,,,,,,9/22/2021,,,,,,,,,,10/25/2021,,,,,,,,10/25/2021,,,,,,,
1-26UP5I,TIMP-GLIA-5001,'TIMP-GLIA-5001,,TAK-101,Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge,TIMP-GLIA Phase 0 Gluten Challenge,0,All Activities Closed,Diabetic Macular Edema (DME),GI,Early GI,,,,,,,20,16,24,,8,16,2,80.00%,2,,,PRA,,"Alexandra Minn, Natalie Jones",,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,8/1/2017,8/1/2017,10/11/2017,10/11/2017,,,4/24/2018,4/24/2018,6/25/2018,6/25/2018,,,3/20/2019,3/20/2019,,,4/29/2019,4/29/2019,,,,,,,,,,,9/20/2019,9/20/2019,,,,,,,,,5/21/2019,5/21/2019,,,,,,,,,,,,,10/8/2019,10/8/2019,,,,,,,,,5/17/2021,5/17/2021,,,,,,,,,,,,,,,5/17/2021,5/17/2021,,,,,,
1-26UPD0,Ponatinib-3001,'Ponatinib-3001,,Iclusig,"A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)",Ph 3 Ph+ ALL,III,Recruiting,(Ph+ ALL) Philadelphia chromosome-positive acute lymphoblastic leukemia,Oncology,Late Oncology,Non-Registry,,,,,,230,174,246,,69,174,80,75.65%,120,116,,PRA,,Vijay Maharaj,,,, 2018-000397-30,,,,,NA,Advance,,Medidata CTMS (Pharma),,,11/14/2017,11/14/2017,5/24/2018,5/24/2018,,,,,1/10/2019,1/10/2019,,,2/28/2022,,5/31/2023,,2/17/2021,2/17/2021,,,6/6/2022,,,,8/30/2024,,,,5/19/2021,5/19/2021,,,8/30/2022,,,,11/2/2024,,6/10/2021,6/10/2021,,,10/9/2022,,,,12/2/2024,,,,,,,,,,11/1/2022,,,,1/8/2025,,,,5/6/2022,,1/31/2023,,,,4/2/2025,,,,,,,,2/16/2028,,,,,,,
1-26UPDM,TBD-1-26UPDM,'TBD-1-26UPDM,,TAK-522,Phase 2/3 MBC Her2 High Pivotal,Ph 2/3 MBC Her2 High Pivotal,II/III,Cancelled,Solid.Breast.Breast,Oncology,,,,,,,,470,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-26UPDW,TBD-1-26UPDW,'TBD-1-26UPDW,,TAK-522,Phase 2/3 MBC Her2 Low Pivotal,Ph 2/3 MBC Her2 Low Pivotal,II/III,Cancelled,Solid.Breast.Breast,Oncology,,,,,,,,444,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-26UPE5,TBD-1-26UPE5,'TBD-1-26UPE5,,TAK-522,Phase 2 MBC Exploratory vs  Kadcyla,Ph 2 MBC Exploratory vs  Kadcyla,II,Cancelled,Solid.Breast.Breast,Oncology,,,,,,,,120,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-26UPEE,TBD-1-26UPEE,'TBD-1-26UPEE,,TAK-522,Phase 2 MBC Support vs Herceptin+cytotoxic,Ph 2 MBC Support vs Herceptin+cytotoxic,II/III,Cancelled,Solid.Breast.Breast,Oncology,,,,,,,,120,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-26UPEN,TBD-1-26UPEN,'TBD-1-26UPEN,,TAK-522,Phase 2/3 NSCLC Pivotal vs Docetaxel,,II/III,Cancelled,Solid.Lung.NSCLC,Oncology,,,,,,,,454,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-26UPEW,AP24534-07-101,'AP24534-07-101,,Iclusig,A Phase 1 Dose Escalation/Safety,A Ph 1 Dose Escalation/Safety,I,Closed,Heme.Other,Oncology,,,,,,,,81,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,1/31/2008,1/31/2008,,,,,5/31/2008,5/31/2008,,,11/18/2009,11/18/2009,8/16/2010,8/16/2010,,,,,,,,,,,,,5/31/2016,5/31/2016,,,,,,,,,2/16/2010,2/16/2010,,,,,,,,,,,,,,,,,,,,,,,1/8/2016,1/8/2016,,,,,,,5/30/2017,5/30/2017,,,,,,,5/30/2017,5/30/2017,,,,,,
1-26UPF5,AP24534-10-201,'AP24534-10-201,,Iclusig,PACE: Phase 2,PACE: Ph 2,II,Reported,(CML) Chronic myeloid leukemia,Oncology,Late Oncology,,,,,,,449,244,,,,,,54.34%,42,,,INC Research,,Gina Gualtiere,,,,2010-020414-28,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,6/1/2010,6/1/2010,,,,,9/30/2010,9/30/2010,,,10/31/2011,10/31/2011,10/12/2015,10/12/2015,10/10/2015,10/10/2015,,,,,,,1/17/2019,1/17/2019,,,3/31/2017,3/31/2017,,,,,,,3/28/2019,3/28/2019,4/28/2017,4/28/2017,,,,,,,,,,,,,5/8/2017,5/8/2017,,,,,,,,,8/31/2017,8/31/2017,,,,,,,5/27/2020,5/27/2020,,,,,,,5/27/2020,5/27/2020,,,,,,
1-26UPFL,AP24534-11-106,'AP24534-11-106,,Iclusig,Phase 1/2 Study in Japanese Patients,Ph 1/2 Study in Japanese Patients,II,Reported,(CML) Chronic myeloid leukemia,Oncology,Late Oncology,,,,,,,40,,,,,,,,1,,,CMIC,,Oluchi Adedoyin,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,4/30/2012,4/30/2012,,,,,8/14/2012,8/14/2012,,,9/30/2013,9/30/2013,10/7/2015,10/7/2015,11/14/2015,11/14/2015,,,,,,,8/2/2018,8/2/2018,,,11/17/2014,11/17/2014,,,,,,,10/26/2018,10/26/2018,5/23/2014,5/23/2014,,,,,,,5/23/2014,5/23/2014,,,,,,,,,,,,,8/10/2020,8/10/2020,6/30/2015,6/30/2015,,,,,,,10/19/2020,10/19/2020,,,,,,,10/19/2020,10/19/2020,,,,,,
1-26UPFW,AP24534-14-203,'AP24534-14-203,,Iclusig,OPTIC: Phase 2 CML Efficacy/Safety,OPTIC: Ph 2 CML Efficacy/Safety,II,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Oncology,Late Oncology,,,,,,,276,283,371,,92,291,140,102.54%,150,60,,PRA,,"Gina Gualtiere, Oluchi Adedoyin",,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,2/2/2015,2/2/2015,,,,,8/6/2015,8/6/2015,,,5/15/2019,5/15/2019,5/15/2021,5/15/2021,7/20/2019,7/20/2019,5/31/2020,5/31/2020,,,,,6/15/2021,6/15/2021,,,9/10/2019,9/10/2019,12/21/2020,12/21/2020,,,,,7/31/2021,,9/20/2019,9/20/2019,1/6/2021,1/6/2021,,,,,8/7/2021,,,,,,4/1/2020,4/1/2020,2/17/2021,2/17/2021,,,,,8/28/2021,,4/24/2020,4/24/2020,5/21/2021,5/21/2021,,,,,1/7/2022,,,,,,,,12/1/2022,,,,,,,
1-30EDQR,TAK-831-2003,'TAK-831-2003,,TAK-831,Essential Tremor POC,Essential Tremor,II,Withdrawn,Friedreich's ataxia,NS,,,,,,,,30,,,,,,,,1,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/4/2018,12/4/2018,2/25/2019,2/25/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/27/2019,3/27/2019,,,,,,
1-30EDS3,TAK-925-1004,'TAK-925-1004,,,"A Phase 1B ,Randomized, Double Blind, Placebo Controlled Study Utilizing Continuous EEG to Evaluate TAK-925 in TN1 & TN2 Narcolepsy and Idiopathic Hypersomnia Patients",Phase 1B Continuous EEG Study Evaluating TAK-925 i,IB,Cancelled,Other,,,,,,,,,15,15,,,,,,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-30EE6J,TAK-653-1003,'TAK-653-1003,,TAK-653,"A randomized, double blind, placebo-controlled, single dose, cross-over study to evaluate the pharmacodynamic aspects, tolerability and safety of TAK-653 in healthy volunteers assessing responses evoked by transcranial magnetic stimulation (TMS).",TAK-653 in HVT assessing TMS,I,All Activities Closed,(TRD) Treatment Resistance to Depression,NS,,,,,,,,24,24,24,,,,,100.00%,1,,,PRA,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,10/19/2018,10/19/2018,11/26/2018,11/26/2018,,,1/21/2019,1/21/2019,2/11/2019,2/11/2019,,,5/30/2019,5/30/2019,,,6/14/2019,6/14/2019,,,,,,,,,,,7/15/2019,7/15/2019,,,,,,,,,7/22/2019,7/22/2019,,,,,,,,,,,,,8/14/2019,8/14/2019,,,,,,,,,2/11/2020,2/11/2020,,,,,,,,,,,,,,,2/11/2020,2/11/2020,,,,,,
1-30EP0F,TBD-1-30EP0F,'TBD-1-30EP0F,,TAK-418,BCH KS Natural Chip Seq,Takeda Boston Children's Biomarker Study,0,Terminated,Kabuki Syndrome,NS,,,,,,,,40,,,,,,,,1,,,TBD,,"Michael Stieber, Nancy Goodman",,,,,,,,,,,,Medidata CTMS (Pharma),,,6/8/2018,6/8/2018,8/6/2018,8/6/2018,,,10/29/2018,10/29/2018,11/14/2018,11/14/2018,,,2/6/2019,2/6/2019,,,2/7/2019,2/7/2019,,,,,,,,,,,2/26/2019,2/26/2019,,,,,,,,,3/12/2019,3/12/2019,,,,,,,,,,,,,,,,,,,,,,,8/20/2019,8/20/2019,,,,,,,,,,,,,,,8/20/2019,8/20/2019,,,,,,
1-30LDV9,TAK-071-2002,'TAK-071-2002,,TAK-071,"A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls",ePOC PD Gait,II,Recruiting,(HH) Male hypogonadotropic hypogonadism,NS,Late NS,,,Interventional,Treatment,,,74,16,0,,0,0,1,21.62%,20,20,,PPD,,Eric Henricks,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,11/22/2019,11/22/2019,3/23/2020,3/23/2020,,,10/20/2020,10/20/2020,11/30/2020,11/30/2020,,,6/7/2022,,,,11/1/2022,,,,,,,,,,,,12/6/2022,,,,,,,,,,12/13/2022,,,,,,,,,,,,,,2/14/2023,,,,,,,,,,4/25/2023,,,,,,,,,,,,,,,,4/25/2023,,,,,,,
1-30LDVL,TAK-951-1002,'TAK-951-1002,,TAK-951,"A Randomized, Double-Blind, Placebo-Controlled, One-Part Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of TAK 951 in Healthy Subjects in the setting of a glucose clamp",Glucose Clamp study,I,Cancelled,Normal Healthy Volunteer,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,PRA,,,,,,,,,,,Wave 2,Accelerate,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-31OP17,TBD-1-31OP17,'TBD-1-31OP17,,TAK-831,Cognitive Impairment in MDD,Cognitive Impairment in MDD,II,Cancelled,00149 Schizophrenia,NS,,,,,,,,70,0,0,,0,,0,0.00%,12,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-32C6FX,TAK-951-2001,'TAK-951-2001,,TAK-951,PONV POC,PONV POC,IIa,Recruiting,Post-operative Nausea Vomiting (PONV),GI,Early GI,,,,,,,100,65,0,,0,0,0,65.00%,5,10,,PPD,,Veronique Copalu,,,,,,,,,,,Wave 2/Acc,Medidata CTMS (Pharma),,,12/13/2019,12/13/2019,6/24/2020,6/24/2020,,,10/20/2020,10/20/2020,10/23/2020,10/23/2020,,,11/1/2021,,,,11/15/2021,,,,,,,,,,,,12/29/2021,,,,,,,,,,8/6/2021,,,,,,,,1/14/2022,,,,,,1/26/2022,,,,,,,,,,5/18/2022,,,,,,,,,,,,,,,,5/18/2022,,,,,,,
1-32C6HB,TBD-1-32C6HB,'TBD-1-32C6HB,,TAK-951,Adult/Adolescent CVS treatment pivotal trial 1,Adult/Adolescent CVS treatment pivotal trial 1,III,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,,,,,,,,500,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,10/29/2024,,8/19/2025,,,,11/25/2025,,12/23/2025,,,,9/29/2026,,,,3/16/2027,,,,,,,,,,,,5/11/2027,,,,,,,,,,5/25/2027,,,,,,,,,,,,,,,,,,,,,,,,8/31/2027,,,,,,,,,,,,,,,,3/14/2028,,,,,,,
1-32C6HM,TBD-1-32C6HM,'TBD-1-32C6HM,,TAK-951,Adult/Adolescent CVS treatment pivotal trial 2,Adult/Adolescent CVS treatment pivotal trial 2,III,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,,,,,,,,500,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,10/29/2024,,8/19/2025,,,,11/25/2025,,12/23/2025,,,,9/29/2026,,,,3/16/2027,,,,,,,,,,,,5/11/2027,,,,,,,,,,5/25/2027,,,,,,,,,,,,,,,,,,,,,,,,8/31/2027,,,,,,,,,,,,,,,,3/14/2028,,,,,,,
1-32C6R5,Darvadstrocel-3004,'Darvadstrocel-3004,,Alofisel,Darvadstrocel in the treatment of complex perianal fistula in pediatric crohn’s disease patients.,Change to ‘efficacy and safety of darvadstrocel in,III,Not Yet Recruiting,Complex Perianal Fistulas,GI,Late GI,,,,,,,20,,,,,,,,20,,,IQVIA,,Jennifer Gillespie,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,12/19/2019,12/19/2019,6/24/2020,6/24/2020,,,6/30/2021,6/30/2021,7/30/2021,,,,5/1/2023,,,,4/30/2024,,,,,,,,,,,,5/29/2024,,,,,,,,,,6/4/2024,,,,,,,,,,,,,,6/26/2024,,,,,,,,,,10/24/2024,,,,,,,,,,,,,,,,4/29/2025,,,,,,,
1-32C60I,TBD-1-32C60I,'TBD-1-32C60I,,TAK-039,Global ePOC,P2a Global ePOC,IIA,Cancelled,00020 (UC) Ulcerative colitis,GI,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-32C60R,TBD-1-32C60R,'TBD-1-32C60R,,TAK-039,Global phase 3,Ph3 study,III,Cancelled,Hepatic Encephalopathy (HE),GI,,,,,,,,600,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-32C609,TBD-1-32C609,'TBD-1-32C609,,TAK-039,UC POM/ePOC study,Ph1b UC POM/ePOC,IB,Cancelled,00020 (UC) Ulcerative colitis,GI,,,,,,,,30,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-32PVRW,VedolizumabSC-1024,'VedolizumabSC-1024,,Entyvio SC,Vedolizumab jet injector BE study,Human PK Study - 1024,I,Planned,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,Late GI,,,,,,,160,,,,,,,,2,,,Celerion,,Katie Savage,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,6/5/2019,6/5/2019,9/23/2019,9/23/2019,,,1/6/2022,,1/6/2022,,,,2/9/2022,,,,6/16/2022,,,,,,,,,,,,7/21/2022,,,,,,,,,,8/5/2022,,,,,,,,,,,,,,9/28/2022,,,,,,,,,,10/26/2022,,,,,,,,,,,,,,,,11/23/2022,,,,,,,
1-32PVS7,TAK-994-1001,'TAK-994-1001,,TAK-994,"A Combined Single Rising Dose and  Multiple Rising Dose Study to Access the Safety, Tolerability, Pharmacodynamics and Pharmacodynamics  of TAK-994 in Normal Healthy Volunteers and Patients with Narcolepsy",TAK-994 SRD and MRD Study in NHVs and Narcoplesy p,I,Completed,Sleep Disorders,NS,Early NS,,,,,,,160,121,354,,234,,3,75.63%,2,,,PRA,,Anne Crissey,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,2/4/2019,2/4/2019,3/18/2019,3/18/2019,,,5/1/2019,5/1/2019,5/22/2019,5/22/2019,,,3/4/2020,3/4/2020,,,3/29/2020,3/29/2020,,,,,,,,,,,6/24/2020,6/24/2020,,,,,,,,,7/11/2020,7/11/2020,,,,,,,,,,,,,8/6/2020,8/6/2020,,,,,,,,,12/10/2020,12/10/2020,,,,,,,,,,,,,,,3/26/2021,,,,,,,
1-32PVSK,TAK-169-1001,'TAK-169-1001,,TAK-169,Ph1 Dose Escalation/Expansion,Ph1 Dose Esc/Expansion,I,Recruiting,Multiple cancer,Oncology,Early Oncology,,,,,,,102,4,7,,2,,4,3.92%,10,3,,PRA,,"Lorraine Mehltretter, Katie Kinney",,,,,,,,,,,,Medidata CTMS (Pharma),,,12/13/2018,12/13/2018,5/8/2019,5/8/2019,,,,,2/18/2020,2/18/2020,,,9/4/2023,,3/3/2024,,9/3/2024,,,,,,,,,,,,11/1/2024,,,,,,,,,,2/14/2023,,11/7/2024,,,,,,,,,,,,12/1/2024,,,,,,,,,,1/1/2025,,,,,,,,,,,,,,,,1/1/2025,,,,,,,
1-32PVSU,TBD-1-32PVSU,'TBD-1-32PVSU,,TAK-169,Relative Bioavailability,Relative Bioavailability TAK-169,I,Planned,Multiple cancer,Oncology,,,,,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/27/2023,,8/5/2023,,,,,,12/3/2023,,,,11/27/2024,,4/26/2025,,4/26/2025,,,,,,,,,,,,5/26/2025,,,,,,,,,,6/2/2025,,,,,,,,,,,,,,6/20/2025,,,,,,,,,,1/12/2026,,,,,,,,,,,,,,,,1/12/2026,,,,,,,
1-32PVTA,TBD-1-32PVTA,'TBD-1-32PVTA,,TAK-169,Ind.1 - 1st Ph1b/2 Randomized,Ph 2 MM SA,II,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,110,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/2/2022,,6/23/2022,,,,,,11/25/2022,,,,5/18/2024,,5/13/2025,,5/13/2025,,,,,,,,,,,,7/15/2025,,,,,,,,,,7/22/2025,,,,,,,,,,,,,,8/11/2025,,,,,,,,,,12/22/2025,,,,,,,,,,11/14/2024,,,,,,12/22/2025,,,,,,,
1-33DTPV,TBD-1-33DTPV,'TBD-1-33DTPV,,TAK-169,Ph1b/2 Combo Single Arm,Ph1b/2 Combo Single Arm TAK-169,II,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/20/2022,,1/3/2023,,,,,,6/2/2023,,,,8/25/2024,,5/22/2025,,5/22/2025,,,,,,,,,,,,6/21/2025,,,,,,,,,,6/28/2025,,,,,,,,,,,,,,7/17/2025,,,,,,,,,,11/29/2025,,,,,,,,,,,,,,,,11/29/2025,,,,,,,
1-33DTQ5,TBD-1-33DTQ5,'TBD-1-33DTQ5,,TAK-169,Ph1 SA Safety/PK-J&A TAK-169,Ph1 SA Safety/PK-J&A TAK-169,I,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/9/2022,,10/17/2021,,,,,,2/14/2022,,,,11/11/2022,,5/10/2023,,5/10/2023,,,,,,,,,,,,6/9/2023,,,,,,,,,,6/16/2023,,,,,,,,,,,,,,7/6/2023,,,,,,,,,,11/17/2023,,,,,,,,,,,,,,,,11/17/2023,,,,,,,
1-33DTU5,TBD-1-33DTU5,'TBD-1-33DTU5,,TAK-169,Ind.1- 2nd Ph1b/2 Randomized,TBD-1-33DTU5 Ind.1-2nd Ph1b/2 Randomized,II,Planned,Multiple cancer,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/29/2022,,9/21/2022,,,,,,2/23/2023,,,,2/12/2025,,2/7/2026,,2/7/2026,,,,,,,,,,,,4/11/2026,,,,,,,,,,4/18/2026,,,,,,,,,,,,,,5/7/2026,,,,,,,,,,9/17/2026,,,,,,,,,,8/11/2025,,,,,,9/17/2026,,,,,,,
1-33DTUF,TBD-1-33DTUF,'TBD-1-33DTUF,,TAK-169,Ph1 Food Effect,Ph1 Food Effect,I,Planned,,Oncology,,,,,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/27/2026,,7/7/2026,,,,,,10/5/2026,,,,3/4/2027,,6/2/2027,,6/2/2027,,,,,,,,,,,,7/2/2027,,,,,,,,,,7/9/2027,,,,,,,,,,,,,,7/29/2027,,,,,,,,,,12/10/2027,,,,,,,,,,,,,,,,12/10/2027,,,,,,,
1-33DTUY,TBD-1-33DTUY,'TBD-1-33DTUY,,TAK-169,Human ADME,Human ADME TAK-169,I,Planned,,Oncology,,,,,,,,6,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/6/2024,,7/17/2024,,,,,,11/14/2024,,,,5/13/2025,,2/7/2026,,2/7/2026,,,,,,,,,,,,3/9/2026,,,,,,,,,,3/16/2026,,,,,,,,,,,,,,4/3/2026,,,,,,,,,,10/26/2026,,,,,,,,,,,,,,,,10/26/2026,,,,,,,
1-33DTVH,TBD-1-33DTVH,'TBD-1-33DTVH,,TAK-169,QT Study,QT Study TAK-169,I,Planned,,Oncology,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,10/29/2025,,12/9/2025,,,,,,4/8/2026,,,,7/2/2027,,3/28/2028,,3/28/2028,,,,,,,,,,,,4/27/2028,,,,,,,,,,5/4/2028,,,,,,,,,,,,,,5/24/2028,,,,,,,,,,12/14/2028,,,,,,,,,,,,,,,,12/14/2028,,,,,,,
1-33DTVQ,TBD-1-33DTVQ,'TBD-1-33DTVQ,,TAK-169,DDI #1,DDI #1 TAK-169,I,Planned,,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/6/2024,,7/17/2024,,,,,,11/14/2024,,,,2/7/2026,,5/8/2026,,5/8/2026,,,,,,,,,,,,6/7/2026,,,,,,,,,,6/14/2026,,,,,,,,,,,,,,7/2/2026,,,,,,,,,,1/24/2027,,,,,,,,,,,,,,,,1/24/2027,,,,,,,
1-33DTVZ,TBD-1-33DTVZ,'TBD-1-33DTVZ,,TAK-169,DDI #2,DDI #2 TAK-169,I,Planned,,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,4/28/2026,,6/7/2026,,,,,,10/5/2026,,,,12/29/2027,,3/28/2028,,3/28/2028,,,,,,,,,,,,4/27/2028,,,,,,,,,,5/4/2028,,,,,,,,,,,,,,5/24/2028,,,,,,,,,,12/14/2028,,,,,,,,,,,,,,,,12/14/2028,,,,,,,
1-33DTW8,TBD-1-33DTW8,'TBD-1-33DTW8,,TAK-169,Ind.1- First Ph3,Ind.1- First Ph3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/17/2025,,9/10/2025,,,,,,1/8/2026,,,,12/29/2027,,9/14/2030,,9/14/2030,,,,,,,,,,,,10/12/2030,,,,,,,,,,11/9/2030,,,,,,,,,,,,,,11/7/2030,,,,,,,,,,3/1/2031,,,,,,,,,,,,,,,,3/1/2031,,,,,,,
1-33DTWI,TBD-1-33DTWI,'TBD-1-33DTWI,,TAK-169,Ind.1- Second Ph3,Ind.1- Second Ph3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/13/2026,,9/5/2026,,,,,,1/3/2027,,,,12/23/2028,,9/9/2031,,9/9/2031,,,,,,,,,,,,10/7/2031,,,,,,,,,,11/4/2031,,,,,,,,,,,,,,11/3/2031,,,,,,,,,,2/24/2032,,,,,,,,,,,,,,,,2/24/2032,,,,,,,
1-33DTWR,TBD-1-33DTWR,'TBD-1-33DTWR,,TAK-169,Renal Impairment,Renal Impairment TAK-169,I,Planned,,Oncology,,,,,,,,60,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,4/22/2027,,6/2/2027,,,,,,9/30/2027,,,,9/19/2029,,9/14/2030,,9/14/2030,,,,,,,,,,,,10/14/2030,,,,,,,,,,10/21/2030,,,,,,,,,,,,,,11/8/2030,,,,,,,,,,6/2/2031,,,,,,,,,,,,,,,,6/2/2031,,,,,,,
1-33DTX0,TBD-1-33DTX0,'TBD-1-33DTX0,,TAK-169,Hepatic Impairment,Hepatic Impairment TAK-169,I,Planned,,Oncology,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,4/22/2027,,6/2/2027,,,,,,9/30/2027,,,,9/19/2029,,9/14/2030,,9/14/2030,,,,,,,,,,,,10/9/2031,,,,,,,,,,10/16/2031,,,,,,,,,,,,,,11/5/2031,,,,,,,,,,5/27/2032,,,,,,,,,,,,,,,,5/27/2032,,,,,,,
1-33DTX9,TBD-1-33DTX9,'TBD-1-33DTX9,,TAK-169,Ind.2 - 1st Ph1b/2 Randomized,Ind.2 - 1st Ph1b/2 Randomized,II,Planned,,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/22/2023,,11/15/2023,,,,,,4/18/2024,,,,3/9/2026,,6/2/2027,,6/2/2027,,,,,,,,,,,,7/2/2027,,,,,,,,,,7/9/2027,,,,,,,,,,,,,,7/29/2027,,,,,,,,,,12/10/2027,,,,,,,,,,,,,,,,12/10/2027,,,,,,,
1-33DTXI,TBD-1-33DTXI,'TBD-1-33DTXI,,TAK-169,Ind.2 - 2nd Ph1b/2 Randomized,Ind.2 - 2nd Ph1b/2 Randomized,II,Planned,,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/20/2024,,5/13/2024,,,,,,10/15/2024,,,,9/5/2026,,11/29/2027,,11/29/2027,,,,,,,,,,,,12/29/2027,,,,,,,,,,1/5/2028,,,,,,,,,,,,,,1/25/2028,,,,,,,,,,6/7/2028,,,,,,,,,,,,,,,,6/7/2028,,,,,,,
1-33DTXR,TBD-1-33DTXR,'TBD-1-33DTXR,,TAK-169,Ind.2 - 1st Phase 3,Ind.2 - 1st Phase 3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/10/2027,,7/2/2027,,,,,,10/30/2027,,,,10/19/2029,,7/5/2032,,7/5/2032,,,,,,,,,,,,8/2/2032,,,,,,,,,,8/30/2032,,,,,,,,,,,,,,8/27/2032,,,,,,,,,,12/20/2032,,,,,,,,,,,,,,,,12/20/2032,,,,,,,
1-33DTY0,TBD-1-33DTY0,'TBD-1-33DTY0,,TAK-169,Ind.2 - 2nd Phase 3,Ind.2 - 2nd Phase 3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/2/2028,,6/26/2028,,,,,,10/24/2028,,,,10/14/2030,,6/30/2033,,6/30/2033,,,,,,,,,,,,7/28/2033,,,,,,,,,,8/25/2033,,,,,,,,,,,,,,8/24/2033,,,,,,,,,,12/15/2033,,,,,,,,,,,,,,,,12/15/2033,,,,,,,
1-33DTYJ,TBD-1-33DTYJ,'TBD-1-33DTYJ,,TAK-169,Ind.3 - 1st Ph1b/2 Randomized,Ind.3 - 1st Ph1b/2 Randomized,II,Planned,,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/17/2024,,11/9/2024,,,,,,4/13/2025,,,,3/4/2027,,5/27/2028,,5/27/2028,,,,,,,,,,,,6/26/2028,,,,,,,,,,7/3/2028,,,,,,,,,,,,,,7/21/2028,,,,,,,,,,12/4/2028,,,,,,,,,,,,,,,,12/4/2028,,,,,,,
1-33DTYS,TBD-1-33DTYS,'TBD-1-33DTYS,,TAK-169,Ind.3 - 2nd Ph1b/2 Randomized,Ind.3 - 2nd Ph1b/2 Randomized,II,Planned,,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/17/2025,,5/8/2025,,,,,,10/10/2025,,,,8/31/2027,,11/23/2028,,11/23/2028,,,,,,,,,,,,12/23/2028,,,,,,,,,,12/30/2028,,,,,,,,,,,,,,1/18/2029,,,,,,,,,,6/2/2029,,,,,,,,,,,,,,,,6/2/2029,,,,,,,
1-33DTZ1,TBD-1-33DTZ1,'TBD-1-33DTZ1,,TAK-169,Ind.3 - 1st Phase 3,Ind.3 - 1st Phase 3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/2/2028,,6/26/2028,,,,,,10/24/2028,,,,10/14/2030,,6/30/2033,,6/30/2033,,,,,,,,,,,,7/28/2033,,,,,,,,,,8/25/2033,,,,,,,,,,,,,,8/24/2033,,,,,,,,,,12/15/2033,,,,,,,,,,,,,,,,12/15/2033,,,,,,,
1-33DTZA,TBD-1-33DTZA,'TBD-1-33DTZA,,TAK-169,Ind.3 – 2nd Phase 3,Ind.3 – 2nd Phase 3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,4/27/2029,,6/21/2029,,,,,,10/19/2029,,,,10/9/2031,,6/25/2034,,6/25/2034,,,,,,,,,,,,7/23/2034,,,,,,,,,,8/20/2034,,,,,,,,,,,,,,8/17/2034,,,,,,,,,,12/10/2034,,,,,,,,,,,,,,,,12/10/2034,,,,,,,
1-33FJ4E,TAK-676-1003,'TAK-676-1003,,TAK-676,Ph1 dose escalation/expansion w radiation (US only) (100 pts),aPh1 dose escalation/expansion w radiation,I,Not Yet Recruiting,Multiple cancer,Oncology,Early Oncology,,Non-pediatric only (>18 yr),,Treatment,,,46,,,,,,,,1,6,,PPD,,"Sarah Noah, Kate Stumpo",,,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,8/7/2020,8/7/2020,10/23/2020,10/23/2020,,,,,6/29/2021,,,,4/20/2023,,2/12/2024,,2/12/2024,,,,,,,,,,,,3/27/2024,,,,,,,,,,4/2/2024,,,,,,,,,,,,,,4/26/2024,,,,,,,,,,7/26/2024,,,,,,,,,,,,,,,,7/26/2024,,,,,,,
1-33FJ4O,TBD-1-33FJ4O,'TBD-1-33FJ4O,,TAK-676,Ind.1 - 1st Ph1b/2 Randomized,Ind.1 - 1st Ph1b/2 Randomized,II,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,6/19/2024,,8/13/2024,,,,,,1/14/2025,,,,12/5/2026,,2/28/2028,,2/28/2028,,,,,,,,,,,,3/29/2028,,,,,,,,,,4/5/2028,,,,,,,,,,,,,,4/25/2028,,,,,,,,,,9/6/2028,,,,,,,,,,,,,,,,9/6/2028,,,,,,,
1-33FJ4X,TBD-1-33FJ4X,'TBD-1-33FJ4X,,TAK-676,Ind.1-2nd Ph1b/2 Randomized,Ind.1-2nd Ph1b/2 Randomized,II,Planned,Multiple cancer,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,8/6/2025,,9/30/2025,,,,,,3/3/2026,,,,1/22/2028,,4/16/2029,,4/16/2029,,,,,,,,,,,,5/16/2029,,,,,,,,,,5/23/2029,,,,,,,,,,,,,,6/12/2029,,,,,,,,,,1/2/2030,,,,,,,,,,,,,,,,1/2/2030,,,,,,,
1-33FJ5F,TBD-1-33FJ5F,'TBD-1-33FJ5F,,TAK-676,Ph1b/2 Combo Single Arm,Ph1b/2 Combo Single Arm TAK-676,II,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,4/18/2022,,6/10/2022,,,,,,11/7/2022,,,,7/27/2023,,1/23/2024,,1/23/2024,,,,,,,,,,,,2/22/2024,,,,,,,,,,3/20/2024,,,,,,,,,,,,,,3/20/2024,,,,,,,,,,8/21/2024,,,,,,,,,,,,,,,,8/21/2024,,,,,,,
1-33FJ5O,TBD-1-33FJ5O,'TBD-1-33FJ5O,,TAK-676,Ph1 SA Safety/PK-J&A,Ph1 SA Safety/PK-J&A,I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJ5Y,TBD-1-33FJ5Y,'TBD-1-33FJ5Y,,,Ph1 Food Effect TAK-676,Ph1 Food Effect TAK-676,I,Planned,,,,,,,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJ6P,TBD-1-33FJ6P,'TBD-1-33FJ6P,,TAK-676,QT Study,QT Study TAK-676,I,Planned,,Oncology,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/7/2028,,12/17/2028,,,,,,4/16/2029,,,,7/10/2030,,4/6/2031,,4/6/2031,,,,,,,,,,,,5/6/2031,,,,,,,,,,5/13/2031,,,,,,,,,,,,,,6/2/2031,,,,,,,,,,12/23/2031,,,,,,,,,,,,,,,,12/23/2031,,,,,,,
1-33FJ7I,TBD-1-33FJ7I,'TBD-1-33FJ7I,,TAK-676,Ind.1 - First Ph3,Ind.1 - First Ph3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/5/2024,,4/29/2024,,,,,,8/27/2024,,,,6/23/2025,,10/21/2025,,10/21/2025,,,,,,,,,,,,11/18/2025,,,,,,,,,,10/21/2025,,,,,,,,12/16/2025,,,,,,12/15/2025,,,,,,,,,,4/7/2026,,,,,,,,,,,,,,,,4/7/2026,,,,,,,
1-33FJ7R,TBD-1-33FJ7R,'TBD-1-33FJ7R,,TAK-676,Ind.1 - Second Ph3,Ind.1 - Second Ph3,III,Planned,,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/22/2028,,1/16/2029,,,,,,5/16/2029,,,,5/6/2031,,1/20/2034,,1/20/2034,,,,,,,,,,,,2/17/2034,,,,,,,,,,3/17/2034,,,,,,,,,,,,,,3/16/2034,,,,,,,,,,7/7/2034,,,,,,,,,,,,,,,,7/7/2034,,,,,,,
1-33FJ8D,TBD-1-33FJ8D,'TBD-1-33FJ8D,,TAK-676,Renal Impairment,Renal Impairment TAK-676,I,Planned,,Oncology,,,,,,,,60,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/9/2025,,1/19/2026,,,,,,5/19/2026,,,,5/8/2028,,5/3/2029,,5/3/2029,,,,,,,,,,,,6/2/2029,,,,,,,,,,6/9/2029,,,,,,,,,,,,,,6/28/2029,,,,,,,,,,1/19/2030,,,,,,,,,,,,,,,,1/19/2030,,,,,,,
1-33FJ8P,TBD-1-33FJ8P,'TBD-1-33FJ8P,,TAK-676,Hepatic Impairment,Hepatic Impairment TAK-676,I,Planned,,Oncology,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,12/9/2025,,1/19/2026,,,,,,5/19/2026,,,,5/8/2028,,5/3/2029,,,,,,,,,,,,,,2/19/2034,,,,,,,,,,2/26/2034,,,,,,,,,,,,,,3/16/2034,,,,,,,,,,10/8/2034,,,,,,,,,,,,,,,,10/8/2034,,,,,,,
1-33FJ9I,TBD-1-33FJ9I,'TBD-1-33FJ9I,,,Ind.2 - 2nd Ph1b/2 Randomized,Ind.2 - 2nd Ph1b/2  Randomized,II,Planned,,,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJ9R,TBD-1-33FJ9R,'TBD-1-33FJ9R,,,Ind.2 - First Phase 3,Ind.2 - First Phase 3,III,Planned,,,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJ15,C16051,'C16051,,Ninlaro,Ph 1 Pediatrics IV,Ph 1 Pediatrics IV,I,Cancelled,Support - Oncology,Oncology,Early Oncology,,,,,,,15,,,,,,,,1,,,PPD,,Judie Ackerman,,,,2018-003907-20,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJ56,TAK-676-1001,'TAK-676-1001,,TAK-676,Ph1 Dose Escalation,Ph1 Dose Escalation,I,Planned,Multiple cancer,Oncology,,,,,,,,100,,,,,,,,2,,,PRA,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJ67,TBD-1-33FJ67,'TBD-1-33FJ67,,TAK-676,Human ADME,Human ADME TAK-676,I,Planned,,Oncology,,,,,,,,6,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,10/11/2023,,11/21/2023,,,,,,3/20/2024,,,,9/16/2024,,3/15/2025,,3/15/2025,,,,,,,,,,,,4/14/2025,,,,,,,,,,4/21/2025,,,,,,,,,,,,,,5/9/2025,,,,,,,,,,12/1/2025,,,,,,,,,,,,,,,,12/1/2025,,,,,,,
1-33FJ70,TBD-1-33FJ70,'TBD-1-33FJ70,,TAK-676,DDI #1,DDI #1 TAK-676,I,Planned,,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,10/11/2023,,11/21/2023,,,,,,3/20/2024,,,,6/13/2025,,3/15/2025,,3/15/2025,,,,,,,,,,,,4/14/2025,,,,,,,,,,4/21/2025,,,,,,,,,,,,,,5/9/2025,,,,,,,,,,12/1/2025,,,,,,,,,,,,,,,,12/1/2025,,,,,,,
1-33FJ79,TBD-1-33FJ79,'TBD-1-33FJ79,,TAK-676,DDI #2,DDI #2 TAK-676,I,Planned,,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/2/2025,,10/11/2025,,,,,,2/8/2026,,,,5/4/2027,,8/2/2027,,8/2/2027,,,,,,,,,,,,9/1/2027,,,,,,,,,,9/8/2027,,,,,,,,,,,,,,9/28/2027,,,,,,,,,,4/19/2028,,,,,,,,,,,,,,,,4/19/2028,,,,,,,
1-33FJ97,TBD-1-33FJ97,'TBD-1-33FJ97,,,Ind.2 - 1st Ph1b/2 Randomized,Ind.2 - 1st Ph1b/2  Randomized,II,Planned,,,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJA0,TBD-1-33FJA0,'TBD-1-33FJA0,,,Ind.2 - Second Phase 3,Ind.2 - Second,III,Planned,,,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJAB,TBD-1-33FJAB,'TBD-1-33FJAB,,,Ind.3 - 1st Ph1b/2 Randomized,Ind.3 - 1st Ph1b/2,II,Planned,,,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJAK,TBD-1-33FJAK,'TBD-1-33FJAK,,,Ind.3 - 2nd Ph1b/2 Randomized TAK-676,Ind.3 - 2nd Ph1b/2 Randomized TAK-676,II,Planned,,,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJAT,TBD-1-33FJAT,'TBD-1-33FJAT,,,Ind.3 - First Phase 3,Ind.3 - First Phase 3,II,Planned,,,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJB2,TBD-1-33FJB2,'TBD-1-33FJB2,,,Ind.3 - Second Phase 3,Ind.3 - Second Phase 3,II,Planned,,,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33FJBF,TBD-1-33FJBF,'TBD-1-33FJBF,,Iclusig,Iclusig Roll Over Study,Iclusig Roll Over Study,II,Planned,,Oncology,Late Oncology,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,5/8/2024,,,,,,10/5/2024,,,,7/11/2029,,6/20/2033,,6/20/2033,,,,,,,,,,,,8/1/2033,,,,,,,,,,8/15/2033,,,,,,,,,,,,,,8/26/2033,,,,,,,,,,12/5/2033,,,,,,,,,,,,,,,,12/5/2033,,,,,,,
1-33JCPH,TAK-018-2001,'TAK-018-2001,,Sibofimloc (TAK-018),"A Randomized, Double-blind, Placebo-controlled, Multi-center, Proof-of-Mechanism, Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of TAK-018 (EB8018) for the Prevention of Post-Operative Crohn’s Disease Recurrence",TAK-018 P2a POM POCD Study,IIa,Recruiting,(CD) Crohn's disease,GI,Late GI,,,Interventional,,,,96,17,31,,10,17,3,17.71%,40,28,,PRA,,Brian Sontag,,,,2019-000886-19,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,10/31/2018,10/31/2018,7/3/2019,7/3/2019,,,8/4/2020,8/4/2020,8/14/2020,8/14/2020,,,3/31/2022,,,,10/31/2022,,,,,,,,,,,,12/30/2022,,,,,,,,,,1/6/2023,,,,,,,,,,,,,,2/3/2023,,,,,,,,,,5/8/2023,,,,,,,,,,,,,,,,5/8/2023,,,,,,,
1-33RH8X,Pevonedistat-2002,'Pevonedistat-2002,,pevonedistat (TAK-924),"A Randomized, Open-label, Controlled, Phase 3 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults  With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy",Ph 3 Pevo/Ven/Aza vs Ven/Aza,III,Recruiting,NEC/AS/NS,Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Other,430,131,217,,69,131,,30.47%,120,,,TBD,,Gabriel Berman,,"Douglas Faller, Farhad Sedarati",,,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,8/16/2019,8/16/2019,11/21/2019,11/21/2019,,,,,11/23/2020,11/23/2020,,,6/26/2023,,9/30/2024,,6/3/2023,,4/5/2024,,12/8/2025,,,,10/11/2026,,,,7/15/2023,,5/17/2024,,1/19/2026,,,,11/21/2026,,,,5/24/2024,,1/26/2026,,,,11/28/2026,,,,,,7/22/2023,,6/14/2024,,2/23/2026,,,,12/27/2026,,8/12/2023,,9/6/2024,,6/16/2026,,,,3/26/2027,,,,,,,,3/26/2027,,,,,,,
1-33RH9C,C14023,'C14023,,Alisertib,Phase 3 Alisertib + (7+3) vs (7+3) in fit AML,Ph3 Alisertib+(7+3) vs (7+3),III,Cancelled,(AML) Acute myeloid leukemia,Oncology,,,,,,,,350,,,,,,,,120,,,PPD,,Zahir Rajiwate,,,,,,,,,NA,,,Medidata CTMS (Pharma),,,,,7/26/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/3/2025,,,,,,,
1-33RHA1,TBD-1-33RHA1,'TBD-1-33RHA1,,TAK-418,BCH KS Natural History,Takeda-Boston Children’s Kabuki Syndrome Naturalis,0,Planned,Kabuki Syndrome,NS,,,,,,,,75,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33RHUL,TAK-418-1005,'TAK-418-1005,,TAK-418,Asia bridging,An Early Proof of Concept Efficacy and Safety Stud,I,Cancelled,Kabuki Syndrome,NS,Early NS,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33RHY7,TAK-788-1502,'TAK-788-1502,,Mobocertinib (TAK-788),Ph1/2 HER2 combo basket (48 pts),Ph1/2 HER2 combo basket (48 pts),II/III,Withdrawn,Hemostasis and tissue sealing in GI Anastomosis,Oncology,Early Oncology,,,,,,,53,,,,,,,,20,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/14/2020,2/14/2020,5/6/2020,5/6/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/6/2020,5/6/2020,,,,,,
1-33RHYI,TBD-1-33RHYI,'TBD-1-33RHYI,,,Phase 1 HER2 Mutation Other (110 pts),Ph2 HER2 SA basket,II,Cancelled,00032 Solid tumor,,,,,,,,,110,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-33RHYU,TBD-1-33RHYU,'TBD-1-33RHYU,,Mobocertinib (TAK-788),Phase 1/2 EGFR combo (140 pts),Ph1/2 EGFR ex20 combo,I,Cancelled,Prevention of H5N1 pandemic influenza (pediatric),Oncology,,,,,,,,140,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/29/2021,,3/1/2022,,,,,,7/29/2022,,,,7/28/2024,,4/27/2025,,4/27/2025,,,,,,,,,,,,6/28/2025,,,,,,,,,,7/7/2025,,,,,,,,,,,,,,7/29/2025,,,,,,,,,,12/8/2025,,,,,,,,,,,,,,,,12/8/2025,,,,,,,
1-33RHZ3,TBD-1-33RHZ3,'TBD-1-33RHZ3,,Mobocertinib (TAK-788),Ph3 RCT EGFR exon 20 combo in NSCLC,Ph3 EGFR ex20 combo,III,Cancelled,Prevention of H5N1 pandemic influenza (pediatric),Oncology,,,,,,,,250,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-34Q1U7,MVT-601-3201,'MVT-601-3201,,relugolix,"HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer",MVT-601-3201,III,Planned,(PC) Prostate cancer_,Oncology,,,,,,,,108,68,98,,30,,16,62.96%,15,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,3/29/2019,3/29/2019,,,12/31/2020,12/31/2020,,,12/31/2021,,,,,,,,,,,,2/28/2022,,,,,,,,,,3/21/2022,,,,,,,,,,,,,,3/29/2022,,,,,,,,,,6/30/2022,,,,,,,,,,,,,,,,6/30/2022,,,,,,,
1-34Q1ZH,VedolizumabSC-1023,'VedolizumabSC-1023,,,"A Phase 1, Open-Label, Randomized Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects",Vedolizumab SC pinch/stretch study,I,Cancelled,Normal Healthy Volunteer,,,,,,,,,228,0,0,,0,,0,0.00%,2,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-34Q2IX,TAK-079-1001,'TAK-079-1001,,Mezagitamab (TAK-079),"An open label, multicenter phase 1b study investigating the safety of TAK-079 in combination with backbone regimen for the treatment of patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplant (SCT)","An open label, multicenter phase 1b",Ib,Cancelled,(MM) Multiple myeloma relapsed/refractory,RGH,,,,,,,,18,,,,,,,,4,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-34Q2J8,TAK-079-1002,'TAK-079-1002,,Mezagitamab (TAK-079),"An open label, multicenter phase 1b study investigating the safety of TAK-079 in combination with backbone regimens for the treatment of patients with newly diagnosed multiple myeloma and for whom SCT is not planned as initial therapy",TAK-079-1002 TAK-079,Ib,Recruitment Complete,(MM) Multiple myeloma relapsed/refractory,RGH,Others,,,,,,,24,23,30,,7,,4,95.83%,10,9,,PPD,,Rachel McComb,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/1/2019,2/1/2019,5/8/2019,5/8/2019,,,,,8/2/2019,8/2/2019,,,3/31/2021,,3/31/2023,,3/31/2023,,,,,,,,,,,,8/5/2023,,,,,,,,,,8/12/2023,,,,,,,,,,,,,,8/12/2023,,,,,,,,,,11/30/2023,,,,,,,,,,,,,,,,11/30/2023,,,,,,,
1-34WP2F,TAK-653-2002,'TAK-653-2002,,TAK-653,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects With Treatment-Resistant Depression",TAK-653: Patient Study in Treatment Resistent Depr,II,Cancelled,(TRD) Treatment Resistance to Depression,NS,Late NS,,,,,,,80,,,,,,,,12,,,PPD,,Michael Stieber,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-34WP2Q,TAK-954-1009,'TAK-954-1009,,TAK-954,"A Double-Blind, Placebo-Controlled, Multiple Ascending, 3 Period, Incomplete Block Design Trial to Investigate the Safety, Tolerability and Pharmacokinetics of TAK 954 Administered as a 60-minute IV Infusion to Healthy Adult Participants","TAK-954: Healthy Volunteers, dose escalation, doub",I,Closed,Other,GI,,,,Dose Ranging,,,,6,6,18,,0,0,0,100.00%,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,12/16/2018,12/16/2018,2/4/2019,2/4/2019,,,3/6/2019,3/6/2019,3/24/2019,3/24/2019,,,3/24/2019,3/24/2019,,,5/12/2019,5/12/2019,,,,,,,,,,,6/14/2019,6/14/2019,,,,,,,,,6/17/2019,6/17/2019,,,,,,,,,,,,,6/17/2019,6/17/2019,,,,,,,,,10/1/2019,10/1/2019,,,,,,,,,,,,,,,10/1/2019,10/1/2019,,,,,,
1-34WP30,TAK-390MR-1002,'TAK-390MR-1002,,"DEXILANT (dexlansoprazole, MR)","A Phase 1, Randomized, Open-Label, Single-Dose, Two-Period Crossover Study to Compare the Bioavailability of Dexlansoprazole Capsules Manufactured by Takeda GmbH Relative to Dexlansoprazole Capsules Manufactured by Takeda Osaka Following a High Fat Meal",Oranienburg BE Study (Fed),I,Closed,00002 GERD,Others,,,,BE,,,,120,122,,,,,2,101.67%,1,,,Celerion,,,,,,,,,,,,,,STARS Inactive,,,11/29/2018,11/29/2018,12/17/2018,12/17/2018,,,1/10/2019,1/10/2019,1/28/2019,1/28/2019,,,2/19/2019,2/19/2019,,,3/18/2019,3/18/2019,,,,,,,,,,,,,,,,,,,,,3/28/2019,3/28/2019,,,,,,,,,,,,,5/24/2019,5/24/2019,,,,,,,,,6/29/2019,6/29/2019,,,,,,,,,,,,,,,6/29/2019,6/29/2019,,,,,,
1-36QQIR,TAK-925-1005,'TAK-925-1005,,,"A  Phase 1, Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of a Sustained Release TAK-925 Patches in Health Adults",,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-36QQJG,TAK-925-1006,'TAK-925-1006,,TAK-925,"A  Phase 1, Single Crossover, Open Label Study Evaluating the Relative Bioavailability of a TAK-925 Sustained Release Patch Compared to IV TAK-925  formulation in Health Adults",Phase 1 Single Crossover,I,Planned,Sleep Disorders,NS,Early NS,,,,,,,12,,,,,,,,1,,,TBD,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,6/1/2022,,7/13/2022,,,,9/13/2022,,9/14/2022,,,,10/15/2022,,,,10/21/2022,,,,,,,,,,,,12/9/2022,,,,,,,,,,12/30/2022,,,,,,,,,,,,,,2/17/2023,,,,,,,,,,6/21/2023,,,,,,,,,,,,,,,,10/20/2023,,,,,,,
1-36QQJP,TAK-925-1007,'TAK-925-1007,,,"A  Phase 2, Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamics of a Sustained Release Patch of TAK-925  in Type 1 Narcolepsy Patients",,II,Cancelled,Other,,,,,POC,,,,40,0,0,,0,,0,0.00%,15,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-36QQKT,TAK-041-2003,'TAK-041-2003,,TAK-041,ePOC trial in patients with Anhedonia,ePOC,II,Cancelled,Other,NS,,,,POC,,,,100,0,0,,0,,0,0.00%,20,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-36QR0J,TAK-925-1008,'TAK-925-1008,,TAK-925,"A  Phase 1, Randomized, Placebo-Controlled Relative Bioavailability Study Evaluating the Safety, Tolerability, Pharmacokinetics of the Phase 3 TAK-925 Sustained Release Patches in Healthy Adults",TAK-925-1008 Phase 1 BA Patch evaluation study for,I,Planned,,NS,,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,6/19/2023,,7/17/2023,,,,8/28/2023,,9/27/2023,,,,10/13/2023,,,,10/17/2023,,,,,,,,,,,,11/20/2023,,,,,,,,,,12/11/2023,,,,,,,,,,,,,,1/29/2024,,,,,,,,,,5/30/2024,,,,,,,,,,,,,,,,10/14/2024,,,,,,,
1-37FQY1,Brigatinib-5007,'Brigatinib-5007,,Alunbrig,A Cohort Study of Early-Onset Pulmonary Events in Patients with ALK+ NSCLC treated with Brigatinib or Other Tyrosine Kinase Inhibitors,Brigatinib-5007,IV,Recruiting,Hemostasis and tissue sealing in GI Anastomosis,Oncology,Real World Evidence,,,,Other,Prospective,Cohort,120,9,1,,0,0,,7.50%,50,32,,IQVIA,,Neil Yadav,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,10/17/2019,10/17/2019,,,,,1/15/2021,1/15/2021,,,1/20/2024,,1/20/2024,,3/1/2024,,,,,,,,,,,,3/29/2024,,,,,,,,,,7/31/2024,,,,,,,,,,,,,,,,,,,,,,,,8/14/2024,,,,,,,,,,,,,,,,8/14/2024,,,,,,,
1-37HZ3U,TAK-831-2004,'TAK-831-2004,,TAK-831,Early Schz Cognition ePOC,SCZD Cognition POC,II,Cancelled,Schizophrenia,NS,,,,,,,,90,,,,,,,,9,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/12/2015,,,,,,,
1-39F7HP,TAK-988-1502,'TAK-988-1502,,TAK-988,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study in Patients with Narcolepsy Type 1 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-988",TAK-988 MRD Study in Narcoleptic Patients,II,Planned,Sleep Disorders,NS,Early NS,,,,,,,72,,,,,,,,30,,,INC Research,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,11/4/2021,,2/17/2022,,,,5/6/2022,,5/6/2022,,,,7/28/2023,,,,9/1/2023,,,,,,,,,,,,10/6/2023,,,,,,,,,,10/20/2023,,,,,,,,,,,,,,11/2/2023,,,,,,,,,,1/25/2024,,,,,,,,,,,,,,,,8/30/2024,,,,,,,
1-39F7S9,TAK-653-2004,'TAK-653-2004,,TAK-653,"A Randomized, Double-blind, Placebo-Controlled, 3-Period Crossover Study Evaluate Central Pharmacodynamic Activity and efficacy of TAK 653 compared to ketamine in MDD patients Using Transcranial Magnetic Stimulation",TAK-653:  Patient Study with TMS & Ketamine,II,Cancelled,(TRD) Treatment Resistance to Depression,NS,Late NS,,,,,,,48,,,,,,,,2,,,TBD,,Michael Stieber,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/27/2023,,,,,,,
1-39REHV,TAK-925-1009,'TAK-925-1009,,TAK-925,"An Open-Label, Trial to Evaluate the Effect of the Cobicistat on two Single-Doses Pharmacokinetics of Oral TAK-925 in Healthy Adult Subjects",TAK-925-1009 TAK-925,I,All Activities Closed,Sleep Disorders,NS,Early NS,,,,,,,16,16,54,,0,0,0,100.00%,1,,,Celerion,,Natalie Jones,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,6/25/2019,6/25/2019,8/16/2019,8/16/2019,,,10/11/2019,10/11/2019,10/11/2019,10/11/2019,,,11/12/2019,11/12/2019,,,12/3/2019,12/3/2019,,,,,,,,,,,1/24/2020,1/24/2020,,,,,,,,,2/7/2020,2/7/2020,,,,,,,,,,,,,8/14/2020,8/14/2020,,,,,,,,,11/4/2020,11/4/2020,,,,,,,,,,,,,,,12/1/2020,,,,,,,
1-39REQR,TAK-988-1001,'TAK-988-1001,,TAK-988,"A Randomized, Double Blind, Placebo-Controlled Single and Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-988 in Healthy Subjects",Phase 1 HV SRD and MRD Study (TAK-988-1001),I,Withdrawn,Sleep Disorders,NS,Early NS,,,,,,,152,,,,,,,,2,,,PRA,,Anne Crissey,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,7/12/2019,7/12/2019,1/13/2020,1/13/2020,,,11/10/2021,,11/15/2021,,,,6/17/2022,,,,6/23/2022,,,,,,,,,,,,7/22/2022,,,,,,,,,,8/5/2022,,,,,,,,,,,,,,9/2/2022,,,,,,,,,,11/24/2022,,,,,,,,,,,,,,,,6/22/2023,,,,,,,
1-42QP63,TAK-788-3003,'TAK-788-3003,,Mobocertinib (TAK-788),A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of Mobocertinib Versus Docetaxel in Non–Small Cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutations who have received  Platinum-based Chemotherapy,A Randomized Phase 3 Multicenter Open-Label Study,III,Not Yet Recruiting,(NSCLC) Non-small cell lung cancer,Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,,,,250,,,,,,,,125,,,PPD,,Lam Calderon,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,4/15/2021,4/15/2021,5/25/2021,5/25/2021,,,,,9/30/2021,,,,3/29/2023,,1/28/2024,,12/23/2022,,,,,,,,3/29/2025,,,,2/26/2023,,,,,,,,5/24/2025,,3/2/2023,,,,,,,,6/1/2025,,,,,,3/23/2023,,,,,,,,6/22/2025,,6/16/2023,,,,,,,,9/14/2025,,,,,,,,9/14/2025,,,,,,,
1-73BQ6,C13004,'C13004,,,"A Phase 2,Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002",,IIA,Closed,Other,,,,,,,,,80,72,0,,0,,57,90.00%,20,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-73M1D,C14013,'C14013,,Alisertib,"A Phase 1 Dose Escalation and Pharmacokinetic Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, in Adult East Asian Patients with Advanced Solid Tumors and Lymphomas",,I,Closed,Solid.All Comers,Oncology,,,,,,,,30,36,44,,10,,9,120.00%,9,7,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,10/11/2011,10/11/2011,,,,,2/7/2012,2/7/2012,,,2/27/2013,2/27/2013,10/8/2013,10/8/2013,,,,,,,,,,,,,11/8/2013,11/8/2013,,,,,,,,,12/16/2013,12/16/2013,,,,,,,,,,,,,,,,,,,,,,,3/31/2014,3/31/2014,,,,,,,3/31/2014,3/31/2014,,,,,,,3/31/2014,3/31/2014,,,,,,
1-104X35,TAK-058-1003,'TAK-058-1003,,TAK-058,"Phase 1, TAK-058 P50 Auditory Gating in Subjects With Stable Schizophrenia",TES,I,Terminated,00149 Schizophrenia,NS,,,,Other Phase 1,,,,39,16,63,,35,,,41.03%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106BXP,TBD-5414,'TBD-5414,,TAK-063,Comparator Study,3.3 Comparator Study,III,Cancelled,Other,NS,,,,Other P3A - Pre NDA,,,,288,0,0,,0,,0,0.00%,32,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106BXY,Namilumab-1003,'Namilumab-1003,,MT203,"A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic
Characterization of Subjects That Previously Received Namilumab and Participated in
the Phase 1 PRIORA Study",1003 Priora PGx,I,Closed,Other,Immunology,,,,Other Phase 1,,,,10,5,0,,0,7,0,50.00%,6,,,IQVIA,Rudi Taljaard,,,,,,,,,,,,,STARS Inactive,,,,,2/19/2015,2/19/2015,,,11/19/2015,11/19/2015,11/19/2015,11/19/2015,,,4/15/2016,,,,4/5/2016,4/5/2016,,,,,,,,,,,5/2/2016,,,,,,,,,,5/23/2016,,,,,,,,,,,,,,,,,,,,,,,,11/30/2016,11/30/2016,,,,,,,,,,,,,,,11/30/2016,,,,,,,
1-106C0P,ROF-ASTHMA_202,'ROF-ASTHMA_202,,ROF-ASTHMA,Roflumilast/Montelukast Combination POM Study in Asthma,Asthma POM Study,II,Closed,Other,Marketed Products,,,,Other Phase 2,,,,60,64,0,,39,43,0,106.67%,15,1,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106C1S,TBD-6315,'TBD-6315,,,Phase 2 Dose Ranging study of TAK-079 in SLE patients,Phase 2 Dose Ranging,II,Closed,Other,,,,,Dose Ranging,,,,400,0,0,,0,,0,0.00%,200,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106C2B,TBD-7077,'TBD-7077,,,ADME,1.4 ADME,I,Cancelled,Other,,,,,ADME,,,,8,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106C3N,TBD-6858,'TBD-6858,,,CYP Inhibition study #2,1.3 CYP Inhibition #2,I,Cancelled,Other,,,,,DI Low Complexity,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106C4S,TAK-648-1003,'TAK-648-1003,,TAK-648,"A Phase 1, Randomized, Open-Label, Single-Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of a TAK-648 Tablet Compared With a TAK-648 Oral Solution, and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Subjects",Relative BA/Food Effect,I,Closed,00050 Type 2 diabetes,CVM,,,,BA,,,,24,24,57,,33,,2,100.00%,1,,,PPD,Deborah Keeter,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106C5B,TAK-058-1005,'TAK-058-1005,,TAK-058,"Relative BA, Food Effect and DDI",Relative BA/Food Effect/DDI,I,Cancelled,Other,NS,,,,BA,,,,30,0,0,,0,,0,0.00%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106C5U,MT203-2004,'MT203-2004,,MT203,A Phase 2 Exploratory Study of Namilumab vs Anti-Tumor Necrosis Factor in Patients With Early Rheumatoid Arthritis Inadequately Responding to Methotrexate,TELLUS,II,Terminated,(RA) Rheumatoid arthritis,Immunology,,,,,,,,36,7,0,,8,0,0,19.44%,15,,,IQVIA,,Dilini Reynold,,"Didier Saurigny, Robert Jenkins",,,,,,,,,,Medidata CTMS (Pharma),,,6/19/2014,6/19/2014,8/18/2014,8/18/2014,,,4/8/2015,4/8/2015,4/29/2015,4/29/2015,,,1/14/2016,1/14/2016,,,11/1/2016,11/1/2016,,,,,,,,,,,12/19/2016,12/19/2016,,,,,,,,,1/23/2017,1/23/2017,,,,,,,,,,,,,,,,,,,,,,,5/15/2017,5/15/2017,,,,,,,,,,,,,,,5/15/2017,5/15/2017,,,,,,
1-106C34,TBD-6857,'TBD-6857,,,DDI CYP Inhibition,1.2  CYP Inhibition #1,I,Cancelled,Other,,,,,DI Low Complexity,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106CYP,TBD-7042,'TBD-7042,,,MLN0002 Phase 3 SC UC Study,MLN0002 Phase 3 UC,IIIB,Cancelled,Other,,,,,Other P3b - Post NDA,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106CZ8,TAK-875_126,'TAK-875_126,,TAK-875,"A Phase 1, Randomized, Open-Label, Single-Dose, 2-Period Crossover Study to Assess the Relative Bioavailability of Two Formulation Strengths of TAK-875 and Metformin HCl (US Sourced Glucophage) When Administered as a Fixed-Dose Combination Tablet Compared With Individually Administered Tablets in Healthy Adult Subjects",BE - FDC US Metformin,I,Closed,Other,CVM,,,,BE,,,,60,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106CZR,TBD-7081,'TBD-7081,,,Formulation Dev BE Study,1.7 Formulation Dev BE,I,Cancelled,Other,,,,,BE,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106L1R,TAK-875_119,'TAK-875_119,,TAK-875,"A Phase 1, Open-Label, Single and Multiple-Dose Study of the Pharmacokinetics of TAK-875 25 mg and 50 mg in Healthy Chinese Subjects.",Pk study - China,I,Closed,Other,CVM,,,,Other Phase 1,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106L17,TAK-385_106,'TAK-385_106,,relugolix,"A Randomized, Double-Blind, Placebo-and Positive-Controlled (open-label moxifloxacin), 4-Arm Parallel-Group Study to Evaluate the Effect of TAK-385 on Cardiac Repolarization in Healthy Subjects",QTC,I,Closed,Other,CVM,,,,QTc Interval,,,,280,0,0,,0,,0,0.00%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106L20,TAK-390MR(OD)_206,'TAK-390MR(OD)_206,,,"Safety and effectiveness of TAK-390MR in 12-17 yr. olds with symptomatice non-erosive GERD
Safety/Efficacy",Peds 12-17yo GERD (ODT),II,Closed,Other,,,,,Pediatric Safety/Efficacy,,,,104,0,0,,0,,0,0.00%,71,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-106L29,TAK-390MR(OD)_104,'TAK-390MR(OD)_104,,,"A Phase 1, Randomized, Open-Label, Single Center, Multiple-Dose, Two-Period, Crossover Study to Assess the Bioavailability, Safety, and Pharmacodynamics of Two 30 mg Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Administered on the Tongue Relative to Oral Administration of One 60 mg Dexlansoprazole Delayed-Release Capsule in Healthy Subjects",ODT PK Bioavail / PD-60 mg,I,Closed,Other,,,,,BA,,,,52,61,0,,8,0,0,117.31%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126W9L,SGN35-0001,'SGN35-0001,,,SGN35-0001: Phase 1 r/r CD30+ Heme (q3w) (45),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WA1,SGN35-0002,'SGN35-0002,,,SGN35-0002: Phase 1 r/r CD30+ Heme (q1w) (39),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WAA,SGN35-0003,'SGN35-0003,,,SGN35-0003: Phase 2 Pivotal  Study r/r HL (102),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WAJ,SGN35-0004,'SGN35-0004,,,SGN35-0004: Phase 2 r/r sALCL (58 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WAS,SGN35-0006,'SGN35-0006,,,SGN35-0006: Phase 2 CD30+ Heme Retreatment (100 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WB1,SGN35-0008,'SGN35-0008,,,SGN35-0008: Phase 1 CD30+ DDI & Renal/Hepatic Impairment (64 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WBA,SGN35-0009,'SGN35-0009,,,SGN-35-0009: Phase 1 +ABVD Safety in FL HL(40 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WBJ,SGN35-0007,'SGN35-0007,,,SGN35-0007: Phase 1 CD30+QTc Cardiac Safety (40 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WBS,SGN35-0005,'SGN35-0005,,,SGN35-0005: Phase 3 Post-ASCT High-Risk HL Relapse Prevention (AETHERA) (322 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-126WC1,SGN35-0010,'SGN35-0010,,,SGN-35-010 (TOPP/EAP) (40 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-134OP9,TBD-1-134OP9,'TBD-1-134OP9,,,PET Single Dose,PET Single Dose,I,Suspended,,,,,,,,,,1,,,,,,,,1,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-134OQH,TBD-1-134OQH,'TBD-1-134OQH,,TAK-831,Ataxia feasibility (P0 study),Ataxia feasibility (P0 study),0,Cancelled,Other,NS,,,,,,,,30,0,0,,0,,0,0.00%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-169BOB,TBD- 1-169BOB,'TBD- 1-169BOB,,,Ph3 Long-term Add-on Metformin vs Liraglutide,Ph3 LT Add- on Met vs Liraglutide,III,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,300,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-231UXH,C31007,'C31007,,,"A randomized, open-label, multicenter phase 1b/2 study to evaluate the safety and tolerability of TAK-228 (a catalytic TORC1/2 inhibitor) in combination with  VEGF tyrosine kinase inhibitors- VEGF TKI (axitinib or cabozantinib) and to compare the efficacy of the combinations (TAK-228 plus either axitinib or cabozantinib) with single-agent VEGF TKI in advanced or metastatic clear-cell renal cell carcinoma following progression on prior systemic therapy","A randomized, open-label, multicenter phase 1b/2 s",I/II,Cancelled,00037 (RCC) Renal cell cancer,,,,,,,,,190,0,0,,0,,0,0.00%,50,,,PRA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-231UZF,TBD-1-231UZF,'TBD-1-231UZF,,soticlestat (TAK-935),TBD,TAK-935 Pediatric POC Study,II,Cancelled,Other,NS,,,,POC,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PSD,AP24534-15-303,'AP24534-15-303,,Iclusig,OPTIC-2L: Phase 3 Ponatinib vs Nilotinib,OPTIC-2L: Ph 3 Ponatinib vs Nilotinib,III,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Oncology,Late Oncology,,,Interventional,,,,44,44,60,,16,,3,100.00%,90,,,INC Research,,"Oluchi Adedoyin, Gina Gualtiere",,,,2015-001318-92,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,10/12/2015,10/12/2015,,,1/28/2016,1/28/2016,2/11/2016,2/11/2016,,,10/24/2017,10/24/2017,10/23/2018,10/23/2018,11/26/2020,11/26/2020,,,,,,,,,,,3/22/2021,3/22/2021,,,,,,,,,4/28/2021,4/28/2021,,,,,,,,,,,,,4/28/2021,4/28/2021,,,,,,,,,7/28/2021,,,,,,,,,,,,,,,,7/28/2021,,,,,,,
1-274PSO,AP24534-14-401,'AP24534-14-401,,Iclusig,GMA Trial List - OMNI Study: A Post Marketing Study,OMNI Study: A Post Marketing Study,IV,Cancelled,Heme.Other,Oncology,,,,,,,,300,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PT2,TBD-1-274PT2,'TBD-1-274PT2,,Mobocertinib (TAK-788),Definitive Food Effect,Definitive Food Effect,I,Planned,Support - Oncology,Oncology,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PTB,TAK-788-1005,'TAK-788-1005,,Mobocertinib (TAK-788),"A Phase 1, Randomized, 2-Period, 2-Sequence, Crossover Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics in Healthy Adult Subjects",High-fat Meal NHVs,I,Reported,Support - Oncology,Oncology,Late Oncology,,,,,,,14,14,25,,9,,,100.00%,1,,,Celerion,,Veronique Copalu,,,,,,,,,,,,Medidata CTMS (Pharma),,,9/10/2019,9/10/2019,6/10/2020,6/10/2020,,,,,7/1/2020,7/1/2020,,,7/1/2020,7/1/2020,7/21/2020,7/21/2020,7/21/2020,7/21/2020,,,,,,,,,,,9/14/2020,9/14/2020,,,,,,,,,9/24/2020,9/24/2020,,,,,,,,,,,,,10/16/2020,10/16/2020,,,,,,,,,12/16/2020,12/16/2020,,,,,,,,,,,,,,,12/16/2020,12/16/2020,,,,,,
1-274PTK,TAK-788-1002,'TAK-788-1002,,Mobocertinib (TAK-788),Human ADME – Absolute BA,Human ADME – Absolute BA,I,Completed,Support - Oncology,Oncology,Late Oncology,,,,,,,6,7,18,,0,0,0,116.67%,1,,,Celerion,,Natalie Jones,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/13/2018,7/13/2018,12/19/2018,12/19/2018,,,,,1/31/2019,1/31/2019,,,2/1/2019,2/1/2019,3/11/2019,3/11/2019,3/11/2019,3/11/2019,,,,,,,,,,,8/15/2019,8/15/2019,,,,,,,,,9/9/2019,9/9/2019,,,,,,,,,,,,,10/19/2020,10/19/2020,,,,,,,,,7/8/2027,,,,,,,,,,,,,,,,7/8/2027,,,,,,,
1-274PTT,TAK-788-1003,'TAK-788-1003,,Mobocertinib (TAK-788),Phase 1 Japan,Phase 1 Japan,I,Recruitment Complete,Hemostasis and tissue sealing in GI Anastomosis,Oncology,Late Oncology,,,,,,,53,53,59,,6,,37,100.00%,25,,,PRA,,Yumi Oomuku,,,,,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,8/23/2018,8/23/2018,10/22/2018,10/22/2018,,,,,2/14/2019,2/14/2019,,,3/10/2021,3/10/2021,9/10/2021,,11/8/2021,,,,,,,,3/1/2024,,,,2/7/2022,,,,,,,,5/24/2024,,2/14/2022,,,,,,,,5/31/2024,,,,,,3/7/2022,,,,,,,,6/21/2024,,6/6/2022,,,,,,,,11/1/2024,,,,,,,,11/1/2024,,,,,,,
1-274PU2,TAK-788-1004,'TAK-788-1004,,Mobocertinib (TAK-788),Induction w/ Sensitive CYP3A Substrate,Induction w/ Sensitive CYP3A Substrate,I,Recruitment Complete,Support - Oncology,Oncology,Late Oncology,,,,,,,26,26,36,,10,,23,100.00%,8,,,PRA,,Lam Calderon,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/16/2018,11/16/2018,2/18/2019,2/18/2019,,,,,1/6/2020,1/6/2020,,,11/16/2020,11/16/2020,7/16/2021,,12/17/2020,12/17/2020,,,,,,,8/11/2021,,,,3/15/2021,3/15/2021,,,,,,,10/6/2021,,4/6/2021,4/6/2021,,,,,,,10/13/2021,,,,,,4/28/2021,4/28/2021,,,,,,,11/3/2021,,7/1/2021,7/1/2021,,,,,,,3/16/2022,,,,,,,,3/16/2022,,,,,,,
1-274PUB,TBD-1-274PUB,'TBD-1-274PUB,,Mobocertinib (TAK-788),pH Effect Famotidine & Antacid,pH Effect Famotidine & Antacid,I,Cancelled,Solid.Lung.NSCLC,Oncology,,,,,,,,18,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PUK,TAK-788-1007,'TAK-788-1007,,Mobocertinib (TAK-788),Renal Impairment,Renal Impairment,I,Recruiting,Support - Oncology,Oncology,Late Oncology,,,,,,,24,6,17,,11,,,25.00%,2,,,Celerion,,Katie Savage,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/14/2019,5/14/2019,7/18/2019,7/18/2019,,,,,3/10/2020,3/10/2020,,,3/31/2022,,3/31/2022,,3/31/2022,,,,,,,,,,,,5/21/2022,,,,,,,,,,4/21/2022,,,,,,,,,,,,,,6/30/2022,,,,,,,,,,11/30/2022,,,,,,,,,,,,,,,,11/30/2022,,,,,,,
1-274PUT,TAK-788-1008,'TAK-788-1008,,Mobocertinib (TAK-788),Hepatic Impairment,Hepatic Impairment,I,Recruiting,Support - Oncology,Oncology,Late Oncology,,,,,,,32,17,28,,10,,,53.13%,2,,,Celerion,,Katie Savage,,,,,,,,,,,,Medidata CTMS (Pharma),,,5/14/2019,5/14/2019,7/17/2019,7/17/2019,,,,,10/23/2020,10/23/2020,,,12/31/2021,,12/31/2021,,1/30/2022,,,,,,,,,,,,3/30/2022,,,,,,,,,,2/21/2022,,,,,,,,,,,,,,4/29/2022,,,,,,,,,,6/30/2022,,,,,,,,,,,,,,,,6/30/2022,,,,,,,
1-274PV2,TBD-1-274PV2,'TBD-1-274PV2,,TAK-522,Ph 1 SA Safety/PK – J&A,Phase 1 SA Safety/PK J&A,I,Cancelled,Solid.Lung.NSCLC,Oncology,,,,,,,,30,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PWV,TAK-573-1002,'TAK-573-1002,,TAK-573,Ph1b/2 MM combination,Ph1b/2 MM combination,I/II,Cancelled,Heme.Multiple Myeloma,Oncology,,,,,,,,135,0,0,,0,,0,0.00%,20,,,,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PX6,TBD-1-274PX6,'TBD-1-274PX6,,TAK-573,Ph1b/2 solid tumor combination,Ph1b/2 solid tumor combination,I/II,Cancelled,Multiple cancer,Oncology,Early Oncology,,,,,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PXF,TBD-1-274PXF,'TBD-1-274PXF,,TAK-573,Phase 2 Single Agent pivotal study R/R MM (180 pts),Phase 2 Single Agent pivotal study R/R MM (180 pts),II,Planned,MM DN Dara,Oncology,Early Oncology,,,,,,,110,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/29/2021,,10/28/2021,,,,,,3/27/2022,,,,3/28/2024,,11/23/2024,,3/23/2025,,,,,,,,,,,,4/22/2025,,,,,,,,,,12/23/2024,,,,,,,,,,,,,,5/16/2025,,,,,,,,,,9/30/2025,,,,,,,,,,,,,,,,9/30/2025,,,,,,,
1-274PXO,TBD-1-274PXO,'TBD-1-274PXO,,TAK-573,Phase 1 SA Safety/PK - J&A,Ph 1 SA Safety/PK - J&A,I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/21/2022,,7/21/2022,,,,,,11/21/2022,,,,8/18/2023,,2/14/2024,,2/14/2024,,,,,,,,,,,,3/15/2024,,,,,,,,,,3/22/2024,,,,,,,,,,,,,,4/10/2024,,,,,,,,,,8/23/2024,,,,,,,,,,,,,,,,8/23/2024,,,,,,,
1-274PXX,TBD-1-274PXX,'TBD-1-274PXX,,TAK-573,QT Study,QT Study TAK-573,I,Planned,Multiple cancer,Oncology,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,4/15/2009,,5/15/2009,,,,,,9/12/2009,,,,12/6/2010,,9/2/2011,,9/2/2011,,,,,,,,,,,,10/2/2011,,,,,,,,,,10/9/2011,,,,,,,,,,,,,,10/27/2011,,,,,,,,,,5/20/2012,,,,,,,,,,,,,,,,5/20/2012,,,,,,,
1-274PY6,TBD-1-274PY6,'TBD-1-274PY6,,TAK-573,DDI #1,DDI #1,I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PYF,TBD-1-274PYF,'TBD-1-274PYF,,TAK-573,DDI #2,DDI #2,I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PYO,TBD-1-274PYO,'TBD-1-274PYO,,TAK-573,Phase 2/3 MM Combo (MVP) study,Phase 2/3 MM Combo (MVP) study,III,Planned,MM DN Dara,Oncology,Early Oncology,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,3/27/2022,,5/26/2022,,,,,,9/23/2022,,,,9/12/2024,,5/30/2027,,5/30/2027,,,,,,,,,,,,6/27/2027,,,,,,,,,,7/25/2027,,,,,,,,,,,,,,8/5/2027,,,,,,,,,,11/14/2027,,,,,,,,,,,,,,,,11/14/2027,,,,,,,
1-274PYX,TBD-1-274PYX,'TBD-1-274PYX,,TAK-573,Ind. 1: Second Phase 3 Pivotal,Ind. 1: Second Ph 3,III,Planned,Multiple cancer,Oncology,,,,,,,,300,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,11/22/2022,,1/21/2023,,,,,,5/25/2023,,,,5/14/2025,,1/29/2028,,1/29/2028,,,,,,,,,,,,2/26/2028,,,,,,,,,,3/25/2028,,,,,,,,,,,,,,3/23/2028,,,,,,,,,,7/15/2028,,,,,,,,,,,,,,,,7/15/2028,,,,,,,
1-274PZ6,TBD-1-274PZ6,'TBD-1-274PZ6,,TAK-573,Renal Impairment TAK-573,Renal Impairment TAK-573,I,Planned,Multiple cancer,Oncology,,,,,,,,60,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PZF,TBD-1-274PZF,'TBD-1-274PZF,,TAK-573,Hepatic Impairment TAK-573,Hepatic Impairment TAK-573,I,Planned,Multiple cancer,Oncology,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274PZO,TAK-573-1001,'TAK-573-1001,,TAK-573,Ph1 solid tumor #1,Ph1 solid tumor #1,I,Recruiting,Multiple cancer,Oncology,Early Oncology,,,,,,,84,20,29,,9,,19,23.81%,22,4,,PRA,,Lorraine Mehltretter,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,7/15/2019,7/15/2019,8/5/2019,8/5/2019,,,,,12/19/2019,12/19/2019,,,11/8/2021,,2/1/2023,,2/1/2023,,,,,,,,,,,,3/3/2023,,,,,,,,,,3/10/2023,,,,,,,,,,,,,,3/30/2023,,,,,,,,,,8/11/2023,,,,,,,,,,,,,,,,8/11/2023,,,,,,,
1-274PZX,TBD-1-274PZX,'TBD-1-274PZX,,TAK-573,Ph2 randomized-solid tumor #2,Ph1 CART maintenance USA/EU,II,Cancelled,Multiple cancer,Oncology,Early Oncology,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,11/29/2021,,1/28/2022,,,,,,5/28/2022,,,,4/17/2024,,7/11/2025,,7/11/2025,,,,,,,,,,,,8/10/2025,,,,,,,,,,8/17/2025,,,,,,,,,,,,,,9/4/2025,,,,,,,,,,1/18/2026,,,,,,,,,,,,,,,,1/18/2026,,,,,,,
1-274Q0F,TBD-1-274Q0F,'TBD-1-274Q0F,,TAK-573,Ind. 2: Second Phase 3 Pivotal,Ind. 2: Second Phase 3,III,Planned,Multiple cancer,Oncology,,,,,,,,300,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,12/28/2023,,2/26/2024,,,,,,6/29/2024,,,,6/19/2026,,3/5/2029,,3/5/2029,,,,,,,,,,,,4/2/2029,,,,,,,,,,4/30/2029,,,,,,,,,,,,,,4/23/2029,,,,,,,,,,8/20/2029,,,,,,,,,,,,,,,,8/20/2029,,,,,,,
1-274Q0O,TBD-1-274Q0O,'TBD-1-274Q0O,,TAK-573,Ind. 3: First Phase 1b/2 Randomized,Pivotal study R/R MM China study,II,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/29/2022,,7/25/2022,,,,,,12/27/2022,,,,11/16/2024,,2/9/2026,,2/9/2026,,,,,,,,,,,,3/11/2026,,,,,,,,,,3/18/2026,,,,,,,,,,,,,,4/6/2026,,,,,,,,,,8/19/2026,,,,,,,,,,,,,,,,8/19/2026,,,,,,,
1-274Q0X,TBD-1-274Q0X,'TBD-1-274Q0X,,TAK-573,Ind. 3: Second Phase 1b/2 Randomized,Ph 1b/2 randomized non-MM heme,II,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,10/14/2022,,1/12/2023,,,,,,3/31/2023,,,,2/18/2025,,5/14/2026,,5/14/2026,,,,,,,,,,,,6/13/2026,,,,,,,,,,6/20/2026,,,,,,,,,,,,,,7/9/2026,,,,,,,,,,11/21/2026,,,,,,,,,,,,,,,,11/21/2026,,,,,,,
1-274Q1F,TBD-1-274Q1F,'TBD-1-274Q1F,,TAK-573,Ind. 3: Second Phase 3 Pivotal,Ind. 3: Second Phase 3,III,Planned,Multiple cancer,Oncology,,,,,,,,300,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,1/5/2027,,3/6/2027,,,,,,7/8/2027,,,,6/27/2029,,3/13/2032,,3/13/2032,,,,,,,,,,,,4/10/2032,,,,,,,,,,5/8/2032,,,,,,,,,,,,,,5/3/2032,,,,,,,,,,8/28/2032,,,,,,,,,,,,,,,,8/28/2032,,,,,,,
1-274Q4X,TAK-788-1006,'TAK-788-1006,,Mobocertinib (TAK-788),DDI w/ Strong CYP3A Inh. & Inducer,DDI w/ Strong CYP3A Inh. & Inducer,I,All Activities Closed,Support - Oncology,Oncology,Late Oncology,Non-Registry,,,,,,28,24,28,,,,,85.71%,1,,,Celerion,,Lam Calderon,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/28/2019,2/28/2019,4/23/2019,4/23/2019,,,,,5/21/2019,5/21/2019,,,7/5/2019,7/5/2019,8/16/2019,8/16/2019,8/16/2019,8/16/2019,,,,,,,,,,,9/25/2019,9/25/2019,,,,,,,,,10/25/2019,10/25/2019,,,,,,,,,,,,,10/25/2019,10/25/2019,,,,,,,,,4/8/2020,4/8/2020,,,,,,,,,,,,,,,4/8/2020,4/8/2020,,,,,,
1-274Q6L,TBD-1-274Q6L,'TBD-1-274Q6L,,sapanisertib,Phase 1b/2 Renal VEGF Combo 3 Arm BUY-UP,Ph 1b/2 Renal VEGF Combo,II,Cancelled,Other,Oncology,,,,,,,,190,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-274Q06,TBD-1-274Q06,'TBD-1-274Q06,,TAK-573,Ind. 2: First Phase 3 Pivotal,Ind. 2: First Phase 3,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,1/2/2023,,3/3/2023,,,,,,7/5/2023,,,,6/24/2025,,3/10/2028,,3/10/2028,,,,,,,,,,,,4/7/2028,,,,,,,,,,5/5/2028,,,,,,,,,,,,,,4/28/2028,,,,,,,,,,8/25/2028,,,,,,,,,,,,,,,,8/25/2028,,,,,,,
1-274Q16,TBD-1-274Q16,'TBD-1-274Q16,,TAK-573,Ind. 3: First Phase 3 Pivotal,Ind. 3: First Phase 3,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,1/10/2026,,3/11/2026,,,,,,7/13/2026,,,,7/2/2028,,3/19/2031,,3/19/2031,,,,,,,,,,,,4/16/2031,,,,,,,,,,5/14/2031,,,,,,,,,,,,,,5/6/2031,,,,,,,,,,9/3/2031,,,,,,,,,,,,,,,,9/3/2031,,,,,,,
1-304JYV,TBD-1-304JYV,'TBD-1-304JYV,,TAK-951,A Phase 0 pilot study in healthy subjects to assess the effects of an NK-1 receptor antagonist compared to placebo on nausea of vomiting after an apomorphine challenge.,Apo Pilot-Parexel Study #242240,0,Completed,Cyclic Vomiting Syndrome-Prodrome,GI,Early GI,,,,,,,14,14,22,,8,,,100.00%,1,,,Parexel,,Holly Oakley,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,8/27/2018,8/27/2018,10/1/2018,10/1/2018,,,10/22/2018,10/22/2018,11/12/2018,11/12/2018,,,12/6/2018,12/6/2018,,,12/6/2018,12/6/2018,,,,,,,,,,,1/31/2019,1/31/2019,,,,,,,,,2/7/2019,2/7/2019,,,,,,,,,,,,,2/28/2019,2/28/2019,,,,,,,,,5/23/2019,5/23/2019,,,,,,,,,,,,,,,9/8/2022,,,,,,,
1-359QIP,TBD-1-359QIP,'TBD-1-359QIP,,Mobocertinib (TAK-788),Ph2 Pivotal Japan EGFR exon20 RR NSCLC,Ph2 Pivotal JP EGFR exon20 RR NSCLC,II,Cancelled,Other,Oncology,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-359QJ9,TBD-1-359QJ9,'TBD-1-359QJ9,,sapanisertib,Ph2/Pivotal SqNSCLC Study,Ph2 Squamous NSCLC,II,Cancelled,(RCC) Renal cell cancer,Oncology,,,,,,,,120,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-359QOT,TAK-935-2008,'TAK-935-2008,,soticlestat (TAK-935),"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome- Takeda study",CRPS POC study (Takeda Study),II,Completed,Prevention of arteriovenous shunt (hemodialysis) failure,NS,Late NS,,,Interventional,,,,24,24,59,,35,24,9,100.00%,6,,,PRA,,Siew Tin Gan,,Dimitrios Arkilo,,2018-004750-21,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,11/20/2018,11/20/2018,1/31/2019,1/31/2019,,,7/23/2019,7/23/2019,7/31/2019,7/31/2019,,,3/16/2020,3/16/2020,,,10/21/2020,10/21/2020,,,,,,,,,,,2/16/2021,2/16/2021,,,,,,,,,,,,,,,,,,,,,,,3/12/2021,3/12/2021,,,,,,,,,8/31/2021,,,,,,,,,,,,,,,,10/19/2021,,,,,,,
1-359QPS,TAK-988-1501,'TAK-988-1501,,,"A Combined Single Rising Dose and  Multiple Rising Dose Study to Access the Safety, Tolerability, Pharmacodynamics and Pharmacodynamics  of TAK-998 in Normal Healthy Volunteers and Patients with Narcolepsy",TAK-998 SRD and MRD Study in NHVs and Narcoplesy p,I,Cancelled,Other,,,,,,,,,81,0,0,,0,,0,0.00%,16,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-374J5D,TBD-1-374J5D,'TBD-1-374J5D,,,"A  Phase 1, Randomized, Placebo-Controlled Relative Bioavailability Study Evaluating the Safety, Tolerability, Pharmacokinetics of the Phase 3 TAK-994 tablets in Healthly Adults",TBD-1-374J5D TAK-994,I,Planned,,,,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-374J5O,TBD-1-374J5O,'TBD-1-374J5O,,,"A  Phase 1, Open Label, Absorbtion,  Distribution, Metabolism, and Excretion Study of TAK-994 tablets in Healthly Adults",,I,Cancelled,Other,,,,,ADME,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-374J5X,TAK-994-1003,'TAK-994-1003,,,"A  Phase 1, Open Label, Thorough QT Study, Evaluating the Effect of TAK-994  on Cardiac Repolarization, Detected by QT/QTc prolongations in Healthly Adults",,I,Cancelled,Other,,,,,,,,,12,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-382WJR,TAK-994-1501,'TAK-994-1501,,TAK-994,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)",TAK-994 POC in NT1 and NT2 Patients,II,Recruiting,Sleep Disorders,NS,Late NS,,,,Treatment,Prospective,Cohort,188,72,177,,79,72,5,38.30%,75,72,,IQVIA,,"Nannette Eckert, Reyna Dodds, Sandra Mockoviak",,,,,,,,,Wave 1,Accelerate,Wave 1,Medidata CTMS (Pharma),,,6/14/2019,6/14/2019,11/15/2019,11/15/2019,,,2/27/2020,2/27/2020,6/26/2020,6/26/2020,,,3/31/2022,,,,6/2/2022,,,,,,,,,,,,8/3/2022,,,,,,,,,,8/18/2022,,,,,,,,,,,,,,8/31/2022,,,,,,,,,,12/2/2022,,,,,,,,,,,,,,,,6/1/2023,,,,,,,
1-382WX7,TAK-831-1008,'TAK-831-1008,,TAK-831,ADME TAK-831,ADME TAK-831,I,Reported,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Early NS,,,,,,,6,6,17,,0,0,0,100.00%,1,,,Celerion,,Katie Savage,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/29/2019,8/29/2019,10/29/2019,10/29/2019,,,2/25/2020,2/25/2020,2/26/2020,2/26/2020,,,2/27/2020,2/27/2020,,,4/1/2020,4/1/2020,,,,,,,,,,,9/14/2020,9/14/2020,,,,,,,,,9/22/2020,9/22/2020,,,,,,,,,,,,,10/12/2020,10/12/2020,,,,,,,,,3/19/2021,3/19/2021,,,,,,,,,,,,,,,3/19/2021,3/19/2021,,,,,,
1-994OP,C16011,'C16011,,Ninlaro,"A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis",Ph3 amyloid,III,Recruitment Complete,(AL) Amyloidosis,Oncology,Late Oncology,,,,,,,248,177,282,,105,177,,71.37%,74,30,,PPD,,"Erik Lakes, Helena Zhu, Sanjay Vara, Vandy Xu, Lee williams",,"Debbie Berg, Douglas Faller",,,,,,,,,,Medidata CTMS (Pharma),,,,,6/1/2012,6/1/2012,,,,,1/2/2013,1/2/2013,,,5/31/2019,5/31/2019,5/30/2020,5/30/2020,2/20/2019,2/20/2019,,,,,,,5/30/2022,,,,4/23/2019,4/23/2019,,,,,,,,,5/30/2019,5/30/2019,,,,,,,,,,,,,5/30/2019,5/30/2019,,,,,,,,,12/24/2020,12/24/2020,,,,,,,,,,,,,,,5/30/2022,,,,,,,
1-1026F0,LuAA21004_402,'LuAA21004_402,,Trintellix (vortioxetine),"A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder",Relapse Prevention Study,IV,Closed,Other,NS,,,,Other Phase IV,,,,"1,100",995,0,,712,0,0,90.45%,65,,,IQVIA,Beth Hudgins,,,,,,,,,,,,,STARS Inactive,,,8/27/2014,8/27/2014,10/27/2014,10/27/2014,,,2/10/2015,2/10/2015,2/18/2015,2/18/2015,,,4/30/2018,4/30/2018,,,4/25/2019,4/25/2019,,,,,,,,,,,6/25/2019,6/25/2019,,,,,,,,,7/15/2019,7/15/2019,,,,,,,,,,,,,7/31/2019,7/31/2019,,,,,,,,,11/25/2019,11/25/2019,,,,,,,,,,,,,,,11/25/2019,11/25/2019,,,,,,
1-1146BQ,Vonoprazan-2001,'Vonoprazan-2001,,vonoprazan,"A randomized, double-blind, proof-of-concept, phase 2 study to evaluate the efficacy and safety of once daily oral vonoprazan 20mg or vonoprazan 40mg compared to esomeprazole 40mg for the treatment of subjects With symptomatic gastro oesophageal reflux disease who have a partial response following treatment with a high dose of proton pump inhibitor",,II,Closed,00002 GERD,GI,,,,POC,,,,214,120,0,,151,0,0,56.07%,38,,,IQVIA,,,,,,2015-001154-14,,,,,,,,STARS Inactive,,,12/19/2014,12/19/2014,12/4/2015,12/4/2015,,,4/21/2016,4/21/2016,7/14/2016,7/14/2016,,,9/7/2018,9/7/2018,,,10/5/2018,10/5/2018,,,,,,,,,,,2/20/2019,2/20/2019,,,,,,,,,3/6/2019,3/6/2019,,,,,,,,,,,,,5/16/2019,5/16/2019,,,,,,,,,12/6/2019,12/6/2019,,,,,,,,,,,,,,,12/6/2019,,,,,,,
1-1274ON,SGN35-0011,'SGN35-0011,,,SGN-011 Ph 1 CHOP +SGN-35 Safety (60 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274OY,SGN35-0014,'SGN35-0014,,,SGN-014 CD30+ MTCL (ECHELON 2) (360 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274P7,TB-MA010030,'TB-MA010030,,,TB-MA010030 Phase 1 Solid Tumor (17pts) (Japan),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274PG,TB-MA010033,'TB-MA010033,,,TB-MA010033 Phase 1 Lymphoma (15 pts),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274PP,MONET1,'MONET1,,,Phase 3 MONET1 Global (n=1450) (Asian LTFU),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,149,0,,0,,1,14900.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274QI,TB-AB030103,'TB-AB030103,,,TB-AB030103 Phase 3 MONET-A (n=400) (Asia),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274QR,TB-AB290107,'TB-AB290107,,,TB-AB290107 Phase 3 JP Rollover (MONET1 & GIST) (n=3),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274R0,TB-AB010002,'TB-AB010002,,,TB-AB010002 Phase 1b/2 Pem Cis Combo (n=10/125),,I,Cancelled,Heme.Lymphoma.Hodgkins,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274R9,TB-MC010034,'TB-MC010034,,Ninlaro,TB-MC010034 Ph 1/1b RRMM (SA/I+Rd) (Japan) - 20 pts,TB-MC010034,I,Cancelled,Other,Oncology,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274RI,VISTA 5 Year,'VISTA 5 Year,,VELCADE (Bortezomib),VISTA 5 Year OS (158pts),,I,Closed,Heme.Multiple Myeloma,Marketed Products,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,8/26/2009,8/26/2009,,,,,,,,,,,3/15/2011,3/15/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/15/2011,3/15/2011,,,,,,
1-1274S4,TB-MB0100084,'TB-MB0100084,,,TB-MB0100084 Phase 1 Solid Tumor (18 pts) (Japan),,I,Cancelled,Other,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274SG,TB-AK180108,'TB-AK180108,,,TB-AK180108 Phase 1a/1b (48 pts)- Japan only,,I,Cancelled,Other,,,,,Other Phase 1,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274SY,TBD-19417,'TBD-19417,,TAK-931,Human ADME (6pts),Human ADME (6pts),I,Cancelled,Solid.Other,Oncology,,,,ADME,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274TD,TBD-19426,'TBD-19426,,TAK-931,QT Study (70pts),QT Study (70pts),I,Cancelled,Solid.Other,Oncology,,,,QTc Interval,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274UR,TBD-19427,'TBD-19427,,TAK-931,Pediatrics (100pts),Pediatrics (100pts),I,Cancelled,Solid.Other,Oncology,,,,Other Phase 1,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274V3,TBD-19428,'TBD-19428,,TAK-931,BA Study (70pts),BA Study (70pts),I,Cancelled,Solid.Other,Oncology,,,,BA,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274VD,TBD-19429,'TBD-19429,,TAK-931,Bridging Study (70pts),Bridging Study (70pts),I,Cancelled,Solid.Other,Oncology,,,,Other Phase 1,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274VM,TBD-19430,'TBD-19430,,TAK-931,Hepatic Impairment (70pts),Hepatic Impairment (70pts),I,Cancelled,Solid.Other,Oncology,,,,Hepatic Impairment,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274VW,TBD-19431,'TBD-19431,,TAK-931,Renal Impairment (70pts),Renal Impairment (70pts),I,Cancelled,Solid.Other,Oncology,,,,Renal Impairment,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274WF,TBD-1-1274WF,'TBD-1-1274WF,,TAK-117,Phase 1 JNA PK/Safety MLN1117 SA and Combo with Docetaxel (12 + 28 = 40pts),Phase 1 JNA PK/Safety MLN,I,Cancelled,Solid.Other,Oncology,,,,Other Phase 1,,,,60,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274WO,TBD-1-1274WO,'TBD-1-1274WO,,TAK-904,Phase 1 Dose Escalation/Expansion w/ Prelim Food (70 pts),Phase 1 Dose Escalation/E,I,Planned,Multiple cancer,Oncology,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274X0,TBD-1-1274X0,'TBD-1-1274X0,,TAK-117,Phase 1 PK study in Asian’s living in the US vs non-Asians (24NHV),Phase 1 PK study in Asian,I,Cancelled,Solid.Other,Oncology,,,,Other Phase 1,,,,30,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274XE,TBD-1-1274XE,'TBD-1-1274XE,,TAK-904,Phase 1 SA Safety/PK - Japan/North Asia (30 pts),Phase 1 SA Safety/PK - Ja TAK-904,I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274XQ,TBD-1-1274XQ,'TBD-1-1274XQ,,TAK-904,Phase 1b/2 Randomized (150 pts) - Indication 1,Phase 1b/2 Randomized (15 TAK-904,II,Planned,Multiple cancer,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274XZ,TBD-1-1274XZ,'TBD-1-1274XZ,,TAK-904,Phase 1b/2 Combination Single Arm (70 pts) - Indication 1,Phase 1b/2 Combination Si,II,Planned,Multiple cancer,Oncology,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274YA,TBD-1-1274YA,'TBD-1-1274YA,,TAK-904,Relative Bioavailability (20 pts),Relative Bioavailability,I,Planned,Multiple cancer,Oncology,,,,,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274YJ,TBD-1-1274YJ,'TBD-1-1274YJ,,TAK-904,Phase 1b/2 Randomized (150 pts) - Indication 2,Phase 1b/2 Randomized (15,II,Planned,Multiple cancer,Oncology,,,,,,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274YS,TBD-1-1274YS,'TBD-1-1274YS,,Ninlaro,Phase 2 Post-Marketing Commitment,Phase 2 Post-Marketing Co,II,Cancelled,Heme.Multiple Myeloma,Oncology,,,,Other Phase 2,,,,150,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274Z9,TBD-1-1274Z9,'TBD-1-1274Z9,,TAK-904,Human ADME (6 pts),Human ADME (6 pts),I,Planned,Multiple cancer,Oncology,,,,,,,,6,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274ZI,TBD-1-1274ZI,'TBD-1-1274ZI,,TAK-904,DDI #1 (30 pts),DDI #1 (30 pts),I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1274ZR,TBD-1-1274ZR,'TBD-1-1274ZR,,TAK-904,Ind. 1 – First Phase 3 Pivotal (300-400 pts) - Indication 1,Ind. 1 - First Ph 3,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1275A6,TBD-1-1275A6,'TBD-1-1275A6,,TAK-981,Phase 3 Pivotal (300-400 pts) - Indication 2,Phase 3 Pivotal (300-400 pts) - Indication 2,III,Cancelled,Heme.Other,Oncology,,,,Benchmark Phase 3,,,,400,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1275AF,TBD-1-1275AF,'TBD-1-1275AF,,TAK-981,Phase 3 Pivotal (300-400 pts) - Indication 3,Phase 3 Pivotal (300-400,III,Cancelled,Heme.Other,Oncology,,,,Benchmark Phase 3,,,,400,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669GD,TBD-1-1669GD,'TBD-1-1669GD,,TAK-648,T2DM Ph2b-Dose Ranging (US),T2DM Ph2b-Dose Ranging (US),II,Cancelled,Other,CVM,,,,,,,,360,0,0,,0,,0,0.00%,125,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669H8,TBD-1-1669H8,'TBD-1-1669H8,,,T2DM Ph 2a-POCC,T2DM Ph 2a-POCC,II,Cancelled,Other,,,,,,,,,90,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669HR,TBD-1-1669HR,'TBD-1-1669HR,,,Monotherapy,Monotherapy,III,Cancelled,Other,,,,,,,,,420,0,0,,0,,0,0.00%,150,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669I7,TBD-1-1669I7,'TBD-1-1669I7,,,Ph3 Add-on Metformin vs. DPP4-1,Ph3 Add-on Met vs. DPP4-1,III,Cancelled,Other,,,,,,,,,980,0,0,,0,,0,0.00%,200,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669IG,TBD-1-1669IG,'TBD-1-1669IG,,,Ph3 Add-on Metformin vs. SGLT-2,Ph3 Add-on Met vs. SGLT-2,III,Cancelled,Other,,,,,,,,,980,0,0,,0,,0,0.00%,200,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669IZ,TBD-1-1669IZ,'TBD-1-1669IZ,,,Ph3 Add-on thearpy to sitagliptin w or w/o metformin,Ph3 Add-on thearpy  Sitagliptin w-w/o Met,III,Cancelled,Other,,,,,,,,,390,0,0,,0,,0,0.00%,90,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669J8,TBD-1-1669J8,'TBD-1-1669J8,,,Ph3 Long-term Add-on Metformin vs SU,Ph3 Long-term Add-on Met vs SU,III,Cancelled,Other,,,,,,,,,430,0,0,,0,,0,0.00%,300,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669JH,TBD-1-1669JH,'TBD-1-1669JH,,,Ph3 CVOT,Ph3 CVOT,III,Cancelled,Other,,,,,,,,,"5,000",0,0,,0,,0,0.00%,1000,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669JQ,TBD-1-1669JQ,'TBD-1-1669JQ,,,Ph3 Add-on Therapy Metformin + SU,Ph3 Add-on Therapy Met+SU,III,Cancelled,Other,,,,,,,,,260,0,0,,0,,0,0.00%,100,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669JZ,TAK-648-1004,'TAK-648-1004,,TAK-648,Ph 1 Renal Impairment Study,Ph1 Renal Impairment,I,Cancelled,Other,CVM,,,,Renal Impairment,,,,80,0,0,,0,,0,0.00%,2,,,PPD,Deborah Keeter,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669K8,TBD-1-1669K8,'TBD-1-1669K8,,TAK-648,Ph2 DN US POM Study (Microalbuminaria),Ph2 DN US POM Micro,II,Cancelled,Other,CVM,,,,,,,,84,0,0,,0,,0,0.00%,50,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-1669KH,TBD-1-1669KH,'TBD-1-1669KH,,,Ph2/3 DN Macroalbuminuria Study,Ph2/3 DN Macro,III,Cancelled,Other,,,,,,,,,"2,300",0,0,,0,,0,0.00%,550,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2683VB,SYR-322-4001,'SYR-322-4001,,,"Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Efficacy of Alogliptin as Monotherapy or Add on Therapy in Indian Patients with Type 2 Diabetes Mellitus",Alo mono study conducted in India,IV,Cancelled,Other,,,,,,,,,300,0,0,,0,,0,0.00%,18,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-2683VO,Alogliptin-Met-4001,'Alogliptin-Met-4001,,,"A Prospective, Multicenter, Single-arm, Phase 4 Study to Evaluate the Safety and Efficacy of Alogliptin and Metformin Fixed-Dose Combination in Indian Subjects With Type 2 Diabetes Mellitus",Alo Met study conducted in India,IV,Cancelled,Other,,,,,,,,,600,0,0,,0,,0,0.00%,18,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3414MR,Brigatinib-1002,'Brigatinib-1002,,Alunbrig,"An Open-Label, Phase 1/2 Dose Escalation and Expansion Trial to Evaluate Pharmacokinetics, Safety, and Efficacy of Brigatinib as Monotherapy in Pediatric and Young Adult Patients with ALK + ALCL, inflammatory myofibroblastic tumors (IMT) or Other Solid Tumors",Ph1/2 Pediatric Safety/Expansion,I/II,Planned,Support - Oncology,Oncology,Late Oncology,,,,,,,73,,,,,,,,1,,,PPD,,Brittany Demers,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-3414N2,Brigatinib-1003,'Brigatinib-1003,,Alunbrig,"Ph2 Pediatric Combo Study in ND, High-Risk ALK+ALCL",Ph2 Pediatric Combo Study,II,Planned,Support - Oncology,Oncology,Late Oncology,,,,,,,150,,,,,,,,1,,,TBD,,Brittany Demers,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/25/2025,,8/2/2025,,,,,,3/9/2026,,,,6/12/2028,,6/13/2030,,9/2/2030,,,,,,,,,,,,11/2/2030,,,,,,,,,,11/9/2030,,,,,,,,,,,,,,12/7/2030,,,,,,,,,,2/4/2031,,,,,,,,,,,,,,,,2/4/2031,,,,,,,
1-3414NB,Brigatinib-1004,'Brigatinib-1004,,Alunbrig,Ph1 Adult HV Relative BA,HV BA Study,I,Planned,Support - Oncology,Oncology,,,,,,,,12,,,,,,,,1,,,Celerion,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/1/2021,,7/9/2021,,,,,,10/18/2021,,,,11/1/2021,,11/15/2021,,11/15/2021,,,,,,,,,,,,12/20/2021,,,,,,,,,,12/3/2021,,,,,,,,,,,,,,1/17/2022,,,,,,,,,,3/18/2022,,,,,,,,,,,,,,,,3/18/2022,,,,,,,
1-12750S,TBD-1-12750S,'TBD-1-12750S,,TAK-904,Phase 1 Definitive Food Effect (15-20 pts),Phase 1 Definitive Food E,I,Planned,Multiple cancer,Oncology,,,,,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12752Q,TBD-1-12752Q,'TBD-1-12752Q,,TAK-904,Renal Impairment (40-60 pts),Renal Impairment (40-60 pts),I,Planned,Multiple cancer,Oncology,,,,,,,,60,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12752Z,TBD-1-12752Z,'TBD-1-12752Z,,TAK-904,Hepatic Impairment (60-70 pts),Hepatic Impairment (60-70 pts),I,Planned,Multiple cancer,Oncology,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12753I,TBD-1-12753I,'TBD-1-12753I,,TAK-904,Ind. 2 – Second Phase 3 Pivotal (300-400 pts) - Indication 2,Ind. 2 - Second Ph 3,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12754G,TAK-981-1001,'TAK-981-1001,,,Phase 1 Dose Escalation/Expansion w/ Prelim Food (150 pts),Phase 1 Dose Escalation/Expansion w/ Prelim Food (,I,Cancelled,Heme.Other,,,,,SRD/FIM,,,,175,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12754S,TBD-1-12754S,'TBD-1-12754S,,TAK-981,Phase 2 Single Agent (40 pts),Phase 1b/2 Randomized (15 TAK-981),II,Planned,,Oncology,Early Oncology,,,,,,,40,,,,,,,,1,,,PPD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,4/4/2023,,,,,,8/2/2023,,,,7/27/2024,,7/22/2025,,11/24/2024,,,,,,,,,,,,1/19/2025,,,,,,,,,,,,,,,,,,,,,,,,2/16/2025,,,,,,,,,,5/11/2025,,,,,,,,,,,,,,,,7/22/2025,,,,,,,
1-12755L,TBD-1-12755L,'TBD-1-12755L,,TAK-981,Phase 1 SA Safety/PK - Japan/North Asia (10 pts),Phase 1 SA Safety/PK - Ja,I,Cancelled,Multiple cancer,Oncology,,,,,,,,10,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,6/3/2023,,,,,,10/1/2023,,,,4/28/2024,,10/25/2024,,8/26/2024,,,,,,,,,,,,10/21/2024,,,,,,,,,,11/18/2024,,,,,,,,,,,,,,,,,,,,,,,,2/10/2025,,,,,,,,,,,,,,,,2/10/2025,,,,,,,
1-12755U,TAK-981-1501,'TAK-981-1501,,TAK-981,Phase 1/2 combo w/ Rituximab (90 pts),Phase 1b/2 Randomized (15 TAK-981,I/II,Recruiting,Multiple cancer,Oncology,Early Oncology,Non-Registry,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,125,26,32,,6,,20,20.80%,50,46,,PPD,,Sarah Noah,,,,,,,,,Wave 2,Accelerate,Wave 2/Acc,Medidata CTMS (Pharma),,,,,6/4/2019,6/4/2019,,,,,10/22/2019,10/22/2019,,,12/21/2022,,6/21/2023,,7/7/2023,,,,,,,,7/7/2023,,,,9/23/2023,,,,,,,,9/23/2023,,9/30/2023,,,,,,,,,,,,,,10/7/2023,,,,,,,,10/21/2023,,12/16/2023,,,,,,,,12/16/2023,,,,,,,,12/16/2023,,,,,,,
1-12756C,TBD-1-12756C,'TBD-1-12756C,,TAK-981,Phase 1b/2 Randomized (150 pts) - Indication 2,Phase 1b/2 Randomized (150 pts) - Indication 2,II,Cancelled,Heme.Other,Oncology,,,,Benchmark Phase 2,,,,150,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12756L,TBD-1-12756L,'TBD-1-12756L,,TAK-981,Human ADME (6 pts) TAK-981,Human ADME (6 pts) TAK-981,I,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,6,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,1/29/2023,,,,,,4/29/2023,,,,4/23/2024,,1/18/2025,,1/18/2025,,,,,,,,,,,,2/17/2025,,,,,,,,,,3/14/2025,,,,,,,,,,,,,,,,,,,,,,,,6/6/2025,,,,,,,,,,,,,,,,6/6/2025,,,,,,,
1-12756U,TBD-1-12756U,'TBD-1-12756U,,TAK-981,DDI #1 (30 pts) TAK-981,DDI #1 (30 pts) TAK-981,I,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,30,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,1/29/2023,,,,,,4/29/2023,,,,4/23/2024,,10/20/2024,,10/20/2024,,,,,,,,,,,,12/15/2024,,,,,,,,,,1/12/2025,,,,,,,,,,,,,,,,,,,,,,,,4/6/2025,,,,,,,,,,,,,,,,9/11/2025,,,,,,,
1-12757D,TBD-1-12757D,'TBD-1-12757D,,TAK-981,Phase 1b/2 Randomized (150 pts) - Indication 3,Phase 1b/2 Randomized (15,II,Cancelled,Heme.Other,Oncology,,,,Benchmark Phase 2,,,,150,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12757M,TBD-1-12757M,'TBD-1-12757M,,TAK-981,Phase 3 Pivotal (300-400 pts) - Indication 1,Phase 3 Pivotal (300-400,III,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,10/24/2024,,,,,,2/21/2025,,,,2/6/2028,,12/2/2028,,1/31/2029,,,,,,,,,,,,3/28/2029,,,,,,,,,,4/25/2029,,,,,,,,,,,,,,,,,,,,,,,,7/18/2029,,,,,,,,,,,,,,,,7/18/2029,,,,,,,
1-12758F,TBD-1-12758F,'TBD-1-12758F,,TAK-981,QT Study (40 pts) TAK-981,QT Study (40 pts) TAK-981,I,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,40,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,1/14/2023,,,,,,4/14/2023,,,,7/7/2024,,4/3/2025,,4/3/2025,,,,,,,,,,,,5/3/2025,,,,,,,,,,5/29/2025,,,,,,,,,,,,,,,,,,,,,,,,8/21/2025,,,,,,,,,,,,,,,,1/28/2026,,,,,,,
1-12758O,TBD-1-12758O,'TBD-1-12758O,,TAK-981,DDI #2 (30 pts) TAK-981,DDI #2 (30 pts) TAK-981,I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,1/29/2023,,,,,,4/29/2023,,,,4/23/2024,,4/23/2024,,7/22/2024,,,,,,,,,,,,9/16/2024,,,,,,,,,,,,,,,,,,,,,,,,10/14/2024,,,,,,,,,,1/6/2025,,,,,,,,,,,,,,,,6/13/2025,,,,,,,
1-12758X,TBD-1-12758X,'TBD-1-12758X,,TAK-981,Phase 3 Pivotal (300-400 pts) - Indication 1,Phase 3 Pivotal (300-400 pts) - Indication 1,III,Cancelled,Heme.Other,Oncology,,,,Benchmark Phase 3,,,,400,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-12759F,TBD-1-12759F,'TBD-1-12759F,,TAK-981,Hepatic Impairment (60-70 pts) TAK-981,Hepatic Impairment (60-70 pts) TAK-981,I,Planned,Multiple cancer,Oncology,,,,,,,,70,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,7/16/2026,,,,,,11/13/2026,,,,11/2/2028,,10/28/2029,,10/28/2029,,,,,,,,,,,,11/27/2029,,,,,,,,,,12/24/2029,,,,,,,,,,,,,,12/24/2029,,,,,,,,,,8/5/2030,,,,,,,,,,,,,,,,8/5/2030,,,,,,,
1-12759O,TBD-1-12759O,'TBD-1-12759O,,TAK-981,Renal Impairment (40-60 pts) TAK-981,Renal Impairment (40-60 pts) TAK-981,I,Planned,Multiple cancer,Oncology,,,,,,,,60,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,7/16/2026,,,,,,11/13/2026,,,,11/2/2028,,10/28/2029,,10/28/2029,,,,,,,,,,,,11/27/2029,,,,,,,,,,12/24/2029,,,,,,,,,,,,,,12/24/2029,,,,,,,,,,8/5/2030,,,,,,,,,,,,,,,,8/5/2030,,,,,,,
1-12759X,TBD-1-12759X,'TBD-1-12759X,,TAK-981,Phase 3 Pivotal (300-400 pts) - Indication 3,Phase 3 Pivotal (300-400 TAK-981,III,Planned,Multiple cancer,Oncology,Early Oncology,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,4/10/2033,,,,,,8/12/2033,,,,8/2/2035,,4/18/2038,,4/18/2038,,,,,,,,,,,,5/16/2038,,,,,,,,,,6/10/2038,,,,,,,,,,,,,,6/10/2038,,,,,,,,,,9/30/2038,,,,,,,,,,,,,,,,9/30/2038,,,,,,,
1-29750D,C34015,'C34015,,TAK-659,"A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With NKTR-214 for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy",Ph1b/2 Heme NKTR-214 Combo,II,Withdrawn,Hunter syndrome treatment of CNS Symptoms,Oncology,,,,,,,,40,,,,,,,,12,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,8/17/2018,8/17/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/17/2018,8/17/2018,,,,,,
1-29750Q,TBD-1-29750Q,'TBD-1-29750Q,,TAK-659,Phase 2 BTK resistent combo CLL (50 pts) ( Buy up),Phase 2 BTK resistent combo CLL (50 pts) ( Buy up),II,Cancelled,Heme.Other,Oncology,,,,,,,,50,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-29750Z,TBD-1-29750Z,'TBD-1-29750Z,,TAK-659,Phase 2 Front Line combo DLBCL,Ph 2 Front Line combo DLBCL,II,Cancelled,Heme.Lymphoma.NHL,Oncology,,,,,,,,100,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-127500,TBD-1-127500,'TBD-1-127500,,TAK-904,QT Study (40 pts),QT Study (40 pts),I,Planned,Multiple cancer,Oncology,,,,,,,,40,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-127509,TBD-1-127509,'TBD-1-127509,,TAK-904,DDI #2 (30 pts),DDI #2 (30 pts),I,Planned,Multiple cancer,Oncology,,,,,,,,30,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-127539,TBD-1-127539,'TBD-1-127539,,TAK-904,Ind. 3 - First Phase 3 Pivotal (300-400 pts) - Indication 3,Ind. 3 - First Ph 3,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-127542,TBD-19308,'TBD-19308,,,"DDI w/P-gp, anti-Microbial (~40 pts) (BUY-UP)","DDI w/P-gp, anti-Microbial (~40 pts) (BUY-UP)",III,Cancelled,Solid.Other,,,,,Benchmark Phase 3,,,,400,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-127552,TBD-1-127552,'TBD-1-127552,,,Phase 1b/2 Combination Single Arm (70 pts) - Indication 1,Phase 1b/2 Combination Si,II,Cancelled,Heme.Other,,,,,Benchmark Phase 2,,,,70,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-127563,TBD-1-127563,'TBD-1-127563,,TAK-981,Phase 1b/2 Randomized (150 pts) - Indication 2,Phase 1b/2 Randomized (TAK-981),II,Planned,Multiple cancer,Oncology,,,,,,,,150,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,8/29/2028,,,,,,1/31/2029,,,,12/22/2030,,3/16/2032,,3/16/2032,,,,,,,,,,,,4/15/2032,,,,,,,,,,5/12/2032,,,,,,,,,,,,,,5/12/2032,,,,,,,,,,10/13/2032,,,,,,,,,,,,,,,,10/13/2032,,,,,,,
1-127574,TBD-1-127574,'TBD-1-127574,,TAK-981,Phase 1b/2 Randomized (150 pts) - Indication 3,Phase 1b/2 Randomized (150 pts) - Indication 3,II,Planned,Multiple cancer,Oncology,,,,,,,,150,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,8/24/2029,,,,,,1/26/2030,,,,12/17/2031,,3/11/2033,,3/11/2033,,,,,,,,,,,,4/10/2033,,,,,,,,,,5/5/2033,,,,,,,,,,,,,,5/5/2033,,,,,,,,,,10/6/2033,,,,,,,,,,,,,,,,10/6/2033,,,,,,,
1-127596,TBD-1-127596,'TBD-1-127596,,TAK-981,Phase 3 Pivotal (300-400 pts) - Indication 2,Phase 3 Pivotal (300-400 pts) - Indication 2,III,Planned,Multiple cancer,Oncology,,,,,,,,400,,,,,,,,1,,,PPD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,,,4/15/2032,,,,,,8/17/2032,,,,8/7/2034,,4/23/2037,,4/23/2037,,,,,,,,,,,,5/21/2037,,,,,,,,,,6/17/2037,,,,,,,,,,,,,,6/17/2037,,,,,,,,,,10/7/2037,,,,,,,,,,,,,,,,10/7/2037,,,,,,,
1-ACL3H,C16013,'C16013,,Ninlaro,A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients with Relapsed and/or Refractory Multiple Myeloma,Ph1 Asian PK,I,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,24,43,53,,10,,2,179.17%,8,8,,PPD,Vandy Xu,,,,,,,,,,,,,STARS Inactive,,,,,2/10/2012,2/10/2012,,,,,12/17/2012,12/17/2012,,,6/17/2014,6/17/2014,1/31/2016,1/31/2016,7/14/2014,7/14/2014,,,,,,,4/4/2017,4/4/2017,,,10/2/2014,10/2/2014,,,,,,,5/15/2017,5/15/2017,10/30/2014,10/30/2014,,,,,,,,,,,,,10/30/2014,10/30/2014,,,,,,,,,4/10/2015,4/10/2015,,,,,,,10/6/2017,10/6/2017,,,,,,,10/6/2017,,,,,,,
1-ACL6F,C21012,'C21012,,TAK-700,"A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients with Metastatic Castration Resistant Prostate Cancer",,II,Closed,Solid.GU.Prostate,Oncology,,,,,,,,40,50,81,,31,,50,125.00%,18,1,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-BLX6F,C16008PH2,'C16008PH2,,,"An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment",,I/II,Closed,Heme.Multiple Myeloma,,,,,,,,,58,49,0,,2,28,0,84.48%,20,,,IQVIA,Cathy O'Connell,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-CJRPD,INK128-001,'INK128-001,,sapanisertib,"A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Advanced Malignancies Followed by an Expansion in Subjects with Measurable Disease",Legacy INK-001,I,Closed,Solid.All Comers,Oncology,,,,,,,,170,198,273,,75,,,116.47%,16,17,,Synteract,"Heather Davidson, Mary-Anne McKenna, Tara Sadowski",,,,,,,,,,,,,STARS Inactive,,,,,11/3/2009,11/3/2009,,,,,12/22/2009,12/22/2009,,,1/30/2015,1/30/2015,10/2/2015,10/2/2015,10/2/2015,10/2/2015,,,,,,,2/7/2019,2/7/2019,,,3/4/2016,3/4/2016,,,,,,,5/9/2019,5/9/2019,8/31/2016,8/31/2016,,,,,,,5/24/2019,5/24/2019,,,,,,,,,,,,,5/24/2019,5/24/2019,9/22/2016,9/22/2016,,,,,,,,,,,,,,,5/24/2019,,,,,,,
1-CJYDO,INK128-002,'INK128-002,,sapanisertib,"A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia",,I,Closed,Heme.Lymphoma.Waldenstroms,Oncology,,,,,,,,60,39,39,,0,,4,65.00%,12,1,,Synteract,,,,,,,,,,,,,,STARS Inactive,,,,,4/7/2010,4/7/2010,,,,,11/19/2010,11/19/2010,,,10/25/2012,10/25/2012,,,5/29/2013,5/29/2013,,,,,,,12/2/2016,12/2/2016,,,6/25/2013,6/25/2013,,,,,,,,,7/22/2013,7/22/2013,,,,,,,,,,,,,,,,,,,,,,,11/15/2013,11/15/2013,,,,,,,,,,,,,,,12/2/2016,,,,,,,
1-CK4HM,INK128-003,'INK128-003,,sapanisertib,"A Phase I, Open Label, Dose Escalation Study of Oral Administration of INK128 in Combination with Paclitaxel, with/without Trastuzumab, in Subjects with Advanced Solid Malignancies",Legacy INK-003,I,Closed,Solid.All Comers,Oncology,,,,,,,,95,69,107,,38,,11,72.63%,3,4,,Sarah Cannon Research Institut,"Jonathan Young, Tara Sadowski",,,,,,,,,,,,,STARS Inactive,,,,,1/12/2011,1/12/2011,,,,,3/1/2011,3/1/2011,,,7/23/2013,7/23/2013,7/29/2016,7/29/2016,5/29/2014,5/29/2014,,,,,,,9/15/2017,9/15/2017,,,7/30/2014,7/30/2014,,,,,,,1/30/2018,1/30/2018,8/13/2014,8/13/2014,,,,,,,,,,,,,,,,,,,,,,,3/9/2015,3/9/2015,,,,,,,,,,,,,,,1/30/2018,,,,,,,
1-CK4V5,INK1117-001,'INK1117-001,,TAK-117,"A Phase I, Dose Escalation Study of INK1117 in Subjects with Advanced Solid Malignancies Followed by Expansion in Subjects with Measurable Disease",INK1117-001,I,Closed,Solid.All Comers,Oncology,,,,Dose Ranging,,,,130,125,133,,9,,9,96.15%,10,6,,Novella,Angela Gibson-White,,,,,,,,,,,,,STARS Inactive,,,,,4/20/2011,4/20/2011,,,,,10/6/2011,10/6/2011,,,11/23/2015,11/23/2015,1/11/2016,1/11/2016,,,,,,,,,,,,,3/4/2016,3/4/2016,,,,,,,,,3/10/2016,3/10/2016,,,,,,,,,,,,,,,,,,,,,,,12/7/2016,12/7/2016,,,,,,,1/23/2017,1/23/2017,,,,,,,1/23/2017,1/23/2017,,,,,,
1-CP5PJ,C16014,'C16014,,Ninlaro,"A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma",Ph3 IRD NDMM,III,Recruitment Complete,(NDMM) Newly diagnosed multiple myeloma (9Rd),Oncology,Late Oncology,,,,,,,60,748,1148,,400,748,,1246.67%,200,127,,PPD,,"Diane Charleston, Emma Rouse, Jason Chen, Jill Rodstrom, Rebecca Donovan, Sanjay Vara, Lee williams",,"Danielle Deangelis, Frank Neumann, Richard Lee",,2013-000326-54,,,,,,,,Medidata CTMS (Pharma),,,,,2/14/2013,2/14/2013,,,,,5/17/2013,5/17/2013,,,12/31/2015,12/31/2015,3/31/2018,3/31/2018,2/15/2018,2/15/2018,12/2/2019,12/2/2019,,,,,12/31/2021,,,,3/27/2018,3/27/2018,1/22/2020,1/22/2020,,,,,,,5/1/2018,5/1/2018,2/28/2020,2/28/2020,,,,,,,,,,,,,3/16/2020,3/16/2020,,,,,,,,,6/16/2020,6/16/2020,,,,,5/31/2022,,,,,,,,5/31/2022,,,,,,,
1-CRRHT,C14014,'C14014,,Alisertib,"Mass balance, Pharmacokinetics and Metabolism of 14C-Alisertib in Patient with Advanced Solid Tumors or Lymphomas",,I,Closed,Solid.Other,Oncology,,,,,,,,6,3,5,,2,,0,50.00%,2,,,In-House,,,,,,,,,,,,,,STARS Inactive,,,,,7/16/2012,7/16/2012,,,,,1/25/2013,1/25/2013,,,3/21/2013,3/21/2013,4/3/2013,4/3/2013,,,,,,,,,,,,,5/30/2013,5/30/2013,,,,,,,,,5/23/2013,5/23/2013,,,,,,,,,,,,,,,,,,,,,,,5/23/2013,5/23/2013,,,,,,,5/23/2013,5/23/2013,,,,,,,5/30/2013,5/30/2013,,,,,,
1-CRRLC,C14015,'C14015,,Alisertib,Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas,Ph 1 DDI and QTc,I,Closed,Solid.Other,Oncology,,,,,,,,55,52,0,,7,0,0,94.55%,6,,,IQVIA,Mary-Anne McKenna,,,,,,,,,,,,,STARS Inactive,,,,,8/20/2012,8/20/2012,,,,,7/2/2013,7/2/2013,,,6/2/2014,6/2/2014,8/4/2014,8/4/2014,,,,,,,,,,,,,9/30/2016,9/30/2016,,,,,,,,,11/28/2014,11/28/2014,,,,,,,,,,,,,,,,,,,,,,,12/15/2015,12/15/2015,,,,,,,9/9/2016,9/9/2016,,,,,,,9/30/2016,9/30/2016,,,,,,
1-CRRRC,C14016,'C14016,,,"An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Studies of Alisertib",,I,Closed,Solid.Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-CRRRR,C14017,'C14017,,Alisertib,An Open Label Phase 1 Two-Way Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients with Advanced Solid Tumors,Ph 1 Food Effect,I,Closed,Solid.Other,Oncology,,,,,,,,25,24,0,,0,0,0,96.00%,3,,,IQVIA,Mary-Anne McKenna,,,,,,,,,,,,,STARS Inactive,,,,,9/24/2012,9/24/2012,,,,,7/23/2013,7/23/2013,,,1/15/2014,1/15/2014,3/9/2014,3/9/2014,,,,,,,,,,,,,2/22/2017,2/22/2017,,,,,,,,,10/20/2014,10/20/2014,,,,,,,,,,,,,,,,,,,,,,,10/29/2014,10/29/2014,,,,,,,2/15/2017,2/15/2017,,,,,,,2/22/2017,2/22/2017,,,,,,
1-CWZC6,C21013,'C21013,,TAK-700,A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer,PKPD chemo naive,I/II,Closed,Solid.GU.Prostate,Oncology,,,,,,,,144,137,,,,,,95.14%,80,41,,PPD,,,,,,2012-001539-30,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-DSQUJ,C18003,'C18003,,,"A Phase 1, Open-Label Study in Healthy Older Male Volunteers to Evaluate the Pharmacokinetics and Testosterone Lowering Efficacy of 1-month Depot Injection Formulation(s) of the Investigational Metastin Analog, TAK-448",,I,Cancelled,Normal Healthy Volunteer,,,,,,,,,55,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-DT93H,C16015,'C16015,,Ninlaro,Phase 1/1b Pharmacokinetics Study of Oral MLN9708 in Patients With Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors With Normal Renal Function or Severe Renal Impairment,Ph1 renal impairment,I,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,40,40,0,,0,0,39,100.00%,10,,,ICON,Kalpana Sawant,,,,,,,,,,,,,STARS Inactive,,,,,10/23/2012,10/23/2012,,,,,9/24/2013,9/24/2013,,,2/17/2015,2/17/2015,6/20/2015,6/20/2015,3/3/2015,3/3/2015,,,,,,,11/18/2016,11/18/2016,,,4/9/2015,4/9/2015,,,,,,,1/25/2017,1/25/2017,4/23/2015,4/23/2015,,,,,,,,,,,,,,,,,,,,,2/23/2017,2/23/2017,6/29/2015,6/29/2015,,,,,,,6/15/2017,6/15/2017,,,,,,,6/15/2017,6/15/2017,,,,,,
1-EEZ99,C16017,'C16017,,Ninlaro,"An Open-Label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma",Ph2 lymphoma,II,Closed,Heme.Lymphoma.MCL,Oncology,,,,,,,,44,29,0,,0,0,26,65.91%,26,,,PPD,Kalpana Sawant,,,,,,,,,,,,,STARS Inactive,,,,,5/23/2013,5/23/2013,,,,,11/18/2013,11/18/2013,,,11/19/2015,11/19/2015,3/19/2016,3/19/2016,3/23/2017,3/23/2017,,,,,,,3/23/2017,3/23/2017,,,5/10/2017,5/10/2017,,,,,,,5/10/2017,5/10/2017,6/12/2017,6/12/2017,,,,,,,6/12/2017,6/12/2017,,,,,7/10/2017,7/10/2017,,,,,,,2/20/2018,2/20/2018,9/29/2017,9/29/2017,,,,,,,3/21/2018,3/21/2018,,,,,,,3/21/2018,,,,,,,
1-EGKBL,C15009,'C15009,,pevonedistat (TAK-924),"A Phase 1B, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients with Acute Myelogenous Leukemia Who are 60 Years or Older",Ph1b ND Elderly AML,I,Closed,Heme.Leukemia.Acute,Oncology,,,,Interventional,,,,64,64,78,,14,,63,100.00%,4,8,,PPD,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,10/11/2012,10/11/2012,,,,,4/15/2013,4/15/2013,,,11/30/2015,11/30/2015,6/30/2016,6/30/2016,6/30/2016,6/30/2016,,,,,,,5/17/2018,5/17/2018,,,9/13/2016,9/13/2016,,,,,,,7/10/2018,7/10/2018,11/14/2016,11/14/2016,,,,,,,,,,,,,,,,,,,,,8/24/2018,8/24/2018,9/6/2017,9/6/2017,,,,,,,12/17/2018,12/17/2018,,,,,,,12/17/2018,,,,,,,
1-EGKIN,C16016,'C16016,,Ninlaro,"A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients with Advanced Solid Tumors or Lymphoma",Ph1 ADME,I,Closed,Solid.All Comers,Oncology,,,,,,,,6,7,12,,5,,2,116.67%,1,1,,ICON,Cathy O'Connell,,,,,,,,,,,,,STARS Inactive,,,,,11/12/2012,11/12/2012,,,,,3/19/2014,3/19/2014,,,11/12/2014,11/12/2014,3/21/2015,3/21/2015,2/20/2015,2/20/2015,,,,,,,1/21/2016,1/21/2016,,,2/28/2015,2/28/2015,,,,,,,,,4/9/2015,4/9/2015,,,,,,,,,,,,,,,,,,,,,,,6/3/2015,6/3/2015,,,,,,,1/25/2017,1/25/2017,,,,,,,1/25/2017,1/25/2017,,,,,,
1-EGPUV,C21014,'C21014,,,"An Open-Label, Multicenter, Extension Study of Orteronel (TAK-700) in Patients with Castration-Resistant Prostate Cancer Who Were Previously Enrolled in Millennium-Sponsored Studies",,II,Cancelled,Solid.GU.Prostate,,,,,,,,,143,0,0,,0,,0,0.00%,106,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ELOS9,C15008,'C15008,,,Randomized Phase 2 Study of the Neddylation-Inhibitor MLN4924 Plus Docetaxel versus Docetaxel alone in Patients with Relapsed or Refractory Squamous Non-Small-Cell Lung Cancer Preceded by a Phase 1b Lead-in in Patients with Solid Tumors,,I/II,Cancelled,Solid.Lung.NSCLC,,,,,,,,,180,0,0,,0,,0,0.00%,55,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-EO8TL,C21015,'C21015,,,"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orteronel (TAK-700) in Patients with Nonmetastatic CastrationResistant Prostate Cancer and Rising Prostate-Specific Antigen",,III,Cancelled,Solid.GU.Prostate,,,,,,,,,"1,150",1,0,,0,0,0,0.09%,350,8,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2F6,TAK-285_101,'TAK-285_101,,,"A Multicenter, Open-Label, Noncomparative Phase 1 Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients with Advanced Cancer",,I,Closed,Solid.Other,,,,,,,,,60,56,0,,0,,55,93.33%,4,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2FJ,TAK-901_101,'TAK-901_101,,,A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies,,I,Terminated,Heme.All Comers,,,,,,,,,65,31,0,,0,,19,47.69%,4,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2FY,C17001,'C17001,,,"A Multicenter, Open-Label, Dose Escalation, Phase 1 Study of TAK-701 in Adult Patients with Advanced Nonhematologic Malignancies",,I,Closed,Solid.All Comers,,,,,,,,,42,27,0,,0,,27,64.29%,3,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2GD,C18001,'C18001,,,"A randomized, Placebo-Controlled, Double-blind, Ascending Dose Phase 1 Study of the safety and tolerability of TAK-448 administered by 14 days of continuous subcutaneous administration (Multiple Dose) to healthy male subjects",,I,Closed,Solid.GU.Prostate,,,,,,,,,32,30,0,,0,,0,93.75%,1,1,,,,,,,,2009-011667-36,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2GS,C18002,'C18002,,,"A Phase 1/2, Open-Label Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin",,I/II,Closed,Solid.GU.Prostate,,,,,,,,,9,18,9,,0,,0,200.00%,5,7,,ICON,,,,,,2009-017668-18,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2HL,C25001,'C25001,,ADCETRIS,"A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma",Phase 3  CTCL Open Label with Comparators,III,Closed,Heme.Lymphoma.T-Cell,Oncology,,,,,,,,136,132,236,,104,0,0,97.06%,52,10,,ICON,Mary McCombie,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,1/24/2012,1/24/2012,,,,,8/13/2012,8/13/2012,,,7/31/2015,7/31/2015,2/28/2016,2/28/2016,5/30/2016,5/30/2016,,,,,,,7/6/2018,7/6/2018,,,7/20/2016,7/20/2016,,,,,,,10/17/2018,10/17/2018,7/29/2016,7/29/2016,,,,,,,11/1/2018,11/1/2018,,,,,,,,,,,,,11/6/2018,11/6/2018,2/10/2017,2/10/2017,,,,,,,3/20/2019,3/20/2019,,,,,,,3/20/2019,3/20/2019,,,,,,
1-F2HY,C28001,'C28001,,TAK-580,"An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma",Ph1 Esc of solid tumors & Exp in melanoma,I,Closed,Solid.All Comers,Oncology,,,,,,,,150,122,1,,12,89,0,81.33%,17,,,IQVIA,Eric Hoberman,,,,,,,,,,,,,STARS Inactive,,,,,7/7/2011,7/7/2011,,,,,9/15/2011,9/15/2011,,,9/30/2016,9/30/2016,4/11/2017,4/11/2017,4/11/2017,4/11/2017,,,,,,,3/30/2018,,,,6/22/2017,6/22/2017,,,,,,,5/18/2018,,6/29/2017,6/29/2017,,,,,,,,,,,,,7/19/2017,7/19/2017,,,,,,,5/18/2018,,2/12/2018,,,,,,,,6/8/2018,6/8/2018,,,,,,,6/8/2018,,,,,,,
1-F2IG,C19001,'C19001,,,"An Open-Label, Dose Escalation, Phase 1 Study of TAK-901 in Adult Patients with Advanced Solid Tumors or Lymphoma",,I,Terminated,Solid.All Comers,,,,,,,,,54,20,0,,0,,3,37.04%,4,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2IW,C20001,'C20001,,,"A Multicenter, Open-Label, Dose-Escalation, Phase 1 Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies",,I,Closed,Solid.All Comers,,,,,,,,,60,51,0,,0,,9,85.00%,5,1,,Parexel,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2JB,C21006,'C21006,,,"A Phase 2 Multicenter double blind, randomized, placebo-controlled Study Evaluating the Safety and Efficacy of Orteronel (TAK-700) in Patients with Progressive Non-metastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA)",,II,Cancelled,Solid.GU.Prostate,,,,,,,,,300,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F2JQ,C26001,'C26001,,TAK-264,"An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C",,I,Closed,Solid.GI.Esophageal,,,,,,,,,60,41,54,,11,,4,68.33%,4,2,,ICON,,,,,,,,,,,,,,STARS Inactive,,,,,12/20/2011,12/20/2011,,,,,6/11/2012,6/11/2012,,,11/19/2013,11/19/2013,2/12/2014,2/12/2014,,,,,,,,,,,,,5/9/2014,5/9/2014,,,,,,,,,6/10/2014,6/10/2014,,,,,,,,,,,,,,,,,,,,,,,12/19/2014,12/19/2014,,,,,,,,,,,,,,,12/19/2014,12/19/2014,,,,,,
1-F6HHL,MA25101,'MA25101,,ADCETRIS,An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma,An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma,IV,All Activities Closed,,Oncology,,,,,,,,,22,0,,0,4,0,,,,,IQVIA,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,6/14/2012,6/14/2012,,,,,6/26/2013,6/26/2013,,,1/9/2018,1/9/2018,8/22/2018,8/22/2018,9/21/2018,9/21/2018,,,,,,,,,,,11/15/2018,11/15/2018,,,,,,,,,11/16/2018,11/16/2018,,,,,,,,,,,,,1/18/2019,1/18/2019,,,,,,,,,11/28/2019,11/28/2019,,,,,,,,,,,,,,,11/28/2019,11/28/2019,,,,,,
1-F8SR3,C20003,'C20003,,,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TAK-733 in Normal Healthy Volunteers",,I,Cancelled,Normal Healthy Volunteer,,,,,,,,,36,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-F9CI7,C25005,'C25005,,ADCETRIS,A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Receiving Brentuximab Vedotin,Phase 1 Metabolite/PK,I,Closed,Heme.Lymphoma.Hodgkins,Oncology,,,,ADME,,,,20,20,21,,1,,,100.00%,7,1,,ICON,Mary Ellen Devereaux,,,,,,,,,,,,,STARS Inactive,,,,,3/20/2013,3/20/2013,,,,,3/21/2014,3/21/2014,,,8/6/2014,8/6/2014,6/16/2015,6/16/2015,,,,,,,,,6/16/2015,6/16/2015,,,8/14/2015,8/14/2015,,,,,,,,,2/28/2015,2/28/2015,,,,,,,,,,,,,,,,,,,,,,,9/13/2015,9/13/2015,,,,,,,11/21/2017,11/21/2017,,,,,,,11/21/2017,11/21/2017,,,,,,
1-F9CII,C25006,'C25006,,ADCETRIS,"A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma",Phase 4 Open Label r/r sALCL,IV,Recruitment Complete,"Influenza, Tetanus, others",Oncology,Late Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Other,49,50,62,,12,50,,102.04%,40,,,IQVIA,,"Angela Gibson-White, Zahir Rajiwate, Calvin Gooden",,Shalini Singh,,2012-004128-39,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,11/29/2012,11/29/2012,,,,,1/30/2014,1/30/2014,,,10/10/2019,10/10/2019,5/1/2020,5/1/2020,5/4/2021,5/4/2021,,,,,,,9/20/2024,,,,6/25/2021,6/25/2021,,,,,,,11/23/2024,,7/9/2021,7/9/2021,,,,,,,11/30/2024,,,,,,8/6/2021,,,,,,,,12/20/2024,,12/10/2021,,,,,,,,5/11/2025,,,,,,,,5/11/2025,,,,,,,
1-F01P,C05008,'C05008,,VELCADE (Bortezomib),"Phase 1/2 Study of VELCADE® (Bortezomib), Dexamethasone, and Revlimid® (Lenalidomide) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) versus VELCADE, Dexamethasone, and Cyclophosphamide (VDC) in Subjects with Previously Untreated Multiple Myeloma",EVOLUTION,I/II,Closed,Heme.Multiple Myeloma,Marketed Products,,,,,,,,148,158,,,,,44,106.76%,29,,,Novella,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,8/10/2007,8/10/2007,,,8/31/2009,8/31/2009,10/7/2010,10/7/2010,,,,,,,,,,,,,,,,,,,,,,,12/7/2010,12/7/2010,,,,,,,,,,,,,,,,,,,,,,,5/24/2011,5/24/2011,,,,,,,5/24/2011,5/24/2011,,,,,,,5/24/2011,5/24/2011,,,,,,
1-F28N,C16001,'C16001,,Ninlaro,"An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies",,I,Closed,Solid.All Comers,Oncology,,,,,,,,116,116,137,,22,,35,100.00%,7,,,Dobbs Consulting,,,,,,,,,,,,,,STARS Inactive,,,,,12/15/2008,12/15/2008,,,,,3/4/2009,3/4/2009,,,1/10/2012,1/10/2012,4/20/2012,4/20/2012,4/20/2012,4/20/2012,,,,,,,,,,,5/24/2012,5/24/2012,,,,,,,,,6/5/2012,6/5/2012,,,,,,,,,,,,,,,,,,,,,,,3/27/2013,3/27/2013,,,,,,,,,,,,,,,3/27/2013,3/27/2013,,,,,,
1-F29M,C16002,'C16002,,Ninlaro,"An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma",Ph1 lymphoma,I,Closed,Heme.Lymphoma.All Comers,Oncology,,,,,,,,34,31,44,,13,,6,91.18%,6,4,,Dobbs Consulting,,,,,,,,,,,,,,STARS Inactive,,,,,2/26/2009,2/26/2009,,,,,8/20/2009,8/20/2009,,,10/1/2012,10/1/2012,10/20/2014,10/20/2014,10/20/2014,10/20/2014,,,,,,,10/20/2014,10/20/2014,,,12/20/2014,12/20/2014,,,,,,,,,7/25/2014,7/25/2014,,,,,,,,,,,,,,,,,,,,,,,12/10/2014,12/10/2014,,,,,,,4/10/2015,4/10/2015,,,,,,,4/10/2015,4/10/2015,,,,,,
1-F025,C05012,'C05012,,VELCADE (Bortezomib),"A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE® (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma",,II,Closed,Heme.Lymphoma.Follicular,Marketed Products,,,,,,,,88,55,0,,0,,46,62.50%,40,1,,Novella,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,9/4/2008,9/4/2008,,,,,3/18/2011,3/18/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/29/2011,6/29/2011,,,,,,,,,,,,,,,6/29/2011,6/29/2011,,,,,,
1-FDS2X,C23005,'C23005,,MEPACT (mifamurtide),"A Phase 1, Single- Dose Study to Characterize the Pharmacokinetics of Mifamurtide Following Intravenous Infusion of a 4 mg Dose in Healthy Adult Chinese Subjects",,I,Closed,Normal Healthy Volunteer,Oncology,,,,,,,,16,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-G14DR,C15010,'C15010,,pevonedistat (TAK-924),"A Phase 1b, Open-Label, Dose-Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel, in Patients with Solid Tumors",Ph1b solid tumors,I,Closed,Solid.All Comers,Oncology,,,,Interventional,,,,64,48,0,,16,0,0,75.00%,6,,,IQVIA,"Greg Wright, Rachel Ruggieri",,,,,,,,,,,,,STARS Inactive,,,,,3/8/2013,3/8/2013,,,,,7/1/2013,7/1/2013,,,5/4/2015,5/4/2015,2/15/2016,2/15/2016,2/15/2016,2/15/2016,,,,,,,5/21/2018,5/21/2018,,,9/12/2016,9/12/2016,,,,,,,6/26/2018,6/26/2018,9/19/2016,9/19/2016,,,,,,,,,,,,,3/13/2017,3/13/2017,,,,,,,7/18/2018,7/18/2018,8/8/2017,8/8/2017,,,,,,,10/8/2018,10/8/2018,,,,,,,10/8/2018,,,,,,,
1-GAVZE,C21016,'C21016,,,"A Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Asian Patients With Chemotherapy Naïve Metastatic Castration-Resistant Prostate Cancer",,II,Cancelled,Solid.GU.Prostate,,,,,,,,,200,0,0,,0,,0,0.00%,30,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-GG0OZ,C32001,'C32001,,sapanisertib,"A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Ka Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies",Ph1b PIKTOR,I,Closed,Solid.Breast.Breast,Oncology,,,,,,,,101,85,0,,16,2,0,84.16%,10,,,IQVIA,"Jonathan Young, Melinda Snyder, Tara Sadowski",,,,,,,,,,,,,STARS Inactive,,,,,3/7/2013,3/7/2013,,,,,7/3/2013,7/3/2013,,,9/26/2016,9/26/2016,3/24/2017,3/24/2017,3/24/2017,3/24/2017,,,,,,,6/28/2018,6/28/2018,,,4/19/2017,4/19/2017,,,,,,,6/29/2018,6/29/2018,5/10/2017,5/10/2017,,,,,,,,,,,,,,,,,,,,,,,10/6/2017,10/6/2017,,,,,,,,,,,,,,,6/29/2018,,,,,,,
1-HC2H3,C16018,'C16018,,Ninlaro,A Phase 1 Pharmacokinetic Study of Oral MLN9708 in Patients with Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction,Ph1 hepatic impairment,I,Closed,Heme.Multiple Myeloma,Oncology,,,,,,,,45,48,0,,0,0,48,106.67%,4,,,PPD,Katie Savage,,,,,,,,,,,,,STARS Inactive,,,,,4/19/2013,4/19/2013,,,,,8/27/2013,8/27/2013,,,1/22/2015,1/22/2015,3/25/2015,3/25/2015,3/25/2015,3/25/2015,,,,,,,3/25/2015,3/25/2015,,,5/19/2015,5/19/2015,,,,,,,,,6/19/2015,6/19/2015,,,,,,,,,,,,,,,,,,,,,,,7/2/2015,7/2/2015,,,,,,,11/20/2015,11/20/2015,,,,,,,11/20/2015,,,,,,,
1-HRYDH,C35001,'C35001,,TAK-264,"A Phase 1, Single-Dose, Exploratory, Open-Label, Positron Emission Tomography (PET) Imaging Study of MLN6907 in Patients with Colorectal Carcinoma",Ph1 MLN6907 CRC PET,I,Cancelled,Support - Oncology,Oncology,,,,,,,,20,2,0,,0,0,0,10.00%,2,,,PPD,,"Aminry Reyna, Stephen Curwen",,Thea Kalebic,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-HTT6P,C25007,'C25007,,ADCETRIS,A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy,Phase 4 Open Label r/r HL,IV,All Activities Closed,Maintenance of healed erosive esophagitis,Oncology,Late Oncology,,,,,,,60,61,0,,7,8,0,101.67%,21,,,IQVIA,,"Andrew Hart, Angela Gibson-White, Mary Ellen Devereaux, Zahir Rajiwate",,Shalini Singh,,2013-000232-10,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,7/11/2013,7/11/2013,,,,,3/21/2014,3/21/2014,,,3/11/2015,3/11/2015,10/11/2015,10/11/2015,3/24/2016,3/24/2016,,,,,,,3/11/2020,3/11/2020,,,5/23/2016,5/23/2016,,,,,,,4/10/2020,4/10/2020,,,,,,,,,6/5/2020,6/5/2020,,,,,,,,,,,,,6/26/2020,6/26/2020,10/25/2016,10/25/2016,,,,,,,10/5/2020,10/5/2020,,,,,,,10/5/2020,10/5/2020,,,,,,
1-HTWUL,C14018,'C14018,,Alisertib,A Randomized Double-blind Placebo-controlled Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination with Paclitaxel versus Placebo in Combination with Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),Ph 2 SCLC,II,Closed,Solid.Lung.SCLC,Oncology,,,,Benchmark Phase 2,,,,166,126,0,,59,178,0,75.90%,80,,,IQVIA,"Aminry Reyna, Stephen Curwen",,,,,,,,,,,,,STARS Inactive,,,,,9/16/2013,9/16/2013,,,,,5/12/2014,5/12/2014,,,9/30/2015,9/30/2015,1/31/2016,1/31/2016,1/31/2016,,,,,,,,,,,,4/8/2016,4/8/2016,,,,,,,,,4/21/2016,4/21/2016,,,,,,,,,,,,,,,,,,,,,,,11/28/2016,11/28/2016,,,,,,,,,,,,,,,7/31/2017,,,,,,,
1-HXXOT,C33001,'C33001,,TAK-243,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, a Novel Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients with Advanced Malignant Solid Tumors",Ph1 solid tumors,I,Cancelled,Multiple cancer,Oncology,,,,,,,,119,29,0,,0,0,18,24.37%,8,,,PPD,,Aminry Reyna,,Vivek Samnotra,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-HYLJP,C16019,'C16019,,Ninlaro,"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of MLN9708 Maintenance Therapy in Patients With Multiple Myeloma Post Autologous Stem Cell Transplant",Ph3 Post TX Maint,III,Recruitment Complete,Osteosarcoma,Oncology,Late Oncology,,,Interventional,,,,654,657,854,,197,657,,100.46%,221,154,,PPD,,"Morgan Crovetti, Sally Buelta, Sarva Tadepalli, Laurie Lobue",,"Kaveri Suryanarayan, Xiaoquan Zhang",,2013-002076-41,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,1/8/2014,1/8/2014,,,,,7/31/2014,7/31/2014,,,3/14/2016,3/14/2016,3/30/2018,3/30/2018,1/27/2020,1/27/2020,1/29/2021,1/29/2021,12/15/2021,,5/31/2022,,1/25/2025,,,,,,3/9/2021,3/9/2021,1/29/2022,,6/30/2022,,3/30/2025,,,,4/9/2021,4/9/2021,3/30/2022,,7/30/2022,,4/24/2025,,,,,,,,3/23/2021,3/23/2021,4/29/2022,,8/29/2022,,4/24/2025,,,,,,5/29/2022,,9/28/2022,,7/30/2025,,,,,,,,7/30/2025,,,,,,,
1-IDSVB,C34001,'C34001,,TAK-659,"An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies",TAK-659 Ph 1 FIH,I,Recruitment Complete,Multiple cancer,Oncology,Early Oncology,,,,,,,182,144,1,,51,0,0,79.12%,16,,,IQVIA,,"Vijay Maharaj, Sarah Noah, Michelle Thompson",,"Igor Proscurshim, Kate Stumpo, Yaping Shou",,,,,,,,,,Medidata CTMS (Pharma),,,,,9/10/2013,9/10/2013,,,,,12/12/2013,12/12/2013,,,4/9/2018,4/9/2018,7/13/2018,7/13/2018,7/13/2018,7/13/2018,,,,,,,,,,,2/26/2019,2/26/2019,,,,,,,,,3/4/2019,3/4/2019,,,,,,,,,,,,,4/5/2019,4/5/2019,,,,,,,,,9/4/2019,9/4/2019,,,,,,,,,,,,,,,9/4/2019,9/4/2019,,,,,,
1-INX3G,C16020,'C16020,,Ninlaro,"An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone In Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment",Ph 2 ICD,II,Closed,Heme.Multiple Myeloma,Oncology,,,,Interventional,,,,148,148,0,,0,0,0,100.00%,26,,,PPD,Rebecca Liguori,,,,,,,,,,,,,STARS Inactive,,,,,7/23/2013,7/23/2013,,,,,3/12/2014,3/12/2014,,,5/20/2015,5/20/2015,12/8/2016,12/8/2016,6/29/2016,6/29/2016,,,,,,,6/29/2018,6/29/2018,,,8/24/2016,8/24/2016,,,,,,,7/30/2018,7/30/2018,11/11/2016,11/11/2016,,,,,,,,,,,,,10/12/2016,10/12/2016,,,,,,,9/7/2018,9/7/2018,12/14/2017,12/14/2017,,,,,,,11/26/2018,11/26/2018,,,,,,,11/26/2018,,,,,,,
1-JLM1X,C31001,'C31001,,sapanisertib,A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant,Ph1b/2 breast ex or fulv,I/II,Closed,Solid.Breast.Breast,Oncology,,,,Interventional,,,,118,86,0,,39,3,0,72.88%,40,,,IQVIA,"Jonathan Young, Tara Sadowski",,,,,,,,,,,,,STARS Inactive,,,6/27/2013,6/27/2013,9/9/2013,9/9/2013,,,,,2/18/2014,2/18/2014,,,1/5/2018,1/5/2018,7/3/2018,7/3/2018,7/3/2018,7/3/2018,,,,,,,,,,,9/7/2018,9/7/2018,,,,,,,,,10/31/2018,10/31/2018,,,,,,,,,,,,,10/31/2018,10/31/2018,,,,,,,,,3/8/2019,3/8/2019,,,,,,,,,,,,,,,3/8/2019,,,,,,,
1-K5QL9,C13005,'C13005,,,"A Phase 1, Single Dose, Open-Label Study to Determine the Pharmacokinetics, Safety, and Tolerability of MLN0002 in Healthy Subjects at the Extremes of Body Weight",,I,Closed,Normal Healthy Volunteer,,,,,,,,,24,26,81,,0,,4,108.33%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K5TQ7,L299-016,'L299-016,,,Crohn’s disease (CD),,I,Closed,Other,,,,,,,,,180,185,237,,0,,27,102.78%,25,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K5TT0,M200-021,'M200-021,,,M200-021,,I,Closed,Other,,,,,,,,,30,30,38,,0,,0,100.00%,30,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K5TVO,M200-022,'M200-022,,,M200-022,,I,Closed,Other,,,,,,,,,180,181,249,,0,,27,100.56%,21,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K6A6X,C13002,'C13002,,,"A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN0002 Following Multiple Intravenous Doses in Patients with Ulcerative Colitis",,II,Closed,Other,,,,,,,,,45,47,56,,0,,1,104.44%,17,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K6AV8,C05002 (BAC) (PEAK),'C05002 (BAC) (PEAK),,,"A Multicenter, Open-label, Phase 2 Study of VELCADE (bortezomib) for Injection in Previously Treated Patients with Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveolar Features",,IIB,Closed,Other,,,,,,,,,150,69,71,,0,,69,46.00%,50,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8G4B,C12001,'C12001,,,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single Ascending Oral Doses of MLN0415-046 Administered to Healthy Subjects to Assess Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Outcomes with a Preliminary Assessment of Food Effect",,I,Closed,Other,,,,,,,,,72,64,201,,0,,0,88.89%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8G6C,C12002,'C12002,,,"A Phase 1, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study of MLN0415-046 in Healthy Adult Male and Female Subjects",,I,Closed,Other,,,,,,,,,80,50,250,,0,,0,62.50%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8G89,C06002,'C06002,,,"Single Dose of MLN1202 Administered to Healthy Volunteers via Subcutaneous Injection – Pharmacokinetics, Pharmacodynamics, Safety and Tolerability",,I,Terminated,Other,,,,,,,,,24,24,30,,0,,0,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GA4,C06004,'C06004,,,"A Double-blind, Randomized, Placebo-controlled Trial Measuring the Effects of MLN1202 on C-Reactive Protein Levels in Patients with Risk Factors for Cardiovascular Disease",,IIA,Closed,Other,,,,,,,,,110,108,243,,0,,5,98.18%,9,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GC3,M120202-046,'M120202-046,,,M120202-046,,I,Closed,Other,,,,,,,,,48,48,70,,0,,2,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GDT,M120203-055,'M120203-055,,,"A Phase 2a Multiple Ascending Dose, Randomized, Placebo-Controlled, Double-blind Study of MLN1202 Administered to Patients with Rheumatoid Arthritis to Determine Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Outcomes",,IIA,Closed,Other,,,,,,,,,42,32,37,,0,,0,76.19%,5,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GFI,M120204-063,'M120204-063,,,A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients with Multiple Sclerosis,,IIA,Closed,Other,,,,,,,,,40,0,0,,0,,5,0.00%,24,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GHR,C11001,'C11001,,,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Single Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3701, A Novel CCR1 Antagonist, in Healthy Male Subjects",,I,Closed,Other,,,,,,,,,60,60,100,,0,,2,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GJF,C11002,'C11002,,,"A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3701 in Healthy Subjects",,I,Closed,Other,,,,,,,,,80,80,195,,0,,1,100.00%,24,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GLB,C08001,'C08001,,,A Phase 1 Open-Label Mass Balance Study to Evaluate the Metabolism and Excretion of [14C]-MLN3897 in Healthy Male Subjects,,I,Closed,Other,,,,,,,,,12,12,21,,0,,0,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GN0,C08003,'C08003,,,A Phase 1 Study to Investigate The Effect Of Ketoconazole On MLN3897 Pharmacokinetics In Healthy Subjects,,I,Closed,Other,,,,,,,,,24,24,61,,0,,2,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GOP,C08004,'C08004,,,"A Phase 1, Open-Label, Relative Bioavailability, Randomized Study to Evaluate Single Doses of MLN3897 Polymorphs A and B in Healthy Male Subjects",,I,Closed,Other,,,,,,,,,24,24,47,,0,,1,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GQG,C08005,'C08005,,,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate",,IIA,Closed,Other,,,,,,,,,186,191,266,,0,,23,102.69%,36,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GSC,C08006,'C08006,,,A Phase 1 Study to Investigate the Effect of MLN3897 on CYP3A Activity and the Effect of a Moderate CYP3A Inhibitor on the Pharmacokinetics of MLN3897 in Healthy Subjects,,I,Closed,Other,,,,,,,,,20,20,87,,0,,3,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K8GU2,M389703-057,'M389703-057,,,M389703-057,,I,Closed,Other,,,,,,,,,88,72,271,,0,,0,81.82%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K9O5N,M34101-035,'M34101-035,,,"An Open Label, Dose Escalation Study to Evaluate the Safety and Tolerability of PS-341 and Docetaxel Administered in Combination to Patients with Advanced and/or Metastatic Breast Cancer Previously Treated with an Anthracycline-Containing Regimen",,I,Closed,Solid.Breast.Breast,,,,,,,,,50,49,57,,0,,40,98.00%,6,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K9O37,M389704-064,'M389704-064,,,M389704-064 MAD,,I,Closed,Other,,,,,,,,,80,60,141,,0,,1,75.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K27LB,MLN9708 Program Tracker,'MLN9708 Program Tracker,,,MLN9708 Program Tracker,,Program,Enrolling,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,1,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K71B7,C05004  (EVEREST),'C05004  (EVEREST),,,"A Phase IV, Open Label, Trial Using VELCADE for Re-Treatment of Multiple Myeloma Patients Following an Initial Response to VELCADE",,IV,Closed,Heme.Multiple Myeloma,,,,,,,,,78,33,0,,0,,1,42.31%,60,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K873D,C05005  (POINT I),'C05005  (POINT I),,,"A Randomized, Non-comparative, Multicenter, Open-Label, Phase 2 Study of Tarceva™ (erlotinib) Alone and of Tarceva plus VELCADE* (bortezomib) for Injection in Patients with Relapsed or Refractory, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",,IIB,Closed,Solid.Lung.NSCLC,,,,,,,,,100,57,110,,0,,4,57.00%,30,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K876D,M34101-033,'M34101-033,,,M34101-033,,I,Closed,Solid.GU.Prostate,,,,,,,,,90,83,0,,0,,57,92.22%,4,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-K0787,C13001,'C13001,,,"A Phase 1, Single Ascending Dose, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN0002 in Healthy Subjects",,I,Closed,Other,,,,,,,,,50,49,352,,0,,0,98.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAO4D,M34101-039,'M34101-039,,,M34101-039,,III,Closed,Heme.Multiple Myeloma,,,,,,,,,612,669,694,,0,,549,109.31%,106,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAPVW,M34101-040,'M34101-040,,,"An International, Non-Comparative, Open-Label Study of PS-341 Administered to Patients With Multiple Myeloma who Received High-dose Dexamethasone in Millennium Protocol M34101-039 or Experienced Progressive Disease after Receiving at Least Four Previous Therapies",,III,Closed,Heme.Multiple Myeloma,,,,,,,,,600,451,482,,0,,388,75.17%,98,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAPWB,M34102-048,'M34102-048,,,"A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE plus Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer",,IIA,Closed,Solid.Lung.NSCLC,,,,,,,,,155,158,188,,0,,158,101.94%,20,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAPYU,M34102-049,'M34102-049,,,"A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE plus Irinotecan in Patients with Relapsed or Refractory Colorectal Carcinoma",,IIB,Closed,Other,,,,,,,,,175,107,125,,0,,22,61.14%,22,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAQ0T,M34103-053  (PINNACLE),'M34103-053  (PINNACLE),,,A Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma,,IIA,Closed,Heme.Lymphoma.MCL,,,,,,,,,152,155,161,,0,,54,101.97%,48,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAQ1U,M34103-058,'M34103-058,,,Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma,,I,Closed,Heme.Multiple Myeloma,,,,,,,,,40,42,44,,0,,42,105.00%,7,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAQ44,M34103-059,'M34103-059,,,Effect of Ketoconazole Administration on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Advanced Solid Tumors,,I,Closed,Solid.Other,,,,,,,,,24,21,29,,0,,17,87.50%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAQIK,M34103-061,'M34103-061,,,A Phase 2 Study of VELCADE with Rituximab in Subjects with Relapsed or Refractory Indolent B-cell Lymphoma,,IIA,Closed,Heme.Lymphoma.NHL,,,,,,,,,66,81,87,,0,,21,122.73%,15,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAVED,X05176 [IFM2005-01],'X05176 [IFM2005-01],,,"Open-label, multi-centre, randomised Phase III study to compare the combination of Velcade® and dexamethasone with VAD-type chemotherapy in the treatment of patients up to the age of 65 with newly diagnosed multiple myeloma",,III,Closed,Heme.Multiple Myeloma,,,,,,,,,480,482,470,,0,,32,100.42%,147,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAZ83,C03001,'C03001,,,A Phase 1 Study of MLN518 Given in Combination with Standard Induction Chemotherapy for the Treatment of Patients with Newly Diagnosed Acute Myelogenous Leukemia,,I,Closed,Other,,,,,,,,,40,30,35,,0,,28,75.00%,5,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAZAN,MLN0518,'MLN0518,,,"""A Phase 2 Trial of Tandutinib In Combination With Bevacizumab For Patients With Recurrent High-Grade Gliomas 

(Howard Fine- Investigator sponsored study)""",,I/II,Closed,Other,,,,,,,,,80,42,48,,0,,27,52.50%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAZER,98-34,'98-34,,,98-34,,I,Closed,Heme.Other,,,,,,,,,20,49,51,,0,,0,245.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAZI2,M34100-024,'M34100-024,,,M34100-024,,II,Closed,Heme.Multiple Myeloma,,,,,,,,,64,54,58,,0,,19,84.38%,10,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KAZL1,M34100-025,'M34100-025,,,M34100-025,,II,Closed,Heme.Multiple Myeloma,,,,,,,,,202,202,213,,0,,126,100.00%,14,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBD8J,M34102-052,'M34102-052,,,M34102-052,,II,Closed,Heme.Multiple Myeloma,,,,,,,,,"1,000",2,2,,0,,0,0.20%,300,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBDB4,98-194,'98-194,,,98-194,,I,Closed,Other,,,,,,,,,54,54,0,,0,,0,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBNEA,98-104,'98-104,,,98-104,,I,Closed,Other,,,,,,,,,43,49,51,,0,,0,113.95%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBNHG,M34100-026,'M34100-026,,,M34100-026,,0,Closed,Heme.Lymphoma.CLL,,,,,,,,,22,22,25,,0,,22,100.00%,6,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBOX6,M34100-027,'M34100-027,,,M34100-027,,0,Closed,Solid.Other,,,,,,,,,54,31,38,,0,,0,57.41%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBP75,M34101-028,'M34101-028,,,M34101-028,,0,Closed,Solid.Other,,,,,,,,,62,51,60,,0,,0,82.26%,4,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBPBC,M34101-034,'M34101-034,,,M34101-034,,0,Closed,Solid.Lung.NSCLC,,,,,,,,,46,36,40,,0,,31,78.26%,4,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KBRPD,C24001,'C24001,,,A Method Study of the Measurement of Gli1 RNA Expression in Skin as Assessed in Healthy Subjects,,I,Closed,Other,,,,,,,,,20,20,0,,0,,0,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KC9WS,M34101-029,'M34101-029,,,M34101-029,,0,Closed,Other,,,,,,,,,106,72,74,,0,,0,67.92%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KCG6M,M59102-042,'M59102-042,,,M59102-042,,I,Closed,Other,,,,,,,,,29,23,26,,0,,4,79.31%,2,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KCG8K,M59102-051,'M59102-051,,,"
A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 conjugated monoclonal antibody MLN591) in Subjects with Metastatic Androgen-Independent Prostate Cancer",,I,Closed,Other,,,,,,,,,73,62,68,,0,,16,84.93%,4,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KCGB7,C10001,'C10001,,,"An Open Label, Dose Escalation Phase 1 Study of MLN8054, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors",,I,Closed,Other,,,,,,,,,60,63,66,,0,,5,105.00%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KCL0K,C10002,'C10002,,,A Phase 1 Trial of Extended MLN8054 Dosing in Patients with Advanced Malignancies,,I,Closed,Other,,,,,,,,,60,44,48,,0,,1,73.33%,2,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KCL4K,TAK-683_102,'TAK-683_102,,,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 1, Continuous Subcutaneous Administration (Multiple Dose), Dose-Escalation Study of the Safety and Tolerability of TAK-683 in Healthy Male Subjects",,I,Closed,Other,,,,,,,,,36,24,0,,0,,0,66.67%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KCL38,TAK-683_101,'TAK-683_101,,,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 1, Subcutaneous Administration Single Dose, Dose-Escalation Study of the Safety and Tolerability of TAK-683 in Healthy Male Subjects",,I,Closed,Other,,,,,,,,,60,60,0,,0,,0,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KCLEY,tAK-041,'tAK-041,,,01-042,,I,Cancelled,Other,,,,,,,,,"5,640",149,0,,0,,1,2.64%,245,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-KG2OT,SGN-35 Program Tracker,'SGN-35 Program Tracker,,,Program Tracker,,Program,Closed,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,1,,ICON,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-L6PF9,C27002,'C27002,,relugolix,"A Phase 2 Randomized Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of the oral GnRH Antagonist TAK-385, together with a Leuprorelin Observational Cohort,  in Patients with Prostate Cancer",Ph2 Adv PC,II,Closed,Solid.GU.Prostate,Oncology,,,,,,,,125,48,0,,27,138,0,38.40%,25,,,IQVIA,Eric Hoberman,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,12/3/2013,12/3/2013,,,,,4/17/2014,4/17/2014,,,2/19/2015,2/19/2015,8/21/2016,8/21/2016,3/31/2016,3/31/2016,,,,,,,3/7/2017,3/7/2017,,,6/14/2016,6/14/2016,,,,,,,5/24/2017,5/24/2017,7/30/2016,7/30/2016,,,,,,,6/16/2017,6/16/2017,,,,,,,,,,,,,9/20/2017,9/20/2017,6/1/2017,6/1/2017,,,,,,,3/29/2018,3/29/2018,,,,,,,3/29/2018,,,,,,,
1-L7IAF,C31002,'C31002,,sapanisertib,A Phase 1 Study to Evaluate the Effect of MLN0128 on the Qtc Interval in Patients with Advanced Solid Tumors,Ph 1 QTc Trial,I,Closed,Solid.All Comers,Oncology,,,,,,,,30,32,0,,22,30,0,106.67%,6,,,IQVIA,"Jonathan Young, Tara Sadowski",,,,,,,,,,,,,STARS Inactive,,,,,6/19/2014,6/19/2014,,,,,9/15/2014,9/15/2014,,,8/12/2015,8/12/2015,1/31/2016,1/31/2016,,,,,,,,,2/28/2019,2/28/2019,,,6/10/2016,6/10/2016,,,,,,,3/25/2019,3/25/2019,12/21/2015,12/21/2015,,,,,,,4/30/2019,4/30/2019,,,,,,,,,,,,,4/30/2019,4/30/2019,12/19/2016,12/19/2016,,,,,,,,,,,,,,,4/30/2019,,,,,,,
1-LSEIL,C27003,'C27003,,relugolix,"Phase 2, Randomized, Open-label, Parallel Group Study of the Safety and Efficacy for Medical Castration of the Oral GnRH antagonist, TAK-385, in Patients with Moderate Risk Localized Prostate Cancer Who Require NeoAdjuvant / Adjuvant Therapy to xRT (EBMT or IMRT)",Ph2 Adj/Neo,II,Closed,Solid.GU.Prostate,Oncology,,,,,,,,100,80,0,,17,108,0,80.00%,28,,,IQVIA,Eric Hoberman,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,1/17/2014,1/17/2014,,,,,6/10/2014,6/10/2014,,,3/30/2015,3/30/2015,12/13/2015,12/13/2015,12/14/2015,12/14/2015,,,,,,,,,,,3/28/2016,3/28/2016,,,,,,,,,6/6/2016,6/6/2016,,,,,,,,,,,,,,,,,,,,,,,11/30/2016,11/30/2016,,,,,,,,,,,,,,,11/30/2016,11/30/2016,,,,,,
1-LT0LP,C27004,'C27004,,relugolix,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, and Parallel Cohort Study to Evaluate the Safety, Pharmacokinetics, and Electrophysiological Effects on QT Intervals of single doses of TAK-385 in Healthy Male Subjects",,I,Cancelled,Solid.GU.Prostate,Oncology,,,,,,,,48,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-LWMZ,C24002,'C24002,,,"A Multicenter, Open-Label, Dose-Escalation, Phase 1 Study of TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies",,I,Closed,Other,,,,,,,,,34,32,36,,6,,11,94.12%,5,1,,ICON,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-LWNA,TAK-593_101,'TAK-593_101,,,A Multicenter Phase 1 Clinical and Pharmacokinetic Study of Oral TAK-593 in Subjects With Nonhematologic Advanced Cancer,,I,Closed,Other,,,,,,,,,10,10,0,,0,,7,100.00%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-LWNL,TAK-700_201,'TAK-700_201,,TAK-700,"A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects",,I/II,Closed,Solid.GU.Prostate,Oncology,,,,,,,,123,118,126,,11,,54,95.93%,13,1,,ICON,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-MBI1J,MLN8237 Program Tracker,'MLN8237 Program Tracker,,,MLN8237 Program Tracker,,Program,Closed,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,1,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-MGEGX,C15011,'C15011,,pevonedistat (TAK-924),"A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",Ph1 DDI inhibitor solid tumors,I,Closed,Solid.All Comers,Oncology,,,,,,,,52,51,0,,0,0,11,98.08%,4,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,2/3/2014,2/3/2014,,,,,5/13/2014,5/13/2014,,,7/18/2016,7/18/2016,1/18/2017,1/18/2017,6/5/2017,6/5/2017,,,,,,,,,,,8/28/2017,8/28/2017,,,,,,,,,1/18/2018,1/18/2018,,,,,,,,,,,,,1/18/2018,1/18/2018,,,,,,,,,5/8/2018,5/8/2018,,,,,,,,,,,,,,,5/8/2018,,,,,,,
1-N61SX,C27005,'C27005,,relugolix,"A Phase 1, Open-label, Drug-drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Fluconazole or Atorvastatin on the Pharmacokinetics of a Single Oral Dose of TAK-385 in Healthy Subjects",,I,Closed,Solid.GU.Prostate,Oncology,,,,,,,,40,40,90,,50,,1,100.00%,1,2,,In-House,,,,,,,,,,,,,,STARS Inactive,,,,,1/6/2014,1/6/2014,,,,,3/29/2014,3/29/2014,,,3/29/2014,3/29/2014,4/19/2014,4/19/2014,4/19/2014,4/19/2014,,,,,,,,,,,5/27/2014,5/27/2014,,,,,,,,,6/13/2014,6/13/2014,,,,,,,,,,,,,,,,,,,,,,,12/16/2014,12/16/2014,,,,,,,,,,,,,,,12/16/2014,12/16/2014,,,,,,
1-O0YDZ,C25004,'C25004,,ADCETRIS,"An open-label study of brentuximab vedotin + Adriamycin®, vinblastine, and dacarbazine in paediatric patients with advanced stage newly diagnosed Hodgkin lymphoma",Phase 1/2 Pediatric FL HL,I/II,Recruitment Complete,Metastatic melanoma with B-raf and N-ras mutations,Oncology,Late Oncology,,Pediatric only (<18 yr),Interventional,Treatment,Prospective,,67,59,63,,4,,59,88.06%,28,,,IQVIA,,"Deborah Bruce, Deborah Scarcella",,"E. Jane Leonard, Frank Campana, Vicky Xiang Bai",,2015-004112-38,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,,,8/12/2016,8/12/2016,,,,,9/11/2017,9/11/2017,,,9/25/2019,9/25/2019,4/15/2020,4/15/2020,12/18/2020,12/18/2020,,,,,,,9/12/2029,,,,1/28/2021,1/28/2021,,,,,,,11/8/2029,,2/2/2021,2/2/2021,,,,,,,11/13/2029,,,,,,3/10/2021,3/10/2021,,,,,,,12/19/2029,,6/14/2021,6/14/2021,,,,,,,3/12/2030,,,,,,,,3/12/2030,,,,,,,
1-O1BUN,C16021,'C16021,,Ninlaro,"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation",Ph3 TX ineligible Maint,III,Recruitment Complete,other,Oncology,Late Oncology,,,Interventional,,,,706,727,1000,,284,716,,102.97%,229,166,,PPD,,"Calvin Gooden, Gina Gualtiere",,"Alexander Vorog, Richard Labotka",,2014-001394-13,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,9/15/2014,9/15/2014,,,,,4/23/2015,4/23/2015,,,10/8/2018,10/8/2018,10/8/2020,,8/12/2019,8/12/2019,10/15/2020,10/15/2020,9/30/2022,,,,2/8/2024,,,,9/18/2019,9/18/2019,11/25/2020,11/25/2020,10/30/2022,,,,4/4/2024,,11/1/2019,11/1/2019,1/8/2021,1/8/2021,11/29/2022,,,,,,,,,,11/22/2019,11/22/2019,,,12/29/2022,,,,5/2/2024,,2/13/2020,2/13/2020,,,1/28/2023,,,,7/25/2024,,,,,,,,7/25/2024,,,,,,,
1-OH0VT,C26002,'C26002,,TAK-264,A phase 2 trial of MLN0264 in previously treated patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C (GCC),Ph2 MLN0264 GI,II,Terminated,First Line Cytomegalovirus,Oncology,,,,,,,,38,14,0,,21,7,0,36.84%,35,,,IQVIA,,"Aminry Reyna, Sarah Jane Constantine",,Thea Kalebic,,,,,,,,,,Medidata CTMS (Pharma),,,,,2/27/2014,2/27/2014,,,,,8/5/2014,8/5/2014,,,6/2/2015,6/2/2015,10/23/2015,10/23/2015,10/23/2015,10/23/2015,,,,,,,,,,,3/28/2016,3/28/2016,,,,,,,,,4/13/2016,4/13/2016,,,,,,,,,,,,,,,,,,,,,,,8/3/2016,8/3/2016,,,,,,,,,,,,,,,8/3/2016,8/3/2016,,,,,,
1-OH0W6,C26003,'C26003,,TAK-264,A phase 2 trial of MLN0264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC),Ph2 MLN0264 Pancreatic,II,Terminated,Pancreas cancer,Oncology,,,,,,,,43,18,1,,48,0,0,41.86%,35,,,IQVIA,,Aminry Reyna,,Thea Kalebic,,,,,,,,,,Medidata CTMS (Pharma),,,,,2/27/2014,2/27/2014,,,,,10/14/2014,10/14/2014,,,6/30/2015,6/30/2015,11/13/2015,11/13/2015,11/13/2015,11/13/2015,,,,,,,,,,,4/27/2016,4/27/2016,,,,,,,,,5/12/2016,5/12/2016,,,,,,,,,,,,,,,,,,,,,,,8/25/2016,8/25/2016,,,,,,,,,,,,,,,8/25/2016,8/25/2016,,,,,,
1-OMAA5,C16010CCS,'C16010CCS,,Ninlaro,"A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma",Ph3 IRD RRMM (China),III,Recruitment Complete,(MM) Multiple myeloma relapsed/refractory,Oncology,Late Oncology,,,,,,,115,115,146,,31,,7,100.00%,11,,,PPD,,"Vandy Xu, Fuquan, Kenneth Chen",,Hui Wang,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,11/27/2013,11/27/2013,,,,,5/6/2014,5/6/2014,,,5/4/2015,5/4/2015,11/21/2016,11/21/2016,7/12/2015,7/12/2015,,,,,,,9/15/2021,,,,8/19/2015,8/19/2015,,,,,,,,,9/30/2015,9/30/2015,,,,,,,,,,,,,1/8/2016,1/8/2016,,,,,,,,,4/8/2016,4/8/2016,,,,,,,,,,,,,,,9/15/2021,,,,,,,
1-OYT2H,C14020,'C14020,,Alisertib,"A Phase 1 Study to Evaluate the Effect of Itraconazole, A Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients with Advanced Solid Tumors or Relapsed/Refractory Lymphoma",Ph 1 DDI CYP3A inhibitor,I,Closed,Solid and Heme.Multi-Disease,Oncology,,,,,,,,24,17,1,,0,0,0,70.83%,4,,,IQVIA,Robyn Horrigan,,,,,,,,,,,,,STARS Inactive,,,,,6/4/2014,6/4/2014,,,,,11/7/2014,11/7/2014,,,3/9/2015,3/9/2015,3/25/2015,3/25/2015,,,,,,,,,,,,,8/7/2015,8/7/2015,,,,,,,,,9/30/2015,9/30/2015,,,,,,,,,,,,,,,,,,,,,,,3/4/2016,3/4/2016,,,,,,,10/21/2016,10/21/2016,,,,,,,12/17/2016,,,,,,,
1-P2K8B,C26004,'C26004,,TAK-264,A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC),Asian Phase 1/2 Dose Finding,I/II,Terminated,First Line Cytomegalovirus,Oncology,,,,,,,,95,12,12,,,,12,12.63%,21,,,IQVIA,,Yung Wa Cheng,,Hui Wang,,,,,,,,,,Medidata CTMS (Pharma),,,,,5/15/2014,5/15/2014,,,,,1/19/2015,1/19/2015,,,6/11/2015,6/11/2015,10/8/2015,10/8/2015,10/8/2015,10/8/2015,,,,,,,,,,,1/12/2016,1/12/2016,,,,,,,,,3/23/2016,3/23/2016,,,,,,,,,,,,,,,,,,,,,,,5/5/2016,5/5/2016,,,,,,,,,,,,,,,5/5/2016,5/5/2016,,,,,,
1-P37UL,C28002,'C28002,,TAK-580,"A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies",C28002 Phase 1b combo - NSCLC/CRC (81pts),IB,Closed,Solid.All Comers,Oncology,,,,,,,,81,78,0,,8,26,0,96.30%,16,,,IQVIA,Eric Hoberman,,,,,,,,,,,,,STARS Inactive,,,,,10/7/2014,10/7/2014,,,,,2/2/2015,2/2/2015,,,5/31/2017,5/31/2017,7/2/2018,,7/2/2018,,,,,,,,,,,,9/10/2018,9/10/2018,,,,,,,,,10/5/2018,10/5/2018,,,,,,,,,,,,,10/5/2018,10/5/2018,,,,,,,,,4/25/2019,4/25/2019,,,,,,,,,,,,,,,4/25/2019,,,,,,,
1-P73H9,C34002,'C34002,,TAK-659,"An Open Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK 659  in Adult Patients with Relapsed or Refractory AML",TAK-659 Ph1b/2 AML,I/II,Closed,Heme.Leukemia.Acute,Oncology,,,,Other Phase 1,,,,106,39,1,,19,12,0,36.79%,15,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,9/24/2014,9/24/2014,,,,,4/2/2015,4/2/2015,,,3/29/2018,3/29/2018,9/27/2018,9/27/2018,9/27/2018,9/27/2018,,,,,,,,,,,4/23/2019,4/23/2019,,,,,,,7/30/2019,7/30/2019,4/30/2019,4/30/2019,,,,,,,,,,,,,7/2/2019,7/2/2019,,,,,,,,,12/6/2019,12/6/2019,,,,,,,12/6/2019,12/6/2019,,,,,,,12/6/2019,12/6/2019,,,,,,
1-PLQI5,C14019,'C14019,,Alisertib,Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,Ph 1 pk hepatic dysfuntcion,I,Closed,Heme.All Comers,Oncology,,,,,,,,48,30,0,,33,16,0,62.50%,7,,,IQVIA,Robyn Horrigan,,,,,,,,,,,,,STARS Inactive,,,,,3/20/2014,3/20/2014,,,,,9/8/2014,9/8/2014,,,12/7/2015,12/7/2015,5/30/2016,5/30/2016,,,,,,,,,,,,,12/23/2016,12/23/2016,,,,,,,,,2/13/2017,2/13/2017,,,,,,,,,,,,,,,,,,,,,,,4/28/2017,4/28/2017,,,,,,,8/28/2016,8/28/2016,,,,,,,4/28/2017,,,,,,,
1-Q8FEM,C14022,'C14022,,Alisertib,A phase 1/1b study of Alsertib (MLN8237) in combination of weekly paclitaxel in Asian patients with relapsed/refratory advanced solid tumors,Ph 1 pan-Asia combo pk,I,Closed,Solid.Gyn.Ovarian,Oncology,,,,,,,,9,7,0,,3,6,0,77.78%,9,,,IQVIA,Lara Grace Gonzales Marzo,,,,,,,,,,,,,STARS Inactive,,,,,9/30/2014,9/30/2014,,,,,3/25/2015,3/25/2015,,,12/29/2015,12/29/2015,4/15/2016,4/15/2016,,,,,,,,,,,,,5/15/2017,5/15/2017,,,,,,,,,6/12/2017,6/12/2017,,,,,,,,,,,,,,,,,,,,,,,10/3/2017,10/3/2017,,,,,,,5/23/2017,5/23/2017,,,,,,,10/3/2017,,,,,,,
1-Q8GRT,C14021,'C14021,,,Alisertib/Paclitaxel in Resistant/Refractory Recurrent Ovarian Cancer Randomized Ph3 Study,,III,Cancelled,Solid.Gyn.Ovarian,,,,,,,,,500,0,0,,0,,0,0.00%,130,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-QCXRT,C31003,'C31003,,sapanisertib,"A Phase 1, Randomized, Open-Label, Study of the Relative Bioavailability, Food Effect, and pH Effect Evaluation of MLN0128 in Healthy Subjects",C31003 INK128,I,Planned,Support - Oncology,Oncology,,,,,,,,88,,,,,,,,1,,,IQVIA,,Mark Patti,,"Fabian Zohren, Michelle Kneissl",,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-QCXSG,C31004,'C31004,,sapanisertib,"A phase 2, randomized study of MLN0128 (a dual TORC1/2 inhibitor), MLN0128 + MLN1117 (a PI3Ka inhibitor), weekly paclitaxel, or the combination of weekly paclitaxel and MLN0128 in women with advanced, recurrent, or persistent endometrial cancer",Ph2 endo 128/pac/PIKTOR,II,Reported,Pouchitis,Oncology,Late Oncology,,,,,,,242,245,411,,166,245,245,101.24%,77,,,PRA,,Katie Kinney,,"Aaron Enke, Fabian Zohren",,2014-005394-37,,,,,NA,,,Medidata CTMS (Pharma),,,4/9/2014,4/9/2014,5/26/2015,5/26/2015,,,,,9/22/2016,9/22/2016,,,10/25/2018,10/25/2018,4/30/2019,4/30/2019,4/30/2019,4/30/2019,,,,,,,10/30/2020,10/30/2020,,,7/29/2019,7/29/2019,,,,,,,2/8/2021,,8/19/2019,8/19/2019,,,,,,,2/22/2021,,,,,,8/19/2019,8/19/2019,,,,,,,2/24/2021,,12/4/2019,12/4/2019,,,,,,,,,,,,,,,2/24/2021,,,,,,,
1-R9C2G,MLN1117-1002,'MLN1117-1002,,TAK-117,"A Phase 1, Open-Label Study of the Relative Bioavailability, Food and Gastric pH Effects of MLN1117 in Healthy Subjects",MLN1117-1002 BA Food & pH on PK,I,Closed,Normal Healthy Volunteer,Oncology,,,,,,,,54,54,140,,86,,3,100.00%,1,1,,PPD,Kelley Micklus,,,,,,,,,,,,,STARS Inactive,,,,,9/24/2015,9/24/2015,,,,,2/5/2016,2/5/2016,,,4/29/2016,4/29/2016,6/17/2016,6/17/2016,,,,,,,,,,,,,6/26/2016,6/26/2016,,,,,,,,,7/5/2016,7/5/2016,,,,,,,,,,,,,,,,,,,,,,,3/10/2017,3/10/2017,,,,,,,,,,,,,,,3/10/2017,3/10/2017,,,,,,
1-R9C03,MLN1117-1501,'MLN1117-1501,,TAK-117,A Phase 1b/2 Study of Docetaxel with or without MLN1117 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer,MLN1117-1501,I/II,Closed,Solid.Lung.NSCLC,Oncology,,,,Other Phase 2,,,,155,13,0,,3,1,0,8.39%,32,,,IQVIA,"Angela Gibson-White, Jeff Conlon",,,,,2014-004281-25,,,,,,,,STARS Inactive,,,,,12/15/2014,12/15/2014,,,,,6/30/2015,6/30/2015,,,7/25/2016,7/25/2016,1/20/2017,1/20/2017,,,,,,,,,,,,,3/29/2017,3/29/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/11/2017,9/11/2017,,,,,,,,,,,,,,,9/11/2017,,,,,,,
1-RP5YP,Pevonedistat-2001,'Pevonedistat-2001,,pevonedistat (TAK-924),"A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia",Ph2 HR MDS,II,Recruitment Complete,Blood cancer,Oncology,Late Oncology,,,,,,,120,123,0,,0,0,9,102.50%,72,26,,PPD,,"Tara Sadowski, Elizabeth Halter",,"Douglas Faller, Robert Fram",,2015-000221-37,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,2/25/2015,2/25/2015,,,,,4/14/2016,4/14/2016,,,6/21/2017,6/21/2017,6/21/2018,,9/4/2019,9/4/2019,,,,,,,1/2/2022,,,,10/29/2019,10/29/2019,,,,,,,3/26/2022,,11/6/2019,11/6/2019,,,,,,,,,,,,,11/27/2019,11/27/2019,,,,,,,4/21/2022,,9/18/2020,9/18/2020,,,,,,,8/12/2022,,,,,,,,8/12/2022,,,,,,,
1-SCYED,Pevonedistat-1012,'Pevonedistat-1012,,pevonedistat (TAK-924),"A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in
Combination with Azacitidine in Adult East Asian Patients with Acute Myeloid Leukemia (AML)
or Myelodysplastic Syndromes (MDS)",Ph1b Japan/North Asia PK,I,Recruitment Complete,Support - Oncology,Oncology,Late Oncology,,,,,,,37,23,0,,0,0,20,62.16%,9,4,,PPD,,"Irene Yung Wa Cheng, Sakiko Kaizuka, Kyeongeun Park",,"Douglas Faller, Farhad Sedarati, Sergio Santillana",,,,,,,,,,Medidata CTMS (Pharma),,,,,2/4/2016,2/4/2016,,,,,5/30/2016,5/30/2016,,,11/20/2017,11/20/2017,11/30/2018,,4/16/2018,4/16/2018,,,,,,,7/29/2021,,,,6/18/2018,6/18/2018,,,,,,,9/21/2021,,7/16/2018,7/16/2018,,,,,,,,,,,,,8/3/2018,8/3/2018,,,,,,,10/19/2021,,11/26/2018,11/26/2018,,,,,,,2/8/2022,,,,,,,,2/8/2022,,,,,,,
1-T87PR,C31005,'C31005,,sapanisertib,"A Phase 1b/2, Open-Label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and Combination of MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced Clear-Cell Renal Cell Carcinoma That Has Progressed During or After VEGF-Targeted Therapy",Ph2 Renal H2H Everolimus,II,Reported,(RCC) Renal cell cancer,Oncology,Late Oncology,,,,,,,96,95,147,,51,37,87,98.96%,55,3,,PRA,,"Katie Savage, Lydia Wilhelm, Katie Kinney",,Aaron Enke,,2015-002133-22,,,,,,,,Medidata CTMS (Pharma),,,11/4/2014,11/4/2014,5/22/2015,5/22/2015,,,,,9/9/2016,9/9/2016,,,4/10/2018,4/10/2018,10/10/2018,10/10/2018,3/6/2020,3/6/2020,,,,,,,10/13/2020,10/13/2020,,,4/30/2020,4/30/2020,,,,,,,1/15/2021,,9/23/2020,9/23/2020,,,,,,,2/15/2021,,,,,,9/23/2020,9/23/2020,,,,,,,2/5/2021,2/5/2021,1/19/2021,1/19/2021,,,,,,,,,3/29/2018,3/29/2018,,,,,3/9/2021,,,,,,,
1-U0EGW,MLN0128-1004,'MLN0128-1004,,sapanisertib,"A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLN0128 (an Oral mTORC 1/2 Inhibitor) as a Single Agent and in Combination With Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies",Ph1 PK study SCRI,I,Closed,Solid.All Comers,Oncology,,,,,,,,56,61,80,,19,,,108.93%,5,5,,Sarah Cannon Research Institut,"Jonathan Young, Rebecca Nuzzo, Tara Sadowski",,,,,,,,,,,,,STARS Inactive,,,,,9/30/2014,9/30/2014,,,,,3/16/2015,3/16/2015,,,2/9/2016,2/9/2016,8/9/2016,8/9/2016,,,,,,,,,6/29/2018,6/29/2018,,,6/30/2016,6/30/2016,,,,,,,7/30/2018,7/30/2018,7/21/2016,7/21/2016,,,,,,,,,,,,,,,,,,,,,,,12/2/2016,12/2/2016,,,,,,,,,,,,,,,7/30/2018,,,,,,,
1-U0EP3,TAK-385-1010,'TAK-385-1010,,relugolix,"A Phase 1, Three-Way Crossover, Single Dose Bioavailability/Food Effect Study in Healthy Subjects to Evaluate the Relative Bioavailability of two Phase 3 Tablet Formulations of TAK-385",,I,Closed,Normal Healthy Volunteer,Oncology,,,,,,,,54,54,84,,10,,,100.00%,1,2,,In-House,Eric Hoberman,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-V5BIE,MLN1117-1003,'MLN1117-1003,,TAK-117,An Umbrella Study to Evaluate MLN1117 in Combination with Docetaxel and Other Investigational Anticancer Agents for the Treatment of Patients with Previously Treated Advanced and Metastatic Gastric Cancer,Umbrella 4 Arm Gastric,IB,Closed,Solid.GI.Gastric,Oncology,,,,,,,,178,32,37,,5,,15,17.98%,5,25,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,6/24/2015,6/24/2015,,,,,10/26/2015,10/26/2015,,,7/27/2016,7/27/2016,2/17/2017,2/17/2017,2/17/2017,2/17/2017,,,,,,,,,,,,,,,,,,,,,4/7/2017,4/7/2017,,,,,,,,,,,,,,,,,,,,,,,11/30/2017,11/30/2017,,,,,,,,,,,,,,,11/30/2017,,,,,,,
1-XO5JP,TAK-385-3006,'TAK-385-3006,,relugolix,"A Phase 3, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist Relugolix (TAK-385) Compared with a 3-Month Leuprorelin Depot, in Patients With Advanced Prostate Cancer",Ph3 prostate cancer,III,Cancelled,Solid.GU.Prostate,Oncology,,,,Benchmark Phase 3,,,,600,0,0,,0,,0,0.00%,100,,,IQVIA,Robyn Horrigan,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-XO5KK,TAK-385-3007,'TAK-385-3007,,relugolix,TBD,Ph3 adjuv/neo,III,Cancelled,Solid.GU.Prostate,Oncology,,,,,,,,360,0,0,,0,,0,0.00%,100,,,,,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-Z4VLK,TBD,'TBD,,,TBD,Ph3 China/Pan-Asia,III,Cancelled,Solid.GU.Prostate,,,,,,,,,20,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-Z9VLF,Vortioxetine-3003,'Vortioxetine-3003,,Trintellix (vortioxetine),LCM Placeholder: GAD,LCM Placeholder: (GAD Ph 3) #1,III,Cancelled,(ADHD) Attention-deficit hyperactivity disorder,NS,Marketed Products,,,,,,,550,,,,,,,,50,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-Z9VLQ,TBD-7047,'TBD-7047,,Trintellix (vortioxetine),LCM Placeholder:GAD,LCM Placeholder: GAD (Adol/Ped),IV,Cancelled,(ADHD) Attention-deficit hyperactivity disorder,NS,,,,,,,,290,,,,,,,,30,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-Z9VMJ,TBD-7053,'TBD-7053,,Trintellix (vortioxetine),LCM Placeholder:GAD,LCM Placeholder: (GAD Ph 3) #2,III,Cancelled,(ADHD) Attention-deficit hyperactivity disorder,NS,,,,,,,,550,,,,,,,,50,,,PRA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA1Z6,TBD-7054,'TBD-7054,,,POM Study in LGMD-2b,POM Study in LGMD-2b,II,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA2IL,TBD-7078,'TBD-7078,,TAK-114,Absolute BA,1.5 Absolute BA,I,Cancelled,Other,GI,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA2IU,TBD-7079,'TBD-7079,,TAK-114,QTc Interval,1.6 QTc,I,Cancelled,Other,GI,,,,,,,,70,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA2W5,TBD-7082,'TBD-7082,,TAK-114,Renal Impairment,1.8 Renal Impairment,I,Cancelled,Other,GI,,,,,,,,64,0,0,,0,,0,0.00%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA4FO,TBD-7083,'TBD-7083,,TAK-114,Hepatic Impairment,1.9 Hepatic Impairment,I,Cancelled,Other,GI,,,,,,,,32,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA4VH,TBD-7084,'TBD-7084,,TAK-114,Age Gender,1.10 Age Gender,I,Cancelled,Other,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6U1,AD-4833/TOMM40_301,'AD-4833/TOMM40_301,,AD-4833/TOMM40,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects",Low Dose Pio/TOMM40,III,Closed,Other,NS,,,,Outcomes,,,,"3,500","3,494",24235,,20741,,3398,99.83%,59,65,,IQVIA,Ryan Walter,,,,,2012-003111-58,,,,,,,,STARS Inactive,,,4/19/2012,4/19/2012,2/8/2013,2/8/2013,,,8/1/2013,8/1/2013,8/28/2013,8/28/2013,,,12/21/2015,12/21/2015,,,8/7/2018,8/7/2018,,,,,,,,,,,9/18/2018,9/18/2018,,,,,,,,,9/27/2018,9/27/2018,,,,,,,,,,,,,10/16/2018,10/16/2018,,,,,,,,,4/23/2019,4/23/2019,,,,,,,,,,,,,,,4/23/2019,4/23/2019,,,,,,
1-ZA6UB,AD-4833/TOMM40_302,'AD-4833/TOMM40_302,,AD-4833/TOMM40,Validation Study to Determine Performance Characteristics and Normative Values for Common Cognitive Instruments used to Detect Dementia and Lesser Cognitive Impairments in the Elderly,Validation Study,III,Closed,Other,NS,,,,Other P3A - Pre NDA,,,,675,678,784,,106,,,100.44%,4,,,Covance,Dominic Fitzsimmons,,,,,,,,,,,,,STARS Inactive,,,8/15/2012,8/15/2012,6/6/2013,6/6/2013,,,11/29/2013,11/29/2013,11/29/2013,11/29/2013,,,11/20/2014,11/20/2014,,,12/18/2014,12/18/2014,,,,,,,,,,,3/18/2015,3/18/2015,,,,,,,,,5/28/2015,5/28/2015,,,,,,,,,,,,,,,,,,,,,,,2/4/2016,2/4/2016,,,,,,,,,,,,,,,2/4/2016,2/4/2016,,,,,,
1-ZA6UK,AD-4833-TOMM40_303,'AD-4833-TOMM40_303,,AD-4833/TOMM40,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the Ad-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impariment Due to Alzheimer Disease,MCI Convertors from 301,III,Closed,Other,NS,,,,Other P3A - Pre NDA,,,,149,40,0,,0,4,0,26.85%,44,,,IQVIA,Ann Haas,,,,,2013-004984-30,,,,,,,,STARS Inactive,,,1/25/2013,1/25/2013,3/26/2014,3/26/2014,,,2/12/2015,2/12/2015,2/12/2015,2/12/2015,,,11/15/2017,11/15/2017,,,5/9/2018,5/9/2018,,,,,,,,,,,9/19/2018,9/19/2018,,,,,,,,,10/9/2018,10/9/2018,,,,,,,,,,,,,10/23/2018,10/23/2018,,,,,,,,,4/29/2019,4/29/2019,,,,,,,,,,,,,,,11/22/2019,11/22/2019,,,,,,
1-ZA6UT,AFX01-06,'AFX01-06,,Peginesatide,An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection,Pure Red Cell Aplasia,IIIB,Closed,Other,Marketed Products,,,,Other P3b - Post NDA,,,,9,0,0,,0,,0,0.00%,5,2,,Parexel,,,,,,2005-004944-30,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6V2,Calcichew-1001,'Calcichew-1001,,Calcichew (calcium),Phase 1 study to support 500/1000 calcium product registration,Swiss Study,I,Closed,Other,Marketed Products,,,,Other Phase 1,,,,27,27,0,,0,0,0,100.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6VB,Calcichew-4001,'Calcichew-4001,,Calcichew (calcium),A study to investigate the preference of the new CalciChew other a comparator product,CalciChew Preference,IV,Closed,Other,Marketed Products,,,,Other Phase IV,,,,276,138,0,,0,0,4,50.00%,9,,,PPD,Matthew Brown,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6VK,CL-9709-301-RD,'CL-9709-301-RD,,Ciclesonide HFA,"Control of moderate or severe asthma with 160, 320 and 640μg
ciclesonide/day. A one-year randomised, double-blind, multicenter trial.",CONTRAST,IIIB,Closed,00184 Asthma,CVM,,,,Other P3b - Post NDA,,,,360,367,538,,171,,89,101.94%,40,,,PPD,Rosalida Leone,,,,,2011-000683-99,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6VT,COLCH_101,'COLCH_101,,COLCRYS (colchicine),MD study to evaluate PK of colchicine in subjects aged 2 to 6 years and adult patients with FMF administered a 0.3 MG crushable tablet formulation,Peds in FMF,I,Cancelled,Other,Marketed Products,,,,,,,,30,0,0,,0,,0,0.00%,1,,,,Tomoka Tsukada,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6W2,e0035,'e0035,,soticlestat (TAK-935),Evaluation of [18F]MNI-792 as PET tracer in Healthy Volunteers,PET Validation,I,Closed,Other,NS,,,,EM Phase 0,,,,11,9,13,,1,,3,81.82%,1,,,In-House,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,8/6/2014,8/6/2014,9/2/2014,9/2/2014,,,10/17/2014,10/17/2014,10/28/2014,10/28/2014,,,2/25/2015,2/25/2015,,,3/2/2015,3/2/2015,,,,,,,,,,,3/4/2015,3/4/2015,,,,,,,,,3/9/2015,3/9/2015,,,,,,,,,,,,,,,,,,,,,,,5/5/2015,5/5/2015,,,,,,,,,,,,,,,5/6/2015,5/6/2015,,,,,,
1-ZA6WB,ENV8058_101,'ENV8058_101,,TAK-058,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and
Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects/Volunteers",SRD,I,Closed,Other,NS,,,,SRD/FIM,,,,48,48,183,,134,,,100.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6WK,Febuxostat XR_1009,'Febuxostat XR_1009,,Febuxostat XR,"A Phase 1, Open-Label, Single-Center, Randomized, 3-Way Crossover Study to Assess the 
Effect of Food on the Bioavailability of a Single Oral Dose of 80 mg Febuxostat Extended-
Release Formulation and the Pharmacokinetics of a Single Oral Dose of 40 mg and 80 mg
Febuxostat Extended-Release Formulation in Healthy Subjects",Food effect study in XR,I,Closed,Other,Marketed Products,,,,Food Effect,,,,36,36,81,,29,,1,100.00%,1,,,PPD,Vicky Fontana,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6WT,febuxostat XR-1010,'febuxostat XR-1010,,Febuxostat XR,"A Phase 1, Open-Label, Single Center, Single-Dose, Randomized, 4-Way Crossover Study to 
Assess the Effect of an Antacid on the Bioavailability of Febuxostat After Oral 
Administration of a 80 mg Febuxostat Extended-Release (XR) Capsule Formulation",DDI with Antacids,I,Closed,Other,Marketed Products,,,,DI Low Complexity,,,,36,36,57,,,,,100.00%,1,,,PPD,Vicky Fontana,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6X2,Febuxostat XR-1011,'Febuxostat XR-1011,,Febuxostat XR,"BE study to support scale up; n=48; single center, single dose, 4 way crossover",BE Study for XR Scale Up,I,Closed,Other,Marketed Products,,,,,,,,76,78,148,,70,,4,102.63%,1,,,PPD,Vicky Fontana,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6XB,FEB-1008,'FEB-1008,,Febuxostat XR,"PK/PD dose ranging and safety study of PO febuxostat pediatric formulation in pediatric subjects, 12 to 17 years of age, with low risk for TLS",PK/PD 12 to 17 Yr Old,I,Cancelled,Other,Marketed Products,,,,Pediatric PK,,,,8,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6XK,FEB-XR_201,'FEB-XR_201,,Febuxostat XR,"A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout and Moderate Renal Impairment",Ph 2- XR in gout subjects,II,Closed,00048 Gout,Marketed Products,,,,Other Phase 2,,,,200,191,0,,0,0,31,95.50%,60,,,PPD,Faisal Khan,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6XT,FEB-XR_301,'FEB-XR_301,,Febuxostat XR,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo.",Ph 3- XR in gout subjects,III,Closed,00048 Gout,Marketed Products,,,,Other P3A - Pre NDA,,,,"1,750","1,795",0,,0,0,298,102.57%,235,,,PPD,Faisal Khan,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6Y2,ITI-214_102,'ITI-214_102,,ITI-214,"Randomized, Placebo-Controlled, D-B, Safety, Tolerability, PK, and Exploratory PD Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214",Multiple Rising Dose,I,Closed,Other,NS,,,,MRD,,,,76,37,91,,54,,3,48.68%,2,,,Covance,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6YB,ITI-214_103,'ITI-214_103,,ITI-214,"1.4 - Relative BA and Food Effect, open-label, 3-period cross-over, highest strength vs. solution formulation, identify potential effect of food on the PK of ITI-214 for the tablet formlation",Relative BA& Food Effect,I,Closed,Other,NS,,,,Food Effect,,,,24,0,0,,0,,0,0.00%,1,,,Covance,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6YK,Leuprorelin-5001,'Leuprorelin-5001,,LEUPLIN (leuprorelin acetate),An Observational Retrospective Study to Evaluate the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty,Retrospective ph4,IV,Closed,Other,Others,,,,Other Phase IV,,,,100,108,129,,20,,1,108.00%,8,,,Hangzhou Tigermed Consulting,Winston Wang,,,,,,,,,,,,,STARS Inactive,,,8/16/2016,8/16/2016,10/10/2016,10/10/2016,,,,,6/24/2017,6/24/2017,,,9/30/2018,9/30/2018,,,9/30/2018,9/30/2018,,,,,,,,,,,1/30/2019,1/30/2019,,,,,,,,,2/18/2019,2/18/2019,,,,,,,,,,,,,2/22/2019,2/22/2019,,,,,,,,,5/6/2019,5/6/2019,,,,,,,,,,,,,,,5/17/2019,5/17/2019,,,,,,
1-ZA6YT,LuAA21004_401,'LuAA21004_401,,Trintellix (vortioxetine),"A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of 5 mg Vortioxetine in Subjects With Normal Hepatic Function or Severe Hepatic Impairment",Severe Hepatic,IV,Closed,Other,NS,,,,Hepatic Impairment,,,,12,12,22,,10,,,100.00%,1,1,,IQVIA,Jennifer Boynton,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6ZB,M1-1188_202,'M1-1188_202,,MT203,"A 24-week randomized, double-blind, placebo-controlled, phase 2 dose finding study to evaluate the efficacy and safety of 3 doses of namilumab (20 mg, 80 mg and 150 mg) in combination with methotrexate (MTX) in subjects with moderate to severe rheumatoid arthritis (RA) NEXUS",NEXUS,II,Closed,Other,Immunology,,,,Dose Ranging,,,,108,48,3,,36,1,0,44.44%,55,,,IQVIA,Nicola Sadler,,,,,,,,,,,,,STARS Inactive,,,6/28/2013,6/28/2013,12/3/2013,12/3/2013,,,12/17/2014,12/17/2014,2/9/2015,2/9/2015,,,2/17/2016,2/17/2016,,,,,,,,,,,11/22/2016,11/22/2016,,,6/21/2016,6/21/2016,,,,,,,1/24/2017,1/24/2017,8/12/2016,8/12/2016,,,,,,,2/7/2017,2/7/2017,,,,,,,,,,,,,,,,,,,,,,,8/11/2017,8/11/2017,,,,,,,8/11/2017,,,,,,,
1-ZA6ZK,M1-1188_203,'M1-1188_203,,MT203,2.1.2  Dose-Ranging Study with Namilumab in Moderate to Severe Psoriasis,Neptune,II,Closed,Other,Immunology,,,,Dose Ranging,,,,120,115,0,,49,15,0,95.83%,25,,,IQVIA,Dilini Reynold,,,,,2013-002806-30,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA6ZT,MLN0002_101,'MLN0002_101,,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Study to Assess the
Absolute Bioavailability and Pharmacokinetics of Vedolizumab in Healthy
Subjects Following Single Subcutaneous Administration",SC_101 Single Dose,I,Closed,Other,GI,,,,SRD/FIM,,,,48,48,83,,35,,,100.00%,1,1,,,Ellen Rhodes,,,,,,,,,,NA,Advance,,STARS Inactive,,,,,9/4/2013,9/4/2013,,,,,6/9/2014,6/9/2014,,,,,,,6/29/2015,6/29/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/8/2015,9/8/2015,,,,,,,,,,,,,,,9/8/2015,9/8/2015,,,,,,
1-ZA7A2,TBD-5314,'TBD-5314,,TAK-063,Relapse Prevention Study,3.6 Relapse Prevention,III,Cancelled,Schizophrenia,RGH,,,,,,,,610,,,,,,,,100,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/13/2020,,,,,,4/14/2021,,,,12/5/2022,,,,6/5/2023,,,,,,,,,,,,7/31/2023,,,,,,,,,,8/14/2023,,,,,,,,,,,,,,,,,,,,,,,,2/8/2024,,,,,,,,,,,,,,,,2/8/2024,,,,,,,
1-ZA7AB,TBD-5315,'TBD-5315,,TAK-063,Open Label Extension,3.5 Open-Label Extension,III,Cancelled,Schizophrenia,RGH,,,,,,,,553,,,,,,,,167,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/13/2020,,,,,,6/23/2021,,,,8/31/2025,,,,7/19/2026,,,,,,,,,,,,9/11/2026,,,,,,,,,,9/25/2026,,,,,,,,,,,,,,,,,,,,,,,,3/24/2027,,,,,,,,,,,,,,,,3/24/2027,,,,,,,
1-ZA7AK,TBD-5316,'TBD-5316,,TAK-063,Acute 1,3.1 Acute 1,III,Cancelled,Schizophrenia,RGH,,,,,,,,480,,,,,,,,45,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/13/2020,,,,,,4/14/2021,,,,12/5/2022,,,,1/16/2023,,,,,,,,,,,,3/13/2023,,,,,,,,,,3/27/2023,,,,,,,,,,,,,,,,,,,,,,,,9/21/2023,,,,,,,,,,,,,,,,9/21/2023,,,,,,,
1-ZA7AT,TBD-5317,'TBD-5317,,TAK-063,Acute 2,3.2 Acute Study 2,III,Cancelled,Schizophrenia,RGH,,,,,,,,480,,,,,,,,45,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/13/2020,,,,,,4/14/2021,,,,6/8/2022,,,,7/20/2022,,,,,,,,,,,,9/14/2022,,,,,,,,,,9/28/2022,,,,,,,,,,,,,,,,,,,,,,,,3/27/2023,,,,,,,,,,,,,,,,3/27/2023,,,,,,,
1-ZA7B2,TBD-5319,'TBD-5319,,TAK-063,Long Term Safety,3.7 Long Term Safety,III,Cancelled,Schizophrenia,RGH,,,,,,,,"1,200",,,,,,,,150,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/13/2020,,,,,,4/14/2021,,,,7/27/2024,,,,7/26/2025,,,,,,,,,,,,9/19/2025,,,,,,,,,,10/3/2025,,,,,,,,,,,,,,,,,,,,,,,,4/1/2026,,,,,,,,,,,,,,,,4/1/2026,,,,,,,
1-ZA7BG,TBD-5474,'TBD-5474,,LATUDA,A double blind study to compare the short & longer term efficacy & safety of lurasidone vs comparator in adolescent patients aged 13-17,Adolescent SCZ study,III,Cancelled,Other,NS,,,,,,,,300,0,0,,0,,0,0.00%,30,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7C7,TBD-7085,'TBD-7085,,TAK-114,Pediatric SRD/MRD,1.11 Ped SRD/MRD,I,Cancelled,Other,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7CI,TBD-7091,'TBD-7091,,TAK-114,Pivotal BE Commercial Formulation,1.12 Pivotal BE Com Form,I,Cancelled,Other,GI,,,,,,,,24,0,0,,0,,0,0.00%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7CT,TBD-7092,'TBD-7092,,TAK-114,Definitive Food Effect Study with Commercial Formulation,1.13 Def FE_Com Form,I,Cancelled,Other,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7DC,TBD-7094,'TBD-7094,,TAK-114,Additional DDI,1.14 Additional DDI,I,Cancelled,Other,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7DL,TBD-7100,'TBD-7100,,TAK-114,3.1 Ph 3 Induction of Clinical Response and Remission,3.1 Induction Study #1,III,Cancelled,Other,GI,,,,,,,,1,0,0,,0,,0,0.00%,356,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7DU,TBD-7104,'TBD-7104,,TAK-114,Ph 3 _3.2 Induction Clinical  Response and  Remission _2,3.2 Induction Study #2,III,Cancelled,Other,GI,,,,,,,,1,0,0,,0,,0,0.00%,356,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7E3,TBD-7108,'TBD-7108,,,Ph 3_3.3 Effect of Nutria on maintenance of clinical remission (Sustained clinical remission),3.3 Maintenance Study,III,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,200,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7EC,TBD-7109,'TBD-7109,,,Ph 3_3/4 Open Label Long-term Safety Study,3.4 Long-term Safety-Open,III,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,200,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7EL,TBD-7517,'TBD-7517,,,DDI Met,DDI Metformin,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7EU,TBD-7518,'TBD-7518,,,DDI Sulfonylureas,DDI Sulfonylureas,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7F5,TBD-5536,'TBD-5536,,AD-4833/TOMM40,"Phase 1, Open-Label, Single-Dose, to Assess Effect of Food on Bioavailability of Pioglitazone Phase 3 Formulation",Food Effect Definitive,I,Cancelled,Delay the onset of MCI due to Alzheimer's disease,NS,,,,,,,,36,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,6/29/2018,,,,7/31/2018,,7/31/2018,,,,9/28/2018,,,,11/17/2018,,,,,,,,,,,,1/11/2019,,,,,,,,,,2/1/2019,,,,,,,,,,,,,,,,,,,,,,,,3/29/2019,,,,,,,,,,,,,,,,3/29/2019,,,,,,,
1-ZA7FK,TBD-5580,'TBD-5580,,,Definative Food Effect with Commercial Formulation,Definative Food Effect,I,Planned,,,,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7FX,TBD-6079,'TBD-6079,,TAK-137,"DDI with common coadministered drugs such as methyphenidate, amphetamine, guanfacine, clonidine and antipsychotic drugs. Single-center, randomized, 2-period cross-over/seqential. Healthy volunteers",Initial DDI (HV)_ADHD,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7G6,TBD-6081,'TBD-6081,,TAK-137,"2.1 - randomized, double-blind, placebo-controlled, 4-period, incomplete crossover, dose-ranging study of 3 doses of TAK-137, lisdexamphtamine or PBO in adults with ADHD",Ph 2a Mono__ADHD,II,Cancelled,Other,NS,,,,,,,,80,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7GH,TBD-7538,'TBD-7538,,TAK-058,ADME,ADME,I,Cancelled,Other,NS,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7GQ,TBD-7557,'TBD-7557,,TAK-058,Initial DDI,Initial DDI,I,Cancelled,Other,NS,,,,,,,,6,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7GZ,TBD-7558,'TBD-7558,,TAK-058,tQT,tQT,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7H8,TBD-7559,'TBD-7559,,TAK-058,DDI with Con meds,DDI with Con meds,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7HJ,TBD-6094,'TBD-6094,,TAK-137,"2.2 - ph 2a randomized, double-blind, placebo-controlled, 4 period, cross-over, dose-ranging study of 3 doses of TAK-137 or placebo with stimulants adults with ADHD.",Ph 2a Adjunctive_ADHD,II,Cancelled,Other,NS,,,,,,,,80,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7HR,TBD-7560,'TBD-7560,,TAK-058,Proof of Concept and Commercialization,POC&C,II,Cancelled,Other,NS,,,,,,,,200,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7I0,TAK-094-1001,'TAK-094-1001,,,TAK-094 FiH Study,SRD/MRD,I,Cancelled,Other,,,,,,,,,120,0,0,,0,,0,0.00%,1,,,PPD,Natalie Jones,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7I2,TBD-6095,'TBD-6095,,TAK-137,"2.3a - randomized, double-blind, placebo-controlled, parallel group, four-arm, dose-ranging study of 2 doses of TAK-137, lisdexamphetamine, or placebo in adults with ADHD. (ph 2b, 4 week monotherpy)",Ph 2b Mono_ADHD,II,Cancelled,Other,NS,,,,,,,,176,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7IT,TBD-7711,'TBD-7711,,,Ph1b Proof of Mechinism in obese otherwise heatlthy subjects as compared to liraglutide,POM,I,Cancelled,Other,,,,,,,,,90,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7J5,TBD-6096,'TBD-6096,,TAK-137,"Ph I - Single-dose, folllowed by multiple dose. Ages 6 to 17.",Peds - SRD/MRD_ADHD,I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA7JE,TBD-6100,'TBD-6100,,TAK-137,"2.4a - Phase 2b double-blind, placeo-controllled, parallel-group, four arm, dose-ranging study of 2 doses of TAK-137, lisdexamphetamine, or placebo in children & adolescents with ADHD.",Peds - Ph 2b  Mono_ADHD,II,Cancelled,Other,NS,,,,,,,,256,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA70B,MLN0002-2003,'MLN0002-2003,,Entyvio,"A Phase 2, Randomized, Double-Blind, Dose Ranging Study to determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease",Ped P2  PK/PD,II,Reported,Delay the onset of MCI due to Alzheimer's disease,GI,Late GI,,,,Treatment,Prospective,Cohort,80,90,138,,48,90,23,112.50%,71,5,,PRA,,,,"Jeffrey Bornstein, William Treem",,2017-002231-41,,,,,NA,Advance,,Medidata CTMS (Pharma),,,8/8/2014,8/8/2014,10/10/2016,10/10/2016,,,11/8/2017,11/8/2017,12/4/2017,12/4/2017,,,12/22/2019,12/22/2019,,,5/26/2020,5/26/2020,,,,,,,,,,,5/27/2020,5/27/2020,,,,,,,,,7/2/2020,7/2/2020,,,,,,,,,,,,,6/26/2020,6/26/2020,,,,,,,,,11/6/2020,11/6/2020,,,,,,,,,,,,,,,5/6/2021,,,,,,,
1-ZA70K,MLN0002-3023,'MLN0002-3023,,Entyvio,"A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease",PSC P3 Safety & Efficacy,III,Cancelled,Other,GI,,,,DI High Complexity,,,,258,0,0,,0,,0,0.00%,90,,,IQVIA,Sonya Gae McKnight,,,,,2014-003942-28,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA70T,MLN0002-3024,'MLN0002-3024,,Entyvio,"P3, randomized, placebo controlled, blinded study of induction and maintenance of clinical response and remission by Vedolizumab in Pediatric patients with moderate to severe UC",Ped P3 UC,III,Recruiting,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,Late GI,,Pediatric only (<18 yr),Expanded Access,,Other,,120,,,,,,,,108,74,,PPD,,Leigh Arrington-Brown,,,,2020-004300-34,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,12/25/2020,12/25/2020,,,,,7/30/2021,,,,1/16/2024,,,,1/28/2025,,,,,,,,,,,,3/31/2025,,,,,,,,,,4/21/2025,,,,,,,,,,,,,,4/28/2025,,,,,,,,,,7/12/2025,,,,,,,,,,,,,,,,7/24/2025,,,,,,,
1-ZA71B,MLN0002-3026,'MLN0002-3026,,Entyvio,"A randomized double blind, double dummy multicenter active controlled study to evaluate the efficacy and safety of Vedolizumab IV compared to Adalimumab SC in subjects with Ulcerative Colitis",P3 UC Active Comparator,IIIB,Closed,00020 (UC) Ulcerative colitis,GI,,,,Other P3b - Post NDA,,,,758,769,1285,,516,,243,101.45%,331,,,IQVIA,"Daniel Detka, Deborah Tyler, Lara Grace Gonzales Marzo",,,,,,,,,,NA,Advance,,STARS Inactive,,,12/12/2014,12/12/2014,2/27/2015,2/27/2015,,,,,7/10/2015,7/10/2015,,,9/27/2017,9/27/2017,,,1/18/2019,1/18/2019,,,,,,,,,,,3/8/2019,3/8/2019,,,,,,,,,2/12/2019,2/12/2019,,,,,,,,,,,,,5/30/2019,5/30/2019,,,,,,,,,7/31/2019,7/31/2019,,,,,,,,,,,,,,,7/31/2019,,,,,,,
1-ZA71K,MLN0002-3028,'MLN0002-3028,,Entyvio,An Open Label Phase 3b Study to Assess Mucosal Healing in Patients with Moderatively to Severely Active Crohn's Disease Treated With Vedolizumab,P3 CD Mucosal Healing,IIIB,Closed,00027 (CD) Crohn's disease,GI,,,,Other P3b - Post NDA,,,,100,80,8,,49,2,0,80.00%,75,,,IQVIA,Leonie Martin,,,,,,,,,,,,,STARS Inactive,,,7/16/2014,7/16/2014,12/3/2014,12/3/2014,,,,,4/13/2015,4/13/2015,,,11/30/2016,11/30/2016,,,2/21/2018,2/21/2018,,,,,,,,,,,4/6/2018,4/6/2018,,,,,,,,,,,,,,,,,,,,,,,5/14/2018,5/14/2018,,,,,,,,,8/3/2018,8/3/2018,,,,,,,,,,,,,,,8/3/2018,8/3/2018,,,,,,
1-ZA71T,MLN0002-3029,'MLN0002-3029,,Entyvio,P3 Open Label study for subjects from P2 and P3 studies to determine long term safety and efficacy of Vedolizumab in peds patients with UC and CD,Ped P3 Open Label Extn,IIIb,Concept,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,Late GI,,Pediatric only (<18 yr),,,,,180,,,,,,,,80,,,IQVIA,,"Diane Balma, Leigh Arrington-Brown",,Arpeat Kaviya,,2021-000630-34,,,,,NA,Advance,,Medidata CTMS (Pharma),,,12/17/2020,12/17/2020,,,,,,,7/29/2022,,,,1/28/2025,,,,1/2/2030,,,,,,,,,,,,3/3/2030,,,,,,,,,,3/17/2030,,,,,,,,,,,,,,3/24/2030,,,,,,,,,,6/16/2030,,,,,,,,,,,,,,,,7/1/2030,,,,,,,
1-ZA72B,MLN0002SC-3030,'MLN0002SC-3030,,Entyvio SC,"A Phase 3b Open-Label Study to Determine the Long-term Safety and Efficacy of
Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn’s Disease",MLN0002SC OLE 3030,IIIb,Recruitment Complete,facilitation of non-invasive ventilation in neonates,GI,Late GI,,,,Treatment,Prospective,Other,746,747,,,,28,387,100.13%,348,,,IQVIA,,"Mayumi Tatenuma, Mary Traynor",,"Krisztina Kisfalvi, Michelle Gruber",,2015-000482-31,,,,,,,,Medidata CTMS (Pharma),,,12/12/2014,12/12/2014,2/27/2015,2/27/2015,,,4/15/2016,4/15/2016,4/15/2016,4/15/2016,,,5/14/2019,5/14/2019,,,5/31/2018,5/31/2018,4/15/2019,4/15/2019,5/17/2019,5/17/2019,7/25/2019,7/25/2019,5/10/2023,,,,11/7/2018,11/7/2018,6/10/2019,6/10/2019,7/30/2019,7/30/2019,9/12/2019,9/12/2019,7/1/2023,,8/28/2018,8/28/2018,,,,,,,7/31/2023,,,,,,12/24/2018,12/24/2018,6/28/2019,6/28/2019,8/23/2019,8/23/2019,11/19/2019,11/19/2019,3/15/2005,,8/29/2023,,7/10/2019,7/10/2019,,,,,,,,,,,,,10/23/2024,,,,,,,
1-ZA72K,MLN0002SC-3031,'MLN0002SC-3031,,Entyvio SC,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy",SC P3 CD Maintenance,III,Closed,00027 (CD) Crohn's disease,GI,,,,Other P3A - Pre NDA,,,,645,644,1072,,428,,169,99.84%,222,,,IQVIA,Mayumi Tatenuma,,,,,2015-000481-58,,,,,NA,Advance,,STARS Inactive,,,12/11/2014,12/11/2014,2/26/2015,2/26/2015,,,12/14/2015,12/14/2015,1/4/2016,1/4/2016,,,4/25/2018,4/25/2018,,,5/6/2019,5/6/2019,,,,,,,8/21/2019,8/21/2019,,,7/2/2019,7/2/2019,,,,,,,10/11/2019,10/11/2019,7/11/2019,7/11/2019,,,,,,,,,,,,,8/8/2019,8/8/2019,,,,,,,1/2/2020,1/2/2020,10/4/2019,10/4/2019,,,,,,,3/17/2020,3/17/2020,,,,,,,3/17/2020,,,,,,,
1-ZA72T,MLN0128_101,'MLN0128_101,,,"A Phase 1b Multiple Ascending Dose Study to Investigate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MLN0128 Following 7 Days Repeat Oral Doses in Subjects With Idiopathic Pulmonary Fibrosis",MRD Dose Escalation Study,I,Reported,,,,,,,,,,36,,,,,,,,5,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA73B,MLN0128BOS_103,'MLN0128BOS_103,,,DDI with Prednisone,DDI w Prednisone,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA73K,MLN0128BOS_104,'MLN0128BOS_104,,,DDI with Azithromycin,DDI w Azithromycin,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA73T,MLN0128BOS_105,'MLN0128BOS_105,,,DDI with Tacrolimus,DDI w Tacrolimus,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA74B,MLN0128BOS_107,'MLN0128BOS_107,,,DDI with Mycophenolate Mofetil,DDI Mycophenolate Mofetil,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA74K,MLN0128BOS_108,'MLN0128BOS_108,,,DDI with Cyclosporine,DDI w Cyclosporine,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA74T,MLN0128BOS_201,'MLN0128BOS_201,,sapanisertib,Phase 2 PoC,Phase 2 PoC,II,Cancelled,Other,CVM,,,,POC,,,,75,0,0,,0,,0,0.00%,11,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA75B,MLN3126_102,'MLN3126_102,,MLN3126,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and
Pharmacokinetics Study of Escalating Single Doses of MLN3126 in Healthy Subjects",SRD,I,Closed,Other,Immunology,,,,SRD/FIM,,,,48,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA75K,MLN3126_103,'MLN3126_103,,MLN3126,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Single and Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Non-Japanese and Japanese Subjects",MRD,I,Closed,Other,Immunology,,,,MRD,,,,64,23,127,,104,,,35.94%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA75T,MLN9708_101,'MLN9708_101,,Ninlaro,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Toelrability and PK Study of Multiple Rising Doses of  of MLN9708 for the Treatment of Subjects ith ISN/RPS Class III or IV Lupus Nephritis",MRD,I,Terminated,"(LN) Class III and IV, Lupus Nephritis",Oncology,,,,,,,,40,12,0,,0,0,0,30.00%,34,,,PPD,,,,Ehsanollah Esfandiari,,2014-000125-21,,,,,,,,Medidata CTMS (Pharma),,,,,12/17/2013,12/17/2013,,,,,7/9/2014,7/9/2014,,,6/19/2017,6/19/2017,1/15/2018,1/15/2018,1/15/2018,1/15/2018,,,,,,,,,,,3/9/2018,3/9/2018,,,,,,,,,3/17/2018,3/17/2018,,,,,,,,,,,,,7/3/2018,7/3/2018,,,,,,,,,9/5/2018,9/5/2018,,,,,,,,,,,,,,,9/5/2018,,,,,,,
1-ZA76D,NaltrexBuprop-1004,'NaltrexBuprop-1004,,Contrave,"A Phase 1, Open-label, Sequential Design Study to Evaluate the Potential Effect of Multiple Oral Doses of Extended-Release Combination of  Naltrexone and Bupropion on the PK of a Single Oral Dose of  Metformin in Healthy Subjectes (DDI)",DDI,I,Closed,Normal Healthy Volunteer,Marketed Products,,,,,,,,30,30,80,,50,,3,100.00%,1,1,,PPD,Sadhana Sonparote,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA76M,NaltrexBuprop-1005,'NaltrexBuprop-1005,,Contrave,"A Randomized, Double-Blind, Placebo- and Moxifloxacin Positive-Controlled (Open Label), Cross-Over Study to Evaluate the Potential Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Subjects",Hepatic Impairment,I,Cancelled,Other,Marketed Products,,,,,,,,48,0,0,,0,,0,0.00%,2,,,PPD,Kumudinie Karunaratne,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA76V,NaltrexBuprop-1006,'NaltrexBuprop-1006,,Contrave,Renal Impairment Study,Renal Impairment,I,Cancelled,Other,Marketed Products,,,,,,,,48,0,0,,0,,0,0.00%,2,,,PPD,Kumudinie Karunaratne,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA77D,TBD-5255,'TBD-5255,,TAK-063,TQT,TQT TAK-063,I,Cancelled,Schizophrenia,RGH,,,,,,,,70,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,4/9/2018,,6/11/2018,,,,9/4/2018,,10/4/2018,,,,10/18/2018,,,,12/6/2018,,,,,,,,,,,,1/25/2019,,,,,,,,,,1/24/2019,,,,,,,,,,,,,,,,,,,,,,,,7/9/2019,,,,,,,,,,,,,,,,7/9/2019,,,,,,,
1-ZA77M,TBD-5256,'TBD-5256,,TAK-063,DDI 1,DDI 1,I,Cancelled,Schizophrenia,RGH,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/6/2020,,1/8/2021,,,,4/5/2021,,5/5/2021,,,,5/7/2021,,,,5/16/2021,,,,,,,,,,,,7/5/2021,,,,,,,,,,7/2/2021,,,,,,,,,,,,,,,,,,,,,,,,12/15/2021,,,,,,,,,,,,,,,,12/15/2021,,,,,,,
1-ZA77V,TBD-5257,'TBD-5257,,TAK-063,DDI 2,DDI 2,I,Cancelled,Schizophrenia,RGH,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/6/2020,,1/26/2021,,,,5/24/2021,,6/23/2021,,,,7/2/2021,,,,7/11/2021,,,,,,,,,,,,9/3/2021,,,,,,,,,,9/9/2021,,,,,,,,,,,,,,,,,,,,,,,,4/5/2022,,,,,,,,,,,,,,,,4/5/2022,,,,,,,
1-ZA78I,TBD-5260,'TBD-5260,,TAK-063,Hepatic Impairment,Hepatic Impairment TAK-063,I,Cancelled,Schizophrenia,RGH,,,,,,,,32,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/6/2020,,1/8/2021,,,,4/5/2021,,5/5/2021,,,,11/5/2021,,,,11/8/2021,,,,,,,,,,,,12/28/2021,,,,,,,,,,12/27/2021,,,,,,,,,,,,,,,,,,,,,,,,6/9/2022,,,,,,,,,,,,,,,,6/9/2022,,,,,,,
1-ZA78R,TBD-1-ZA78R,'TBD-1-ZA78R,,TAK-063,Age/Gender,Age/Gender,I,Cancelled,Schizophrenia,RGH,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/6/2020,,1/8/2021,,,,4/5/2021,,5/5/2021,,,,5/13/2021,,,,7/28/2021,,,,,,,,,,,,9/16/2021,,,,,,,,,,9/15/2021,,,,,,,,,,,,,,,,,,,,,,,,2/28/2022,,,,,,,,,,,,,,,,2/28/2022,,,,,,,
1-ZA79A,TBD-5268,'TBD-5268,,TAK-063,Absolute BA,Absolute BA,I,Cancelled,Schizophrenia,RGH,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/10/2021,,5/12/2021,,,,8/5/2021,,9/6/2021,,,,9/8/2021,,,,9/17/2021,,,,,,,,,,,,11/8/2021,,,,,,,,,,11/5/2021,,,,,,,,,,,,,,,,,,,,,,,,4/20/2022,,,,,,,,,,,,,,,,4/20/2022,,,,,,,
1-ZA79J,TBD-5276,'TBD-5276,,TAK-063,Phase 2b Dose Ranging,2b Dose Ranging,II,Cancelled,Schizophrenia,RGH,,,,,,,,320,,,,,,,,32,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/4/2017,,6/20/2017,,,,9/20/2017,,10/18/2017,,,,4/5/2020,,,,5/17/2020,,,,,,,,,,,,7/10/2020,,,,,,,,,,7/24/2020,,,,,,,,,,,,,,,,,,,,,,,,1/20/2021,,,,,,,,,,,,,,,,1/20/2021,,,,,,,
1-ZA79S,TBD-5280,'TBD-5280,,TAK-063,Acute study #4,3.4 Acute 4,III,Cancelled,Schizophrenia,RGH,,,,,,,,480,,,,,,,,45,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/13/2020,,,,,,4/14/2021,,,,2/28/2024,,,,4/10/2024,,,,,,,,,,,,6/5/2024,,,,,,,,,,6/19/2024,,,,,,,,,,,,,,,,,,,,,,,,12/16/2024,,,,,,,,,,,,,,,,12/16/2024,,,,,,,
1-ZA702,MLN-0002_401,'MLN-0002_401,,Entyvio,Entyvio Long term safety study (PASS),Safety vedolizumab IBD,IV,Recruitment Complete,facilitation of non-invasive ventilation in neonates,GI,Late GI,,,Non - Interventional,,,,"5,200","5,302",5480,,178,,1141,101.96%,384,7,,ICON,,"Kathryn Haas, Leonie Martin, Keisha Taylor",,Paul Dolin,,,,,,,,,,Medidata CTMS (Pharma),,,4/22/2014,4/22/2014,4/18/2014,4/18/2014,,,,,3/24/2015,3/24/2015,,,7/30/2019,7/30/2019,,,7/21/2021,,,,,,,,,,,,9/15/2021,,,,,,,,,,10/5/2021,,,,,,,,,,,,,,11/22/2021,,,,,,,,,,3/23/2022,,,,,,,,,,,,,,,,6/30/2022,,,,,,,
1-ZA712,MLN0002-3025,'MLN0002-3025,,Entyvio SC,"P3, randomized placebo controlled study of the induction and maintenance of clinical response and remission of Vedolizumab in pediatric patients with moderate to severe CD",Ped P3 CD,III,Recruiting,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,Late GI,,Pediatric only (<18 yr),Expanded Access,,,,120,,,,,,,,108,75,,PPD,,Leigh Arrington-Brown,,,,2020-004301-31,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,12/4/2020,12/4/2020,,,,,7/30/2021,,,,1/5/2024,,,,1/17/2025,,,,,,,,,,,,3/18/2025,,,,,,,,,,4/2/2025,,,,,,,,,,,,,,4/8/2025,,,,,,,,,,7/1/2025,,,,,,,,,,,,,,,,7/1/2030,,,,,,,
1-ZA722,MLN0002SC-3027,'MLN0002SC-3027,,Entyvio SC,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV
Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as
Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy",SC P3 UC Maintenance,III,Closed,00020 (UC) Ulcerative colitis,GI,,,,Other P3A - Pre NDA,,,,400,203,1,,116,1,0,50.75%,250,,,IQVIA,Mayumi Tatenuma,,,,,2015-000480-14,,,,,NA,Advance,,STARS Inactive,,,12/12/2014,12/12/2014,2/27/2015,2/27/2015,,,2/19/2016,2/19/2016,1/8/2016,1/8/2016,,,5/31/2017,5/31/2017,,,5/30/2018,5/30/2018,,,,,,,8/21/2018,8/21/2018,,,7/3/2018,7/3/2018,,,,,,,11/30/2018,11/30/2018,7/12/2018,7/12/2018,,,,,,,12/6/2018,12/6/2018,,,,,8/21/2018,8/21/2018,,,,,,,12/6/2018,12/6/2018,,,,,,,,,2/12/2019,2/12/2019,,,,,,,2/12/2019,2/12/2019,,,,,,
1-ZA732,MLN0128BOS_102,'MLN0128BOS_102,,,DDI with Atorvastatin,DDI w Atorvastatin,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA742,MLN0128BOS_106,'MLN0128BOS_106,,,DDI with Azathioprine,DDI w Azathioprine,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA752,MLN0128BOS_301,'MLN0128BOS_301,,,Phase 3 Pbo Comparision,Phase 3 Pbo Comparitor,III,Cancelled,Other,,,,,,,,,200,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA764,MLN9708-2050,'MLN9708-2050,,,"A Phase 2 study to investigate the efficacy, safety and tolerability, pharmacokinetics and pharmacodynamic effects of MLN9708 in highly sensitized adult kidney pre transplant",Solid Organ Transplant,II,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZA774,TBD-5241,'TBD-5241,,TAK-063,ADME,ADME,I,Cancelled,Schizophrenia,RGH,,,,,,,,6,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/15/2018,,3/19/2018,,,,6/12/2018,,7/12/2018,,,,7/12/2018,,,,7/22/2018,,,,,,,,,,,,9/10/2018,,,,,,,,,,9/7/2018,,,,,,,,,,,,,,,,,,,,,,,,2/20/2019,,,,,,,,,,,,,,,,2/20/2019,,,,,,,
1-ZA784,TBD-5259,'TBD-5259,,TAK-063,Renal Impairment,Renal Impairment TAK-063,I,Cancelled,Schizophrenia,RGH,,,,,,,,64,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/6/2020,,1/8/2021,,,,4/5/2021,,5/5/2021,,,,8/10/2022,,,,8/13/2022,,,,,,,,,,,,10/3/2022,,,,,,,,,,9/30/2022,,,,,,,,,,,,,,,,,,,,,,,,3/15/2023,,,,,,,,,,,,,,,,3/15/2023,,,,,,,
1-ZA790,TBD-5267,'TBD-5267,,TAK-063,Definitive BA & FE w C Form,Definitive BA/FE w C Form,I,Cancelled,Schizophrenia,RGH,,,,,,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,11/6/2020,,1/8/2021,,,,4/5/2021,,5/5/2021,,,,5/7/2021,,,,5/16/2021,,,,,,,,,,,,7/5/2021,,,,,,,,,,7/2/2021,,,,,,,,,,,,,,,,,,,,,,,,12/15/2021,,,,,,,,,,,,,,,,12/15/2021,,,,,,,
1-ZD0MT,TBD-6101,'TBD-6101,,TAK-137,"2.5 Double-blind, inpatient placebo controlled study of the procognitive effects of three doses of TAK-137 as add-on treatment to current antippsychotic therapy in stable patients with schizophrenia",Ph 2a Add-on InPat_CIAS,II,Cancelled,Other,NS,,,,,,,,40,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0NC,TBD-6102,'TBD-6102,,TAK-137,"2.3b -  Ph 2b, randomized, double-blind, pbo-controlled, parallel-group, four-arm, dose-rangling study of 3 doses of TAK-137 in comob with stimulants in adults with ADHD.",Ph 2b  Adjunctive_ADHD,II,Cancelled,Other,NS,,,,,,,,176,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0NM,TAK-831-1001,'TAK-831-1001,,TAK-831,"A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF ESCALATING SINGLE AND MULTIPLE DOSES OF TAK-831 IN HEALTHY SUBJECTS",SRD/MRD,I,Closed,Other,NS,,,,,,,,120,280,0,,0,29,0,233.33%,1,,,IQVIA,Veronique Copalu,,,,,,,,,,,,,STARS Inactive,,,3/11/2015,3/11/2015,7/16/2015,7/16/2015,,,9/23/2015,9/23/2015,10/7/2015,10/7/2015,,,6/1/2016,6/1/2016,,,6/9/2016,6/9/2016,,,,,,,,,,,10/12/2016,10/12/2016,,,,,,,,,12/6/2016,12/6/2016,,,,,,,,,,,,,5/8/2017,5/8/2017,,,,,,,,,10/27/2017,10/27/2017,,,,,,,,,,,,,,,10/27/2017,10/27/2017,,,,,,
1-ZD0NV,TBD-6104,'TBD-6104,,TAK-137,"2.6a - 3 month, double-blind, placebo controlled, outpatient study of the procognitive effects of two doses of TAK-137 as add-on treatment to current antipsychotic therapy in stable patients",Ph 2b Add-on Outpat_CIAS,II,Cancelled,Other,NS,,,,,,,,570,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0OO,TBD-6105,'TBD-6105,,TAK-137,"2.7 ph 2, POC randomized, double-blind, placebo controlled, parallel group, dose-rangining study of a single dose of TAK-137 or placebo in adults with slepp apnea. Subjects stratified by apnea type.",Ph 2a-POC Single Dose_SA,II,Cancelled,Other,NS,,,,,,,,20,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0OZ,TAK-831-1003,'TAK-831-1003,,TAK-831,"A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration",PET,I,Closed,Other,NS,,,,,,,,22,16,0,,5,0,0,72.73%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,6/30/2015,6/30/2015,11/25/2015,11/25/2015,,,3/21/2016,3/21/2016,4/6/2016,4/6/2016,,,8/4/2016,8/4/2016,,,8/30/2016,8/30/2016,,,,,,,,,,,11/16/2016,11/16/2016,,,,,,,,,12/20/2016,12/20/2016,,,,,,,,,,,,,6/8/2017,6/8/2017,,,,,,,,,2/28/2017,2/28/2017,,,,,,,,,,,,,,,4/18/2018,4/18/2018,,,,,,
1-ZD0P7,TBD-6106,'TBD-6106,,TAK-137,"2.8 -Ph 2, randomized, double-blind, pbo-group, dose-ranging, 12 week study of 2 doses of TAK-137 or placebo in adults with sleep apnea. As a global trial, 30 Japanese patients per arm to be included.",Ph 2 - Pivotal_SA,II,Cancelled,Other,NS,,,,,,,,293,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0PG,TBD-6135,'TBD-6135,,TAK-137,"2.4b - phase 2b, randomized, double-blind, pbo-controlled, parallel-group, four-arm dose-ranging study of 3 doses of TAK-137 or placebo in combo with simulants in children and adolescents with ADHD",Peds-Ph 2b Adjunct ADHD,II,Cancelled,Other,NS,,,,,,,,256,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0PP,TBD-6137,'TBD-6137,,TAK-137,1.6 Initial DDI CIAS -DDI with common coadministered drugs and antipsychotic drugs that may impact phase 2/3 enrollment,Initial DDI CIAS (HV),I,Cancelled,Other,NS,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0Q2,TAK-831-1501,'TAK-831-1501,,TAK-831,"A Phase II, Randomized, Investigator-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Efficacy, Safety, Tolerability and Pharmacokinetics of Acute Multiple Rising Doses of  Oral TAK-831 in Adult Patients with Friedreich’s Ataxia (FRDA)",POM Ataxia,II,Closed,Other,NS,,,,Interventional,,,,65,63,0,,14,0,0,96.92%,6,,,IQVIA,Jody LaPar,,,,,,,,,,,,,STARS Inactive,,,2/20/2017,2/20/2017,4/15/2017,4/15/2017,,,11/1/2017,11/1/2017,11/28/2017,11/28/2017,,,9/27/2018,9/27/2018,,,12/27/2018,12/27/2018,,,,,,,,,,,2/11/2019,2/11/2019,,,,,,,,,2/21/2019,2/21/2019,,,,,,,,,,,,,3/14/2019,3/14/2019,,,,,,,,,9/16/2019,9/16/2019,,,,,,,,,,,,,,,9/16/2019,9/16/2019,,,,,,
1-ZD0Q8,TBD-6218,'TBD-6218,,MT203,3.4  MTX-IR (Safety & Efficacy of 2 Doses of Namilumab on Background Methotrexate),3.4  MTX-IR (S&E),III,Cancelled,(RA) Rheumatoid arthritis,Immunology,,,,,,,,800,,,,,,,,160,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0RB,TBD-6220,'TBD-6220,,MT203,3.1  TNF-IR (Safety & Efficacy of 2 Doses of Namilumab on Background Methotrexate),3.1  TNF-IR,III,Cancelled,(RA) Rheumatoid arthritis,Immunology,,,,,,,,500,,,,,,,,100,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/22/2016,,5/30/2017,,,,1/23/2018,,2/20/2018,,,,2/19/2019,,,,9/19/2019,,,,,,,,,,,,10/31/2019,,,,,,,,,,11/14/2019,,,,,,,,,,,,,,,,,,,,,,,,1/30/2020,,,,,,,,,,,,,,,,1/30/2020,,,,,,,
1-ZD0RK,TBD-6221,'TBD-6221,,MT203,3.2   Multiple B/DMARDS-IR (Safety & Efficacy of 2 Doses of  Namilumab on Background Methotrexate),3.2  Multiple B/DMARDS-IR,III,Cancelled,(RA) Rheumatoid arthritis,Immunology,,,,,,,,800,,,,,,,,160,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0S0,RO-2455-402-RD,'RO-2455-402-RD,,Daxas,"A 16-week, randomized, placebo- controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease",BIOPSY,III,Closed,Other,Marketed Products,,,,Other Phase IV,,,,150,158,297,,136,,9,105.33%,17,,,PPD,Karen Watkins,,,,,2011-000582-13,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0SD,TBD-6222,'TBD-6222,,MT203,3.6 Remission (Safety & Efficacy of 2 Doses of Namilumab in Methotrexate-Naïve Pat. With Early Agg. RA),3.6 Remission,III,Cancelled,(RA) Rheumatoid arthritis,Immunology,,,,,,,,800,,,,,,,,160,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0SM,TBD-6223,'TBD-6223,,MT203,"3.5  MTX-IR Comparator TNF (Safety & Efficacy of 2 Doses of Namilumab, inadequate response to TNF Inhibitors)",3.5  MTX-IR / TNF,III,Cancelled,(RA) Rheumatoid arthritis,Immunology,,,,,,,,600,,,,,,,,100,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0ST,TAK-831-2002,'TAK-831-2002,,TAK-831,POC SCH,POC SCH,II,Completed,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,234,307,504,,198,257,31,131.20%,48,,,IQVIA,,"Aparna Sawant, Siew Tin Gan",,,,2017-003471-54,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/31/2017,8/31/2017,10/17/2017,10/17/2017,,,1/4/2018,1/4/2018,2/19/2018,2/19/2018,,,10/9/2020,10/9/2020,,,1/12/2021,1/12/2021,,,,,,,,,,,2/17/2021,2/17/2021,,,,,,,,,2/17/2021,2/17/2021,,,,,,,,,,,,,6/29/2021,6/29/2021,,,,,,,,,9/29/2021,,,,,,,,,,,,,,,,9/29/2021,,,,,,,
1-ZD0T5,TBD-6224,'TBD-6224,,MT203,"3.3  TNF-IR Comparator IL-6 (Safety & Efficacy of 2 Doses of Namilumab, inadequate response to TNF Inhibitors)",3.3  TNF-IR / IL-6,III,Cancelled,(RA) Rheumatoid arthritis,Immunology,,,,,,,,600,,,,,,,,100,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0TE,TBD-6303,'TBD-6303,,,PASS Study,PASS,IV,Cancelled,Other,,,,,,,,,"1,500",0,0,,0,,0,0.00%,260,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0TN,TBD-6314,'TBD-6314,,Mezagitamab (TAK-079),Multiple Rising Dose of TAK-079 in RA patients,Multiple Rising Dose,I,Suspended,Multiple Sclerosis,Immunology,,,,,,,,52,,,,,,,,20,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0U6,TBD-7723,'TBD-7723,,TAK-831,DDI,DDI,I,Planned,"(CIAS) Cognitive Impairment Associated with Schizophrenia, (NS) Negative Symptoms of Schizophrenia",NS,Late NS,,,,,,,24,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/13/2024,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0UF,TAK-831-1006,'TAK-831-1006,,TAK-831,T2/T3 Food Effect,Relative BA/FE,I,Closed,Other,NS,,,,Interventional,,,,16,16,58,,42,,,100.00%,1,,,Celerion,,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,8/2/2018,8/2/2018,10/2/2018,10/2/2018,,,10/18/2018,10/18/2018,11/3/2018,11/3/2018,,,11/3/2018,11/3/2018,,,12/22/2018,12/22/2018,,,,,,,,,,,1/30/2019,1/30/2019,,,,,,,,,2/7/2019,2/7/2019,,,,,,,,,,,,,,,,,,,,,,,5/28/2019,5/28/2019,,,,,,,,,,,,,,,12/23/2019,12/23/2019,,,,,,
1-ZD0UY,TAK-831-1004,'TAK-831-1004,,TAK-831,"An Open-Label, Single-Dose, 2-Period Sequential Design Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of  TAK-831 Formulation T2 in Healthy Subjects",PK,I,Closed,Other,NS,,,,,,,,16,15,38,,23,,1,93.75%,1,,,PRA,Kelly Hanna,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,1/11/2017,1/11/2017,2/20/2017,2/20/2017,,,3/29/2017,3/29/2017,4/25/2017,4/25/2017,,,5/2/2017,5/2/2017,,,5/24/2017,5/24/2017,,,,,,,,,,,7/24/2017,7/24/2017,,,,,,,,,6/6/2017,6/6/2017,,,,,,,,,,,,,9/29/2017,9/29/2017,,,,,,,,,2/15/2018,2/15/2018,,,,,,,,,,,,,,,2/15/2018,2/15/2018,,,,,,
1-ZD0VA,TBD-6418,'TBD-6418,,MT203,"Phase 3: 46 weeks treatment , 60 sites, 4 weeks screening 12 w fu",Psoriasis 3.1,III,Cancelled,Other,Immunology,,,,,,,,"1,200",0,0,,0,,0,0.00%,60,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0VT,TBD-6419,'TBD-6419,,MT203,"Phase 3: 46 weeks treatment, 220 sites, 4 weeks screening and 12w follow up",Psoriasis 3.2,III,Cancelled,Other,Immunology,,,,,,,,"1,200",0,0,,0,,0,0.00%,220,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0W2,TBD-6420,'TBD-6420,,MT203,"Phase 3: 60 sites; Treatment 46 weeks, 4 weeks screening, 12 w follow up",Psoriasis 3.3,III,Cancelled,Other,Immunology,,,,,,,,"1,200",0,0,,0,,0,0.00%,60,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0WB,TBD-6701,'TBD-6701,,,TBD,Ph3 Def 1,III,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0WK,TBD-6702,'TBD-6702,,,TBD,Ph3 Def 2,III,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0X3,TBD-6703,'TBD-6703,,,TBD,Ph3 LTS,III,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0XC,TBD-6706,'TBD-6706,,,TBD,ADME,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0XL,TBD-6708,'TBD-6708,,,TBD,Renal Impair,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0XZ,TBD-7727,'TBD-7727,,TAK-831,Ataxia Phase III,Ataxia Phase III,III,Cancelled,Friedreich's ataxia,NS,,,,,,,,180,,,,,,,,10,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD0ZX,TBD-7731,'TBD-7731,,,MRD/POM,MRD/Proof of Mechinism study to assess the safety,I,Cancelled,Other,,,,,,,,,84,0,0,,0,,0,0.00%,2,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD1A7,NaltrexBuprop-1002,'NaltrexBuprop-1002,,Contrave,"Open-Label, Single-Dose, Pharmacokinetic (PK) Study of Sustained-Release (SR) Naltrexone/Bupropion (NB) Combination in Obese Adolescent Subjects 7 to 11 Years of Age Inclusive",Peds PK Ph 1 Study 7-11,I,Cancelled,Other,Marketed Products,,,,,,,,16,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD1AG,NB-CVOT,'NB-CVOT,,Contrave,"Light Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of MACE in Overweight and Obese Subjects Receiving Naltrexone SR/Bupropion SR",LIGHT Study,IIIB,Closed,00078 Obesity,Marketed Products,,,,Outcomes,,,,"8,900","8,910",13192,,4282,,8910,100.11%,300,307,,In-House,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD1AP,TBD-6984,'TBD-6984,,Contrave,Pediatric Safety and Efficacy Phase 3 (12-17),Peds Eff Ph 3 Study 12-17,IIIB,Cancelled,Other,Marketed Products,,,,,,,,300,0,0,,0,,0,0.00%,35,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD1AY,TBD-6985,'TBD-6985,,Contrave,Peds Safety and Efficacy Ph 3 (7-11),Peds Eff Ph 3 Study 7-11,IIIB,Cancelled,Other,Marketed Products,,,,,,,,450,0,0,,0,,0,0.00%,35,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD1B7,NaltrexBuprop-1001,'NaltrexBuprop-1001,,Contrave,"A Randomized, Double-Blind, Placebo and Moxifloxacin Positive-Controlled (open Label) Cross-Over Study to Evaluate the Potential Effect of Naltrexone and Bupoprion Extended-Release Combination on Cardiac Repolarization in Healthy Subjects",TQT Study,I,Closed,Other,Marketed Products,,,,QTc Interval,,,,84,84,194,,110,,15,100.00%,1,1,,PPD,Kumudinie Karunaratne,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD1BG,TBD-7039,'TBD-7039,,Contrave,Dose Escalation Study,Dose Escalation,IV,Cancelled,Other,Marketed Products,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD1BP,NaltrexBuprop-4001,'NaltrexBuprop-4001,,Contrave,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride Extended Release Combination on the Occurrence ofMACE in Overweight and Obese Subjects with CV Disease",Naltrexone/Bupropion Cardiovascular Outcomes Study,IV,Terminated,00078 Obesity,Marketed Products,,,,Outcomes,,,,"8,800",58,0,,0,0,58,0.66%,500,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD6LE,RO-2455-404-RD,'RO-2455-404-RD,,Daxas,Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS.,REACT,IV,Closed,Other,Marketed Products,,,,Other Phase IV,,,,"1,940",0,0,,0,,0,0.00%,220,,,PPD,,,,,,2010-019685-87,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7LH,ROF-ALZ_102,'ROF-ALZ_102,,ROF-ALZ,Scopolamine-induced memory impairment in HVs 4 period crossover,Alzheimer's POM Study,I,Closed,Other,NS,,,,Other Phase 1,,,,24,27,72,,45,,4,112.50%,1,1,,IQVIA,,,,,,2012-002089-11,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7OP,ROF-ALZ_103,'ROF-ALZ_103,,ROF-ALZ,"A randomized, double-blind, placebo controlled, four-period, cross-over study to evaluate the cognitive effects of single oral administration of roflumilast in aging-related memory impairment",Aging Study,I,Closed,Other,NS,,,,Other Phase 1,,,,40,39,0,,151,2,0,97.50%,1,,,IQVIA,,,,,,2013-001223-39,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7Q2,ROF-BAM_101,'ROF-BAM_101,,,"multiple-dose, open-label, randomized, 3-sequence, 3-period, crossover, pharmacokinetic, DDI study of rof and bambuterol administered orally once-daily in healthy adult subjects of Chinese descent",Rof Bam DDI,I,Terminated,Other,,,,,,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7QL,ROF-BAM_102,'ROF-BAM_102,,,"single-dose, randomized, 4-sequence, 4-period study to assess the relative FDC BA and dose proportionality & food efffect on the FDC PK following oral admin in healthy Chinese adult",Rof Bam BA/Food Effect,I,Terminated,Other,,,,,,,,,30,0,0,,0,,0,0.00%,15,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7QU,ROF-DERM_203,'ROF-DERM_203,,,"A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation – on Atopic Dermatitis Patients With Skin Lesions of Moderate Severity",Atopic Dermatitis POM,II,Closed,Other,,,,,Other Phase 2,,,,40,0,0,,0,,0,0.00%,6,,,IQVIA,,,,,,2012-003000-12,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7R3,ROF-IPF_103,'ROF-IPF_103,,Cross TA,"A randomized, open-label, Phase 1b study to evaluate the safety and tolerability of roflumilast and bortezomib co-administration for the treatment of patients with idiopathic pulmonary fibrosis",IPF POM Study,I,Closed,Other,Marketed Products,,,,Other Phase 1,,,,30,0,0,,0,,0,0.00%,15,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7RH,ROF-NASH_205,'ROF-NASH_205,,ROF-NASH,"A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis",NASH POM Study,II,Closed,Other,Marketed Products,,,,Other Phase 2,,,,75,20,71,,51,,10,26.67%,20,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7RS,ROF-PSOR_104,'ROF-PSOR_104,,ROF-PSOR,"A Randomized, Single-Center, Observer-Blind, Vehicle- and Active
Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and
Tolerability of Roflumilast and BYK321084 – Phosphodiesterase Type 4 Inhibitors (PDE4i)
Dermal Formulations in Patients with Chronic Plaque Psoriasis using a Psoriasis Plaque
Test",Psoriasis POM Study,I,Closed,Other,Immunology,,,,Other Phase 1,,,,15,0,0,,0,,0,0.00%,2,,,IQVIA,,,,,,2012-002998-62,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7S4,ROF-SCHZ_106,'ROF-SCHZ_106,,ROF-SCHZ,fMRI/cognition/ERP studies in Stable Schizophrenia Patients,SCHZ fMRI POM,I,Closed,Other,NS,,,,Other Phase 1,,,,20,20,0,,11,18,0,100.00%,1,,,IQVIA,,,,,,2012-002091-13,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7U1,RS-7261-201-RD,'RS-7261-201-RD,,,RS-7261-201-RD (Precursor Trial),Precursor Trial,0,Closed,Other,,,,,Other Phase 2,,,,1,0,0,,0,,0,0.00%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7VH,SYR-322_104,'SYR-322_104,,Nesina (Alogliptin),"A Single Dose PK, PD and Safety Study of 12.5 and 25 mg SYR-322 Administered Orally to Children and Adolescents and  Adults with Type 2 (Non-Insulin Dependent) Diabetes Mellitus",Pediatric PK,I,Closed,Other,CVM,,,,Pediatric PK,,,,48,47,126,,80,,1,97.92%,4,,,Covance,,,,,,2009-011221-13,,,,,,,,STARS Inactive,,,,,11/20/2008,11/20/2008,,,,,11/9/2009,11/9/2009,,,11/14/2013,11/14/2013,,,11/22/2013,11/22/2013,,,,,,,,,,,3/10/2014,3/10/2014,,,,,,,,,2/11/2014,2/11/2014,,,,,,,,,,,,,,,,,,,,,,,6/13/2014,6/13/2014,,,,,,,,,,,,,,,6/13/2014,6/13/2014,,,,,,
1-ZD7WD,SYR-322_306,'SYR-322_306,,Nesina (Alogliptin),"12-week Double-Blind (alogliptin vs. placebo) treatment period, followed by a 52-week Open-Label Period in Severe renally impaired subjects.",Severe Renal Impair 52 wk,IIIb,Cancelled,Type 2 diabetes,CVM,,,,,,,,164,,,,,,,,30,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7WM,SYR-322_307,'SYR-322_307,,Nesina (Alogliptin),Pediatric AloMet Efficacy Study EU - 52 Week Study (treatment naive),AloMet Pediatric Efficacy,IIIb,Cancelled,,CVM,,,,,,,,300,,,,,,,,105,,,TBD,,,,,,2009-017919-15,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7X5,SYR-322_309,'SYR-322_309,,Nesina (Alogliptin),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 26-Week Study to Evaluate the Efficacy and Safety of Alogliptin Compared with Placebo in Subjects Aged 10 to 17 Years with Type 2 Diabetes",322_309 Pediatric Efficacy US,IIIb,Recruitment Complete,Type 2 diabetes,CVM,Marketed Products,,Pediatric only (<18 yr),,,,,150,151,285,,125,139,22,100.67%,60,50,,TBD,,David Manning,,Neila Smith,,2015-000208-25,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,10/14/2016,10/14/2016,11/28/2016,11/28/2016,,,2/3/2021,2/3/2021,,,2/18/2022,,,,,,,,,,,,4/4/2022,,,,,,,,,,4/13/2022,,,,,,,,,,,,,,,,,,,,,,,,8/5/2022,,,,,,,,,,,,,,,,8/5/2022,,,,,,,
1-ZD7XO,SYR-322MET_303,'SYR-322MET_303,,Nesina (Alogliptin),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects with Type 2 Diabetes Mellitus",P3 Alo-Met Efficacy-China,III,Closed,Other,CVM,,,,Other P3A - Pre NDA,,,,659,651,1266,,431,,134,98.79%,71,22,,Covance,Ai Meng Tan,,,,,,,,,,,,,STARS Inactive,,,3/29/2011,3/29/2011,8/18/2011,8/18/2011,,,8/27/2013,8/27/2013,10/7/2013,10/7/2013,,,3/31/2015,3/31/2015,,,10/5/2015,10/5/2015,,,,,,,,,,,6/29/2016,6/29/2016,,,,,,,,,7/14/2016,7/14/2016,,,,,,,,,,,,,,,,,,,,,,,9/8/2016,9/8/2016,,,,,,,,,,,,,,,10/31/2018,10/31/2018,,,,,,
1-ZD7XX,SYR322MET-1003,'SYR322MET-1003,,Nesina (Alogliptin),"An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Comparative Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC with Metformin) in Russian Healthy Subjects.",Alo-Met BE Russia,I,Closed,Other,CVM,,,,BE,,,,24,24,36,,8,,,100.00%,1,1,,PPD,Veronique Copalu,,,,,,,,,,,,,STARS Inactive,,,10/9/2014,10/9/2014,2/11/2015,2/11/2015,,,3/17/2016,3/17/2016,4/8/2016,4/8/2016,,,4/15/2016,4/15/2016,,,4/27/2016,4/27/2016,,,,,,,,,,,6/15/2016,6/15/2016,,,,,,,,,5/26/2016,5/26/2016,,,,,,,,,,,,,,,,,,,,,,,9/28/2016,9/28/2016,,,,,,,,,,,,,,,11/10/2017,11/10/2017,,,,,,
1-ZD7YL,Tachosil-3005,'Tachosil-3005,,,TBD,TachoSil GI Anastomosis,III,Closed,Other,,,,,Other P3A - Pre NDA,,,,"1,300",0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7YX,TAK-058-1002,'TAK-058-1002,,TAK-058,"A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Tolerability, and
Pharmacokinetic Study in Healthy Subjects After Multiple Oral Doses of TAK-058",MRD (HV),I,Closed,Other,NS,,,,MRD,,,,40,40,0,,83,40,0,100.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD7ZJ,TAK-063_102,'TAK-063_102,,TAK-063,"A Randomized, Investigator and Subject-Blind, Placebo-Controlled, Single-Dose, 3-Period,
Incomplete Block Cross-Over Study to Evaluate the Effects of Single Oral Administration
of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as
Psychotic-Like Symptoms in Healthy Male Adults",Phase 1 TAK-063 Ketamine BOLD Study,I,Closed,Other,RGH,,,,Other Phase 1,,,,27,27,58,,31,,7,100.00%,1,,,Covance,Ellen Rhodes,,,,,,,,,,,,,STARS Inactive,,,6/25/2012,6/25/2012,3/28/2013,3/28/2013,,,6/27/2013,6/27/2013,8/5/2013,8/5/2013,,,7/21/2014,7/21/2014,,,8/28/2014,8/28/2014,,,,,,,,,,,8/13/2015,8/13/2015,,,,,,,,,8/13/2015,8/13/2015,,,,,,,,,,,,,,,,,,,,,,,5/16/2017,5/16/2017,,,,,,,,,,,,,,,5/16/2017,5/16/2017,,,,,,
1-ZD7ZX,TAK-063_103,'TAK-063_103,,TAK-063,"An Open-Label [11C]T-773 Positron Emission Tomography Study to Determine
Phosphodiesterase10A Occupancy by TAK-063 After a Single Oral Dose in Human
Volunteers",PET Study,I,Closed,Other,RGH,,,,Other Phase 1,,,,18,13,36,,21,,1,72.22%,1,,,Covance,,,,,,2012-004576-18,,,,,,,,STARS Inactive,,,10/17/2012,10/17/2012,5/14/2013,5/14/2013,,,8/13/2013,8/13/2013,10/9/2013,10/9/2013,,,2/27/2014,2/27/2014,,,3/12/2014,3/12/2014,,,,,,,,,,,6/12/2014,6/12/2014,,,,,,,,,7/15/2014,7/15/2014,,,,,,,,,,,,,,,,,,,,,,,3/4/2015,3/4/2015,,,,,,,,,,,,,,,3/4/2015,3/4/2015,,,,,,
1-ZD8A2,TAK-491_109,'TAK-491_109,,,"A comparative single dose pharmacokinetic and safety study of TAK-491 between infants, children and adolescents with hypertension an healthy adults.",Pediatric PK,I,Closed,Other,,,,,Pediatric PK,,,,34,29,59,,30,,,85.29%,11,,,IQVIA,,,,,,2009-013165-25,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD8AE,TAK-491_304,'TAK-491_304,,,"Study to evaluate the antihyperglycemic effects of TAK-491 in a hypertensive, diabetic population",Diabetes Study,IIIB,Closed,Other,,,,,Other P3b - Post NDA,,,,600,0,0,,0,,0,0.00%,75,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD8AP,TAK-491_305,'TAK-491_305,,EDARBI (azilsartan medoxomil),"Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 with Valsartan in Chinese Subjects with Essential Hypertension",China Mono PIII,III,Closed,Other,CVM,,,,Other P3A - Pre NDA,,,,600,582,0,,95,12,0,97.00%,30,,,IQVIA,Yi Li,,,,,,,,,,,,,STARS Inactive,,,2/16/2011,2/16/2011,4/28/2011,4/28/2011,,,8/27/2015,8/27/2015,9/21/2015,9/21/2015,,,8/31/2017,8/31/2017,,,10/27/2017,10/27/2017,,,,,,,,,,,12/8/2017,12/8/2017,,,,,,,,,,,,,,,,,,,,,,,2/8/2018,2/8/2018,,,,,,,,,5/31/2018,5/31/2018,,,,,,,,,,,,,,,5/31/2018,5/31/2018,,,,,,
1-ZD8B1,TAK-491_307,'TAK-491_307,,EDARBI (azilsartan medoxomil),"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects with Essential Hypertension",Korea Bridging Mono PIII,IIIB,Closed,Other,CVM,,,,Other P3A - Pre NDA,,,,325,429,0,,142,36,0,132.00%,30,,,IQVIA,Ai Meng Tan,,,,,,,,,,,,,STARS Inactive,,,5/10/2012,5/10/2012,5/23/2012,5/23/2012,,,7/12/2014,7/12/2014,8/2/2014,8/2/2014,,,12/16/2015,12/16/2015,2/3/2016,2/3/2016,,,,,,,,,,,,,4/5/2016,4/5/2016,,,,,,,,,4/14/2016,4/14/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/13/2016,7/13/2016,,,,,,,7/13/2016,,,,,,,
1-ZD8BA,TAK-491_112,'TAK-491_112,,EDARBI (azilsartan medoxomil),"A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in
Healthy Chinese Subjects",China Mono PI: 40 & 80mg,I,Closed,Other,CVM,,,,China PK,,,,64,53,0,,147,0,0,82.81%,1,,,IQVIA,Yi Li,,,,,,,,,,,,,STARS Inactive,,,3/18/2011,3/18/2011,4/26/2011,4/26/2011,,,11/17/2015,11/17/2015,11/20/2015,11/20/2015,,,2/22/2017,2/22/2017,,,3/19/2017,3/19/2017,,,,,,,,,,,5/3/2017,5/3/2017,,,,,,,,,,,,,,,,,,,,,,,6/16/2017,6/16/2017,,,,,,,,,5/4/2018,5/4/2018,,,,,,,,,,,,,,,5/4/2018,,,,,,,
1-ZD8BJ,TAK-648_101,'TAK-648_101,,TAK-648,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single Oral TAK-648 Doses in Healthy Subjects",SRD,I,Closed,00050 Type 2 diabetes,CVM,,,,SRD/FIM,,,,40,39,96,,57,,,97.50%,1,,,IQVIA,Deborah Keeter,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD8BZ,TAK-648_1002,'TAK-648_1002,,TAK-648,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Multiple Oral TAK-648 Doses in Healthy Japanese Subjects and Subjects with T2DM",MRD,I,Closed,00050 Type 2 diabetes,CVM,,,,MRD,,,,48,48,87,,39,,2,100.00%,2,,,IQVIA,Deborah Keeter,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD8CA,TAK-653-1001,'TAK-653-1001,,TAK-653,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects",SRDMRD  Study,I,Closed,00082 Depression,NS,,,,Other Phase 1,,,,72,88,0,,0,0,1,122.22%,1,,,PPD,Helen Crane,,,,,,,,,,Wave 2,De-Risk,,STARS Inactive,,,5/1/2015,5/1/2015,6/24/2015,6/24/2015,,,8/26/2015,8/26/2015,9/14/2015,9/14/2015,,,8/17/2017,8/17/2017,,,9/23/2017,9/23/2017,,,,,,,,,,,10/20/2017,10/20/2017,,,,,,,,,10/30/2017,10/30/2017,,,,,,,,,,,,,12/5/2017,12/5/2017,,,,,,,,,4/23/2018,4/23/2018,,,,,,,,,,,,,,,4/23/2018,4/23/2018,,,,,,
1-ZD10A,TAK-915-1002,'TAK-915-1002,,TAK-915,"A Phase 1, Open-Label, Positron Emission Tomography Study with [18F]MNI-794 to Determine Phosphodieterase 2A Brain Enzyme Occupancy of TAK-915 After Single-Dose Oral Administration in Healthy Subjects",PET Occupancy,I,Closed,Other,NS,,,,,,,,16,12,33,,21,,,75.00%,1,,,PPD,Betty Katz,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD10J,TBD-7744,'TBD-7744,,TAK-915,POC&C,POC&C,I,Cancelled,Other,NS,,,,,,,,140,0,0,,0,,0,0.00%,15,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD11G,TBD-6709,'TBD-6709,,,TBD,Hepatic Impair,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD11Q,TBD-7937,'TBD-7937,,,TBD,BE,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD11Z,TBD-6710,'TBD-6710,,,TBD,Age/Gender,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD12C,TBD-7938,'TBD-7938,,,TBD,BA,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD12I,TBD-6798,'TBD-6798,,,TBD,Midazolam DDI,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD12V,RO-2455-408-RD,'RO-2455-408-RD,,,"Randomized Double-Blind, Placebo-Controlled, to Evaluate Once-daily Oral Administration of Roflumilast 250 and 500 ug for the treatment of COPD in Chinese Subjects",Ph IV Safety and Efficacy,IV,Closed,Other,,,,,Other Phase IV,,,,240,0,0,,0,,0,0.00%,20,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD13B,TBD-6799,'TBD-6799,,,TBD,Ketoconazole DDI,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD13K,TBD-6800,'TBD-6800,,,TBD,Rifampicin DDI,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD14D,TBD-6713,'TBD-6713,,,TBD,Ph2 POC/DRF,II,Cancelled,Other,,,,,,,,,320,0,0,,0,,0,0.00%,100,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD14O,TBD-6715,'TBD-6715,,,Phase 3 Induction Trial #1,Ph3 Ind 1,III,Cancelled,Other,,,,,,,,,450,0,0,,0,,0,0.00%,100,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD14Z,TBD-6716,'TBD-6716,,,Phase 3 Induction Trial #2,Ph3 Ind 2,III,Cancelled,Other,,,,,,,,,450,0,0,,0,,0,0.00%,60,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD15A,TBD-6717,'TBD-6717,,,Phase 3 Open Label Long Term Extension,Ph3 OL/LT,III,Cancelled,Other,,,,,,,,,140,0,0,,0,,0,0.00%,120,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD15L,TBD-6898,'TBD-6898,,,Ph 1 Initial Food Effect,Ph 1 Initial Food Effect,I,Cancelled,Other,,,,,,,,,16,0,0,,0,,0,0.00%,10,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD15W,TBD-6899,'TBD-6899,,,Ph 1 ADME,Ph 1 ADME,I,Cancelled,Other,,,,,,,,,6,0,0,,0,,0,0.00%,3,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD16I,TBD-6901,'TBD-6901,,,Ph 1 Renal Impairment in LN,Ph 1 Renal Imp,I,Cancelled,Other,,,,,,,,,32,0,0,,0,,0,0.00%,10,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD16T,TBD-6902,'TBD-6902,,,Ph 1 Hepatic Impairment in LN,Ph 1 Hepatic Imp,I,Cancelled,Other,,,,,,,,,32,0,0,,0,,0,0.00%,10,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD17F,TBD-6904,'TBD-6904,,,Ph 1 Definitive Food Effect with Commercial Formulation,Ph 1 Def Food,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,8,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD17Q,TBD-6905,'TBD-6905,,,Ph 1 DDI #1,Ph 1 DDI #1,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,8,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD18F,TBD-6906,'TBD-6906,,,Ph 1 DDI #2,Ph 1 DDI #2,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,8,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD18Q,TBD-6907,'TBD-6907,,,Ph 1 DDI #3 in LN,Ph 1 DDI #3,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,8,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD19C,TBD-6909,'TBD-6909,,,Ph 1 Oral Contraceptive Interaction Study,Ph 1 Oral Cont DDI,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,10,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD19N,TBD-6937,'TBD-6937,,,Ph 1 Oral Contraceptive Interaction Study,Ph 3 Maint,III,Cancelled,Other,,,,,,,,,400,0,0,,0,,0,0.00%,120,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD19Y,NaltrexBuprop-1003,'NaltrexBuprop-1003,,Contrave,"Open-Label, Single-Dose, Pharmacokinetic (PK) Study of Sustained-Release (SR) Naltrexone/Bupropion (NB) Combination in Obese Adolescent Subjects 12 to 17 Years of Age Inclusive",Peds PK Ph 1 Study 12-17,I,Cancelled,Other,Marketed Products,,,,,,,,16,0,0,,0,,0,0.00%,1,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD80F,TAK-063-2002,'TAK-063-2002,,TAK-063,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-week Study to Evaluate the Efficacy and Safety of  Three Doses (5 mg,10 mg, 20 mg) of Oral TAK-063 in Patients (Acute SZC)",TAK-063-2002,II,Closed,Other,RGH,,,,POC,,,,160,115,0,,42,0,0,71.88%,16,,,IQVIA,Kerrin Young,,,,,,,,,,,,,STARS Inactive,,,1/13/2015,1/13/2015,3/26/2015,3/26/2015,,,7/1/2015,7/1/2015,7/7/2015,7/7/2015,,,5/31/2016,5/31/2016,,,7/27/2016,7/27/2016,,,,,,,,,,,9/9/2016,9/9/2016,,,,,,,,,9/20/2016,9/20/2016,,,,,,,,,,,,,,,,,,,,,,,5/22/2017,5/22/2017,,,,,,,,,,,,,,,5/22/2017,5/22/2017,,,,,,
1-ZD80O,TAK-079_101,'TAK-079_101,,Mezagitamab (TAK-079),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and
Pharmacokinetic Study of Escalating Single Intravenous Infusion and Subcutaneous
Administration of TAK-079 in Healthy Subjects",Single Rising Dose,I,Closed,Other,Immunology,,,,,,,,74,74,0,,0,0,0,100.00%,1,,,PPD,Karen Watkins,,,,,2013-004210-18,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD81F,TAK-114-2001,'TAK-114-2001,,TAK-114,"A Phase 2b Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Safety and Efficacy of TAK-114 in Subjects With Moderately to Severely Active Ulcerative Colitis",2.1 Dose Ranging,IIB,Cancelled,Other,GI,,,,Dose Ranging,,,,230,0,0,,0,,0,0.00%,120,,,IQVIA,Ming Jing,,,,,2014-001899-58,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD81O,TAK-137_101,'TAK-137_101,,TAK-137,"1.1 - Single-Rising Dose in healthy volunteers. Preliminary evaluation of food effect. Single-center, randomized, double-blind, placebo controlled.",SRD_ADHD,I,Closed,Other,NS,,,,SRD/FIM,,,,48,47,148,,101,,,97.92%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD82A,TAK-137_103,'TAK-137_103,,TAK-137,137 CIAS EM study - fMRI,137 CIAS EM study - fMRI,I,Cancelled,Other,NS,,,,Other Phase 1,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,2014‐000787‐18,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD82J,TAK-137_104,'TAK-137_104,,TAK-137,Experimental Medicine: Sleep Apnea  - evaluate the pharmacodynamics of TAK-137,EM Sleep Apnea,I,Cancelled,Other,NS,,,,Other Phase 1,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD82U,TAK-137_2004,'TAK-137_2004,,TAK-137,Phase 2 Study to Evaluate the Efficacy and Safety of Oral TAK-137 in subjects with MDD and Inadequate Response to Prior Antidepressant Therapy,Ph 2a Study_TRD,II,Cancelled,Other,NS,,,,Other Phase 2,,,,136,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD83F,TAK-375SL_201,'TAK-375SL_201,,ROZEREM (ramelteon sublingal),"Rand, Dbl Bld, Pbo-Control, POC to Eval the S&E of 1Xday, 375SL 0.1mg, 0.4mg, & 0.8mg In The Tx of Acute Depress Episodes Assoc with Bipolar I Disorder in Adult Pts who are on Lith and/or Valp",201 Bipolar Acute,II,Terminated,Other,Marketed Products,,,,Other P3A - Pre NDA,,,,624,453,2,,614,0,0,72.60%,120,2,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD83O,TAK-375SL_203,'TAK-375SL_203,,ROZEREM (ramelteon sublingal),"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the
Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive
Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in
Adult Subjects",203 Bipolar Maintenance,III,Terminated,Other,Marketed Products,,,,Other P3A - Pre NDA,,,,640,636,0,,628,0,0,99.38%,120,1,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD83X,TAK-375SL_301,'TAK-375SL_301,,ROZEREM (ramelteon sublingal),"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy
and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration
(TAK-375SL Tablet) 0.1 mg and 0.4 mg as an Adjunctive Therapy in the Treatment of
Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects",301 Bipolar Acute,III,Closed,Other,Marketed Products,,,,Other P3A - Pre NDA,,,,618,535,823,,288,,101,86.57%,120,,,IQVIA,,,,,,2012-001357-10,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD84G,TAK-375SL-1026,'TAK-375SL-1026,,,DDI with Valproic Acid,DDI with Valproic Acid,I,Cancelled,Other,,,,,DI High Complexity,,,,24,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD84P,TAK-385_108,'TAK-385_108,,,Open-Label Phase1 Study with Healthy Chinese Subjects,Ph1 China PKDDI with Valproic Acid,I,Cancelled,Other,,,,,China PK,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD84Y,TAK-385-1009,'TAK-385-1009,,relugolix,"Absorption, Distribution, Metabolism, and Excretion",ADME,I,Closed,Other,CVM,,,,ADME,,,,12,12,0,,0,0,0,100.00%,1,,,PPD,Karen Watkins,,,,,2014-001564-35,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD85G,TAK-390MR_108,'TAK-390MR_108,,"DEXILANT (dexlansoprazole, MR)","A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the
Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release
Capsules in Infants Aged 1 to 11 Months With Acid-Related Diseases",Peds PK/PD in 1-11 month,I,Withdrawn,facilitation of non-invasive ventilation in neonates,Marketed Products,,,,,,,,24,,,,,,,,22,,,IQVIA,,Melanie Helmick,,"Lhanoo Gunawardhana, Oluwakemi Bankole",,2014-001642-16,,,,,,,,Medidata CTMS (Pharma),,,3/6/2013,3/6/2013,8/20/2014,8/20/2014,,,12/1/2028,,1/26/2029,,,,1/16/2031,,,,4/12/2031,,,,,,,,,,,,6/6/2031,,,,,,,,,,,,,,,,,,,,,,,,6/20/2031,,,,,,,,,,11/14/2031,,,,,,,,,,,,,,,,,,,,,,,
1-ZD85P,TAK-390MR_203,'TAK-390MR_203,,"DEXILANT (dexlansoprazole, MR)","Mulitple center, open label, parallel 6 month study with first 7 days are PK/PD",Peds 1-11mo LT Safety,II,Cancelled,Support - GI,Marketed Products,Marketed Products,,,,,,,26,,,,,,,,16,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,8/6/2031,,10/15/2031,,,,2/16/2032,,3/1/2032,,,,2/19/2034,,,,3/2/2035,,,,,,,,,,,,5/1/2035,,,,,,,,,,,,,,,,,,,,,,,,5/23/2035,,,,,,,,,,9/27/2035,,,,,,,,,,,,,,,,9/27/2035,,,,,,,
1-ZD86C,TAK-390MR_205,'TAK-390MR_205,,"DEXILANT (dexlansoprazole, MR)","A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE",Peds 2-11yo EE Healing,II,Planned,Erosive esophagitis healing,Marketed Products,Marketed Products,,,,,,,76,,,,,,,,30,,,IQVIA,,"Kathryn Haas, Margaret Szerszunowicz",,"Andreas Schneider, John Petan, Linda Mulkerin",,2014-004507-73,,,,,,,,Medidata CTMS (Pharma),,,6/10/2011,6/10/2011,7/30/2015,7/30/2015,,,5/20/2022,,7/21/2022,,,,2/24/2027,,,,11/17/2027,,,,,,,,,,,,1/7/2028,,,,,,,,,,,,,,,,,,,,,,,,2/4/2028,,,,,,,,,,6/2/2028,,,,,,,,,,,,,,,,6/2/2028,,,,,,,
1-ZD87D,TAK-390MR_207,'TAK-390MR_207,,"DEXILANT (dexlansoprazole, MR)","A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral
Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive
Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in
Adolescent Subjects Aged 12 to 17 Years",Peds 12-17yo EE Healing,II,Closed,Other,Marketed Products,,,,Other Phase 2,,,,63,0,0,,0,,0,0.00%,58,2,,IQVIA,,,,,,2012-001681-15,,,,,,,,STARS Inactive,,,6/6/2011,6/6/2011,2/9/2012,2/9/2012,,,7/17/2012,7/17/2012,7/18/2012,7/18/2012,,,3/4/2014,3/4/2014,,,11/10/2014,11/10/2014,,,,,,,,,,,12/18/2014,12/18/2014,,,,,,,,,1/8/2015,1/8/2015,,,,,,,,,,,,,,,,,,,,,,,4/22/2015,4/22/2015,,,,,,,,,,,,,,,5/4/2015,5/4/2015,,,,,,
1-ZD87O,TAK-390MR_208,'TAK-390MR_208,,"DEXILANT (dexlansoprazole, MR)",Open label long term safety of TAK-390MR administered for 6 months to 1-17 yr. olds,Peds 1-17yo LTSafety,II,Suspended,Support - GI,Marketed Products,Marketed Products,,,,,,,86,,,,,,,,61,,,TBD,,Margaret Szerszunowicz,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/24/2021,,,,6/20/2022,,6/20/2022,,,,6/4/2025,,,,6/17/2026,,,,,,,,,,,,9/14/2026,,,,,,,,,,,,,,,,,,,,,,,,9/14/2026,,,,,,,,,,1/4/2027,,,,,,,,,,,,,,,,1/4/2027,,,,,,,
1-ZD87X,TAK-438_114,'TAK-438_114,,vonoprazan,"An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese Subjects",China Registration PK,I,Closed,Other,GI,,,,China PK,,,,36,33,104,,71,,,91.67%,1,,,IQVIA,Wei Zhao,,,,,,,,,,,,,STARS Inactive,,,8/1/2012,8/1/2012,8/1/2012,8/1/2012,,,,,4/25/2017,4/25/2017,,,8/1/2017,8/1/2017,,,8/18/2017,8/18/2017,,,,,,,,,,,10/4/2017,10/4/2017,,,,,,,,,10/12/2017,10/12/2017,,,,,,,,,,,,,11/9/2017,11/9/2017,,,,,,,,,12/26/2017,12/26/2017,,,,,,,,,,,,,,,2/9/2018,2/9/2018,,,,,,
1-ZD88A,TAK-438_303,'TAK-438_303,,vonoprazan,"Randomized, Double-Blind, Double-Dummy, TAK-438 20 mg, QD vs, Lansoprazole 30 mg QD,  Erosive Esophagitis",Comparator Study; EE,III,Closed,00002 GERD,GI,,,,Other P3A - Pre NDA,,,,480,288,0,,91,4,0,60.00%,63,,,IQVIA,Wei Zhao,,,,,,,,,,,,,STARS Inactive,,,5/9/2012,5/9/2012,8/8/2012,8/8/2012,,,3/9/2015,3/9/2015,3/30/2015,3/30/2015,,,6/13/2017,6/13/2017,,,7/27/2017,7/27/2017,,,,,,,,,,,9/1/2017,9/1/2017,,,,,,,,,9/25/2017,9/25/2017,,,,,,,,,,,,,10/9/2017,10/9/2017,,,,,,,,,12/15/2017,12/15/2017,,,,,,,,,,,,,,,4/25/2018,4/25/2018,,,,,,
1-ZD88J,TAK-438_305,'TAK-438_305,,vonoprazan,"A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis",Comparator Study; EE Main,III,All Activities Closed,Maintenance of healed erosive esophagitis,GI,Late GI,,Non-pediatric only (>18 yr),Interventional,Treatment,,,693,630,1,,181,5,0,90.91%,72,,,IQVIA,,"Sook Koon Michelle Foo, Cynthia Lee",,Chui Fung Chong,,,,Approved,,,,,,Medidata CTMS (Pharma),,,8/22/2012,8/22/2012,8/29/2012,8/29/2012,,,4/1/2015,4/1/2015,4/8/2015,4/8/2015,,,7/3/2018,7/3/2018,,,12/31/2018,12/31/2018,,,,,,,,,,,11/18/2019,11/18/2019,,,,,,,,,11/18/2019,11/18/2019,,,,,,,,,,,,,11/18/2019,11/18/2019,,,,,,,,,1/8/2020,1/8/2020,,,,,,,,,,,,,,,3/19/2020,3/19/2020,,,,,,
1-ZD89G,TAK-448-2001,'TAK-448-2001,,TAK-448,"A Phase I pharmacokinetic and pharmacodynamic study of different dosing regimens of TAK-448, a kisspeptin agonist, in obese T2DM patients with  hypogonadism.",Phase 2a in T2D HH,II,Closed,Other,CVM,,,,Other Phase 1,,,,48,13,0,,63,0,0,27.08%,1,,,IQVIA,Rudi Taljaard,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD89S,TAK-448-2002,'TAK-448-2002,,TAK-448,"A Trial of the Stimulatory Effects of a Kisspeptin Analog, TAK-448, Administered Intermittently in Healthy Middle-aged and Older Men with Low Testosterone Status",Phase 2a in NHV,II,Closed,Other,CVM,,,,Other Phase 1,,,,66,17,213,,196,,,25.76%,1,,,IQVIA,Melanie Helmick,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD110,TBD-7898,'TBD-7898,,TAK-137,Elderly SRD/MRD,Elderly SRD/MRD Study_AD,I,Cancelled,Other,NS,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD137,RO-2455-302-RD,'RO-2455-302-RD,,Daxas,"Evaluation of tolerability and pharmacokinetics of roflumilast, 250ug and 500ug, as add-on to standard COPD treatment to treat severe COPD - the OPTIMIZE study.",OPTIMIZE,IIIB,Closed,Other,Marketed Products,,,,Other P3b - Post NDA,,,,"1,323","1,302",0,,234,15,0,98.41%,200,2,,IQVIA,Rosalida Leone,,,,,2013-001788-21,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD167,TBD-6900,'TBD-6900,,,Ph 1 QTc,Ph 1 QTc,I,Cancelled,Other,,,,,,,,,40,0,0,,0,,0,0.00%,12,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD174,TBD-6903,'TBD-6903,,,Ph 1 Age / Gender in LN,Ph 1 Age_Gen,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,6,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD191,TBD-6908,'TBD-6908,,,Ph 1 Absolute Bioavailability,Ph 1 Abs BA,I,Cancelled,Other,,,,,,,,,24,0,0,,0,,0,0.00%,8,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD806,TAK-063_104,'TAK-063_104,,TAK-063,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK-063 in Subjects with Stable Schizophrenia and Healthy Japanese Subjects",Multiple Rising Dose,I,Closed,Other,RGH,,,,MRD,,,,90,77,162,,85,,4,85.56%,1,,,Covance,,,,,,,,,,,,,,STARS Inactive,,,2/6/2013,2/6/2013,3/26/2013,3/26/2013,,,6/21/2013,6/21/2013,7/19/2013,7/19/2013,,,6/10/2014,6/10/2014,,,6/23/2014,6/23/2014,,,,,,,,,,,8/20/2014,8/20/2014,,,,,,,,,10/29/2014,10/29/2014,,,,,,,,,,,,,,,,,,,,,,,6/9/2015,6/9/2015,,,,,,,,,,,,,,,6/9/2015,6/9/2015,,,,,,
1-ZD813,TAK-114-1001,'TAK-114-1001,,TAK-114,DDI Co-administration Drug (oral contraceptive),1.1 DDI-Co-admin Drug,I,Cancelled,Other,GI,,,,DI High Complexity,,,,32,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD821,TAK-137_102,'TAK-137_102,,TAK-137,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and
Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With
Attention-Deficit/Hyperactivity Disorder",MRD_ADHD,I,Terminated,Other,NS,,,,MRD,,,,50,47,99,,52,,14,94.00%,1,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD833,TAK-375_112,'TAK-375_112,,Rozerem (ramelteon),Peds PK Study #2 (FDA requested),Peds PK Study #2,I,Cancelled,Other,Marketed Products,,,,Other Phase 1,,,,112,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD847,TAK-375SL_303,'TAK-375SL_303,,ROZEREM (ramelteon sublingal),"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL Tablet 0.1 mg and 0.4 mg as an Adjunctive Therapy to Treatment-As-Usual in the Maintenance Treatment of Bipolar I in  Adult Subjects",303 Bipolar Maintenance,III,Terminated,Other,Marketed Products,,,,Other P3A - Pre NDA,,,,624,0,0,,0,,0,0.00%,111,,,IQVIA,,,,,,2012-001373-85,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZD857,TAK-390MR_104,'TAK-390MR_104,,"DEXILANT (dexlansoprazole, MR)","Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Effect of TAK-390MR 60 mg and Esomeprazole 40 mg on Bone Metabolism in Healthy Postmenopausal Female Subjects",LCM Bone Homeostasis,I,Closed,Other,Others,,,,Other Phase 1,,,,240,247,1488,,1241,,38,102.92%,11,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,4/16/2009,4/16/2009,6/30/2010,6/30/2010,,,11/4/2010,11/4/2010,1/24/2011,1/24/2011,,,1/18/2013,1/18/2013,,,1/19/2014,1/19/2014,,,,,,,,,,,12/10/2014,12/10/2014,,,,,,,,,4/16/2015,4/16/2015,,,,,,,,,,,,,6/4/2015,6/4/2015,,,,,,,,,7/22/2015,7/22/2015,,,,,,,,,,,,,,,8/5/2016,8/5/2016,,,,,,
1-ZD863,TAK-390MR_204,'TAK-390MR_204,,"DEXILANT (dexlansoprazole, MR)","A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease",Peds 2-11yo GERD,II,Planned,Erosive esophagitis healing,Marketed Products,Marketed Products,,,,,,,70,,,,,,,,30,,,IQVIA,,"Kathryn Haas, Margaret Szerszunowicz",,"Andreas Schneider, John Petan, Linda Mulkerin",,2014-004506-15,,,,,,,,Medidata CTMS (Pharma),,,9/16/2013,9/16/2013,7/30/2015,7/30/2015,,,5/20/2022,,6/17/2022,,,,10/16/2024,,,,1/20/2025,,,,,,,,,,,,3/10/2025,,,,,,,,,,,,,,,,,,,,,,,,4/7/2025,,,,,,,,,,7/21/2025,,,,,,,,,,,,,,,,7/21/2025,,,,,,,
1-ZD894,TAK-441-1003,'TAK-441-1003,,TAK-441,POM Study,POM Study,I,Cancelled,Other,CVM,,,,Other Phase 1,,,,8,0,0,,0,,0,0.00%,1,6,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5SJ,TAK-875_132,'TAK-875_132,,TAK-875,"A Phase 1, Randomized, Open- Label, Single-Dose, 2-Period Crossover Study to Determine the Absolute Bioavailability of Fasiglifam (TAK-875) in Healthy Adult Subjects Absolute BA of TAK-875",Absolute BA,I,Closed,Other,CVM,,,,BA,,,,12,12,57,,45,,1,100.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5TM,TAK-875_203,'TAK-875_203,,TAK-875,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",BID vs QD comparison,II,Cancelled,Other,CVM,,,,Other Phase 2,,,,400,0,0,,0,,0,0.00%,105,,,,,,,,,2013-000886-35,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5TV,TAK-875_301,'TAK-875_301,,TAK-875,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes",Monotherapy,III,Cancelled,Other,CVM,,,,Other P3A - Pre NDA,,,,420,0,0,,0,,0,0.00%,141,,,,,,,,,2011-002741-35,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5U4,TAK-875_302,'TAK-875_302,,TAK-875,"Randomized, Double-Blind, Pbo & Active-Controlled, study to evaluate the efficacy & safety of TAK-875 25 mg & 50 mg compared to Pbo & Sitagliptin 100 mg When Used in Combination with Metformin",Add-on Met/Januvia comp,III,Terminated,Other,CVM,,,,Other P3A - Pre NDA,,,,"1,078",916,2073,,1157,,890,84.97%,191,,,,,,,,,2011-001752-10,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5UD,TAK-875_303,'TAK-875_303,,TAK-875,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",Add-on DPP-IV,III,Cancelled,Other,CVM,,,,Other P3A - Pre NDA,,,,390,0,0,,0,,0,0.00%,90,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5UM,TAK-875_304,'TAK-875_304,,TAK-875,"Ph 3 Randomized, Double-Blind, Active-Controlled, study to Evaluate the Efficacy & Safety of TAK-875 25mg & 50mg Compared to Glimepiride When Used in Combination with Mett Subjects with T2DM",Active Comparator vs SU,III,Terminated,Other,CVM,,,,Other P3A - Pre NDA,,,,"2,430",0,0,,0,,0,0.00%,353,,,,,,,,,2011-001731-24,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5UV,TAK-875_306,'TAK-875_306,,TAK-875,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",CV Safety,III,Cancelled,Other,CVM,,,,Outcomes,,,,"5,031",0,0,,0,,0,0.00%,712,,,,,,,,,2011-001732-37,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5V4,TAK-875_307,'TAK-875_307,,TAK-875,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes",APAC Monotherapy Study,III,Cancelled,00050 Type 2 diabetes,CVM,,,,Other P3A - Pre NDA,,,,630,0,0,,0,,0,0.00%,64,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5VF,TAK-875_308,'TAK-875_308,,TAK-875,Phase III TAK-875 Factorial study with metformin,Factorial combo w/Met,III,Cancelled,Other,CVM,,,,Other P3A - Pre NDA,,,,"1,080",0,0,,0,,0,0.00%,145,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5VO,TAK-875_309,'TAK-875_309,,TAK-875,"Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes",Add-on SU,III,Terminated,Other,CVM,,,,Other P3A - Pre NDA,,,,260,0,0,,0,,0,0.00%,73,,,,,,,,,2013-000007-17,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5VY,TAK-875_310,'TAK-875_310,,TAK-875,Add-on metformin study with active comparator to Januvia  (2nd head-to-head study against Januvia),2 Add-on Met/Januvia comp,III,Terminated,Other,CVM,,,,Other P3A - Pre NDA,,,,620,96,383,,242,,88,15.48%,105,,,,,,,,,2013-000542-19,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5W7,TAK-875_311,'TAK-875_311,,TAK-875,Demonstrate efficacy of TAK-875 in subjects with moderate to severe renal impairment (Restricited 1st Line Indication),Severe Renal Impairment,III,Cancelled,Other,CVM,,,,Other P3A - Pre NDA,,,,164,0,0,,0,,0,0.00%,75,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5WG,TAK-875_312,'TAK-875_312,,,Demonstrate efficay of TAK-875 in subjects intolerant to metformin (GI & renal) - Restricted 1st line indication,Met Intolerant Study,III,Cancelled,Other,,,,,Other P3A - Pre NDA,,,,360,0,0,,0,,0,0.00%,60,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5WP,TAK-935_101,'TAK-935_101,,soticlestat (TAK-935),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects",SRD,I,Closed,Other,NS,,,,SRD/FIM,,,,48,48,177,,129,,,100.00%,1,,,PPD,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,3/17/2014,3/17/2014,4/24/2014,4/24/2014,,,7/9/2014,7/9/2014,7/31/2014,7/31/2014,,,7/10/2015,7/10/2015,,,7/16/2015,7/16/2015,,,,,,,,,,,9/10/2015,9/10/2015,,,,,,,,,8/7/2015,8/7/2015,,,,,,,,,,,,,10/12/2015,10/12/2015,,,,,,,,,2/9/2016,2/9/2016,,,,,,,,,,,,,,,2/19/2016,2/19/2016,,,,,,
1-ZF5X1,TAK-935_1002,'TAK-935_1002,,soticlestat (TAK-935),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and
Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects",MRD,I,Closed,Other,NS,,,,MRD,,,,40,40,176,,136,,16,100.00%,1,,,PPD,Betty Katz,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,3/30/2015,3/30/2015,7/7/2015,7/7/2015,,,9/2/2015,9/2/2015,9/27/2015,9/27/2015,,,3/20/2016,3/20/2016,,,4/19/2016,4/19/2016,,,,,,,,,,,6/17/2016,6/17/2016,,,,,,,,,5/20/2016,5/20/2016,,,,,,,,,,,,,8/26/2016,8/26/2016,,,,,,,,,11/6/2016,11/6/2016,,,,,,,,,,,,,,,11/6/2016,11/6/2016,,,,,,
1-ZF5XB,RO-2455-405-RD,'RO-2455-405-RD,,Daxas,Effect of roflumilast 500 micg tablets once daily at acute COPD exacerbations treated with standard therapy of oral steroids and antibiotics. TREAT,TREAT,II,Closed,Other,Marketed Products,,,,Other Phase 2,,,,140,95,95,,,,19,67.86%,1,,,,Karen Watkins,,,,,2011-002905-31,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5XK,TAK-935_1003,'TAK-935_1003,,soticlestat (TAK-935),"An Open-Label, Positron Emission Tomography, Phase 1 Study with [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects",PET Occupancy,I,Closed,Other,NS,,,,,,,,11,11,26,,15,,,100.00%,1,,,PPD,Betty Katz,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,5/14/2015,5/14/2015,,,7/1/2015,7/1/2015,7/15/2015,7/15/2015,,,11/20/2015,11/20/2015,,,1/6/2016,1/6/2016,,,,,,,,,,,3/4/2016,3/4/2016,,,,,,,,,12/18/2015,12/18/2015,,,,,,,,,,,,,5/20/2016,5/20/2016,,,,,,,,,8/18/2016,8/18/2016,,,,,,,,,,,,,,,8/26/2016,8/26/2016,,,,,,
1-ZF5XT,TC-2402-039-SP,'TC-2402-039-SP,,TachoSil (Fribrinogen and thrombin),"TA randomized, open label, parallel-group, multi-center trial to compare
efficacy and safety of TachoSil® versus Surgicel® Original for the secondary
hemostatic treatment of needle hole bleeding in vascular surgery.",VASUS,IIIB,Closed,Other,Marketed Products,,,,Other P3b - Post NDA,,,,150,150,185,,35,,28,100.00%,24,,,PPD,Rosalida Leone,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5YF,TMX-67_107,'TMX-67_107,,Febuxostat XR,"PK/PD dose ranging and safety study of PO doses of febuxostat pediatric formulation in pediatric subjects, 2 to 11 years of age, with low risk for TLS",PK/PD 2 to 11 Yr Olds,II,Cancelled,Other,Marketed Products,,,,Pediatric PK,,,,27,0,0,,0,,0,0.00%,15,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF5YO,TMX-67_204,'TMX-67_204,,ULORIC (febuxostat),"A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects with Early Gout",Early Gout,II,Closed,Other,Others,,,,Other Phase 2,,,,300,0,0,,0,,0,0.00%,85,,,Covance,,,,,,,,,,,,,,STARS Inactive,,,5/8/2009,5/8/2009,8/19/2009,8/19/2009,,,,,3/25/2010,3/25/2010,,,8/25/2011,8/25/2011,,,9/3/2013,9/3/2013,,,,,,,,,,,12/9/2013,12/9/2013,,,,,,,,,2/3/2014,2/3/2014,,,,,,,,,,,,,,,,,,,,,,,12/8/2015,12/8/2015,,,,,,,,,,,,,,,12/8/2015,12/8/2015,,,,,,
1-ZF5Z0,TMX-67_206,'TMX-67_206,,ULORIC (febuxostat),"A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension",Blood Pressure,II,Closed,Other,Others,,,,POC,,,,120,0,0,,0,,0,0.00%,40,,,Covance,,,,,,,,,,,,,,STARS Inactive,,,5/24/2011,5/24/2011,9/13/2011,9/13/2011,,,1/14/2012,1/14/2012,2/4/2012,2/4/2012,,,6/12/2014,6/12/2014,,,8/4/2014,8/4/2014,,,,,,,,,,,10/14/2014,10/14/2014,,,,,,,,,1/30/2015,1/30/2015,,,,,,,,,,,,,,,,,,,,,,,12/11/2015,12/11/2015,,,,,,,,,,,,,,,12/11/2015,12/11/2015,,,,,,
1-ZF5ZJ,TMX-67_301,'TMX-67_301,,ULORIC (febuxostat),"A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities",Uloric CV Outcomes,IIIB,Closed,00048 Gout,Others,,,,Outcomes,,,,"7,500","6,193",0,,0,0,2737,82.57%,450,,,PPD,Brette Evans,,,,,,,,,,,,,STARS Inactive,,,4/9/2009,4/9/2009,8/24/2009,8/24/2009,,,4/23/2010,4/23/2010,4/30/2010,4/30/2010,,,7/25/2016,7/25/2016,,,5/15/2017,5/15/2017,,,,,,,,,,,8/8/2017,8/8/2017,,,,,,,,,,,,,,,,,,,,,,,9/5/2017,9/5/2017,,,,,,,,,12/21/2017,12/21/2017,,,,,,,,,,,,,,,12/21/2017,12/21/2017,,,,,,
1-ZF60M,Vedolizumab-4001,'Vedolizumab-4001,,Entyvio,Conduct a milk-only lactation study in lactating women receiving MLN0002 therapeutically to assess concentrations of vedolizumab in breast milk using a validated assay,P4 PMR Lactation Study,IV,Closed,Other,GI,,,,Other Phase IV,,,,12,11,0,,0,0,1,91.67%,8,,,PPD,Angela Gamble,,,,,,,,,,,,,STARS Inactive,,,8/18/2014,8/18/2014,3/31/2015,3/31/2015,,,11/29/2017,11/29/2017,12/12/2017,12/12/2017,,,12/27/2018,12/27/2018,,,2/22/2019,2/22/2019,,,,,,,,,,,4/5/2019,4/5/2019,,,,,,,,,4/5/2019,4/5/2019,,,,,,,,,,,,,6/3/2019,6/3/2019,,,,,,,,,7/24/2019,7/24/2019,,,,,,,,,,,,,,,9/10/2019,,,,,,,
1-ZF60Y,Vedolizumab-4002,'Vedolizumab-4002,,Entyvio,Evaluate in a step-wise approach the disease-drug-drug interaction (Disease-DDI) potential for vedolizumab to indirectly affect the exposure of CYP substrate drugs,P4 PMR DDDI Study,IV,Not Yet Recruiting,Support - GI,GI,Late GI,,,,,,,60,,,,,,,,3,,,IQVIA,,"Angela Gamble, Helen Crane, Mark Patti",,Arpeat Kaviya,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZF603,TMX-67_302,'TMX-67_302,,Febuxostat XR,"Randomized, controlled safety and efficacy study  in pediatric subjects 2 to 17 years of age with low-to-intermediate risk for TLS",S&E in 2 to 17 Yr Olds,III,Cancelled,Other,Marketed Products,,,,Other P3A - Pre NDA,,,,100,0,0,,0,,0,0.00%,68,,,PPD,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZFFCM,TBD-7718,'TBD-7718,,,EM POM Ataxia Single Dose,EM POM Ataxia SD,I,Cancelled,Other,,,,,,,,,1,0,0,,0,,0,0.00%,1,,,,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZG5ZJ,MLN1202_2005,'MLN1202_2005,,TAK-202,"A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Mechanism, Phase 2 Study to Evaluate the  Efficacy and Safety of Biweekly SC MLN1202, in Improving DN in CKD3 Subjects.",PII for DN,II,Cancelled,00283 Diabetic nephropathy,CVM,,,,POC,,,,156,0,0,,0,,0,0.00%,70,1,,IQVIA,Maria Ephrem,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZG5ZS,MLN1202-2006,'MLN1202-2006,,TAK-202,"A Randomized, Double-Blind, Placebo-Controlled, POM, Phase 2 Study to Evaluate the Efficacy and Safety of  IV Multiple Doses MLN 1202 For  6 wks in Patients with Stable Cardiovascular Disease",PET/CT POM Study,II,Terminated,Other,CVM,,,,Other Phase 2,,,,108,0,0,,0,,0,0.00%,16,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZG601,MLN1202-2007,'MLN1202-2007,,TAK-202,"A Randomized, Double Blind, Placebo Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Monthly Intravenous Administration of MLN1202 in Preserving In-Stent Patency in Subjects with Peripheral Artery Disease",PII for PAD,II,Terminated,Other,CVM,,,,POC,,,,350,0,0,,0,,0,0.00%,80,,,IQVIA,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZOEF2,TAK-020-1001,'TAK-020-1001,,TAK-020,"Ph 1 Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single, MRD to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Healthy Volunteers",SRD/MRD Study,I,Closed,Other,Immunology,,,,SRD/FIM,,,,128,114,0,,377,120,0,89.06%,1,,,IQVIA,Kelly Hanna,,,,,,,,,,,,,STARS Inactive,,,11/4/2014,11/4/2014,12/19/2014,12/19/2014,,,3/9/2015,3/9/2015,4/6/2015,4/6/2015,,,4/17/2017,4/17/2017,,,5/4/2017,5/4/2017,,,,,,,,,,,7/25/2017,7/25/2017,,,,,,,,,7/27/2017,,,,,,,,,,,,,,8/21/2017,8/21/2017,,,,,,,,,12/22/2017,12/22/2017,,,,,,,,,,,,,,,12/22/2017,,,,,,,
1-ZOEFB,TAK-020-1002,'TAK-020-1002,,TAK-020,"A Randomized, Open Label Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of a Single Dose of Various Test Solid Formulations of TAK-020 Compared With a Single Dose of Reference Oral Solution and to Evaluate the Food Effect and Potentially the Dose Proportionality of the Optimal Solid Dose Formulation",Relative BA-Form'n Study,I,Closed,Other,Immunology,,,,BA,,,,25,23,0,,62,25,0,92.00%,1,,,IQVIA,Kelly Hanna,,,,,,,,,,,,,STARS Inactive,,,5/20/2015,5/20/2015,12/11/2015,12/11/2015,,,4/28/2016,4/28/2016,5/25/2016,5/25/2016,,,7/26/2016,7/26/2016,,,8/19/2016,8/19/2016,,,,,,,,,,,11/7/2016,11/7/2016,,,,,,,,,,,,,,,,,,,,,,,1/18/2017,1/18/2017,,,,,,,,,5/10/2017,5/10/2017,,,,,,,,,,,,,,,5/10/2017,,,,,,,
1-ZVIRN,TAK-915-1001,'TAK-915-1001,,TAK-915,"A Phase 1 Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-915 in Healthy Volunteers",SRD/MRD in HV,I,Closed,Other,NS,,,,SRD/FIM,,,,92,88,333,,245,,1,95.65%,1,,,PPD,Vicky Fontana,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZVIRW,TBD-7743,'TBD-7743,,TAK-915,TAK-915 PET Validation Study with [18F]MNI-794,PET Validation,I,Closed,Other,NS,,,,Other Phase 1,,,,6,6,6,,,,,100.00%,1,,,In-House,,,,,,,,,,,,,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1-ZYOC0,TAK-935-5001,'TAK-935-5001,,soticlestat (TAK-935),"Assessment and validation of plasma biomarker, 24 Hydroxycholesterol (24 HC), in Rare Epilepsy Syndromes in children and adults",Non-interventional Plasma 24-HC in Epileptic,0,Cancelled,Other,NS,,,,EM Phase 0,,,,150,25,50,,,,,16.67%,3,,,In-House,,,,,,,,,,,Wave 1,Advance,,STARS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-124-997,TBD-13-124-997,'TBD-13-124-997,,pevonedistat (TAK-924),Ph 1b/2 Pevonedistat/Magrolimab/Aza combination in 1L HR MDS,Ph 1b/2 Pevonedistat/Magrolimab/Aza combination in 1L HR MDS,I/II,Planned,(MDS) Myelodysplastic syndromes,Oncology,Early Oncology,,,,,,,30,,,,,,,,15,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,9/30/2021,,,,,,1/28/2022,,,,1/28/2023,,10/28/2023,,8/21/2023,,,,,,,,10/28/2025,,,,10/9/2023,,,,,,,,12/23/2025,,10/14/2023,,,,,,,,12/28/2025,,,,,,10/30/2023,,,,,,,,,,11/27/2023,,,,,,,,1/28/2026,,,,,,,,1/28/2026,,,,,,,
13-138-813,TAK-994-1014,'TAK-994-1014,,TAK-994,Healthy Volunteers Drug Drug Interaction with CYP3A4 inhibition,TAK-994 HV DDI with CYP3A4 inhibition,I,Planned,other,NS,Neurology,,,Interventional,,,,24,,,,,,,,1,,,Celerion,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,5/7/2021,5/7/2021,7/9/2021,7/9/2021,,,8/6/2021,,8/26/2021,,,,10/4/2021,,,,10/29/2021,,,,,,,,,,,,11/29/2021,,,,,,,,,,12/6/2021,,,,,,,,,,,,,,,,,,,,,,,,5/9/2022,,,,,,,,,,,,,,,,10/28/2022,,,,,,,
13-171-778,TAK-925-1020,'TAK-925-1020,,TAK-925,"Phase 1b, Randomized, Double-blind, Placebo-controlled, 3-Period Crossover Study to Evaluate the Efficacy of Intravenous TAK-925 on Upper Airway Collapsibility in Subjects with Obstructive Sleep Apnea","TAK-925 PK, PD Safety Tolerability Study in Patients with OSA",Ib,Planned,OSA (Obstructive Sleep Apnea),NS,Early NS,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,8/4/2021,,9/17/2021,,,,11/26/2021,,12/29/2021,,,,6/27/2022,,,,7/26/2022,,,,,,,,,,,,8/22/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/3/2023,,,,,,,,,,,,,,,,1/3/2023,,,,,,,
13-252-879,TBD-13-252-879,'TBD-13-252-879,,TAK-007,TBD,TAK-007-2001_13-252-879_Ph 2 Pivotal SA r/r LBCL and iNHL,II,Planned,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,150,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/6/2023,,4/30/2023,,,,,,7/29/2023,,,,11/20/2024,,12/20/2024,,5/19/2025,,,,,,,,10/26/2029,,,,,,,,,,,,12/21/2029,,,,,,,,,,12/28/2029,,,,,,,,,,,,,,1/18/2030,,,,,,,,,,5/31/2030,,,,,,,,5/31/2030,,,,,,,
13-253-015,TBD-13-253-015,'TBD-13-253-015,,,TBD,Ph2 DLBCL Combo 2L,II,Cancelled,,,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-253-086,TBD-13-253-086,'TBD-13-253-086,,,TBD,Ph2 iNHL Combo 2L,II,Cancelled,,,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-253-221,TBD-13-253-221,'TBD-13-253-221,,TAK-007,TBD,Ph2 CLL Combo 2L,II,Cancelled,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,100,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-253-292,TBD-13-253-292,'TBD-13-253-292,,TAK-007,TBD,Ph3 DLBCL Combo 1L,III,Planned,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,450,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-253-835,TBD-13-253-835,'TBD-13-253-835,,TAK-007,TBD,Ph3 iNHL Combo 1L,III,Planned,,Oncology,Early Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,,,450,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-253-906,TBD-13-253-906,'TBD-13-253-906,,TAK-007,TBD,Ph3 CLL Combo 1L,III,Planned,,Oncology,Early Oncology,,Non-pediatric only (>18 yr),Interventional,Treatment,,,450,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-253-977,TBD-13-253-977,'TBD-13-253-977,,TAK-007,TBD,Ph1 MCL Japan-only,I,Cancelled,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,10,,,,,,,,5,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-255-988,TAK-935-1009,'TAK-935-1009,,soticlestat (TAK-935),A Phase 1 study to evaluate drug-drug interaction of TAK-935 with rifampin in healthy adult subjects,"TAK-935 PK, DDI (Induction) Study with Rifampin",I,Planned,Disease-modifying in epilepsy,NS,Early NS,,Non-pediatric only (>18 yr),Interventional,,,,14,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,6/14/2021,6/14/2021,8/20/2021,,,,11/8/2021,,12/3/2021,,,,12/3/2021,,,,12/31/2021,,,,,,,,,,,,2/4/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/13/2022,,,,,,,,,,,,,,,,5/13/2022,,,,,,,
13-256-294,TBD-13-256-294,'TBD-13-256-294,,,A 2 Period Crossover in Healthy Subjects with Opioid-induced Respiratory Depression,"TAK-925 PK, PD to evaluate the safety and tolerability hi dose, low dose and placebo, randomized 1:1 in healthy subjects with OIRD. The subjects will be anesthetized",Ib,Cancelled,,,Early NS,,,,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-257-676,TBD-13-257-676,'TBD-13-257-676,,TAK-007,TBD,Ph1 Pediatric,I,Planned,,Oncology,Cell Therapy,,Pediatric only (<18 yr),Interventional,Treatment,,,42,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-289-376,TAK-925-1021,'TAK-925-1021,,TAK-925,"TAK-925 PK, PD to evaluate the safety and tolerability hi dose, low dose and placebo, randomized 1:1 in healthy subjects with OIRD. The subjects will be anesthetized.",A 2 Period Crossover in Healthy Subjects with Opioid-induced Respiratory Depression,Ib,Planned,other,NS,Early NS,,Non-pediatric only (>18 yr),Interventional,Basic Science,Other,Case-Crossover,14,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,4/15/2021,4/15/2021,7/26/2021,,,,10/6/2021,,10/20/2021,,,,12/15/2021,,,,1/17/2022,,,,,,,,,,,,2/15/2022,,,,,,,,,,2/24/2022,,,,,,,,,,,,,,,,,,,,,,,,7/15/2022,,,,,,,,,,,,,,,,7/15/2022,,,,,,,
13-289-512,TBD-13-289-512,'TBD-13-289-512,,TAK-007,"A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",Prior CD19 CART Patients,II/III,Planned,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,30,,,,,,,,70,,,TBD,,,,,,2021-002086-18,,,,,,,,Medidata CTMS (Pharma),,,1/31/2023,,3/27/2023,,,,,,7/17/2023,,,,7/11/2024,,8/10/2024,,1/7/2025,,6/18/2029,,,,,,,,,,8/13/2029,,,,,,,,,,8/20/2029,,,,,,,,,,,,,,9/10/2029,,,,,,,,,,1/21/2030,,,,,,,,,,,,,,,,1/21/2030,,,,,,,
13-290-429,TBD-13-290-429,'TBD-13-290-429,,TAK-007,"A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",ALL,II/III,Cancelled,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,30,,,,,,,,70,,,TBD,,,,,,2021-002086-18,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-292-517,TBD-13-292-517,'TBD-13-292-517,,TAK-007,"A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",MCL,II/III,Cancelled,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,30,,,,,,,,70,,,TBD,,,,,,2021-002086-18,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-292-676,TBD-13-292-676,'TBD-13-292-676,,TAK-007,"A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",Richter's,II/III,Cancelled,,Oncology,Cell Therapy,,Non-pediatric only (>18 yr),Interventional,Treatment,,,30,,,,,,,,70,,,TBD,,,,,,2021-002086-18,,,,,Wave 1,Accelerate,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-312-851,TAK-935-1010,'TAK-935-1010,,,"Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Subjects with Mild, Moderate or Severe Hepatic Impairment and Normal Hepatic Function",TAK-935 Hepatic Impairment Study,I,Planned,,,Early NS,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,36,,,,,,,,3,,,Celerion,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-340-941,TAK-880-5001,'TAK-880-5001,,,In vitro safety and tolerability of TAK-880 in blood from primary immunodeficiency (PID) patients at increased risk of developing hypersensitivity reactions to IgA - In vitro analysis and assessment of medical history.,TAK-880: In vitro safety and tolerability study on blood from PID patients.,N/A,Planned,,,PDT,,Non-pediatric only (>18 yr),Observational,,,,60,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-347-725,TAK-935-1011,'TAK-935-1011,,soticlestat (TAK-935),"A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety,Tolerability and Pharmacokinetics of Single Doses and Multiple Doses with Titration of TAK-935 in Healthy Chinese Subjects",A phase 1 PK study in Chinese healthy adults,I,Planned,,NS,Late NS,,Non-pediatric only (>18 yr),Interventional,Treatment,,,36,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,8/12/2021,,10/25/2021,,,,7/26/2022,,7/26/2022,,,,9/22/2022,,,,10/16/2022,,,,,,,,,,,,12/9/2022,,,,,,,,,,12/16/2022,,,,,,,,,,,,,,1/6/2023,,,,,,,,,,4/14/2023,,,,,,,,,,,,,,,,4/14/2023,,,,,,,
13-347-725,TBD-13-347-725,'TBD-13-347-725,,soticlestat (TAK-935),"A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety,Tolerability and Pharmacokinetics of Single Doses and Multiple Doses with Titration of TAK-935 in Healthy Chinese Subjects",A phase 1 PK study in Chinese healthy adults,I,Planned,,NS,Late NS,,Non-pediatric only (>18 yr),Interventional,Treatment,,,36,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,8/12/2021,,10/25/2021,,,,7/26/2022,,7/26/2022,,,,9/22/2022,,,,10/16/2022,,,,,,,,,,,,12/9/2022,,,,,,,,,,12/16/2022,,,,,,,,,,,,,,1/6/2023,,,,,,,,,,4/14/2023,,,,,,,,,,,,,,,,4/14/2023,,,,,,,
13-349-683,Pevonedistat-2003,'Pevonedistat-2003,,,"A Phase 2, Open-Label Study of Pevonedistat in Combination with Decitabine+Cedazuridine  in Adult Patients with Higher-Risk Myelodysplastic Syndromes (HR MDS)",TBD-Pevonedistat,II,Planned,,,Real World Evidence,,Non-pediatric only (>18 yr),Interventional,Treatment,,,76,,,,,,,,19,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-354-250,TBD-13-354-250,'TBD-13-354-250,,,"Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn’s Disease Risk Prediction Tool",Vedo COMPASS CD,IV,Planned,,,Real World Evidence,,Non-pediatric only (>18 yr),Interventional,Other,Prospective,,200,,,,,,,,50,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-362-366,TBD-13-362-366,'TBD-13-362-366,,,TBC,"Adult PAC CTCL, China only single arm Study",IV,Planned,(CTCL) CD30+ cutaneous T cell lymphoma,,Early Oncology,,Non-pediatric only (>18 yr),,Treatment,,,10,,,,,,,,3,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-371-098,TBD-13-371-098,'TBD-13-371-098,,Entyvio,P3 Pediatric Pouchitis,P3 Pediatric Pouchitis,III,Planned,Pouchitis,GI,Late GI,,Pediatric only (<18 yr),Interventional,Treatment,,,20,,,,,,,,18,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,9/1/2022,,,,,,1/23/2023,,,,6/23/2025,,,,7/6/2026,,,,,,,,,,,,8/31/2026,,,,,,,,,,,,,,,,,,,,,,,,9/28/2026,,,,,,,,,,12/21/2026,,,,,,,,,,,,,,,,12/21/2026,,,,,,,
13-376-890,TAK-935-3003,'TAK-935-3003,,soticlestat (TAK-935),"A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)",Open-Label Extension Study of Soticlestat in Dravet and Lennox-Gastaut Syndromes,III,Planned,,NS,Early NS,,Both pediatric and non-pediatric,Interventional,Treatment,,,338,,,,,,,,90,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,4/28/2021,4/28/2021,7/7/2021,7/7/2021,,,11/10/2021,,11/10/2021,,,,9/6/2022,,,,11/1/2022,,,,,,,,6/8/2025,,,,11/29/2022,,,,,,,,7/4/2025,,12/6/2022,,,,,,,,7/11/2025,,,,,,1/4/2023,,,,,,,,8/11/2025,,3/21/2023,,,,,,,,11/13/2025,,,,,,,,11/13/2025,,,,,,,
13-377-047,TBD-13-377-047,'TBD-13-377-047,,TAK-925,"A, Phase 1 Study to Assess the absorption, distribution, metabolism, and excretion (ADME) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Danavorexton in Healthy Subjects",TAK-925 hADME study,I,Planned,other,NS,Early NS,,,Interventional,Treatment,Prospective,Cohort,6,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,1/2/2023,,2/15/2023,,,,4/14/2023,,4/14/2023,,,,11/24/2023,,,,12/25/2023,,,,,,,,,,,,2/26/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/28/2024,,,,,,,,,,,,,,,,8/28/2024,,,,,,,
13-377-116,TBD-13-377-116,'TBD-13-377-116,,TAK-925,"A, Phase 1 Study to Assess the Drug-Drug Interaction (DDI) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Danavorexton in Healthy Subjects",Safety DDI study,I,Planned,other,NS,Early NS,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,12,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/1/2022,,9/15/2022,,,,11/1/2022,,11/1/2022,,,,2/2/2023,,,,2/15/2023,,,,,,,,,,,,3/27/2023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/18/2023,,,,,,,,,,,,,,,,8/18/2023,,,,,,,
13-387-263,TAK-510-1003,'TAK-510-1003,,TAK-510,TAK-510 ADME Study in Normal Healthy Volunteers,TAK-510 ADME Study,I,Planned,Cyclic Vomiting Syndrome-Prodrome,GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,4/24/2023,,5/22/2023,,,,7/17/2023,,8/14/2023,,,,8/28/2023,,,,11/20/2023,,,,,,,,,,,,2/12/2024,,,,,,,,,,2/19/2024,,,,,,,,,,,,,,3/11/2024,,,,,,,,,,6/3/2024,,,,,,,,,,,,,,,,11/18/2024,,,,,,,
13-387-400,TAK-105-1003,'TAK-105-1003,,TAK-105,TAK-105  ADME Study in Normal Healthy Volunteers,TAK-105 ADME Study,I,Planned,Cyclic Vomiting Syndrome-Prophylaxis,GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,5/1/2023,,5/29/2023,,,,7/17/2023,,8/14/2023,,,,8/28/2023,,,,11/20/2023,,,,,,,,,,,,2/12/2024,,,,,,,,,,2/19/2024,,,,,,,,,,,,,,3/11/2024,,,,,,,,,,6/3/2024,,,,,,,,,,,,,,,,11/3/2025,,,,,,,
13-396-567,TBD-13-396-567,'TBD-13-396-567,,TAK-510,TAK-510 rBA Study In Normal Healthy Volunteers,TAK-510 rBA Study-1,I,Planned,,GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,,,24,,,,,,,,1,,,Celerion,,,,,,,,Not yet submitted,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,9/5/2022,,10/3/2022,,,,11/28/2022,,12/26/2022,,,,1/9/2023,,,,2/20/2023,,,,,,,,,,,,3/20/2023,,,,,,,,,,3/27/2023,,,,,,,,,,,,,,4/17/2023,,,,,,,,,,7/10/2023,,,,,,,,,,,,,,,,10/28/2025,,,,,,,
13-396-641,TBD-13-396-641,'TBD-13-396-641,,TAK-510,TAK-510 rBA Study of Prefilled Syringes In Normal Healthy Volunteers,TAK-510 rBA Study-2,I,Planned,,GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,,,24,,,,,,,,1,,,Celerion,,,,,,,,Not yet submitted,,,Wave 2,Accelerate,,Medidata CTMS (Pharma),,,5/14/2024,,6/11/2024,,,,8/6/2024,,9/3/2024,,,,9/17/2024,,,,10/29/2024,,,,,,,,,,,,11/26/2024,,,,,,,,,,12/3/2024,,,,,,,,,,,,,,12/24/2024,,,,,,,,,,3/18/2025,,,,,,,,,,,,,,,,10/28/2025,,,,,,,
13-396-784,TBD-13-396-784,'TBD-13-396-784,,TAK-105,TAK-105 rBA Study In Normal Healthy Volunteers,TAK-105 rBA Study-1,I,Planned,,GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,3/23/2022,,4/20/2022,,,,6/15/2022,,7/13/2022,,,,7/27/2022,,,,10/19/2022,,,,,,,,,,,,11/16/2022,,,,,,,,,,11/23/2022,,,,,,,,,,,,,,12/14/2022,,,,,,,,,,3/8/2023,,,,,,,,,,,,,,,,11/3/2025,,,,,,,
13-396-926,TBD-13-396-926,'TBD-13-396-926,,TAK-105,TAK-105 rBA Study of Prefilled Syringes in Normal Healthy Volunteers,TAK-105 rBA Study-2,I,Planned,,GI,Early GI,,Non-pediatric only (>18 yr),Interventional,Basic Science,,,24,,,,,,,,1,,,TBD,,,,,,,,,,,NA,Accelerate,,Medidata CTMS (Pharma),,,4/8/2024,,5/6/2024,,,,7/1/2024,,7/29/2024,,,,8/12/2024,,,,11/4/2024,,,,,,,,,,,,12/2/2024,,,,,,,,,,12/9/2024,,,,,,,,,,,,,,12/30/2024,,,,,,,,,,3/24/2025,,,,,,,,,,,,,,,,11/3/2025,,,,,,,
13-398-432,TAK-280-1501,'TAK-280-1501,,TAK-280,Phase 1/2 First in Human Escalation + Expansion,Phase 1/2 First in Human,I/II,Planned,,Oncology,Early Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,6/10/2021,6/10/2021,8/4/2021,,,,11/30/2021,,12/30/2021,,,,10/6/2023,,12/5/2023,,12/5/2023,,,,,,,,,,,,1/30/2024,,,,,,,,,,2/6/2024,,,,,,,,,,,,,,2/27/2024,,,,,,,,,,7/9/2024,,,,,,,,,,,,,,,,7/9/2024,,,,,,,
13-398-434,TBD-13-398-434,'TBD-13-398-434,,TAK-280,Ph 2/3 Registration Study,Ph 2/3 Registration Study,III,Planned,,Oncology,Early Oncology,,,,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/14/2023,,9/22/2023,,,,,,1/11/2024,,,,12/27/2025,,5/26/2026,,4/28/2026,,,,,,,,,,,,7/14/2026,,,,,,,,,,7/21/2026,,,,,,,,,,,,,,8/11/2026,,,,,,,,,,11/3/2026,,,,,,,,,,,,,,,,11/3/2026,,,,,,,
13-426-309,TAK-935-1012,'TAK-935-1012,,soticlestat (TAK-935),Phase 1 Human Abuse Liability study with TAK-935 and IV Ketamine,TAK-935 Human Abuse Liability Study,I,Planned,Disease-modifying in epilepsy,NS,Early NS,,Non-pediatric only (>18 yr),Interventional,Treatment,Other,Cohort,54,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,9/6/2021,,7/15/2022,,,,9/5/2022,,9/5/2022,,,,5/23/2023,,,,5/23/2023,,,,,,,,,,,,6/6/2023,,,,,,,,,,6/20/2023,,,,,,,,,,,,,,,,,,,,,,,,8/30/2023,,,,,,,,,,,,,,,,10/13/2023,,,,,,,
13-470-362,Darvadstrocel-3008,'Darvadstrocel-3008,,,Phase 3 Study of Cx601 in Subjects with Complex Perianal Fistulising Crohn's Disease,Phase 3 Study of Cx601 in Subjects with Complex Perianal Fistulising Crohn's Disease,III,Planned,,,Late GI,,,,,,,20,,,,,,,,1,,,TBD,,Michelle Foo,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-482-362,TAK-834-1001,'TAK-834-1001,,,"A Randomized, Open-label, Single-dose, Two-treatment, Two period Crossover Study to Determine the Bioequivalence of new and old formulation of  Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously with the Haselmeier Injector Pens in Healthy Volunteers.",Phase 1 BE study for adult new formulation,I,Planned,,,RGH,,,Interventional,,,,150,,,,,,,,1,,,Celerion,,,,,,NA,,Not yet submitted,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-489-801,TBD-13-489-801,'TBD-13-489-801,,,"A Phase 1 Study to Assess the absorption, distribution, metabolism, and excretion (ADME) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-861 in Healthy Subjects",TAK-861 hADME study,I,Planned,Sleep Disorders,,Early NS,,,,Treatment,Prospective,Cohort,8,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-489-962,TBD-13-489-962,'TBD-13-489-962,,,"A Phase 1 Study to Assess the Drug-Drug Interaction (DDI) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Danavorexton in Healthy Subjects",TAK-861 DDI study,I,Planned,Sleep Disorders,,Early NS,,Non-pediatric only (>18 yr),,Treatment,Prospective,Cohort,12,,,,,,,,1,,,TBD,,,,,,,,Not yet submitted,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-490-214,TBD-13-490-214,'TBD-13-490-214,,,"A Phase 1 Study to Assess the Drug-Drug Interaction (DDI) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Danavorexton in Healthy Subjects",TAK-861 DDI Study#2,I,Planned,Sleep Disorders,,Early NS,,Non-pediatric only (>18 yr),,Treatment,Prospective,Cohort,12,,,,,,,,1,,,TBD,,,,,,,,Not yet submitted,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13-491-562,TBD-13-491-562,'TBD-13-491-562,,,A Phase 1 Evaluation of Effects of TAK-861 on cardiac repolarization and proarrhythmic potential (TQT)l interval in Healthy Volunteer Subjects,TAK-861 TQT,I,Planned,Sleep Disorders,,Early NS,,,,Treatment,Prospective,Cohort,12,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
33xxxA,33xxxA,'33xxxA,'33xxxA,,BAX2400 nal-IRI Gastric ph III APAC,BAX2400 nal-IRI Gastric APAC,III,Study Withdrawn,Pancreatic Cancer,,,Non-Registry,,Interventional,,,,550,0,0,0,0,,0,0.00%,70,,Baxalta,IQVIA,Eli Taube,,Qi Zhu,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
33xxxB,33xxxB,'33xxxB,'33xxxB,,BAX2400 nal_IRI Gastric IO - Global,BAX2400 nal_IRI Gastric IO - G,I,Study Withdrawn,Pancreatic Cancer,,,Non-Registry,,Interventional,,,,1,0,0,0,0,,0,0.00%,1,,Baxalta,,Eli Taube,,Deyaa Adib,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
90xxxa,90xxxa,'90xxxa,'90xxxa,,CLI - US: Critical Limb Ischemia / Peripheral Arterial Disease,CLI - US,II/III,Study Withdrawn,Critical Limb Ischemia (CLI),,,Non-Registry,,Interventional,,,,450,0,0,0,0,,0,0.00%,60,,Baxalta,,George Chen,,Adel Nada,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
90xxxb,90xxxb,'90xxxb,'90xxxb,,CLI - Japan: Critical Limb Ischemia,CLI - Japan,III,Study Withdrawn,Critical Limb Ischemia (CLI),,,Non-Registry,,Interventional,,,,40,0,0,0,0,,0,0.00%,5,,Baxalta,,George Chen,,Adel Nada,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-100,0624-100,'0624-100,,,"OPEN-LABEL, SINGLE-DOSE, RANDOMIZED, THREE-WAY CROSSOVER STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF SUBCUTANEOUS ADMINISTRATION OF CINRYZE®
[C1 ESTERASE INHIBITOR (HUMAN)] IN HEALTHY VOLUNTEERS",0624-100: BA of SC in Healthy Adults,I,Completed,Hereditary Angioedema (HAE),,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,7,9,0,0,0,0,0,128.57%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,12/16/2010,,,4/6/2009,4/6/2009,,,,,6/12/2009,6/12/2009,,,7/7/2009,7/7/2009,,,,,,,,,,,,,8/26/2009,8/26/2009,8/26/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-101,0624-101,'0624-101,,,"A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-WAY PARALLEL GROUP AND TWO-WAY CROSSOVER DOSE-RANGING STUDY TO EVALUATE THE PHARMACOKINETICS/PHARMACODYNAMICS OF THREE DOSES OF RECOMBINANT HUMAN HYALURONIDASE (rHuPH20) ADMINISTERED WITH 2000 UNITS OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) AS A SINGLE DOSE AT TWO SEPARATE SUBCUTANEOUS INJECTION SITES IN HEALTHY VOLUNTEERS",0624-101: PD SC w/ rHuPH20,I,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,24,24,24,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,1/13/2014,,,12/19/2011,12/19/2011,,,,,1/30/2012,1/30/2012,,,2/1/2012,2/1/2012,,,,,,,,,,,,,3/21/2012,3/21/2012,3/21/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-102,0624-102,'0624-102,,,0624-102 -Lynx Study,0624-102 -Lynx Study,I,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,56,53,53,0,0,0,30,94.64%,999,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-200,0624-200,'0624-200,,,"AN OPEN-LABEL, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF CINRYZE IN ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA",0624-200: SC Adlsc & Adults,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,24,26,30,0,4,0,2,108.33%,7,,ViroPharma,,,,,,Alece Ellis,,,,N,No,,,,COSMOS Inactive,,9/6/2011,,,1/28/2010,1/28/2010,,,,,6/7/2010,6/7/2010,,,9/21/2010,9/21/2010,,,,,,,,,,,,,12/16/2010,12/16/2010,12/16/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-201,0624-201,'0624-201,'SHP616-201,,"An Open-label Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of CINRYZE® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema who Previously Participated in CINRYZE Study 0624 200",0624-204: SC Adlsc & Adults from C-200,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,12,18,20,0,2,0,0,150.00%,5,,ViroPharma,,,,,,,2012-000441-12,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-203,0624-203,'0624-203,'SHP620-203,,Open-label single-dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different doses of CINRYZE® [C1 inhibitor (human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema,0624-203: Ped HAE,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,12,1,10,0,0,0,0,8.33%,11,,ViroPharma,Viropharma INC,,,,,"Erzsebet Kocsis, Melody Cabardo, Susanne Keffel",2011-000369-11,,,N,No,,,,COSMOS Inactive,,12/6/2013,,,2/22/2010,2/22/2010,,,,,6/2/2010,6/2/2010,,,4/10/2012,4/10/2012,,,,,,,,,,,,,4/17/2012,4/17/2012,4/17/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-204,0624-204,'0624-204,,,0624-204 -Lynx Study,0624-204: Lynx Study,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,999,0,13,0,1,0,0,0.00%,999,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,10/23/2012,,,7/26/2011,7/26/2011,,,,,9/12/2011,9/12/2011,,,10/24/2011,10/24/2011,,,,,,,,,,,,,11/28/2011,11/28/2011,11/28/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-206,0624-206,'0624-206,'SHP616-206,,0624-206 -Lynx Study,0624-206: Lynx Study,I,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,ViroPharma,,,,,,,2012-000083-24,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-209,0624-209,'0624-209,'SHP616-209,CINRYZE,"A PHASE 3, OPEN-LABEL, SINGLE-PERIOD STUDY TO EVALUATE THE SAFETY AND TREATMENT EFFECT OF INTRAVENOUS ADMINISTRATION OF CINRYZE™ (C1 INHIBITOR [HUMAN]) FOR THE PREVENTION OF ANGIOEDEMA ATTACKS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA (HAE)",SHP616-209 (0624-209) HAE OL JAPAN,III,Completed,Hereditary Angioedema (HAE),Plasma Derived Therapy,,Non-Registry,,Interventional,Open Label,,,8,8,8,0,0,8,0,100.00%,10,,ViroPharma,Parexel,,"Laura McCarthy, Steve Gust",,,,,,,N,No,,,,COSMOS Inactive,,,12/10/2015,12/10/2015,2/17/2016,2/17/2016,,,9/12/2016,9/12/2016,9/13/2016,9/13/2016,,,3/7/2017,3/7/2017,,,6/23/2017,6/23/2017,,,,,,,,,,,7/27/2017,7/27/2017,,,,,,,,,8/10/2017,8/10/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0624-400,0624-400,'0624-400,,,A PHASE 4 STUDY TO EVALUATE THE SAFETY AND EFFECT OF ESCALATING DOSES OF CINRYZE™ (C1 INHIBITOR [HUMAN]) AS PROPHYLACTIC THERAPY IN SUBJECTS WITH INADEQUATELY CONTROLLED HEREDITARY ANGIOEDEMA ATTACKS,0624-400: DR Prevention,IV,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Non-Interventional_CDO Support,,,,20,20,24,0,4,0,2,100.00%,10,,ViroPharma,,,,,,"Alece Ellis, Djenawa Bowman, Huamin Bowman, Huamin Donato, Huamin Ellis, Sharon Donato",,,,N,No,,,,COSMOS Inactive,,,,,12/17/2008,12/17/2008,,,,,8/31/2009,8/31/2009,,,8/1/2011,8/1/2011,,,,,,,,,,,,,5/24/2012,5/24/2012,5/24/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0713xa,0713xa,'0713xa,'0713xa,,BAX111 rVWF Continuation,BAX 111 rVWF Continuation,III,Study Withdrawn,Von Willebrand Disease,,,Non-Registry,,Interventional,,,,15,0,0,0,0,,0,0.00%,1,,Baxalta,,Lorraine Ampaw,,Isabella Presch,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-100,1263-100,'1263-100,,,"A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-PROBE DRUG INTERACTION STUDY TO ASSESS THE POTENTIAL FOR REPEAT DOSES OF MARIBAVIR TO AFFECT CYTOCHROME P450 ENZYME ACTIVITY IN HEALTHY ADULT SUBJECTS",1263-100: Multi-Probe Interaction,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,20,20,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,10/29/2004,,,12/15/2003,12/15/2003,,,,,2/3/2004,2/3/2004,,,3/5/2004,3/5/2004,,,,,,,,,,,,,3/31/2004,3/31/2004,3/31/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-101,1263-101,'1263-101,,,"OPEN-LABEL, SINGLE-DOSE PHARMACOKINETIC EVALUATION OF ORAL MARIBAVIR IN ADULT SUBJECTS WITH RENAL IMPAIRMENT AS COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION",1263-101: Renal Impairment,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,32,31,0,0,0,0,0,96.88%,3,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,7/6/2006,,,1/23/2004,1/23/2004,,,,,3/6/2004,3/6/2004,,,,,,,,,,,,,,,,,11/5/2004,11/5/2004,11/5/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-102,1263-102,'1263-102,,,"AN OPEN-LABEL, RANDOM-SEQUENCE, TWO-WAY CROSSOVER STUDY EVALUATING THE EFFECT OF KETOCONAZOLE ON THE PHARMACOKINETICS OF MARIBAVIR IN HEALTHY ADULT SUBJECTS",1263-102: Ketaconazole Interaction,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,20,20,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,7/11/2005,,,9/24/2004,9/24/2004,,,,,11/16/2004,11/16/2004,,,,,,,,,,,,,,,,,1/4/2005,1/4/2005,1/4/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-103,1263-103,'1263-103,,,"OPEN-LABEL, SINGLE-DOSE PHARMACOKINETIC EVALUATION OF ORAL MARIBAVIR IN ADULT SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT AS COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION",1263-103: Hepatic Impairment,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,20,20,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,7/10/2006,,,1/18/2005,1/18/2005,,,,,4/14/2005,4/14/2005,,,5/26/2005,5/26/2005,,,,,,,,,,,,,6/8/2005,6/8/2005,6/8/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-104,1263-104,'1263-104,,,"OPEN-LABEL, SINGLE-DOSE, RANDOMIZED, THREE-WAY CROSSOVER STUDY IN HEALTHY ADULT SUBJECTS TO EVALUATE THE RELATIVE BIOAVAILABILITY OF OLD MARIBAVIR TABLETS (FORMULA CODE 41263TAB302) AND NEW MARIBAVIR TABLETS (FORMULA CODE 41263TAB304) AND THE EFFECT OF FOOD ON THE BIOAVAILABILITY OF THE NEW MARIBAVIR TABLET",1263-104: BA Food Effect,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,30,30,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,12/21/2006,,,4/18/2005,4/18/2005,,,,,9/20/2005,9/20/2005,,,9/28/2005,9/28/2005,,,,,,,,,,,,,10/26/2005,10/26/2005,10/26/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-105,1263-105,'1263-105,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFECT OF REPEAT DOSES OF MARIBAVIR ON THE PHARMACOKINETICS OF TACROLIMUS IN STABLE RENAL TRANSPLANT RECIPIENTS",1263-105: Tacrolimus interaction,I,Completed,CMV Treatment,,,Non-Registry,,Interventional,,,,25,25,0,0,0,0,0,100.00%,3,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/11/2005,10/11/2005,,,,,4/11/2006,4/11/2006,,,8/25/2008,8/25/2008,,,,,,,,,,,,,3/18/2008,3/18/2008,3/18/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-106,1263-106,'1263-106,,,"A phase 1, open-label mass balance and metabolite profiling study following enteric administration of 400 mg of a solution formulation of [14C] maribavir (200 nCi) in healthy subjects (Protocol 1263-106).",1263-106: Mass Balance Study,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,6,6,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,11/30/2007,,,5/3/2006,5/3/2006,,,,,6/20/2006,6/20/2006,,,,,,,,,,,,,,,,,7/13/2006,7/13/2006,7/13/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-107,1263-107,'1263-107,,,"A randomized, double-blind, placebo-controlled drug interaction study to assess the potential for repeat doses of maribavir to affect the pharmacokinetics of the cytochrome P450 2C19 substrate voriconazole in healthy adult subjects (Protocol 1263-107)",1263-107: Voriconazole Interaction,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Interaction,,,24,23,0,0,0,0,0,95.83%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,5/2/2008,,,5/30/2007,5/30/2007,,,,,10/26/2007,10/26/2007,,,,,,,,,,,,,,,,,11/29/2007,11/29/2007,11/29/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-108,1263-108,'1263-108,,,"A RANDOMIZED, PHASE 1, PLACEBO- AND POSITIVE-CONTROLLED FOUR PERIOD CROSSOVER SINGLE-DOSING STUDY OF THE EFFECTS OF MARIBAVIR ON ELECTROCARDIOGRAM PARAMETERS (WITH A FOCUS ON QTc INTERVAL PROLONGATION) IN HEALTHY MALE AND FEMALE SUBJECTS",1263-108: QTc INT. PROLONGATION,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Interaction,,,52,52,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,1/22/2009,,,8/9/2007,8/9/2007,,,,,12/4/2007,12/4/2007,,,,,,,,,,,,,,,,,2/16/2008,2/16/2008,2/16/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-109,1263-109,'1263-109,,,"OPEN-LABEL, SINGLE-DOSE, RANDOMIZED, THREE-WAY CROSSOVER STUDY IN HEALTHY ADULT SUBJECTS TO EVALUATE THE RELATIVE BIOAVAILABILITY OF CRUSHED MARIBAVIR TABLETS AND WHOLE MARIBAVIR TABLETS AND THE EFFECT OF ANTACID ON THE BIOAVAILABILITY OF THE WHOLE MARIBAVIR TABLET",1263-109: Crushed tablet,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,15,15,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,7/17/2008,,,9/21/2007,9/21/2007,,,,,11/26/2007,11/26/2007,,,11/26/2007,11/26/2007,,,,,,,,,,,,,12/28/2007,12/28/2007,12/28/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-110,1263-110,'1263-110,,,An open-label drug interaction study to assess the potential for repeat doses of rifampin to affect the pharmacokinetics of maribavir in healthy adult subjects,1263-110: Rifampin interaction,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,15,15,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,7/15/2008,,,10/19/2007,10/19/2007,,,,,11/28/2007,11/28/2007,,,,,,,,,,,,,,,,,12/26/2007,12/26/2007,12/26/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-113,1263-113,'1263-113,,,An Open-Label Taste Assessment of Maribavir Solutions in Healthy Panelists,1263-113: Solution Taste Assessment,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,5,5,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,2/12/2009,,,12/19/2008,12/19/2008,,,,,2/9/2009,2/9/2009,,,,,,,,,,,,,,,,,2/10/2009,2/10/2009,2/10/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-200,1263-200,'1263-200,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PROPHYLACTIC ANTI-CYTOMEGALOVIRUS ACTIVITY OF MARIBAVIR IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS",1263-200: Allogeneic SCT Patients,II,Completed,CMV Treatment,,,Non-Registry,,Interventional,,,,108,111,0,0,0,0,0,102.78%,14,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,8/10/2006,,,6/10/2004,6/10/2004,,,,,10/28/2004,10/28/2004,,,11/23/2005,11/23/2005,,,,,,,,,,,,,4/5/2006,4/5/2006,4/5/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-202,1263-202,'1263-202,,,1263-202 Maribavir for treatment of resistant or refractory CMV infections in transplant recipients,1263-202 PK Treatment for CMV infections,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,PK,,,120,119,130,0,10,0,0,99.17%,32,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-203,1263-203,'1263-203,'SHP620-203,,1263-203,1263-203 Lynx study,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,161,157,175,0,14,0,0,97.52%,48,,ViroPharma,,,,,,,2010-024247-32,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-300,1263-300,'1263-300,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS",1263-300: PBO SCT Prophylaxis,III,Completed,CMV Treatment,,,Non-Registry,,Interventional,,,,613,681,0,0,0,0,0,111.09%,85,,ViroPharma,,,,,,"Adrienne Gillies, Anette Larsson, Ann Igrec, Barbara Welte, Betiana Taverna, Carmel Sabatini, Cheryl Hilbe, Cheryl Hosterman, Gloria Pinkus, Ingrid Nielsen, Janice Huggler, Katie Russell, Kevin Fishwick, Kim Ferguson, Klara Huelsmann, Kvetoslava Gorecka, Marina Tultschin, Martin Velkopolszky, Michaela Gotschl, Nicolas Honhon, Nikola Vukasinovic, Pam Kohlbeck, Patricia Blackmon, Patricia Price, Patrick Bohan, Per Hedlund, Robert Johnson, Rosemary Satterlee, Sebastien Block, Sharon Donato, Sheri Fletcher, Sherri Taylor, Silvia Peschke, Sue Ann Igrec, Thumlert Sheila Robertson, Ulrike Sauerwald",2006-005692-18,,,N,No,,,,COSMOS Inactive,,,,,9/25/2006,9/25/2006,,,,,12/13/2006,12/13/2006,,,5/26/2008,5/26/2008,,,,,,,,,,,,,5/23/2009,5/23/2009,5/23/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263-301,1263-301,'1263-301,,,"A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR VERSUS ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ORTHOTOPIC LIVER TRANSPLANTS",1263-301: Ganciclovir-cont Liver Prophyl,III,Completed,CMV Treatment,,,Non-Registry,,Interventional,,,,348,307,350,0,43,0,143,88.22%,85,,ViroPharma,,,,,,"Terry Peltier-Siemers, Tracy Thomas, Yann Blandin, Anette Larsson, Annabel Webb, Anne-Laure Tuppin, Bethany Ingraham, Betiana Taverna, Britta Schallhammer, Carol Uleman, Erin Kraus, Francesco Iacovacci, Gerd Skjoldebrand, Giovanni Monopoli, Isabelle Crosset, Judith Pinon, Katie Russell, Kirstin Cuellar, Kvetoslava Gorecka, Magali Constant, Marina Tultschin, Michelle Vermillion, Nicolas Honhon, Nikola Vukasinovic, Patrick Bohan, Per Hedlund, Racquel Henry",2007-004729-16,,,N,No,,,,COSMOS Inactive,,,,,3/14/2007,3/14/2007,,,,,7/23/2007,7/23/2007,,,2/12/2009,2/12/2009,,,,,,,,,,,,,9/14/2009,9/14/2009,9/14/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1616xa,1616xa,'1616xa,'1616xa,,HyQvia (BAX1510) Ph4,HYQ (BAX1510) Ph4,IV,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,50,0,0,0,0,,0,0.00%,5,,Baxalta,,,,David Gelmont,Katharina Trinks,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1616xb,1616xb,'1616xb,'1616xb,,HyQvia (BAX1510) Ramp Up:  Tolerability and Safety of HyQvia Within Alternate Ramp Up Schedules,HYQ (BAX1510) Ramp Up Ph4,IV,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,30,0,0,0,0,,0,0.00%,1,,Baxalta,IQVIA,Fang Liu,,Leon Rozen,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1616xc,1616xc,'1616xc,'1616xc,,HyQvia US Registry,HyQvia US Registry,IV,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Non-Interventional_CDO Support,,,,225,0,0,0,0,,0,0.00%,25,,Baxalta,IQVIA,Fang Liu,,Robert Honigberg,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1712xa,1712xa,'1712xa,'1712xa,,CUV 20% HyQ Phase I,CUV 20% HyQ Phase I,I,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,60,0,0,0,0,,0,0.00%,1,,Baxalta,,Edward Tan,,David Gelmont,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1816xa,1816xa,'1816xa,'1816xa,,BAX1850 SM211 in IgAN,BAX1850 SM211 in IgAN,I,Study Withdrawn,IgAN,,,Non-Registry,,Interventional,,,,72,0,0,0,0,,0,0.00%,1,,Baxalta,,Evelyn Roth-Geissler,,Christopher Tehlirian,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2316xa,2316xa,'2316xa,'2316xa,,BAX335 FIX Gene Therapy - Pivotal,BAX335 FIX Gene Therapy,III,Study Withdrawn,Hemophilia B,,,Non-Registry,,Interventional,,,,40,0,0,0,0,,0,0.00%,40,,Baxalta,IQVIA,Frank Stout,,John Chapin,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2616xa,2616xa,'2616xa,'2616xa,,"BAX855 3000IU: Phase 3, Open-label, Prospective, Randomized, Controlled, Cross over, Multi-Center Study of the Pharmacokinetic Comparison of BAX 855 3000 IU Potency Vials with BAX 855 1000 IU Potency Vials in Previously Treated Patients with Severe Hemophilia A",BAX855 3000IU,III,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,18,0,0,0,0,,0,0.00%,10,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2916xx,2916xx,'2916xx,'2916xx,,SHP656 (BAX826) Pivotal,SHP656 2916xx Pivotal,III,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,150,0,0,0,0,,0,0.00%,80,,Baxalta,,Dikla Sharon,,Shouryadeep Srivastava,,Brittney Boisvert,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2916xy,2916xy,'2916xy,'2916xy,,SHP656 (BAX826) Surgery,SHP656 2916xy Surgery,III,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,50,0,0,0,0,,0,0.00%,50,,Baxalta,,Dikla Sharon,,Shouryadeep Srivastava,,Brittney Boisvert,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3916xx,3916xx,'3916xx,'3916xx,,SHP653 Imalumab (BAX2070/BAX69) mCRC: Randomized Study of Bax69 in Combination with either Lonsuri in RAS Mutated or Vectibix in RAS Wild Type Metastatic Colorectal Cancer Subjects,Imalumab 3916xx mCRC,III,Study Withdrawn,Neoplasm – malignant,,,Non-Registry,,Interventional,,,,750,0,0,0,0,,0,0.00%,40,,Baxalta,Monipol,Sara Coulter,,Jenny Chen,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10918-100,10918-100,'10918-100,,,10918-100 -Lynx Study,10918-100:Lynx Study,I,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,999,31,31,0,0,0,0,3.10%,999,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11931-02,11931-02,'11931-02,'11931-02,,ACT34-CLI: Injection of Autologous CD34-Positive Cells for Improved Symptomatic Relief and Ischemic wound healing in Subjects with Moderate or High-Risk Critical Limb Ischemia,ACT34-CLI,I/II,Completed,Critical Limb Ischemia (CLI),,,Non-Registry,,Interventional,,,,75,28,43,0,15,0,8,37.33%,12,,Baxalta,ICON / MAPI / Paradigm,Debra McCarthy,,,,,,,,,,,,,COSMOS Inactive,,1/13/2011,,,,8/17/2007,,,,,,,,11/20/2007,,,,,,,,,,,,,,,,4/29/2010,,8/3/2010,,,,,,,,,,,,,,,,,,,,,,8/4/2010,,,,,,,,,,,,1/13/2011,,,,,,,,,,,,,,,,,,,,,,
20621-100,20621-100,'20621-100,,,"A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Assess the Safety and Tolerability of Non Toxigenic Clostridium difficile (NTCD M3) Dosed Orally in Healthy Adult Subjects",20621-100: NTCD in Healthy Adults,I,Completed,C. difficile Treatment,,,Non-Registry,,Interventional,,,,80,80,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,Irena Zukliene,,,,N,No,,,,COSMOS Inactive,,,,,5/8/2008,5/8/2008,,,,,8/9/2009,8/9/2009,,,3/25/2010,3/25/2010,,,,,,,,,,,,,4/21/2010,4/21/2010,4/21/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20621-200,20621-200,'20621-200,,,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) in Adults Previously Treated for CDI",20621-200: Previously Treated for CDI,II,Completed,C. difficile Treatment,,,Non-Registry,,Interventional,,,,240,174,215,0,41,0,0,72.50%,50,,ViroPharma,,,,,,,2010-020484-20,,,N,No,,,,COSMOS Inactive,,,,,8/3/2010,8/3/2010,,,,,6/27/2011,6/27/2011,,,12/19/2012,12/19/2012,,,,,,,,,,,,,6/11/2013,6/11/2013,6/11/2013,3/7/2013,,,,,,,,,,,,,,,,,,,4/13/2013,4/13/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20621-900,20621-900,'20621-900,,,Long-term Follow-up Study of Subjects with Positive Fecal Clostridium difficile Cultures Following Participation in a Non-Toxigenic Clostridium difficile (NTCD-M3) Clinical Study,20621-900: LTFU NTCD+ from 20621-100,I,Completed,C. difficile Treatment,,,Non-Registry,,Interventional,,,,999,5,0,0,0,0,0,0.50%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,5/8/2008,5/8/2008,,,,,3/23/2010,3/23/2010,,,5/19/2010,5/19/2010,,,,,,,,,,,,,8/3/2010,8/3/2010,8/3/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20629-100,20629-100,'20629-100,,,20629-100,20629-100: Lynx study,II,Completed,Friedreich's Ataxia,,,Non-Registry,,Interventional,,,,26,0,53,0,0,0,0,0.00%,5,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
24779,24779,'24779,'24779,,"A Double-Blind, Prospective, Randomized, Placebo-Controlled Study to Determine the Tolerability, Efficacy, Safety & Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto-CD34+ Cells for Reduction of Angina Episodes in Patients with CMI",ACT34-CMI,II,Completed,Chronic Myocardial Isch. (CMI),,,Non-Registry,,Interventional,,,,150,167,321,6,154,0,11,111.33%,27,,Baxalta,PPD,,,,,,,,,,,,,,COSMOS Inactive,,,,,,11/8/2005,,,,,,,,4/4/2006,,,,,,,,,,,,,,,,3/5/2009,,4/15/2009,,,,,,,,,,,,,,,,,,,,,,5/15/2009,,,,,,,,,,,,9/30/2009,,,,,,,,,,,,,,,,,,,,,,
34976,34976,'34976,'34976,,TRAC-R Study: A 12-Month Follow-Up Study to Protocol 24779 (ACT34-CMI),TRAC-R Study,II,Completed,Chronic Myocardial Isch. (CMI),,,Non-Registry,,Interventional,,,,167,0,0,0,0,0,0,0.00%,23,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,3/12/2007,,4/19/2007,,,,,,,,5/21/2007,,,,,,,,,,,,,,,,3/31/2010,,5/3/2010,,,,,,,,,,,,,,,,,,,,,,6/18/2010,,,,,,,,,,,,9/24/2010,,,,,,,,,,,,,,,,,,,,,,
63843-052,63843-052,'63843-052,,,"A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND ANTIVIRAL ACTIVITY OF PLECONARIL SUSPENSION IN THE TREATMENT OF CHILDREN 2 TO 12 YEARS OF AGE WITH PICORNAVIRAL RESPIRATORY ILLNESS",63843-052: Peds Anti-viral Activity,II,Completed,Anti-Picornavirus Treatment,,,Non-Registry,,Interventional,,,,120,119,0,0,0,0,0,99.17%,3,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,11/6/2000,11/6/2000,,,,,,,,,,,,,,,,,2/26/2001,2/26/2001,2/26/2001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
63843-062,63843-062,'63843-062,,,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROPHYLACTIC ADMINISTRATION OF PLECONARIL IN THE PREVENTION OF PICORNAVIRAL RESPIRATORY ILLNESS IN HEALTHY ADULT PATIENTS",63843-062:Picornaviral in healthy adults,II,Completed,Anti-Picornavirus Treatment,,,Non-Registry,,Interventional,,,,"1,000","1,069",0,0,0,0,0,106.90%,999,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,8/29/2001,8/29/2001,,,,,,,,,,,,,,,,,1/17/2002,1/17/2002,1/17/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
801,801,'000801,'000801,,"Anti PEG antibodies: Evaluation of the prevalence of anti-PEG antibodies and binding anti-FVIII/anti-FIX antibodies in hemophilia A or B patients of any severity, with or without detectable inhibitory antibodies to FVIII or FIX",Anti PEG,IV,Completed,Hemophilia A,,,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,Tolerability,,,360,336,336,0,0,336,0,93.33%,1,,Baxalta,ICON / MAPI / Paradigm,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1001,1001,'001001,'001001,,OP & MRI: Bone & Joint Health in Adult Hemophilia Population:  Bone Mineral Density Measurement and Magnetic Resonance Imaging of Knee Cartilage Changes in a Hemophilia Population,OP & MRI,N/A,Study Terminated,Hemophilia A,,,Non-Registry,,Interventional,,,,100,0,2,0,2,0,0,0.00%,12,,Baxalta,"Medidata, RPS Inc.",lliana Leony Lasso,,Linda Yamamoto,,,,,,,,,,,COSMOS Inactive,,,,1/13/2011,,5/6/2011,,,,,,,,10/30/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1101,1101,'001101,'001101,,JP Surgical Study: Evaluation of Hemophilia Joint Tissues and Synovial Fluid from Human Surgical Samples,JP Surgical Study,IV,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,20,,,,,,,,2,,Baxalta,RPS Inc.,lliana Leony Lasso,,Linda Yamamoto,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1102,1102,'001102,'001102,,Longitudinal Biomarker Study,Longitudinal Biomarker Study,N/A,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,45,0,0,0,0,,0,0.00%,5,,Baxalta,,lliana Leony Lasso,,Linda Yamamoto,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1501,1501,'001501,'001501,,"GAS-Hemophilia Feasibility Study:  A New Patient-Centric Outcome Measure for Patients with Hemophilia: Testing the Feasibility of GAS-Hem in Pediatric, Adolescent and Adult Hemophilia A Patients",GAS-HEM Feasibility,IV,Completed,Hemophilia A,,,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,,,,48,44,44,0,2,0,2,91.67%,5,,Baxalta,DGI Clinical,,Manfred Pirck,,,,,,,,,,,,COSMOS Inactive,,,,,,10/16/2015,,,,,,8/5/2016,,12/21/2015,,,,,,,,,,,,,,,,11/2/2016,,2/7/2017,,,,,,,,,,,,,,,,,,,,,,4/7/2017,,,,,,,,,,,,4/7/2017,,,,,,,,,,,,,,,,,,,,,,
11101,11101,'011101,'011101,,Recombinate PASS,ECE Recombinate PASS,IV,Study Withdrawn,Hemophilia A,,,Non-Registry,,Non-Interventional_CDO Support,,,,208,0,0,0,0,,0,0.00%,21,,Baxalta,,,,Armin Reininger,,Richard Steinbrugger,,,,,,,,,COSMOS Inactive,,,,5/11/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20801,20801,'020801,'020801,,"BAX817 rFVIIaBI: Ph 1, Prospective, Dose-escalation/Finding Study to Evaluate Pharmacokinetics and Immediate Tolerability of Recombinant Activated FVII in Patients with Hemophilia A or B and Inhibitors",BAX817 rFVIIa BI,I,Completed,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Interventional,,,,43,45,63,0,17,27,4,104.65%,25,,Baxalta,"Almac, Omnicare CR, Psi, RPS Inc., Siro Clinpharm Pvt. Ltd",Michael Zoerer,,"Heinrich Farin, Wing Yen Wong",,"Gina Cooper, Gudrun Jeindl",2009-012589-29,,,,,,,,COSMOS Inactive,,12/16/2011,,2/22/2008,,9/18/2009,,,,,,,,4/15/2010,,,,,,,,,,,,,,,,9/9/2011,,10/21/2011,,,,,,,,,,,,,,,,,,,,,,11/4/2011,,,,,,,,,,,,12/16/2011,,,,,,,,,,,,,,,,,,,,,,
21101,21101,'021101,'021101,,"BAX817 rFVIIaBI:Pivotal, Prospective, Open-label Study to Evaluate Safety and Efficacy of Recombinant Activated FVII BI (rFVIIa BI) in the Treatment of Acute Bleeding Episodes per an On-demand Regimen in Patients with Hemophilia A or B Inhibitors",BAX817 rFVIIaBI Pivotal,III,Completed,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Interventional,,,,51,38,40,0,1,39,4,74.51%,12,,Baxalta,IQVIA,,Shouryadeep Srivastava,,,,2011-006294-26,,,,,,,,COSMOS Inactive,,3/19/2015,,11/29/2011,,4/24/2012,,,,,,,,2/20/2013,,,,,,,,,,,,,,,,11/11/2014,,1/7/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/19/2015,,,,,,,,,,,,,,,,,,,,,,
21201,21201,'021201,'021201,,"BAX817 rFVIIaBI Pediatric: Prospective, Uncontrolled, Multicentre Study Evaluating Pharmacokinetics, Efficacy, Safety, Immunogenicity, and Thrombogenicity of BAX 817 in Pediatric Patients with Hemophilia A or B with inhibitors",BAX817 rFVIIaBI Pediatric,II/III,Study Withdrawn,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Interventional,,,,16,0,0,0,0,,0,0.00%,12,,Baxalta,,Katharina Trinks,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21202,21202,'021202,'021202,,"BAX817 rFVIIaBI Surgery: Prospective, Uncontrolled, Multicentre Study Evaluating Efficacy and Safety of BAX 817 in patients with Hemophilia A or B with inhibitors Undergoing Surgical or Other Invasive Procedures",BAX817 rFVIIaBI Surgery,II/III,Study Withdrawn,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Interventional,,,,12,0,0,0,0,,0,0.00%,10,,Baxalta,,Katharina Trinks,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50801,50801,'050801,'050801,,IMMUNINE PASS:  A Post-Marketing Surveillance of IMMUNINE in Pediatric Patients with Haemophilia B,IMMUNINE PASS,IV,Completed,Hemophilia B,,,Non-Registry,Pediatric only (<18 yr),Non-Interventional_CDO Support,Open Label,,,12,11,12,0,3,0,3,91.67%,13,1,Baxalta,Monipol,Senta Habenicht,,Robert Numerof,,,,,,,,,,,COSMOS Inactive,,,,4/1/2008,,4/20/2009,,,,,,,,11/6/2009,,,,,,,,,,,,,,,,7/20/2013,,7/5/2014,,,,,,,,,,,,,,,,,,,,,,10/16/2014,,,,,,,,,,,,11/4/2014,,,,,,,,,,,,,,,,,,,,,,
50901,50901,'050901,'050901,,"Immunine Pre-Treatment:  A Phase IV, Prospective, Uncontrolled, Open-Label Multicenter Study to document the Exposure to IMMUNINE and to monitor FIX Inhibitors in PTPs with severe/moderately severe Hemophilia B",Immunine Pre-Treatment,IV,Completed,Hemophilia B,,,Non-Registry,,Interventional,,,,57,49,57,4,9,0,2,85.96%,25,,Baxalta,"Almac, Psi, Syneos Health, Theorem Clinical Research",Kathleen O'Hara,,Brigitt Abbuehl,,Elisabeth Pamperl,2009-016719-39,,,,,,,,COSMOS Inactive,,5/3/2013,,9/28/2009,,11/17/2009,,,,,,,,5/31/2010,,,,,,,,,,,,,,,,8/28/2012,,10/25/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/3/2013,,,,,,,,,,,,,,,,,,,,,,
60103,60103,'060103,'060103,,"Advate PUP: Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A",Advate PUP,III,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,57,18,19,0,1,0,0,31.58%,20,,Baxalta,PPD,Minal Ashtekar,,Brigitt Abbuehl,,,2004-001623-38,,,,,,,,COSMOS Inactive,,9/28/2010,,9/17/2003,,9/17/2003,,,,,,,,4/1/2004,,,,,,,,,,,,,,,,9/11/2009,,5/19/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/28/2010,,,,,,,,,,,,,,,,,,,,,,
60201,60201,'060201,'060201,,"PIV Advate Prophylaxis: Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A",PIV Advate Prophylaxis,IV,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,66,66,76,0,4,0,8,100.00%,37,,Baxalta,PPD,"Christiane Thomasser, Minal Ashtekar",,Wing Yen Wong,,"Gina Cooper, Sabine Gruber",2005-000347-29,,,,,,,,COSMOS Inactive,,12/9/2010,,,,5/11/2005,,,,,,,,1/4/2006,,,,,,,,,,,,,,,,6/16/2010,,10/13/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/9/2010,,,,,,,,,,,,,,,,,,,,,,
60401,60401,'060401,'060401,,Advate Pediatric Continuation,Advate Pediatric Continuation,IV,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,4,,,,,,,,1,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,8/16/2004,,,,,,,,,,,,,,,,,,,,,,,,11/10/2006,,9/4/2007,,,,,,,,,,,,,,,,,,,,,,10/31/2007,,,,,,,,,,,,11/14/2007,,,,,,,,,,,,,,,,,,,,,,
60402,60402,'060402,'060402,Advate (Antihemophilic Factor (Recombinant)),"ADVATE Randomized Surgery: Ph 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare Efficacy & Safety of CI vs Intermittent BI in Subjects with Severe/Moderately Severe Hemophilia A in Subjects Undergoing Major Orthopedic Surgery",ADVATE Randomized Surgery,IV,Completed,Hemophilia A,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,60,61,86,3,15,0,12,101.67%,30,,Baxalta,IQVIA,,Manfred Pirck,,,,2005-005697-71,,,,,,,,COSMOS Inactive,,11/24/2016,,,11/18/2004,11/18/2004,,,5/29/2006,5/29/2006,6/13/2006,6/13/2006,,,8/24/2015,8/24/2015,,,5/9/2016,5/9/2016,,,,,,,,,,,3/11/2016,3/11/2016,,,,,,,,,10/26/2016,10/26/2016,,,,,,,,,,,,,11/2/2016,11/2/2016,,,,,,,,,11/24/2016,11/24/2016,,,,,,,,,,,,,,,1/23/2017,1/23/2017,,,,,,
60403,60403,'060403,'060403,,Advate Dose-Response,Advate Dose-Response,IV,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,25,,,,,,,,8,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,2/9/2005,,9/12/2005,,,,,,,,2/7/2006,,,,,,,,,,,,,,,,4/1/2007,,4/30/2008,,,,,,,,,,,,,,,,,,,,,,5/15/2008,,,,,,,,,,,,6/25/2008,,,,,,,,,,,,,,,,,,,,,,
60601,60601,'060601,'060601,,"BONN Advate PK:  PHARMACOKINETIC COMPARISON OF ADVATE rAHF-PFM WITH RECOMBINATE rAHF IN PATIENTS WITH SEVERE HEMOPHILIA A: A PHASE IV, PROSPECTIVE, RANDOMIZED, CONTROLLED, CROSS-OVER, SINGLE CENTER STUDY",BONN Advate PK,IV,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,20,9,9,0,0,0,0,45.00%,1,,Baxalta,InClin Incorporated,Katrin Koelling-Schlebusch,,Brigitt Abbuehl,,,2007-004834-18,,,,,,,,COSMOS Inactive,,3/23/2010,,8/22/2007,,11/14/2007,,,,,,,,4/30/2008,,,,,,,,,,,,,,,,2/18/2009,,12/10/2009,,,,,,,,,,,,,,,,,,,,,,2/16/2010,,,,,,,,,,,,3/23/2010,,,,,,,,,,,,,,,,,,,,,,
60702,60702,'060702,'060702,,"ADVATE 2 mL RECONSTITUTION PK:Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2mL versus 5mL SWFI in Previously Treated Severe Hemophilia A Patients",ADVATE 2 mL RECONSTITUTION PK,I,Completed,Hemophilia A,,,Non-Registry,,Interventional,Randomized,,,48,0,0,0,11,0,2,0.00%,15,,Baxalta,,Sandra Parsons,,Wing Yen Wong,,,,,,,,,,,COSMOS Inactive,,3/29/2010,,8/31/2007,,2/12/2008,,,,,,,,8/18/2008,,,,,,,,,,,,,,,,10/23/2009,,1/8/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/29/2010,,,,,,,,,,,,,,,,,,,,,,
60703,60703,'060703,'060703,,Advate PrePAIR Registry,Advate PrePAIR Registry,IV,Completed,Hemophilia A,,,Non-Registry,,Non-Interventional_CDO Support,,,,15,37,37,0,5,0,0,246.67%,19,,Baxalta,PPD,,,,,,,,,,,,,,COSMOS Inactive,,,,1/21/2008,,2/26/2008,,,,,,,,4/3/2009,,,,,,,,,,,,,,,,8/10/2009,,11/10/2009,,,,,,,,,,,,,,,,,,,,,,1/22/2010,,,,,,,,,,,,2/26/2010,,,,,,,,,,,,,,,,,,,,,,
60801,60801,'060801,'060801,,ADVATE 3000: Pharmacokinetic comparison of 3000 IU Advate rAHF-PFM (using one 3000 IU potency vial) with 3000 IU Advate rAHF PFM (using two 1500 IU potency vials) in previously treated patients with severe hemophilia A,Advate 3000,IV,Completed,Hemophilia A,,,Non-Registry,,Interventional,Crossover,,,23,23,29,3,6,23,0,100.00%,4,,Baxalta,,Catherine Weenink,,Brigitt Abbuehl,,Sabine Gruber,2008-007347-13,,,,,,,,COSMOS Inactive,,6/11/2012,,8/8/2008,,12/19/2008,,,,,,,,6/29/2009,,,,,,,,,,,,,,,,3/27/2012,,5/11/2012,,,,,,,,,,,,,,,,,,,,,,5/23/2012,,,,,,,,,,,,6/11/2012,,,,,,,,,,,,,,,,,,,,,,
60901,60901,'060901,'060901,,Advate Once Weekly,AOW,III,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,60,,,,,,,,20,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
60902,60902,'060902,,Advate (Antihemophilic Factor (Recombinant)),AHEAD Germany: ADVATE/ADYNOVI Hemophilia A Outcome Database,AHEAD Germany,IV,Recruiting,,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,,,,450,405,1067,,4,,170,90.00%,40,39,,TBD,,,Helger Brondke,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,6/7/2010,6/7/2010,6/7/2010,6/7/2010,,,2/2/2021,,,,1/15/2025,,,,,,,,,,,,,,,,,,,,,,4/30/2025,,,,,,,,,,,,,,,,,,,,,,,,7/1/2025,,,,,,,,,,,,,,,,7/1/2025,,,,,,,
61001,61001,'061001,,Advate (Antihemophilic Factor (Recombinant)),ADVATE HEMOPHILIA A OUTCOME DATABASE,AHEAD,IV,Recruiting,Hemophilia A,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,Prevention,Prospective,Cohort,"1,130",907,917,,10,,292,80.27%,112,88,,Synteract,,"Derek Bell, Edgar Berger","Alejandro Fernandez, Kayode Badejo",,,,,,,,,,,Medidata CTMS (Pharma),,,,,11/17/2010,11/17/2010,,,6/29/2011,6/29/2011,6/29/2011,6/29/2011,,,1/2/2022,,,,1/15/2025,,,,,,,,,,,,3/12/2025,,,,,,,,,,5/14/2025,,,,,,,,,,,,,,,,,,,,,,,,7/16/2025,,,,,,,,,,,,,,,,7/16/2025,,,,,,,
61002,61002,'061002,'061002,,Advate EPIC: Early Prophylaxis Immunologic Challenge (EPIC): Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients with Hemophilia A,Advate EPIC,IIIb,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,100,19,22,0,1,0,18,19.00%,75,,Baxalta,IQVIA,Senta Habenicht,,Armin Reininger,,"Gabrielle Palluconi, Petra Merz",2011-000410-18,,,,,,,,COSMOS Inactive,,10/15/2013,,11/25/2010,,3/16/2011,,,,,,,,8/26/2011,,,,,,,,,,,,,,,,11/16/2012,,4/30/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/15/2013,,,,,,,,,,,,,,,,,,,,,,
61101,61101,'061101,'061101,Advate (Antihemophilic Factor (Recombinant)),ADVATE 2ml (reconstituted in 2 ml SWFI) Post-Authorization Safety Surveillance Study,ADVATE 2mL PASS,IV,Completed,Hemophilia A,RGH,,Non-Registry,,Non-Interventional_CDO Support,PASS (Post Authorization Safety Study),,,60,65,65,0,0,0,1,108.33%,30,,Baxalta,Synteract,,Andras Nagy,,,"Elisabeth Pamperl, Sabine Geyer",,,,,,,,,COSMOS Inactive,,,,,2/23/2012,2/23/2012,,,,,9/20/2013,9/20/2013,,,7/23/2015,7/23/2015,,,1/20/2016,1/20/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/31/2017,8/31/2017,,,,,,,,,,,,,,,8/31/2017,8/31/2017,,,,,,
61301,61301,'061301,'061301,,"ADVATE China PMR: Prospective, Open-label, Interventional, Multicenter, Sequential Study to Investigate Efficacy of Prophylaxis with ADVATE to Reduce Bleeding Frequency in Previously Treated Pateints with Hemophilia A",ADVATE China PMR,IV,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,54,60,81,0,10,0,5,111.11%,15,,Baxalta,IQVIA,,Rocio Iturbe,,,,,,,,,,,,COSMOS Inactive,,9/17/2016,,,,3/21/2014,,,,,,6/26/2014,,6/26/2014,,,,,,,,,,,,,,,,5/31/2016,,6/23/2016,,,,,,,,,,,,,,,,,,,,,,9/15/2016,,,,,,,,,,,,9/17/2016,,,,,,,,,,,,,,,,,,,,,,
61302,61302,'061302,'061302,,"ADVATE SPACE: Study of Prophylaxis, Activity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated with ADVATE or RIXUBIS",ADVATE SPACE,IV,Completed,Hemophilia A,,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,,,,50,64,64,0,3,0,18,128.00%,25,,Baxalta,IQVIA,,Sanhita Abrol,,,,,,,,,,,,COSMOS Inactive,,,,1/14/2014,,5/5/2014,,,,,,7/22/2014,,7/22/2014,,,,,,,,,,,,,,,,3/29/2016,,5/20/2016,,,,,,,,,,,,,,,,,,,,,,9/9/2016,,,,,,,,,,,,6/14/2017,,,,,,,,,,,,,,,,,,,,,,
61501,61501,'061501,'061501,,ADVATE China PUP: Retrospective chart review to evaluate safety and tolerability of ADVATE among previously untreated patients with severe hemophilia A,ADVATE China PUP,IV,Completed,Hemophilia A,,,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,,,,21,21,21,0,0,0,0,100.00%,6,,Baxalta,IQVIA,,Manfred Pirck,,,,,,,,,,,,COSMOS Inactive,,,,9/15/2015,,10/2/2015,,,,,,12/23/2015,,12/23/2015,,,,,,,,,,,,,,,,6/1/2016,,6/30/2016,,,,,,,,,,,,,,,,,,,,,,7/19/2016,,,,,,,,,,,,8/31/2016,,,,,,,,,,,,,,,,,,,,,,
70701,70701,'070701,'070701,,BAX111 rvWF:rFVIII Phase 1,BAX111 rvWF:rFVIII Ph 1,I,Completed,Von Willebrand Disease,,,Non-Registry,,Interventional,,,,61,38,57,2,17,0,5,62.30%,28,,Baxalta,IQVIA,Jorge Escobar,,,,,,,,,,,,,COSMOS Inactive,,12/19/2010,,10/18/2007,,2/25/2008,,,,,,,,11/11/2008,,,,,,,,,,,,,,,,8/31/2010,,11/6/2010,,,,,,,,,,,,,,,,,,,,,,12/2/2010,,,,,,,,,,,,12/19/2010,,,,,,,,,,,,,,,,,,,,,,
71001,71001,'071001,'071001,Vonvendi (von Willebrand factor (recombinant)),"BAX111 rVWF:rFVIII (Bleeds): Phase 3a, Safety and Efficacy of  rVWF in treatment of bleeding episodes in patients with von Willebrand's disease",BAX111 - rVWF Bleeds,III,Completed,Von Willebrand Disease,RGH,,Non-Registry,,Interventional,,,,36,37,49,1,8,1,13,102.78%,45,,Baxalta,PPD,"Jeanette Fait, Kristen Foye, Marcia Hill, Siddhesh Darne",,Isabella Presch,,"Gabrielle Palluconi, Liz Mickels, Paz Carrasco",2010-024108-84,,,,,,,,COSMOS Inactive,,5/2/2014,8/26/2013,8/26/2013,12/20/2013,12/20/2013,,,4/4/2014,4/4/2014,5/9/2014,5/9/2014,,,10/24/2014,10/24/2014,,,1/16/2015,1/16/2015,,,,,,,,,,,,,,,,,,,,,3/10/2015,3/10/2015,,,,,,,,,,,,,,,,,,,,,,,6/15/2015,6/15/2015,,,,,,,,,,,,,,,6/15/2015,6/15/2015,,,,,,
71101,71101,'071101,'071101,Vonvendi (von Willebrand factor (recombinant)),"SHP677 Vonvendi (BAX111) rvWF:rFVIII (Surgery): A Phase 3 Prospective, Multicenter Study to Evaluate Efficacy and Safety of rVWF:rFVIII and rVWF in Elective Surgical and Invasive Procedures in Subjects with von Willebrand Disease",VON 071101 vWD Surgery Ph3,III,Completed,Von Willebrand Disease,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,17,15,24,0,9,0,0,88.24%,36,,Baxalta,IQVIA,,Sanhita Abrol,,,,2014-003575-38,,,,,,,,COSMOS Inactive,,4/14/2017,1/26/2012,1/26/2012,,,,,2/21/2014,2/21/2014,5/5/2015,5/5/2015,,,10/23/2015,10/23/2015,,,1/22/2016,1/22/2016,,,,,,,,,,,,,,,,,,,,,10/11/2016,10/11/2016,,,,,,,,,,,,,,,,,,,,,,,12/1/2016,12/1/2016,,,,,,,,,,,,,,,12/1/2016,12/1/2016,,,,,,
71102,71102,'071102,,Vonvendi (von Willebrand factor (recombinant)),"SHP677 Vonvendi (BAX111) rVWF Pediatrics: A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed with Severe von Willebrand Disease",VON 071102 (vWD) Pediatrics,III,Recruiting,Support - Rare Diseases,RGH,RGH,,Pediatric only (<18 yr),Interventional,,,,34,26,2,,14,28,,76.47%,48,33,,IQVIA,,Angela Calvillo,Arthur Sytkowski,Sarah Hale,,2016-001477-33,,,,,,,,Medidata CTMS (Pharma),,,,,6/10/2016,6/10/2016,,,10/18/2017,10/18/2017,12/18/2017,12/18/2017,,,2/28/2022,,,,2/24/2023,,,,,,,,,,,,4/11/2023,,,,,,,,,,4/20/2023,,,,,,,,,,,,,,5/12/2023,,,,,,,,,,7/31/2023,,,,,,,,,,,,,,,,8/3/2026,,,,,,,
71104,71104,'071104,'071104,,"BAX111: rVWF (Hem A): Co-infusion of rVWF:rFVIII: A Phase 1 Study Evaluating the Pharmacokinetics, Safety & Tolerability in Severe Hemophilia A",BAX 111 rVWF (Hem A),I,Completed,Von Willebrand Disease,,,Non-Registry,,Interventional,,,,12,12,17,1,4,0,2,100.00%,7,,Baxalta,ICON / MAPI / Paradigm,Suzanne Wilson,,Wing Yen Wong,Jorge Escobar,Gudrun Jeindl,,,,,,,,,COSMOS Inactive,,10/31/2012,,,,8/29/2011,,,,,,,,1/26/2012,,,,,,,,,,,,,,,,7/6/2012,,8/31/2012,,,,,,,,,,,,,,,,,,,,,,9/25/2012,,,,,,,,,,,,10/31/2012,,,,,,,,,,,,,,,,,,,,,,
71301,71301,'071301,,Vonvendi (von Willebrand factor (recombinant)),"SHP677 Vonvendi (BAX111) rVWF LT Prophy: A Prospective, Phase 3, Open Label, International Multicenter Study on Efficacy and Safety of Prophylaxis with  rVWF in Severe vonWillebrand Disease",VON 071301 (vWD) LT Prophy Ph3,III,Completed,Sarcoma,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,Treatment,,,22,23,0,,6,0,,104.55%,32,,,IQVIA,,Angela Calvillo,Arthur Sytkowski,,,2016-001478-14,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,2/19/2014,2/19/2014,,,10/25/2017,10/25/2017,12/22/2017,12/22/2017,,,6/17/2019,6/17/2019,,,8/25/2020,8/25/2020,,,,,,,,,,,10/22/2020,10/22/2020,,,,,,,,,10/29/2020,10/29/2020,,,,,,,,,,,,,11/19/2020,11/19/2020,,,,,,,,,3/8/2021,3/8/2021,,,,,,,,,,,,,,,10/30/2024,,,,,,,
71401,71401,'071401,'071401,,"BAX111  rVWF Surgery EIND:  Ph 3, Prospective, Uncontrolled Study to Assess the Safety, Efficacy of rVWF in Treatment of Bleeding Event and Perioperative Use in a Single VWD Subject Experiencing Anaphylactic Reactions After Administration of pdVWF",BAX111  rVWF Surgery EIND,III,Completed,Von Willebrand Disease,,,Non-Registry,,Interventional,,,,1,1,1,0,0,0,0,100.00%,1,,Baxalta,IQVIA,Ferdinando D'amato,,Arthur Sytkowski,,Paz Carrasco,,,,,,,,,COSMOS Inactive,,,,,,1/13/2015,,,,,,,,12/10/2014,,,,,,,,,,,,,,,,1/17/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
71601,71601,'071601,'071601,,"Vonvendi Observational Study: Post-Approval  Prospective, Observational  Study in von Willebrand Disease (VWD) Patients Treated with  Recombinant von Willebrand factor  (VONVENDI®)",Vonvendi Observational Study,IV,Study Withdrawn,Von Willebrand Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,100,0,0,0,0,,0,0.00%,40,,Baxalta,,Sanhita Abrol,,Arthur Sytkowski,,,,,,,,,,,COSMOS Inactive,,,,3/7/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
90701,90701,'090701,'090701,,"FEIBA NF Prophy: Prospective, Open-label, Randomized, Crossover Study to Evaluate Efficacy and Safety of On-demand versus Prophylactic Treatment in Subjects with Hemophilia A or B and a High Titer Inhibitor",FEIBA NF Prophy Ph3,III,Completed,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Interventional,,,,34,36,52,2,19,36,3,105.88%,22,,Baxalta,IQVIA,Eli Taube,,Wing Yen Wong,,"Gina Cooper, Maria Proupin-perez",2008-003855-65,,,,,,,,COSMOS Inactive,,1/16/2013,,2/1/2008,,5/30/2008,,,,,,,,3/31/2009,,,,,,,,,,,,,,,,10/17/2012,,11/19/2012,,,,,,,,,,,,,,,,,,,,,,1/15/2013,,,,,,,,,,,,1/16/2013,,,,,,,,,,,,,,,,,,,,,,
90901,90901,'090901,'090901,,"FEIBA NF:  A Phase 4, Prospective, Randomized, Double-Blind Crossover Study to Evaluate the Safety of Faster Infusion of FEIBA NF in Patients with Hemophilia A or B with Inhibitors",FEIBA NF Fast,III,Study Withdrawn,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Interventional,,,,30,,,,,,,,20,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91002,91002,'091002,'091002,,"FEIBA Factor VIII Inhibitor Bypassing Activity: An open, uncontrolled, non-interventional observational cohort study of FEIBA NF in hemophiliacs with inhibitors in North America",FEIBA NF PASS NA,IV,Study Withdrawn,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Non-Interventional_CDO Support,,,,10,0,0,0,0,,0,0.00%,7,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91201,91201,'091201,'091201,,"FEIBA PK: Phase IV, Prospective, Open-Label, Multidose, Pharmacodynamic (PD), and Pharmacokinetic (PK) Study in Hemophilia A Subjects with Inhibitors",FEIBA PK,IV,Study Withdrawn,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Interventional,,,,8,0,0,0,0,,0,0.00%,3,,Baxalta,,Michael Cecerle,,Srilatha Tangada,,,,,,,,,,,COSMOS Inactive,,,,1/24/2012,,3/26/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91301,91301,'091301,,FEIBA,FEIBA NF Global Outcome Study,FEIBA - GO,IV,Completed,Hemophilia A,Plasma Derived Therapy,Real World Evidence,,Non-pediatric only (>18 yr),Observational,Treatment,Prospective,Cohort,55,53,53,,,,42,96.36%,40,,,Synteract,,Derek Bell,Aurelia Lelli,,,,,,,,,,,Medidata CTMS (Pharma),,,,,9/30/2013,9/30/2013,,,,,9/3/2014,9/3/2014,,,12/19/2017,12/19/2017,,,2/28/2020,2/28/2020,,,,,,,,,,,8/31/2020,8/31/2020,,,,,,,,,9/21/2020,9/21/2020,,,,,,,,,,,,,9/21/2020,9/21/2020,,,,,,,,,11/30/2020,11/30/2020,,,,,,,,,,,,,,,11/30/2020,11/30/2020,,,,,,
91501,91501,'091501,,FEIBA,"A phase 3b/4, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors",FEIBA STAR,IIIb,Recruiting,Hemophilia A,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Interventional,,,,24,22,1,,10,1,,91.67%,30,20,,IQVIA,,Simon Purnell,Sherry Weigand,,,2015-005781-39,,,,,,,,Medidata CTMS (Pharma),,,12/2/2016,12/2/2016,3/9/2018,3/9/2018,,,,,3/13/2019,3/13/2019,,,10/29/2021,,,,1/27/2022,,,,,,,,,,,,3/10/2022,,,,,,,,,,3/31/2022,,,,,,,,,,,,,,4/21/2022,,,,,,,,,,6/16/2022,,,,,,,,,,,,,,,,7/14/2023,,,,,,,
160601,160601,'160601,'160601,,10% Gammagard Liquid SubQ (alone):Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (Gammagard Liquid) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases (PID),10% Gammagard Liquid SubQ (alo,II/III,Completed,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,45,0,0,0,0,0,0,0.00%,11,,Baxalta,IQVIA,Sandra Parsons,,Richard Ivan Schiff,,Jennifer Polidori,,,,,,,,,COSMOS Inactive,,,,,,3/20/2007,,,,,,,,10/3/2007,,,,,,,,,,,,,,,,7/8/2009,,9/14/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/30/2009,,,,,,,,,,,,,,,,,,,,,,
160602,160602,'160602,'160602,,Gammagard Liquid Hylenex SubQ Pilot,Gammagard Liquid Hylenex SubQ,II,Completed,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,12,,,,,,,,3,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,9/26/2006,,,,,,,,12/4/2006,,,,,,,,,,,,,,,,11/14/2007,,1/23/2008,,,,,,,,,,,,,,,,,,,,,,4/17/2008,,,,,,,,,,,,5/21/2008,,,,,,,,,,,,,,,,,,,,,,
160603,160603,'160603,'160603,,"10% HyQ:  EFFICACY, TOLERABILITY & PHARMACOKINETIC COMPARISON OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% (GAMMAGARD LIQUID) ADMINISTERED IV OR SUBQ FOLLOWING ADMINISTRATION OF RECOMBINANT HUMAN HYALURONIDASE in Subjects with PID",10% HyQ **A,III,Completed,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,80,86,90,0,2,0,12,107.50%,15,,Baxalta,IQVIA,Judith Sosa,,Richard Ivan Schiff,,,,,,,,,,,COSMOS Inactive,,,,6/26/2008,,9/23/2008,,,,,,,,12/31/2008,,,,,,,,,,,,,,,,11/11/2010,,2/15/2011,,,,,,,,,,,,,,,,,,,,,,2/28/2011,,,,,,,,,,,,3/30/2011,,,,,,,,,,,,,,,,,,,,,,
160604,160604,'160604,'160604,,"10% GGL in MMN (IV):  A Randomized, double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV) for the Treatment of Multifocal Motor Neuropathy",10% GGL in MMN (IV),III,Completed,Multifocal Motor Neuropathy,,,Non-Registry,,Interventional,,,,44,44,57,2,13,44,3,100.00%,20,,Baxalta,IQVIA,Nancy Sullivan,,Carol Koski,,"Friederike Huettenrauch, Sabine Geyer",2009-013841-27,,,,,,,,COSMOS Inactive,,,,2/1/2007,,2/25/2008,,,,,,,,9/29/2008,,,,,,,,,,,,,,,,8/11/2011,,9/5/2011,,,,,,,,,,,,,,,,,,,,,,9/26/2011,,,,,,,,,,,,10/24/2011,,,,,,,,,,,,,,,,,,,,,,
160701,160701,'160701,'160701,,"10% IGIV Alzheimer's (GAP Study):  Randomized, Double-Blind, Placebo-controlled, two Dose-Arm, Parrallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% IGIV for the Treatment of Mild to Moderate Alzheimer's Disease",10% IGIV Alzheimer's (GAP),III,Completed,Alzheimer's Disease,,,Non-Registry,,Interventional,,,,385,386,736,1,355,0,108,100.26%,40,,Baxalta,IQVIA,Marcia Hill,,David Gelmont,,"Clifford Baum, Gina Cooper",,,,,,,,,COSMOS Inactive,,,,11/2/2007,,3/6/2008,,,,,,,,12/19/2008,,,,,,,,,,,,,,,,12/10/2012,,4/1/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/20/2013,,,,,,,,,,,,,,,,,,,,,,
160801,160801,'160801,'160801,,Phase 2 GAMMAGARD LIQUID/KIOVIG and rHuPH20 in Alzheimer’s Disease,Phase 2 GAMMAGARD LIQUID/KIOVI,II,Study Withdrawn,Alzheimer's Disease,,,Non-Registry,,Interventional,,,,60,,,,,,,,1,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,10/6/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
160901,160901,'160901,'160901,,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropat",IGIV 10% in CIDP,III,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,118,0,0,0,0,,0,0.00%,40,,Baxalta,IQVIA,,,,,,,,,,,,,,COSMOS Inactive,,,,10/8/2010,,5/4/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
160902,160902,'160902,'160902,,"10% HyQ (160603 Extension): Long-Term Tolerability & Safety of Immune Globulin Intravenous (Human), 10% GGL, Administered SubQ following Administration of Recombinant Human Hyaluranidase (rHuPH20) in Subjects with Primary Immunodeficiency Diseases",10% HyQ (160603 Extension),III,Completed,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,66,66,66,0,0,0,16,100.00%,15,,Baxalta,IQVIA,Julie McLaren,,Richard Ivan Schiff,,Prashant Nunna,,,,,,,,,COSMOS Inactive,,,,,,2/24/2010,,,,,,,,7/28/2010,,,,,,,,,,,,,,,,8/6/2013,,9/25/2013,,,,,,,,,,,,,,,,,,,,,,11/12/2013,,,,,,,,,,,,12/20/2013,,,,,,,,,,,,,,,,,,,,,,
161001,161001,'161001,'161001,,IGSC 10% HyQ Phase 1,10% HyQ Phase 1,I,Completed,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,52,0,0,0,0,0,0,0.00%,1,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,5/27/2010,,7/5/2010,,,,,,,,9/2/2010,,,,,,,,,,,,,,,,12/29/2010,,1/25/2011,,,,,,,,,,,,,,,,,,,,,,2/11/2011,,,,,,,,,,,,3/31/2011,,,,,,,,,,,,,,,,,,,,,,
161003,161003,'161003,'161003,,"10% IGIV Alzheimer's- 2nd Confirmatory Study:  A Phase 3 Randomized Double-Blind, Placebo-Controlled Study of the Safety & Effectiveness of Immune Globulin Intravenous (Human), 10% IGIV, for the Treatment of Mile to Moderate Alzheimer's Disease",10% Alzheimer's-2nd Study,III,Completed,Alzheimer's Disease,,,Non-Registry,,Interventional,,,,402,253,532,0,271,0,252,62.94%,74,,Baxalta,IQVIA,Lorraine Ampaw,,Kathy Tobias,,"Christine Lyu, Paul Del Castillo, Rocio Iturbe",2011-000914-21,,,,,,,,COSMOS Inactive,,,,2/10/2011,,4/8/2011,,,,,,,,1/23/2012,,,,,,,,,,,,,,,,7/16/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/20/2014,,,,,,,,,,,,,,,,,,,,,,
161101,161101,'161101,'161101,,"10% HyQ Profiling (US): Tolerability, Safety and Administration Mode Evaluation of rHuPH20 Facilitated Subcutaneous Treatment with Immune Globulin Infusion (Human), 10% in Subjects with Primary Immunodeficiency Diseases",10% HyQ Profiling (US),II/III,Completed,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,60,37,54,0,16,0,13,61.67%,15,,Baxalta,IQVIA,Lorraine Ampaw,,"Leman Yel, Richard Ivan Schiff",,Devin Bartlett,,,,,,,,,COSMOS Inactive,,,,7/18/2011,,9/9/2011,,,,,,,,12/29/2011,,,,,,,,,,,,,,,,1/4/2013,,3/1/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/22/2013,,,,,,,,,,,,,,,,,,,,,,
161102,161102,'161102,'161102,,"10% HyQ Profiling (EU): Tolerability, Safety, Product Administration Evaluation of rHuPH20 Facilitated Subcutaneous Treatment with Immune Globulin (Human) 10% in Subjects with Primary Immunodeficiency Diseases-A study in Europe",10% HyQ Profiling (EU),II/III,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,40,0,0,0,0,,0,0.00%,14,,Baxalta,IQVIA,Janet Connolly-Giwa,,"Leman Yel, Richard Ivan Schiff",,"Gudrun Jeindl, Zinah Hong",,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
161201,161201,'161201,'161201,,"10% HyQ Profiling (MoA): Prospective, Open-Label Noncontrolled Study to Evaluate Levels of IgG in Bronchial Secretions and  Efficacy of Immune Globulin Infusion (IGI), 10% in Reducing Levels of Inflammatory Mediators in PID Subjects",10% HyQ Profiling (MoA),II/III,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,36,0,0,0,0,,0,0.00%,1,,Baxalta,,Judith Sosa,,David Gelmont,,,,,,,,,,,COSMOS Inactive,,,,4/13/2012,,3/29/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
161202,161202,'161202,'161202,,"10% IGIV Alzheimer's - GAP Extension:  Study of Long Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Alzheimer’s Disease (AD)",10% Alzheimer's- GAP Extension,III,Completed,Alzheimer's Disease,,,Non-Registry,,Interventional,,,,160,4,6,0,2,0,4,2.50%,25,,Baxalta,IQVIA,Lorraine Ampaw,,Kathy Tobias,,,,,,,,,,,COSMOS Inactive,,,,2/24/2012,,4/13/2012,,,,,,,,11/29/2012,,,,,,,,,,,,,,,,6/4/2013,,7/2/2013,,,,,,,,,,,,,,,,,,,,,,7/30/2013,,,,,,,,,,,,11/27/2013,,,,,,,,,,,,,,,,,,,,,,
161301,161301,'161301,,HYQVIA,"HyQvia (BAX1510) HyQvia Pregnancy Registry:  To Collect Long-Term Safety Data from Female Subjects Who Become Pregnant During Treatment with HyQvia (Immune Globulin (Human), 10% with rHuPH20",HyQ 161301 Pregnancy Registry,IV,Reported,Replacement for Daxas oral,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Observational,,,,8,16,0,,0,4,,200.00%,30,,,IQVIA,,Simon Purnell,Leman Yel,,,,,,,,,,,Medidata CTMS (Pharma),,,6/27/2013,6/27/2013,6/27/2013,6/27/2013,,,12/4/2015,12/4/2015,12/4/2015,12/4/2015,,,12/17/2017,12/17/2017,,,12/17/2019,12/17/2019,,,,,,,,,,,,,,,,,,,,,8/13/2020,8/13/2020,,,,,,,,,,,,,,,,,,,,,,,11/13/2020,11/13/2020,,,,,,,,,,,,,,,11/13/2020,11/13/2020,,,,,,
161302,161302,'161302,,HYQVIA,"HyQvia PASS (EU):  Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects with Primary Immunodeficiency Diseases, Myeloma, or Chronic Lymphocytic Leukemia",HyQvia 161302 PASS EU,IV,Completed,Primary Immunodeficiency,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Observational,,,,110,111,0,,0,31,,100.91%,30,,,IQVIA,,Simon Purnell,Leman Yel,,,,,,,,,,,Medidata CTMS (Pharma),,,7/26/2013,7/26/2013,7/26/2013,7/26/2013,,,7/17/2014,7/17/2014,7/17/2014,7/17/2014,,,12/11/2016,12/11/2016,,,2/24/2020,2/24/2020,,,,,,,,,,,,,,,,,,,,,4/30/2021,4/30/2021,,,,,,,,,,,,,,,,,,,,,,,7/12/2021,,,,,,,,,,,,,,,,7/12/2021,,,,,,,
161403,161403,'161403,,HYQVIA,"SHP671 HyQ (CIDP-1): A Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HyQvia) and Immune Globulin Infusion (Human), 10% (Gammargard Liquid/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",SHP671 (CIDP) 161403 Pivotal,III,Recruiting,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Interventional,Supportive Care,Prospective,,125,129,5,,60,1,,103.20%,126,19,,IQVIA,,Jennifer Mccall,"Shailesh Chavan, Hakan Ay",,,2014-005496-87,,,,,,,,Medidata CTMS (Pharma),,,,,5/27/2015,5/27/2015,,,12/15/2015,12/15/2015,5/9/2016,5/9/2016,,,8/31/2021,,,,2/28/2022,,,,,,,,,,,,,,,,,,,,,,5/31/2022,,,,,,,,,,,,,,,,,,,,,,,,7/29/2022,,,,,,,,,,,,,,,,8/31/2022,,,,,,,
161406,161406,'161406,,HYQVIA,HyQvia PASS (US) PMR:  Non-Interventionall Post-Marketing Safety Study on the Long-Term Safety of HyQvia (Global),HyQvia 161406 PASS (US) PMR,IV,Recruitment Complete,Primary Immunodeficiency,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Observational,,,,250,264,0,,0,0,,105.60%,30,,,IQVIA,,Simon Purnell,Leman Yel,,,,,,,,,,,Medidata CTMS (Pharma),,,3/2/2015,3/2/2015,3/2/2015,3/2/2015,,,11/12/2015,11/12/2015,11/12/2015,11/12/2015,,,10/31/2018,10/31/2018,,,10/30/2021,,,,,,,,,,,,,,,,,,,,,,3/14/2022,,,,,,,,,,,,,,,,,,,,,,,,5/16/2022,,,,,,,,,,,,,,,,5/16/2022,,,,,,,
161502,161502,'161502,'161502,,HyQvia (BAX1510) QPIT 20-10: Safety and Tolerability of HyQvia in Subjects with Primary Immunodeficiency Diseases Previously Treated with 20% Subcutaneous Immunoglobulin,HyQvia 161502 QPIT 20-10,IV,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,50,0,0,0,0,,0,0.00%,5,,Baxalta,,Rocio Iturbe,,Leon Rozen,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
161503,161503,'161503,,HYQVIA,"HyQvia SHP671 (BAX1510) PIDD Pediatric (US): Efficacy. Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Disease",HyQvia 161503 PIDD Peds US,III,Recruitment Complete,Primary Immunodeficiency,Plasma Derived Therapy,PDT,,Pediatric only (<18 yr),Interventional,,,,40,44,0,,4,0,,110.00%,21,,,IQVIA,,"Enrique Garcia, Shailesh Chavan, Lee Hughes, Simon Purnell","Nino Joy, Shumyla Saeed-Khawaja",,,,,,,,,,,Medidata CTMS (Pharma),,,8/7/2015,8/7/2015,7/22/2016,7/22/2016,,,10/17/2017,10/17/2017,10/17/2017,10/17/2017,,,5/2/2019,5/2/2019,,,6/30/2022,,,,,,,,,,,,,,,,,,,,,,8/31/2023,,,,,,,,,,,,,,8/31/2023,,,,,,,,,,10/30/2023,,,,,,,,,,,,,,,,10/30/2023,,,,,,,
161504,161504,'161504,,HYQVIA,"HyQvia (BAX1510) PIDD Pediatric EU:  Post-Authorization, Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Disease",HYQvia 161504 PIDD Peds EU,IV,Recruitment Complete,Primary Immunodeficiency,Plasma Derived Therapy,PDT,,Pediatric only (<18 yr),Interventional,,,,40,48,0,,2,0,,120.00%,20,,,IQVIA,,"Shailesh Chavan, Lee Hughes","Henry Jacotin, Nino Joy, Shumyla Saeed-Khawaja",Enrique Garcia,,2016-003438-26,,,,,,,,Medidata CTMS (Pharma),,,10/7/2016,10/7/2016,10/7/2016,10/7/2016,,,6/13/2017,6/13/2017,6/13/2017,6/13/2017,,,10/21/2019,10/21/2019,,,1/15/2021,1/15/2021,,,,,,,,,,,,,,,,,,,,,8/5/2021,,,,,,,,,,,,,,8/5/2021,,,,,,,,,,10/1/2021,,,,,,,,,,,,,,,,10/1/2021,,,,,,,
161505,161505,'161505,,HYQVIA,SHP671 HyQ (CIDP-3) Extension: Long Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy,SHP671 (CIDP) 161505 Extension,IIIb,Recruiting,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Interventional,Supportive Care,Prospective,,124,76,0,,0,74,,61.29%,78,45,,IQVIA,,Jennifer Mccall,"Leman Yel, Shailesh Chavan, Hakan Ay",,,2016-000374-37,,,,,,,,Medidata CTMS (Pharma),,,,,1/20/2016,1/20/2016,,,11/14/2016,11/14/2016,12/12/2016,12/12/2016,,,2/28/2022,,,,1/1/2024,,,,,,,,,,,,1/31/2024,,,,,,,,,,3/1/2024,,,,,,,,,,,,,,3/31/2024,,,,,,,,,,5/30/2024,,,,,,,,,,,,,,,,5/30/2024,,,,,,,
161601,161601,'161601,'161601,,"SHP671 HyQ (CIDP-2): Ph 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)A Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA) in the Treatment of Chronic Inflammatory Demyelinating Polyradic",SHP671 (CIDP-2) 161601 Ph 2,II,Study Withdrawn,CIDP,,,Non-Registry,,Interventional,,,,25,0,0,0,0,,0,0.00%,25,,Baxalta,"Omnicare CR, Synteract",Andras Nagy,,Steve Glyman,,,,,,,,,,,COSMOS Inactive,,,,4/15/2016,,5/10/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
170901,170901,'170901,'170901,,"CUV (BAX1585) 20% GGL Plus Hylenex: Phase 1 Safety, tolerability, and feasibility study of GAMMAGARD LIQUID 20% and rHuPH20 (GEN2; Halozyme product) administered subcutaneously in Healthy Volunteers",CUV 20% GGL Plus Hylenex,I,Completed,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,47,0,0,0,0,0,0,0.00%,1,,Baxalta,,Judith Sosa,,Richard Ivan Schiff,,,,,,,,,,,COSMOS Inactive,,,,3/18/2009,,5/28/2009,,,,,,,,9/22/2009,,,,,,,,,,,,,,,,10/31/2009,,6/10/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/31/2011,,,,,,,,,,,,,,,,,,,,,,
170903,170903,'170903,'170903,CUVITRU,"CUV (BAX1585) IG PID 20% SubQ (EU): A Clinical Study of Immune Globulin SubQ (Human) IGSC 20%, for the Evaluation of Efficacy, Safety & Pharmacokenetics in Subjects with Primary Immunodeficiency Diseases",CUV 170903 IG PID 20% SubQ EU,II/III,Completed,,Plasma Derived Therapy,,Non-Registry,,Interventional,,,,49,49,55,1,6,0,4,100.00%,18,,Baxalta,IQVIA,,Leman Yel,,,,2010-019459-23,,,,,,,,COSMOS Inactive,,9/25/2014,,,12/30/2010,12/30/2010,,,8/18/2011,8/18/2011,1/28/2013,1/28/2013,,,2/5/2013,2/5/2013,,,5/16/2014,5/16/2014,,,,,,,,,,,,,,,,,,,,,7/9/2014,7/9/2014,,,,,,,,,,,,,,,,,,,,,,,9/23/2014,9/23/2014,,,,,,,,,,,,,,,9/23/2014,9/23/2014,,,,,,
170904,170904,'170904,'170904,CUVITRU,"CUV (BAX1585) IG PID 20% SubQ (US): A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability, and Pharmacokinetics in Subjects with Primary Immunodeficiency Diseases",CUV 170904 IG PID 20% SubQ US,II/III,Completed,Primary Immunodeficiency,Plasma Derived Therapy,,Non-Registry,,Interventional,,,,85,0,0,0,0,0,0,0.00%,15,,Baxalta,"Almac, assisTek, Coram Central Pharmacy, MediRent, Parexel, RPS Inc., Theorem Clinical Research",,Leman Yel,,,,,,,,,,,,COSMOS Inactive,,,,,10/12/2012,10/12/2012,,,1/28/2013,1/28/2013,2/5/2013,2/5/2013,,,12/10/2013,12/10/2013,,,3/10/2015,3/10/2015,,,,,,,,,,,,,,,,,,,,,5/1/2015,5/1/2015,,,,,,,,,,,,,,,,,,,,,,,6/30/2015,6/30/2015,,,,,,,,,,,,,,,6/30/2015,6/30/2015,,,,,,
171301,171301,'171301,'171301,,"CUV 20% IGSC: US PK Study on Efficacy, Pharmacokinetics, and Safety of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) Administered via Frequent Dosing in Subjects with Primary Immunodeficiency Diseases",CUV 20% IGSC: US PK Study,II,Study Withdrawn,Primary Immunodeficiency,,,Non-Registry,,Interventional,,,,60,0,0,0,0,,0,0.00%,10,,Baxalta,,Janet Connolly-Giwa,,Richard Ivan Schiff,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
181501,181501,'181501,'181501,,BAX1810 SM101 in IgAN PoC:  Assess the Efficacy and Safety of Intravenous Infusion with Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX1810) in Subjects with Immunoglobulin A Nephropathy (IgAN),BAX1810 SM101 in IgAN PoC,II,Study Withdrawn,IgAN,,,Non-Registry,,Interventional,,,,51,0,0,0,0,,0,0.00%,40,,Baxalta,PPD,Evelyn Roth-Geissler,,David Gelmont,,,,,,,,,,,COSMOS Inactive,,,,3/30/2015,,5/22/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
181601,181601,'181601,'181601,,"SHP652 (BAX1811) SM101 SLE:A Phase 2b, Multidose, Multicenter, Double-blind, Placebocontrolled, 24 Week Study to Evaluate the Efficacy and Safety of Intravenous Infusion with Recombinant Human Soluble Fc-gamma IIB Receptor SM101 in Subjects with Systemic Lupus Erythematosus (SLE)",SHP652 181601 SM101 SLE Ph2,IIb,Study Terminated,Systemic Lupus Erythematosus,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,240,0,0,0,0,0,0,0.00%,110,,Baxalta,IQVIA,Marc Buggelsheim,,Steve Glyman,,Jade Alphonse,,,,,,,,,COSMOS Inactive,,,3/25/2016,3/25/2016,7/7/2016,7/7/2016,,,,,1/1/2049,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,1/1/2049,,,,,,,,,,,,,,,,,,,,,,,
181701,181701,'181701,,,SHP652 (BAX1811) SM101 SLE LTE: A Phase IIb Long Term Extension Multicenter Study of Intravenous Infusion with Human Soluble Recombinant Fc-gamma IIB Receptor SM101 in Subjects with Systemic Lupus Erythematosus (SLE),SHP652 181701 SM101 SLE LTE,IIb,All Activities Closed,,,,,Non-pediatric only (>18 yr),Interventional,,,,180,,,,,,,,115,,,TBD,,,Steve Glyman,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
181702,181702,'181702,,,"SHP652 (BAX1811) SM101: Phase I, Open-label, Single-Sequence, Dose-escalation to Compare the Pharmacokinetics, Safety and Tolerability of Recombinant Human Soluble Fc-gamma IIB Receptor SM101 in Japanese versus Matched Caucasian (Non-Hispanic) Healthy Volunteers",SHP652 181702 SM101 PK/Safety,I,All Activities Closed,,,,,Non-pediatric only (>18 yr),Interventional,,,,20,,,,,,,,1,,,TBD,,,Steve Glyman,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
201501,201501,'201501,,TAK-754,"SHP654  FVIII Gene Therapy: A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion",SHP654 (FVIII GT) 201501 HEM A,I/II,Recruiting,Hemophilia A,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,10,11,5,,29,0,,110.00%,30,,,IQVIA,,"Cornelia Henkel, Eileen Meulbroek, Olivia Sahnas",,"Jorge Caicedo, Nympha Menezes",,2015-005576-22,,,,,NA,,,Medidata CTMS (Pharma),,,,,2/1/2016,2/1/2016,,,7/16/2018,7/16/2018,11/5/2018,11/5/2018,,,6/28/2021,,,,7/8/2024,,,,,,,,,,,,9/9/2024,,,,,,,,,,11/26/2021,,,,,,,,,,,,,,10/22/2024,,,,,,,,,,11/29/2024,,,,,,,,,,,,,,,,11/29/2024,,,,,,,
201601,201601,'201601,,TAK-754,SHP654 (BAX888) Epi-FVIII Gene Therapy Prevalence: A Global Epidemiologic Study to Determine the Prevalence of Neutralizing Antibody and Related Adaptive Immune Responses to Adeno-assoicated Virus (AAV) in Adults with Hemophilia,SHP654 Epi-FVIII GT Prevalence,IV,Recruitment Complete,Hemophilia A,RGH,RGH,,Non-pediatric only (>18 yr),Observational,,,,250,250,0,,4,0,,100.00%,25,1,,IQVIA,,"Angela Calvillo, Tina Banks",Tejdip Singh,,,,,,,,NA,,,Medidata CTMS (Pharma),,,,,12/12/2016,12/12/2016,,,,,6/14/2017,6/14/2017,,,11/9/2018,11/9/2018,,,4/30/2022,,,,,,,,,,,,5/31/2022,,,,,,,,,,7/29/2022,,,,,,,,,,,,,,7/29/2022,,,,,,,,,,8/30/2022,,,,,,,,,,,,,,,,8/30/2022,,,,,,,
220801,220801,'220801,'220801,,Prothromplex NF PASS,Prothromplex NF PASS,IV,Study Withdrawn,Prothrombin Coag Deficiency,,,Non-Registry,,Non-Interventional_CDO Support,,,,1,,,,,,,,1,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
220901,220901,'220901,'220901,,"Prothromplex Phase IV: International, Multi-Centre, Prospective, Open-Label, Non-Randomized, Uncontrolled Study to Assess Efficacy, Safety of Prothromplex Total in Oral Anticoagulant Reversal in Pts w Acquired Prothrombin Coag Deficiency",ProthromplexTotal,IV,Completed,Prothrombin Coag Deficiency,,,Non-Registry,,Interventional,,,,50,59,60,0,1,0,0,118.00%,6,,Baxalta,IQVIA,Siddhesh Darne,,David Gelmont,,,2010-019250-41,,,,,,,,COSMOS Inactive,,,,,,4/7/2010,,,,,,,,7/11/2010,,,,,,,,,,,,,,,,4/7/2012,,6/1/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/22/2012,,,,,,,,,,,,,,,,,,,,,,
241301,241301,'241301,'241301,,BAX801 OBI-1 rpFVIII in aHem A: Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Autoimmune Anti-Factor VIII Inhibitory Antibodies,BAX801 rpFVIII in aHem A,II/III,Completed,Hemophilia A with inhibitor,,,Non-Registry,,Interventional,,,,28,0,0,0,0,,0,0.00%,25,,Baxalta,,Salvador Dominguez,,Heinrich Farin,,,2011-000181-34,,,,,,,,COSMOS Inactive,,,,,,5/17/2010,,,,,,,,11/9/2010,,,,,,,,,,,,,,,,10/9/2013,,2/28/2014,,,,,,,,,,,,,,,,,,,,,,5/14/2014,,,,,,,,,,,,5/30/2014,,,,,,,,,,,,,,,,,,,,,,
241302,241302,'241302,,Obizur (antihemophilic factor [recombinant] porcine sequence),OBIZUR US PMR: Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A,OBIZUR 241302 US PMR,IV,Completed,Support,RGH,Real World Evidence,,Non-pediatric only (>18 yr),Observational,Other,Cross-sectional,Cohort,40,53,0,,0,0,,132.50%,40,,,IQVIA,,Neil Yadav,Lydia Abad Franch,,,,,,,,,,,Medidata CTMS (Pharma),,,10/31/2013,10/31/2013,3/11/2015,3/11/2015,,,12/30/2015,12/30/2015,12/30/2015,12/30/2015,,,10/19/2018,10/19/2018,,,6/7/2019,6/7/2019,,,,,,,,,,,4/16/2021,4/16/2021,,,,,,,,,,,,,,,,,,,,,,,5/27/2021,5/27/2021,,,,,,,,,7/1/2021,,,,,,,,,,,,,,,,7/1/2021,,,,,,,
241501,241501,'241501,,Obizur (antihemophilic factor [recombinant] porcine sequence),"OBIZUR EU PMR: Prospective and retrospective, Non-Interventional Study to Evaluate the Safety and Effectiveness of OBIZUR in Real Life Practice",OBIZUR 241501 EU PMR,IV,Recruitment Complete,Support,RGH,Real World Evidence,,Non-pediatric only (>18 yr),Observational,Other,Cross-sectional,Cohort,50,50,0,,0,0,,100.00%,36,,,IQVIA,,Neil Yadav,"Lydia Abad Franch, Nataliya Kemenyash",,,,,,,,,,,Medidata CTMS (Pharma),,,1/28/2015,1/28/2015,3/21/2016,3/21/2016,,,12/14/2016,12/14/2016,12/14/2016,12/14/2016,,,4/21/2021,4/21/2021,,,8/30/2021,,,,,,,,,,,,11/8/2021,,,,,,,,,,,,,,,,,,,,,,,,1/25/2022,,,,,,,,,,4/7/2022,,,,,,,,,,,,,,,,4/7/2022,,,,,,,
241502,241502,'241502,,Obizur (antihemophilic factor [recombinant] porcine sequence),"OBIZUR (BAX802) CHAWI Surgery: A Phase 3, Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX802) in Subjects with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures",OBIZUR 241502  CHAWI Surgery,III,Terminated,Support,RGH,RGH,,Both pediatric and non-pediatric,Interventional,,,,12,8,,,,,,66.67%,24,16,,IQVIA,,"Christoph Cirillo, Rachel McComb",,,,2015-005521-39,,,,,,,,Medidata CTMS (Pharma),,,10/9/2015,10/9/2015,9/30/2015,9/30/2015,,,12/22/2016,12/22/2016,5/10/2017,5/10/2017,,,6/30/2021,,,,10/16/2021,,,,,,,,,,,,5/4/2021,5/4/2021,,,,,,,,,,,,,,,,,,,,,,,5/27/2021,,,,,,,,,,7/26/2021,,,,,,,,,,5/7/2019,5/7/2019,,,,,10/16/2021,,,,,,,
250901,250901,'250901,'250901,,"BAX326 Pivotal: Recombinant Factor IX: Phase I/III Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Safety, Efficacy & Immunogenicity in Previously Treated Patients with Severe or Moderately Severe Hemophilia B",BAX326 Pivotal,III,Completed,Hemophilia B,,Early Oncology,Non-Registry,,Interventional,,,,86,73,86,8,5,29,12,84.88%,25,,Baxalta,IQVIA,Oliver Ammann,,Brigitt Abbuehl,,"Carina Dollenz, Liz Mickels",2009-016720-31,,,,,,,,COSMOS Inactive,,,,3/25/2009,,12/15/2009,,,,,,,,7/29/2010,,,,,,,,,,,,,,,,5/3/2012,,7/11/2012,,,,,,,,,,,,,,,,,,,,,,8/1/2012,,,,,,,,,,,,9/13/2012,,,,,,,,,,,,,,,,,,,,,,
251001,251001,'251001,'251001,Rixubis (Coagulation factor IX (recombinant)),"BAX326 Continuation:  Recombinant Factor IX Evaluation of Efficacy, Safety & Immunogenicity in Previously Treated Patients with Severe or Moderately Severe Hemophilia B",RIXUBIS 251001 Continuation,III,Completed,Hemophilia B,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Open Label,,,100,113,117,2,1,0,20,113.00%,34,,Baxalta,IQVIA,,Michael Krammer,,,,2010-022726-33,,,,,,,,COSMOS Inactive,,,,,,,,,4/12/2011,4/12/2011,,,,,5/4/2016,5/4/2016,,,6/30/2017,6/30/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/30/2017,11/30/2017,,,,,,,,,,,,,,,11/30/2017,11/30/2017,,,,,,
251002,251002,'251002,'251002,,"BAX326 Surgery: Recombinant Factor IX, Phase 3, Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients with Severe or Moderately Severe Hemophilia B Undergoing Surgical or Invasive Procedures",RIXUBIS (BAX 326 Surgery,III,Completed,Hemophilia B,,Early Oncology,Non-Registry,,Interventional,,,,40,38,41,2,0,0,3,95.00%,25,,Baxalta,IQVIA,Christiane Thomasser,,Srilatha Tangada,,Elisabeth Pamperl,2011-000413-39,,,,,,,,COSMOS Inactive,,,,10/6/2010,,3/21/2011,,,,,,,,12/19/2011,,,,,,,,,,,,,,,,5/15/2014,,7/24/2014,,,,,,,,,,,,,,,,,,,,,,9/12/2014,,,,,,,,,,,,10/14/2014,,,,,,,,,,,,,,,,,,,,,,
251101,251101,'251101,'251101,,"BAX326 Pediatric: Phase 2/3 Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, Immunogenicity, and Thrombogenicity in PTP Patients with Severe (FIX level <1%) or Moderately Severe (FIX level <=2%) Hemophilia B",BAX 326 Pediatric,II/III,Completed,Hemophilia B,,Early Oncology,Non-Registry,,Interventional,,,,24,23,23,0,0,0,1,95.83%,18,,Baxalta,IQVIA,Kathleen O'Hara,,Eva Maria Poellabauer,,Elisabeth Pamperl,2011-002437-19,,,,,,,,COSMOS Inactive,,,,12/15/2010,,8/26/2011,,,,,,,,12/20/2011,,,,,,,,,,,,,,,,5/14/2013,,7/3/2013,,,,,,,,,,,,,,,,,,,,,,7/25/2013,,,,,,,,,,,,8/27/2013,,,,,,,,,,,,,,,,,,,,,,
251401,251401,'251401,'251401,Rixubis (Coagulation factor IX (recombinant)),PARIXS:  Post-Authorization RIXubis Study,PARIXS,IV,Study Terminated,Hemophilia B,Others,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,,,,80,2,2,0,0,2,0,2.50%,30,,Baxalta,IQVIA,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,9/29/2015,9/29/2015,,,,,,,,,4/25/2016,4/25/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/9/2016,6/9/2016,,,,,,,,,,,,,,,6/9/2016,6/9/2016,,,,,,
261101,261101,'261101,'261101,,"BAX855 (NHL) FVIII Half Life: Phase 1 Single Dose, Dose Escalation, Dose-Finding, Tolerability, Safety & PK Study, Severe Hemophilia A Patients",BAX855: FVIII Half Life,I,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,18,19,23,0,3,0,0,105.56%,5,,Baxalta,IQVIA,Marzena Murawska,,Maureen Conlan,,"Marlene Reisinger, Sabine Gruber",2011-002011-28,,,,,,,,COSMOS Inactive,,,,2/22/2011,,5/30/2011,,,,,,,,9/30/2011,,,,,,,,,,,,,,,,7/27/2012,,8/24/2012,,,,,,,,,,,,,,,,,,,,,,9/17/2012,,,,,,,,,,,,10/19/2012,,,,,,,,,,,,,,,,,,,,,,
261201,261201,'261201,'261201,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),"BAX855 -PEGrFVIII: Ph 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A",BAX855 - Pivotal,II/III,Completed,Hemophilia A,RGH,,Non-Registry,,Interventional,Open Label,,,132,137,159,0,22,0,9,103.79%,90,,Baxalta,IQVIA,Dikla Sharon,,Brigitt Abbuehl,,"Annette Schoeringhumer, Gina Cooper, Rocio Iturbe",2012-003599-38,,,,,,,,COSMOS Inactive,,,10/19/2012,10/19/2012,10/19/2012,10/19/2012,,,1/31/2013,1/31/2013,1/31/2013,1/31/2013,,,11/15/2013,11/15/2013,,,7/17/2014,7/17/2014,,,,,,,,,,,,,,,,,,,,,8/31/2012,8/31/2012,,,,,,,,,,,,,,,,,,,,,,,9/29/2014,9/29/2014,,,,,,,,,,,,,,,9/29/2014,9/29/2014,,,,,,
261202,261202,'261202,'261202,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),"Adynovate (BAX855) Pediatric: Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics Efficacy Safety and Immunogenicity of BAX 855 (Pegylated Full Length Recombinant FVIII) in Previously Treated Pediatric Patients with Severe Hemophilia A",ADN 261202 Pediatric Ph3,III,Completed,Hemophilia A,RGH,,Non-Registry,Pediatric only (<18 yr),Interventional,Safety,,,75,66,75,0,9,0,2,88.00%,60,,Baxalta,IQVIA,,Eli Taube,,,,2014-000742-30,,,,,,,,COSMOS Inactive,,,3/7/2014,3/7/2014,3/7/2014,3/7/2014,,,9/18/2014,9/18/2014,10/31/2014,10/31/2014,,,3/23/2015,3/23/2015,,,10/23/2015,10/23/2015,,,,,,,,,,,,,,,,,,,,,5/28/2014,5/28/2014,,,,,,,,,,,,,,,,,,,,,,,12/30/2015,12/30/2015,,,,,,,,,,,,,,,12/30/2015,12/30/2015,,,,,,
261203,261203,'261203,,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),"SHP660 Adynovate (BAX855) HemA PUP: Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of Pegylated Factor VIII (BAX855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)",ADN 261203 HemA PUP,III,Recruiting,Sjogren's syndrom,RGH,RGH,,Pediatric only (<18 yr),Interventional,Treatment,,,118,115,5,,21,6,,97.46%,100,85,,IQVIA,,Ashley Antoine,Srilatha Tangada,,,2015-002136-40,,,,,,,,Medidata CTMS (Pharma),,,5/27/2015,5/27/2015,5/27/2015,5/27/2015,,,11/12/2015,11/12/2015,12/18/2015,12/18/2015,,,8/31/2021,,,,10/10/2024,,,,,,,,,,,,1/11/2025,,,,,,,,,,12/21/2024,,,,,,,,,,,,,,2/11/2025,,,,,,,,,,4/12/2025,,,,,,,,,,,,,,,,4/12/2025,,,,,,,
261204,261204,'261204,'261204,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),"SHP660 Adynovate (BAX855) Surgery: A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated FVIII (BAX855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures",ADN 261204 Surgery Ph3,III,Completed,Hemophilia A,RGH,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Open Label,,,30,29,30,0,1,0,3,96.67%,29,,Baxalta,IQVIA,,Archana Savla,,,,2013-001359-11,,,,,,,,COSMOS Inactive,,,1/28/2013,1/28/2013,1/28/2013,1/28/2013,,,12/20/2013,12/20/2013,1/17/2014,1/17/2014,,,7/15/2016,7/15/2016,,,9/23/2016,9/23/2016,,,,,,,,,,,,,,,,,,,,,3/27/2015,3/27/2015,,,,,,,,,,,,,,,,,,,,,,,3/14/2017,3/14/2017,,,,,,,,,,,,,,,3/14/2017,3/14/2017,,,,,,
261302,261302,'261302,'261302,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),SHP660 Adynovate (BAX855) Continuation: A Phase 3b Continuation Study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A,ADN 261302 Continuation,IIIb,Completed,Hemophilia A,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Safety,,,149,216,218,0,2,0,29,144.97%,94,,Baxalta,IQVIA,,Celine Kefurt,,,,2013-002236-24,Not Available,,N,No,,,,COSMOS Inactive,4-Jan-18,7/26/2018,3/22/2016,3/22/2016,6/18/2013,6/18/2013,,,10/15/2013,10/15/2013,11/11/2013,11/11/2013,,,11/22/2013,11/22/2013,,,2/28/2018,2/28/2018,,,,,,,,,,,,,,,,,,,,,6/14/2018,6/14/2018,,,,,,,,,,,,,,,,,,,,,,,7/26/2018,7/26/2018,,,,,,,,,,,,,,,7/26/2018,7/26/2018,,,,,,
261303,261303,'261303,'261303,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),"SHP660 Adynovate (BAX855) Propel: Phase 3, Prospective, Randomized, Multi-center Clinical Study to Compare Safety and Efficacy Following PK and FVIII Trough Level Guided Treatment With PEGylated rFVIII Targeting 1% or 10% FVIII Levels in Subjects with Severe Hemophilia A",ADN 261303 Propel Ph3,III,Completed,Hemophilia A,RGH,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Randomized,,,116,115,136,0,15,0,15,99.14%,97,,Baxalta,IQVIA,,"Dmitrii Tkachenko, Ashley Antoine",,,,2014-005477-37,,,N,No,,,,COSMOS Inactive,,,1/13/2015,1/13/2015,1/13/2015,1/13/2015,,,11/21/2015,11/21/2015,6/7/2016,6/7/2016,,,7/31/2017,7/31/2017,,,8/3/2018,8/3/2018,,,,,,,,,,,,,,,,,,,,,11/9/2018,11/9/2018,,,,,,,,,,,,,,,,,,,,,,,12/19/2018,12/19/2018,,,,,,,,,,,,,,,12/19/2018,12/19/2018,,,,,,
261601,261601,'261601,,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),Adynovate Japan Drug Use-Results Survey (DURS),Adynovate 261601 Japan DURS,IV,Recruiting,Hemophilia A,RGH,Real World Evidence,,Non-pediatric only (>18 yr),Observational,,,,165,126,,,,,,76.36%,70,,,IQVIA,,Brittney Thompson,Morio Arai,,,,,,,,,,,Medidata CTMS (Pharma),,,,,12/7/2016,12/7/2016,,,4/12/2017,4/12/2017,4/12/2017,4/12/2017,,,1/31/2022,,,,1/30/2023,,,,,,,,,,,,,,,,,,,,,,3/3/2024,,,,,,,,,,,,,,,,,,,,,,,,3/3/2024,,,,,,,,,,,,,,,,3/3/2024,,,,,,,
271101,271101,'271101,'271101,,BAX 499 Phase 1: ARC19499-001 - First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients,BAX 499 Phase I,I,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,21,17,19,1,1,17,3,80.95%,3,,Baxalta,IQVIA,Michael Cecerle,,Wing Yen Wong,,,2010-020373-17,,,,,,,,COSMOS Inactive,,,,,,8/5/2010,,,,,,,,9/15/2010,,,,,,,,,,,,,,,,12/28/2011,,8/7/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/19/2013,,,,,,,,,,,,,,,,,,,,,,
271102,271102,'271102,'271102,,"BAX 499 Phase IIa, **A","BAX 499 Phase IIa, **A",IIa,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,1,0,0,0,0,,0,0.00%,40,,Baxalta,,"Durojaye Akintola, Michael Cecerle",,Maureen Conlan,,Paz Carrasco,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
271103,271103,'271103,'271103,,"BAX 499 Phase IIb, **A","BAX 499 Phase IIb, **A",IIb,Study Withdrawn,Hemophilia A,,,Non-Registry,,Interventional,,,,64,0,0,0,0,,0,0.00%,1,,Baxalta,,"Durojaye Akintola, Michael Cecerle",,Maureen Conlan,,Barbara Kleczka,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
281101,281101,'281101,'281101,,"SHP655 (BAX930) rADAMTS13 (TTP): A Phase 1 prospective, uncontrolled, open-label, multicenter, dose-escalation study evaluating the safety and pharmacokinetics in hereditary TTP (thrombotic thrombocytopenic purpura)",SHP655 (rADAMTS13) 281101 hTTP,I,Completed,TTP,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,14,15,16,0,1,0,0,107.14%,13,,Baxalta,IQVIA,,Sara Coulter,,,,2012-003221-19,,,,,,,,COSMOS Inactive,,2/22/2016,,9/28/2010,,7/12/2012,,,,,,9/30/2014,,9/30/2014,,,,,,,,,,,,,,,,2/22/2016,,3/18/2016,,,,,,,,,,,,,,,,,,,,,,5/20/2016,,,,,,,,,,,,6/10/2016,,,,,,,,,,,,,,,,,,,,,,
281102,281102,'281102,,TAK-755,"SHP655 (BAX930) rADAMTS13: Phase 3, Prospective, Randomized, Controlled, Open-Label, Multicenter, Two-period Crossover Study with a single Arm Continuation Evaluating the Safety and Efficacy of BAX930 (rADAMTS13) in the Prophylactic and On-Demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura, hTTP)",SHP655 (rADAMTS13) 281102 hTTP,III,Recruiting,Congenital Thrombotic Thrombotocytopenic Purpura,RGH,RGH,,Both pediatric and non-pediatric,Interventional,Prevention,,,68,36,0,,10,37,,52.94%,28,33,,IQVIA,,"Archana Savla, Emily Skelton","Bruce Ewenstein, Cecilia Marquez, Nisha Jain",,,2017-000858-18,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,12/13/2016,12/13/2016,1/30/2017,1/30/2017,,,10/6/2017,10/6/2017,10/20/2017,10/20/2017,,,12/1/2021,,,,7/3/2023,,4/30/2021,,8/2/2021,,,,,,,,,,,,,,,,8/7/2023,,,,,,,,,,8/14/2023,,,,,,,,,,,,,,,,10/23/2023,,,,,,,,,,,,,,,,10/23/2023,,,,,,,
281701,281701,'281701,,,"SHP655: Psychometric Evaluation of PRO Tool for cTTP: Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman syndrome [USS], herediatry thrombotic thrombocytopenic purpura, hTTP)",SHP655 281701 (PRO Tool) cTTP,IV,Completed,,,RGH,,Both pediatric and non-pediatric,Observational,,,,40,,,,,,,,4,,,IQVIA,,Leona Zheng,Bruce Ewenstein,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
291501,291501,'291501,'291501,,"SHP656 (BAX826) PSA-rFVIII: A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX826 (PSA-rVFIII) in Previously Treated Patients with Severe (FVIII < 1%) Hemophilia A",SHP656 Dose-Escalate/Safety,I,Completed,Hemophilia A,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Safety,,,30,40,44,0,4,0,2,133.33%,35,,Baxalta,IQVIA,,Dikla Sharon,,,,2015-004079-60,,,,,,,,COSMOS Inactive,,1/17/2017,,2/10/2015,,9/30/2015,,,,,,3/16/2016,,3/3/2016,,,,,,,,,,,,,,,,1/17/2017,,4/6/2017,,,,,,,,,,,,,,,,,,,,,,5/31/2017,,,,,,,,,,,,7/24/2017,,,,,,,,,,,,,,,,,,,,,,
321401 - Aes-103-003,321401 - Aes-103-003,'321401 - Aes-103-003,'321401 - Aes-103-003,,"BAX555 Sickle Cell Cohort A: Ph 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of 2- Dose Regimens of Aes-103 Given for 28 Days-Subjects w Stable Sickle Cell Disease",BAX555 Sickle Cell Cohort A,II,Study Terminated,Sickle Cell Anemia,,,Non-Registry,,Interventional,Safety,,,20,14,33,0,10,0,10,70.00%,2,,Baxalta,IQVIA,"Dikla Sharon, Ferdinando D'amato, Lorraine Ampaw",,Brahm Goldstein,,,2013-001534-18,,,,,,,,COSMOS Inactive,,,,,,7/31/2013,,,,,,,,11/25/2013,,,,,,,,,,,,,,,,3/9/2015,,8/21/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
321501,321501,'321501,'321501,,BAX555 Sickle Cell PK: To Evaluate the PK of Oral Doses of BAX555 (5-HMF) in Parallel Dosing Groups Administered Either Once Daily or Twice Daily in Healthy Subjects,BAX555 Sickle Cell PK,I,Study Terminated,Sickle Cell Anemia,,,Non-Registry,,Interventional,,,,30,0,13,0,0,0,0,0.00%,1,1,Baxalta,IQVIA,,,,,,,,,,,,,,COSMOS Inactive,,,,5/11/2015,,6/8/2015,,,,,,,,9/3/2015,,,,,,,,,,,,,,,,10/12/2015,,1/7/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
331501,331501,'331501,'331501,,"ONIVYDE (BAX2398) nal-IRI Pancreatic Cancer L2 JP:  Onivyde - Open-label, Non-comparative Phase II Study with BAX2398 in Combination with 5-Fluorouracil and Calcium Levofolinate in Japanese Patients with Metastatic Pancreatic Cancer Which Progressed or Recurred after Prior Gemcitabine-based Therapy",ONV 331501 Pancreatic L2 JP,II,Completed,Pancreatic Cancer,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,84,84,101,0,17,0,84,100.00%,16,,Baxalta,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/19/2015,8/19/2015,9/29/2015,9/29/2015,,,,,3/30/2016,3/30/2016,3/30/2016,3/30/2016,10/17/2016,10/17/2016,,,,,,,,,,,,,1/31/2018,8/8/2018,1/31/2018,8/28/2018,,,,,,,,,,,,,,,,,,,1/1/2049,,3/27/2018,11/6/2018,,,,,,,,,,,5/31/2018,,,,,,,,,,,,,,,,,,,,,,,
331602,331602,'331602,'331602,,ONIVYDE Post Marketing Surveillance Study in South Korea,Adynovate 261601 Japan DURS,IV,Study Terminated,Pancreatic Cancer,,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,,,,78,22,17,0,0,0,0,28.21%,10,,Baxalta,IQVIA,,Petra Schoengrundner,,,,,,,N,No,,,,COSMOS Inactive,,,1/1/2049,1/1/2049,9/12/2017,9/12/2017,,,,,3/8/2018,3/8/2018,3/8/2018,3/8/2018,2/28/2021,1/1/2049,,,,,,,,,,,,,8/28/2022,1/1/2049,8/28/2022,1/1/2049,,,,,,,,,,,,,,,,,,,1/1/2049,1/1/2049,1/1/2049,1/1/2049,,,,,,,,,,,11/23/2022,1/1/2049,,,,,,,,,,,,,,,,,,,,,,
341601,341601,'341601,'341601,,Cal Peg (BAX2304) AML: Open Label Study to Assess the Safety and Tolerability of Calaspargase Pegol with Cytarabine in Subjects with Relapsed /Refractory Acute Myeloid Leukemia (AML),Cal Peg 341601 AML,I/II,Study Withdrawn,Leukemia,,,Non-Registry,,Interventional,,,,40,0,0,0,0,,0,0.00%,18,,Baxalta,IQVIA,Eli Taube,,Claudia Lebedisnsky,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
351601,351601,'351601,,,PV Monitoring Study of Oncaspar in Mexico,PV Monitoring Study of Oncaspar in Mexic,IV,Study Withdrawn,Acute Lymphoblastic Leukemia,,,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,,,,60,0,0,0,0,0,0,0.00%,12,,,,Zorana Radak Jovanovic,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
381401,381401,'381401,'381401,,"Pacritinib (BAX2201): Prospective, Non-Controlled, Open label, Efficacy, Safety, & Pharmacokinetic Study of Pacritinib in Asian Pts with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis",Pacritinib 381401 Myelofibros,II,Study Withdrawn,Myelofibrosis,,,Non-Registry,,Interventional,,,,59,0,0,0,0,0,0,0.00%,30,,Baxalta,IQVIA,"Eli Taube, Suzanne Wilson",,Ellen Hooper,,Claudia Rieder,,,,,,,,,COSMOS Inactive,,,,2/6/2015,,6/19/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
391001,391001,'391001,'391001,,"BAX69 Anti-MIF LN: A First-in-Human, Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of BAX69 After Single & Multiple Dose Administrations in Subjects with Stable Proliferative LN & Persistent Proteinuria",BAX69 Anti-MIF LN,I,Study Terminated,Neoplasm – malignant,,,Non-Registry,,Interventional,,,,70,0,4,0,3,0,0,0.00%,46,3,Baxalta,Synteract,Julie McLaren,,Mahmoud Loghman-Adham,,,,,,,,,,,COSMOS Inactive,,,,2/7/2011,,5/10/2011,,,,,,,,11/28/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
391101,391101,'391101,'391101,,"SHP653 Imalumab (BAX2070/BAX69) - Oncology: A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAX69 in Subjects with Malignant Solid Tumors",Imalumab 391101 Oncology ph1,I,Completed,Neoplasm – malignant,,,Non-Registry,,Interventional,,,,44,50,68,0,17,0,48,113.64%,5,,Baxalta,PPD,,Mary Lau,,,,2013-002870-31,,,,,,,,COSMOS Inactive,,,,8/22/2011,,12/12/2011,,,,,,,,6/15/2012,,,,,,,,,,,,,,,,7/28/2016,,2/9/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/8/2016,,,,,,,,,,,,,,,,,,,,,,
391401,391401,'391401,'391401,,"SHP653 Imalumab (BAX2070/BAX69) mCRC PoC 3rd line:  Phase 2a Randomized, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination with 5-FU/Leucovorin or Panitumumab versus Standard of Care in Subjects with Metastatic Colorectal Cancer",Imalumab 391401 mCRC PoC 3rd,IIa,Completed,Neoplasm – malignant,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,93,86,115,0,23,0,92,92.47%,40,,Baxalta,IQVIA,,Eli Taube,,,,2015-000896-28,,,,,,,,COSMOS Inactive,,,,11/7/2014,,12/10/2014,,,,,,6/2/2015,,5/20/2015,,8/8/2016,,,,,,,,,,,,,,2/15/2017,,10/25/2017,,,,,,,,,,,,,,,,,,,,,,1/12/2018,,,,,,,,,,,,2/2/2018,,,,,,,,,,,,,,,,,,,,,,
391402,391402,'391402,'391402,,"SHP653 Imalumab (BAX2070/BAX69) MA/OC PoC: Assess the Pharmacokinetics (PK), MTD, Safety, Pharmacodynamics (PD) and Biomarker of BAX 2070 in Subjects with Malignant Ascites of Ovarian Cancer (Inter-Peritoneal treatment)",Imalumab 391402 MA/OC PoC,I,Study Terminated,Neoplasm – malignant,,,Non-Registry,,Interventional,,,,60,1,2,0,1,0,0,1.67%,30,,Baxalta,PPD,Sara Coulter,,Rekha Abichandani,,Brittney Boisvert,2015-003492-29,,,,,,,,COSMOS Inactive,,,,12/17/2014,,3/25/2015,,,,,,,,11/2/2015,,,,,,,,,,,,,,,,5/3/2016,,7/20/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/19/2016,,,,,,,,,,,,,,,,,,,,,,
400701,400701,'400701,'400701,,CEPROTIN Treatment Registry,CEPROTIN (Protein C) Registry,IV,Completed,Protein C Deficiency,,,Non-Registry,,Non-Interventional_CDO Support,PASS (Post Authorization Safety Study),,,43,43,43,0,0,0,5,100.00%,30,,Baxalta,Dr. Oestreich + Partner GmbH,,Siddhesh Darne,,,,,,,,,,,,COSMOS Inactive,,,,,,9/22/2009,,,,,,6/22/2010,,6/22/2010,,,,,,,,,,,,,,,,6/22/2015,,8/12/2015,,,,,,,,,,,,,,,,,,,,,,9/29/2015,,,,,,,,,,,,1/15/2016,,,,,,,,,,,,,,,,,,,,,,
450501,450501,'450501,'450501,,ARALAST alpha-1-Proteinase Inhibitor (a1-PI) Surveillance Study (for 2 yr),Aralast Coram Surveillance,IV,Completed,Alpha-1 antitrypsin deficiency,,,Non-Registry,,Interventional,,,,60,0,0,0,0,0,0,0.00%,1,,Baxalta,,Nancy Sullivan,,David Gelmont,,,,,,,,,,,COSMOS Inactive,,,,,,5/4/2006,,,,,,,,6/9/2006,,,,,,,,,,,,,,,,12/15/2008,,5/8/2009,,,,,,,,,,,,,,,,,,,,,,9/3/2009,,,,,,,,,,,,9/30/2009,,,,,,,,,,,,,,,,,,,,,,
460501,460501,'460501,'460501,,Aralast PK,Aralast PK,IV,Completed,Alpha-1 antitrypsin deficiency,,,Non-Registry,,Interventional,,,,25,,,,,,,,7,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,9/26/2005,,,,,,,,12/20/2005,,,,,,,,,,,,,,,,6/5/2006,,7/5/2006,,,,,,,,,,,,,,,,,,,,,,8/23/2006,,,,,,,,,,,,10/9/2006,,,,,,,,,,,,,,,,,,,,,,
460502,460502,'460502,'460502,,Aralast BAL: The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (Fr IV-1) Alpha1-Proteinase Inhibitor (PI) on the Level of Alpha 1-PI and Other Analytes in the Bronchoalveolar Epithelial Lining Fluid (ELF),Aralast BAL,IV,Completed,Alpha-1 antitrypsin deficiency,,,Non-Registry,,Interventional,,,,12,0,0,0,0,0,0,0.00%,5,,Baxalta,,Alison Nimchuk,,David Gelmont,,,,,,,,,,,COSMOS Inactive,,,,9/26/2006,,,,,,,,,,12/6/2006,,,,,,,,,,,,,,,,12/14/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
460503,460503,'460503,,,"Aralast/GLASSIA (BAX1335) Stage 1: A Prospective, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy & Safety of ARALAST NP & GLASSIA in Subjects with Alpha1-Proteinase Inhibitor (A1PI) Deficiency & Chronic Obstructive Pulmonary Disease (COPD)",Aralast/GLASSIA 460503 Stage1,IV,All Activities Closed,,,,,Non-pediatric only (>18 yr),Interventional,,,,110,7,51,,15,,7,6.36%,34,,,IQVIA,,,Leman Yel,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
471101,471101,'471101,,GLASSIA,"A Phase 3/4 Study to Evaluate the Safety, Immunogenicity,
and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels
in Epithelial Lining Fluid Following GLASSIA Therapy in
A1PI-Deficient Subjects",Ph 3/4 GLASSIA Study,IV,Completed,Alpha1-Antitrypsin Deficient Emphysema,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Interventional,Treatment,,,36,36,0,,25,0,,100.00%,20,,,IQVIA,,Salvador Dominguez,"Enrique Garcia, Michael Czorniak",,,,,Approved,,,,,,Medidata CTMS (Pharma),,,10/21/2015,10/21/2015,1/19/2016,1/19/2016,,,3/8/2016,3/8/2016,4/21/2016,4/21/2016,,,2/5/2020,2/5/2020,,,7/29/2020,7/29/2020,,,,,,,,,,,11/9/2020,11/9/2020,,,,,,,,,1/27/2021,1/27/2021,,,,,,,,,,,,,,,,,,,,,,,12/31/2021,,,,,,,,,,,,,,,,12/31/2021,,,,,,,
471201,471201,'471201,'471201,,GLASSIA Infusion Rate: Ph 1 Healthy Adult Safety and Tolerability Study of ARALAST NP and GLASSIA,GLASSIA 471201 Infusion Rate,IV,Completed,Alpha-1 antitrypsin deficiency,,,Non-Registry,,Interventional,,,,30,30,273,0,232,0,0,100.00%,1,,Baxalta,IQVIA,lliana Leony Lasso,,Leman Yel,,,,,,,,,,,COSMOS Inactive,,,,,,3/28/2012,,,,,,,,7/26/2012,,,,,,,,,,,,,,,,1/11/2013,,2/5/2013,,,,,,,,,,,,,,,,,,,,,,3/26/2013,,,,,,,,,,,,4/29/2013,,,,,,,,,,,,,,,,,,,,,,
471501,471501,'471501,'471501,,"GLASSIA (BAX1337) Treatment of Acute GvHD: A 2-part , Multicenter, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-on Biopharmacotherapy to Conventional Steroid Treatment in Subjects with aGvHD with Lower Gastrointestional Involvement",GLASSIA 471501 GvHD Ph2,II,Study Terminated,Alpha-1 antitrypsin deficiency,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,168,1,1,0,0,0,0,0.60%,40,,Baxalta,IQVIA,Andrea Ayad,,Steve Glyman,,Suraj Krishnamurthi,,,,,,,,,COSMOS Inactive,,,1/5/2016,1/5/2016,4/19/2016,4/19/2016,,,,,4/26/2017,4/26/2017,4/26/2017,4/26/2017,4/26/2017,4/26/2017,,,,,,,,,,,,,5/3/2018,5/3/2018,5/3/2018,5/25/2018,,,,,,,,,,,,,,,,,,,1/1/2049,,8/22/2018,8/22/2018,,,,,,,,,,,7/21/2018,8/28/2018,,,,,,,,,,,,,,,,,,,,,,
670701,670701,'670701,'670701,,"OPEN-LABEL, RANDOMIZED, THREE-ARM, PHASE IIIb CLINICAL STUDY TO INVESTIGATE THE SAFETY AND IMMUNOGENICITY OF A CONCOMITANT ADMINISTRATION OF GROUP C MENINGOCOCCAL POLYSACCHARIDE-TETANUS TOXOID CONJUGATE (MENC-TT) VACCINE AND 7-VALENT PNEUMOCOCCAL CRM",MENINGOCOCCAL GROUP C CONJUGAT,III,Completed,Meningitis,,,Non-Registry,,Interventional,,,,330,333,333,0,1,0,0,100.91%,27,,Baxalta,"Dr. Oestreich + Partner GmbH, Omnicare CR, Siro Clinpharm Pvt. Ltd, World Courier",,,,,,2007-004276-39,,,,,,,,COSMOS Inactive,,,,,,9/19/2007,,,,,,,,3/25/2008,,,,,,,,,,,,,,,,7/30/2009,,12/15/2009,,,,,,,,,,,,,,,,,,,,,,3/9/2010,,,,,,,,,,,,3/29/2010,,,,,,,,,,,,,,,,,,,,,,
670901,670901,'670901,'670901,,"NeisVac 1+1: Phase IIIb Randomized , Open label, Feasibility study of a single priming dose of Meningococcal Group C conjugate vaccine (NeisVac-C) in infants",NeisVac 1+1,IIIb,Completed,Meningitis,,,Non-Registry,,Interventional,,,,948,956,980,0,21,0,4,100.84%,20,,Baxalta,IQVIA,Jennifer Bremner,,Eva Maria Poellabauer,,Maria Proupin-perez,2010-019383-36,,,,,,,,COSMOS Inactive,,,,,,4/21/2010,,,,,,,,9/28/2010,,,,,,,,,,,,,,,,1/31/2012,,6/11/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/10/2012,,,,,,,,,,,,,,,,,,,,,,
671401,671401,'671401,'671401,,"NeisVac Toddler Study: Open-Label, Randomized, Ph IIIB Study to Investigate Safety and Immunogenicity Against Neisseria Meningitidis Serogroup C of a Single Priming Dose of Four Meningococcal Conjungate Vaccines in Healthy Toddlers Ages 12 to 13 Mos",NeisVac Toddler Study,IIIb,Study Withdrawn,Meningitis,,,Non-Registry,,Interventional,,,,180,,,,,,,,10,,Baxalta,IQVIA,Kathleen O'Hara,,Eva Maria Poellabauer,,,,,,,,,,,COSMOS Inactive,,,,2/3/2014,,6/25/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
690501,690501,'690501,'690501,,Single Blind randomized multicenter comparison of FSME Immun NEW and Encepur: Safety and tolerability of 2 vaccinations in healthy volunteers aged 16-65 yrs,TBE Safety Study in volunteers,III,Study Withdrawn,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,"3,800",0,0,0,0,,0,0.00%,15,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
690601,690601,'690601,'690601,,TBE Rapid Immunization Adults Ph 3b,TBE Rapid Immunization Adults,III,Completed,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,340,,,,,,,,4,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,4/20/2006,,5/2/2006,,,,,,,,9/18/2006,,,,,,,,,,,,,,,,5/21/2007,,12/12/2007,,,,,,,,,,,,,,,,,,,,,,1/11/2008,,,,,,,,,,,,4/30/2008,,,,,,,,,,,,,,,,,,,,,,
690701,690701,'690701,'690701,,OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMMUN 0.5ML IN ADULTS,FSME-IMMUN 0.5ml,IV,Completed,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,314,315,315,0,0,0,38,100.32%,2,,Baxalta,PPD,,,,Michael Krammer,,2007-00044027,,,,,,,,COSMOS Inactive,,,,3/8/2007,,3/8/2007,,,,,,,,7/27/2007,,,,,,,,,,,,,,,,7/17/2010,,9/22/2010,,,,,,,,,,,,,,,,,,,,,,2/14/2011,,,,,,,,,,,,3/18/2011,,,,,,,,,,,,,,,,,,,,,,
691101,691101,'691101,'691101,,FU of 690701: TBE Adult Antibody Persistance: Investigate the Seropersistence of Tick-Borne Encephalitis (TBE) Virus Antibodies From 7 - 10 Yrs After the First Booter and the Response to Second Booster Vaccination with FSME-IMMUN 0.5ML in Adults,TBE adult Antibody Persistance,IV,Completed,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,243,243,243,0,0,0,0,100.00%,2,,Baxalta,PPD,Christiane Thomasser,,Eva Maria Poellabauer,,,,,,,,,,,COSMOS Inactive,,,,,,11/21/2011,,,,,,,,5/30/2012,,,,,,,,,,,,,,,,6/17/2015,,8/27/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
700401,700401,'700401,'700401,,Open-Label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-Borne Encephalitis Vaccine in Children and Adolescents Aged 3-18 Years,FSME Peds Ab Pers (F/U 209),IV,Completed,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,202,,,,,,,,4,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,11/19/2004,,2/25/2005,,,,,,,,5/13/2005,,,,,,,,,,,,,,,,7/25/2008,,11/21/2008,,,,,,,,,,,,,,,,,,,,,,6/24/2009,,,,,,,,,,,,7/23/2009,,,,,,,,,,,,,,,,,,,,,,
700501,700501,'700501,'700501,,"Multicenter Ph 4 study to investigate the seropersistence of TBE Virus Antibodies approximately 3 years after a Booster Vaccination with FSME-IMMUN 0,25ml junior in children","TBE Seropersistence Children,",IV,Completed,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,97,,,,,,,,12,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,2/15/2005,,6/14/2005,,,,,,,,6/30/2005,,,,,,,,,,,,,,,,7/5/2006,,11/23/2006,,,,,,,,,,,,,,,,,,,,,,11/28/2006,,,,,,,,,,,,6/13/2007,,,,,,,,,,,,,,,,,,,,,,
700801,700801,'700801,'700801,,"Single Blind randomized Phase IIIB Study in children aged 1-11yrs to investigate the immunogenicity, Safety and Interchangeability of two Tick-borne Encephalitis (TBE) vaccines administered according to a conventional schedule",FSME Peds - Jr 0.25mL Compare,III,Completed,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,300,303,303,0,0,0,5,101.00%,8,,Baxalta,IQVIA,,,,,,2008-002691-10,,,,,,,,COSMOS Inactive,,,,11/14/2008,,11/14/2008,,,,,,,,2/6/2009,,,,,,,,,,,,,,,,5/20/2010,,8/13/2010,,,,,,,,,,,,,,,,,,,,,,9/29/2010,,,,,,,,,,,,10/21/2010,,,,,,,,,,,,,,,,,,,,,,
700802,700802,'700802,'700802,,"FSME Ped F/U of 700401: Open-label Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination to FSME-IMMUN in children, adolescents & young adults",FSME Ped F/U of 700401,IV,Completed,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,160,160,160,0,0,0,0,100.00%,4,,Baxalta,IQVIA,Christiane Thomasser,,Eva Maria Poellabauer,,,,,,,,,,,COSMOS Inactive,,,,,,1/26/2009,,,,,,,,4/26/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
701001,701001,'701001,'701001,,TBE Rapid Immunization children,TBE Rapid Immunization childre,IV,Study Withdrawn,Tick-borne encephalitis,,,Non-Registry,,Interventional,,,,240,0,0,0,0,,0,0.00%,7,,Baxalta,,,,,,,2010-0020097-42,,,,,,,,COSMOS Inactive,,,,,,4/19/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
710501,710501,'710501,'710501,,Interpandemic Flu Ph1/2 (Whole Virus),Interpandemic Flu Ph 1/2,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,423,,,,,,,,3,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,8/31/2005,,10/13/2005,,,,,,,,1/29/2006,,,,,,,,,,,,,,,,10/2/2006,,6/13/2007,,,,,,,,,,,,,,,,,,,,,,7/3/2007,,,,,,,,,,,,9/5/2007,,,,,,,,,,,,,,,,,,,,,,
720601,720601,'720601,'720601,,Interpandemic Flu Ph1/2 (Split Virus),Interpandemic Flu Ph1/2 (Split,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,940,,,,,,,,7,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,8/31/2006,,10/20/2006,,,,,,,,1/15/2007,,,,,,,,,,,,,,,,9/25/2007,,11/22/2007,,,,,,,,,,,,,,,,,,,,,,12/17/2007,,,,,,,,,,,,12/20/2007,,,,,,,,,,,,,,,,,,,,,,
720701,720701,'720701,'720701,,DHHS Seasonal Flu Pediatric: Phase 1 Study in Children and Adolescents of the Safety and Immunogenicity of an Investigational Vero cell derived Influenza Vaccine (VCIV) as Compared to a Licensed Egg Derived Influenza Vaccine (EIV),DHHS Seasonal Flu Pediatric,I,Study Withdrawn,Influenza,,,Non-Registry,,Interventional,,,,420,0,0,0,0,,0,0.00%,9,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
720703,720703,'720703,'720703,,Seasonal Flu Adult Ph3-Culture Confirmed Influenza,Flu Adult Ph3-Culture Confirm,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,"3,600","3,683",3981,0,292,0,321,102.31%,35,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,9/6/2007,,,,,,,,11/26/2007,,,,,,,,,,,,,,,,6/11/2008,,12/19/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/24/2009,,,,,,,,,,,,,,,,,,,,,,
720801,720801,'720801,'720801,,Seasonal Flu 50+Ph3,Seasonal Flu 50+Ph3,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,"3,195","3,207",3335,0,129,0,60,100.38%,30,,Baxalta,IQVIA,,,,,,,,,,,,,,COSMOS Inactive,,,,8/27/2008,,8/27/2008,,,,,,,,11/13/2008,,,,,,,,,,,,,,,,6/7/2009,,7/24/2009,,,,,,,,,,,,,,,,,,,,,,8/31/2009,,,,,,,,,,,,9/25/2009,,,,,,,,,,,,,,,,,,,,,,
720802,720802,'720802,'720802,,Seasonal Flu Adult Ph3-Culture Confirmed Influenza,Seasonal Flu Adult Ph3-Culture,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,"7,200","7,246",7777,0,531,0,410,100.64%,36,,Baxalta,IQVIA Japan,Julie McLaren,,,,,,,,,,,,,COSMOS Inactive,,,,10/22/2008,,10/22/2008,,,,,,,,12/1/2008,,,,,,,,,,,,,,,,6/27/2009,,10/26/2009,,,,,,,,,,,,,,,,,,,,,,11/20/2009,,,,,,,,,,,,12/23/2009,,,,,,,,,,,,,,,,,,,,,,
720901,720901,'720901,'720901,,Yearly Strain Variation Study 2009/2010,Yearly Strain Variation Study,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,110,110,110,0,0,0,0,100.00%,1,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,3/19/2009,,3/19/2009,,,,,,,,6/24/2009,,,,,,,,,,,,,,,,7/20/2009,,7/31/2009,,,,,,,,,,,,,,,,,,,,,,8/13/2009,,,,,,,,,,,,9/28/2009,,,,,,,,,,,,,,,,,,,,,,
720903,720903,'720903,'720903,,"Seasonal Flu-Proof of Principle (Safety, Confirmatory Study): An Open Label, Phase 3 Study to Assess the Safety and Immunogenicity  of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population",Seasonal Flu - PoP,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,100,110,110,0,0,0,0,110.00%,1,,Baxalta,,Yuri Martina,,Maria Allende,,Sabine Geyer,,,,,,,,,COSMOS Inactive,,,,12/1/2009,,1/1/2010,,,,,,,,5/4/2010,,,,,,,,,,,,,,,,5/27/2010,,6/7/2010,,,,,,,,,,,,,,,,,,,,,,7/21/2010,,,,,,,,,,,,8/18/2010,,,,,,,,,,,,,,,,,,,,,,
721001,721001,'721001,'721001,,"AN OPEN-LABEL PHASE 3 STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A VERO CELL-DERIVED TRIVALENT SEASONAL INFLUENZA VACCINE, STRAIN COMPOSITION 2010/2011, IN AN ADULT AND ELDERLY POPULATION",YSV 2010/11,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,110,110,115,0,0,0,0,100.00%,1,,Baxalta,,,,,,,2010-020026-17,,,,,,,,COSMOS Inactive,,,,3/25/2010,,4/14/2010,,,,,,,,7/8/2010,,,,,,,,,,,,,,,,8/6/2010,,8/12/2010,,,,,,,,,,,,,,,,,,,,,,8/17/2010,,,,,,,,,,,,8/19/2010,,,,,,,,,,,,,,,,,,,,,,
721002,721002,'721002,'721002,,MAPO Ph 3,MAPO Ph 3,III,Study Withdrawn,Influenza,,,Non-Registry,,Interventional,,,,100,0,0,0,0,,0,0.00%,2,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
721103,721103,'721103,'721103,,PREFLUCEL Effectiveness: Vaccination against infection with seasonal influenza virus in an adult and elderly population aged 50 years and older,PREFLUCEL Effectiveness,IV,Study Withdrawn,Influenza,,,Non-Registry,,Interventional,,,,"2,040",0,0,0,0,,0,0.00%,80,,Baxalta,,Michael Krammer,,Barbara Izay,,Sabine Geyer,,,,,,,,,COSMOS Inactive,,,,5/12/2011,,8/5/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
721104,721104,'721104,'721104,,"DHHS IPAN Comparability: Randomized, Age-Stratified, Double Blind, Controlled Study Comparing Vero Cell-Derived Trivalent Seasonal Flu Vaccine Made by Modified Manufacturing Process with Vaccine made by Current Manufacturing Process in Adult > 18",DHHS IPAN Comparability,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,0,"1,800",1800,0,0,0,32,,20,,Baxalta,PPD,"Kathleen O'Hara, Michael Krammer",,Nirjhar Chatterjee,,Kelly Nicholls,,,,,,,,,COSMOS Inactive,,,,5/18/2012,,5/18/2012,,,,,,,,1/22/2013,,,,,,,,,,,,,,,,4/13/2013,,5/24/2013,,,,,,,,,,,,,,,,,,,,,,7/2/2013,,,,,,,,,,,,9/5/2013,,,,,,,,,,,,,,,,,,,,,,
730901,730901,'730901,'730901,,"Lyme snyOspA: Randomized, double-blind, ph 1 study to investigate the safety & immunogenicity of four doses of multivalent recombinant OspA Lyme Borreliosis vaccine (rOspA LB Vaccine) with & without aluminum hydroxide in seronegative adults 18-45",Lyme snyOspA,I/II,Completed,Lyme Borreliosis,,,Non-Registry,,Interventional,,,,650,650,1630,0,174,0,28,100.00%,8,,Baxalta,PPD,Michael Krammer,,Eva Maria Poellabauer,,Sabine Geyer,2010-023384-18,,,,,,,,COSMOS Inactive,,,,11/25/2010,,11/25/2010,,,,,,,,3/1/2011,,,,,,,,,,,,,,,,2/28/2014,,3/26/2014,,,,,,,,,,,,,,,,,,,,,,5/19/2014,,,,,,,,,,,,6/23/2014,,,,,,,,,,,,,,,,,,,,,,
731201,731201,'731201,'731201,,LYME Phase III - EU,LYME Phase III - EU,III,Study Withdrawn,Lyme Borreliosis,,,Non-Registry,,Interventional,,,,"11,000",0,0,0,0,,0,0.00%,75,,Baxalta,PPD,Michael Krammer,,Eva Maria Poellabauer,,Sabine Geyer,2012-001572-10,,,,,,,,COSMOS Inactive,,,,3/9/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
731202,731202,'731202,'731202,,Lyme: US - Phase II,Lyme:  US - Phase II,IIb,Study Withdrawn,Lyme Borreliosis,,,Non-Registry,,Interventional,,,,550,0,0,0,0,,0,0.00%,5,,Baxalta,Almac,Michael Krammer,,Eva Maria Poellabauer,,Sabine Geyer,,,,,,,,,COSMOS Inactive,,,,10/2/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
810501,810501,'810501,'810501,,Pandemic Flu Ph 1/2 (Whole Virus),Pandemic Flu Ph 1/2 (Whole Vir,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,275,,,,,,,,3,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,1/27/2006,,4/11/2006,,,,,,,,6/12/2006,,,,,,,,,,,,,,,,2/16/2007,,6/27/2007,,,,,,,,,,,,,,,,,,,,,,10/15/2007,,,,,,,,,,,,10/17/2007,,,,,,,,,,,,,,,,,,,,,,
810601,810601,'810601,'810601,,AN OPEN LABEL PHASE III STUDY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE TO ASSESS THE IMMUNOGENICITY AND SAFETY AND TO INVESTIGATE THE NEED FOR AND TIMING OF A BOOSTER VACCINATION,Flu Vaccine - EU Pandemic,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,550,558,583,0,25,0,129,101.45%,8,,Baxalta,,Michael Krammer,,,,Sabine Geyer,,,,,,,,,COSMOS Inactive,,,,12/22/2006,,12/22/2006,,,,,,,,4/10/2007,,,,,,,,,,,,,,,,10/28/2009,,1/25/2010,,,,,,,,,,,,,,,,,,,,,,2/26/2010,,,,,,,,,,,,5/24/2010,,,,,,,,,,,,,,,,,,,,,,
810701,810701,'810701,'810701,,Asian Pandemic Flu Ph 1/2 (Whole Virus),Asian Pandemic Flu Ph 1/2 (Who,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,128,,,,,,,,4,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,5/2/2007,,5/10/2007,,,,,,,,7/31/2007,,,,,,,,,,,,,,,,2/26/2008,,7/31/2008,,,,,,,,,,,,,,,,,,,,,,8/27/2008,,,,,,,,,,,,9/29/2008,,,,,,,,,,,,,,,,,,,,,,
810703,810703,'810703,'810703,,Pandemic Flu Ph 1/2 F/U (Whole Virus),Pandemic Flu Ph 1/2 F/U (Whole,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,77,,,,,,,,1,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,6/14/2007,,6/29/2007,,,,,,,,9/20/2007,,,,,,,,,,,,,,,,4/30/2008,,10/17/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
810705,810705,'810705,'810705,,"EU Prepandemic Licensure Adult/Elderly and Specific Risk Groups: Ph 3, Vero cell derived Whole Virus H5N1 Influenza Vaccine",EU Prepandemic Lic **C,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,"3,560",,,,,,,,47,,Baxalta,PPD,Yuri Martina,,Alexander Geisberger,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,8/8/2008,,,,,,,,,,,,,,,,10/1/2010,,11/17/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/21/2011,,,,,,,,,,,,,,,,,,,,,,
810706,810706,'810706,'810706,,"Prepandemic Peds (EU) *C: PH I/II Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years",Prepandemic Peds (EU),I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,670,672,672,0,8,0,0,100.30%,16,,Baxalta,SynteractHCR,Jennifer Bremner,,Eva Maria Poellabauer,,Barbara Kleczka,2009-013105-34,,,,,,,,COSMOS Inactive,,,,2/19/2009,,6/1/2009,,,,,,,,12/21/2009,,,,,,,,,,,,,,,,5/24/2012,,8/10/2012,,,,,,,,,,,,,,,,,,,,,,9/11/2012,,,,,,,,,,,,11/6/2012,,,,,,,,,,,,,,,,,,,,,,
810801,810801,'810801,'810801,,US RG Pan Ph1,US RG Pan Ph1,I,Completed,Influenza,,,Non-Registry,,Interventional,,,,420,420,578,0,158,0,18,100.00%,6,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,11/19/2007,,4/9/2008,,,,,,,,7/7/2008,,,,,,,,,,,,,,,,2/13/2009,,8/13/2009,,,,,,,,,,,,,,,,,,,,,,9/30/2009,,,,,,,,,,,,10/27/2009,,,,,,,,,,,,,,,,,,,,,,
810802,810802,'810802,'810802,,"Pandemic Flu Vaccine Prime Boost: Ph I/II Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 months to 17 Years",Pandemic Flu PrimeBoost,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,230,199,231,0,0,0,39,86.52%,3,,Baxalta,Kendle/INC Research,,,Alexander Geisberger,,Gudrun Jeindl,,,,,,,,,COSMOS Inactive,,,,10/17/2008,,10/17/2008,,,,,,,,5/5/2009,,,,,,,,,,,,,,,,1/17/2011,,5/10/2011,,,,,,,,,,,,,,,,,,,,,,6/22/2011,,,,,,,,,,,,7/25/2011,,,,,,,,,,,,,,,,,,,,,,
810901,810901,'810901,'810901,,RG Pandemic Flu Adults Phase II,RG Pandemic Flu Adults Phase I,II,Study Withdrawn,Influenza,,,Non-Registry,,Interventional,,,,930,0,0,0,0,,0,0.00%,14,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
810902,810902,'810902,'810902,,"An Observer Blinded, Multi-Center, Phase 1/2 Study of H5N1 Pandemic Influenza Vaccine (RG Strain, Whole Virus, Vero-cell Derived, Inactivated in Subjects 3 to 17 Years of Age",Phase 1/2 RG Pandemic Influenz,I/II,Study Withdrawn,Influenza,,,Non-Registry,,Interventional,,,,666,,,,,,,,20,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
811001,811001,'811001,'811001,,"H5N1 (JP) BIRD - Takeda Project: Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years",H5N1 (JP) BIRD - (Takeda),II/III,Completed,Influenza,,,Non-Registry,,Interventional,,,,340,339,352,0,12,0,16,99.71%,3,,Baxalta,INC Research,Julie McLaren,,Alexander Geisberger,,,,,,,,,,,COSMOS Inactive,,,,,,12/3/2010,,,,,,,,6/17/2011,,,,,,,,,,,,,,,,2/7/2012,,5/11/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/27/2012,,,,,,,,,,,,,,,,,,,,,,
811201,811201,'811201,'811201,,H5N1 (JP) BIRD -  Elderly: An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older,H5N1 (JP) BIRD - Elderly,III,Completed,Influenza,,,Non-Registry,,Interventional,,,,85,85,91,0,6,0,0,100.00%,2,,Baxalta,PPD,Kathleen O'Hara,,Nirjhar Chatterjee,,Sabine Geyer,,,,,,,,,COSMOS Inactive,,,,7/24/2012,,8/2/2012,,,,,,,,3/4/2013,,,,,,,,,,,,,,,,10/9/2013,,12/9/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/23/2014,,,,,,,,,,,,,,,,,,,,,,
811202,811202,'811202,'811202,,"H5N1 (JP) BIRD - Pediatric: Open-Label Ph 3-Assess Immunogenicity, Safety of Vero Cell-Derived Whole Virus H5N1 Influenza, Japanese Aged 6 mos to 17 yrs",H5N1 (JP) BIRD - Pediatric,II/III,Completed,Influenza,,,Non-Registry,,Interventional,,,,61,60,60,0,0,0,0,98.36%,2,,Baxalta,IQVIA,"Kathleen O'Hara, Prashant Nunna",,Nirjhar Chatterjee,,Sabine Geyer,,,,,,,,,COSMOS Inactive,,,,,,4/17/2013,,,,,,,,8/6/2013,,,,,,,,,,,,,,,,4/8/2014,,6/6/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/17/2014,,,,,,,,,,,,,,,,,,,,,,
820901,820901,'820901,'820901,,"H1N1 Observational Cohort Study: A prospective NIV study to assess the safety of two vaccinations of a vero cell-derived, whole virus H1N1 pandemic flu vaccine in subjects exposed to the vaccine through policies by goverments or health authorities",H1N1 Observational Cohort Stud,IV,Completed,Influenza,,,Non-Registry,,Non-Interventional_CDO Support,,,,"3,216","3,216",3216,0,0,0,0,100.00%,30,,Baxalta,IQVIA,,,,,,,,,,,,,,COSMOS Inactive,,,,,,8/12/2009,,,,,,,,11/4/2009,,,,,,,,,,,,,,,,12/20/2010,,2/28/2011,,,,,,,,,,,,,,,,,,,,,,6/8/2011,,,,,,,,,,,,10/25/2011,,,,,,,,,,,,,,,,,,,,,,
820902,820902,'820902,'820902,,H1N1 - Adults: An Open Label Phase 1/2 Study to Assess Immunogenicity and Safety of Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Adults Aged 18 Years and Older,H1N1 - Adults,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,400,408,415,0,7,0,0,102.00%,5,,Baxalta,IQVIA,,,,,,2009-013394-17,,,,,,,,COSMOS Inactive,,,,6/11/2009,,6/25/2009,,,,,,,,8/13/2009,,,,,,,,,,,,,,,,3/2/2010,,4/28/2010,,,,,,,,,,,,,,,,,,,,,,6/24/2010,,,,,,,,,,,,7/26/2010,,,,,,,,,,,,,,,,,,,,,,
820903,820903,'820903,'820903,,"H1N1 - Peds: An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of 2 Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years",H1N1 - Peds,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,400,341,341,0,0,0,228,85.25%,10,,Baxalta,IQVIA,,,,Barbara Gastl,Sabine Geyer,2009-013131-38,,,,,,,,COSMOS Inactive,,,,5/22/2009,,6/26/2009,,,,,,,,9/7/2009,,,,,,,,,,,,,,,,12/14/2010,,3/18/2011,,,,,,,,,,,,,,,,,,,,,,5/12/2011,,,,,,,,,,,,7/21/2011,,,,,,,,,,,,,,,,,,,,,,
831001,831001,'831001,'831001,,"H9N2 US - DHHS: Double-blind, Multi-Center, Ph 1/2 Study to Assess Safety and Immunogenicity of Four Different Dose Levels of a Reverse Genetic (RG Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years",H9N2 US -DHHS,I/II,Completed,Influenza,,,Non-Registry,,Interventional,,,,275,275,275,0,70,0,27,100.00%,5,,Baxalta,Almac,Julie McLaren,,Barbara Izay,,,,,,,,,,,COSMOS Inactive,,,,,,10/26/2010,,,,,,,,3/16/2011,,,,,,,,,,,,,,,,10/20/2011,,5/29/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/13/2012,,,,,,,,,,,,,,,,,,,,,,
850801,850801,'850801,'850801,,"West Nile Virus Ph1: Double-Blind, Non-Controlled, Eight-Arm Safety and Dose Finding Study in Healthy Adult 18 Years of Age and Older",West Nile Virus Ph I,I,Completed,West Nile Virus,,,Non-Registry,,Interventional,,,,320,320,453,0,133,0,46,100.00%,5,,Baxalta,PPD,Michael Krammer,,Gerald Aichinger,,,,,,,,,,,COSMOS Inactive,,,,6/24/2008,,6/19/2009,,,,,,,,9/16/2009,,,,,,,,,,,,,,,,12/9/2010,,3/4/2011,,,,,,,,,,,,,,,,,,,,,,6/6/2011,,,,,,,,,,,,2/28/2014,,,,,,,,,,,,,,,,,,,,,,
880701,880701,'880701,'880701,,"Ross River Virus Ph I/II: A Blinded Phase I/II Dose Escalation study to assess safety & immunogenicity & investigate the optimal dose level of a formalin-treated, UV-inactivated, vero cell-derived RRV vaccine in healthy volunteers aged 18-40 years",Ross River Virus PI/II,I/II,Completed,Ross River Virus (RRV),,,Non-Registry,,Interventional,,,,400,381,381,0,0,0,0,95.25%,10,,Baxalta,SynteractHCR,,,,,,,,,,,,,,COSMOS Inactive,,,,1/31/2008,,4/17/2008,,,,,,,,6/9/2008,,,,,,,,,,,,,,,,4/17/2009,,7/29/2009,,,,,,,,,,,,,,,,,,,,,,10/19/2009,,,,,,,,,,,,11/27/2009,,,,,,,,,,,,,,,,,,,,,,
880801,880801,'880801,'880801,,"Ross River Virus Phase 3:  Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older",Ross River Virus Ph 3,III,Completed,Ross River Virus (RRV),,,Non-Registry,,Interventional,,,,"1,968","1,964",2119,0,151,0,311,99.80%,20,,Baxalta,Kendle/INC Research,Kathleen O'Hara,,Barbara Izay,,Kelly Nicholls,,,,,,,,,COSMOS Inactive,,,,5/6/2010,,9/22/2010,,,,,,,,4/18/2011,,,,,,,,,,,,,,,,10/15/2012,,12/20/2012,,,,,,,,,,,,,,,,,,,,,,5/6/2013,,,,,,,,,,,,6/7/2013,,,,,,,,,,,,,,,,,,,,,,
881201,881201,'881201,'881201,,RRV 6-Mo Safety Extension: Open Label Study to Investigate the Safety of the Ross River Virus (RRV) Vaccine from 6-12 Months After the Third Vaccination in Healthy Adults (follow up to study 880801),RRV 6-Mo Safety Extension,IIIb,Completed,Ross River Virus (RRV),,,Non-Registry,,Interventional,,,,"1,300","1,146",1146,0,0,0,0,88.15%,17,,Baxalta,INC Research,Kathleen O'Hara,,Gerald Aichinger,,Iris Schaafsma,,,,,,,,,COSMOS Inactive,,,,,,2/8/2012,,,,,,,,7/27/2012,,,,,,,,,,,,,,,,4/16/2013,,5/16/2013,,,,,,,,,,,,,,,,,,,,,,6/27/2013,,,,,,,,,,,,7/22/2013,,,,,,,,,,,,,,,,,,,,,,
900801,900801,'900801,'900801,,"ACT34-CMI-2: An Open-Label, Feasibility Study To Determine the Initial Safety & Performance of the HELIX® Injection Catheter for Intramyocardial Delivery of G-CSF Mobilized Auto-CD34+ Cells for Reduction of Angina Episodes in Subjects with CMI",ACT34-CMI-2,I,Study Withdrawn,Chronic Myocardial Isch. (CMI),,,Non-Registry,,Interventional,,,,30,,,,,,,,10,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
901001,901001,'901001,'901001,,CMI Renew Study: Controlled study to determine the efficacy and safety of targeted intramyocardial delivery of G-CSF mobilized autologous CD34+ cells for the improvment in total exercise time in subjects w refractory angina pectoris and CMI,CMI Renew Study,III,Completed,Chronic Myocardial Isch. (CMI),,,Non-Registry,,Interventional,,,,444,110,293,0,180,112,17,24.77%,50,,Baxalta,PPD,,Kathleen O'Hara,,,,,,,,,,,,COSMOS Inactive,,,,11/9/2010,,7/6/2011,,,,,,,,5/17/2012,,,,,,,,,,,,,,,,11/23/2015,,12/23/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/10/2016,,,,,,,,,,,,,,,,,,,,,,
901101,901101,'901101,'901101,,"CMI and Refractory Angina:A prospective, randomized, double-blinded, active-controlled study to determine the efficacy and safety of targeted intramyocardial delivery of autologous CD34+ cells (Auto-CD34+ cells) for increasing exercise capacity",CMI and Refractory Angina,III,Study Withdrawn,Chronic Myocardial Isch. (CMI),,,Non-Registry,,Interventional,,,,330,0,0,0,0,,0,0.00%,40,,Baxalta,,George Chen,,Adel Nada,,Mary Shea,,,,,,,,,COSMOS Inactive,,,,11/21/2011,,6/26/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
911301,911301,'911301,'911301,,"SHP651 (BAX2923 - M923) 3way PK/PD Equivalence: Randomized, Double-blind, 3-arm, Parallel Group, Single-dose Study Compare Pharmacokinetics, Safety, Tolerability, & Immunogenicity of Three Formulations of Adalimumab (M923, US & EU Sourced Humira) in Healthy Subjects",SHP651 3way PK/PD Equivalence,I,Completed,Psoriasis,,,Non-Registry,,Interventional,,,,975,322,1339,0,1004,0,0,33.03%,3,,Baxalta,IQVIA,Marilyn White,,John Caminis,,,2014-001043-20,,,,,,,,COSMOS Inactive,,,,12/12/2013,,10/16/2014,,,,,,,,1/5/2015,,,,,,,,,,,,,,,,10/3/2015,,10/28/2015,,,,,,,,,,,,,,,,,,,,,,12/18/2015,,,,,,,,,,,,1/6/2016,,,,,,,,,,,,,,,,,,,,,,
911401,911401,'911401,'911401,,"SHP651 (BAX2923 - M923) Psoriasis: Safety & Immunogenicity: Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy, Safety, and  Immunogenicity of an Adalimumab Biosimilar (M923) and Humira in Adults with Moderate to Severe Chronic Plaque-Type Psoriasis",SHP651 911401 Psoriasis,III,Study Terminated,Psoriasis,,,Non-Registry,,Interventional,,,,516,572,827,0,255,0,79,110.85%,115,80,Baxalta,IQVIA,Rocio Iturbe,,John Caminis,,,2015-001751-76,,,,,,,,COSMOS Inactive,,,,1/7/2015,,4/23/2015,,,,,,,,9/30/2015,,,,,,,,,,,,,,,,4/4/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
911501,911501,'911501,'911501,,"SHP651 (BAX2923 - M923) Autoinjector PK: Randomized, Open-label, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of M923 Administered via Autoinjector or Prefilled Syringe, in Healthy Subjects",SHP651 911501 Autoinjector PK,I,Completed,Rheumatoid Arthritis,,,Non-Registry,,Interventional,,,,156,156,603,0,447,0,4,100.00%,2,,Baxalta,IQVIA,Rocio Iturbe,,John Caminis,,,2015-005200-29,,,,,,,,COSMOS Inactive,,,,7/6/2015,,11/25/2015,,,,,,,,1/27/2016,,,,,,,,,,,,,,,,7/19/2016,,9/12/2016,,,,,,,,,,,,,,,,,,,,,,10/27/2016,,,,,,,,,,,,2/20/2017,,,,,,,,,,,,,,,,,,,,,,
911502,911502,'911502,'911502,,SHP651 (BAX2923 - M923) AI PhIII:  Open-Label Singel-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for an Adalimumab Biosimilar (M923) Delivered to Subjects With Moderate to Severe Rheumatoid Arthritis (RA),SHP651 911502 AI Usability RA,III,Study Terminated,Rheumatoid Arthritis,,,Non-Registry,,Interventional,,,,32,33,51,0,18,0,7,103.13%,10,8,Baxalta,IQVIA,Rocio Iturbe,,John Caminis,,,,,,,,,,,COSMOS Inactive,,,,10/28/2015,,1/29/2016,,,,,,,,4/13/2016,,,,,,,,,,,,,,,,2/20/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
950901,950901,'950901,'950901,,950901: BAX 513 - A Phase I Study to Evaluate the Effects of BAX 513 on Hemostatic Parameters in Healthy Volunteers.,Phase I Dosing Study of BAX 51,I,Completed,Hemophilia A,,,Non-Registry,,Interventional,,,,40,21,25,5,1,0,0,52.50%,1,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,7/22/2009,,9/7/2009,,,,,,,,1/29/2010,,,,,,,,,,,,,,,,7/23/2010,,9/13/2010,,,,,,,,,,,,,,,,,,,,,,11/26/2010,,,,,,,,,,,,2/10/2011,,,,,,,,,,,,,,,,,,,,,,
6201501,6201501,'06201501,,Advate (Antihemophilic Factor (Recombinant)),"ADVANCE China: Compare Joint Health Outcomes in Moderate and Severe Hemophilia A Patients Treated with ADVATE Under Different Treatment REgimens in China:  A Multicenter, Non-Interventional, Prospective Observational Study (ADVANCE)",ADVANCE China PMR,IV,Completed,,RGH,RGH,,Non-pediatric only (>18 yr),Observational,,Prospective,Case-Only,160,160,498,,18,,6,100.00%,10,10,,"Shanghai Bestudy Medical Technology Co., LTD",,"Hai Fang, Ortrun Obermann-Slupetzky",James Mao,,,,,,,,,,,Medidata CTMS (Pharma),,,10/20/2015,10/20/2015,10/20/2015,10/20/2015,,,1/22/2016,1/22/2016,1/22/2016,1/22/2016,,,9/30/2017,9/30/2017,,,8/31/2018,8/31/2018,,,,,,,,,,,,,,,,,,,,,3/1/2019,3/1/2019,,,,,,,,,,,,,,,,,,,,,,,4/30/2019,4/30/2019,,,,,,,,,,,,,,,4/30/2019,4/30/2019,,,,,,
10201806002,Cabozantinib-2001,'Cabozantinib-2001,,cabozantinib,Cabozantinib-2001 Japan Ph 2 study (RCC 2nd Line),Cabozantinib-2001 Japan Ph 2 study (RCC 2nd Line),II,Enrollment Complete,,Oncology,,,,,,,,35,35,46,,11,,,100.00%,19,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,8/24/2017,8/24/2017,,,11/16/2017,11/16/2017,12/27/2017,12/27/2017,,,7/3/2018,7/3/2018,4/30/2019,4/30/2019,10/23/2018,10/23/2018,,,,,,,8/25/2020,8/25/2020,,,12/18/2018,12/18/2018,,,,,,,11/19/2020,11/19/2020,12/25/2018,12/25/2018,,,,,,,11/19/2020,11/19/2020,,,,,12/25/2018,12/25/2018,,,,,,,12/18/2020,12/18/2020,3/20/2019,3/20/2019,,,,,,,3/10/2021,3/10/2021,,,,,,,3/10/2021,3/10/2021,,,,,,
10201806003,Cabozantinib-2002,'Cabozantinib-2002,,cabozantinib,Cabozantinib-2002 Japan Ph2 study (RCC 1st Line),Cabozantinib-2002 Japan Ph2 study (RCC 1st Line),II,Cancelled,,Oncology,,,,,,,,23,0,0,,0,,0,0.00%,15,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201806004,Cabozantinib-2003,'Cabozantinib-2003,,cabozantinib,Cabozantinib-2003 Japan Ph2 study (HCC 2nd Line),Cabozantinib-2003 Japan Ph2 study (HCC 2nd Line),II,Enrollment Complete,,Oncology,,,,,,,,32,34,39,,8,,,106.25%,18,,,Takeda PRA Development Center,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,4/26/2018,4/26/2018,,,8/12/2018,8/12/2018,8/27/2018,8/27/2018,,,1/29/2019,1/29/2019,7/28/2019,7/28/2019,7/23/2019,7/23/2019,,,,,,,12/24/2020,12/24/2020,,,9/19/2019,9/19/2019,,,,,,,3/24/2021,3/24/2021,9/27/2019,9/27/2019,,,,,,,4/14/2021,4/14/2021,,,,,9/27/2019,9/27/2019,,,,,,,4/14/2021,4/14/2021,12/26/2019,12/26/2019,,,,,,,7/21/2021,,,,,,,,7/21/2021,,,,,,,
10201806005,Darvadstrocel-3002,'Darvadstrocel-3002,,Alofisel,"A Phase 3, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Efficacy and
Safety of Cx601 in the Treatment of Complex Perianal Fistulas in Adult Patients with
Crohn's Disease",,III,Enrollment Complete,,GI,,,,,,,,20,22,,,4,,,110.00%,7,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,Advance,,DDWORKS,,,9/26/2017,9/26/2017,4/20/2018,4/20/2018,,,3/6/2019,3/6/2019,3/28/2019,3/28/2019,,,2/4/2020,2/4/2020,,,7/20/2020,7/20/2020,2/1/2021,2/1/2021,,,,,1/31/2023,,,,11/11/2020,11/11/2020,3/26/2021,3/26/2021,,,,,4/4/2023,,11/16/2020,11/16/2020,4/6/2021,4/6/2021,,,,,4/11/2023,,,,,,12/1/2020,12/1/2020,5/7/2021,5/7/2021,,,,,5/9/2023,,12/18/2020,12/18/2020,5/13/2021,5/13/2021,,,,,8/1/2023,,,,,,,,8/21/2023,,,,,,,
10201806006,Lu AA21004/CCT-004,'Lu AA21004/CCT-004,,Trintellix (vortioxetine),Lu AA21004/CCT-004 Phase 3 - MDD Pivotal Study,Lu AA21004/CCT-004 Phase 3 - MDD Pivotal Study,III,Closed,,NS,,,,,,,,492,492,,,,,,100.00%,68,,,EPS,,,,,,,,,,,,,,DDWORKS,,,,,1/9/2015,1/9/2015,,,4/7/2015,4/7/2015,4/24/2015,4/24/2015,,,12/27/2017,12/27/2017,3/30/2018,3/30/2018,,,,,,,,,,,,,6/25/2018,6/25/2018,,,,,,,,,7/9/2018,7/9/2018,,,,,,,,,,,,,9/3/2018,9/3/2018,,,,,,,,,,,,,,,,,10/31/2018,10/31/2018,,,,,,,10/31/2018,10/31/2018,,,,,,
10201806007,vortioxetine-1001,'vortioxetine-1001,,Trintellix (vortioxetine),1001 Ph1 BE study (Lu 21004) (Lu AA21004),1001 Ph1 BE study (Lu 21004) (Lu AA21004),I,Closed,,NS,,,,,,,,56,56,,,,,,100.00%,1,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201806008,C16010,'C16010,,Ninlaro,MLN9708/ONC-013 MLN9708 C16010 - GP3 Relapsed or Refractory Multiple Myeloma Combo w/ Rd (capsule),MLN9708/ONC-013 MLN9708 C16010 - GP3 Relapsed or Refractory Multiple Myeloma Combo w/ Rd (capsule),III,In Follow-Up,,Oncology,Late Oncology,,,,,,,41,838,1066,,228,838,,2043.90%,30,,,EPS,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201806010,C16014,'C16014,,Ninlaro,MLN9708/ONC-004 MLN9708 C16014 (ONC-004) - GP3 Newly Diagnosed Multiple Myeloma w/ Rd,MLN9708/ONC-004 MLN9708 C16014 (ONC-004) - GP3 Newly Diagnosed Multiple Myeloma w/ Rd,III,In Follow-Up,,Oncology,Late Oncology,,,,,,,60,748,1148,,400,748,,1246.67%,20,,,EPS,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201806013,C16028,'C16028,,Ninlaro,"C16028 A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myelom",,II,Closed,,Oncology,,,,,,,,30,34,43,,9,,6,113.33%,20,,,EPS,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,8/23/2016,8/23/2016,,,11/4/2016,11/4/2016,11/22/2016,11/22/2016,,,8/4/2017,8/4/2017,8/4/2019,8/4/2019,8/3/2018,8/3/2018,,,,,,,8/4/2019,8/4/2019,,,10/2/2018,10/2/2018,,,,,,,11/1/2019,11/1/2019,10/9/2018,10/9/2018,,,,,,,11/29/2019,11/29/2019,,,,,11/2/2018,11/2/2018,,,,,,,11/29/2019,11/29/2019,1/25/2019,1/25/2019,,,,,,,2/19/2020,2/19/2020,,,,,,,2/19/2020,,,,,,,
10201806014,TB-MC010034,'TB-MC010034,,Ninlaro,MLN9708/ONC-001 MLN9708 TB-MC010034 (ONC-001) - P1/1b Relapased or Refractory Multiple Myeloma Mono+Combo (capsule),,I,Closed,,Oncology,,,,,,,,1,0,,,,,,0.00%,5,,,Takeda PRA Development Center,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,1/16/2012,1/16/2012,,,5/23/2012,5/23/2012,6/6/2012,6/6/2012,,,10/2/2013,10/2/2013,3/21/2015,3/21/2015,2/15/2019,2/15/2019,,,,,,,,,,,5/15/2019,5/15/2019,,,,,,,,,6/14/2019,6/14/2019,,,,,,,,,,,,,7/24/2019,7/24/2019,,,,,,,,,9/3/2019,9/3/2019,,,,,,,,,,,,,,,9/3/2019,9/3/2019,,,,,,
10201806015,Niraparib-1001,'Niraparib-1001,,Niraparib,JPN Ph1 study (Ovarian) (Niraparib),,I,Closed,,Oncology,,,,,,,,9,9,11,,2,,8,100.00%,1,,,Takeda PRA Development Center,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,1/23/2018,1/23/2018,,,4/23/2018,4/23/2018,4/27/2018,4/27/2018,,,10/23/2018,10/23/2018,12/29/2018,12/29/2018,12/3/2018,12/3/2018,,,,,,,2/10/2020,2/10/2020,,,5/20/2019,5/20/2019,,,,,,,6/18/2020,6/18/2020,5/23/2019,5/23/2019,,,,,,,6/18/2020,6/18/2020,,,,,5/23/2019,5/23/2019,,,,,,,6/29/2020,6/29/2020,7/23/2019,7/23/2019,,,,,,,9/24/2020,9/24/2020,,,,,,,9/24/2020,9/24/2020,,,,,,
10201806016,C25003,'C25003,,ADCETRIS,SGN-35/ONC-004 SGN35 C25003 (ONC-004) - GP3 Frontline HL (ECHELON 1),SGN-35/ONC-004 SGN35 C25003 (ONC-004) - GP3 Frontline HL (ECHELON 1),III,In Follow-Up,,Oncology,Late Oncology,,,,,,,23,"1,309",1546,,236,0,0,5691.30%,10,,,CIMIC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201806022,SYR-472-3003,'SYR-472-3003,,Zafatek (Trelagliptin),SYR-472/CCT-201 Phase 3 - Pivotal/Long-term Safety Study,SYR-472/CCT-201 Phase 3 - Pivotal/Long-term Safety Study,III,Closed,,Others,,,,,,,,107,107,267,,160,,25,100.00%,51,,,A2 Healthcare,,,,,,,,,,,,,,DDWORKS,,,2/5/2015,2/5/2015,4/1/2015,4/1/2015,,,8/7/2015,8/7/2015,9/14/2015,9/14/2015,,,4/11/2017,4/11/2017,,,4/24/2018,4/24/2018,,,,,,,,,,,6/18/2018,6/18/2018,,,,,,,,,6/29/2018,6/29/2018,,,,,,,,,,,,,7/23/2018,7/23/2018,,,,,,,,,8/28/2018,8/28/2018,,,,,,,,,,,,,,,9/10/2018,,,,,,,
10201806025,Vonoprazan-3001,'Vonoprazan-3001,,vonoprazan,3001 P3 NERD (TAK-438),3001 P3 NERD (TAK-438),III,Closed,,GI,,,,,,,,484,484,,,,,,100.00%,45,,,EPS,,,,,,,,,,,,,,DDWORKS,,,1/19/2016,1/19/2016,8/31/2016,8/31/2016,,,11/15/2016,11/15/2016,11/25/2016,11/25/2016,,,1/29/2018,1/29/2018,,,2/26/2018,2/26/2018,,,,,,,,,,,5/29/2018,5/29/2018,,,,,,,,,6/12/2018,6/12/2018,,,,,,,,,,,,,7/4/2018,7/4/2018,,,,,,,,,9/10/2018,9/10/2018,,,,,,,,,,,,,,,9/28/2018,9/28/2018,,,,,,
10201806026,TAK-438ASA-1001,'TAK-438ASA-1001,,vonoprazan ASA,1001 BE Study (TAK-438 ASA) (vonoprazan ASA (TAK-438 ASA)),1001 BE Study (TAK-438 ASA) (vonoprazan ASA (TAK-438 ASA)),I,Closed,,GI,,,,,,,,552,548,,,,,,99.28%,1,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,De-Risk,,DDWORKS,,,10/19/2017,10/19/2017,12/29/2017,12/29/2017,,,3/8/2018,3/8/2018,4/2/2018,4/2/2018,,,10/10/2018,10/10/2018,,,10/12/2018,10/12/2018,,,,,,,,,,,12/27/2018,12/27/2018,,,,,,,,,1/7/2019,1/7/2019,,,,,,,,,,,,,1/23/2019,1/23/2019,,,,,,,,,3/13/2019,3/13/2019,,,,,,,,,,,,,,,8/9/2018,8/9/2018,,,,,,
10201806027,TAK-536/OCT-101,'TAK-536/OCT-101,,Azilva (azilsartan),TAK-536/OCT-101 Phase 3 - Long-term Safety Study in 6 to 16 y/o HTN patients,TAK-536/OCT-101 Phase 3 - Long-term Safety Study in 6 to 16 y/o HTN patients,III,Closed,,CVM,,,,,,,,30,27,35,,8,,4,90.00%,32,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,,,,DDWORKS,,,,,3/22/2016,3/22/2016,,,8/2/2016,8/2/2016,9/9/2016,9/9/2016,,,5/29/2018,5/29/2018,,,6/4/2019,6/4/2019,,,,,,,,,,,7/23/2019,7/23/2019,,,,,,,,,7/30/2019,7/30/2019,,,,,,,,,,,,,8/22/2019,8/22/2019,,,,,,,,,10/3/2019,10/3/2019,,,,,,,,,,,,,,,5/7/2020,5/7/2020,,,,,,
10201806029,TAK-831-1002,'TAK-831-1002,,TAK-831,Asia SRD/MRD (TAK-831),Asia SRD/MRD (TAK-831),I,Closed,,NS,,,,,,,,40,40,,,,,,100.00%,1,,,Takeda PRA Development Center,,,,,,,,,,,Wave 2,De-Risk,,DDWORKS,,,6/19/2018,6/19/2018,9/5/2018,9/5/2018,,,10/9/2018,10/9/2018,10/19/2018,10/19/2018,,,5/22/2019,5/22/2019,,,6/19/2019,6/19/2019,,,,,,,,,,,7/23/2019,7/23/2019,,,,,,,,,8/23/2019,8/23/2019,,,,,,,,,,,,,8/23/2019,8/23/2019,,,,,,,,,9/19/2019,9/19/2019,,,,,,,3/19/2020,3/19/2020,,,,,,,3/31/2020,3/31/2020,,,,,,
10201806030,TAK-906-1004,'TAK-906-1004,,TAK-906,1.1 TAK-906-1004 Japan SAD/MAD study,1.1 TAK-906-1004 Japan SAD/MAD study,I,Closed,,GI,,,,,,,,24,24,,,,,,100.00%,1,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,Wave 2,De-Risk,,DDWORKS,,,2/22/2017,2/22/2017,5/26/2017,5/26/2017,,,8/7/2017,8/7/2017,8/25/2017,8/25/2017,,,9/14/2017,9/14/2017,,,10/7/2017,10/7/2017,,,,,,,,,,,12/15/2017,12/15/2017,,,,,,,,,12/21/2017,12/21/2017,,,,,,,,,,,,,1/12/2018,1/12/2018,,,,,,,,,4/11/2018,4/11/2018,,,,,,,,,,,,,,,4/12/2018,4/12/2018,,,,,,
10201806031,Pevonedistat-1012,'Pevonedistat-1012,,pevonedistat (TAK-924),MLN4924/ONC-010 MLN4924 Pevonedistat-1012 (ONC-010) - Asian P1/1b Hematology SA and Combo,MLN4924/ONC-010 MLN4924 Pevonedistat-1012 (ONC-010) - Asian P1/1b Hematology SA and Combo,I,Enrollment Complete,,Oncology,Late Oncology,,,,,,,37,23,0,,0,0,20,62.16%,9,,,PPD SNBL,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201806033,TAK-925-1001,'TAK-925-1001,,TAK-925,1001 Ph1 SRD POM study (TAK-925),1001 Ph1 SRD POM study (TAK-925),I,Closed,,NS,,,,,,,,101,101,,,,,,100.00%,1,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,Wave 1,Accelerate,,DDWORKS,,,7/12/2017,7/12/2017,9/11/2017,9/11/2017,,,11/11/2017,11/11/2017,11/20/2017,11/20/2017,,,8/31/2018,8/31/2018,,,9/4/2018,9/4/2018,,,,,,,,,,,10/12/2018,10/12/2018,,,,,,,,,10/26/2018,10/26/2018,,,,,,,,,,,,,12/4/2018,12/4/2018,,,,,,,,,3/18/2019,3/18/2019,,,,,,,,,,,,,,,9/3/2019,9/3/2019,,,,,,
10201806036,TAK-935-1004,'TAK-935-1004,,soticlestat (TAK-935),1004 P1 SRD MRD Study (TAK-935),,I,On-going,,NS,,,,,,,,32,0,0,,0,,0,0.00%,1,,,PRA,,,,,,,,,,,Wave 1,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201806038,TAK-438ODT-1001,'TAK-438ODT-1001,,vonoprazan OD,"An Open-Label, Crossover Phase 1 Study to Evaluate the Bioequivalence of TAK-438 OD (Orally Disintegrating) Tablet When Administered without Water (Study 1) or with Water (Study 2) and TAK-438 tablet in Healthy Adult Male Subjects",1001 BE Study (TAK-438 OD),I,Closed,,GI,,,,,,,,96,96,,,,,,100.00%,1,,,Takeda PRA Development Center,,,,,,,,,,,NA,De-Risk,,DDWORKS,,,9/20/2018,9/20/2018,12/12/2018,12/12/2018,,,1/30/2019,1/30/2019,2/14/2019,2/14/2019,,,3/2/2019,3/2/2019,,,3/12/2019,3/12/2019,,,,,,,,,,,6/17/2019,6/17/2019,,,,,,,,,6/20/2019,6/20/2019,,,,,,,,,,,,,7/23/2019,7/23/2019,,,,,,,,,8/29/2019,8/29/2019,,,,,,,,,,,,,,,7/23/2019,,,,,,,
10201806040,MLN0002/CCT-101,'MLN0002/CCT-101,,Entyvio,CCT-101 P3 Comparator study UC (Vedolizumab),CCT-101 P3 Comparator study UC (Vedolizumab),III,Closed,,GI,,,,,,,,278,292,344,,52,,49,105.04%,100,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,11/11/2013,11/11/2013,,,2/4/2014,2/4/2014,2/13/2014,2/13/2014,,,11/10/2015,11/10/2015,,,12/3/2016,12/3/2016,,,,,,,2/27/2018,2/27/2018,,,2/20/2017,2/20/2017,,,,,,,8/16/2018,8/16/2018,3/13/2017,3/13/2017,,,,,,,8/23/2018,8/23/2018,,,,,4/4/2017,4/4/2017,,,,,,,9/13/2018,9/13/2018,6/15/2017,6/15/2017,,,,,,,11/7/2018,11/7/2018,,,,,,,11/5/2019,,,,,,,
10201806041,MLN0002/CCT-001,'MLN0002/CCT-001,,Entyvio,CCT-001 P3 Comparator study CD (Vedolizumab),,III,Closed,,GI,,,,,,,,110,157,194,,37,,25,142.73%,60,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,11/11/2013,11/11/2013,,,1/28/2014,1/28/2014,2/10/2014,2/10/2014,,,9/29/2016,9/29/2016,,,11/16/2017,11/16/2017,,,,,,,1/25/2019,1/25/2019,,,2/6/2018,2/6/2018,,,,,,,7/10/2019,7/10/2019,2/20/2018,2/20/2018,,,,,,,7/19/2019,7/19/2019,,,,,3/7/2018,3/7/2018,,,,,,,8/22/2019,8/22/2019,6/7/2018,6/7/2018,,,,,,,10/21/2019,10/21/2019,,,,,,,10/21/2019,10/21/2019,,,,,,
10201806042,Azilsartan-1005,'Azilsartan-1005,,Azilva (azilsartan),1005 Definitive FE with Ped (TAK-536) (Azilva (azilsartan)),1005 Definitive FE with Ped (TAK-536) (Azilva (azilsartan)),I,Closed,,CVM,,,,,,,,23,23,,,,,,100.00%,1,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,,,,DDWORKS,,,10/3/2017,10/3/2017,12/5/2017,12/5/2017,,,2/14/2018,2/14/2018,2/28/2018,2/28/2018,,,3/6/2018,3/6/2018,,,3/11/2018,3/11/2018,,,,,,,,,,,4/6/2018,4/6/2018,,,,,,,,,4/13/2018,4/13/2018,,,,,,,,,,,,,4/23/2018,4/23/2018,,,,,,,,,6/18/2018,6/18/2018,,,,,,,,,,,,,,,6/29/2018,6/29/2018,,,,,,
10201806043,Niraparib-2002,'Niraparib-2002,,Niraparib,JPN Ph2 study (Ovarian) (Niraparib),,II,"Active, Not Recruiting",,Oncology,,,,,,,,16,20,35,,15,,8,125.00%,30,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,11/14/2018,11/14/2018,,,12/26/2018,12/26/2018,1/21/2019,1/21/2019,,,4/1/2019,4/1/2019,6/9/2020,6/9/2020,7/1/2019,7/1/2019,,,,,,,9/30/2022,,,,8/23/2019,8/23/2019,,,,,,,11/25/2022,,8/29/2019,8/29/2019,,,,,,,11/25/2022,,,,,,9/18/2019,9/18/2019,,,,,,,12/23/2022,,10/29/2019,10/29/2019,,,,,,,3/17/2023,,,,,,,,3/17/2023,,,,,,,
10201806044,Niraparib-2001,'Niraparib-2001,,Niraparib,JPN Ph2 2nd line maintenance study (Ovarian) (Niraparib),JPN Ph2 2nd line maintenance study (Ovarian) (Niraparib),II,Enrollment Complete,,Oncology,,,,,,,,15,19,21,,2,,9,126.67%,30,,,MEDISCIENCE PLANNING INC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,11/14/2018,11/14/2018,,,12/28/2018,12/28/2018,1/8/2019,1/8/2019,,,2/12/2019,2/12/2019,11/3/2020,11/3/2020,3/17/2019,3/17/2019,,,,,,,9/30/2022,,,,5/20/2019,5/20/2019,,,,,,,11/26/2022,,5/27/2019,5/27/2019,,,,,,,11/26/2022,,,,,,6/13/2019,6/13/2019,,,,,,,12/24/2022,,7/26/2019,7/26/2019,,,,,,,3/18/2023,,,,,,,,3/18/2023,,,,,,,
10201806045,Azilsartan-3004,'Azilsartan-3004,,Azilva (azilsartan),Azilsartan-3004 Phase 3 - Long-term Safety Study from 2 to less than 6 y/o HTN patients,,III,Enrollling,,CVM,,,,,,,,10,1,2,,1,,,10.00%,20,,,IQVIA,,,,,,,,,,,,,,DDWORKS,,,7/6/2020,7/6/2020,9/18/2020,9/18/2020,,,,,6/17/2021,6/17/2021,,,1/9/2023,,,,6/26/2023,,,,,,,,1/22/2024,,,,8/7/2023,,,,,,,,2/19/2024,,8/18/2023,,,,,,,,2/26/2024,,,,,,9/5/2023,,,,,,,,3/14/2024,,10/31/2023,,,,,,,,5/30/2024,,,,,,,,7/22/2024,,,,,,,
10201807001,TAK-925-1003,'TAK-925-1003,,TAK-925,1003 Ph1 MRD POM study (TAK-925),,I,Closed,,NS,,,,,,,,54,57,,,,,,105.56%,3,,,Takeda PRA Development Center,,,,,,,,,,,Wave 1,Accelerate,,DDWORKS,,,8/29/2018,8/29/2018,10/5/2018,10/5/2018,,,11/21/2018,11/21/2018,12/15/2018,12/15/2018,,,10/11/2019,10/11/2019,,,10/25/2019,10/25/2019,,,,,,,,,,,11/21/2019,11/21/2019,,,,,,,,,11/22/2019,11/22/2019,,,,,,,,,,,,,12/17/2019,12/17/2019,,,,,,,,,3/6/2020,3/6/2020,,,,,,,,,,,,,,,10/23/2020,,,,,,,
10201807002,SGN35-014,'SGN35-014,,ADCETRIS,SGN-35/ONC-005 SGN35 SGN35-014 (ONC-005) - GP3 Frontline MTCL (ECHELON 2),SGN35-014 - GP3 Frontline MTCL (ECHELON 2),III,In Follow-Up,,Oncology,,,,Interventional,,,,45,43,0,,0,,0,95.56%,13,,,CIMIC,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201810001,TBD-Niraparib,'TBD-Niraparib,,Niraparib,JPN Ph2 1st line maintenance study (Ovarian) (Niraparib),,II,Cancelled,,Oncology,,,,,,,,15,0,0,,0,,0,0.00%,30,,,TBD,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201810002,TAK-951-1003,'TAK-951-1003,,TAK-951,Japanese ES PK study (TAK-951),Japanese ES PK study (TAK-951),I,Planned,,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,Takeda PRA Development Center,,,,,,,,,,,Wave 2,Accelerate,,DDWORKS,,,8/12/2022,,9/23/2022,,,,,,12/5/2022,,,,12/27/2022,,,,1/28/2023,,,,,,,,,,,,2/23/2023,,,,,,,,,,,,,,,,,,,,,,,,3/22/2023,,,,,,,,,,4/19/2023,,,,,,,,,,,,,,,,4/25/2023,,,,,,,
10201811001,TBD-MET-2,'TBD-MET-2,,TAK-039,MET-2 Phase 1b Japan,,I,Planned,,GI,,,,,,,,30,0,0,,0,,0,0.00%,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201901001,TAK-123-1001,'TAK-123-1001,,Ammonul (sodium phenylacetate and sodium benzoate),TAK-123 Ph-1 Japan study,,I,Closed,,Others,,,,,,,,10,10,,,,,,100.00%,1,,,PRA,,,,,,,,,,,,,,DDWORKS,,,5/22/2019,5/22/2019,8/21/2019,8/21/2019,,,11/13/2019,11/13/2019,11/29/2019,11/29/2019,,,11/29/2019,11/29/2019,,,12/18/2019,12/18/2019,,,,,,,,,,,1/10/2020,1/10/2020,,,,,,,,,2/7/2020,2/7/2020,,,,,,,,,,,,,2/7/2020,2/7/2020,,,,,,,,,3/6/2020,3/6/2020,,,,,,,,,,,,,,,3/11/2020,3/11/2020,,,,,,
10201902001,TAK-102-1501,'TAK-102-1501,,TAK-102,"An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors",,I,Enrolling,,Oncology,Cell Therapy,,,,,,,14,7,0,,0,0,0,50.00%,2,,,PPD,,,,,,,,,,,Wave 2,De-Risk,,DDWORKS,,,1/24/2020,1/24/2020,3/18/2020,3/18/2020,,,,,8/19/2020,8/19/2020,,,3/2/2022,,5/1/2022,,5/2/2023,,,,,,,,5/1/2025,,,,5/30/2023,,,,,,,,5/29/2025,,6/6/2023,,,,,,,,6/5/2025,,,,,,6/27/2023,,,,,,,,6/26/2025,,11/7/2023,,,,,,,,11/6/2025,,,,,,,,11/6/2025,,,,,,,
10201906001,Vedolizumab-3039,'Vedolizumab-3039,,Entyvio SC,3039 Japan Q4W Maintenance Study,,III,Cancelled,,GI,,,,,,,,158,2,3,,,,,1.27%,20,,,TBD,,,,,,,,,,,,,,DDWORKS,,,12/26/2019,12/26/2019,7/30/2020,,,,,,12/15/2020,,,,9/1/2023,,,,11/24/2023,,,,,,,,9/18/2025,,,,1/11/2024,,,,,,,,10/31/2025,,1/18/2024,,,,,,,,11/10/2025,,,,,,2/7/2024,,,,,,,,12/1/2025,,3/1/2024,,,,,,,,12/24/2025,,,,,,,,1/5/2026,,,,,,,
10201910001,TBD-TAK-721 JP1,'TBD-TAK-721 JP1,,budesonide (TAK-721),TBD,,I,Planned,,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201910002,TBD-TAK-721 JAP3,'TBD-TAK-721 JAP3,,budesonide (TAK-721),TBD,,III,Planned,,GI,,,,,,,,104,0,0,,0,,0,0.00%,50,,,TBD,,,,,,,,,,,Wave 1,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201910003,TAK-672-3001,'TAK-672-3001,,Obizur (antihemophilic factor [recombinant] porcine sequence),"Efficacy and Safety Evaluation of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672) in Japanese Subjects with AHA",,II/III,Start Up,,RGH,,,,,,,,5,0,1,,0,0,,0.00%,5,,,IQVIA,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,6/23/2020,6/23/2020,,,,,11/30/2021,,,,6/30/2022,,,,11/30/2022,,,,,,,,,,,,12/30/2022,,,,,,,,,,1/13/2023,,,,,,,,,,,,,,1/20/2023,,,,,,,,,,2/28/2023,,,,,,,,,,,,,,,,2/28/2023,,,,,,,
10201911001,TBD-TAK-018,'TBD-TAK-018,,Sibofimloc (TAK-018),TBD,,I,Planned,,GI,,,,,,,,24,0,0,,0,,0,0.00%,1,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,DDWORKS,,,5/12/2022,,6/23/2022,,,,5/22/2023,,5/25/2023,,,,8/10/2023,,,,11/2/2023,,,,,,,,,,,,1/27/2024,,,,,,,,,,2/2/2024,,,,,,,,,,,,,,2/28/2024,,,,,,,,,,7/11/2024,,,,,,,,,,,,,,,,9/13/2024,,,,,,,
10201912001,TBD-TAK-620,'TBD-TAK-620,,maribavir (TAK-620),TAK-620 Ph3 Japan study,,III,Planned,,RGH,,,,,,,,12,0,0,,0,,0,0.00%,6,,,TBD,,,,,,,,,,,Wave 1,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10201912002,TAK-664-3002,'TAK-664-3002,,CUVITRU,TBD,,III,Planned,,Plasma Derived Therapy,,,,,,,,10,1,,,,,,10.00%,10,,,IQVIA,,,,,,,,,,,,,,DDWORKS,,,,,12/31/2020,12/31/2020,,,,,4/27/2021,4/27/2021,,,1/27/2022,,,,4/30/2024,,,,,,,,,,,,6/28/2024,,,,,,,,,,7/31/2024,,,,,,,,,,,,,,,,,,,,,,,,10/15/2024,,,,,,,,,,,,,,,,10/15/2024,,,,,,,
10201912003,TAK-771-3002,'TAK-771-3002,,HYQVIA,TBD,,III,Planned,,Plasma Derived Therapy,,,,,,,,21,0,0,,0,,0,0.00%,16,,,IQVIA,,,,,,,,,,,,,,DDWORKS,,,,,3/31/2021,3/31/2021,,,,,12/31/2021,,,,4/30/2023,,,,10/31/2023,,,,,,,,,,,,12/31/2023,,,,,,,,,,1/31/2024,,,,,,,,,,,,,,,,,,,,,,,,4/30/2024,,,,,,,,,,,,,,,,4/30/2024,,,,,,,
10202001001,TAK-743-5007,'TAK-743-5007,,Takhzyro (Lanadelumab),"Open-arm, Japan Expanded Access Program with Lanadelumab for Japanese Patients with Hereditary Angioedema",,NA,Enrolling,,RGH,,,,,,,,15,12,2,,,,1,80.00%,15,,,IQVIA,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,10/15/2020,10/15/2020,,,,,2/10/2021,2/10/2021,,,4/30/2022,,,,5/31/2022,,,,,,,,,,,,6/30/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/31/2022,,,,,,,,,,,,,,,,10/31/2022,,,,,,,
10202002001,TBD-TAK-102,'TBD-TAK-102,,TAK-102,TBD,,II,Planned,,Oncology,,,,,,,,20,0,0,,0,,0,0.00%,2,,,PPD SNBL,,,,,,,,,,,,,,DDWORKS,,,8/30/2021,,10/25/2021,,,,,,2/14/2022,,,,6/30/2023,,,,6/28/2024,,,,,,,,,,,,8/23/2024,,,,,,,,,,8/30/2024,,,,,,,,,,,,,,9/20/2024,,,,,,,,,,12/13/2024,,,,,,,,,,,,,,,,12/13/2024,,,,,,,
10202002002,TBD,'TBD,,,Ph3 JECT (Takhzyro),,III,Planned,,,,,,,,,,20,0,0,,0,,0,0.00%,20,,,IQVIA,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10202003001,CONTACT-01,'CONTACT-01,,cabozantinib,Cabozantinib + Atezolizumab vs Docetaxel - Ph3 2L/3L NSCLC,,III,Planned,,Oncology,,,,,,,,30,0,0,,0,,0,0.00%,6,,,TBD,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10202003002,CONTACT-02,'CONTACT-02,,cabozantinib,Cabozantinib + Atezolizumab vs Second NHT - Ph3 1L/2L mCRPC,,III,Planned,,Oncology,,,,,,,,40,0,0,,0,,0,0.00%,20,,,TBD,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,8/7/2020,8/7/2020,,,1/20/2021,1/20/2021,2/3/2021,2/3/2021,,,7/13/2022,,1/9/2023,,5/27/2022,,,,,,,,5/9/2023,,,,8/19/2022,,,,,,,,6/24/2023,,9/2/2022,,,,,,,,7/22/2023,,,,,,9/23/2022,,,,,,,,8/19/2023,,12/16/2022,,,,,,,,12/17/2023,,,,,,,,3/26/2020,,,,,,,
10202005001,TAK-667-3001,'TAK-667-3001,,Firazyr (Icatibant),TAK-667 Japan pediatric study,,III,Enrolling,,RGH,,,,,,,,3,1,6,,0,0,0,33.33%,4,,,PRA,,,,,,,,,,,,,,DDWORKS,,,9/2/2020,9/2/2020,10/19/2020,10/19/2020,,,,,1/15/2021,1/15/2021,,,7/23/2021,,,,7/31/2021,,,,,,,,,,,,9/2/2021,,,,,,,,,,9/10/2021,,,,,,,,,,,,,,10/4/2021,,,,,,,,,,10/27/2021,,,,,,,,,,,,,,,,11/1/2023,,,,,,,
10202005002,TBD-TAK-341,'TBD-TAK-341,,TAK-341,TBD,,I,Planned,,NS,,,,,,,,24,0,0,,0,,0,0.00%,10,,,TBD,,,,,,,,,,,Wave 2,De-Risk,,DDWORKS,,,1/28/2022,,3/17/2022,,,,6/17/2022,,6/1/2022,,,,6/1/2022,,,,1/3/2023,,,,,,,,,,,,1/31/2023,,,,,,,,,,2/2/2023,,,,,,,,,,,,,,,,,,,,,,,,4/25/2023,,,,,,,,,,,,,,,,8/4/2023,,,,,,,
10202006001,TBD-CIDPex,'TBD-CIDPex,,HYQVIA,TBD,,III,Cancelled,,Plasma Derived Therapy,,,,,,,,8,0,0,,0,,0,0.00%,10,,,TBD,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,10/31/2023,,,,6/30/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/31/2025,,,,,,,,,,,,,,,,12/31/2025,,,,,,,
10202006002,TBD-MMN,'TBD-MMN,,,TBD,,III,Cancelled,,,,,,,,,,5,0,0,,0,,0,0.00%,5,,,TBD,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10202006003,TBD-MMNex,'TBD-MMNex,,,TBD,,III,Cancelled,,,,,,,,,,4,0,0,,0,,0,0.00%,5,,,TBD,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10202006004,TAK-771-3004,'TAK-771-3004,,HYQVIA,TBD,,III,Planned,,Plasma Derived Therapy,,,,,,,,15,0,0,,0,,0,0.00%,10,,,IQVIA,,,,,,,,,,,,,,DDWORKS,,,,,6/30/2021,6/30/2021,,,,,2/28/2022,,,,10/31/2022,,,,4/30/2023,,,,,,,,,,,,6/30/2023,,,,,,,,,,7/31/2023,,,,,,,,,,,,,,,,,,,,,,,,10/31/2023,,,,,,,,,,,,,,,,10/31/2023,,,,,,,
10202006005,TBD-PIDex,'TBD-PIDex,,HYQVIA,TBD,,III,Planned,,Plasma Derived Therapy,,,,,,,,10,0,0,,0,,0,0.00%,10,,,TBD,,,,,,,,,,,,,,DDWORKS,,,,,8/31/2021,,,,,,7/29/2022,,,,4/28/2023,,,,4/30/2025,,,,,,,,,,,,,,,,,,,,,,7/31/2025,,,,,,,,,,,,,,,,,,,,,,,,10/31/2025,,,,,,,,,,,,,,,,10/31/2025,,,,,,,
10202007001,TBD-Niraparib-CRPC JP Ph2,'TBD-Niraparib-CRPC JP Ph2,,Niraparib,Niraparib + Abiraterone + Pred JP Ph2 mCPRC,,II,Planned,,Oncology,,,,,,,,20,0,0,,0,,0,0.00%,30,,,IQVIA,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,5/19/2022,,,,9/16/2022,,10/14/2022,,,,6/11/2023,,1/31/2025,,9/9/2023,,,,,,,,7/14/2028,,,,11/18/2023,,,,,,,,8/28/2028,,12/2/2023,,,,,,,,9/25/2028,,,,,,12/16/2023,,,,,,,,10/9/2028,,3/15/2024,,,,,,,,12/29/2028,,,,,,,,12/29/2028,,,,,,,
10202009001,TAK-662-1501,'TAK-662-1501,,Ceprotin (protein C concentrate (human)),TBD,,II,Planned,,Plasma Derived Therapy,,,,,,,,3,0,0,,0,,0,0.00%,5,,,TBD,,,,,,,,,,,,,,DDWORKS,,,12/21/2020,12/21/2020,3/9/2021,3/9/2021,,,,,9/11/2021,,,,2/25/2022,,,,3/4/2022,,,,,,,,,,,,4/3/2022,,,,,,,,,,5/3/2022,,,,,,,,,,,,,,5/17/2022,,,,,,,,,,6/7/2022,,,,,,,,,,,,,,,,6/7/2022,,,,,,,
10202010001,TAK-633-3008,'TAK-633-3008,,Gattex (teduglutide),TBD,,III,Planned,,GI,,,,,,,,5,0,0,,0,,0,0.00%,6,,,IQVIA,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10202101001,TAK-103-1001,'TAK-103-1001,,TAK-103,"An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients with Mesothelin-Expressing Advanced or Metastatic Solid Tumors",,I,Planned,,Oncology,,,,,,,,21,0,0,,0,,0,0.00%,3,,,IQVIA,,,,,,,,,,,NA,De-Risk,,DDWORKS,,,12/17/2020,12/17/2020,7/30/2021,,,,,,11/24/2021,,,,7/24/2023,,9/18/2023,,8/28/2024,,,,,,,,8/28/2026,,,,10/23/2024,,,,,,,,10/23/2026,,,,,,,,,,,,,,,,11/20/2024,,,,,,,,11/20/2026,,3/19/2025,,,,,,,,3/19/2027,,,,,,,,3/19/2027,,,,,,,
10202103001,Nira-do not use,'Nira-do not use,,,Nira-do not use,,0,Cancelled,,,,,,,,,,0,0,0,,0,,0,,0,,,TBD,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10202103002,213831,'213831,,Niraparib,A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy (ZEST),,III,Start Up,,Oncology,,,,,,,,60,0,0,,0,,0,0.00%,25,,,IQVIA,,,,,,,,,,,NA,Advance,,DDWORKS,,,,,4/28/2021,4/28/2021,,,11/30/2021,,12/30/2021,,,,5/18/2024,,5/13/2025,,11/14/2024,,,,,,,,9/19/2029,,,,1/22/2025,,,,,,,,10/19/2029,,1/29/2025,,,,,,,,11/16/2029,,,,,,3/19/2025,,,,,,,,11/30/2029,,5/18/2025,,,,,,,,2/21/2030,,,,,,,,2/21/2030,,,,,,,
90201806039,4001,'4001,,,4001 P4 China Prospective (TAP-144-SR 3M),4001 P4 China Prospective (TAP-144-SR 3M),IV,CLOSED,,,,,,,,,,0,0,0,,0,,0,,0,,,NA,,,,,,,,,,,,,,DDWORKS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A7281001,A7281001,'A7281001,'SHP647,,"A Multicenter Phase 2, Open label, safety extension study for feeder studies which evaluate PF-00546759 in subjects with moderate to severe Crohn's disease",A7281001,II,Completed,Inflammatory Bowel Disease,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,999,80,96,0,16,0,27,8.01%,999,28,Pfizer,ICON Clinical Research,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A7281006,A7281006,'A7281006,'SHP647,,"A Multicenter Phase 2, Open label, safety extension study for feeder studies which evaluate PF-00546759 in subjects with moderate to severe Crohn's disease",A7281006,II,Completed,Inflammatory Bowel Disease,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,999,265,497,0,232,0,38,26.53%,999,124,Pfizer,ICON / MAPI / Paradigm,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A7281007,A7281007,'A7281007,'SHP647,,"A Multicenter Phase2, Open label, safety extension study for feeder studies which evaluate PF-00546759 in subjects with moderate to severe Crohn's disease",A7281007,II,Completed,Inflammatory Bowel Disease,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,999,267,267,0,0,0,118,26.73%,999,148,Pfizer,ICON Clinical Research,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A7281008,A7281008,'A7281008,'SHP647,,"A Multicenter Phase 2, Open label, safety extension study for feeder studies which evaluate PF-00546759 in subjects with moderate to severe Crohn's disease",A7281008,II,Completed,Inflammatory Bowel Disease,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,999,49,68,0,19,0,3,4.90%,999,2,Pfizer,ICON / MAPI / Paradigm,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A7281009,A7281009,'A7281009,'SHP647,,"A Multicenter Phase 2, Open label, safety extension study for feeder studies which evaluate PF-00546759 in subjects with moderate to severe Crohn's disease",A7281009,II,Completed,Inflammatory Bowel Disease,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,999,357,589,0,232,0,23,35.74%,999,159,Pfizer,ICON Clinical Research,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A7281010,A7281010,'A7281010,'SHP647,,"MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM
SAFETY OF PF-00547659 IN SUBJECTS WITH ULCERATIVE COLITIS (TURANDOT II)",A7281010,II,Completed,Inflammatory Bowel Disease,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Safety,,,270,331,1,0,0,331,198,122.59%,101,,Pfizer,ICON / MAPI / Paradigm,Sharon Donato,"Allison MacDonald, Joanne Totosy De Zepetnek, Maria Ponsillo, Prabhakar Viswanathan",,,"Desislava Lozanova, Duthika Mallawaaratchy, Esmare Human, Anthony Joseph, Genalyn Lorezca, Hanbyul Jin, Kasen Whitehouse, Maksim Tretyakov, Malgorzata Powidel, Maria Somogyi, Massimo Cremascoli, Mateusz Wegrzyniak, May Oren, Mercedes Monterde Estrada, Susanne Schayen, Suzanne Marney, Tatiana Kohusova, Vera Szilvasipohorala, Nikola Grbovic, Philip Calvillo, Raz Oren, Remco Lusthuis, Rob Akinola",,Not Available,,N,No,,,,COSMOS Inactive,,,6/26/2012,6/26/2012,6/26/2012,6/26/2012,,,,,3/18/2013,3/18/2013,,,10/1/2014,10/1/2014,,,,,,,,,,,,,12/13/2017,12/13/2017,12/13/2017,3/9/2018,,,,,,,,,,,,,,,,,,,4/13/2018,4/13/2018,10/4/2018,10/12/2018,,,,,,,,,,,11/23/2018,,,,,,,,,,,,,,,,,,,,,,,
ASKBIO009-101,ASKBIO009-101,'ASKBIO009-101,,,"A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults with Hemophilia B",231401 BAX335 FIX Gene Therapy,I/II,Recruitment Complete,,,RGH,,Non-pediatric only (>18 yr),Interventional,,,,8,8,0,,22,0,,100.00%,4,,,IQVIA,,Angela Calvillo,Tejdip Singh,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BAX2303- DFCI 1101,BAX2303- DFCI 1101,'BAX2303- DFCI 1101,'BAX2303- DFCI 1101,,SHP663 (BAX2303) Calaspargase Pegol DFCI ALL: Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase. IND #100594) or Intravenous Oncaspar in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL),SHP663 (Cal Peg) DFCI ALL Ph2,II,Completed,Leukemia,,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,240,239,240,0,0,0,1,99.58%,9,,Baxalta,IQVIA,,,Anna Wijatyk,Eli Taube,,,,,,,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/20/2016,,7/28/2016,,,,,,,,,,,,,,,,,,,,,,4/24/2017,,,,,,,,,,,,12/8/2017,,,,,,,,,,,,,,,,,,,,,,
BAX2303-AALL07P4,BAX2303-AALL07P4,'BAX2303-AALL07P4,'BAX2303-AALL07P4,,SHP663 (BAX2303) Calaspargase Pegol COG ALL: Randomized study of intravenous Calapargase Pegol (SC-PEG Asperginase) and Intravenous Oncaspar in children and adolescents with acute lymphoblastic leukemia or lymphoblastic lymphma,SHP663 (Cal Peg) COG ALL Ph2/3,II/III,Completed,Leukemia,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,166,166,166,0,0,0,0,100.00%,1,,Baxalta,IQVIA,,,Anna Wijatyk,Eli Taube,,,,,,,,,,COSMOS Inactive,,,,,,5/13/2013,,,,,,,,,,,,,,,,,,,,,,,,,,12/28/2015,,,,,,,,,,,,,,,,,,,,,,4/24/2017,,,,,,,,,,,,11/8/2017,,,,,,,,,,,,,,,,,,,,,,
BB-IND 11013,BB-IND 11013,'BB-IND 11013,,,Replagal Physician Sponsored IND,BB-IND 11013,IIIb,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,1,0,0,0,0,0,0.10%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BB-IND 11163,BB-IND 11163,'BB-IND 11163,,,Replagal Physician Sponsored IND,BB-IND 11163,IIIb,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,6,0,0,0,0,0,0.60%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BB-IND 11164,BB-IND 11164,'BB-IND 11164,,,Replagal Physician Sponsored IND,BB-IND 11164,IIIb,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,10,0,0,0,0,0,1.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BB-IND 11195,BB-IND 11195,'BB-IND 11195,,,Replagal Physician Sponsored IND,BB-IND 11195,IIIb,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,2,0,0,0,0,0,0.20%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BLB-010-001,BLB-010-001,'BLB-010-001,'BLB-010-001,,"10% IGIV Alzheimer's (Japan Ph 1):  Randomized, Double Blind, Placebo Controlled, Multiple Doses, Safety and Tolerability Trial of BLB-010 in Patients with Mild to Moderate Alzheimer's Disease",10% IGIV Alzheimer Japan ph 1,I,Completed,Alzheimer's Disease,,,Non-Registry,,Interventional,,,,16,16,22,0,6,16,0,100.00%,5,,Baxalta,,Shigeyoshi Yokokawa,,Kathy Tobias,,,,,,,,,,,COSMOS Inactive,,,,,,9/6/2011,,,,,,,,11/14/2011,,,,,,,,,,,,,,,,9/12/2012,,9/27/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/24/2013,,,,,,,,,,,,,,,,,,,,,,
BLB-010-002,BLB-010-002,'BLB-010-002,'BLB-010-002,,"10% IGIV Alzheimer's: (Japan Ph 2)  Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease (AD)",10% IGIV Alzheimer: Japan Ph 2,II,Completed,Alzheimer's Disease,,,Non-Registry,,Interventional,,,,192,6,20,0,10,0,14,3.13%,25,,Baxalta,"Cinven (formerly Bioclinica), Parexel",Shigeyoshi Yokokawa,,Kathy Tobias,,,,,,,,,,,COSMOS Inactive,,,,,,3/23/2012,,,,,,,,11/20/2012,,,,,,,,,,,,,,,,5/30/2013,,6/25/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/2/2013,,,,,,,,,,,,,,,,,,,,,,
BM-001,BM-001,'BM-001,,,"Measuring contact pathway biomarkers in subjects diagnosed with hereditary angioedema (HAE) and non-HAE angioedema during and in between an acute attack, or diagnosed with other inflammatory diseases, using novel assays to measure protein markers of inflammatory disease biology, including plasma kallikrein (pKal) and pKal degradation products Legacy Dyax Study",BM-001  Legacy Dyax Study,x,Completed,Hereditary Angioedema,,,Non-Registry,,Non-Interventional_CDO Support,Biomarker,,,85,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CAL-C13-001,CAL-C13-001,'CAL-C13-001,,,"Open-label Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous NPSP795 in Autosomal Dominant Hypocalcemia Due to Mutations in the Calcium-sensing Receptor Gene: A Drug Repurposing Study",NIH POC,IIa,Completed,Autosomal Dominant Hypocalcemi,,,Non-Registry,,Interventional,,,,12,7,0,0,0,0,0,58.33%,1,,"(NPS) National Pharmaceutical Services, Inc",,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/24/2013,9/24/2013,6/2/2014,6/2/2014,,,,,7/20/2015,7/21/2014,7/20/2015,7/20/2015,4/2/2015,3/15/2015,,,,,,,,,,,,,6/1/2015,4/2/2015,6/1/2015,6/26/2015,,,,,,,,,,,,,,,,,,,7/3/2015,7/3/2015,9/1/2015,9/1/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CAL-C14-001,CAL-C14-001,'CAL-C14-001,,,"An open-label, 3-period, non-randomised study in healthy subjects designed to evaluate the pharmacokinetic profile of NPSP795 following oral administration",IVPO,I,Completed,Autosomal Dominant Hypocalcemi,,,Non-Registry,,Interventional,,,,10,12,0,0,0,0,0,120.00%,1,,"(NPS) National Pharmaceutical Services, Inc",PPD,,,,,,2014-000403-27,,,N,No,,,,COSMOS Inactive,,,,,6/12/2014,6/12/2014,,,,,9/19/2014,9/19/2014,,,,,,,,,,,,,,,,,9/19/2014,10/16/2014,9/19/2014,1/13/2015,,,,,,,,,,,,,,,,,,,,,5/19/2015,1/13/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CAL-C14-002,CAL-C14-002,'CAL-C14-002,,,"An Open-Label, Non-Randomised, Fixed Sequence Study in Healthy Subjects Designed to Evaluate the Pharmacokinetic Profile of NPSP795 Prototype Liquid Formulations",RapidFact,I,Completed,Autosomal Dominant Hypocalcemi,,,Non-Registry,,Interventional,,,,10,15,0,0,0,0,0,150.00%,1,,"(NPS) National Pharmaceutical Services, Inc",IQVIA,,,,,,2014-003393-16,,,N,No,,,,COSMOS Inactive,,,,,11/18/2014,11/18/2014,,,,,1/13/2015,1/13/2015,,,7/14/2015,1/14/2015,,,,,,,,,,,,,1/14/2015,3/11/2015,1/14/2015,4/7/2015,,,,,,,,,,,,,,,,,,,,,6/26/2015,6/26/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CL1-11-040,CL1-11-040,'CL1-11-040,,,"REPLACE
NPS Legacy Study",REPLACE   NPS Legacy,III,Completed,Hypoparathyroidism,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,2008-005063-34,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CL0600-020,CL0600-020,'CL0600-020,,,"DBL Parallel-PBO
NPS Legacy Study",NPS Legacy,III,Completed,Short Bowel Syndrome,,,Non-Registry,,Interventional,Double-Blind,,,999,0,0,0,0,0,0,0.00%,1,,"(NPS) National Pharmaceutical Services, Inc",,,,,,,2008-006193-15,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CL0600-021,CL0600-021,'CL0600-021,,,"OLE of CL0600-020
NPS Legacy Study",OLE of 020     NPS Legacy,III,Completed,Short Bowel Syndrome,,,Non-Registry,,Interventional,Open Label,,,999,0,0,0,0,0,0,0.00%,999,,"(NPS) National Pharmaceutical Services, Inc",,,,,,,2009-011679-65,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CS02,CS02,'CS02,,Replagal (agalsidase alfa),Home infusion therapy with Replagal in patients with Morbus Fabry,German Replagal home therapy study,IV,Completed,Morbus Fabry Disease,RGH,,Non-Registry,,Non-Interventional_CDO Support,,,,50,104,0,0,0,0,0,208.00%,50,,,Clinsupport,,Anja Lachmann,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/8/2016,12/8/2016,,,,,3/8/2017,3/8/2017,,,,,,,11/14/2017,11/14/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/28/2018,2/28/2018,,,,,,,,,4/30/2018,4/30/2018,,,,,,,,,,,,,,,4/30/2018,4/30/2018,,,,,,
CS03,CS03,'CS03,,,Home infusion therapy with VPRIV(Velaglucerase alfa) in patients with Morbus Gaucher type 1,German Vpriv home therapy study,IV,Completed,Gaucher's Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,50,34,0,0,0,0,0,68.00%,20,,,Clinsupport,,Anja Lachmann,,,,,,,N,No,,,,COSMOS Inactive,,,1/15/2011,1/15/2011,1/19/2011,1/19/2011,,,,,5/20/2011,5/20/2011,5/20/2011,5/20/2011,10/2/2017,,,,,,,,,,,,,,9/30/2017,9/30/2017,9/30/2017,11/30/2017,,,,,,,,,,,,,,,,,,,12/11/2017,,2/28/2018,2/28/2018,,,,,,,,,,,4/30/2018,4/30/2018,,,,,,,,,,,,,,,,,,,,,,
D3101002,D3101002,'D3101002,,,Clinical Study of SMP-536 in patients with Fabry disease (phase II),D3101002 - SMP-536 Fabry,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,12,0,0,0,0,0,1.20%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/22/2001,8/22/2001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D3101003,D3101003,'D3101003,,,Clinical Study of SMP-536 in patients with Fabry disease (extension study),D3101003 - SMP-536 EXT,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,9,11,0,0,0,0,0.90%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/22/2001,8/22/2001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D3101004,D3101004,'D3101004,,,Post-marketing clinical study of SMP-536 in Fabry disease patients (second continuous administration),D3101004 - PAC SMP-536 Fabry,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,10/23/2002,10/23/2002,,,,,,,,,,,,,,,,,9/5/2007,9/5/2007,9/5/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DC 06/01,DC 06/01,'DC 06/01,,,"A RANDOMIZED, TWO-WAY CROSS-OVER, DOUBLE-BLIND, CONTROLLED PHARMACOKINETIC STUDY OF ORAL HYDROCORTISONE (MODIFIED RELEASE; 5 & 20 MG) WITH AN OPEN FOOD-INTERACTION ARM IN HEALTHY VOLUNTEERS.","(SHP617) DC 06/01: FOOD-INTX, HEALTHY",I,Completed,Adrenal Insufficiency,,,Non-Registry,,Interventional,,,,16,16,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,8/21/2006,8/21/2006,,,,,,,,,,,,,,,,,10/4/2006,10/4/2006,10/4/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DC 06/02 A,DC 06/02 A,'DC 06/02 A,,,"Part A: A randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency",(SHP617) DC 06/02: Part A,II,Completed,Adrenal Insufficiency,,,Non-Registry,,Interventional,,,,64,64,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,8/21/2007,8/21/2007,,,,,,,,,,,,,,,,,7/28/2008,7/28/2008,7/28/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DC 06/02 B,DC 06/02 B,'DC 06/02 B,,,"Part B: A randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency",(SHP617) DC 06/02: Part B,II,Completed,Adrenal Insufficiency,,,Non-Registry,,Interventional,,,,64,0,0,0,0,0,0,0.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,8/21/2007,8/21/2007,,,,,,,,,,,,,,,,,1/28/2009,1/28/2009,1/28/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DX-88/24,DX-88/24,'DX-88/24,,,"A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity with Exposure to KALBITOR (ecallantide) for the Treatment of Acute
Attacks of HAE. Legacy Dyax Study.",LTOSS,IV,Completed,Hereditary Angioedema,,,Non-Registry,,Non-Interventional_CDO Support,Safety,,,200,0,0,0,0,0,0,0.00%,999,,Dyax,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DX-2930-01,DX-2930-01,'DX-2930-01,,,"A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics (PK) of DX-2930 in Healthy Subjects. Legacy Dyax Study",DX-2930-01,I,Completed,Hereditary Angioedema,,,Non-Registry,,Interventional,Placebo-Controlled,,,32,0,0,0,0,0,0,0.00%,999,,Dyax,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/12/2014,,,,,,,,,,,,,,,,,,,,,,
DX-2930-02,DX-2930-02,'DX-2930-02,,Takhzyro (Lanadelumab),"A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects. Legacy Dyax Study",DX-2930-02,I,Completed,Hereditary Angioedema,RGH,,Non-Registry,,Interventional,Tolerability,,,36,0,0,0,0,0,0,0.00%,999,,Dyax,,,Laura McCarthy,,,,,,,N,No,,,,COSMOS Inactive,,,3/1/2014,3/1/2014,4/11/2014,4/11/2014,,,,,6/16/2014,6/16/2014,,,7/14/2014,7/14/2014,,,,,,,,,,,,,,,,,,,,,,,,,11/28/2014,11/28/2014,,,,,,,,,,,,,,,,,,,,,,,3/6/2015,3/6/2015,,,,,,,,,,,,,,,3/6/2015,3/6/2015,,,,,,
DX-2930-03,DX-2930-03,'DX-2930-03,,Takhzyro (Lanadelumab),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE).",HELP Study,III,Completed,Hereditary Angioedema,RGH,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Multi-Centre,,,120,125,0,0,6,125,11,104.17%,60,,Dyax,IQVIA,,"Herb De Riesthal, Kim Paes, Robert Bradley",,,,2015-003943-20,Approved for Marketing,,N,No,,,,COSMOS Inactive,1-Aug-17,4/13/2017,8/5/2015,8/5/2015,9/14/2015,9/14/2015,,,,,3/3/2016,3/3/2016,,,9/6/2016,9/6/2016,,,4/13/2017,4/13/2017,,,,,,,,,,,5/10/2017,5/10/2017,,,,,,,,,5/17/2017,5/17/2017,,,,,,,,,,,,,,,,,,,,,,,9/18/2017,9/18/2017,,,,,,,,,,,,,,,9/18/2017,9/18/2017,,,,,,
DX-2930-04,DX-2930-04,'DX-2930-04,,Takhzyro (Lanadelumab),"HELP Study Extension: An Open-Label Study to Evaluate the
Long-Term Safety and Efficacy of DX-2930 for Prevention Against
Acute Attacks of Hereditary Angioedema (HAE).",HELP Study Extension,III,Completed,Hereditary Angioedema,RGH,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Open Label,,,250,,,,,,,,60,,Dyax,"Red Maple Trials, Rho, Triumpharma",,"Herb De Riesthal, Kim Paes, Robert Bradley, Rohan Sopariwala, Safwan Abbassy",,Katherine Norton,Amanda Mulkey,2015-005255-27,Approved for Marketing,,N,No,,,,COSMOS Inactive,26-Feb-20,,8/5/2015,8/5/2015,12/14/2015,12/14/2015,,,,,5/26/2016,5/26/2016,,,3/30/2017,3/30/2017,,,10/31/2019,10/31/2019,,,,,,,,,,,12/17/2019,12/17/2019,,,,,,,,,2/5/2020,2/5/2020,,,,,,,,,,,,,,,,,,,,,,,4/8/2020,4/8/2020,,,,,,,,,,,,,,,4/8/2020,4/8/2020,,,,,,
FOS,FOS,'FOS,,Replagal (agalsidase alfa),Fabry Outcome Survey,Fabry Outcome Survey,IV,Recruiting,Risk reduction of thrombosis/embolism and prevention of GU associated with L-ASA,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,,Prospective,Other,"6,537","4,154",1,,0,0,1271,63.55%,999,90,,PPD,,Dalia Jazukeviciene,Michael Carter,Joern Schenk,,,,,,,,,,Medidata CTMS (Pharma),,,,,8/4/2001,8/4/2001,,,,,10/1/2001,10/1/2001,,,12/30/2024,,,,1/13/2025,,,,,,,,,,,,9/8/2025,,,,,,,,,,9/22/2025,,,,,,,,,,,,,,10/6/2025,,,,,,,,,,12/1/2025,,,,,,,,,,,,,,,,12/1/2025,,,,,,,
FST100-AVC-004,FST100-AVC-004,'FST100-AVC-004,'SHP640,,"A Proof-of-Concept, Multi-center, Randomized, Double-
Masked Study to Evaluate the Clinical Efficacy and Safety
of FST-100 (0.1% Dexamethasone and 0.6% PVP-Iodine)
Ophthalmic Suspension in the Treatment of Acute
Adenoviral Conjunctivitis   Legacy Foresight Study",Efficacy and Safety Legacy Foresight,II,Completed,Infective Conjunctivitis,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Proof of Concept,,,176,0,0,0,0,0,0,0.00%,999,,Foresight,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FST100-AVC-005,FST100-AVC-005,'FST100-AVC-005,'SHP640,,"A Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 (0.1% Dexamethasone and 0.6% PVP-Iodine) ophthalmic suspension in the Treatment of Acute Viral Conjunctivitis   Legacy Foresight Study",Efficacy and Safety Legacy Foresight,II,Completed,Infective Conjunctivitis,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Efficacy,,,155,0,0,0,0,0,0,0.00%,999,,Foresight,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FT011-001,FT011-001,'FT011-001,,,"PhI, double blind, randomised, placebo-controlled, dose-escalating study of safety, tolerability, food effect & PK of single & repeat oral doses of FT011 to healthy volunteers & patients with diabetic nephropathy associated with Type 1 or 2 diabetes.",FT011 to healthy volunteers,I,Completed,Hereditary Angioedema,,,Non-Registry,,Interventional,,,,80,80,143,0,63,80,0,100.00%,2,,,Syneos Health,,,Sunita Goyal,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,6/5/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GMA-001,GMA-001,'GMA-001,,,FASC (Fabry Screening): NON-INTERVENTIONAL STUDY FABRY DISEASE IN CHILDREN: FEDERAL SCREENING PROGRAM (RUSSIA),FASC,x,Completed,,,,Non-Registry,,Non-Interventional_CDO Support,,,,214,214,0,0,0,0,0,100.00%,9,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/5/2013,,10/18/2013,,,,,,12/20/2013,,,,12/20/2013,,,,,,,,,,,,,,3/6/2015,,3/6/2015,,,,,,,,,,,,,,,,,,,,3/25/2015,,4/29/2015,,,,,,,,,,,,6/24/2015,,,,,,,,,,,,,,,,,,,,,,,
GOS,GOS,'GOS,,VPRIV (velaglucerase alfa),"Gaucher Disease Outcome Survey (GOS)
An Observational, International, Multicenter, Long-Term Registry of Patients with Gaucher Disease",Gaucher Outcome Survey,IV,Recruiting,Stress urinary incontinence,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,,,,"1,600","1,929",0,,0,0,317,120.56%,50,42,,PPD,,Jeffrey Back,"Joern Schenk, Noga Gadir",,,,,Approved,,,,,,Medidata CTMS (Pharma),,,,,9/27/2010,9/27/2010,,,,,12/29/2010,12/29/2010,,,7/6/2023,,,,8/5/2023,,,,,,,,,,,,10/6/2023,,,,,,,,,,10/20/2023,,,,,,,,,,,,,,11/3/2023,,,,,,,,,,12/29/2023,,,,,,,,,,,,,,,,12/29/2023,,,,,,,
HGT-ACE-074,HGT-ACE-074,'HGT-ACE-074,'SHP619,,"A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study of ACE-031 in Ambulatory Steroid-naÃ¯ve Patients with Duchenne Muscular Dystrophy.",HGT-ACE-074 - ACE-031,IIb,Completed,Duchenne Muscular Dystrophy,,,Non-Registry,,Interventional,,,,238,0,0,0,0,0,0,0.00%,999,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-ELA-038,HGT-ELA-038,'HGT-ELA-038,'TKT1I0,,"A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy",Safety Clinical Outcomes in Hunter Syndr,IV,Completed,Hunter Syndrome,,,Non-Registry,,Non-Interventional_CDO Support,,,,30,28,0,0,0,0,0,93.33%,3,,Shire HGT,Pharmanet,,,,,,2007-006044-22,,,N,No,,,,COSMOS Inactive,,,,,5/7/2007,5/7/2007,,,,,1/3/2008,1/3/2008,,,6/16/2010,6/16/2010,,,,,,,,,,,,,7/8/2011,7/8/2011,7/8/2011,9/12/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-ELA-042,HGT-ELA-042,'HGT-ELA-042,'TKT1I0,,A Multi-Center Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients Enrolled in the Hunter Outcome Survey (HOS) Receiving Idursulfase Enzyme Replacement Therapy,Observational Study,IV,Completed,Hunter Syndrome,,,Non-Registry,,Interventional,,,,100,26,0,0,0,0,0,26.00%,7,,Shire HGT,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,8/5/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-FIR-054,HGT-FIR-054,'HGT-FIR-054,,,"A Phase III randomized double-blind, placebo-controlled multicenter study of icatibant for subcutaneous injection in patients with acute attacks of Hereditary Angioedema (HAE)","HGT-FIR-054 - Randomized, DB, Placebo",III,Completed,Hereditary Angioedema,,,Non-Registry,,Interventional,,,,88,96,0,0,0,0,0,109.09%,999,,Shire HGT,Averion International Corporation,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,1/25/2010,1/25/2010,,,,,6/25/2009,6/25/2009,,,9/27/2010,9/27/2010,,,,,,,,,,,,,6/12/2012,6/12/2012,6/12/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-FIR-061,HGT-FIR-061,'HGT-FIR-061,,,"The Effect of Icatibant on QT and QTc Intervals: A Randomized, Placebo Controlled, Active Comparator, Crossover Study in Healthy Adult Volunteers",HGT-FIR-061 - Crossover Healthy Adult,I,Completed,Hereditary Angioedema,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,72,0,0,0,0,0,0,0.00%,999,,Shire HGT,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/3/2009,12/3/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-FIR-062,HGT-FIR-062,'HGT-FIR-062,,,"A Phase I Double-Blind, Randomized, Placebo-Controlled, Single Center Study to Assess the Effect of Icatibant on Serum Reproductive Levels and Semen Analysis in Male and Premenopausal Female Healthy Adult Subjects","HGT-FIR-062 - DB, Placebo Healthy Adult",I,Completed,Hereditary Angioedema,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,20,39,0,0,0,0,0,195.00%,999,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/31/2010,8/31/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-FIR-065,HGT-FIR-065,'HGT-FIR-065,,,"An Open-label, Phase I, Single-Center Study to Determine the Pharmacokinetics and Safety of Multiple Doses of Subcutaneously Administered Icatibant in Healthy Adult Male and Female Subjects","HGTFIR-065 - OL, PK Safety Healthy Adult",I,Completed,Hereditary Angioedema,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,24,0,0,0,0,0,0,0.00%,999,,Shire HGT,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/25/2010,3/25/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-FIR-086,HGT-FIR-086,'HGT-FIR-086,,,"A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Hereditary Angioedema",HGTFIR-086 OL PED HAE,III,Completed,Hereditary Angioedema,,,Non-Registry,Pediatric only (<18 yr),Interventional,PASS (Post Authorization Safety Study),,,30,32,131,0,16,32,103,106.67%,27,,Shire HGT,INC Research,,Laura McCarthy,,,,2011-003825-81,,,N,No,,,,COSMOS Inactive,,3/12/2018,3/17/2011,3/17/2011,6/14/2011,6/14/2011,,,,,5/9/2012,5/9/2012,1/27/2012,1/27/2012,12/19/2017,12/19/2017,,,,,,,,,,,,,3/12/2018,3/12/2018,3/12/2018,4/27/2018,,,,,,,,,,,,,,,,,,,5/21/2018,5/21/2018,5/21/2018,5/21/2018,,,,,,,,,,,8/2/2018,8/2/2018,,,,,,,,,,,,,,,,,,,,,,
HGT-FIR-096,HGT-FIR-096,'HGT-FIR-096,,,"A Phase III, Randomized, Double Blind, Placebo-Controlled Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults",HGTFIR-096 RAND DB PCB ACE-I AE,III,Completed,Hereditary Angioedema,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,,121,0,,0,0,4,,56,,Shire HGT,PPD,,Laura McCarthy,,,"Emma Hunt, Titus Durojaye",2014-001213-12,,,N,No,,,,COSMOS Inactive,,8/20/2015,3/15/2013,3/15/2013,6/10/2013,6/10/2013,,,,,12/2/2013,12/2/2013,12/2/2013,12/2/2013,8/20/2015,8/20/2015,,,,,,,,,,,,,8/20/2015,8/20/2015,8/20/2015,9/21/2015,,,,,,,,,,,,,,,,,,,9/29/2015,9/29/2015,9/29/2015,9/29/2015,,,,,,,,,,,12/4/2015,12/6/2015,,,,,,,,,,,,,,,,,,,,,,
HGT-GCB-039,HGT-GCB-039,'HGT-GCB-039,,,"A Multicenter, Randomized, Double-Blind, Parallel Group  Study of Gene-ActivatedÂ® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy compared with Imiglucerase in Patients with Type 1 Gaucher Disease","HGTGCB-039- Randomized, DB, Parallel Grp",III,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,35,30,0,0,0,0,0,85.71%,20,,Shire HGT,IQVIA,,,,,,2007-002840-21,,,N,No,,,,COSMOS Inactive,,,,,6/10/2008,6/10/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-GCB-044,HGT-GCB-044,'HGT-GCB-044,,,An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type I Gaucher Disease,"HGT-GCB-044 - EXT 032,034,039 - OL",III,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,102,95,0,0,0,0,0,93.14%,21,,Shire HGT,IQVIA,,,,,,2008-001965-27,,,N,No,,,,COSMOS Inactive,,,,,10/19/2007,10/19/2007,,,,,3/13/2008,3/13/2008,,,7/2/2009,7/2/2009,,,,,,,,,,,,,12/28/2012,12/28/2012,12/28/2012,3/12/2013,,,,,,,,,,,,,,,,,,,,,4/9/2013,4/9/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-GCB-058,HGT-GCB-058,'HGT-GCB-058,,,"A multicenter open-label treatment protocol to observe the safety of gene activated human glococerebrosidase (GA-GCB, Velaglucerase alfa) enzyme replacement therapy in newly diagnosed or previously treated (with Imiglucerase) patients with Type 1 Gauche",HGT-GCB-058 - OL,III,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,500,211,212,0,0,0,0,42.20%,999,,Shire HGT,United BioSource Corporation,,,Gabriel Cohn,,,,,,N,No,,,,COSMOS Inactive,,,,,1/9/2010,1/9/2010,,,,,9/9/2009,9/9/2009,,,7/7/2010,7/7/2010,,,,,,,,,,,,,4/29/2011,4/29/2011,4/29/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-GCB-068,HGT-GCB-068,'HGT-GCB-068,,VPRIV (velaglucerase alfa),"A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents with Type 3 Gaucher Disease",PIP Type 3 Gaucher,II,Completed,Gaucher's Disease,RGH,,Non-Registry,,Interventional,,,,6,6,7,0,1,0,0,100.00%,6,,Shire HGT,IQVIA,,"Leslie Grushkin-Lerner, Lynn Bayless",,,,,,,N,No,,,,COSMOS Inactive,,,5/21/2010,5/21/2010,7/28/2010,7/28/2010,,,8/7/2012,8/7/2012,9/14/2012,9/14/2012,,,,,3/14/2014,3/14/2014,3/17/2015,3/17/2015,,,,,,,,,,,,,,,,,,,,,5/18/2015,5/18/2015,,,,,,,,,,,,,,,,,,,,,,,7/28/2015,7/28/2015,,,,,,,,,,,,,,,7/28/2015,7/28/2015,,,,,,
HGT-GCB-069,HGT-GCB-069,'HGT-GCB-069,,,Open-label Study of Three Dose Levels of Velaglucerase alfa in Children and Adolescents with Type 1 Gaucher Disease,HGT-GCB-069 - OL Children & Adolescents,IV,Completed,Gaucher's Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-GLD-056,HGT-GLD-056,'HGT-GLD-056,,,"A Multi-center, Prospective, Longitudinal, Observational, Surrogate Endpoint Study of Pediatric Subjects with Globoid Cell Leukodystrophy (Krabbe Disease)",HGT-GLD-056 - Natural History Ped study,0,Completed,Globoid Cell Leukodystrophy,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,2/4/2010,2/4/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-HIT-045,HGT-HIT-045,'HGT-HIT-045,,idursulfase IT (TAK-609),A phase I/II randomized safety and ascending dose ranging study of idursulfase (intrathecal) administration via an intrathecal drug delivery device in pediatric patients with Hunter Syndrome who demonstrate evidence of central nervous system involvement,HGT-HIT-045 -I/II  open label No Comp,II,Completed,Hunter CNS,RGH,,Non-Registry,,Interventional,,,,16,16,20,0,0,0,0,100.00%,5,,Shire HGT,PRA,,,,,,2010-020048-36,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,1/15/2010,1/15/2010,,,,,,,,,,,,,,,,,,,12/3/2012,12/3/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/31/2013,7/31/2013,,,,,,
HGT-HIT-046,HGT-HIT-046,'HGT-HIT-046,,idursulfase IT (TAK-609),An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase� in Pediatric Patients with Hunter Syndrome and Cognitive Impairment,"HGTHIT-046, OL,Ped,Extn of 045",II,Recruitment Complete,Schizophrenia / Alzheimer's disease,RGH,RGH,,Pediatric only (<18 yr),Interventional,,,,16,15,0,,0,0,4,93.75%,9,12,,PPD,,"Steve Gust, Kerri Whyte",,David Alexanderian,,2011-000212-25,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,4/29/2009,4/29/2009,,,,,9/13/2010,9/13/2010,,,10/19/2012,10/19/2012,,,12/31/2022,,,,,,,,,,,,2/28/2023,,,,,,,,,,3/7/2023,,,,,,,,,,,,,,,,,,,,,,,,8/7/2023,,,,,,,,,,,,,,,,8/7/2023,,,,,,,
HGT-HIT-050,HGT-HIT-050,'HGT-HIT-050,,,A screening study to identify pediatric patients with Hunter Syndrome who demonstrate evidence of central nervous system involvement and who are currently receiving treatment with Elaprase,HGT-HIT-050 - Screening Study No Comp,0,Completed,Hunter CNS,,,Non-Registry,,Non-Interventional_CDO Support,,,,40,33,0,0,0,0,0,82.50%,2,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/10/2008,10/10/2008,,,,,6/2/2009,6/2/2009,,,6/13/2011,6/13/2011,,,,,,,,,,,,,7/20/2011,7/20/2011,7/20/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-HIT-073,HGT-HIT-073,'HGT-HIT-073,,idursulfase IT (TAK-609),A Cerebrospinal Fluid Collection Study in Normal Healthy Adult Volunteers,HGT-HIT-073 -CSF - Adult Healthy No Comp,0,Completed,Hunter Syndrome,RGH,,Non-Registry,,Non-Interventional_CDO Support,,,,30,32,0,0,0,0,0,106.67%,1,,Shire HGT,"The Total Approach, INC",,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-HIT-083,HGT-HIT-083,'HGT-HIT-083,,idursulfase IT (TAK-609),"A Multicenter, Non-interventional Cerebrospinal Fluid Biomarker Analysis Study in Pediatric Subjects Who Will Undergo Procedures Allowing Access to CSF for other Clinical Reasons",HGT-HIT-083 - CSF - Pediatric No Comp,0,Completed,Hunter Syndrome,RGH,,Non-Registry,,Non-Interventional_CDO Support,,,,150,50,0,0,0,0,0,33.33%,2,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-HIT-094,HGT-HIT-094,'HGT-HIT-094,'SHP609,idursulfase IT (TAK-609),"A Controlled, Randomized, Two-Arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Patients with Hunter Syndrome and Early Cognitive Impairment",HGTHIT-094 Ped PhII/III OL No Comparator,III,Completed,Hunter Syndrome,RGH,,Non-Registry,Pediatric only (<18 yr),Interventional,Multi-Centre,,,,58,0,,0,0,2,,12,,Shire HGT,PPD,,"Sharon Kunder, Helen Fitch, Kate Reid, Maria Humagain",,,"Rosa Barrio, Rosa Perez, Ryan Guthrie, Scott Prangley, Sharon Clarke, Veronica Mele, Viviana Gomez Martinez, Nadia Bensaid, Nadihelli Resendiz, Ouadah Hadjebi, Pablo Mastrazzi, Paola Russo, Patricia Salgado, Penelope Charles, Qiana Quinn, Quentin Liffran, Alison Dobbie, Ana Robledano, Ana Maria De Los Angeles Vetrano, Andrea Findlay-Batchelor, Angela Scalzo, Ann Sloand, Araceli Barron, Ayanna Reynolds, Ayanna Sissoko, Begona Maganto, Claudia Lopez, Consuelo Noetinger, Craig Brown, Danielle Foerster, Diana Ceron, Elfie Hensch, Elizabeth Bernardo, Emma Sealey, Friso Van Gent, Gabriela Paredes, Helen Burkill, Joseph Newkirk, Joseph Tiedeken, Karen Rose, Kirstin Robertson, Kirsty Stanton, Laura Rodriguez Tomagra, Lavanya Gupta, Lynn Cherney, Mabel Riveros Vanegas, Madonna Dela Cruz, Marco Parente, Maria Armanino, Maria Tantses, Marie-Christine Gautier, Mark Colindres, Erika Nunez, Ravi Patel",2013-002885-38,,,N,No,,,,COSMOS Inactive,,1/9/2017,9/11/2012,9/11/2012,4/4/2013,4/4/2013,,,4/3/2014,4/3/2014,4/3/2014,4/3/2014,,,9/30/2016,9/30/2016,,,9/28/2017,9/28/2017,,,,,,,,,,,12/4/2017,12/4/2017,,,,,,,,,12/11/2017,12/11/2017,,,,,,,,,,,,,12/18/2017,12/18/2017,,,,,,,,,6/11/2018,6/11/2018,,,,,,,,,,,,,,,6/11/2018,6/11/2018,,,,,,
HGT-LAL-085,HGT-LAL-085,'HGT-LAL-085,,,A Screening Study to Assess the Prevalence of Subjects with Late Onset Lysosomal Acid Lipase Deficiency in Targeted Populations,HGT-LAL-085 - screening study,0,Completed,Lysosomal Acid Lipase Deficncy,,,Non-Registry,,Non-Interventional_CDO Support,,,,180,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/3/2011,3/3/2011,,,,,6/1/2011,6/1/2011,,,,,,,,,,,,,,,,,11/30/2011,11/30/2011,11/30/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-MLD-048,HGT-MLD-048,'HGT-MLD-048,,,"A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and long-term safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of patients with late infantile metachromatic leukodystrophy",LT Metazym Treatment of Patients w/ MLD,II,Completed,Metachromatic Leukodystrophy,,,Non-Registry,,Interventional,,,,13,13,0,0,0,0,0,100.00%,1,,,,,,,,,2007-006345-40,,,N,No,,,,COSMOS Inactive,,,,,2/21/2008,2/21/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-MLD-049,HGT-MLD-049,'HGT-MLD-049,,,"A multi-center, open-label extension study of HGT-1111 (recombinant human arylsulfatase A or rhASA) treatment in patients with late infantile metachromatic leukodystrophy (MLD)",HGT-MLD-049 - OL EXT of HGT-1111,II,Completed,Metachromatic Leukodystrophy,,,Non-Registry,,Interventional,,,,12,11,0,0,0,0,0,91.67%,1,,,PPD,,,,,,2008-000084-41,,,N,No,,,,COSMOS Inactive,,,,,2/19/2009,2/19/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-MLD-070,HGT-MLD-070,'HGT-MLD-070,,arylsulfatase A (TAK-611),A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally (IT) in Children with Metachromatic Leukodystrophy,SHP611 OL Ped DR Multi dose,II,Completed,Metachromatic Leukodystrophy,RGH,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,24,24,34,0,11,24,2,100.00%,6,,,ICON / MAPI / Paradigm,,Yelena Shvenke,,Sean Seyffert,"Shrey Shah, Anne Greve, Karla Kacmarova, Marisa Andrea Mazzarello",2011-002044-28,,,N,No,,,,COSMOS Inactive,,,6/24/2010,6/24/2010,1/24/2011,1/24/2011,,,2/17/2012,2/17/2012,8/1/2012,8/1/2012,,,4/7/2016,4/7/2016,,,2/20/2017,2/20/2017,,,,,,,,,,,3/13/2017,3/13/2017,,,,,,,,,4/3/2017,4/3/2017,,,,,,,,,,,,,5/12/2017,5/12/2017,,,,,,,,,8/3/2017,8/3/2017,,,,,,,,,4/30/2015,4/30/2015,,,,,6/6/2025,,,,,,,
HGT-MLD-071,HGT-MLD-071,'HGT-MLD-071,,arylsulfatase A (TAK-611),An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy,SHP611 MLD Phase I/II Extn,II,Recruitment Complete,Schizophrenia/ Bipolar,RGH,RGH,,Pediatric only (<18 yr),Interventional,Treatment,Prospective,Cohort,24,41,41,,0,0,0,170.83%,12,20,,ICON Clinical Research,,"Alex Linica, Stephanie Lawson, Olivia Sahnas","Leslie Jacobsen, CJ Malanga, David Alexanderian","Amy Fisher, Claudio Santos, Joern Schenk",,2012-003775-20,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,11/2/2011,11/2/2011,8/27/2012,8/27/2012,,,5/23/2013,5/23/2013,5/23/2013,5/23/2013,,,1/20/2017,1/20/2017,,,12/31/2024,,,,,,,,,,,,1/31/2025,,,,,,,,,,1/31/2025,,,,,,,,,,,,,,3/28/2025,,,,,,,,,,6/6/2025,,,,,,,,,,,,,,,,6/6/2025,,,,,,,
HGT-MLD-092,HGT-MLD-092,'HGT-MLD-092,,arylsulfatase A (TAK-611),Natural History Study of Children with Metachromatic Leukodystrophy,SHP611 Natural History of Children,0,Completed,Metachromatic Leukodystrophy,RGH,,Non-Registry,,Interventional,,,,30,1,4,0,3,1,0,3.33%,18,,Shire HGT,ICON / MAPI / Paradigm,Nicole Yocum,Pallavi Tadimeti,,Sean Seyffert,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-OB2-089,HGT-OB2-089,'HGT-OB2-089,,,"A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending, Oral, Doses of HGT-3711 in Healthy Adult Subjects",Tolerability & PK study of HGT-3711,I,Study Withdrawn,Hereditary Angioedema,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-REP-059,HGT-REP-059,'HGT-REP-059,,,An open-label treatment protocol to evaluate the safety of Replagal treatment in patients with Fabry disease,HGT-REP-059 - US treatment Protocol,III,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,150,132,134,0,0,0,0,88.00%,999,,Shire HGT,Parexel,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,7/6/2009,7/6/2009,,,,,2/16/2010,2/16/2010,,,6/27/2011,6/27/2011,,,,,,,,,,,,,7/30/2012,7/30/2012,7/30/2012,1/28/2013,,,,,,,,,,,,,,,,,,,,,4/10/2013,4/10/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-REP-060,HGT-REP-060,'HGT-REP-060,,,An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients with Fabry Disease,028 OL Ext study,III,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,43,35,0,0,0,0,0,81.40%,10,,,Syneos Health,,,,,,2009-015985-75,,,N,No,,,,COSMOS Inactive,,,10/9/2013,,10/9/2013,,,,,,10/22/2013,,10/9/2013,,9/2/2014,,,,,,,,,,,,,,10/9/2013,,10/9/2013,10/9/2013,,,,,,,,,,,,,,,,,,,10/25/2013,10/25/2013,11/15/2013,11/15/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-REP-066,HGT-REP-066,'HGT-REP-066,,,A Pharmacokinetic Study in Normal Healthy Adult Volunteers to Compare Replagal Produced from Agalsidase Alfa Manufactured by 2 Different Processes,HGT-REP-066 - PK Adult,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,96,0,0,0,0,0,0,0.00%,999,,,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/16/2010,4/16/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-REP-081,HGT-REP-081,'HGT-REP-081,,Replagal (agalsidase alfa),A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (agalsidase alfa) Enzyme Replacement Therapy in Canadian Patients with Fabry Disease,CAN Treatment (AF),III,Completed,Fabry Disease,RGH,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Safety,,,200,171,180,4,1,0,31,85.50%,14,,,inVentiv Health Clinical (iHC),,"Tosha Marie Doornek, Yelena Shvenke, Yune Kunes, Deana Rabinovich",,,,,Approved for Marketing,,N,No,,,,COSMOS Inactive,,,,,,,,,5/5/2011,5/5/2011,8/10/2011,8/10/2011,,,5/5/2017,5/5/2017,,,9/21/2017,9/21/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/17/2018,4/17/2018,,,,,,,,,,,,,,,4/17/2018,4/17/2018,,,,,,
HGT-REP-082,HGT-REP-082,'HGT-REP-082,,,A Phase II Comparability Study between Replagal Produced from Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients with Fabry Disease who are Currently Receiving Treatment with Replagal,HGT-REP-082 - PK/PD in CAN (RB to  AF),II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,20,17,24,0,0,0,0,85.00%,4,,,"Syneos Health, United BioSource Corporation",,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/5/2012,3/5/2012,,,,,12/6/2011,12/6/2011,,,9/6/2012,9/6/2012,,,,,,,,,,,,,12/28/2012,12/28/2012,12/28/2012,2/22/2013,,,,,,,,,,,,,,,,,,,3/15/2013,3/15/2013,4/1/2013,4/1/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-REP-084,HGT-REP-084,'HGT-REP-084,,,An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children with Fabry Disease who are Naïve to Enzyme Replacement Therapy,HGT-REP-083 - Naïve peds on Replagal AF,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,14,14,0,0,0,0,0,100.00%,5,,,"Pharmanet, Syneos Health",,,,,,,,,N,No,,,,COSMOS Inactive,,,,,2/10/2011,2/10/2011,,,,,5/17/2011,5/17/2011,,,2/29/2012,2/29/2012,,,,,,,,,,,,,5/3/2013,5/3/2013,5/3/2013,6/4/2013,,,,,,,,,,,,,,,,,,,6/6/2013,6/6/2013,7/9/2013,7/9/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-SAN-053,HGT-SAN-053,'HGT-SAN-053,,,"A 24-month Longitudinal, Prospective, Natural History Study of Patients with Sanfilippo Syndrome Type A (MPS IIIA)",HGT-SAN-053 - Natural History,I,Completed,Sanfilippo A Syndrome,,,Non-Registry,,Interventional,,,,25,25,0,0,0,0,0,100.00%,2,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,2/11/2009,2/11/2009,,,,,2/15/2010,2/15/2010,,,5/9/2011,5/9/2011,,,,,,,,,,,,,7/10/2013,7/10/2013,7/10/2013,9/24/2013,,,,,,,,,,,,,,,,,,,,,8/28/2013,8/28/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-SAN-055,HGT-SAN-055,'HGT-SAN-055,,,"A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan N-Sulfatase (rhHNS) Intrathecal Administration via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)","HGT-SAN-055 - Safety, Ascending Dose",II,Completed,Sanfilippo A Syndrome,,,Non-Registry,,Interventional,,,,12,12,0,0,0,0,0,100.00%,2,,Shire HGT,Covance,,,,,,2009-015984-15,,,N,No,,,,COSMOS Inactive,,,,,10/29/2009,10/29/2009,,,,,7/15/2010,7/15/2010,,,3/26/2012,3/26/2012,,,,,,,,,,,,,9/10/2012,9/10/2012,9/10/2012,10/4/2012,,,,,,,,,,,,,,,,,,,,,11/2/2012,11/2/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGT-SAN-067,HGT-SAN-067,'HGT-SAN-067,,,An Open-Label Extension of Study HGT-SAN-055 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients with Sanfilippo Syndrome Type A (MPS IIIA),I/II Extn of 055 OL Ped,II,Completed,Sanfilippo A Syndrome,,,Non-Registry,Pediatric only (<18 yr),Interventional,Safety,,,12,12,0,,0,0,12,100.00%,2,,,PPD,Jeffrey Bernier,"Maria Ignacia Berraondo, Sharon Kunder",David Alexanderian,,"Elisa Kuiper, Friso Van Gent, Janis Riley, Laura Flynn",2010-021348-16,,,N,No,,,,COSMOS Inactive,,,3/29/2010,3/29/2010,6/21/2010,6/21/2010,,,,,3/1/2011,3/1/2011,3/1/2011,3/1/2011,9/10/2012,9/10/2012,,,,,,,,,,,,,12/19/2018,,12/19/2018,,,,,,,,,,,,,,,,,,,,8/5/2019,,8/15/2019,,,,,,,,,,,,10/10/2019,,,,,,,,,,,,,,,,,,,,,,,
HGT-SAN-093,HGT-SAN-093,'HGT-SAN-093,,,A Phase II B Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Patients with Early Stages of Mucopolysaccaridosis Type IIIA Disease,IIB POC OL Safety & Efficacy,IIb,Completed,Sanfilippo A Syndrome,,,Non-Registry,,Interventional,,,,,21,0,,0,0,0,,10,,,PPD,Nicole Yocum,Sharon Kunder,,,"Angela Scalzo, Annemarie Groesbeek, Begona Maganto, Benjamin Charles, Claudia Lopez, Consuelo Noetinger, Dan Russo, Daniela Panico, Diana Ceron, Diane Kas, Elfie Hensch, Erika Nunez, Helen Burkill, Joseph Newkirk, Joseph Tiedeken, Karen Rose, Katharina Gebendorfer, Katja Koch, Kylie Gillberg, Loes Pelgrim, Lotte Boonstra, Luis Rodrigues, Marco Balzarotti, Maria Armanino, Maria Tantses, Marjet Munsters, Nadia Macedo, Nadia Martins, Nikolyn Thull, Pablo Mastrazzi, Penelope Charles, Peter Ten Tuijnte, Rafaela Vazquez, Salima Benchanaa, Sandra Golz, Sebastien Minguet, Simona Ruocco, Sophie Paskarajesudasan, Sylvanie Malouitre, Thomas Dubrunfaut, Veronica Mele, Viola Jansen, Wieteke Beerling, Ana Robledano, Ana Maria De Los Angeles Vetrano",2013-003450-24,,,N,No,,,,COSMOS Inactive,,6/1/2016,12/11/2012,12/11/2012,8/27/2013,8/27/2013,,,,,2/28/2014,3/16/2014,2/10/2014,,3/31/2015,4/8/2015,,,,,,,,,,,,,5/30/2016,6/1/2016,5/30/2016,,,,,,,,,,,,,,,,,,,,7/20/2016,,8/9/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGTGCB-087,HGTGCB-087,'HGTGCB-087,,,"A Multicenter, Open-Label Study of Velaglucerase alfa Enzyme Replacement Therapy in Japanese Patients with Gaucher Disease",24W Japanese Pediatric Bridging,III,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,7,6,0,0,0,0,0,85.71%,3,,Shire HGT,IQVIA,,Colin Bunnell,,,,,,,N,No,,,,COSMOS Inactive,,,4/21/2011,4/21/2011,10/5/2011,10/5/2011,,,,,3/14/2012,3/14/2012,3/14/2012,3/14/2012,5/26/2012,5/26/2012,,,,,,,,,,,,,5/25/2013,5/25/2013,5/25/2013,8/14/2013,,,,,,,,,,,,,,,,,,,8/20/2013,8/20/2013,8/20/2013,8/20/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGTGCB-091,HGTGCB-091,'HGTGCB-091,,VPRIV (velaglucerase alfa),"A Multicenter, Open-label Extension Study of Velaglucerase alfa Enzyme Replacement Therapy in Japanese Patients with Gaucher Disease",HGT-GCB-091 Japan Extension,III,Completed,Gaucher's Disease,RGH,,Non-Registry,,Interventional,,,,6,5,0,0,0,0,0,83.33%,5,,Shire HGT,IQVIA,,"Chris Allaire, Colin Bunnell",,,,,,,N,No,,,,COSMOS Inactive,,,7/13/2012,7/13/2012,9/27/2012,9/27/2012,,,3/13/2013,3/13/2013,3/13/2013,3/13/2013,,,,,6/8/2013,6/8/2013,9/24/2014,9/24/2014,,,,,,,,,,,,,,,,,,,,,11/20/2014,11/20/2014,,,,,,,,,,,,,,,,,,,,,,,2/3/2015,2/3/2015,,,,,,,,,,,,,,,2/3/2015,2/3/2015,,,,,,
HGTHIT-072,HGTHIT-072,'HGTHIT-072,,,A Cerebrospinal Fluid Collection Study in Pediatric and Adult Patients with Hunter Syndrome,HGTHIT-072,0,Completed,Hunter Syndrome,,,Non-Registry,,Non-Interventional_CDO Support,,,,10,10,0,0,0,0,0,100.00%,7,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/12/2010,7/12/2010,10/26/2010,10/26/2010,,,,,10/31/2012,10/31/2012,10/31/2012,10/31/2012,12/20/2013,12/20/2013,,,,,,,,,,,,,12/20/2013,12/20/2013,12/20/2013,,,,,,,,,,,,,,,,,,,,4/4/2014,,4/11/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGTHIT-090,HGTHIT-090,'HGTHIT-090,,idursulfase IT (TAK-609),"A prospective, Longitudinal, Observational Study to Evaluate Neurodevelopment Status in Pediatric Patients with Hunter Syndrome (MPS II)","HGTHIT-090 Ped,non-interven",II,Completed,Hunter Syndrome,RGH,,Non-Registry,Pediatric only (<18 yr),Non-Interventional_CDO Support,,,,100,55,74,0,19,55,31,55.00%,7,,,Psi,Helen Fitch,,David Alexanderian,Rebecca Pyle,Shrey Shah,2013-002885-38,,,N,No,,,,COSMOS Inactive,,,4/2/2012,4/2/2012,6/8/2012,6/8/2012,,,1/18/2013,1/18/2013,1/18/2013,1/18/2013,,,12/31/2014,12/31/2014,,,10/5/2016,10/5/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/7/2018,2/7/2018,,,,,,,,,,,,,,,2/7/2018,2/7/2018,,,,,,
HGTSNB-088,HGTSNB-088,'HGTSNB-088,,,"An Observational Prospective Natural History Study of Patients with Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)",HGT-SNB-088 Natural History,0,Completed,Mucopolysaccharidosis,,,Non-Registry,,Non-Interventional_CDO Support,Adolescent,,,25,19,0,0,0,0,5,76.00%,4,,Shire HGT,,Jeffrey Bernier,,David Alexanderian,,,,,,N,No,,,,COSMOS Inactive,,,7/26/2011,7/26/2011,10/19/2011,10/19/2011,,,,,4/9/2012,4/9/2012,4/9/2012,4/9/2012,9/30/2013,9/30/2013,,,,,,,,,,,,,11/19/2014,10/10/2013,11/19/2014,,,,,,,,,,,,,,,,,,,,2/24/2015,,3/3/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HOS,HOS,'HOS,,Elaprase (idursulfase),Hunter Outcome Survey,Hunter Outcome Survey,IV,Recruiting,Hunter Syndrome treatment of somatic symptoms,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,,Other,Other,"1,435","1,303",0,,0,0,682,90.80%,999,117,,Ppd,,Dalia Jazukeviciene,"Joern Schenk, Daniel Fertek",,,,,,,,,,,Medidata CTMS (Pharma),,,,,8/8/2005,8/8/2005,,,,,10/3/2005,10/3/2005,,,12/30/2021,,,,12/30/2022,,,,,,,,,,,,2/20/2023,,,,,,,,,,4/3/2023,,,,,,,,,,,,,,,,,,,,,,,,5/26/2023,,,,,,,,,,,,,,,,5/26/2023,,,,,,,
IOS,IOS,'IOS,,Firazyr (Icatibant),Icatibant Outcome Survey,Icatibant Outcome Survey,IV,Recruiting,Support - Rare Diseases,RGH,Marketed Products,,Both pediatric and non-pediatric,Observational,Other,Prospective,Cohort,999,"1,732",0,,0,0,600,173.37%,60,53,,PPD,,Rana Radmard,Irmgard Andresen,,,,,,,,,,,Medidata CTMS (Pharma),,,,,8/27/2008,8/27/2008,,,,,7/10/2009,7/10/2009,,,11/25/2022,,,,5/24/2023,,,,,,,,,,,,6/30/2023,,,,,,,,,,7/17/2023,,,,,,,,,,,,,,8/7/2023,,,,,,,,,,5/24/2024,,,,,,,,,,,,,,,,5/24/2024,,,,,,,
JE049-3101,JE049-3101,'JE049-3101,,,"Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema","JE049-3101 - OL, self-admin formulation",IV,Completed,Hereditary Angioedema,,,Non-Registry,,Non-Interventional_CDO Support,,,,150,151,0,0,0,0,0,100.67%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,7/30/2010,7/30/2010,,,,,,,,,,,,,,,,,,,,,,,6/22/2011,6/22/2011,6/22/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LEV-2005-1 A,LEV-2005-1 A,'LEV-2005-1 A,,,"LEVP 2005-1/Part A CHANGE Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation evaluating Efficacy): A Double-blind, Placebo-controlled, Clinical Study to Investigate the Efficacy and Safety of C1INH-nf (Cinryze™), Purified C1 Esterase Inhibitor (Human) for the Treatment of Hereditary Angioedema (HAE) in Acute Attacks (Part A)","(SHP616) LEVP 2005-1/Part A, ""CHANGE""",III,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,68,71,0,0,0,0,0,104.41%,30,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,3/14/2005,3/14/2005,,,,,,,,,,,,,,,,,4/13/2007,4/13/2007,4/13/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LEV-2005-1 B,LEV-2005-1 B,'LEV-2005-1 B,,,"LEVP 2005-1/Part B CHANGE Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation evaluating Efficacy): A Double-blind, Placebo-controlled, Clinical Study to Investigate the Efficacy and Safety of C1INH-nf (Cinryze™), Purified C1 Esterase Inhibitor (Human) for the Prevention of Hereditary Angioedema (HAE) Attacks","(SHP616) LEVP 2005-1/Part B, ""CHANGE""",III,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,20,24,0,0,0,0,0,120.00%,30,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,3/14/2005,3/14/2005,,,,,,,,,,,,,,,,,8/22/2007,8/22/2007,8/22/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LEV-2006-1,LEV-2006-1,'LEV-2006-1,,,CHANGE 2 TRIAL (Cl-INHIBITOR IN HEREDITARY ANGIOEDEMA NANOFILTRATION GENERATION EVALUATING EFFICACY): OPEN-LABELSAFETY/EFFICACY REPEAT EXPOSURE STUDY OF C1 ESTERASE INHIBITOR (HUMAN) IN THE TREATMENT OF ACUTE HEREDITARY ANGIOEDEMA (HAE) ATTACKS,"(SHP616) LEV 2006-1, CHANGE 2",III,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,999,113,0,0,0,0,0,11.31%,75,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,5/30/2006,5/30/2006,,,,,9/21/2006,9/21/2006,,,,,,,,,,,,,,,,,3/31/2009,3/31/2009,3/31/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LEV-2006-4,LEV-2006-4,'LEV-2006-4,,,CHANGE 3 TRIAL (CI-INHIBITOR IN HEREDITARY ANGIOEDEMA NANOFILTRATION GENERATION EVALUATING EFFICACY): OPEN-LABEL USE OF C1 ESTERASE INHIBITOR (HUMAN) FOR THE PROPHYLACTIC TREATMENT TO PREVENT HEREDITARY ANGIOEDEMA (HAE) ATTACKS AND AS A TREATMENT IN ACUTE HAE ATTACKS,"(SHP616) LEV 2006-4, CHANGE 3:",III,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,146,146,0,0,0,0,0,100.00%,999,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,6/27/2006,6/27/2006,,,,,,,,,,,,,,,,,3/31/2009,3/31/2009,3/31/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LUM001-201,LUM001-201,'LUM001-201,'SHP625,,"CLARITY: 13 wk, double blind, placebo controlled combo w/UDCA","CLARITY 13wk, DB, placebo;  combo w/UDCA",II,Completed,PBC,,,Non-Registry,,Interventional,Proof of Concept,,,62,66,87,0,21,66,5,106.45%,24,,Lumena Pharmaceuticals LLC,,,,,,,2013-000482-36,,,N,No,,,,COSMOS Inactive,,,4/16/2013,4/16/2013,4/16/2013,4/16/2013,7/2/2015,,,,9/16/2013,9/16/2013,7/2/2015,7/2/2015,12/10/2014,12/10/2014,,,,,,,,,,,,,3/12/2015,3/12/2015,3/12/2015,5/15/2015,,,,,,,,,,,,,,,,,,,5/22/2015,5/22/2015,6/19/2015,6/19/2015,,,,,,,,,,,11/3/2015,11/3/2015,,,,,,,,,,,,,,,,,,,,,,
LUM001-202,LUM001-202,'LUM001-202,'SHP625,,SHP625-202 CASCADE long term 48 week extension study,CASCADE: long term 48 wk extension study,II,Study Withdrawn,PBC,,,Non-Registry,,Interventional,Efficacy,,,61,0,0,0,0,0,0,0.00%,20,,Lumena Pharmaceuticals LLC,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,11/28/2014,11/6/2014,,,,,5/29/2015,,,,10/28/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/15/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LUM001-301,LUM001-301,'LUM001-301,'SHP625,,"ITCH: Registration 13 wk, double blind, placebo controlled","ITCH: Reg 13 wk, db, placebo",II,Completed,ALGS,,,Non-Registry,Pediatric only (<18 yr),Interventional,Proof of Concept,,,36,37,54,0,16,37,2,102.78%,13,,Lumena Pharmaceuticals LLC,,,"Lisette Acevedo, Monique Meigio, Nedjia Boumediene",,,,,Not Available,,N,Yes,,,,COSMOS Inactive,16-Nov-16,11/16/2016,10/22/2013,10/22/2013,10/22/2013,10/22/2013,,,,,12/15/2014,12/15/2014,11/24/2014,11/24/2014,8/17/2016,8/17/2016,,,,,,,,,,,,,11/16/2016,11/16/2016,11/16/2016,2/23/2017,,,,,,,,,,,,,,,,,,,3/1/2017,3/1/2017,3/28/2017,3/28/2017,,,,,,,,,,,10/26/2018,10/5/2018,,,,,,,,,,,,,,,,,,,,,,
LUM001-302,LUM001-302,'LUM001-302,'SHP625,,"IMAGO: Registration 13 wk, double blind, placebo controlled","IMAGO: Reg 13 wk, db, placebo",II,Completed,ALGS,,,Non-Registry,,Interventional,Proof of Concept,,,18,20,30,0,10,20,1,111.11%,3,,Lumena Pharmaceuticals LLC,,,,,,,2012-005346-38,,,N,No,,,,COSMOS Inactive,,,4/29/2013,4/29/2013,4/29/2013,4/29/2013,1/1/2049,,,,9/17/2013,9/17/2013,9/17/2013,9/17/2013,11/28/2014,11/28/2014,,,,,,,,,,,,,2/23/2015,2/23/2015,2/23/2015,3/30/2015,,,,,,,,,,,,,,,,,,,4/9/2015,4/9/2015,4/29/2015,4/29/2015,,,,,,,,,,,8/7/2015,8/7/2015,,,,,,,,,,,,,,,,,,,,,,
LUM001-303,LUM001-303,'LUM001-303,'SHP625,,IMAGINE: Long term 72 wk extension study,IMAGINE: LT 72 wk ext study,II,Study Terminated,ALGS,,,Non-Registry,Pediatric only (<18 yr),Interventional,Efficacy,,,18,19,19,0,0,19,5,105.56%,3,3,Lumena Pharmaceuticals LLC,PPD,,"Stephanie Wagner, Tracy Dew",,,,2013-003832-54,,,N,No,,,,COSMOS Inactive,,,9/13/2013,9/13/2013,9/13/2013,9/13/2013,,,,,12/20/2013,12/20/2013,12/20/2013,12/20/2013,2/16/2015,2/16/2015,,,,,,,,,,,,,5/30/2019,,5/30/2019,,,,,,,,,,,,,,,,,,,,9/10/2019,,9/30/2019,,,,,,,,,,,,10/29/2019,,,,,,,,,,,,,,,,,,,,,,,
LUM001-304,LUM001-304,'LUM001-304,'SHP625,,ICONIC:  100 wk open label with randomized discontinuation phase,ICONIC:  100 wk open label with randomiz,II,Study Terminated,ALGS,,,Non-Registry,Pediatric only (<18 yr),Interventional,Efficacy,,,30,31,36,0,5,29,7,103.33%,13,9,Lumena Pharmaceuticals LLC,Premier,,Stephanie Wagner,,,,2013-005373-43,,,N,No,,,,COSMOS Inactive,,,3/20/2014,3/20/2014,3/20/2014,3/20/2014,,,,,11/25/2014,11/25/2014,10/28/2014,10/28/2014,9/11/2015,9/11/2015,,,,,,,,,,,,,5/15/2019,,5/15/2019,,,,,,,,,,,,,,,,,,,,9/10/2019,,9/30/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LUM001-305,LUM001-305,'LUM001-305,'SHP625,,IMAGINE II: Long term 48 wk extension study,IMAGINE II: LT 48 wk ext study,II,Study Terminated,ALGS,,,Non-Registry,Pediatric only (<18 yr),Interventional,Efficacy,,,36,34,34,0,0,34,9,94.44%,13,12,Lumena Pharmaceuticals LLC,Premier,,"Lisette Acevedo, Monique Meigio, Stephanie Wagner",,,,,,,N,No,,,,COSMOS Inactive,,,4/14/2014,4/14/2014,4/14/2014,4/14/2014,,,,,3/16/2015,3/16/2015,3/16/2015,3/16/2015,1/11/2017,1/11/2017,,,,,,,,,,,,,5/30/2019,,5/30/2019,,,,,,,,,,,,,,,,,,,,9/10/2019,,9/30/2019,,,,,,,,,,,,10/29/2019,,,,,,,,,,,,,,,,,,,,,,,
LUM001-401,LUM001-401,'LUM001-401,'SHP625,,CAMEO:  14 wk open label study,CAMEO:  14 wk OL,II,Completed,PSC,,,Non-Registry,,Interventional,Proof of Concept,,,22,27,37,0,10,27,4,122.73%,9,,Lumena Pharmaceuticals LLC,,"Arthur Van Leerberghe, Trish Novak",,Beatriz Caballero,,,2014-005558-21,,,N,No,,,,COSMOS Inactive,,,11/12/2013,11/12/2013,11/12/2013,11/12/2013,,,,,5/27/2014,5/27/2014,4/14/2014,4/14/2014,10/7/2015,10/7/2015,,,,,,,,,,,,,2/12/2016,2/12/2016,2/12/2016,3/25/2016,,,,,,,,,,,,,,,,,,,3/29/2016,3/29/2016,4/21/2016,4/21/2016,,,,,,,,,,,11/11/2016,11/11/2016,,,,,,,,,,,,,,,,,,,,,,
LUM001-501,LUM001-501,'LUM001-501,'SHP625,,INDIGO:  124 wk open label with interim efficacy at weeks 13 and 48,INDIGO:124 wk open label w/optional ext,II,Study Terminated,PFIC,,,Non-Registry,Pediatric only (<18 yr),Interventional,Efficacy,,,29,33,38,0,5,33,16,113.79%,11,10,Lumena Pharmaceuticals LLC,Premier,,"Lisette Acevedo, Monique Meigio, Nokutula Condon, Stephanie Wagner",,,,2013-003833-14,,,N,No,,,,COSMOS Inactive,,,10/23/2013,10/23/2013,10/23/2013,10/23/2013,,,,,3/9/2014,3/9/2014,2/12/2014,2/12/2014,3/9/2014,3/9/2014,,,,,,,,,,,,,1/31/2019,,1/31/2019,,,,,,,,,,,,,,,,,,,,5/21/2019,,5/31/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LUM001-601,LUM001-601,'LUM001-601,'SHP625,,2-year ALGS Global Extension Study,2-year ALGS Global Extension Study,II,Study Withdrawn,ALGS,,,Non-Registry,,Interventional,Efficacy,,,120,0,0,0,0,0,0,0.00%,28,,Lumena Pharmaceuticals LLC,,,"Kristina Man, Alexandra Rossi",,,,2015-000906-20,,,N,No,,,,COSMOS Inactive,,,,,3/2/2015,3/6/2015,,,,,6/15/2015,,,,10/6/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/24/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Met-001,Met-001,'Met-001,,,"Open-label, Randomized, Two-way Crossover Study to Compare the Pharmacokinetics of Single Doses of 375 mg Metronidazole Capsules Versus Over-encapsulated 375 mg Metronidazole Capsules in Healthy Volunteers",Met-001: Capsule v Over-encapsulated,I,Completed,Antibiotic Treatment,,,Non-Registry,,Interventional,,,,24,24,0,0,0,0,0,100.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,7/12/2011,7/12/2011,,,,,10/12/2011,10/12/2011,,,10/12/2011,10/12/2011,,,,,,,,,,,,,10/23/2011,10/23/2011,10/23/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT4546581,NCT4546581,'NCT4546581,,,"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",Tx with Anti-Coronavirus Ig (ITAC),III,Planned,,,,,,Interventional,,,,500,,,,,,,,30,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P-321-101,P-321-101,'P-321-101,'SHP659,,"A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P-321 Ophthalmic Solution in Subjects with Dry Eye Disease",P-321-101 PlaceboControlled Escalation,IIa,Completed,Dry eye,,,Non-Registry,,Interventional,,,,48,0,0,0,0,0,0,0.00%,1,,Parion,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P-321-201,P-321-201,'P-321-201,'SHP659,,"Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease Characterized by Low Tear Volume",P-321-201 Crossover Pharmacodynamic,IIa,Study Terminated,Dry eye,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,Parion,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P-321-202,P-321-202,'P-321-202,'SHP659,,"Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease Assessing Safety and Efficacy Over 28 Days",P-321-202 Parallel Group Efficacy,IIb,Completed,Dry eye,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,Parion,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PAR-C10-007,PAR-C10-007,'PAR-C10-007,'SHP634,,"RELAY
NPS Legacy Study",RELAY  NPS Legacy,III,Completed,Hypoparathyroidism,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,"(NPS) National Pharmaceutical Services, Inc",,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PAR-C10-008,PAR-C10-008,'PAR-C10-008,'SHP634,Natpara (parathyroid hormone),"A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults with Hypoparathyroidism – A Clinical Extension Study (RACE)",PAR-C10-008 RACE,III,Completed,Hypoparathyroidism,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,40,53,0,0,0,0,13,132.50%,12,,"(NPS) National Pharmaceutical Services, Inc",Medpace,,Elena Tokareva,,,"Cynthia Rutherford, Louis Noble, Tammy Gilbreath",,,,N,No,,,,COSMOS Inactive,,7/2/2019,11/22/2010,11/22/2010,12/30/2010,12/30/2010,,,3/30/2011,3/30/2011,4/6/2011,4/6/2011,,,1/30/2012,1/30/2012,,,1/30/2018,1/30/2018,,,,,,,,,,,7/3/2018,7/3/2018,,,,,,,,,7/27/2018,7/27/2018,,,,,,,,,,,,,7/30/2018,7/30/2018,,,,,,,,,11/8/2018,11/8/2018,,,,,,,,,,,,,,,11/8/2018,11/8/2018,,,,,,
PAR-C10-009,PAR-C10-009,'PAR-C10-009,'SHP634,,"REPEAT
NPS Legacy Study",PAR-C10-009 REPEAT   NPS Legacy,III,Completed,Hypoparathyroidism,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,"(NPS) National Pharmaceutical Services, Inc",,,,,,,2011-001265-40,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PAR-C14-007,PAR-C14-007,'PAR-C14-007,'SHP634,,"An Open-label, Single-dose Study to Determine the Pharmacokinetic/Pharmacodynamic Profile of Parathyroid Hormone (rDNA) Administered Subcutaneously at a Dose of 50 µg in Subjects with Hypoparathyroidism Who Are 12 to Less Than 18 Years of Age",PIP #3,I,Study Terminated,Hypoparathyroidism,,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,10,0,0,0,0,0,0,0.00%,5,,"(NPS) National Pharmaceutical Services, Inc",,,,,Rebekah Gorney,,,,,N,No,,,,COSMOS Inactive,,,12/18/2015,8/14/2014,4/29/2015,4/29/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PAR-R13-001,PAR-R13-001,'PAR-R13-001,,Natpara (parathyroid hormone),"Protocol PAR-R13-001
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Natural History Registry for Patients with Chronic Hypoparathyroidism",PARADIGHM,IV,Recruiting,Endometrial cancer,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,Treatment,Prospective,Cohort,900,"1,201",1230,,29,,310,133.44%,101,46,,ICON Clinical Research,,Edgar Berger,"Claudio Marelli, John Germak, Sharon Kunder, Tina Angelin","Claudio Marelli, John Germak",,EUPAS16927,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,4/23/2013,4/23/2013,4/23/2013,4/23/2013,,,7/30/2013,7/30/2013,7/30/2013,7/30/2013,,,11/29/2024,,,,11/30/2034,,,,,,,,,,,,2/28/2035,,,,,,,,,,3/30/2035,,,,,,,,,,,,,,4/13/2035,,,,,,,,,,5/25/2035,,,,,,,,,,,,,,,,5/25/2035,,,,,,,
PASS-EU-001,PASS-EU-001,'PASS-EU-001,'PASS-EU-001,,"ADVATE PASS EU: A Post-Authorisation Safety Surveillance Of ADVATE rAHF-PFM In Haemophilia A - This is a prospective, multi-centre, uncontrolled, open-label post-authorisation safety surveillance of ADVATE",ADVATE PASS EU,IV,Completed,Hemophilia A,,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,300,,,,,,,,165,,Baxalta,PPD,,,,,,,,,,,,,,COSMOS Inactive,,,,2/16/2004,,3/11/2004,,,,,,,,10/14/2004,,,,,,,,,,,,,,,,5/15/2008,,11/24/2008,,,,,,,,,,,,,,,,,,,,,,12/9/2008,,,,,,,,,,,,7/24/2009,,,,,,,,,,,,,,,,,,,,,,
PASS-EU-002,PASS-EU-002,'PASS-EU-002,'PASS-EU-002,,SUBCUVIA PASS: A Post-Authorisation Safety Surveillance of SUBCUVIA in Immunodeficiency,SUBCUVIA PASS,IV,Completed,Primary Immunodeficiency,,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,50,,,,,,,,29,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,,,9/12/2005,,,,,,,,3/21/2006,,,,,,,,,,,,,,,,10/1/2008,,12/17/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/18/2009,,,,,,,,,,,,,,,,,,,,,,
PASS-EU-005,PASS-EU-005,'PASS-EU-005,'PASS-EU-005,,"KIOVIG PASS: Post Authorisation Safety Surveillance of KIOVIG - An open, uncontrolled, non-interventional observational cohort study in immunodeficiencies and auto-immune diseases",KIOVIG PASS,IV,Completed,Autoimmune Disease,,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,150,,,,,,,,29,,Baxalta,PPD,,,,,,,,,,,,,,COSMOS Inactive,,,,,,11/20/2006,,,,,,,,10/20/2007,,,,,,,,,,,,,,,,12/29/2009,,3/4/2010,,,,,,,,,,,,,,,,,,,,,,5/7/2010,,,,,,,,,,,,11/24/2010,,,,,,,,,,,,,,,,,,,,,,
PASS-EU-006,PASS-EU-006,'PASS-EU-006,'PASS-EU-006,,"FEIBA NF PASS: Post-Authorization Safety Study of FEIBA NF(Factor VIII Inhibitor Bypassing Activity).  An open, uncontrolled, non-interventional observational cohort study of FEIBA NF in haemophiliacs with inhibitors",FEIBA NF PASS,IV,Completed,"Hemophilia A or B, w Inhibitor",,,Non-Registry,Both Pediatric & Non-pediatric,Non-Intervention_Other Support,Open Label,,,85,85,85,0,6,81,7,100.00%,47,,Baxalta,PPD,Manfred Pirck,,"Robert Numerof, Vadim Romanov",,,,,,,,,,,COSMOS Inactive,,,,4/17/2006,,3/7/2008,,,,,,,,10/21/2008,,,,,,,,,,,,,,,,10/28/2013,,2/10/2014,,,,,,,,,,,,,,,,,,,,,,7/26/2014,,,,,,,,,,,,10/10/2014,,,,,,,,,,,,,,,,,,,,,,
PASS-EU-009,PASS-EU-009,'PASS-EU-009,'PASS-EU-009,,"FACTOR VII PASS: This is a prospective, multi-centre, uncontrolled, open-label, non-interventional, post-authorisation safety surveillance in patients with congenital FVII deficiency",FACTOR VII PASS,IV,Completed,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,12,14,14,0,0,14,0,116.67%,6,,Baxalta,Msource,,,,,,,,,,,,,,COSMOS Inactive,,,,,,6/28/2007,,,,,,,,9/2/2008,,,,,,,,,,,,,,,,2/5/2010,,4/9/2010,,,,,,,,,,,,,,,,,,,,,,8/18/2010,,,,,,,,,,,,9/29/2010,,,,,,,,,,,,,,,,,,,,,,
PASS-INT-003,PASS-INT-003,'PASS-INT-003,'PASS-INT-003,,"FEIBA SURF Global: Prospective, Open and Uncontrolled  Surveillance of Surgical Interventions with FEIBA (SURF)",FEIBA SURF Global,IV,Completed,"Hemophilia A or B, w Inhibitor",,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,50,,,,,,,,23,,Baxalta,Msource,,,,,,,,,,,,,,COSMOS Inactive,,,,,,10/11/2006,,,,,,,,12/15/2006,,,,,,,,,,,,,,,,12/25/2009,,6/16/2010,,,,,,,,,,,,,,,,,,,,,,6/18/2010,,,,,,,,,,,,12/13/2010,,,,,,,,,,,,,,,,,,,,,,
PASS-INT-004,PASS-INT-004,'PASS-INT-004,'PASS-INT-004,,"ADVATE PAIR Global: Prospective ADVATE Immune Tolerance Induction Registry (PAIR) - A prospective, multi-center, uncontrolled, open-label, non-interventional post-authorization registry",ADVATE PAIR Global,IV,Completed,Hemophilia A,,,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,,,,44,44,44,0,0,0,0,100.00%,31,,Baxalta,ICON / MAPI / Paradigm,,,,,,,,,,,,,,COSMOS Inactive,,,,3/15/2005,,12/4/2006,,,,,,,,7/27/2007,,,,,,,,,,,,,,,,12/29/2014,,4/16/2015,,,,,,,,,,,,,,,,,,,,,,6/25/2015,,,,,,,,,,,,10/9/2015,,,,,,,,,,,,,,,,,,,,,,
PASS-US-001,PASS-US-001,'PASS-US-001,'PASS-US-001,,"ADVATE PASS US: Evaluation of safety, efficacy, and immunogenicity of ADVATE in hemophilia A - An ADVATE Post-authorization Safety Surveillance (PASS) study",ADVATE PASS US,IV,Completed,Hemophilia A,,,Non-Registry,,Non-Interventional_CDO Support,,,,150,0,0,0,0,,0,0.00%,37,,Baxalta,,,,,,,,,,,,,,,COSMOS Inactive,,,,2/27/2004,,5/24/2004,,,,,,,,12/3/2004,,,,,,,,,,,,,,,,12/22/2006,,12/22/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/6/2009,,,,,,,,,,,,,,,,,,,,,,
PFP-A1296800,PFP-A1296800,'PFP-A1296800,,,TAK-330 Prothromplex Phase 2/3 PDT Placeholder Study,TAK-330 Phase 2/3 Study,II/III,Study Withdrawn,,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,Aleksandar Stevanovic,,,,,N,No,,,,COSMOS Inactive,,,*,,*,,1/1/2049,,3/2/2022,,*,,1/1/2049,,*,,,,4/3/2024,,,,,,,,,,1/1/2049,,*,,,,,,,,,,7/12/2024,,,,,,,,,,1/1/2049,,1/1/2049,,9/11/2024,,,,,,,,,,*,,,,,,,,,,,,,,,,11/12/2024,,1/1/2049,,1/1/2049,,,
PFP-A1296900,PFP-A1296900,'PFP-A1296900,,,TAK-330 Prothromplex Phase 3 PDT Placeholder Study,TAK-330 Phase 3 Study,III,Study Withdrawn,,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,Aleksandar Stevanovic,,,,,N,No,,,,COSMOS Inactive,,,*,,*,,1/1/2049,,3/2/2022,,*,,1/1/2049,,*,,,,4/3/2024,,,,,,,,,,1/1/2049,,*,,,,,,,,,,7/12/2024,,,,,,,,,,1/1/2049,,1/1/2049,,9/11/2024,,,,,,,,,,*,,,,,,,,,,,,,,,,11/12/2024,,1/1/2049,,1/1/2049,,,
PFP-A1312100,PFP-A1312100,'PFP-A1312100,,HYQVIA,TAK-771 AVA - Development PDT Placeholder Study,TAK-771 HyQvia HyHub (AVA) Device,I,Planned,Support - Plasma Derived Therapy,Plasma Derived Therapy,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PFP-A1312500,PFP-A1312500,'PFP-A1312500,,,TAK-771 Japan CIDP PDT Placeholder Study,TAK-771 Japan CIDP Study,I,Planned,,,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PFP-A1312700,PFP-A1312700,'PFP-A1312700,,HYQVIA,TAK-771 HyQvia - MMN PDT Placeholder Study,TAK-771  HyQvia - MMN Study,I,Planned,Support - Plasma Derived Therapy,Plasma Derived Therapy,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,3/9/2022,,,,,,6/7/2022,,,,3/4/2023,,,,3/7/2028,,,,,,,,,,,,5/2/2028,,,,,,,,,,5/30/2028,,,,,,,,,,,,,,,,,,,,,,,,8/22/2028,,,,,,,,,,,,,,,,8/22/2028,,,,,,,
PFP-A1324700,PFP-A1324700,'PFP-A1324700,,TAK-880 Low IgA,IgG - Low IgA PDT Placeholder Study,TAK-880 IgG - Low IgA Placeholder Study,I,Planned,Primary Immunodeficiency,Plasma Derived Therapy,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PFP-A1344300,PFP-A1344300,'PFP-A1344300,,TAK-882 Inter-Alpha Proteins Inhibitor,BD - Project Pebbles PDT Placeholder Study,TAK-882 SAD/MAD PK Study,I,Planned,Support - Plasma Derived Therapy,Plasma Derived Therapy,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PFP-A1345200,PFP-A1345200,'PFP-A1345200,,CINRYZE,TAK-616 Ischemic Stroke ePOC PDT Placeholder Study,TAK-616 Phase 2/3 Acute Human TBI,II/III,Planned,Support - Plasma Derived Therapy,Plasma Derived Therapy,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PFP-A1345400,PFP-A1345400,'PFP-A1345400,,FEIBA,TAK-666 Acute Human ICH ePOC PDT Placeholder Study,TAK-666 Acute Human ICH ePOC,I,Planned,Hemophilia A,Plasma Derived Therapy,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/30/2021,,6/23/2022,,,,,,12/8/2022,,,,4/1/2024,,,,9/28/2024,,,,,,,,,,,,11/27/2024,,,,,,,,,,1/26/2025,,,,,,,,,,,,,,,,,,,,,,,,3/27/2025,,,,,,,,,,,,,,,,3/27/2025,,,,,,,
REP001a,REP001a,'REP001a,,,A Phase IV Study of Alternative Dosing Regimens of Replagal for Canadian Patients with Fabry Disease.,REP001a - Canadian Study,IV,Completed,Fabry Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,6,0,0,0,0,0,0.60%,999,,,Pharmanet,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/31/2006,3/31/2006,,,,,,,,,,,,,,,,,,,,,,,2/7/2012,2/7/2012,2/7/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
rhASA-01,rhASA-01,'rhASA-01,,,"A single center, open-label, non-randomized, uncontrolled, multiple-dose, dose escalation study of the safety, pharmacokinetics and efficacy of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of patients with late infantile metach","rhASA-01 - OL, Non-Randomized",I,Completed,Metachromatic Leukodystrophy,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,Cyncron A/s,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/27/2008,3/27/2008,3/27/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ROPP-2008-01,ROPP-2008-01,'ROPP-2008-01,,TAK-607 (mecasermin rinfabate),"Determination of the rhIGF-I/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-I Levels within Physiological Levels in Premature Infants, to prevent Retinopathy of Prematurity A Phase II, Randomized Controlled, Assessor-blind, Dose-Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study.",ROP Phase 2,II,Completed,Retinopathy of Prematurity,RGH,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,120,121,0,0,0,121,28,100.83%,25,,,PPD,Clara Kebabian,"Amy Yee, Nedjia Boumediene",,,"Amit Bhatia, Coral Rodriguez, Hemalatha Venkatesh, Janet Warnock, Michele Schrett, Patricia Bak",2007-007872-40,,,N,No,,,,COSMOS Inactive,,,6/8/2014,6/8/2014,8/27/2014,8/27/2014,,,3/19/2015,3/19/2015,3/26/2015,3/26/2015,,,12/31/2015,12/31/2015,,,4/27/2016,4/27/2016,,,,,,,,,,,6/8/2016,6/8/2016,,,,,,,,,6/22/2016,6/22/2016,,,,,,,,,,,,,,,,,,,,,,,9/26/2016,9/26/2016,,,,,,,,,,,,,,,9/26/2016,9/26/2016,,,,,,
SHP429-102,SHP429-102,'SHP429-102,,Lialda (mesalamine),SHP429 Sprinkle study,SHP429 Sprinkle study HV,I,Completed,Ulcerative Colitis,Others,,Non-Registry,,Interventional,Crossover,,,18,0,0,0,0,0,0,0.00%,1,,,,,Jeff Dragone,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP465-3xb,SHP465-3xb,'SHP465-3xb,,,SHP465-3xb Adolescent LT Safety Study,"SHP465-3xb Adlsc, LT, OL, Safety",III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Extension,,,231,0,0,0,0,0,0,0.00%,65,,,,,,,Colleen Anderson,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP465-4xa,SHP465-4xa,'SHP465-4xa,,,SHP465-4xa Adult ADHD Low Dose Efficacy Study,"SHP465-4xa Adlt, DB, Rand, Efficacy",IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Efficacy,,,412,0,0,0,0,0,0,0.00%,65,,,,,,,Colleen Anderson,,,,,N,No,,,,COSMOS Inactive,,,2/2/2018,,3/16/2018,,,,,,7/26/2018,,,,5/25/2020,,,,,,,,,,,,,,7/13/2020,,7/13/2020,,,,,,,,,,,,,,,,,,,,9/2/2020,,10/7/2020,,,,,,,,,,,,12/2/2020,,,,,,,,,,,,,,,,,,,,,,,
SHP465-111,SHP465-111,'SHP465-111,,Mydayis (Mixed Amphetamine Salts),SHP465-111 A phase 1 randomized open label single dose pharmacokinetic study of children diagnosed with ADHD aged 6-17years,SHP465-111 pediatric PK,I,Completed,ADHD,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,Adolescent,,,28,28,36,0,8,28,1,100.00%,3,,,Qps-mra,Debra Ennis,Glenn Frick,,Margo Jaffee,,,,,N,No,,,,COSMOS Inactive,,,6/15/2015,6/15/2015,7/17/2015,7/17/2015,,,10/6/2015,10/6/2015,10/24/2015,10/24/2015,,,11/7/2015,11/7/2015,,,11/10/2015,11/10/2015,,,,,,,,,,,,,,,,,,,,,3/30/2016,3/30/2016,,,,,,,,,,,,,,,,,,,,,,,5/11/2016,5/11/2016,,,,,,,,,,,,,,,5/11/2016,5/11/2016,,,,,,
SHP465-112,SHP465-112,'SHP465-112,,Mydayis (Mixed Amphetamine Salts),"A Phase 1, open-label study of the pharmacokinetics of d- and l-amphetamine after  multiple doses of SHP465 6.25 mg, 12.5 mg, and 25 mg administered to children aged 4 through 5 years with Attention-Deficit Hyperactivity Disorder (ADHD)",SHP465-112 Pediatric PK,I,Completed,ADHD,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,Multi-Centre,,,,24,0,,0,0,2,,10,,,PPD,,"Ashleth Sheth, Brigitte Robertson, Maria Humagain, Ming Yu, Shakay Grenier",,Steven Johnson Jr.,,,Approved for Marketing,,N,No,,,,COSMOS Inactive,15-Feb-19,1/31/2019,,,9/21/2017,9/21/2017,,,,,3/13/2018,3/13/2018,,,9/7/2018,9/7/2018,,,10/5/2018,10/5/2018,,,,,,,,,,,11/16/2018,11/16/2018,,,,,,,,,12/12/2018,12/12/2018,,,,,,,,,,,,,12/5/2018,12/5/2018,,,,,,,,,1/31/2019,1/31/2019,,,,,,,,,,,,,,,1/31/2019,1/31/2019,,,,,,
SHP465-305,SHP465-305,'SHP465-305,,Mydayis (Mixed Amphetamine Salts),SHP465-305 Adolescent Efficacy Study,"SHP465-305 Adlsc, DB, Rand, Efficacy",III,Completed,ADHD,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,Adolescent,,,264,264,338,0,74,0,30,100.00%,40,,,Premier Research,Michelle Durgin,Bao Le,,Margo Jaffee,,,,,N,No,,,,COSMOS Inactive,,,11/21/2014,11/21/2014,4/1/2015,4/1/2015,,,6/12/2015,6/12/2015,6/22/2015,6/22/2015,,,1/11/2016,1/11/2016,,,2/9/2016,2/9/2016,,,,,,,,,,,,,,,,,,,,,3/31/2016,3/31/2016,,,,,,,,,,,,,,,,,,,,,,,7/1/2016,7/1/2016,,,,,,,,,,,,,,,7/1/2016,7/1/2016,,,,,,
SHP465-306,SHP465-306,'SHP465-306,,Mydayis (Mixed Amphetamine Salts),"SHP465-306 Adlt, DB, Rand, Efficacy","SHP465-306 Adlt, DB, Rand, Efficacy",III,Completed,ADHD,NS,Marketed Products,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,258,275,369,0,94,0,38,106.59%,45,,,Premier Research,,Robert Pavia,,,"Ann Sloand, Darren Hilson, David Brockwell, Georgina Perez, Maria Catherine Villegas, Michelle Calcetas, Michelle Shivers, Mimi Renaldo, Nancy Shahdoost, Nicole Dickerson, Orlando Oliveros, Petra Czismadia, Tracey Thompson, Vickie Osteen",,,,N,No,,,,COSMOS Inactive,,,7/7/2015,7/7/2015,8/18/2015,8/18/2015,,,11/19/2015,11/19/2015,11/30/2015,11/30/2015,,,2/25/2016,2/25/2016,,,3/25/2016,3/25/2016,,,,,,,,,,,,,,,,,,,,,6/29/2016,6/29/2016,,,,,,,,,,,,,,,,,,,,,,,10/20/2016,10/20/2016,,,,,,,,,,,,,,,10/20/2016,10/20/2016,,,,,,
SHP465-307,SHP465-307,'SHP465-307,,,"A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-dose , Efficacy and Safety Study of SHP465 in Preschool Children Aged 4-5 Years with Attention-deficit/ Hyperactivity Disorder (ADHD)",SHP465 PWR - Efficacy study,III,Study Terminated,ADHD,,,Non-Registry,Pediatric only (<18 yr),Interventional,Double-Blind,,,60,0,0,0,0,0,0,0.00%,45,,,PPD,,"Ashleth Sheth, Sevag Donabedian, Srikanth Kurra",,"Brigitte Robertson, Richard Sawyer, Victoria Irzhevsky",,,,,N,No,,,,COSMOS Inactive,,,6/2/2017,,9/1/2017,,,,,,2/5/2018,,,,9/24/2018,,,,,,,,,,,,,,10/29/2018,,10/29/2018,,,,,,,,,,,,,,,,,,,,12/11/2018,,1/3/2019,,,,,,,,,,,,2/28/2019,,,,,,,,,,,,,,,,,,,,,,,
SHP465-308,SHP465-308,'SHP465-308,,Mydayis (Mixed Amphetamine Salts),"A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder",SHP465 PWR - OLE study,III,Study Terminated,ADHD,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,Open Label,,,,282,0,,0,0,172,,45,,,Endpoint,,"Frank Sprecher, Richard Sawyer, Samantha Rogers, Shakay Grenier, Steven Johnson Jr., Adam DaSilva, Ashleth Sheth, Atyia Allen",,,,,Not Available,,N,No,,,,COSMOS Inactive,2-Feb-19,5/22/2019,,,9/11/2017,9/11/2017,,,,,1/22/2018,1/22/2018,,,5/9/2018,5/9/2018,,,1/18/2019,1/18/2019,,,,,,,,,,,2/15/2019,2/15/2019,,,,,,,,,,,,,,,,,,,,,,,3/8/2019,3/8/2019,,,,,,,,,6/14/2019,6/14/2019,,,,,,,,,,,,,,,6/14/2019,6/14/2019,,,,,,
SHP465-309,SHP465-309,'SHP465-309,,Mydayis (Mixed Amphetamine Salts),"A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled,  Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit Hyperactivity Disorder (ADHD)",SHP465 PWR,III,Completed,ADHD,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,Placebo-Controlled,,,,89,0,,0,0,6,,45,,,PPD,,"Adam DaSilva, Ashleth Sheth, Frank Sprecher, Katherine Norton, Maria Humagain, Peter Aquino, Samantha Rogers, Sevag Donabedian, Shakay Grenier, Steven Johnson Jr.",,,,,Not Available,,N,No,,,,COSMOS Inactive,12-Dec-18,12/14/2018,,,9/7/2017,9/7/2017,,,,,12/26/2017,12/26/2017,,,5/2/2018,5/2/2018,,,6/8/2018,6/8/2018,,,,,,,,,,,8/21/2018,8/21/2018,,,,,,,,,8/27/2018,8/27/2018,,,,,,,,,,,,,9/21/2018,9/21/2018,,,,,,,,,12/12/2018,12/12/2018,,,,,,,,,,,,,,,12/12/2018,12/12/2018,,,,,,
SHP476-121,SHP476-121,'SHP476-121,,Lialda (mesalamine),Phase 1 2 sequence 4 period cross over bioequavilence study of SPD476 300mg tablets,SHP476-121 BE study of 300mg tablet,I,Completed,Ulcerative Colitis,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Bioequivalence,,,36,36,78,0,0,36,0,100.00%,1,,,PRA,,Colette Jarry,,"Colette Jarry, Joseph Murphy",,,,,N,No,,,,COSMOS Inactive,21-Apr-17,4/21/2017,4/15/2015,4/15/2015,10/31/2016,10/31/2016,,,2/27/2017,2/27/2017,3/13/2017,3/13/2017,,,3/14/2017,3/14/2017,,,4/19/2017,4/19/2017,,,,,,,,,,,,,,,,,,,,,9/11/2017,9/11/2017,,,,,,,,,,,,,,,,,,,,,,,11/27/2017,11/27/2017,,,,,,,,,,,,,,,11/27/2017,11/27/2017,,,,,,
SHP476-122,SHP476-122,'SHP476-122,,Lialda (mesalamine),A phase 1 2 sequence 4 period cross over bioequavilence study of 600mg SPD476,SHP476-122 BE study of 600mg tablet,I,Completed,Ulcerative Colitis,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Bioequivalence,,,36,36,71,0,0,36,1,100.00%,1,,,PRA,,Colette Jarry,,,,,Approved for Marketing,,N,No,,,,COSMOS Inactive,20-Jun-17,6/20/2017,4/15/2015,4/15/2015,10/31/2016,10/31/2016,,,4/27/2017,4/27/2017,5/12/2017,5/12/2017,,,5/15/2017,5/15/2017,,,6/18/2017,6/18/2017,,,,,,,,,,,,,,,,,,,,,9/26/2017,9/26/2017,,,,,,,,,,,,,,,,,,,,,,,3/24/2018,3/24/2018,,,,,,,,,,,,,,,3/24/2018,3/24/2018,,,,,,
SHP476-320,SHP476-320,'SHP476-320,,Lialda (mesalamine),"A Phase 3, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Safety and Efficacy of 2.4g/day versus 4.8g/day of MMX  mesalamine / mesalazine or 4.0g/day ETIASA® (delayed-release mesalamine/mesalazine)",SHP476-320 Adlt Rand DB Efficacy Safety,III,Study Withdrawn,Ulcerative Colitis,Others,,Non-Registry,,Interventional,,,,375,0,0,0,0,0,0,0.00%,25,,,,,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP476-321,SHP476-321,'SHP476-321,,,"A Phase 3, Randomized, Multi-center Study, Double-blind, Parallel Group to Compare the Efficacy and Safety of SPD476 (Mesalazine) 2.4g QD versus SPD476 (Mesalazine) 4.8g QD",SHP476-321 Adlt Rand DB Efficacy Safety,III,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,406,0,0,0,0,0,0,0.00%,125,,,,,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,8/11/2014,,1/21/2015,,,,,,6/24/2015,,,,6/23/2017,,,,,,,,,,,,,,12/22/2017,,12/22/2017,,,,,,,,,,,,,,,,,,,,2/15/2018,,3/19/2018,,,,,,,,,,,,5/14/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP476-322,SHP476-322,'SHP476-322,,Lialda (mesalamine),"A Phase 3, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Safety and Efficacy of 2.4g/day of MMX mesalamine/mesalazine versus a competitor  in Chinese Subjects With Ulcerative Colitis in Remission",SHP476-322 Adlt Rand DB Maint,III,Study Withdrawn,Ulcerative Colitis,Others,,Non-Registry,,Interventional,Comparator,,,250,0,0,0,0,0,0,0.00%,25,,,,Jeff Dragone,,Debra Silberg,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP489-126,SHP489-126,'SHP489-126,,Vyvanse (Lisdexamfetamine dimesylate),SHP489-126 Bioavailability study of the alternative formulation (previously 489-1xx),SHP489-126 Adult HV BE Alt Formulation,I,Completed,ADHD,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Bioequivalence,,,18,18,36,0,0,18,0,100.00%,1,,,"Clinical Pharmacology of Miami, INC",Debra Ennis,,,,,,,,N,No,,,,COSMOS Inactive,,,12/1/2014,12/1/2014,1/12/2015,1/12/2015,,,3/24/2015,3/24/2015,,,,,3/27/2015,3/27/2015,,,4/18/2015,4/18/2015,,,,,,,,,,,,,,,,,,,,,7/15/2015,7/15/2015,,,,,,,,,,,,,,,,,,,,,,,10/1/2015,10/1/2015,,,,,,,,,,,,,,,10/1/2015,10/1/2015,,,,,,
SHP489-127,SHP489-127,'SHP489-127,,Vyvanse (Lisdexamfetamine dimesylate),SHP489-127 fed fasted study of alt formulation,SHP489-127 fed/fast HV Alt formulation,I,Completed,ADHD,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Fed/Fasted,,,18,24,47,0,0,24,1,133.33%,1,,,"Clinical Pharmacology of Miami, INC","Debra Ennis, Heather Van Heusen",,,,,,,,N,No,,,,COSMOS Inactive,,,12/1/2014,12/1/2014,1/12/2015,1/12/2015,,,4/28/2015,4/28/2015,,,,,4/30/2015,4/30/2015,,,5/16/2015,5/16/2015,,,,,,,,,,,,,,,,,,,,,7/22/2015,7/22/2015,,,,,,,,,,,,,,,,,,,,,,,11/6/2015,11/6/2015,,,,,,,,,,,,,,,11/6/2015,11/6/2015,,,,,,
SHP489-128,SHP489-128,'SHP489-128,,Vyvanse (Lisdexamfetamine dimesylate),An Open-Label Sensory Evaluation of SPD489 (VYVANSE¿) in Healthy Panelists,SHP489-128 palatability optimization,I,Completed,ADHD,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,6,7,7,0,0,0,0,116.67%,1,,,PRA,Alexander Tankelevich,"David Duesenberg, Glen Frick",Patrick Martin,Laura McCarthy,,,,,N,No,,,,COSMOS Inactive,,,8/24/2015,8/24/2015,8/28/2015,8/28/2015,,,10/13/2015,10/13/2015,,,,,2/9/2016,2/9/2016,,,2/16/2016,2/16/2016,,,,,,,,,,,,,,,,,,,,,4/19/2016,4/19/2016,,,,,,,,,,,,,,,,,,,,,,,8/8/2016,8/8/2016,,,,,,,,,,,,,,,8/8/2016,8/8/2016,,,,,,
SHP555-3xx,SHP555-3xx,'SHP555-3xx,,,"A 12-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in subjects with chronic constipation who have Parkinson’s disease","Phase 3 Rand, DB, PLC, CC in Parkinson's",III,Study Withdrawn,Chronic Constipation,,,Non-Registry,,Interventional,Double-Blind,,,358,0,0,0,0,0,0,0.00%,60,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/13/2015,,12/17/2015,,,,,,5/5/2016,,,,11/16/2017,,,,,,,,,,,,,,3/21/2019,,3/21/2019,,,,,,,,,,,,,,,,,,,,5/6/2019,,6/10/2019,,,,,,,,,,,,8/5/2019,,,,,,,,,,,,,,,,,,,,,,,
SHP555-308,SHP555-308,'SHP555-308,'TAK-555-3010,Motegrity (Prucalopride),"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Determine the Efficacy and Safety of 2 Different Prucalopride Doses Administered Orally for 12 Weeks to Children and Adolescents, Aged 6 Months to <18 Years, who Fulfill Modified Rome IV Criteria for Child/Adolescent Functional Constipation",Phase 3 Prucalopride-Pediatrics,III,Study Withdrawn,Functional Constipation,Others,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,342,0,0,0,0,0,0,0.00%,70,,,IQVIA,,"Kevin Szwarc, Stephanie Wagner",,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP555-309,SHP555-309,'SHP555-309,'TAK-555-3010,,"A Phase 3, Multicenter, Open-Label, Active Comparator Controlled Study to Assess the Long-term Safety and Tolerability of Prucalopride in Pediatric Patients Aged 6 Months to 18 Years with Functional Constipation who participated in study SHP555-308.",Long-term Safety and Tolerability of Pru,III,Study Withdrawn,Functional Constipation,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Open Label,,,255,0,0,0,0,0,0,0.00%,70,,,,,"Stephanie Wagner, William Van Landegem",,,,,,,N,No,,,,COSMOS Inactive,,,1/1/2049,1/1/2049,1/1/2049,1/1/2049,1/1/2049,1/1/2049,,,1/1/2049,1/1/2049,1/1/2049,1/1/2049,1/1/2049,1/1/2049,,,,,,,,,,,,,1/1/2049,1/1/2049,1/1/2049,1/1/2049,,,,,,,,,,,,,,,,,,,1/1/2049,1/1/2049,1/1/2049,1/1/2049,,,,,,,,,,,1/1/2049,1/1/2049,,,,,,,,,,,,,,,,,1/1/2049,1/1/2049,1/1/2049,1/1/2049,,
SHP602-206,SHP602-206,'SHP602-206,,,"A Phase 2, Multicenter Study to Monitor for the Potential Development of Renal Tumors in Subjects with Transfusional Iron Overload Who Were  Previously Exposed to Deferitazole",SHP602-206 LT FU multi-centre Global,II,Completed,Iron Chelation,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Long-Term,,,105,90,90,0,0,90,90,85.71%,17,,,ICON / MAPI / Paradigm,Alissa Sirbu,Mike Spitz,,,,2014-005086-70,,,N,No,,,,COSMOS Inactive,,10/24/2017,5/14/2014,5/14/2014,8/5/2014,8/5/2014,,,,,3/16/2015,3/16/2015,,,7/31/2016,7/31/2016,,,,,,,,,,,,,5/17/2017,,5/17/2017,,,,,,,,,,,,,,,,,,,,7/19/2017,,8/17/2017,,,,,,,,,,,,10/24/2017,10/24/2017,,,,,,,,,,,,,,,,,,,,,,
SHP606-304,SHP606-304,'SHP606-304,,Xiidra (lifitegrast opthalmic solution),"A Phase 3, Multi-Center, Randomized, Double-Masked, and Placebo-Controlled Study Evaluating the Safety and Efficacy of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye and a Recent History of Artificial Tear Use",OPUS-3,III,Completed,Dry eye,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,700,711,1542,0,831,711,74,101.57%,30,,,"Lexitas Pharma Services, Protrials Research",,,,,,,,,N,No,,,,COSMOS Inactive,,,6/16/2014,6/16/2014,7/11/2014,7/11/2014,,,11/13/2014,11/13/2014,11/26/2014,11/26/2014,,,7/13/2015,7/13/2015,,,10/5/2015,10/5/2015,,,,,,,,,,,,,,,,,,,,,11/20/2015,11/20/2015,,,,,,,,,,,,,,,,,,,,,,,1/8/2016,1/8/2016,,,,,,,,,,,,,,,1/8/2016,1/8/2016,,,,,,
SHP606-305,SHP606-305,'SHP606-305,,Xiidra (lifitegrast opthalmic solution),"A Phase 3,  Randomized, Double-masked, Multicenter,  Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Japanese Adult Subjects with Dry Eye Disease and History of Recent Artificial Tear Use","Phase 3, Multicenter, Randomized, Para",III,Study Withdrawn,Dry eye,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Efficacy,,,626,0,0,0,0,0,0,0.00%,50,,,IQVIA,,"Shivakumar Patil, Csaba Siffel, Mary M Sherman",,,,,,,N,No,,,,COSMOS Inactive,,,11/21/2017,11/21/2017,2/28/2018,2/28/2018,,,9/30/2019,,9/30/2019,,,,8/31/2021,,,,8/31/2021,,,,,,,,,,,,10/29/2021,,,,,,,,,,11/30/2021,,,,,,,,,,,,,,1/31/2022,,,,,,,,,,3/31/2022,,,,,,,,,,,,,,,,3/31/2022,,,,,,,
SHP606-306,SHP606-306,'SHP606-306,,Xiidra (lifitegrast opthalmic solution),"SHP606-306 : A Phase 3, Open-Label, Multicenter Study Evaluating the Long Term Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution in Japanese Adult Subjects with Dry Eye Disease and History of Recent Dry Eye Treatment",Japan Long Term Safety,III,Study Withdrawn,Dry eye,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Safety,,,100,0,0,0,0,0,0,0.00%,55,,,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/26/2018,5/26/2018,9/5/2018,9/5/2018,,,10/31/2019,,10/31/2019,,,,9/30/2020,,,,5/29/2020,,,,,,,,,,,,9/30/2021,,,,,,,,,,9/30/2021,,,,,,,,,,,,,,10/29/2021,,,,,,,,,,1/31/2022,,,,,,,,,,,,,,,,1/31/2022,,,,,,,
SHP606-307,SHP606-307,'SHP606-307,,,SHP606-307: China,SHP606-307,III,Study Withdrawn,Dry eye,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,600,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP606-401,SHP606-401,'SHP606-401,,Xiidra (lifitegrast opthalmic solution),"A Phase 4, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease in a European population",EU Subj w PBO or 606,IV,Study Withdrawn,Dry eye,Others,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,,,,400,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP606-402,SHP606-402,'SHP606-402,,,Post Marketing Surveillance Study for Xiidra® in South Korea,Xiidra South Korea Study,IV,Study Withdrawn,Dry eye,,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,Marketing study,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP606-403,SHP606-403,'SHP606-403,,Xiidra (lifitegrast opthalmic solution),"Post Marketing Committment, European Long Term Efficacy and Safety",EU LT Efficacy 6 Mth Dosing,IV,Study Withdrawn,Dry eye,Others,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,Comparator,,,600,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/31/2020,,6/1/2020,,,,10/16/2020,,10/16/2020,,,,3/1/2022,,,,9/1/2022,,,,,,,,,,,,10/4/2022,,,,,,,,,,10/18/2022,,,,,,,,,,,,,,11/22/2022,,,,,,,,,,12/30/2022,,,,,,,,,,,,,,,,12/30/2022,,,,,,,
SHP606-701,SHP606-701,'SHP606-701,,,PV Monitoring Study for Xiidra in Mexico,Xiidra Mexico PMS Study,IV,Study Withdrawn,Dry eye,,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,PASS (Post Authorization Safety Study),,,"3,000",0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP607-202,SHP607-202,'SHP607-202,,TAK-607 (mecasermin rinfabate),"A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age(CA) Compared to Standard Neonatal Care in Extremely Premature Infants",SHP607-202 (Footprints),II,Recruiting,sGERD/ erosive esophagitis,RGH,RGH,,Pediatric only (<18 yr),Interventional,Treatment,Prospective,Cohort,477,81,81,,,81,16,16.98%,60,61,,PPD,,Charlotte Almeida,Linda Han,"John Germak, Victoria Niklas",,2018-001393-16,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/1/2018,8/1/2018,9/19/2018,9/19/2018,,,5/9/2019,5/9/2019,5/9/2019,5/9/2019,,,8/30/2024,,,,12/29/2025,,,,,,,,,,,,2/23/2026,,,,,,,,,,3/2/2026,,,,,,,,,,,,,,3/23/2026,,,,,,,,,,8/3/2026,,,,,,,,,,,,,,,,8/3/2026,,,,,,,
SHP607-203,SHP607-203,'SHP607-203,,TAK-607 (mecasermin rinfabate),Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants,SHP607-203,II,Recruiting,Chronic Lung Disease,RGH,RGH,,,Observational,,,,382,6,0,,0,0,0,1.57%,64,14,,PPD,,Tina Banks,"Alexandra Mangili, Linda Han",,,2020-002726-84,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/1/2019,8/1/2019,11/18/2019,11/18/2019,,,9/15/2020,9/15/2020,9/15/2020,9/15/2020,,,12/29/2025,,,,12/27/2029,,,,,,,,,,,,2/21/2030,,,,,,,,,,2/28/2030,,,,,,,,,,,,,,3/22/2030,,,,,,,,,,8/30/2030,,,,,,,,,,,,,,,,8/30/2030,,,,,,,
SHP607-301,SHP607-301,'SHP607-301,'SHP607-202,TAK-607 (mecasermin rinfabate),"A Phase 2b/3, Multi-Center, Randomized, Controlled, Open-Label, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Reducing the Risk of Moderate or Severe Bronchopulmonary Dysplasia (BPD) and grade III/IV Intraventricular Hemorrhage (IVH) Compared to Standard Neonatal Care in Extemely Premature Infants",SHP607-301,III,Study Withdrawn,Retinopathy of Prematurity,RGH,,Non-Registry,Pediatric only (<18 yr),Interventional,Open Label,,,"1,053",0,0,0,0,0,0,0.00%,90,,,PPD,,,Alexandra Mangili,"Norman Barton, Rebecca Pyle, Robert Pavia, Linda Han, Emily Jochim",Charlotte Almeida,,,,N,No,,,,COSMOS Inactive,,,6/15/2026,,8/24/2026,,,,,,3/22/2027,,,,3/20/2029,,,,7/16/2030,,,,,,,,,,,,9/10/2030,,,,,,,,,,9/17/2030,,,,,,,,,,,,,,10/8/2030,,,,,,,,,,2/18/2031,,,,,,,,,,,,,,,,2/18/2031,,,,,,,
SHP607-302,SHP607-302,'SHP607-302,,TAK-607 (mecasermin rinfabate),Long-Term Safety and Efficacy Outcomes Following Short-Term Treatment With SHP607 in Extremely Premature Infants,,IIIb,Study Withdrawn,Retinopathy of Prematurity,RGH,,Non-Registry,,Interventional,,,,843,,,,,,,,90,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/14/2027,,8/23/2027,,,,6/26/2028,,,,,,7/16/2030,,,,7/17/2034,,,,,,,,,,,,8/28/2034,,,,,,,,,,9/25/2034,,,,,,,,,,,,,,11/24/2034,,,,,,,,,,1/23/2035,,,,,,,,,,,,,,,,1/23/2035,,,,,,,
SHP609-302,SHP609-302,'SHP609-302,,idursulfase IT (TAK-609),An Open-Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase� in Patients with Hunter Syndrome and Cognitive Impairment.,SHP609-302 Ped LT Safety Extn to HIT-094,III,Recruitment Complete,Schizophrenia / Alzheimer's disease,RGH,RGH,,Pediatric only (<18 yr),Interventional,Treatment,Prospective,Case-Only,56,83,0,,0,0,5,148.21%,9,24,,PPD,,"Steve Gust, Kerri Whyte",,,,2014-004143-13,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,7/28/2014,7/28/2014,10/2/2014,10/2/2014,,,,,4/14/2015,4/14/2015,,,9/27/2017,9/27/2017,,,10/17/2022,,,,,,,,,,,,12/12/2022,,,,,,,,,,12/19/2022,,,,,,,,,,,,,,1/9/2023,,,,,,,,,,5/22/2023,,,,,,,,,,,,,,,,5/22/2023,,,,,,,
SHP610-301,SHP610-301,'SHP610-301,,,SHP610-301,SHP610-301,III,Study Withdrawn,Sanfilippo A Syndrome,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,Nicole Yocum,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP611-201,SHP611-201,'SHP611-201,,arylsulfatase A (TAK-611),"A Phase 2/3 Multicenter, Non-concurrent Control, Open-label Study of SHP611 Administered Intrathecally in Children With Motor Metachromatic Leukodystrophy (MLD)",Pivotal Ped Ph2/3 SHP611-201 OL,IIb,Recruitment Complete,Schizophrenia/ Bipolar,RGH,RGH,,Pediatric only (<18 yr),Interventional,Treatment,Prospective,Cohort,42,51,63,,12,51,3,121.43%,16,31,,PPD,,"Rebekah Gorney, Shannon Mee, Helen Fitch",CJ Malanga,"David Alexanderian, David Whiteman",,,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,6/26/2018,6/26/2018,8/23/2018,8/23/2018,,,5/13/2019,5/13/2019,5/23/2019,5/23/2019,,,2/25/2021,2/25/2021,,,3/10/2023,,,,,,,,3/10/2025,,,,4/7/2023,,,,,,,,4/7/2025,,4/14/2023,,,,,,,,,,,,,,5/5/2023,,,,,,,,,,6/30/2023,,,,,,,,6/23/2025,,,,,,,,6/23/2025,,,,,,,
SHP611-202,SHP611-202,'SHP611-202,,,Juvenile MLD Ph III Trial,Infantile extension,III,Study Withdrawn,Metachromatic Leukodystrophy,,RGH,Non-Registry,Pediatric only (<18 yr),Interventional,,,,35,,,,,,,,999,,,PPD,Helen Fitch,,,,,,,,N,No,,,,COSMOS Inactive,,,1/31/2020,,2/21/2020,,,,,,2/28/2022,,2/28/2022,,5/19/2023,,,,,,,,,,,,,,5/16/2025,,5/16/2025,,,,,,,,,,,,,,,,,,,,6/27/2025,,6/27/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP613 Vascugel AVF-01,SHP613 Vascugel AVF-01,'SHP613 Vascugel AVF-01,,,"A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access",SHP613-AVF01 Rand SD,II,Completed,Vascular Repair,,,Non-Registry,,Interventional,Efficacy,,,192,64,0,0,0,64,0,33.33%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/16/2012,7/16/2012,11/28/2012,11/28/2012,,,,,3/28/2013,3/28/2013,3/18/2013,3/18/2013,4/18/2014,4/18/2014,,,,,,,,,,,,,10/27/2014,10/27/2014,10/27/2014,,,,,,,,,,,,,,,,,,,,3/24/2015,,5/13/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP613 Vascugel AVG-01,SHP613 Vascugel AVG-01,'SHP613 Vascugel AVG-01,,,"A Phase 2, Single-blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in the Treatment of Subjects With Vascular Injury Resulting From Arteriovenous Graft Surgery for Hemodialysis Access",SHP613-AVG01 Rand SD,II,Completed,Vascular Repair,,,Non-Registry,,Interventional,Efficacy,,,200,32,0,0,0,32,0,16.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/16/2012,7/16/2012,11/28/2012,11/28/2012,,,,,4/17/2013,4/17/2013,4/17/2013,4/17/2013,4/11/2014,4/11/2014,,,,,,,,,,,,,10/21/2014,10/23/2014,10/21/2014,,,,,,,,,,,,,,,,,,,,3/24/2015,,5/13/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP615-101,SHP615-101,'SHP615-101,,,"Open-label, Two-Period Crossover Study to Assess PK, Safety, and Tolerability of Single 5 mg Oromucosal Dose of Midazolam Hydrochloride  (Buccolam) and Single 5 mg Intravenous Dose of Midazolam Hydrochloride in Healthy Japanese and Caucasian Adult Volunteers.",SHP615-101 OL Cross over PK,I,Study Withdrawn,Acute Convulsive Seizures,,,Non-Registry,,Interventional,Open Label,,,24,0,0,0,0,0,0,0.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/1/2016,,12/12/2016,,,,,,3/1/2017,,,,3/28/2017,,,,,,,,,,,,,,4/25/2017,,4/25/2017,,,,,,,,,,,,,,,,,,,,7/31/2017,,7/27/2017,,,,,,,,,,,,9/21/2017,,,,,,,,,,,,,,,,,,,,,,,
SHP615-102,SHP615-102,'SHP615-102,,Buccolam (Midazolam),"A 3-period Crossover Study, in Healthy Volunteers, to Assess the Relative Bioavailability for the SHP615 Midazolam Buccal Formulation (5 mg) Compared to Oral (5 mg) and Intravenous Formulations (5 mg) of Midazolam",SHP615-102 HV BA Study,I,Planned,Status epilepticus,NS,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,18,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP615-301,SHP615-301,'SHP615-301,,Buccolam (Midazolam),"A Multi-center, Open-label, Single-dose, Phase 3 Study of SHP615 Buccally Administered to Pediatric Subjects (aged 3 months to =18 years) with Status Epilepticus (Convulsive)",SHP615-301 OL Japan SE,III,Completed,Acute Convulsive Seizures,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,,,,25,23,0,,57,0,,92.00%,25,,ViroPharma,IQVIA,Iris Culbert,Simone Gruppuso,,"Brigitte Robertson, Carol Crovisier",,,,,N,Yes,,,,COSMOS Inactive,18-Feb-20,1/9/2020,8/25/2016,8/25/2016,1/23/2017,1/23/2017,,,10/23/2017,10/23/2017,11/24/2017,11/24/2017,,,7/25/2019,7/25/2019,,,8/2/2019,8/2/2019,,,,,,,,,,,9/19/2019,9/19/2019,,,,,,,,,10/29/2019,10/29/2019,,,,,,,,,,,,,10/29/2019,10/29/2019,,,,,,,,,1/9/2020,1/9/2020,,,,,,,,,,,,,,,1/9/2020,1/9/2020,,,,,,
SHP615-302,SHP615-302,'SHP615-302,,Buccolam (Midazolam),"An Open-label, Single-dose, Phase 3 Study of SHP615 Buccally Administered to Pediatric Subjects (aged 6 months to =18 years) with Status Epilepticus (Convulsive) in Community Setting: Extension to Study SHP615-301 in the hospital or emergency room",SHP615-302 OL Japan SE Ext,III,Completed,Acute Convulsive Seizures,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,,,,6,3,0,,9,1,,50.00%,25,,ViroPharma,IQVIA,Iris Culbert,"Simone Gruppuso, Ann Gooding",,"Carol Crovisier, Holly Oakley, Martha Fournier",,,,,N,No,,,,COSMOS Inactive,,,9/2/2016,9/2/2016,3/10/2017,3/10/2017,,,5/24/2018,5/24/2018,5/25/2018,5/25/2018,,,1/10/2020,1/10/2020,,,8/31/2019,8/31/2019,11/22/2019,11/22/2019,,,,,1/17/2020,1/17/2020,,,9/19/2019,9/19/2019,12/20/2019,12/20/2019,,,,,10/30/2020,10/30/2020,11/5/2019,11/5/2019,,,,,,,11/25/2020,11/25/2020,,,,,11/5/2019,11/5/2019,2/10/2020,2/10/2020,,,,,11/25/2020,11/25/2020,1/9/2020,1/9/2020,,,,,,,1/29/2021,1/29/2021,1/31/2020,1/31/2020,,,,,1/29/2021,1/29/2021,,,,,,
SHP615-303,SHP615-303,'SHP615-303,,Buccolam (Midazolam),"A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in the Hospital or Emergency Room",SHP615-303 US pre-hosp,III,All Activities Closed,,NS,,,Pediatric only (<18 yr),Interventional,,,,458,,,,,,,,25,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP615-304,SHP615-304,'SHP615-304,,Buccolam (Midazolam),"A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in Community Settings",SHP615-304 US community,III,All Activities Closed,,NS,,,Pediatric only (<18 yr),Interventional,,,,50,,,,,,,,80,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP616-102,SHP616-102,'SHP616-102,,,"A  Pharmacokinetic,  tolerability and Safety Study to evaluate ease of subcutaneous injection administration of CINRYZE® with and without recombinant human hyaluronidase (rHuPH20) in healthy volunteers",SHP616-102: SC w/ & w/o rHuPH20,I,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,56,53,0,0,0,0,0,94.64%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,6/10/2013,,,,,,6/21/2013,,,,8/30/2013,,,,,,,,,,,,,,9/27/2013,,9/27/2013,,,,,,,,,,,,,,,,,,,,11/28/2013,,6/17/2014,,,,,,,,,,,,7/15/2014,,,,,,,,,,,,,,,,,,,,,,,
SHP616-103,SHP616-103,'SHP616-103,'0624-710,CINRYZE,"A PHASE 1, RANDOMIZED,  SINGLE DOSE, CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND RELATIVE BIOAVAILABILITY OF SUBCUTANEOUS ADMINISTRATION OF C1 ESTERASE INHIBITOR (HUMAN) LIQUID FOR INJECTION IN HEALTHY VOLUNTEERS FOLLOWING AN INITIAL ASSESSMENT USING THE MARKETED IV FORMULATION",SHP616-103 (0624-710) PK BA of SC Admin,I,Completed,Hereditary Angioedema (HAE),Plasma Derived Therapy,,Non-Registry,,Interventional,,,,26,26,0,0,0,23,0,100.00%,1,,ViroPharma,PRA,,"Carrie Kopec, Wendy Fisher, Eric Brown, Laura Smith",,,,,,,N,No,,,,COSMOS Inactive,,,5/19/2014,5/19/2014,7/29/2014,7/29/2014,,,1/7/2015,1/7/2015,1/28/2015,1/28/2015,,,1/28/2015,1/28/2015,,,4/10/2015,4/10/2015,,,,,,,,,,,,,,,,,,,,,6/26/2015,6/26/2015,,,,,,,,,,,,,,,,,,,,,,,8/14/2015,8/14/2015,,,,,,,,,,,,,,,8/14/2015,8/14/2015,,,,,,
SHP616-104,SHP616-104,'SHP616-104,'0624-901,,"A Phase 1, Single-dose, 2-Period, Randomized, Open-label, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Intravenous Formulations of C1 esterase inhibitor [human] in Healthy Adult Subjects.",SHP616-104 (0624-910) PK of IV Admin,I,Study Withdrawn,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,36,0,0,0,0,0,0,0.00%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/19/2014,,9/4/2014,9/4/2014,,,,,2/19/2015,,,,2/25/2015,,,,,,,,,,,,,,4/24/2015,,4/24/2015,,,,,,,,,,,,,,,,,,,,7/31/2015,,8/14/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP616-201,SHP616-201,'SHP616-201,'0624-201,,"A Randomized, DOUBLE-BLIND, PLACEBO-CONTROLLED Pilot Study to Evaluate the Safety AND EFFect of CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) for the treatment of ACUTE antibody-mediated rejection in Recipients of donor-sensitized kidney transplants",0624-201 AMR Safety and Efficacy,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,20,18,0,0,0,0,0,90.00%,6,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,5/18/2010,,,,,,7/6/2011,,,,6/28/2013,,,,,,,,,,,,,,3/14/2012,,3/14/2012,,,,,,,,,,,,,,,,,,,,9/12/2013,,4/3/2014,,,,,,,,,,,,8/6/2014,,,,,,,,,,,,,,,,,,,,,,,
SHP616-206,SHP616-206,'SHP616-206,'0624-206,,"A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Administration of CINRYZE® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema",0624-206 HAE Safety and Efficacy,II,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,36,51,0,0,0,0,0,141.67%,40,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,1/16/2012,1/16/2012,,,,,2/4/2013,2/4/2013,,,5/16/2013,5/16/2013,,,,,,,,,,,,,8/30/2013,8/30/2013,8/30/2013,11/7/2013,,,,,,,,,,,,,,,,,,,11/7/2013,11/7/2013,4/21/2013,4/21/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP616-211,SHP616-211,'SHP616-211,,,C1 esterase inhibitor (CINRYZE®) for the Treatment of Acute Relapse in Neuromyelitis Optica Spectrum Disorders (NMOSD),SHP616-211 RAND DB PCB NMOSD,II,Study Withdrawn,NMOSD,,,Non-Registry,,Interventional,Double-Blind,,,105,0,0,0,0,0,0,0.00%,45,,,,,Megan Teynor,,,,,,,N,No,,,,COSMOS Inactive,,,4/1/2016,,4/1/2016,,,,,,9/5/2016,,,,9/4/2017,,,,,,,,,,,,,,12/3/2017,,12/3/2017,,,,,,,,,,,,,,,,,,,,1/16/2018,,2/20/2018,,,,,,,,,,,,4/17/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP616-300,SHP616-300,'SHP616-300,,CINRYZE,"A Ph3, rand, db, pcb controlled, 2-period, partial x-over study to evaluate the safety and efficacy of sc admin of 2000U of C1 esterase inhibitor [human] liquid for injection for the prevention of angioedema attacks in adolescents and adults w HAE","616-300 DB, PCB, x-over,Safety Efficacy",III,Completed,Hereditary Angioedema,Plasma Derived Therapy,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Double-Blind,,,,75,0,,0,0,17,,40,,,PPD,,"Nedjia Boumediene, Pooja Parulkar, Anthony Baiamonte",,,,,,,N,No,,,,COSMOS Inactive,,,9/8/2014,9/8/2014,5/28/2015,5/28/2015,,,12/17/2015,12/17/2015,1/8/2016,1/8/2016,,,12/5/2016,12/5/2016,,,7/24/2017,7/24/2017,,,,,,,,,,,8/23/2017,8/23/2017,,,,,,,,,9/1/2017,9/1/2017,,,,,,,,,,,,,9/25/2017,9/25/2017,,,,,,,,,12/12/2017,12/12/2017,,,,,,,,,,,,,,,12/12/2017,12/12/2017,,,,,,
SHP616-301,SHP616-301,'SHP616-301,'0624-301,CINRYZE,"A PHASE 3, MULTICENTER, RANDOMIZED, SINGLE-BLIND,  DOSE-RANGING CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY  OF  INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN CHILDREN 6  TO 11 YEARS OF AGE WITH HEREDITARY ANGIOEDEMA",0624-301 HAE Ped,III,Completed,Hereditary Angioedema (HAE),Plasma Derived Therapy,,Non-Registry,Pediatric only (<18 yr),Interventional,Crossover,,,12,12,16,0,4,12,0,100.00%,10,,ViroPharma,Chiltern,,"Laura McCarthy, Alan Clark, Gloria Gamba",,,,2013-002453-29,,,N,No,,,,COSMOS Inactive,,5/4/2017,,,8/7/2013,8/7/2013,,,3/20/2014,3/20/2014,6/17/2014,6/17/2014,,,7/12/2016,7/12/2016,,,,,,,,,,,5/4/2017,5/4/2017,,,,,,,,,,,6/1/2017,6/1/2017,,,,,,,,,6/16/2017,6/16/2017,,,,,,,,,,,,,6/30/2017,6/30/2017,11/25/2015,11/25/2015,,,,,,,9/22/2017,9/22/2017,,,,,,,9/22/2017,9/22/2017,,,,,,
SHP616-302,SHP616-302,'SHP616-302,,CINRYZE,A randomized double-blind placebo-controlled study to evaluate the safety & efficacy of Cinryze for the treatment of acute antibody-mediated rejection in kidney transplant patients with identified donor-specific antibody,SHP616-302 AMR Safety and Efficacy,III,Study Terminated,AMR,Plasma Derived Therapy,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,,41,0,,0,0,41,,40,1,,PPD,Lee Hughes,"Aimee Sunberg, Anthony Baiamonte, Giovanna Devercelli, Ishan Hirji, Lee Hughes, Maria Ignacia Berraondo, Megan Teynor, Obi Umeh, Patrick Kelly",,,"Ayanna Sissoko, Abida Mazin, Al-Karim Khimji, Alexia Ngassaki, Angela Scalzo, Anne Grimaldi, Ryan Guthrie, Sandra Escobar, Silvia Ronconi, Tift Tounsley, Vera Uhrle, Boicho Miloshov, Carrie Mishoe, Deepika Sharma, Elena Sopelana Matamoros, Emmy Wouters, Eric Stelk, Fiona Law, Gene Dillague, Geoffrey Hinchliffe, Lian Smink, Lisa Heckenmuller, Magali Rouquie, Maria Guerrero, Marjet Munsters, Matthieu Vesque, Mavis Ye, Nicole Hagenson-Gordon, Oneke Mfonfu, Pam Dondelinger, Monique Mets, Nathalie Oussoren",2015-000726-11,Not Available,,N,No,,,,COSMOS Inactive,31-May-19,5/31/2019,10/10/2014,10/10/2014,3/26/2015,3/26/2015,,,,,5/20/2016,5/20/2016,,,11/30/2020,,,,1/11/2019,1/11/2019,,,,,,,,,,,,,,,,,,,,,4/30/2019,4/30/2019,,,,,,,,,,,,,,,,,,,,,,,1/8/2020,1/8/2020,,,,,,,,,,,,,,,4/24/2026,,,,,,,
SHP616-303,SHP616-303,'SHP616-303,,,"A Phase III, Randomized, Double-blind, Placebo-controlled, multicenter Study to Evaluate the Efficacy and Safety of C1 Esterase Inhibitor [human] (CINRYZE®) for the Treatment of Acute Relapse of Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica Spectrum Disorders (NMOSD)","SHP616-303 Adlt, RAND, DB, PCB",III,Study Withdrawn,NMOSD,,,Non-Registry,,Interventional,Double-Blind,,,78,0,0,0,0,0,0,0.00%,40,,,,Pooja Parulkar,,Steven Glyman,Jeffrey Bernier,,,,,N,No,,,,COSMOS Inactive,,,1/5/2015,2/13/2015,7/10/2015,,,,,,1/5/2016,,1/1/2016,,1/23/2017,,,,,,,,,,,,,,4/24/2017,,4/24/2017,,,,,,,,,,,,,,,,,,,,6/13/2017,,6/20/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP616-401,SHP616-401,'SHP616-401,'0624-401,,"A European multi-center, multi-country, post-authorisation, observational study (registry) of patients with hereditary angioedema (HAE) who are administered CINRYZE (C1 inhibitor (human)) for the treatment or prevention of HAE attacks",0624-401: EU Registry,IV,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Non-Interventional_CDO Support,PASS (Post Authorization Safety Study),,,125,83,55,0,0,0,9,66.40%,22,,ViroPharma,Cromsource,,"Aizza Hassan, Amandine Perrin, Andrew Sabo, Jennifer Buynitzky, Scott Newcomer, Sophie Berube, Zhenmin Lu",,,,,,,N,No,,,,COSMOS Inactive,,,7/10/2011,7/10/2011,8/10/2011,8/10/2011,,,,,5/11/2012,5/11/2012,,,9/25/2015,9/25/2015,,,,,,,,,,,,,9/25/2016,9/25/2016,9/25/2016,,,,,,,,,,,,,,,,,,,,2/25/2017,,1/28/2016,,,,,,,,,,,,2/8/2017,2/8/2017,,,,,,,,,,,,,,,,,,,,,,
SHP616-PNH1,SHP616-PNH1,'SHP616-PNH1,,,PNH-multiple rising dose,SHP616-PNH-1,I,Study Withdrawn,Hereditary Angioedema,,,Non-Registry,,Interventional,,,,6,0,0,0,0,0,0,0.00%,6,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/13/2015,,8/24/2015,,,,,,12/9/2015,,,,8/17/2016,,,,,,,,,,,,,,9/14/2016,,9/14/2016,,,,,,,,,,,,,,,,,,,,12/20/2016,,12/16/2016,,,,,,,,,,,,2/10/2017,,,,,,,,,,,,,,,,,,,,,,,
SHP617-100,SHP617-100,'SHP617-100,,,"A Phase 1, randomized, open-label, 4-period crossover, single-dose study to evaluate the safety, tolerability, and pharmacokinetics of VP10918 (hydrocortisone) extended release tablets, manufactured at 2 different sites, administered orally in healthy Japanese and Caucasian volunteers",10918-100: Pilot PK,I,Completed,Adrenal Insufficiency,,,Non-Registry,,Interventional,,,,32,31,0,0,0,0,0,96.88%,1,,ViroPharma,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,9/11/2013,9/11/2013,,,,,11/14/2013,11/14/2013,,,12/3/2013,12/3/2013,,,,,,,,,,,,,12/21/2013,12/21/2013,12/21/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP617-301,SHP617-301,'SHP617-301,,Plenadren (hydrocortisone),"An open, multi-centre, phase IIIb, long term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency",SHP617-301  - DC0801 - OL extension,III,Completed,Adrenal Insufficiency,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Safety,,,71,85,0,0,0,0,0,119.72%,5,,ViroPharma,Irw Consulting Ab,,,,Danielle Tierens,,,,,N,No,,,,COSMOS Inactive,,,1/17/2008,1/17/2008,2/28/2008,2/28/2008,,,6/12/2008,6/12/2008,10/3/2008,10/3/2008,,,1/28/2009,1/28/2009,,,6/12/2009,6/12/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/7/2014,7/7/2014,,,,,,,,,1/19/2015,1/19/2015,,,,,,,,,,,,,,,1/19/2015,1/19/2015,,,,,,
SHP617-400,SHP617-400,'SHP617-400,,Plenadren (hydrocortisone),"A EUROPEAN MULTI-CENTRE, MULTI-COUNTRY,POST-AUTHORISATION, OBSERVATIONAL STUDY (REGISTRY) OF PATIENTS WITH CHRONIC ADRENAL INSUFFICIENCY",SHP617-400 EU AIRegistry - PAC,IV,Completed,Adrenal Insufficiency,Others,Real World Evidence,,Both pediatric and non-pediatric,Observational,Other,Prospective,Other,"3,000","3,258",0,,0,0,502,108.60%,20,21,,PPD,,Ali Aslan,Hilary Kaube,Heinrich Achenbach,,,,,,,,,,Medidata CTMS (Pharma),,,2/16/2012,2/16/2012,3/16/2012,3/16/2012,,,8/7/2012,8/7/2012,8/7/2012,8/7/2012,,,10/31/2020,,,,10/31/2020,,,,,,,,,,,,,,,,,,,,,,11/26/2021,,,,,,,,,,,,,,,,,,,,,,,,3/31/2022,,,,,,,,,,,,,,,,4/5/2022,,,,,,,
SHP617-701,SHP617-701,'SHP617-701,,,Resource use and clinical outcomes in patients with adrenal insufficiency prescribed either an immediate release or modified release hydrocortisone formulation or prednisolone: A THIN (The Health Improvement Network) database study,SHP617-701 THIN PLENADREN,IV,Study Withdrawn,Adrenal Insufficiency,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,1,,ViroPharma,,Kamran Iqbal,,Kamran Iqbal,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP620-111,SHP620-111,'SHP620-111,,,"An Open-label, Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]SHP620 Following a Single Oral Dose in Healthy Male Subjects",SHP620-111 ADME,I,Study Withdrawn,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Drug Metabolism Pharmacokinetics (DMPK),,,8,0,0,0,0,0,0,0.00%,1,,,,"Joseph Murphy, Robert Homolka",,,,,,,,N,No,,,,COSMOS Inactive,,,9/15/2017,,10/30/2017,,,,,,2/17/2018,,,,2/17/2018,,,,,,,,,,,,,,3/4/2018,,3/4/2018,,,,,,,,,,,,,,,,,,,,6/7/2018,,6/5/2018,,,,,,,,,,,,7/31/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP620-112,SHP620-112,'SHP620-112,,,"A Phase 1, Open-label, Randomized, Two-period, Crossover Drug Interaction Study Evaluating the Effect of SHP-620 on the Pharmacokinetic Profiles of Various CYP Probe Substrates in the Cooperstown Cocktail when Given to Healthy Adult Subjects",SH620-112 Cocktail DDI,I,Study Withdrawn,CMV Treatment,,,Non-Registry,,Interventional,Drug Interaction,,,30,0,0,0,0,0,0,0.00%,1,,,,Robert Homolka,,,,,,,,N,No,,,,COSMOS Inactive,,,4/3/2015,,5/14/2015,,,,,,8/26/2015,,,,8/26/2015,,,,,,,,,,,,,,9/14/2015,,9/14/2015,,,,,,,,,,,,,,,,,,,,12/4/2015,,12/4/2015,,,,,,,,,,,,1/29/2016,,,,,,,,,,,,,,,,,,,,,,,
SHP620-113,SHP620-113,'SHP620-113,,,"A Phase 1, Open-label, Randomized, 2-Period Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SHP620 Administered Alone and in Combination with Clarithromycin in Healthy Adult Subjects",SHP620-113 DDI with Clarithromycin,I,Study Withdrawn,CMV Treatment,,,Non-Registry,,Interventional,Drug Interaction,,,30,0,0,0,0,0,0,0.00%,1,,,,Robert Homolka,,,,,,,,N,No,,,,COSMOS Inactive,,,4/3/2015,,5/14/2015,,,,,,7/29/2015,,,,7/29/2015,,,,,,,,,,,,,,8/17/2015,,8/17/2015,,,,,,,,,,,,,,,,,,,,10/22/2015,,11/10/2015,,,,,,,,,,,,1/19/2016,,,,,,,,,,,,,,,,,,,,,,,
SHP620-114,SHP620-114,'SHP620-114,,,SHP620-114 DDI Midazolam,SHP620-114 DDI Midazolam,I,Study Withdrawn,CMV Treatment,,,Non-Registry,,Interventional,Drug Interaction,,,20,0,0,0,0,0,0,0.00%,1,,,,Joseph Murphy,,,Robert Homolka,,,,,N,No,,,,COSMOS Inactive,,,2/29/2016,,3/30/2016,,,,,,5/23/2016,,,,5/23/2016,,,,,,,,,,,,,,6/20/2016,,6/20/2016,,,,,,,,,,,,,,,,,,,,8/24/2016,,8/29/2016,,,,,,,,,,,,10/8/2016,,,,,,,,,,,,,,,,,,,,,,,
SHP620-115,SHP620-115,'SHP620-115,,maribavir (TAK-620),"A Phase 1, Open-label, 2-Period Fixed-Sequence Study to Evaluate the Effect of Multiple-Doses of SHP620 on the Pharmacokinetic Profile of Digoxin, a P-glycoprotein Substrate, and Dextromethorphan, a CYP2D6 Substrate, in Healthy Adult Subjects",SHP620-115 PgP Inhib with Digoxin,I,Completed,CMV Treatment,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Drug Interaction,,,18,18,0,0,0,0,1,100.00%,1,,,"Clinical Pharmacology of Miami, INC","Joseph Murphy, Robert Homolka",Jeff Wang,,"Anna Wijatyk, Karen Hager, Obi Umeh",,,,,N,No,,,,COSMOS Inactive,,,12/15/2015,12/15/2015,2/18/2016,2/18/2016,,,8/16/2016,8/16/2016,8/16/2016,8/16/2016,,,8/31/2016,8/31/2016,,,9/9/2016,9/9/2016,,,,,,,,,,,,,,,,,,,,,1/9/2017,1/9/2017,,,,,,,,,,,,,,,,,,,,,,,4/27/2017,4/27/2017,,,,,,,,,,,,,,,4/27/2017,4/27/2017,,,,,,
SHP620-116,SHP620-116,'SHP620-116,,,SHP620-116 2D6 DDI,SHP620-116 DDI 2D6,I,Study Terminated,CMV Treatment,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/4/2016,,8/3/2016,,,,,,11/1/2016,,,,12/8/2016,,,,,,,,,,,,,,12/19/2016,,12/19/2016,,,,,,,,,,,,,,,,,,,,2/21/2017,,2/22/2017,,,,,,,,,,,,4/13/2017,,,,,,,,,,,,,,,,,,,,,,,
SHP620-117,SHP620-117,'SHP620-117,,,"A Phase 1, Open-label, Randomized, Three-way Crossover, Bioavailability Study Comparing the Pharmacokinetics of Two Prototype 400mg Strength Maribavir Formulations to the Phase 3 200mg Strength Maribavir Tablet Formulation Administered as a Single 400mg Dose in Healthy Adult Subjects",SHP620-117 Bioavailability Study,I,Study Withdrawn,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Bioavailability (BA),,,18,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/1/2049,,1/1/2049,,1/1/2049,,,,1/1/2049,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,1/1/2049,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
SHP620-118,SHP620-118,'SHP620-118,,,An Open-Label Sensory Evaluation of Maribavir in Healthy Panelists,SHP620-118 Taste Assessment,I,Completed,CMV Treatment,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Healthy Volunteers,,,10,0,0,0,0,0,0,0.00%,1,,,,"Gaia Sciaranghella, Joseph Murphy","Obi Umeh, Alida Barry",Katarina Ilic,Karen Hager,Ella Rabiu,,,,N,No,,,,COSMOS Inactive,,,7/31/2017,,10/13/2017,,,,,,1/22/2018,,,,2/21/2018,,,,,,,,,,,,,,2/21/2018,,2/21/2018,,,,,,,,,,,,,,,,,,,,3/9/2018,,3/9/2018,,,,,,,,,,,,3/9/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP620-202,SHP620-202,'SHP620-202,,maribavir (TAK-620),"A Phase 2, Randomized Study To Assess The Safety And Anti-Cytomegalovirus (CMV) Activity Of Different Doses Of Maribavir For Treatment Of CMV Infections That Are Resistant Or Refractory To Treatment With Ganciclovir/Valganciclovir Or Foscarnet In Transplant Recipients",SHP620-202 DR Resistant/Refractory CMV,II,Completed,CMV Treatment,RGH,,Non-Registry,,Interventional,Dose-Ranging,,,120,120,130,0,10,120,0,100.00%,32,,,,Calista Gauthier,Charles Kennedy,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP620-203,SHP620-203,'SHP620-203,'1263-203,maribavir (TAK-620),"A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE (EU ONLY)",SHP620-203 DR Asymptomatic CMV,II,Completed,CMV Treatment,RGH,,Non-Registry,,Interventional,Dose-Ranging,,,161,161,175,0,14,161,21,100.00%,48,,ViroPharma,PPD,,Dieudonne Bwirire,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP620-300,SHP620-300,'SHP620-300,,,Phase 3 - CMV prophylaxis study (1263-300),Phase 3-CMV prophylaxis study (620-300),II,Study Terminated,CMV Treatment,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP620-302,SHP620-302,'SHP620-302,,maribavir (TAK-620),"A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of SHP620 Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Stem Cell Transplant Recipients",SHP620-302 Asymptomatic CMV Treatment,III,Recruiting,Severe asthma,RGH,RGH,,Both pediatric and non-pediatric,Interventional,,,,550,487,579,2,90,488,190,88.55%,105,113,,PPD,,"Alexandra Loew-Baselli, Anoop Singh, Gilles Pierrefiche, Hai Fang, Ildiko Fuelep, Ishan Hirji, Jose Ramon Gonzalez, Martina Lejon, Norbert Vincze, Takashi Yamasaki, Calista Gauthier, Adewale Fashina","Martha Fournier, Rose Ann Murray, Tatjana Odrljin",,,2015-004726-34,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,5/16/2016,5/16/2016,8/4/2016,8/4/2016,,,4/14/2017,4/14/2017,4/14/2017,4/14/2017,,,12/31/2021,,,,5/20/2022,,,,,,,,,,,,6/22/2022,,,,,,,,,,6/27/2022,,,,,,,,,,,,,,8/4/2022,,,,,,,,,,9/29/2022,,,,,,,,,,,,,,,,9/29/2022,,,,,,,
SHP620-303,SHP620-303,'SHP620-303,,maribavir (TAK-620),"A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of SHP620 Compared to Standard of Care for the Treatment of Cytomegalovirus (CMV) Infections that are Resistant or Refractory to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir in Transplant Recipients",SHP620-303 Resist/Refract CMV Treatment,III,Reported,Post-Transplant CMV,RGH,RGH,,Both pediatric and non-pediatric,Interventional,,,,351,349,428,4,79,352,74,99.43%,100,4,,PPD,,"Anoop Singh, Claudia Kolligs, Gilles Pierrefiche, Jose Ramon Gonzalez, Martina Lejon, Safwan Abbassy, Takashi Yamasaki, Adriana Shelton",,,,2015-004725-13,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,12/15/2015,12/15/2015,4/28/2016,4/28/2016,,,12/22/2016,12/22/2016,12/29/2016,12/29/2016,,,3/26/2020,3/26/2020,,,8/17/2020,8/17/2020,,,,,,,,,,,11/13/2020,11/13/2020,,,,,,,,,11/23/2020,11/23/2020,,,,,,,,,,,,,12/30/2020,12/30/2020,,,,,,,,,2/26/2021,2/26/2021,,,,,,,,,,,,,,,2/26/2021,2/26/2021,,,,,,
SHP620-801,SHP620-801,'SHP620-801,,,"Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs Among Solid Organ or Stem Cell Transplate Patients with Cytomegalovirus Infection/Disease",CMV Treatment Patterns & HCRU (US),N/A,Completed,CMV Treatment,,,Non-Registry,,Non-Intervention_Other Support,,,,999,0,0,0,0,0,0,0.00%,999,,,"Analysis Group, Inc.",Ishan Hirji,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/28/2018,8/28/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/15/2019,3/15/2019,,,,,,,,,,,4/30/2019,4/30/2019,,,,,,,,,,,,,,,,,,,,,,
SHP621-3Xc,SHP621-3Xc,'SHP621-3Xc,,,"Oral Budesonide Suspension (OBS) in Adolescents and Adult subjects with Eosinophilic Esophagitis: OL, 6 months treatment",SHP621-3Xc LT OL,III,Study Withdrawn,Eosinophilic Esophagitis (EoE),,,Non-Registry,,Interventional,Long-Term,,,195,0,0,0,0,0,0,0.00%,75,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP621-101,SHP621-101,'SHP621-101,,budesonide (TAK-721),"A Phase 1, Open-label, Randomized, Two-Sequence, Five-Period, Crossover Study Comparing the Pharmacoinetics of Four Budesonde Oral Suspension Formulations (BOS) and Entocort EC in Healthy Adults","SHP621-101 BA, HV",I,Completed,Eosinophilic Esophagitis (EoE),GI,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Bioavailability (BA),,,22,0,,0,0,0,0,0.00%,1,,,,,Debra Ennis,Richard Finkelman,,,,,,N,No,,,,COSMOS Inactive,,,3/13/2017,3/13/2017,5/22/2017,5/22/2017,,,11/8/2017,11/8/2017,11/8/2017,11/8/2017,,,11/8/2017,11/8/2017,,,11/26/2017,11/26/2017,,,,,,,,,,,1/22/2018,1/22/2018,,,,,,,,,3/5/2018,3/5/2018,,,,,,,,,,,,,,,,,,,,,,,4/26/2018,4/26/2018,,,,,,,,,,,,,,,4/26/2018,4/26/2018,,,,,,
SHP621-102,SHP621-102,'SHP621-102,,budesonide (TAK-721),An Open-Label Taste Assessment of Oral Viscous Budesonide in Healthy Patients,Sensory Evaluation in Healthy Panelists,I,Completed,Eosinophilic Esophagitis (EoE),GI,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Open Label,,,16,7,7,0,0,7,0,43.75%,1,,,,,Gaia Sciaranghella,,,,,,,N,No,,,,COSMOS Inactive,,,9/11/2017,9/11/2017,10/25/2017,10/25/2017,,,12/22/2017,12/22/2017,12/22/2017,12/22/2017,,,12/22/2017,12/22/2017,,,12/29/2017,12/29/2017,,,,,,,,,,,3/8/2018,3/8/2018,,,,,,,,,4/20/2018,4/20/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/20/2018,4/20/2018,,,,,,
SHP621-301,SHP621-301,'SHP621-301,,budesonide (TAK-721),"Oral Budesonide Suspension (OBS) in Adolescents and Adult subjects with Eosinophilic Esophagitis: DB, Placebo-Controlled, RW",SHP621-301 OBS Induction Study,III,Completed,Eosinophilic Esophagitis (EoE),GI,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Adolescent,,,,323,0,,0,0,26,,60,,,PPD,,Lisa OLoughlin,,,"Karen Williams, Luisrael Santiago, Marcie Tillery, Nicholas Villanova, Penny Pullin, Philip Robinson, Regina Shinault, Angela Sun, Boicho Miloshov, Brittany Kelley, Christopher Wombolt, Cody Overstreet, Daniel Torres, Diana Rodriguez, Elizabeth Johnson, Farah Mompoint, Gay Crocker, Steven Hack, Susan Vogt",,Not Available,,N,No,,,,COSMOS Inactive,19-Apr-19,7/31/2019,7/27/2015,7/27/2015,8/31/2015,8/31/2015,,,11/10/2015,11/10/2015,12/7/2015,12/7/2015,,,10/8/2018,10/8/2018,,,2/15/2019,2/15/2019,,,,,,,,,,,3/15/2019,3/15/2019,,,,,,,,,3/22/2019,3/22/2019,,,,,,,,,,,,,4/17/2019,4/17/2019,,,,,,,,,7/31/2019,7/31/2019,,,,,,,,,12/5/2017,12/5/2017,,,,,7/31/2019,7/31/2019,,,,,,
SHP621-302,SHP621-302,'SHP621-302,,budesonide (TAK-721),"Oral Budesonide Suspension (OBS) in Adolescents and Adult subjects with Eosinophilic Esophagitis: DB, Maintenance",SHP621-302 OBS Maintenance Study,III,Completed,Eosinophilic Esophagitis (EoE),GI,Late GI,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Adolescent,,,200,219,231,,12,219,45,109.50%,60,,,Endpoint,Lisa OLoughlin,,Nirav Desai,Robin Morey,"Steven Hack, Brittany Kelley, Christopher Wombolt, Cody Overstreet, Daniel Torres, Diana Rodriguez, Larry Orogun, Luisrael Santiago, Nicholas Villanova, Regina Shinault, Revalyne Opar",,,,N,No,,,,COSMOS Inactive,,,11/12/2015,11/12/2015,12/3/2015,12/3/2015,,,4/1/2016,4/1/2016,4/29/2016,4/29/2016,,,2/15/2019,2/15/2019,,,11/12/2019,11/12/2019,,,,,,,,,,,12/12/2019,12/12/2019,,,,,,,,,12/17/2019,12/17/2019,,,,,,,,,,,,,1/22/2020,1/22/2020,,,,,,,,,7/23/2020,7/23/2020,,,,,,,,,,,,,,,7/31/2020,7/31/2020,,,,,,
SHP621-303,SHP621-303,'SHP621-303,,budesonide (TAK-721),"Phase 3, Multicenter, Open-Label Continuation Study with Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects with Eosinophilic Esophagitis (EoE)",SHP621-303 Open-label Continuation Study,III,Recruitment Complete,Eosinophilic Esophagitis,GI,Late GI,,Both pediatric and non-pediatric,Interventional,,,,100,134,,,,,52,134.00%,40,45,,PPD,,Lisa Oloughlin,Nirav Desai,,,,,,,,Wave 1,Advance,Wave 1,Medidata CTMS (Pharma),,,10/3/2016,10/3/2016,11/18/2016,11/18/2016,,,10/5/2017,10/5/2017,10/5/2017,10/5/2017,,,11/21/2019,11/21/2019,,,4/29/2022,,,,,,,,,,,,6/10/2022,,,,,,,,,,6/24/2022,,,,,,,,,,,,,,8/5/2022,,,,,,,,,,9/30/2022,,,,,,,,,,,,,,,,3/8/2021,,,,,,,
SHP622-100,SHP622-100,'SHP622-100,,,"A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE  SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ORAL VP 20629 IN ADULT SUBJECTS WITH FRIEDREICH’S ATAXIA",SHP622-100 (20629-100): Pilot,I,Completed,Friedreich's Ataxia,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,56,55,0,0,0,55,0,98.21%,5,,ViroPharma,,,,,Colette Jarry,,,,,N,No,,,,COSMOS Inactive,,,1/29/2013,1/29/2013,1/30/2013,1/30/2013,,,,,8/28/2013,8/28/2013,8/13/2013,8/13/2013,,,,,,,,,,,,,,,6/18/2015,6/18/2015,6/18/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP623-100,SHP623-100,'SHP623-100,,,"A Randomized, Double-blind, Placebo-controlled, Ascending Dose, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intravenous and Subcutaneous Doses of Recombinant C1 Esterase Inhibitor in Healthy Adult Subjects",SHP623-100 SAD,I,Completed,Hereditary Angioedema (HAE),,,Non-Registry,,Interventional,,,,36,48,0,0,0,48,3,133.33%,1,,,,,"Priya Chockalingam, Stacie Lallier, Virginia Parks",,,,,,,N,No,,,,COSMOS Inactive,,,7/17/2015,7/17/2015,11/9/2015,11/9/2015,,,,,2/24/2016,2/24/2016,,,6/6/2016,6/6/2016,,,,,,,,,,,,,12/5/2016,12/5/2016,12/5/2016,2/1/2017,,,,,,,,,,,,,,,,,,,3/20/2017,3/20/2017,2/16/2017,2/16/2017,,,,,,,,,,,5/25/2017,5/25/2017,,,,,,,,,,,,,,,,,,,,,,
SHP623-201,SHP623-201,'SHP623-201,,,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate rC1 Esterase Inhibitor for the Treatment of Acute Relapse in Neuromyelitis Optica Spectrum Disorders (NMOSD)",SHP623-201 rC1 NMO,II,Study Terminated,NMOSD,,,Non-Registry,,Interventional,,,,80,0,0,0,0,0,0,0.00%,30,,,,,"Cassandra Smith, Brendan Decelles, Diane Montross, Tien Bo",,,,,,,N,No,,,,COSMOS Inactive,,,9/2/2016,,6/5/2017,,,,,,6/26/2018,,,,9/17/2019,,,,,,,,,,,,,,12/10/2019,,12/10/2019,,,,,,,,,,,,,,,,,,,,1/30/2020,,3/5/2020,,,,,,,,,,,,4/30/2020,,,,,,,,,,,,,,,,,,,,,,,
SHP625-001,SHP625-001,'SHP625-001,,,"A Retrospective, Observational Study to Assess Real World Data on the Management of Paediatric Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)",SHP625-001,0,Study Withdrawn,PFIC,,,Non-Registry,,Non-Interventional_CDO Support,,,,30,0,0,0,0,0,0,0.00%,5,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP625-101,SHP625-101,'SHP625-101,,,"A Blinded, Placebo-Controlled, Phase I Study, to Assess the Safety, Tolerability and the Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adult Subjects",SHP625-101: Potency LUM001/SHP626,I,Completed,ALGS,,,Non-Registry,,Interventional,Comparator,,,84,84,140,0,56,84,0,100.00%,1,,,,"Lee Jennings, Merri Carpenter, Annette Stevenson",,,"Noelia Martinez Lopez, Robert Homolka",,,,,N,No,,,,COSMOS Inactive,,,5/4/2015,5/4/2015,5/25/2015,5/25/2015,,,,,6/15/2015,6/15/2015,,,12/10/2015,12/14/2015,,,,,,,,,,,,,12/17/2015,12/21/2015,12/17/2015,2/18/2016,,,,,,,,,,,,,,,,,,,2/24/2016,2/29/2016,4/4/2016,4/4/2016,,,,,,,,,,,6/15/2016,6/20/2016,,,,,,,,,,,,,,,,,,,,,,
SHP625-306,SHP625-306,'SHP625-306,,,"Blinded, Randomized, Pediatric Study",SHP625-306: Peds LUM001,III,Study Withdrawn,PFIC,,,Non-Registry,Pediatric only (<18 yr),Interventional,Crossover,,,150,0,0,0,0,0,0,0.00%,20,,,PPD,,,,Arthur Van Leerberghe,Nicole Cuerdon,,,,N,No,,,,COSMOS Inactive,,,6/26/2017,6/15/2017,10/17/2017,10/17/2017,,,,,10/22/2018,,,,1/10/2020,,,,,,,,,,,,,,6/15/2020,,6/15/2020,,,,,,,,,,,,,,,,,,,,8/25/2020,,9/29/2020,,,,,,,,,,,,11/24/2020,,,,,,,,,,,,,,,,,,,,,,,
SHP625-307,SHP625-307,'SHP625-307,,,A long-term extension study to evaluate the long-term safety and efficacy of maralixibat (SHP625) in the treatment of subjects with Progressive Familial Intrahepatic Cholestasis (PFIC),SHP625-307: Extension LUM001,III,Study Withdrawn,PFIC,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,162,0,0,0,0,0,0,0.00%,20,,,PPD,Jennifer Moran,,,Arthur Van Leerberghe,Nicole Cuerdon,,,,N,No,,,,COSMOS Inactive,,,9/29/2017,9/20/2017,8/10/2018,,,,,,11/5/2018,,,,7/15/2020,,,,,,,,,,,,,,5/29/2025,,5/29/2025,,,,,,,,,,,,,,,,,,,,8/4/2025,,9/8/2025,,,,,,,,,,,,11/3/2025,,,,,,,,,,,,,,,,,,,,,,,
SHP625-310,SHP625-310,'SHP625-310,,,"Long-term open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period of maralixibat in patients with Alagille Syndrome.",SHP625-310 Phase III ALGS pediatric,III,Study Withdrawn,ALGS,,,Non-Registry,,Interventional,,,,80,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP626-101,SHP626-101,'SHP626-101,,,"A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects",SHP626-101 MAD adlt PKPD,I,Completed,Non Alcoholic Steato Hepatitis,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,108,98,118,0,34,84,0,90.74%,1,,,,,Pam Sullivan,,,,,,,N,No,,,,COSMOS Inactive,,,9/23/2014,9/23/2014,11/6/2014,11/6/2014,,,,,1/26/2015,1/26/2015,,,6/5/2015,6/5/2015,,,,,,,,,,,,,6/19/2015,6/19/2015,6/19/2015,8/14/2015,,,,,,,,,,,,,,,,,,,10/6/2015,9/9/2015,9/28/2015,9/9/2015,,,,,,,,,,,1/28/2016,2/11/2016,,,,,,,,,,,,,,,,,,,,,,
SHP626-102,SHP626-102,'SHP626-102,,,"An Open-label Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects",SHP626-102 ADME Adlt SD,I,Completed,Non Alcoholic Steato Hepatitis,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Healthy Volunteers,,,8,8,18,0,10,8,0,100.00%,1,,,,Lee Jennings,Laura Epelbaum,,Robert Homolka,,,,,N,No,,,,COSMOS Inactive,,,3/9/2015,3/9/2015,6/15/2015,6/15/2015,,,,,10/1/2015,10/1/2015,,,10/1/2015,10/1/2015,,,,,,,,,,,,,10/8/2015,10/8/2015,10/8/2015,12/21/2015,,,,,,,,,,,,,,,,,,,3/18/2016,3/18/2016,3/18/2016,3/18/2016,,,,,,,,,,,6/2/2016,6/2/2016,,,,,,,,,,,,,,,,,,,,,,
SHP626-103,SHP626-103,'SHP626-103,,,Glucose Clamp in Diabetic Adults with NAFLD/NASH,SHP626-103 Adlt,I,Study Withdrawn,Non Alcoholic Steato Hepatitis,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,45,0,0,0,0,0,0,0.00%,5,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/16/2015,3/16/2015,11/30/2015,,,,,,3/1/2016,,,,9/1/2016,,,,,,,,,,,,,,10/12/2016,,10/12/2016,,,,,,,,,,,,,,,,,,,,1/11/2017,,1/13/2017,,,,,,,,,,,,3/10/2017,,,,,,,,,,,,,,,,,,,,,,,
SHP626-201,SHP626-201,'SHP626-201,,,"A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)",SHP626-201 Adult Rand DB POC,II,Completed,Non Alcoholic Steato Hepatitis,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,266,197,562,0,371,0,149,74.06%,72,,,ICON / MAPI / Paradigm,,,Vincent Philiponis,,,,,,N,No,,,,COSMOS Inactive,,,12/21/2015,12/21/2015,3/1/2016,3/1/2016,7/29/2016,7/29/2016,,,10/24/2016,10/24/2016,8/17/2016,8/17/2016,6/8/2018,6/8/2018,,,,,,,,,,,,,7/27/2018,7/27/2018,7/27/2018,10/2/2018,,,,,,,,,,,,,,,,,,,11/8/2018,11/5/2018,11/8/2018,11/5/2018,,,,,,,,,,,12/21/2018,12/13/2018,,,,,,,,,,,,,,,,,,,,,,
SHP627-2Xa,SHP627-2Xa,'SHP627-2Xa,,,"PhII, double blind, randomised, placebo-controlled, proof-of-concept study of FT011 to patients with Focal Segmental Glomerulosclerosis (FSGS)",,II,Study Withdrawn,Diabetic Neuropathy,,,Non-Registry,,Interventional,Proof of Concept,,,60,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-2Xb,SHP627-2Xb,'SHP627-2Xb,,,"PhII, double blind, randomised, placebo-controlled, extension study of FT011 to patients with Focal Segmental Glomerulosclerosis (FSGS)",,II,Study Withdrawn,Diabetic Neuropathy,,,Non-Registry,,Interventional,Extension,,,60,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-3Xa,SHP627-3Xa,'SHP627-3Xa,,,"PhII, double blind, randomised, placebo-controlled, pivotal study of FT011 to patients with Focal Segmental Glomerulosclerosis (FSGS)",,III,Study Withdrawn,Diabetic Neuropathy,,,Non-Registry,,Interventional,Efficacy,,,80,0,0,0,0,0,0,0.00%,65,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-3Xc,SHP627-3Xc,'SHP627-3Xc,,,"PhII, double blind, randomised, placebo-controlled, pivotal study of FT011 to pediatric patients with Focal Segmental Glomerulosclerosis (FSGS)",,III,Study Withdrawn,Diabetic Neuropathy,,,Non-Registry,,Interventional,Efficacy,,,40,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-101,SHP627-101,'SHP627-101,,,"SHP627-101 A Phase 1, Open-label, Randomized, 3-Period, Relative
Bioavailability Study",SAD,I,Study Terminated,Diabetic Neuropathy,,,Non-Registry,,Interventional,Bioavailability (BA),,,80,0,0,0,0,0,0,0.00%,1,,,PRA,Alexander Tankelevich,Zhenmin Lu,Jay Getsy,Robert Homolka,,,,,N,No,,,,COSMOS Inactive,,,6/29/2015,1/11/2016,8/22/2016,,,,,,12/6/2016,,,,4/3/2017,,,,,,,,,,,,,,4/10/2017,,4/10/2017,,,,,,,,,,,,,,,,,,,,7/13/2017,,7/11/2017,,,,,,,,,,,,9/5/2017,,,,,,,,,,,,,,,,,,,,,,,
SHP627-102,SHP627-102,'SHP627-102,,,MAD in healthy subjects and subjects with FSGS,MAD,I,Study Terminated,Focal Segmental Glomeruloscler,,,Non-Registry,,Interventional,PK,,,96,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-103,SHP627-103,'SHP627-103,,,"A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SRD005817 Following a Single Oral Dose in Healthy Male Subjects",ADME,I,Study Terminated,Focal Segmental Glomeruloscler,,,Non-Registry,,Interventional,PK,,,8,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/3/2017,,5/12/2017,,,,,,7/19/2017,,,,7/14/2017,,,,,,,,,,,,,,8/11/2017,,8/11/2017,,,,,,,,,,,,,,,,,,,,11/16/2017,,11/14/2017,,,,,,,,,,,,1/9/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP627-104,SHP627-104,'SHP627-104,,,DDI #1,DDI #1,I,Study Terminated,Focal Segmental Glomeruloscler,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-105,SHP627-105,'SHP627-105,,,DDI #2,DDI #2,I,Study Terminated,Focal Segmental Glomeruloscler,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/3/2017,,5/12/2017,,,,,,7/19/2017,,,,8/16/2017,,,,,,,,,,,,,,9/13/2017,,9/13/2017,,,,,,,,,,,,,,,,,,,,12/19/2017,,12/15/2017,,,,,,,,,,,,2/9/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP627-106,SHP627-106,'SHP627-106,,,DDI #3,DDI #3,I,Study Terminated,Focal Segmental Glomeruloscler,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-107,SHP627-107,'SHP627-107,,,DDI #4,DDI #4,I,Study Terminated,Focal Segmental Glomeruloscler,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP627-110,SHP627-110,'SHP627-110,,,"A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics,
Safety, and Tolerability of SRD005817 in Healthy Adults
and Elderly Subjects and in Subjects with Impaired Renal Function",Renal,I,Study Terminated,Focal Segmental Glomeruloscler,,,Non-Registry,,Interventional,PK,,,72,0,0,0,0,0,0,0.00%,2,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/4/2017,,10/13/2017,,,,,,12/20/2017,,,,1/17/2018,,,,,,,,,,,,,,2/14/2018,,2/14/2018,,,,,,,,,,,,,,,,,,,,5/22/2018,,5/18/2018,,,,,,,,,,,,7/13/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP630-1Xb,SHP630-1Xb,'SHP630-1Xb,,,MAD,MAD,I,Study Terminated,adRP Class II opsin mutations,,,Non-Registry,,Interventional,Multiple Dose,,,72,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/1/2017,,4/30/2017,,,,,,9/16/2017,,,,9/16/2017,,,,,,,,,,,,,,12/15/2017,,12/15/2017,,,,,,,,,,,,,,,,,,,,2/19/2018,,2/20/2018,,,,,,,,,,,,4/11/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP630-1Xc,SHP630-1Xc,'SHP630-1Xc,,,C14 ADME,C14 ADME,I,Study Terminated,adRP Class II opsin mutations,,,Non-Registry,,Interventional,Drug Metabolism Pharmacokinetics (DMPK),,,8,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/3/2017,,10/1/2017,,,,,,11/17/2017,,,,11/17/2017,,,,,,,,,,,,,,11/17/2017,,11/17/2017,,,,,,,,,,,,,,,,,,,,2/6/2018,,2/8/2018,,,,,,,,,,,,3/30/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP630-1Xd,SHP630-1Xd,'SHP630-1Xd,,,SHP630-1Xd CYP 3A4 inhibition,SHP630-1Xd CYP 3A4 DDI,I,Study Terminated,adRP Class II opsin mutations,,,Non-Registry,,Interventional,,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/3/2017,,1/6/2018,,,,,,3/8/2018,,,,3/8/2018,,,,,,,,,,,,,,3/29/2018,,3/29/2018,,,,,,,,,,,,,,,,,,,,7/3/2018,,8/3/2018,,,,,,,,,,,,9/2/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP630-001,SHP630-001,'SHP630-001,,,"A Prospective, Multi-center, Longitudinal, Observational Natural History Study to Evaluate Disease Progression and the rate of change in the Ellipsoid Zone (EZ) Area in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) with Misfolded Opsin Mutations",SHP630-001: adRP Natural History,0,Study Terminated,adRP Class II opsin mutations,,,Non-Registry,,Non-Interventional_CDO Support,,,,,4,0,,0,0,4,,18,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/7/2016,3/7/2016,6/9/2016,6/9/2016,,,,,4/3/2017,4/3/2017,10/26/2016,10/26/2016,8/26/2018,,,,,,,,,,,,,,9/4/2022,,9/4/2022,,,,,,,,,,,,,,,,,,,,10/31/2022,,11/7/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP630-101,SHP630-101,'SHP630-101,,,SAD,SAD,I,Study Terminated,adRP Class II opsin mutations,,,Non-Registry,,Interventional,Single Dose,,,72,0,0,0,0,0,0,0.00%,1,,,,Robert Homolka,,,Noha Maklad,,,,,N,No,,,,COSMOS Inactive,,,12/19/2016,,3/19/2017,,,,,,6/12/2017,,,,8/11/2017,,,,,,,,,,,,,,8/28/2017,,8/28/2017,,,,,,,,,,,,,,,,,,,,12/12/2017,,12/13/2017,,,,,,,,,,,,2/1/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP631-201,SHP631-201,'SHP631-201,,,"A Phase 2, Open-label Study of AGT-182/SHP631 in Children with MPS II Hunter Syndrome with Cognitive Involvement",SHP631-201 Ped Hunter Study,II,Study Terminated,Hunter Syndrome,,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,24,0,0,0,0,0,0,0.00%,7,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/1/2049,,1/1/2049,,1/1/2049,,,,1/1/2049,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,1/1/2049,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
SHP633-1xa,SHP633-1xa,'SHP633-1xa,,,"A Phase 1, Open- label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of SHP633 (Teduglutide) Administered Subcutaneously in Japanese and Matched Caucasian Healthy Adult Subjects",Japanese Bridging Study,I,Study Withdrawn,Short Bowel Syndrome,,,Non-Registry,,Interventional,Single Dose,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/15/2017,,3/29/2017,,,,,,6/3/2017,,,,6/3/2017,,,,,,,,,,,,,,6/19/2017,,6/19/2017,,,,,,,,,,,,,,,,,,,,9/22/2017,,9/20/2017,,,,,,,,,,,,11/15/2017,,,,,,,,,,,,,,,,,,,,,,,
SHP633-301,SHP633-301,'SHP633-301,,Gattex (teduglutide),"An Open-label, 24-Week Safety and Pharmacodynamic Study of Teduglutide in Infant Subjects Aged 4 Months up to 12 Months, with Short Bowel Syndrome who are Dependent on Parenteral Support",24W EU Infant,III,Completed,Short bowel syndrome,GI,Marketed Products,,Pediatric only (<18 yr),Interventional,Treatment,Other,Cohort,10,10,13,,3,10,3,100.00%,8,,,IQVIA,,"Amy Remick, Lauren Dinsmore",,,,2017-003606-40,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,6/4/2015,6/4/2015,10/10/2017,10/10/2017,,,9/18/2018,9/18/2018,9/18/2018,9/18/2018,,,3/2/2020,3/2/2020,,,9/18/2020,9/18/2020,,,,,,,,,,,10/14/2020,10/14/2020,,,,,,,,,6/23/2020,6/23/2020,,,,,,,,,,,,,,,,,,,,,,,1/26/2021,1/26/2021,,,,,,,,,,,,,,,1/26/2021,1/26/2021,,,,,,
SHP633-302,SHP633-302,'SHP633-302,,Gattex (teduglutide),"A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months through 15 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support",24W Japanese Pediatric Bridging,III,Completed,Short Bowel Syndrome,GI,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,Open Label,,,10,10,0,,0,0,,100.00%,6,,,IQVIA,,"Sasan Sabrdaran, Siddharth Bhatia, Jessica Zhang",Claudio Pasquinelli,Amy Remick,Kaivan Charmchi,,,,N,No,,,,COSMOS Inactive,,,4/7/2015,4/7/2015,12/18/2015,12/18/2015,,,1/13/2017,1/13/2017,2/1/2017,2/1/2017,,,7/3/2019,7/3/2019,,,1/21/2020,1/21/2020,,,,,,,,,,,3/4/2020,3/4/2020,,,,,,,,,,,,,,,,,,,,,,,4/1/2020,4/1/2020,,,,,,,,,5/11/2020,5/11/2020,,,,,,,,,,,,,,,5/11/2020,5/11/2020,,,,,,
SHP633-303,SHP633-303,'SHP633-303,,Gattex (teduglutide),"A retrospective and prospective, open label, long-term safety and efficacy study of teduglutide in pediatric patients with short bowel syndrome who participated in TED-C13-003",SHP633-303 Ped LT Extn,III,Completed,Chronic Sinusitis,GI,Marketed Products,,Pediatric only (<18 yr),Interventional,Treatment,Other,,39,29,,,,,9,74.36%,12,,,IQVIA,,"Laura McCarthy, Takashi Yamasaki, Brittney Thompson","Peter Koefler, Chen Starr, Marjory Fraser, Michael Hoy, Starr Chen",,,2016-000863-17,,,,,NA,Advance,,Medidata CTMS (Pharma),,,12/8/2015,12/8/2015,5/11/2016,5/11/2016,,,11/30/2016,11/30/2016,12/9/2016,12/9/2016,,,8/8/2017,8/8/2017,,,7/14/2020,7/14/2020,,,,,,,,,,,10/9/2020,10/9/2020,,,,,,,,,,,,,,,,,,,,,,,11/5/2020,11/5/2020,,,,,,,,,1/12/2021,1/12/2021,,,,,,,,,,,,,,,1/12/2021,1/12/2021,,,,,,
SHP633-304,SHP633-304,'SHP633-304,,Gattex (teduglutide),"A prospective, open label, long-term safety and efficacy study of teduglutide in pediatric patients with short bowel syndrome who completed TED-C14-006",SHP633-304 Ped LT Extn,III,Completed,Chronic Sinusitis,GI,Marketed Products,,Pediatric only (<18 yr),Interventional,Treatment,Prospective,,57,61,,,,,9,107.02%,28,,,TBD,,"Takashi Yamasaki, Brittney Thompson","Michael Hoy, Starr Chen",,,2016-000849-30,,,,,NA,Advance,,Medidata CTMS (Pharma),,,12/8/2015,12/8/2015,4/8/2016,4/8/2016,,,1/9/2017,1/9/2017,1/9/2017,1/9/2017,,,7/15/2020,7/15/2020,,,11/5/2020,11/5/2020,,,,,,,,,,,1/25/2021,1/25/2021,,,,,,,,,,,,,,,,,,,,,,,2/19/2021,2/19/2021,,,,,,,,,4/5/2021,4/5/2021,,,,,,,,,,,,,,,4/5/2021,4/5/2021,,,,,,
SHP633-305,SHP633-305,'SHP633-305,,Gattex (teduglutide),SHP633-305 Japan Pediatric Long-Term Extension Study to the SHP633-302 Japan Pediatric Bridging Study,SHP633-305 Japan Pediatric LT Extn,III,Recruitment Complete,Short bowel syndrome,GI,Marketed Products,,Pediatric only (<18 yr),Interventional,,,,9,9,0,,0,1,,100.00%,6,,,IQVIA,,"Brian Sontag, Takashi Yamasaki, Chemmene Cassidy","Starr Chen, Claudio Pasquinelli",,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,5/31/2016,5/31/2016,8/26/2016,8/26/2016,,,8/16/2017,8/16/2017,8/23/2017,8/23/2017,,,1/21/2020,1/21/2020,,,12/8/2021,,,,,,,,,,,,12/23/2021,,,,,,,,,,,,,,,,,,,,,,,,1/4/2022,,,,,,,,,,3/8/2022,,11/10/2020,11/10/2020,,,,,,,,,,,,,3/8/2022,,,,,,,
SHP633-306,SHP633-306,'SHP633-306,,Gattex (teduglutide),"A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects with Short Bowel Syndrome who are Dependent on Parenteral Support",SHP633-306 New 24W Japananese Adult,III,Completed,Short bowel syndrome,GI,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,5,7,0,,3,0,,140.00%,5,,,IQVIA,,"Brian Sontag, Takashi Yamasaki, Chemmene Cassidy","Claudio Pasquinelli, Starr Chen",,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,9/21/2017,9/21/2017,1/23/2018,1/23/2018,,,5/28/2018,5/28/2018,7/31/2018,7/31/2018,,,2/25/2019,2/25/2019,,,8/6/2019,8/6/2019,,,,,,,,,,,9/13/2019,9/13/2019,,,,,,,,,,,10/16/2019,10/16/2019,,,,,,,,,,,10/16/2019,10/16/2019,,,,,,,,,2/5/2020,2/5/2020,,,,,,,,,,,,,,,2/5/2020,2/5/2020,,,,,,
SHP633-307,SHP633-307,'SHP633-307,,Gattex (teduglutide),"An Open-Label, Extension Study of Teduglutide in Japanese Subjects with Short Bowel Syndrome who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004",SHP633-307 New Adult Japan Bridging,III,Recruitment Complete,Short bowel syndrome,GI,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,12,11,0,,0,0,,91.67%,5,,,IQVIA,,"Brian Sontag, Takashi Yamasaki, Chemmene Cassidy","Claudio Pasquinelli, Starr Chen",,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,8/22/2017,8/22/2017,1/23/2018,1/23/2018,,,7/9/2018,7/9/2018,7/9/2018,7/9/2018,,,8/6/2019,8/6/2019,,,11/2/2021,,,,,,,,,,,,12/6/2021,,,,,,,,,,,,,,,,,,,,,,,,1/4/2022,,,,,,,,,,3/8/2022,,,,,,,,,,,,,,,,3/8/2022,,,,,,,
SHP633-501,SHP633-501,'SHP633-501,,,Longitudinal descriptive study of the experience of SBS-IF patients treated with teduglutide,Swedish teduglutide SBS observational st,IV,Study Withdrawn,Short Bowel Syndrome,,,Non-Registry,Both Pediatric & Non-pediatric,Non-Intervention_Other Support,Real World Efficacy Monitoring,,,35,,,,,,,,15,,,,,"Antonia Panayi, Tanja Jakobsson",,,,,,,N,No,,,,COSMOS Inactive,,,,,6/23/2019,1/1/2049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/1/2022,1/1/2049,,,,,,,,,,,3/31/2022,1/1/2049,,,,,,,,,,,,,,,,,,,,,,
SHP634-101,SHP634-101,'SHP634-101,,Natpara (parathyroid hormone),"An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of QD versus BID Dose Regimens of recombinant parathyroid hormone (rhPTH(1-84)) Administered Subcutaneously to Subjects with Hypoparathyroidism",SHP634-101 PK/PD QD/BID,I,Completed,Hypoparathyroidism,RGH,Marketed Products,Non-Registry,Non-pediatric only (>18 yr),Interventional,PASS (Post Authorization Safety Study),,,34,34,0,,0,0,1,100.00%,30,,,PPD,Elena Tokareva,"Hanne Rossau, Maria Humagain, Patricia Johnson, Sevag Donabedian, Sharon Kunder",,Elena Tokareva,"Camilla Sorensen, Elizabeth Debnam, Gene Dillague, Gleness Bosha, Janet Lung, Jillian Lobley, Jonathan Eller, Katalin Siagi, Katy Daniel, Peter Sipos",2015-004757-40,,,N,No,,,,COSMOS Inactive,,,10/19/2015,10/19/2015,11/24/2015,11/24/2015,,,2/15/2017,2/15/2017,3/11/2017,3/11/2017,,,2/28/2019,2/28/2019,,,3/8/2019,3/8/2019,,,,,,,,,,,2/17/2020,2/17/2020,,,,,,,,,3/17/2020,3/17/2020,,,,,,,,,,,,,3/25/2020,3/25/2020,,,,,,,,,3/20/2020,3/20/2020,,,,,,,,,,,,,,,3/25/2020,3/25/2020,,,,,,
SHP634-102,SHP634-102,'SHP634-102,,Natpara (parathyroid hormone),"A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneiously in Japanese and Matched Caucasian Healthy Adult Subjects",Japanese Bridging Study,I,Completed,Hypoparathyroidism,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,PKPD,,,24,24,44,0,0,24,0,100.00%,1,,,Parexel,,Robert Homolka,,,,,,,N,No,,,,COSMOS Inactive,,6/26/2017,6/27/2016,6/27/2016,2/7/2017,2/7/2017,,,4/19/2017,4/19/2017,5/16/2017,5/16/2017,,,5/22/2017,5/22/2017,,,6/26/2017,6/26/2017,,,,,,,,,,,8/22/2017,8/22/2017,,,,,,,,,6/20/2018,6/20/2018,,,,,,,,,,,,,7/12/2018,7/12/2018,,,,,,,,,8/27/2018,8/27/2018,,,,,,,,,,,,,,,8/27/2018,8/27/2018,,,,,,
SHP634-103,SHP634-103,'SHP634-103,,Natpara (parathyroid hormone),"A Randomized, Open-label, Single-dose, Two-treatment, Two-period Crossover Study to Determine the Bioequivalence of recombinant human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneiously with the Haselmeier and Scandinavian Health Ltd (SHL) Injection Pens in Healthy Volunteers",BE study,I,Completed,Hypoparathyroidism,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Bioequivalence,,,58,58,0,0,0,58,0,100.00%,1,,,"Clinical Pharmacology of Miami, INC",,Rebekah Gorney,,,,,,,N,No,,,,COSMOS Inactive,,11/10/2017,7/12/2017,7/12/2017,8/3/2017,8/3/2017,,,10/3/2017,10/3/2017,10/17/2017,10/17/2017,,,10/30/2017,10/30/2017,,,11/3/2017,11/3/2017,,,,,,,,,,,3/9/2018,3/9/2018,,,,,,,,,1/10/2018,1/10/2018,,,,,,,,,,,,,5/4/2018,5/4/2018,,,,,,,,,6/26/2018,6/26/2018,,,,,,,,,,,,,,,6/26/2018,6/26/2018,,,,,,
SHP634-104,SHP634-104,'SHP634-104,,Natpara (parathyroid hormone),PIP PK/PD in Hypo patients aged 12- <18y,Parachute,I,All Activities Closed,Hypoparathyroidism,RGH,Marketed Products,,Pediatric only (<18 yr),Interventional,,,,14,,,,,,,,15,,,PPD,,Elena Tokareva,Nicole Sherry,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,11/12/2018,11/12/2018,5/3/2019,5/3/2019,,,11/12/2021,,12/2/2021,,,,9/16/2022,,,,9/16/2022,,,,,,,,,,,,11/25/2022,,,,,,,,,,12/9/2022,,,,,,,,,,,,,,12/16/2022,,,,,,,,,,5/1/2023,,,,,,,,,,,,,,,,5/1/2023,,,,,,,
SHP634-105,SHP634-105,'SHP634-105,,,PK/PD study in hypo patients ages 0-<12y,PIP PK/PD in Hypo patients aged 0-<12y,I,Study Withdrawn,Hypoparathyroidism,,,Non-Registry,,Interventional,,,,8,0,0,0,0,0,0,0.00%,4,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/24/2018,,11/1/2018,,,,,,5/30/2019,,5/2/2019,,1/9/2020,,,,,,,,,,,,,,5/14/2020,,5/14/2020,,,,,,,,,,,,,,,,,,,,7/27/2020,,8/3/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP634-301,SHP634-301,'SHP634-301,,Natpara (parathyroid hormone),"A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects with Chronic Hypoparathyroidism",Japan Bridging Study,III,All Activities Closed,Hypoparathyroidism,RGH,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,12,,,,,,,,10,,,IQVIA,,"Takashi Yamasaki, Yvette Monroe Hinds",Nicole Sherry,,,,,Not yet submitted,,,NA,Advance,,Medidata CTMS (Pharma),,,12/20/2017,12/20/2017,6/27/2018,6/27/2018,,,2/28/2022,,3/31/2022,,,,11/7/2022,,,,5/12/2023,,,,,,,,,,,,7/21/2023,,,,,,,,,,8/4/2023,,,,,,,,,,,,,,9/4/2023,,,,,,,,,,10/6/2023,,,,,,,,,,,,,,,,10/6/2023,,,,,,,
SHP634-302,SHP634-302,'SHP634-302,,Natpara (parathyroid hormone),Extension to Japan Bridging Study,Japan Extension Study,III,All Activities Closed,,RGH,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,12,,,,,,,,10,,,IQVIA,,"Takashi Yamasaki, Yvette Monroe Hinds",,,,,,Not yet submitted,,,,,,Medidata CTMS (Pharma),,,5/16/2019,5/16/2019,5/16/2019,5/16/2019,,,2/4/2022,,2/4/2022,,,,8/19/2022,,,,12/9/2024,,,,,,,,,,,,2/18/2025,,,,,,,,,,3/5/2025,,,,,,,,,,,,,,4/3/2025,,,,,,,,,,5/9/2025,,,,,,,,,,,,,,,,5/9/2025,,,,,,,
SHP634-303,SHP634-303,'SHP634-303,,Natpara (parathyroid hormone),An Open-Label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects with Hypoparathyroidism who have completed SHP634-104,Ph3 Pediatrics,III,Planned,Hypoparathyroidism,RGH,,,,Interventional,,,,15,,,,,,,,12,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,12/29/2023,,7/30/2024,,,,7/31/2024,,7/31/2024,,,,7/31/2025,,,,7/31/2025,,,,,,,,,,,,9/30/2025,,,,,,,,,,10/31/2025,,,,,,,,,,,,,,7/31/2025,,,,,,,,,,1/30/2026,,,,,,,,,,,,,,,,1/30/2026,,,,,,,
SHP634-401,SHP634-401,'SHP634-401,,Natpara (parathyroid hormone),"A Randomized, Double-blind, Placebo-Controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]",EU Study (BALANCE),IV,Recruiting,Endometrial cancer,RGH,Marketed Products,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Other,92,80,177,33,95,86,10,86.96%,40,34,,PPD,,"Barbara Evans, Barbara Busby",,Nicole Sherry,,2017-000284-32,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,5/3/2016,5/3/2016,8/19/2016,8/19/2016,,,1/24/2018,1/24/2018,2/15/2018,2/15/2018,,,10/27/2021,,,,5/25/2022,,,,,,,,,,,,7/18/2022,,,,,,,,,,8/2/2022,,,,,,,,,,,,,,8/24/2022,,,,,,,,,,11/16/2022,,,,,,,,,,6/7/2021,6/7/2021,,,,,12/22/2022,,,,,,,
SHP634-402,SHP634-402,'SHP634-402,,Natpara (parathyroid hormone),EXTENDED USE OF rhPTH(1-84) [NATPARA] IN HYPOPARATHYROIDISM: A PHASE 4 TRIAL,Columbia P4 Study,IV,Reported,Hypoparathyroidism,RGH,Marketed Products,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Other,50,36,0,,0,0,36,72.00%,1,,,PPD,,"Barbara Evans, Barbara Busby",,Nicole Sherry,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,4/18/2016,4/18/2016,5/27/2016,5/27/2016,,,10/26/2016,10/26/2016,12/9/2016,12/9/2016,,,6/30/2017,6/30/2017,,,12/20/2019,12/20/2019,,,,,,,,,,,12/4/2020,12/4/2020,,,,,,,,,12/15/2020,12/15/2020,,,,,,,,,,,,,1/15/2021,1/15/2021,,,,,,,,,5/5/2021,5/5/2021,,,,,,,,,,,,,,,5/5/2021,5/5/2021,,,,,,
SHP634-404,SHP634-404,'SHP634-404,,Natpara (parathyroid hormone),An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Patients with Hypoparathyroidism,-101 OLE,IV,Reported,Hypoparathyroidism,RGH,Marketed Products,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Other,32,20,22,2,2,,8,62.50%,18,,,TBD,,"Barbara Evans, Barbara Busby",,Nicole Sherry,,2017-003067-36,,,,,NA,Advance,,Medidata CTMS (Pharma),,,6/5/2017,6/5/2017,8/30/2017,8/30/2017,,,9/26/2018,9/26/2018,10/3/2018,10/3/2018,,,2/26/2019,2/26/2019,,,4/14/2020,4/14/2020,,,,,,,,,,,12/17/2020,,,,,,,,,,1/4/2021,,,,,,,,,,,,,,1/25/2021,,,,,,,,,,3/19/2021,,,,,,,,,,,,,,,,3/19/2021,,,,,,,
SHP634-701,SHP634-701,'SHP634-701,,,"Defining the epidemiology of hypoparathyroidism in Tayside, Scotland",SHP634-701 TAYSIDE HYPOPARA,IV,Study Withdrawn,Hypoparathyroidism,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,1,,,,Kamran Iqbal,,Kamran Iqbal,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP635-xxx,SHP635-xxx,'SHP635-xxx,,,SHP635-xxx NPS - Calcilytics,SHP635-xxx NPS - Calcilytics,II,Study Terminated,Autosomal Dominant Hypocalcemi,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP637-101,SHP637-101,'SHP637-101,,,"A Phase 1, Randomized, Observer-Blinded, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety and Tolerability of a Single Dose of SHP637 (hCFTR mRNA/bPEI) Administered by Nebulization to Healthy Adult Subjects",SHP637-101 SAD in HV,I,Study Withdrawn,Cystic Fibrosis,,,Non-Registry,,Interventional,First In Man (FIM),,,32,0,0,0,0,0,0,0.00%,1,,,,Heather Van Heusen,,,,,,,,N,No,,,,COSMOS Inactive,,,4/6/2015,4/6/2015,8/21/2015,,,,,,12/1/2016,,,,5/16/2017,,,,,,,,,,,,,,7/20/2017,,7/20/2017,,,,,,,,,,,,,,,,,,,,9/14/2017,,10/23/2017,,,,,,,,,,,,12/18/2017,,,,,,,,,,,,,,,,,,,,,,,
SHP639-101,SHP639-101,'SHP639-101,,TAK-639,"A Randomized, Double-masked, Placebo-controlle Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Signle Daily and Multiple Daily Ascending Doses of SHP639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-angle Glaucoma (POAG)",SHP639-101,I,Completed,Glaucoma,Ophthalmology,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,,63,0,,0,0,1,,7,,,PPD,,"Alisa Cohen, Karen Tam",,,,,Not Available,,N,No,,,,COSMOS Inactive,30-May-18,5/30/2018,8/24/2016,8/24/2016,12/20/2016,12/20/2016,,,5/18/2017,5/18/2017,5/24/2017,5/24/2017,,,3/7/2018,3/7/2018,,,5/30/2018,5/30/2018,,,,,,,,,,,11/13/2018,11/13/2018,,,,,,,,,,,,,,,,,,,,,,,12/17/2018,12/17/2018,,,,,,,,,4/30/2019,,,,,,,,,,,,,,,,4/30/2019,,,,,,,
SHP639-201,SHP639-201,'SHP639-201,,,"A Phase 2 Randomized, Multicenter, Double-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of Two Dose Levels of SHP639 Ophthalmic Solution to Latanoprost and Timolol in Subjects with Open Angle Glaucoma or Ocular Hypertension",,II,Study Withdrawn,Glaucoma,,,Non-Registry,,Interventional,,,,120,0,0,0,0,0,0,0.00%,6,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/5/2017,,2/1/2018,,,,,,5/11/2018,,,,9/8/2018,,,,,,,,,,,,,,11/7/2018,,11/7/2018,,,,,,,,,,,,,,,,,,,,12/14/2018,,1/8/2019,,,,,,,,,,,,2/17/2019,,,,,,,,,,,,,,,,,,,,,,,
SHP640-301,SHP640-301,'SHP640-301,,TAK-640 (dexamethasone),"A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate
the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and
Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine
and Placebo in the Treatment of Adenoviral Conjunctivitis",SHP640-301,III,Completed,Infective Conjunctivitis,Ophthalmology,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Safety,,,540,221,,,,,,40.93%,181,,,IQVIA,,"Atyia Allen, Giovanna Devercelli",,Michael Malicsi,Elizabeth Johnson,2016-002439-14,Not Available,,N,Yes,,,,COSMOS Inactive,20-Jun-20,5/13/2019,5/31/2016,5/31/2016,6/30/2016,6/30/2016,,,3/16/2017,3/16/2017,3/28/2017,3/28/2017,,,5/20/2020,,,,6/4/2020,,,,,,,,,,,,7/8/2020,,,,,,,,,,7/22/2020,,,,,,,,,,,,,,7/27/2020,,,,,,,,,,10/23/2020,,,,,,,,,,,,,,,,10/23/2020,,,,,,,
SHP640-302,SHP640-302,'SHP640-302,,TAK-640 (dexamethasone),"A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis",SHP640-302,III,Completed,Infective Conjunctivitis,Ophthalmology,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Safety,,,284,156,,,,,,54.93%,78,,,IQVIA,Angela Calvillo,"Atyia Allen, Giovanna Devercelli",,,,,Not Available,,N,Yes,,,,COSMOS Inactive,29-Jan-18,5/16/2019,5/31/2016,5/31/2016,6/30/2016,6/30/2016,,,3/6/2017,3/6/2017,4/1/2017,4/1/2017,,,12/17/2019,,,,12/31/2019,,,,,,,,,,,,2/14/2020,,,,,,,,,,2/26/2020,,,,,,,,,,,,,,3/19/2020,,,,,,,,,,4/16/2020,,,,,,,,,,,,,,,,4/16/2020,,,,,,,
SHP640-303,SHP640-303,'SHP640-303,,TAK-640 (dexamethasone),"A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis",SHP640-303,III,Completed,Infective Conjunctivitis,Ophthalmology,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,721,753,1087,0,334,753,57,104.44%,203,,,IQVIA,,"Atyia Allen, Giovanna Devercelli, Michael Malicsi",,,,2016-003361-25,Not Available,,N,No,,,,COSMOS Inactive,20-Oct-18,10/1/2018,8/1/2016,8/1/2016,9/2/2016,9/2/2016,,,3/6/2017,3/6/2017,3/31/2017,3/31/2017,,,12/17/2017,12/17/2017,,,10/3/2018,10/3/2018,,,,,,,,,,,11/15/2018,11/15/2018,,,,,,,,,12/5/2018,12/5/2018,,,,,,,,,,,,,12/11/2018,12/11/2018,,,,,,,,,3/29/2019,3/29/2019,,,,,,,,,,,,,,,3/29/2019,3/29/2019,,,,,,
SHP640-304,SHP640-304,'SHP640-304,,TAK-640 (dexamethasone),"A Phase 3, Multi-center, Randomized, Double-Masked Study - TBD",SHP640-304,III,Study Withdrawn,Infective Conjunctivitis,Ophthalmology,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,770,0,0,0,0,0,0,0.00%,80,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/3/2017,10/3/2017,1/1/2019,,,,2/13/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/13/2019,,,,,,,
SHP640-305,SHP640-305,'SHP640-305,,,TBD,SHP640-305,III,Study Withdrawn,Infective Conjunctivitis,,,Non-Registry,,Interventional,,,,400,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/14/2019,,2/25/2019,,,,,,6/10/2019,,,,9/30/2020,,,,,,,,,,,,,,10/13/2020,,10/13/2020,,,,,,,,,,,,,,,,,,,,12/3/2020,,1/7/2021,,,,,,,,,,,,3/4/2021,,,,,,,,,,,,,,,,,,,,,,,
SHP642-101,SHP642-101,'SHP642-101,,,"A single-center, randomized, double-blind, placebo-controlled, single-ascending dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ASHE1001, a humanized monoclonal antibody, following intravenous (IV) infusion and sub-cutaneous administration (SC)","SHP642-101 FIH, SAD",I,Study Terminated,PNH,,,Non-Registry,,Interventional,,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/3/2017,,4/12/2017,,,,,,8/2/2017,,,,8/23/2017,,,,,,,,,,,,,,1/10/2018,,1/10/2018,,,,,,,,,,,,,,,,,,,,4/17/2018,,4/13/2018,,,,,,,,,,,,6/8/2018,,,,,,,,,,,,,,,,,,,,,,,
SHP643-101,SHP643-101,'SHP643-101,,Takhzyro (Lanadelumab),Phase 1 Japanese Bridging Study,Bridging Study,I,Completed,Hereditary Angioedema,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Healthy Volunteers,,,32,32,75,0,0,0,0,100.00%,1,,,PPD,,"Andrew Sabo, Beverly Stanton, Jennifer Schranz, Jill Davidson, Kim Paes, Laura Epelbaum, Robert Bradley, Srikanth Kurra",,,,,,,N,No,,,,COSMOS Inactive,,10/23/2018,,,11/28/2017,11/28/2017,,,,,1/31/2018,1/31/2018,,,2/7/2018,2/7/2018,,,5/30/2018,5/30/2018,,,,,,,,,,,7/30/2018,7/30/2018,,,,,,,,,9/27/2018,9/27/2018,,,,,,,,,,,,,,,,,,,,,,,10/23/2018,10/23/2018,,,,,,,,,,,,,,,10/23/2018,10/23/2018,,,,,,
SHP643-102,SHP643-102,'SHP643-102,,Takhzyro (Lanadelumab),Pharmacokinetic Comparability of Lanadelumab Using Pre-Filled Syringe or an Auto Injector in Healthy Subjects,PFS v. AI Pharmacokinetic Comparability,I,Completed,Hereditary Angioedema,RGH,N/A,Non-Registry,Non-pediatric only (>18 yr),Interventional,PK,,,190,190,0,,0,0,17,100.00%,1,1,,PPD,"Beverly Stanton, Laura Epelbaum","Andrew Sabo, Eric Brown, Kim Paes",Richard Finkelman,"Catherine Parham, James Hacunda, Peng Lu, Robert Bradley, Scott Drapeau",,,,,N,No,,,,COSMOS Inactive,,,,,2/4/2019,2/4/2019,,,,,5/14/2019,5/14/2019,,,7/25/2019,7/25/2019,,,11/13/2019,11/13/2019,,,,,,,,,,,1/3/2020,1/3/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/31/2020,3/31/2020,,,,,,,,,,,,,,,3/31/2020,3/31/2020,,,,,,
SHP643-301,SHP643-301,'SHP643-301,,Takhzyro (Lanadelumab),Lanadelumab Pediatrics (6-11 year olds),Lanadelumab Pediatrics (6-11 year olds),III,Recruitment Complete,Renal Fibrosis associated with CKD,RGH,RGH,,Pediatric only (<18 yr),Interventional,Prevention,,,25,21,24,,3,,2,84.00%,10,16,,PPD,,Tanya Annunziata,,Ming Yu,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,6/25/2018,6/25/2018,5/10/2019,5/10/2019,,,,,10/14/2019,10/14/2019,,,10/16/2020,10/16/2020,,,11/12/2021,,,,,,,,,,,,1/6/2022,,,,,,,,,,2/2/2022,,,,,,,,,,,,,,,,,,,,,,,,4/27/2022,,,,,,,,,,,,,,,,4/27/2022,,,,,,,
SHP643-302,SHP643-302,'SHP643-302,,Takhzyro (Lanadelumab),Lanadelumab Japan,Lanadelumab Japan,III,Recruitment Complete,Hereditary Angioedema,RGH,RGH,,Both pediatric and non-pediatric,Interventional,Prevention,,,12,12,13,,1,,,100.00%,10,,,IQVIA,,Ian Shempp,,Ming Yu,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,12/8/2018,12/8/2018,4/9/2019,4/9/2019,,,12/11/2019,12/11/2019,1/30/2020,1/30/2020,,,7/30/2020,7/30/2020,,,8/26/2021,,,,,,,,,,,,10/11/2021,,,,,,,,,,10/31/2021,,,,,,,,,,,,,,11/12/2021,,,,,,,,,,12/20/2021,,,,,,,,,,,,,,,,12/20/2021,,,,,,,
SHP643-303,SHP643-303,'SHP643-303,,Takhzyro (Lanadelumab),"A Phase 3A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Bradykinin-mediated Angioedema",SHP643-303 Lanadelumab,III,Recruiting,(BMA) Bradykinin-mediated angioedema,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,Prevention,,,75,46,74,,12,36,1,61.33%,50,43,,IQVIA,,Jennifer Moran,,Ming Yu,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,4/2/2019,4/2/2019,8/7/2019,8/7/2019,,,5/4/2020,5/4/2020,8/4/2020,8/4/2020,,,2/21/2022,,,,9/5/2022,,,,,,,,,,,,10/4/2022,,,,,,,,,,10/18/2022,,,,,,,,,,,,,,,,,,,,,,,,2/8/2023,,,,,,,,,,,,,,,,2/8/2023,,,,,,,
SHP643-304,SHP643-304,'SHP643-304,,Takhzyro (Lanadelumab),SHP643 China Post Approval Commitment (PAC) study,SHP643 China Post Approval Commitment (P,III,Planned,Hereditary Angioedema,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,,,,999,,,,,,,,999,,,IQVIA,,Ian Shempp,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,7/30/2021,,,,,,7/30/2022,,,,11/30/2023,,,,7/15/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/15/2025,,,,,,,,,,,,,,,,1/15/2025,,,,,,,
SHP643-401,SHP643-401,'SHP643-401,,Takhzyro (Lanadelumab),Lanadelumab Time & Motion and Qualitative Patient Preference Study,Lanadelumab Patient Preference Study US,IV,Study Withdrawn,Hereditary Angioedema,RGH,,Non-Registry,,Non-Interventional_CDO Support,,,,50,0,0,0,0,0,0,0.00%,5,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/1/2049,,1/1/2049,,1/1/2049,,,,1/1/2049,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,1/1/2049,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
SHP643-402,SHP643-402,'SHP643-402,,Takhzyro (Lanadelumab),Lanadelumab EU Outcome Study,Lanadelumab EU Outcome Study,IV,Recruiting,Renal Fibrosis associated with CKD,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,Other,Prospective,Cohort,200,85,0,,0,0,5,42.50%,35,27,,PPD,,Rana Radmard,,,,,,Submitted and pending,,,NA,Advance,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP643-403,SHP643-403,'SHP643-403,,,Lanadelumab US-CA Outcome Study,Lanadelumab US-CA Outcome Study,IV,Recruiting,,,Real World Evidence,,Both pediatric and non-pediatric,Observational,Other,Prospective,Cohort,270,145,0,,0,0,,53.70%,30,29,,IQVIA,,Rana Radmard,,Salome Juethner,,,,Approved,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP643-801,SHP643-801,'SHP643-801,,,"An observational, non-interventional, study of patients iwth Hereditary Angioedema in the United States and Canada (HAE Outcome Study)",HAE Outcome Study,IV,Study Terminated,Hereditary Angioedema,,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP647-221,SHP647-221,'SHP647-221,,,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof-of-Concept, Parallel-group study Investigating the Efficacy, Safety and Tolerability of Ontamalimab in Adults with Primary Sclerosing Cholangitis (PSC).","Efficacy, Safety and Tolerabiltiy of 647",II,Study Terminated,PSC,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,100,,,,,,,,63,,Shire,PPD,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/10/2018,12/10/2018,3/29/2019,,6/21/2019,,,,9/12/2019,,7/18/2019,,8/13/2020,,,,,,,,,,,,,,1/28/2021,,1/28/2021,,,,,,,,,,,,,,,,,,,,4/1/2021,,5/20/2021,,,,,,,,,,,,7/15/2021,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
SHP647-222,SHP647-222,'SHP647-222,,,A Phase 2 <TBD>,TBD,II,Study Terminated,PSC,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,Shire,PPD,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/28/2019,,3/19/2019,,1/15/2019,,,,12/16/2019,,11/20/2019,,12/16/2019,,,,,,,,,,,,,,2/9/2022,,2/9/2022,,,,,,,,,,,,,,,,,,,,1/15/2019,,6/1/2022,,,,,,,,,,,,7/27/2022,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
SHP647-301,SHP647-301,'SHP647-301,,SHP647,SHP647-301 UC Induction #1,SHP647-301 UC Induction #1,III,Completed,(UC) Ulcerative colitis,GI,,,,Interventional,,,,825,380,0,,0,0,34,46.06%,167,15,,PPD,,Vasanth Lekkala,"Martina Goestch, Peter Nagy",,,2017-000599-27,,,,,NA,,,Medidata CTMS (Pharma),,,,,7/18/2017,7/18/2017,,,11/9/2017,11/9/2017,2/9/2018,2/9/2018,,,4/22/2020,4/22/2020,,,7/22/2020,7/22/2020,,,,,,,,,,,12/2/2020,12/2/2020,,,,,,,,,12/16/2020,12/16/2020,,,,,,,,,,,,,,,,,,,,,,,4/26/2021,4/26/2021,,,,,,,,,,,,,,,7/21/2021,7/21/2021,,,,,,
SHP647-302,SHP647-302,'SHP647-302,,SHP647,SHP647-302 UC Induction #2,SHP647-302 UC Induction #2,III,Completed,(UC) Ulcerative colitis,GI,,,,Interventional,,,,825,279,0,,0,0,21,33.82%,168,20,,PPD,,Vasanth Lekkala,"Martina Goestch, Peter Nagy",,,2017-000572-28,,,,,NA,,,Medidata CTMS (Pharma),,,,,7/14/2017,7/14/2017,,,10/31/2017,10/31/2017,12/5/2017,12/5/2017,,,4/21/2020,4/21/2020,,,7/15/2020,7/15/2020,,,,,,,,,,,11/9/2020,11/9/2020,,,,,,,,,11/11/2020,11/11/2020,,,,,,,,,,,,,,,,,,,,,,,4/15/2021,4/15/2021,,,,,,,,,,,,,,,7/14/2021,7/14/2021,,,,,,
SHP647-303,SHP647-303,'SHP647-303,,SHP647,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)","SHP647-303 UC Maintenance, Figaro UC",III,Completed,(UC) Ulcerative colitis,GI,Late GI,,Non-pediatric only (>18 yr),Interventional,Treatment,,Other,696,400,0,,0,0,160,57.47%,420,183,,PPD,,Vanessa Taylor,"Martina Goestch, Peter Nagy",,,2017-000573-37,,,,,NA,,,Medidata CTMS (Pharma),,,,,7/14/2017,7/14/2017,,,4/4/2018,4/4/2018,4/4/2018,4/4/2018,,,7/22/2020,7/22/2020,,,6/30/2021,6/30/2021,,,,,,,,,,,8/12/2021,,,,,,,,,,8/12/2021,,,,,,,,,,,,,,,,,,,,,,,,11/18/2021,,,,,,,,,,,,,,,,6/29/2022,,,,,,,
SHP647-304,SHP647-304,'SHP647-304,,SHP647,SHP647-304 UC + CD LTS,SHP647-304 UC + CD LTS,III,Recruitment Complete,(CD/UC) Crohn's disease/ Ulcerative colitis,GI,,,,Interventional,,,,"2,453",583,0,,0,0,184,23.77%,402,229,,PPD,,"Deidre Williams, Vasanth Lekkala","Martina Goestch, Peter Nagy",,,2017-000574-11,,,,,NA,,,Medidata CTMS (Pharma),,,,,7/19/2017,7/19/2017,,,,,2/27/2018,2/27/2018,,,7/1/2021,7/1/2021,,,9/8/2023,,,,,,,,,,,,1/30/2024,,,,,,,,,,2/6/2024,,,,,,,,,,,,,,,,,,,,,,,,5/6/2024,,,,,,,,,,,,,,,,9/6/2024,,,,,,,
SHP647-305,SHP647-305,'SHP647-305,,SHP647,SHP647-305 CD Induction #1,SHP647-305 CD Induction #1,III,Completed,(CD) Crohn's disease,GI,,,Both pediatric and non-pediatric,Interventional,,,,"1,032",30,0,,0,0,2,2.91%,420,5,,PPD,,Vasanth Lekkala,"Martina Goestch, Peter Nagy",,,2017-000575-88,,,,,NA,,,Medidata CTMS (Pharma),,,,,12/21/2017,12/21/2017,,,6/25/2018,6/25/2018,8/29/2018,8/29/2018,,,3/25/2020,3/25/2020,,,7/7/2020,7/7/2020,,,,,,,,,,,11/25/2020,11/25/2020,,,,,,,,,12/9/2020,12/9/2020,,,,,,,,,,,,,,,,,,,,,,,4/16/2021,4/16/2021,,,,,,,,,,,,,,,7/6/2021,7/6/2021,,,,,,
SHP647-306,SHP647-306,'SHP647-306,,SHP647,SHP647-306 Induction #2,SHP647-306 CD Induction #2,III,Completed,(CD) Crohn's disease,GI,Late GI,,Both pediatric and non-pediatric,Interventional,,,,"1,032",34,0,,0,0,7,3.29%,420,8,,PPD,,Vasanth Lekkala,Peter Nagy,,,2017-000576-29,,,,,NA,,,Medidata CTMS (Pharma),,,,,12/21/2017,12/21/2017,,,6/11/2018,6/11/2018,7/17/2018,7/17/2018,,,4/16/2020,4/16/2020,,,8/18/2020,8/18/2020,,,,,,,,,,,11/24/2020,11/24/2020,,,,,,,,,12/4/2020,12/4/2020,,,,,,,,,,,,,,,,,,,,,,,4/16/2021,4/16/2021,,,,,,,,,,,,,,,8/17/2021,8/17/2021,,,,,,
SHP647-307,SHP647-307,'SHP647-307,,SHP647,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)",SHP647-307 CD Maintenance,III,Recruitment Complete,(CD) Crohn's disease,GI,Late GI,,,Interventional,Treatment,,Other,983,47,0,,0,0,21,4.78%,334,56,,PPD,,Vanessa Taylor,"Martina Goestch, Peter Nagy",,,2017-000617-23,,,,,NA,,,Medidata CTMS (Pharma),,,,,12/21/2017,12/21/2017,,,2/6/2019,2/6/2019,2/6/2019,2/6/2019,,,8/18/2020,8/18/2020,,,6/21/2021,6/21/2021,,,,,,,,,,,10/18/2021,,,,,,,,,,10/18/2021,,,,,,,,,,,,,,,,,,,,,,,,1/24/2022,,,,,,,,,,,,,,,,6/20/2022,,,,,,,
SHP647-308,SHP647-308,'SHP647-308,,,"A Multicenter, Open-Label, Two-Period Study to Assess the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of SHP647 in Paediatric Patients aged 6 to less than 18 years old with Moderate to Severe Ulcerative Colitis and Crohn�s Disease",SHP647-308 Pediatric UC + CD,III,Concept,,,,,,Interventional,,,,80,,,,,,,,30,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP648-101,SHP648-101,'SHP648-101,,TAK-748,"An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects",Phase 1/2 FIX Gene therapy in Hem B,I/II,Terminated,sGERD,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,,,,21,0,0,,2,0,,0.00%,20,12,,IQVIA,,Emily Skelton,Kavitha Rajavel,Michael Dockal,,2018-004024-11,,Submitted and pending,,,NA,,,Medidata CTMS (Pharma),,,,,5/15/2019,5/15/2019,,,5/13/2020,5/13/2020,8/19/2020,,,,4/5/2023,,,,4/9/2024,,5/7/2024,,,,,,,,,,8/9/2023,,,,,,,,6/27/2024,,9/1/2023,,,,,,,,,,,,,,9/20/2023,,,,,,,,7/29/2024,,9/9/2024,,,,,,,,,,,,,,,,9/9/2024,5/15/2019,,,,,,
SHP655-101,SHP655-101,'SHP655-101,,TAK-755,"Phase 1/2 randomized, double-blind, placebo controlled, ascending dose, safety and PK/PD study of SHP655 (rADAMTS13) in sickle cell disease at baseline health and during acute vaso-occlusive crisis",SHP655 SCD Phase 1/2,I/II,Recruiting,Short bowel syndrome,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Cohort,56,10,18,,4,10,2,17.86%,16,16,,IQVIA,,"Suman Raj, Laura Flynn","Cecilia Marquez, Nirjhar Chatterjee, Nisha Jain",,,,,,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,8/20/2018,8/20/2018,3/28/2019,3/28/2019,,,10/8/2019,10/8/2019,10/21/2019,10/21/2019,,,5/30/2022,,,,5/30/2022,,,,,,,,,,,,6/27/2022,,,,,,,,,,7/11/2022,,,,,,,,,,,,,,8/9/2022,,,,,,,,,,10/10/2022,,,,,,,,,,,,,,,,10/10/2022,,,,,,,
SHP655-201,SHP655-201,'SHP655-201,,TAK-755,"A Phase 2, multicenter, randomized, placebo-controlled, double-blind study evaluating the safety, efficacy, and pharmacokinetics of rADAMTS13 (SHP655) in the treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP) receiving standard of care (SoC) treatment",SHP655 aTTP Phase 2,II,Recruiting,Immune-mediated Thrombotic Thrombotocytopenic Purpura,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,Treatment,Prospective,Other,30,28,30,,2,28,,93.33%,26,26,,IQVIA,,"Christoph Cirillo, Suman Raj","Christopher Hibbard, Kayode Badejo",,,2018-003775-35,,,,,Wave 2,Advance,Wave 1,Medidata CTMS (Pharma),,,7/31/2018,7/31/2018,10/3/2018,10/3/2018,,,10/9/2019,10/9/2019,10/9/2019,10/9/2019,,,8/31/2021,,,,3/12/2022,,,,,,,,,,,,4/12/2022,,,,,,,,,,4/26/2022,,,,,,,,,,,,,,5/27/2022,,,,,,,,,,8/17/2022,,,,,,,,,,,,,,,,8/17/2022,,,,,,,
SHP659-203,SHP659-203,'SHP659-203,,,"SHP659 phase 2 (3-4 arms): Exploratory Endpoints (THM, Schimer test, OD5, ED5)",SHP659 Phase 2,II,Study Withdrawn,Dry eye,,,Non-Registry,,Interventional,,,,360,0,0,0,0,0,0,0.00%,40,,,,Helen Fitch,,Bruce Oliver,Kristina Man,Charlotte Almeida,,,,N,No,,,,COSMOS Inactive,,,3/5/2018,,5/21/2018,,,,,,10/23/2018,,10/22/2018,,,,,,,,,,,,,,,,10/7/2019,,10/7/2019,,,,,,,,,,,,,,,,,,,,11/25/2019,,12/16/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP660-401,SHP660-401,'SHP660-401,,MyPKFit,"Predictive performance of myPKFiT algorithm for ADVATE and BAX855 in pediatric patients less than 12 years old with severe hemophilia A: a Phase 3b/4, prospective, two arm, multi-center study",SHP660-401 MyPKFiT,IIIb,Planned,Support - Rare Diseases,RGH,,,Pediatric only (<18 yr),Interventional,,,,60,,,,,,,,50,,,TBD,,,William Savage,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP660-403,SHP660-403,'SHP660-403,'TAK-660-403,,"Evaluation of long-term safety of SHP660 (Antihaemophilic Factor [Recombinant] PEGylated, rurioctocog alfa pegol) in adolescents and adults =12 years of age with haemophilia A – A SHP660 Post-Authorisation Safety Study (PASS)
Phase 4 study",SHP660 PASS,IV,Study Withdrawn,Hemophilia A,,,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,PASS (Post Authorization Safety Study),,,200,0,0,0,0,0,0,0.00%,25,,Baxalta,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/13/2018,,1/1/2049,,8/30/2019,,,,10/1/2019,,10/1/2019,,9/30/2021,,,,,,,,,,,,,,9/30/2028,,9/30/2028,,,,,,,,,,,,,,,,,,,,1/1/2049,,1/31/2029,,,,,,,,,,,,3/31/2029,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
SHP660-404,SHP660-404,'SHP660-404,,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),"A Phase 4 Interventional Study Evaluating Safety, Efficacy and Pharmacokinetics of ADYNOVATE in Pediatric Previously Treated Patients (PTPs) with Severe Hemophilia A (FVIII <1%)",ADYNOVATE China PAC Study,III,Not Yet Recruiting,Hemophilia A,RGH,,,,Interventional,,,,24,,,,,,,,999,,,TBD,,Ali Aslan,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,5/31/2023,,,,,,2/25/2024,,,,6/29/2026,,,,12/26/2026,,,,,,,,,,,,1/25/2027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/24/2027,,,,,,,,,,,,,,,,7/24/2027,,,,,,,
SHP664-401,SHP664-401,'SHP664-401,,,"A phase 4  open-label, multidose, multicenter study to evaluate the performance reliability, safety, tolerability, of a wearable, subcutaneous infusion device in subjects with primary (humoral) immunodeficiency (PI)",Cuvitru Wearable device PID study,IV,Concept,,,,,Non-pediatric only (>18 yr),Interventional,,,,40,,,,,,,,4,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP664-402,SHP664-402,'SHP664-402,,CUVITRU,CANadian CUvitru Non-Interventional Study in Patients transitioning from subcutaneous IG,CANCUN,IV,Recruitment Complete,Primary Immunodeficiency,Plasma Derived Therapy,Real World Evidence,,Both pediatric and non-pediatric,Observational,,,,500,126,,,,,,25.20%,10,,,IQVIA,,Jeffrey Back,Enrique Garcia,,,,,,,,,,,Medidata CTMS (Pharma),,,,,7/16/2018,7/16/2018,,,,,9/30/2018,9/30/2018,,,8/31/2020,8/31/2020,,,8/31/2020,8/31/2020,,,,,,,,,,,,,,,,,,,,,10/31/2020,10/31/2020,,,,,,,,,,,,,,,,,,,,,,,1/31/2021,1/31/2021,,,,,,,,,,,,,,,1/31/2021,1/31/2021,,,,,,
SHP669-404,SHP669-404,'SHP669-404,,VPRIV (velaglucerase alfa),"An Open-label Study to Assess the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa Administered to Non-Na�ve Subjects as a Rapid Infusion",VPRIV Rapid Infusion,IV,All Activities Closed,Gaucher's,RGH,,,Both pediatric and non-pediatric,Interventional,,,,50,,,,,,,,12,,,TBD,,,Noga Gadir,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP669-405,SHP669-405,'SHP669-405,,,Canadian VPRIV Non-Interventional Study in Patients previously treated  with other ERTs/SRTs,Canadian VPRIV Switching Study,IV,Recruiting,,,Real World Evidence,,Both pediatric and non-pediatric,Observational,Other,Other,Other,12,2,,,,,,16.67%,6,,,IQVIA,,Claudia Schwarz,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP670-301,SHP670-301,'SHP670-301,,,New efficacy PMC Aralast/Glassia study,SHP670-101 Aralast/Glassia efficacy Ph3/,IIIb,Study Withdrawn,Alpha-1 antitrypsin deficiency,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Randomized,,,300,0,0,0,0,0,0,0.00%,15,,,IQVIA,,Thomas Soucek,,,,,,,N,No,,,,COSMOS Inactive,,,4/19/2019,,6/7/2019,,12/4/2019,,,,2/25/2020,,12/31/2019,,2/14/2022,,,,,,,,,,,,,,2/9/2026,,2/9/2026,,,,,,,,,,,,,,,,,,,,5/10/2026,,5/10/2026,,,,,,,,,,,,8/8/2026,,,,,,,,,,,,,,,,,,1/3/2020,,1/3/2020,,,
SHP670-302,SHP670-302,'SHP670-302,'TAK-670-3002,,"A Prospective, Randomized, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Three Doses of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects with A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)",SHP670-302 Glassia Exacerbations study,IIIb,Study Withdrawn,Alpha-1 antitrypsin deficiency,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Randomized,,,130,0,0,0,0,0,0,0.00%,70,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP670-401a,SHP670-401a,'SHP670-401a,'TAK-670-4001,,Glassia Post Marketing Commitment Human Factors Evaluation - Usability Study,SHP670-401a Human Factors Evaluation,N/A,Study Withdrawn,Alpha-1 antitrypsin deficiency,,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,Post Approval Commitment,,,50,0,0,0,0,0,0,0.00%,5,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP671-101,SHP671-101,'SHP671-101,'TAK-771-1001,,SHP671 HyQ (CIDP-4) Dose Ramp-up,SHP671 CIDP Dose Ramp-up Ph1,I,Study Withdrawn,CIDP,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,10,,,,,,,,1,,Baxalta,,Andras Nagy,,Steve Glyman,,Paz Carrasco,,,,,,,,,COSMOS Inactive,,,1/10/2020,,1/31/2020,,,,,,1/1/2049,,4/14/2020,,7/14/2020,,,,,,,,,,,,,,10/30/2020,,10/30/2020,,,,,,,,,,,,,,,,,,,,1/1/2049,,12/18/2020,,,,,,,,,,,,1/7/2021,,,,,,,,,,,,,,,,,,,,,,,
SHP675-301,SHP675-301,'SHP675-301,,Replagal (agalsidase alfa),"A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of
Replagal in Treatment- naive Subjects with Fabry Disease",Replagal�,III,Recruiting,Risk reduction of thrombosis/embolism and prevention of GU associated with L-ASA,RGH,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,45,,,,,,,,46,12,,TBD,,"Tosha Marie Doornek, Margaret Szerszunowicz",David Alexanderian,,,2018-004689-32,,,,,,,,Medidata CTMS (Pharma),,,3/30/2018,3/30/2018,2/1/2019,2/1/2019,,,9/27/2021,,11/5/2021,,,,5/30/2025,,,,7/22/2027,,7/4/2027,,,,,,,,,,10/28/2027,,,,,,,,,,11/11/2027,,,,,,,,,,,,,,12/13/2027,,,,,,,,,,4/21/2028,,,,,,,,,,,,,,,,4/21/2028,,,,,,,
SHP677-304,SHP677-304,'SHP677-304,,Vonvendi (von Willebrand factor (recombinant)),"A phase 3b, prospective, open-label, uncontrolled, multicenter study on long-term safety and efficacy of rVWF in pediatric and adult subjects with severe von Willebrand disease (VWD)",rVWF Pediatric and Adult Study,IIIb,Recruiting,Support,RGH,RGH,,Both pediatric and non-pediatric,Interventional,Other,Prospective,Cohort,64,33,0,,1,0,,51.56%,55,33,,IQVIA,,Angela Calvillo,,,,2018-003453-16,,,,,,,,Medidata CTMS (Pharma),,,6/7/2018,6/7/2018,8/29/2018,8/29/2018,,,,,4/1/2019,4/1/2019,,,3/25/2022,,,,3/25/2025,,,,,,,,,,,,5/9/2025,,,,,,,,,,5/15/2025,,,,,,,,,,,,,,7/6/2025,,,,,,,,,,9/7/2025,,,,,,,,,,,,,,,,9/7/2025,,,,,,,
SHP677-401,SHP677-401,'SHP677-401,,,General Drug Use Results Survey for Vonvendi in Japan,Vonvendi Japan DURS,IV,All Activities Closed,,,,,Non-pediatric only (>18 yr),Observational,,,,100,,,,,,,,60,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP677-801,SHP677-801,'SHP677-801,,,"Natural History, Treatment Patters and Clinical Outcomes amonth patient with Von Willebrand Disease in the UK CLinical Practice Research Datalink 1989-2016",Von Willebrand Disease in the UK CPRD,N/A,Study Terminated,Von Willebrand Disease,,,Non-Registry,,Non-Intervention_Other Support,Epi Studies (Eg Database Analyses),,,999,0,0,0,0,0,0,0.00%,999,,,The Boston Collaborative Drug Surveillance Program,Lynn Sanders,,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/16/2017,10/16/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/9/2018,6/5/2019,,,,,,,,,,,12/13/2019,,,,,,,,,,,,,,,,,,,,,,,
SHP677-802,SHP677-802,'SHP677-802,,,"Natural History, Burden and Clinical Outcomes among Patients with Von WIllebrand Disease in Denmark",Natural History of VWD in Denmark,N/A,Study Terminated,Von Willebrand Disease,,,Non-Registry,,Non-Intervention_Other Support,Epi Studies (Eg Database Analyses),,,999,0,0,0,0,0,0,0.00%,999,,,Aarhus University Hospital,Lynn Sanders,,,,,,,,N,No,,,,COSMOS Inactive,,,,,7/9/2018,7/9/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/30/2019,,,,,,,,,,,,12/20/2019,,,,,,,,,,,,,,,,,,,,,,,
SHP680-101,SHP680-101,'SHP680-101,,,TBD - SAD,Adult PK CFS,I,All Activities Closed,,,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP680-102,SHP680-102,'SHP680-102,,,TBD - PEDS,Peds PK,I,All Activities Closed,,,,,Pediatric only (<18 yr),Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP680-301,SHP680-301,'SHP680-301,,,Phase 2/3 Pivotal Adult CFS,Phase 2/3 Pivotal 1 Adult CFS,II/III,All Activities Closed,,,,,Non-pediatric only (>18 yr),Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP680-302,SHP680-302,'SHP680-302,,,Phase 3 Pivotal 2 Adult CFS,Phase 3 Pivotal 2 Adult CFS,III,All Activities Closed,,,,,Non-pediatric only (>18 yr),Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP680-303,SHP680-303,'SHP680-303,,,TBD - Open Label Extension CFS,OLE CFS,III,All Activities Closed,,,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP681-101,SHP681-101,'SHP681-101,,TAK-681,"A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 in Healthy Adult Subjects",SHP681-101 FIH SAD MAD,I,Study Terminated,Short Bowel Syndrome,GI,N/A,Non-Registry,Non-pediatric only (>18 yr),Interventional,Safety,,,90,107,,,,,,118.89%,1,1,,IQVIA,Christina Faragalla,"George Apostol, Yinghua Shen, Rhett Behrje",Patrick Martin,"Arnaz Malhi, Laura McCarthy","Dustin Zahm, Kaivan Charmchi",,,,N,No,,,,COSMOS Inactive,,,9/3/2018,9/3/2018,8/19/2018,8/19/2018,,,2/25/2019,2/25/2019,3/25/2019,3/25/2019,,,11/11/2019,11/11/2019,,,1/2/2020,,,,,,,,,,,,10/1/2019,10/1/2019,,,,,,,,,10/21/2019,10/21/2019,,,,,,,,,,,,,3/2/2020,,,,,,,,,,6/1/2020,,,,,,,,,,,,,,,,6/1/2020,,,,,,,
SHP681-301,SHP681-301,'SHP681-301,'TAK-681-300x,TAK-681,N/A at the moment,SHP681-301 SBS-IF DB PCB,II/III,Study Withdrawn,Short Bowel Syndrome,GI,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Safety,,,120,,,,,,,,50,,Shire HGT,IQVIA,,Robin Morey,,,,,,,N,No,,,,COSMOS Inactive,,,2/18/2020,,4/1/2020,,,,8/28/2020,,8/31/2020,,,,6/3/2022,,,,6/2/2023,,,,,,,,,,,,7/28/2023,,,,,,,,,,8/11/2023,,,,,,,,,,,,,,,,,,,,,,,,2/27/2024,,,,,,,,,,,,,,,,11/21/2023,,,,,,,
SHP681-302,SHP681-302,'SHP681-302,'TAK-681-300x,TAK-681,Unknown at this time,SHP681-302 OLE,III,Study Withdrawn,Short Bowel Syndrome,GI,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Extension,,,120,,,,,,,,30,,Shire HGT,IQVIA,,Robin Morey,,,,,,,N,No,,,,COSMOS Inactive,,,4/1/2020,,4/1/2020,,,,,,9/24/2021,,,,6/2/2023,,,,5/31/2024,,,,,,,,,,,,8/9/2024,,,,,,,,,,8/23/2024,,,,,,,,,,,,,,,,,,,,,,,,3/11/2025,,,,,,,,,,,,,,,,3/11/2025,,,,,,,
SHP682-101,SHP682-101,'SHP682-101,,TAK-682 (velaglucerase alfa),"A Randomized, Four-treatment, Parallel-Design, Phase 1 Study to Assess the Pharmacokinetics, Relative Bioavailability, Safety, and Tolerability of a Single Dose of either Intravenous or Subcutaneous of Velaglucerase Alfa in Healthy Adult Subjects",FIH,I,All Activities Closed,,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,,,,48,,,,,,,,1,,,TBD,,Jenny Wallis,,,,,,,,,,,,Medidata CTMS (Pharma),,,7/26/2019,7/26/2019,6/25/2040,,,,,,6/30/2040,,,,7/13/2040,,,,12/21/2040,,,,,,,,,,,,1/28/2041,,,,,,,,,,1/28/2041,,,,,,,,,,,,,,2/27/2041,,,,,,,,,,7/27/2041,,,,,,,,,,,,,,,,7/27/2041,,,,,,,
SHP684-101,SHP684-101,'SHP684-101,,TAK-684,"A Randomized, Double-blind, Placebo-controlled, Single-Center, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Single and Multiple Oral Doses of SHP684 and the Effect of Food in Healthy Volunteer Adult Subjects",SHP684-101,I,All Activities Closed,Hereditary Angioedema,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,,,,166,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,1/31/2019,1/31/2019,8/26/2019,8/26/2019,,,6/30/2020,,,,,,1/6/2022,,,,1/31/2022,,,,,,,,,,,,2/21/2022,,,,,,,,,,,,,,,,,,,,,,,,3/22/2022,,,,,,,,,,6/8/2022,,,,,,,,,,,,,,,,6/8/2022,,,,,,,
SHP-001-801,SHP-001-801,'SHP-001-801,,Elaprase (idursulfase),"Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in combination with Pediatric Ear, Nose and Throat (ENT) Surgery (Adenoidectomy and/or Tonsillectomy and/or Tympanostomy) (The HATT Project))",MPS Screening with GMA,0,Study Terminated,Hunter Syndrome,RGH,,Non-Registry,,Interventional,,,,,65,0,,0,0,0,,25,,,PPD,,,,,"Jennifer Cislo, Joseph Tiedeken, Karen Rose, Latara Lewis, Maria Guerrero, Pilar Saucedo, Rana Smits, Samantha Grant, Samir Bassiouni, Simona Ruocco, Susan Vogt, Volkan Kurtulus, Efrosini Afendra, Elisa Bonacina, Esra Kaplan, Esra Kilic, Francis Hetu, Gerardo Escobar, Giulia Zotti, Isabelle Dupuis, Alicia Rodriguez, Alisa Mikhailova, Angela Scalzo, Anna Kynast, Araceli Barron, Artyom Stepanov, Begona Maganto, Chenying Bao, Christiane Emde, Claudia Lopez, Jennifer Bassiouni",,,,N,No,,,,COSMOS Inactive,,,9/20/2013,9/20/2013,10/11/2013,10/11/2013,,,5/21/2014,5/21/2014,5/21/2014,5/21/2014,,,1/1/2015,1/1/2015,,,8/31/2015,8/31/2015,,,,,,,,,,,,,,,,,,,,,10/30/2015,10/30/2015,,,,,,,,,,,,,,,,,,,,,,,9/30/2016,9/30/2016,,,,,,,,,,,,,,,9/30/2016,9/30/2016,,,,,,
SHP-607-201,SHP-607-201,'SHP-607-201,,TAK-607 (mecasermin rinfabate),Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care,SHP-607-201 PEDAL,II,Recruitment Complete,sGERD/ erosive esophagitis,RGH,RGH,,Pediatric only (<18 yr),Interventional,,,,106,84,0,,0,0,30,79.25%,31,12,,PPD,,Tina Banks,,,,2014-003556-31,,Approved,,,Wave 2,De-Risk,,Medidata CTMS (Pharma),,,6/30/2014,6/30/2014,8/27/2014,8/27/2014,,,3/26/2015,3/26/2015,3/26/2015,3/26/2015,,,6/22/2016,6/22/2016,,,8/11/2021,,,,,,,,,,,,10/20/2021,,,,,,,,,,12/21/2021,,,,,,,,,,,,,,12/21/2021,,,,,,,,,,1/19/2022,,,,,,,,,,,,,,,,1/19/2022,,,,,,,
SHP-608-001,SHP-608-001,'SHP-608-001,,,A Single Center Study to Evaluate Quantitative Methods for Assessment of Skin Involvement by Faux Wounds in Normal Healthy Volunteers,SHP608-001 HV Method Dev study,0,Completed,Dystrophic Epidermolysis Bullo,,,Non-Registry,,Non-Interventional_CDO Support,Healthy Volunteers,,,,3,0,,0,0,0,,1,,,PPD,,Pallavi Tadimeti,Anna Wijatyk,,,,,,N,No,,,,COSMOS Inactive,,,6/14/2013,6/14/2013,9/25/2013,9/25/2013,,,,,12/12/2013,12/12/2013,12/12/2013,12/12/2013,2/17/2014,2/17/2014,,,,,,,,,,,,,2/17/2014,2/17/2014,2/17/2014,4/7/2014,,,,,,,,,,,,,,,,,,,4/21/2014,4/21/2014,5/2/2014,5/2/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP-608-002,SHP-608-002,'SHP-608-002,,,"A Prospective Short-term Study to Evaluate Methodologies for the Assessment of Disease Extent, Impact, and Wound Evolution in Patients with Dystrophic Epidermolysis Bullosa (DEB)",Short Term Observational Study,0,Completed,Dystrophic Epidermolysis Bullo,,,Non-Registry,,Non-Interventional_CDO Support,Adolescent,,,,30,0,,0,0,1,,10,,,PPD,,"Pallavi Tadimeti, Yelena Shvenke",,,"Simona Ruocco, Alison Dobbie",,,,N,No,,,,COSMOS Inactive,,,6/14/2013,6/14/2013,11/18/2013,11/18/2013,,,,,6/24/2014,6/24/2014,6/24/2014,6/24/2014,2/3/2015,1/26/2015,,,,,,,,,,,,,3/5/2015,2/23/2015,3/5/2015,6/16/2015,,,,,,,,,,,,,,,,,,,7/10/2015,7/10/2015,7/31/2015,7/30/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP-609-203,SHP-609-203,'SHP-609-203,,,"An Open-Label Extension of Study HGT-HIT-046: An Open-Label Extension of Study HGT-HIT-045, Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Patients with Hunter Syndrome and Cognitive Impairment",Extension of Study HGT-HIT-045,II,Study Withdrawn,Hunter Syndrome,,,Non-Registry,,Interventional,,,,13,0,0,0,0,0,0,0.00%,9,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP-609-302,SHP-609-302,'SHP-609-302,,,An Open-Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome and Cognitive Impairment.,SHP609-302 Ped LT Safety Extn to HIT-094,III,Study Terminated,Hunter Syndrome,,RGH,Non-Registry,Pediatric only (<18 yr),Interventional,Long-Term,,,43,,,,,,,,9,22,,PPD,Steve Gust,"Amanda Reynolds, Stanislaw Czekalski, Sunetra Chavan, Kate Reid, Navjyot Sangha, Sharon Kunder, Shivakumar Patil",David Alexanderian,Rebecca Pyle,"Amine Ammar, Araceli Barron, Ayanna Sissoko, Claire Coulson, Claudia Lopez, Danielle Foerster, Diana Ceron, Emma Sealey, Friso Van Gent, Judith Barrera, Karen Rose, Khay Leong, Kirstin Robertson, Kirsty Stanton, Laura Flynn, Lynn Cherney, Madonna Dela Cruz, Marco Parente, Maxine Cunningham, Pedro Valdovinos, Qiana Quinn, Quentin Liffran, Rosa Barrio, Ryan Guthrie, Scott Prangley, Sharon Clarke",2014-004143-13,,,N,No,,,,COSMOS Inactive,,,7/28/2014,7/28/2014,10/2/2014,10/2/2014,,,,,4/14/2015,4/14/2015,4/14/2015,4/14/2015,9/29/2017,,,,,,,,,,,,,,6/30/2027,,6/30/2027,,,,,,,,,,,,,,,,,,,,9/29/2027,,9/29/2027,,,,,,,,,,,,12/8/2027,,,,,,,,,,,,,,,,,,,,,,,
SHP-610-201,SHP-610-201,'SHP-610-201,,,An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Pediatric Patients with Mucopolysaccharidosis Type IIIA Disease,IIB Extn of 093 OL Ped,IIb,Completed,Sanfilippo A Syndrome,,,Non-Registry,Pediatric only (<18 yr),Interventional,Safety,,,21,17,0,,0,0,17,80.95%,10,,,PPD,Jeffrey Bernier,Sharon Kunder,David Alexanderian,,"Abibou Ba, Chiara Rigoldi, Claudia Lopez, Dan Russo, Daniela Panico, Dhikra Bouraba, Diana Ceron, Elfie Hensch, Friso Van Gent, Karen Rose, Laura Flynn, Loes Pelgrim, Monique Mets, Peter Ten Tuijnte, Silvia Perez, Sophie Paskarajesudasan, Sylvanie Malouitre",2014-003960-20,,,N,No,,,,COSMOS Inactive,,,7/28/2014,7/28/2014,9/23/2014,9/23/2014,,,,,4/8/2015,4/8/2015,2/17/2016,,6/8/2016,6/8/2016,,,,,,,,,,,,,3/7/2019,,3/7/2019,,,,,,,,,,,,,,,,,,,,8/4/2019,,8/14/2019,,,,,,,,,,,,10/10/2019,,,,,,,,,,,,,,,,,,,,,,,
SHP-ELA-401,SHP-ELA-401,'SHP-ELA-401,,Elaprase (idursulfase),"A Long-Term, Open-Label, Multicenter, Phase IV Study of the Effect of Elaprase on Height and Weight in Participants with MPS II Who Started Treatment With Elaprase at <6 Years of Age",SHP-ELA-401 - Ped PAC #1,IV,Recruitment Complete,Hunter Syndrome treatment of somatic symptoms,RGH,Marketed Products,,Pediatric only (<18 yr),Interventional,,,,20,21,0,,0,0,3,105.00%,12,9,,PPD,,"Kerri Whyte, Christy Saulters",David Whiteman,,,2014-004804-31,,,,,,,,Medidata CTMS (Pharma),,,12/31/2013,12/31/2013,6/11/2014,6/11/2014,,,,,10/28/2015,10/28/2015,,,8/8/2017,8/8/2017,,,7/9/2025,,,,,,,,,,,,8/20/2025,,,,,,,,,,8/25/2025,,,,,,,,,,,,,,10/30/2025,,,,,,,,,,1/2/2026,,,,,,,,,,,,,,,,1/2/2026,,,,,,,
SHP-ELA-402,SHP-ELA-402,'SHP-ELA-402,,Elaprase (idursulfase),A Blood Sample Collection Study for Determination of CRIM Status from Patients with MPS II who Completed Study HGT-ELA-038,SHPELA-402 - Bld Smple CRIM Status,IV,Study Terminated,Hunter Syndrome,RGH,,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,,,,27,0,0,0,0,0,0,0.00%,3,,,PPD,Alkisti Rouvas,"Alex Linica, Anthony Baiamonte, Gilles Pierrefiche, Kate Reid, Safwan Abbassy, Sharon Kunder",David Whiteman,Sean Seyffert,"Ai Honda, Erik Huang",,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP-GCB-402,SHP-GCB-402,'SHP-GCB-402,,VPRIV (velaglucerase alfa),"An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment with Velaglucerase alfa on Bone-related Pathology in Treatment-na�ve Patients with Type 1 Gaucher Disease",VPRIV LCM Bone Study,IV,Completed,Gaucher's,RGH,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,19,21,49,,28,21,5,110.53%,17,8,,PPD,,"Tosha Marie Doornek, Chemmene Cassidy",Richard Finkelman,,,2015-001578-17,,Approved,,,,,,Medidata CTMS (Pharma),,,1/26/2015,1/26/2015,4/30/2015,4/30/2015,,,5/2/2016,5/2/2016,6/29/2016,6/29/2016,,,11/30/2018,11/30/2018,,,2/1/2021,,,,,,,,,,,,4/30/2021,,,,,,,,,,5/17/2021,,,,,,,,,,,,,,6/2/2021,,,,,,,,,,9/29/2021,,,,,,,,,,,,,,,,9/29/2021,,,,,,,
SHP-REP-0xa,SHP-REP-0xa,'SHP-REP-0xa,,,Fabry Natural History Study  placeholder,Fabry Natural History Study placeholder,0,Study Withdrawn,Fabry Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,46,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/9/2015,,1/20/2016,,,,,,7/5/2016,,7/5/2016,,11/21/2019,,,,,,,,,,,,,,5/9/2022,,5/9/2022,,,,,,,,,,,,,,,,,,,,7/4/2022,,7/11/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHP-REP-3xa,SHP-REP-3xa,'SHP-REP-3xa,,,RD SHP-REP-3xa extension study,SHP-REP-302 Extension Trial  placeholder,III,Study Withdrawn,Fabry Disease,,,Non-Registry,,Interventional,Extension,,,60,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/1/2016,,1/31/2017,,,,,,7/31/2017,,,,8/29/2020,,,,,,,,,,,,,,9/30/2022,,9/30/2022,,,,,,,,,,,,,,,,,,,,12/13/2022,,1/17/2023,,,,,,,,,,,,3/14/2023,,,,,,,,,,,,,,,,,,,,,,,
SHP-REP-301,SHP-REP-301,'SHP-REP-301,,,"A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Clinical Study of Efficacy, Pharmacodynamics, and Safety of Replagal® Enzyme Replacement Therapy in Patients with Fabry Disease",Replagal Phase III,III,Study Withdrawn,Fabry Disease,,,Non-Registry,,Interventional,Double-Blind,,,46,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/2/2014,9/2/2014,1/29/2015,,,,,,9/24/2015,,7/30/2015,,11/1/2018,,,,,,,,,,,,,,5/9/2019,,5/9/2019,,,,,,,,,,,,,,,,,,,,6/27/2019,,7/18/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHPELA-701,SHPELA-701,'SHPELA-701,,Elaprase (idursulfase),PV Monitoring Study of Elaprase in Mexico,PV Monitoring Study of Elaprase in Mexic,IV,Completed,Hunter Syndrome,RGH,Real World Evidence,Non-Registry,Both Pediatric & Non-pediatric,Non-Interventional_CDO Support,,,,25,5,0,,0,0,,20.00%,25,3,,IQVIA,Zorana Radak Jovanovic,,,,,,,,N,No,,,,COSMOS Inactive,,,11/16/2016,11/16/2016,11/16/2016,11/16/2016,1/1/2049,,1/19/2018,1/19/2018,*,*,11/30/2017,11/30/2017,11/29/2019,5/10/2019,,,5/11/2020,5/11/2020,,,,,,,,,11/30/2020,5/10/2020,*,8/28/2020,,,,,,,,,,,,,,,,,,,1/1/2049,,2/1/2021,,10/27/2020,10/27/2020,,,,,,,,,*,10/27/2020,,,,,,,,,,,,,,,10/27/2020,10/27/2020,1/1/2049,,1/1/2049,,,
SHPFIR-101,SHPFIR-101,'SHPFIR-101,,Firazyr (Icatibant),"An Open-label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers",Phase 1 Japanese healthy volunteer,I,Completed,Hereditary Angioedema,RGH,,Non-Registry,Non-pediatric only (>18 yr),Interventional,PK,,,12,12,0,0,0,0,0,100.00%,1,,,Parexel,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/2/2013,10/2/2013,12/20/2013,12/20/2013,,,,,2/22/2014,2/22/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/29/2014,5/29/2014,,,,,,,,,,,,,,,,,,,,,,,8/29/2014,8/29/2014,,,,,,,,,,,,,,,8/29/2014,8/29/2014,,,,,,
SHPFIR-301,SHPFIR-301,'SHPFIR-301,,Firazyr (Icatibant),An Open-Label Study of Icatibant in Adult Japanese Subjects with Acute Attacks of Hereditary Angioedema,SHPFIR-301  OL,III,Completed,Hereditary Angioedema,RGH,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,,,,8,8,16,0,0,0,0,100.00%,10,,,Parexel,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/24/2013,10/24/2013,6/30/2014,6/30/2014,,,3/17/2015,3/17/2015,4/7/2015,4/7/2015,,,1/29/2016,1/29/2016,,,2/5/2016,2/5/2016,,,,,,,,,,,,,,,,,,,,,4/5/2016,4/5/2016,,,,,,,,,,,,,,,,,,,,,,,7/28/2016,7/28/2016,,,,,,,,,,,,,,,7/28/2016,7/28/2016,,,,,,
SHPGCB-403,SHPGCB-403,'SHPGCB-403,,,VPRIV LCM Treatment Optimization Study,VPRIV LCM Treatment Optimization Study,IV,Study Withdrawn,Gaucher's Disease,,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,52,0,0,0,0,0,0,0.00%,10,,,,,,,Rebekah Gorney,,,,,N,No,,,,COSMOS Inactive,,,2/22/2016,,4/19/2016,,,,,,1/31/2017,,1/17/2017,,8/19/2019,,,,,,,,,,,,,,8/8/2021,,8/8/2021,,,,,,,,,,,,,,,,,,,,11/12/2021,,11/19/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHPREP-0xb,SHPREP-0xb,'SHPREP-0xb,,,LCM Study placeholder,LCM Biomarker Study placeholder,0,Study Withdrawn,Fabry Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,246,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/18/2015,,1/29/2016,,,,,,7/14/2016,,7/14/2016,,12/31/2018,,,,,,,,,,,,,,3/25/2019,,3/25/2019,,,,,,,,,,,,,,,,,,,,5/21/2019,,5/28/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHPREP-302,SHPREP-302,'SHPREP-302,,,"A Phase III, Double-Blind, Randomized, International Clinical Study of Efficacy and Safety of Replagal® Enzyme Replacement Therapy in Patients with Fabry Disease with Gastrointestinal Symptoms",Replagal Ph 3 GI endpoint trial,III,Study Withdrawn,Fabry Disease,,,Non-Registry,,Interventional,Double-Blind,,,60,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/19/2015,10/19/2015,6/29/2016,,,,,,1/31/2017,,1/17/2017,,1/28/2019,,,,,,,,,,,,,,7/26/2019,,7/26/2019,,,,,,,,,,,,,,,,,,,,10/21/2019,,10/28/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHPREP-401,SHPREP-401,'SHPREP-401,,,Health Canada study,HC PAC study placeholder,IV,Study Withdrawn,Fabry Disease,,,Non-Registry,,Non-Interventional_CDO Support,Efficacy,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/23/2017,,12/15/2017,,,,,,1/12/2019,,7/16/2018,,7/5/2020,,,,,,,,,,,,,,6/25/2022,,6/25/2022,,,,,,,,,,,,,,,,,,,,9/6/2022,,9/13/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-111,SLI381-111,'SLI381-111,,,A Phase 1 Study to Assess the Relative Bioavailability of Single 30mg Doses of ADDERALL XR® Capsules and ADDERALL® Tablets vs. an Oral Solution of Mixed Amphetamine Salts (MAS) in Healthy Adult Volunteers Aged 18-55,SLI381-111 BA Adlt,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Open Label,,,18,18,18,0,0,0,1,100.00%,1,,,"Aris Clinical, INC",Bao-Van Tran,,,,,,,,N,No,,,,COSMOS Inactive,,,2/4/2005,2/4/2005,6/3/2005,6/3/2005,,,,,7/14/2005,7/14/2005,,,,,,,,,,,,,,,,,8/1/2005,8/1/2005,8/1/2005,9/12/2005,,,,,,,,,,,,,,,,,,,,,10/5/2005,10/5/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-201,SLI381-201,'SLI381-201,,,"A Randomized, Double-Blind, Placebo and Active-Controlled, Crossover Study of SLI381 in Children with Attention Deficit Hyperactivity Disorder",SLI381-201,II,Completed,ADHD,,,Non-Registry,,Interventional,,,,60,24,28,0,4,0,0,40.00%,4,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-301,SLI381-301,'SLI381-301,,,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SLI381 in Children with Attention Deficit/Hyperactivity Disorder",SLI381-301 DB Rand PBO,III,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,450,0,0,0,0,0,0,0.00%,47,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,9/20/1999,9/20/1999,,,,,10/20/1999,10/20/1999,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-302,SLI381-302,'SLI381-302,,,An Open Label Study of SL381 in Children with Attention Deficit Hyperactivity Disorder,SLI381-302 OL PED SD,III,Completed,ADHD,,,Non-Registry,,Interventional,Open Label,,,568,0,0,0,0,0,0,0.00%,49,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/17/1999,9/17/1999,,,,,,,11/20/1999,11/20/1999,,,,,,,,,,,,,,,,,5/23/2002,5/23/2002,5/23/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-312,SLI381-312,'SLI381-312,,,"An Open-Label, Multi-Center Study to Assess Tolerability, Effectiveness and Quality of Life Associated with the Use of SLI381 (ADDERALL XR) in Adults with Attention Deficit Hyperactivity Disorder (ADHD) in a Community Practice Setting",SLI381-312 OL CET,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Efficacy,,,724,,,,,0,,,81,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/14/2003,7/14/2003,11/13/2003,11/13/2003,,,,,12/20/2003,12/20/2003,,,,,,,,,,,,,,,,,2/25/2005,2/25/2005,2/25/2005,4/14/2005,,,,,,,,,,,,,,,,,,,4/25/2005,4/25/2005,6/27/2005,6/27/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-315,SLI381-315,'SLI381-315,,,"A Phase III, Multi-center, 18-month, Open-label Safety, Tolerability and Efficacy Study of ADDERALL XR® in the Treatment of Adolescents Aged 13-18 with Attention Deficit Hyperactivity Disorder (ADHD)",SLI381-315 Adol OL,III,Completed,ADHD,,,Non-Registry,,Interventional,Adolescent,,,255,234,0,0,0,0,0,91.76%,55,,,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-316,SLI381-316,'SLI381-316,,,A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment with ADDERALL XR® and STRATTERA® Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults with Attention Deficit Hyperactivity Disorder (ADHD),SLI381-316 Adlt Cog,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Comparator,,,36,,,,,0,,,1,,,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/21/2003,11/21/2003,12/19/2003,12/19/2003,,,,,4/28/2004,4/28/2004,,,,,,,,,,,,,,,,,10/26/2004,10/26/2004,10/26/2004,10/26/2004,,,,,,,,,,,,,,,,,,,12/6/2004,12/6/2004,1/5/2005,1/5/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-317,SLI381-317,'SLI381-317,,,"A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Forced-Dose Escalation Study, to Assess the Safety and Dose Response of ADDERALL XR 60mg Compared to ADDERALL XR 20mg, in Adults with ADHD and Moderate to Severe Symptom Impairment.",SLI381-317 DB Adlt forced,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,560,,,,,0,,,60,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-410,SLI381-410,'SLI381-410,,,SLI381-410,SLI381-410 Adlt,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Multi-Centre,,,999,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-411,SLI381-411,'SLI381-411,,,SLI381-411,SLI381-411 OL Rand,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Efficacy,,,999,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SLI381-412,SLI381-412,'SLI381-412,,,SLI381-412,SLI381-412 Multi-centre,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Multi-Centre,,,"1,000",,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-1xa,SPD405-1xa,'SPD405-1xa,,,EZ Chew BE Study,SPD405-1xa EZ Chew BE Study,I,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/10/2009,,10/23/2009,,,,,,1/11/2010,,,,1/21/2010,,,,,,,,,,,,,,2/12/2010,,2/12/2010,,,,,,,,,,,,,,,,,,,,4/21/2010,,5/26/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-3xa,SPD405-3xa,'SPD405-3xa,,,"A phase III, randomised, multi centre, 6 month parallel group study comparing Fosrenol with placebo in subjects with CKD not on dialysis",CKD Placebo controlled Phase III study,III,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,300,0,0,0,0,0,0,0.00%,60,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/28/2009,,10/2/2009,,,,,,3/12/2010,,,,3/11/2011,,,,,,,,,,,,,,6/10/2011,,6/10/2011,,,,,,,,,,,,,,,,,,,,9/1/2011,,10/13/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-101,SPD405-101,'SPD405-101,,,"A Double Blind Rising Dose Study to Evaluate The Safety, Tolerance And 
Pharmacokinetics Of A Rare Earth Salt Vs Placebo In Twelve (12) Healthy Volunteers",SPD405-101 DB rising dose,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Proof of Concept,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/2/1996,7/2/1996,7/2/1996,7/2/1996,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-104,SPD405-104,'SPD405-104,,,"A Double Blind Rising Dose Study to Evaluate the Safety,
Tolerance and Pharmacokinetics of a Rare Earth Salt vs.
Placebo in Twelve (12) Healthy Volunteers",SPD405-104 DB rising dose,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,PK,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/30/1996,9/30/1996,9/30/1996,9/30/1996,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-105,SPD405-105,'SPD405-105,,,"A Double-Blind Rising Dose Tolerance Study
To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of A Rare Earth Salt vs. Placebo When Administered With Food In Healthy Volunteers",SPD405-105 DB rising food,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,PKPD,,,14,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/6/1997,1/6/1997,1/6/1997,1/6/1997,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-108,SPD405-108,'SPD405-108,,,"A PHASE I, SINGLE CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LANTHANUM CARBONATE CHEWABLE TABLETS IN HEALTHY MALE JAPANESE VOLUNTEERS",SPD405-108 DB rising Japa,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,PK,,,10,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/7/1998,8/7/1998,8/7/1998,8/7/1998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-109,SPD405-109,'SPD405-109,,,"A PHASE I, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTIPLE DOSE STUDY TO ASSESS THE PHARMACOKINETICS AND SAFETY OF LANTHANUM CARBONATE AND TO DETERMINE THE REDUCTION IN URINARY PHOSPHATE EXCRETION IN HEALTHY MALE SUBJECTS",SPD405-109 DB PCB PK,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Double-Blind,,,9,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/21/1999,5/21/1999,5/21/1999,5/21/1999,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-110,SPD405-110,'SPD405-110,,,"A Phase I, Single Centre, Open-Label, Randomised, Three-Way Crossover Study Comparing the Phosphate Ion Binding of Lanthanum Carbonate Chewable Tablets When Administered Before, During, or After Food in Healthy Subjects",SPD405-110 x-over w/ food,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Crossover,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/24/1999,6/24/1999,6/24/1999,6/24/1999,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-111,SPD405-111,'SPD405-111,,,A Pharmacokinetic Study in Healthy Volunteers and Dialysis Patients Following Single and Multiple-doses of Lanthanum,SPD405-111 HV & ESRD,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,PK,,,16,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/10/2000,10/10/2000,10/10/2000,10/10/2000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-112,SPD405-112,'SPD405-112,,,"A Phase I, Single Centre, Open-Label, Randomised, Three Way Crossover Study To Assess The Effects Of Co-Administration Of Citrate On The Systemic Absorption Of Lanthanum Following A Single Oral Dose",SPD405-112 OL w/ citrate,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Coadministration,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/27/2000,9/27/2000,9/27/2000,9/27/2000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-113,SPD405-113,'SPD405-113,,,"A Phase I, Single Centre, Open Label Randomised Crossover Study to Assess the Effects of Lanthanum Carbonate on the Pharmacokinetic Parameters of Warfarin Following a Single Oral Dose",SPD405-113 OL w/ warfarin,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Drug Interaction,,,14,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/20/2000,12/20/2000,12/20/2000,12/20/2000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-114,SPD405-114,'SPD405-114,,,"A Phase I, Single Centre, Open Label Randomised Crossover Study To Assess The Effects Of Lanthanum Carbonate On The Pharmacokinetic Parameters Of Digoxin Following A Single Oral Dose.",SPD405-114 OL w/ digoxin,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Drug Interaction,,,14,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/26/2001,1/26/2001,1/26/2001,1/26/2001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-115,SPD405-115,'SPD405-115,,,"A Phase I, Single Centre, Open Label Randomised Crossover Study To Assess The Effects Of Lanthanum Carbonate On The Pharmacokinetic Parameters Of Metoprolol Following A Single Oral Dose.",SPD405-115 w/metroprolol,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Drug Interaction,,,14,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/7/2001,3/7/2001,3/7/2001,3/7/2001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-116,SPD405-116,'SPD405-116,,,A Phase 1 Pharmacodynamic Equivalence Study Comparing Urinary Phosphate Excretion and Plasma Lanthanum Pharmacokinetics for Three Formulations of Lanthanum Carbonate Chewable Tablets in Healthy Subjects,SPD405-116 Optim. formul.,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Pharmacodynamic,,,54,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/19/2003,2/19/2003,2/19/2003,2/19/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-117,SPD405-117,'SPD405-117,,,"An open label, parallel group, randomised single oral dose study of lanthanum following intravenous and oral dosing in healthy male subjects",SPD405-117 PK oral vs. IV,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Pharmacodynamic,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/18/2003,6/18/2003,6/18/2003,6/18/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-121,SPD405-121,'SPD405-121,,,Phase I pharmacodynamic equivalence study comparing urinary phosphate excretion for two formulations of lanthanum carbonate chewable tablets in healthy subjects.,SPD405-121 PD BE,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Pharmacodynamic,,,52,0,0,0,0,0,0,0.00%,1,,,Richmond Pharmacology,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/20/2004,8/20/2004,8/20/2004,8/20/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-122,SPD405-122,'SPD405-122,,,"Phase I, open label, parallel group, pharmacodynamic dose response study in healthy volunteers comparing five doses of lanthanum carbonate to one dose sevelamer",SPD405-122 PD dose resp.,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Pharmacodynamic,,,70,,,,,0,,,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/22/2005,7/22/2005,7/22/2005,7/22/2005,,,,,8/31/2005,8/31/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/9/2006,5/9/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-123,SPD405-123,'SPD405-123,,,Phase I crossover pharmacodynamic dose response study in healthy volunteers comparing three doses of Fosrenol against placebo.,SPD405-123 x-over PD PCB,I,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,Pharmacodynamic,,,999,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-124,SPD405-124,'SPD405-124,,,Bile canula study,SPD405-124 bile canula,I,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,Hepatic Impairment,,,20,0,0,0,0,0,0,0.00%,999,,,,Les Rose,,,Scharmen Confer,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-125,SPD405-125,'SPD405-125,,,Canceled - no title,SPD405-125 Hep I,I,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,Hepatic Impairment,,,20,0,0,0,0,0,0,0.00%,999,,,,Les Rose,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-126,SPD405-126,'SPD405-126,,,A phase I pharmacodynamic equivalence study comparing urinary phosphate excretion and plasma lanthanum pharmacokinetics for lanthanum carbonate chewable tablets with two different dissolution characteristics administered to healthy adult subjects,SPD405-126 PD dissolution,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Pharmacodynamic,,,60,69,78,0,9,0,20,115.00%,1,,,,Les Rose,,,,,,,,N,No,,,,COSMOS Inactive,,,4/20/2006,4/20/2006,6/1/2006,6/1/2006,,,,,6/30/2006,6/30/2006,,,7/13/2006,7/13/2006,,,,,,,,,,,,,7/21/2006,7/21/2006,7/21/2006,1/24/2007,,,,,,,,,,,,,,,,,,,1/29/2007,1/29/2007,1/31/2007,1/31/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-127,SPD405-127,'SPD405-127,,,SPD405-127,SPD405-127 Granules BE,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Bioequivalence,,,60,72,0,0,0,0,0,120.00%,1,,,Shire,Kristy Fusco,,,,,,,,N,No,,,,COSMOS Inactive,,,11/7/2008,11/6/2008,2/6/2009,2/5/2009,,,,,4/21/2009,4/21/2009,,,4/30/2009,5/29/2009,,,,,,,,,,,,,6/22/2009,6/22/2009,6/22/2009,8/14/2009,,,,,,,,,,,,,,,,,,,9/2/2009,9/2/2009,10/7/2009,10/7/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-128,SPD405-128,'SPD405-128,,,"An Open-Label, Phase I, Pharmacodynamic Study Examining Dietary Phosphorus and Calcium Abosorption, Comparing Fecal Effluent Excretion of Phosphate and Calcium for Lanthanum Carbonate, Sevelamer Carbonate, and Calcium Acetate.",SPD405-128 Balance,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Crossover,,,30,31,99,0,68,0,13,103.33%,1,,,Shire,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/14/2008,11/14/2008,1/21/2009,1/21/2009,,,,,5/5/2009,5/5/2009,,,5/22/2009,5/22/2009,,,,,,,,,,,,,6/13/2009,6/13/2009,6/13/2009,10/1/2009,,,,,,,,,,,,,,,,,,,10/8/2009,10/8/2009,10/30/2009,10/26/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-129,SPD405-129,'SPD405-129,,,"An Open-Label, Randomised, Drug Interaction study comparing the absorption affects on recalcitriol for lanthanum carbonate and sevalamer carbonate",SPD405-129 DDI,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,30,41,86,0,45,0,5,136.67%,1,,,Shire,,Phillip Wang,,,,,,,N,No,,,,COSMOS Inactive,,,11/7/2008,11/7/2008,2/24/2009,2/24/2009,,,,,6/24/2009,6/24/2009,,,7/12/2009,7/12/2009,,,,,,,,,,,,,7/29/2009,7/29/2009,7/29/2009,9/11/2009,,,,,,,,,,,,,,,,,,,11/6/2009,10/30/2009,11/6/2009,10/30/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-130,SPD405-130,'SPD405-130,,,"A Phase I, Multi-Center, Open-Label, Single-dose, Pediatric Study to Assess the Pharmacokinetics, Safety",SPD405-130 Pediatric,I,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,Multi-Centre,,,20,0,0,0,0,0,0,0.00%,10,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/16/2010,3/16/2010,2/28/2011,,,,,,11/2/2011,,,,10/31/2012,,,,,,,,,,,,,,11/4/2012,,11/4/2012,,,,,,,,,,,,,,,,,,,,1/16/2013,,2/20/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-131,SPD405-131,'SPD405-131,,,Gelatin Capsule,SPD405-131 Capsules BE,I,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Bioequivalence,,,96,0,0,0,0,0,0,0.00%,1,,,"Clinical Pharmacology of Miami, INC","Anthony Robinson, David Pierce, James O'Donoghue, Patrick Martin, Shelley Johnson",Laura Epelbaum,,,Heather Van Heusen,,,,N,No,,,,COSMOS Inactive,,,9/23/2009,9/23/2009,11/12/2009,11/11/2009,,,,,9/27/2010,9/27/2010,,,10/10/2010,10/5/2010,,,,,,,,,,,,,11/22/2010,11/22/2010,11/22/2010,1/14/2011,,,,,,,,,,,,,,,,,,,2/25/2011,2/28/2011,3/7/2011,3/1/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-202,SPD405-202,'SPD405-202,,,"A phase II, dose ranging, placebo controlled parallel group study to assess the efficacy and safety of ‘Lambda’ for reduction of gastrointestinal phosphate absorption in patients receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)",SPD405-202 DR PCB CAPD,II,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Dose-Ranging,,,59,0,0,0,0,0,0,0.00%,8,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/2/1998,9/2/1998,9/2/1998,9/2/1998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-204,SPD405-204,'SPD405-204,,,"A Dose Ranging, Placebo-controlled Group Study to Assess the Efficacy and Safety of Lanthanum Carbonate for Reduction of Serum Phosphate in Chronic Renal Failure Subjects Receiving Hemodialysis",SPD405-204 DR PCB,II,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Dose-Ranging,,,150,0,0,0,0,0,0,0.00%,10,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/1/1998,1/1/1998,1/1/1998,1/1/1998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-205,SPD405-205,'SPD405-205,,,"Long Term, Open Label Extension Study of Protocol LAM-IV-204",SPD405-205 OL Ext.,II,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Extension,,,150,0,0,0,0,0,0,0.00%,6,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/2/1998,9/2/1998,9/2/1998,9/2/1998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-206,SPD405-206,'SPD405-206,,,"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy & Safety of Lanthanum Carbonate for the Reduction of Serum Phosphorus in Subjects w/ Stage 3 and 4 Chronic Kidney Disease who Have Elevated Serum Phosphorus Levels",SPD405-206 CKD 3/4 Pilot,II,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Proof of Concept,,,84,114,262,2,148,0,45,135.71%,30,,,Clinical Research Management,Matthew Dauphin,,,Scharmen Confer,"Binesh Desai, Carl Harmon, Gailee Gaither, Kathleen Walker, Laura Brown, Lauri Pixley, Madalyn Reynolds, Mandi Humann, Robert Hickman, Tomas Marchertas, Victoria Jones",,,,N,No,,,,COSMOS Inactive,,,7/11/2005,7/11/2005,9/9/2005,9/9/2005,,,,,1/11/2006,1/11/2006,,,4/4/2007,4/4/2007,,,,,,,,,,,,,6/6/2007,6/1/2007,6/6/2007,7/30/2007,,,,,,,,,,,,,,,,,,,8/9/2007,8/9/2007,9/6/2007,9/6/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-207,SPD405-207,'SPD405-207,,Fosrenol (Lanthanum Carbonate),"A 3-part Open-label Study to Assess the Pharmacokinetics of
Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability
of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium
Carbonate using a Crossover design and Investigate the Efficacy and
Safety of 12 Months of Treatment With Lanthanum Carbonate in
Hyperphosphataemic Children and Adolescents Aged 6 Months to
<18 Years With Chronic Kidney Disease on Dialysis",405-207 OL Ped LT Study,II,Completed,Chronic Kidney Disease,Others,,Non-Registry,Pediatric only (<18 yr),Interventional,Multi-Centre,,,65,63,76,0,13,63,29,96.92%,34,,,ICON / MAPI / Paradigm,,"Chintu Eapen, Paula Wyatt, Robyn White, Svetlana Garafola",,Jorge Lotwin,Jenish Mehta,2012-000171-17,Not Available,,N,No,,,,COSMOS Inactive,10-May-19,5/8/2019,3/9/2012,3/9/2012,4/1/2012,4/1/2012,,,2/11/2013,2/11/2013,3/20/2013,3/20/2013,,,11/18/2018,11/18/2018,,,11/30/2018,11/30/2018,,,,,,,,,,,,,,,,,,,,,3/8/2019,3/8/2019,,,,,,,,,,,,,,,,,,,,,,,4/30/2019,4/30/2019,,,,,,,,,,,,,,,6/28/2019,6/28/2019,,,,,,
SPD405-301,SPD405-301,'SPD405-301,,,"A Phase III, Open Label, Comparator Controlled Parallel Group Study to Assess the Efficacy and Safety of Lanthanum Carbonate for Reduction of Gastrointestinal Phosphate Absorption and Maintenance of Control of Serum Phosphate in Chronic Renal Failure Patients Receiving Haemodialysis.",SPD405-301 CA comp. LT FU,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Comparator,,,805,0,0,0,0,0,0,0.00%,67,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/24/1998,8/24/1998,8/24/1998,8/24/1998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-302,SPD405-302,'SPD405-302,,,"A Phase III, Dose Titration, Randomization, Double Blind, Placebo Controlled Parallel Group Study to Assess the Efficacy and Safety of Lanthanum Carbonate for Reduction and Maintenance of Serum Phosphorus Levels in Chronic Renal Failure Patients Receiving Hemodialysis",SPD405-302 ESRD PCB,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Placebo-Controlled,,,120,0,0,0,0,0,0,0.00%,14,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/20/1999,6/20/1999,6/20/1999,6/20/1999,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-303,SPD405-303,'SPD405-303,,,"A Phase III, Multi-centre, Open Label Study to Investigate the Effect of Lanthanum Carbonate Compared With Calcium Carbonate on Renal Bone Disease in Chronic Renal Failure Patients Receiving Dialysis",SPD405-303 EU bone,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Comparator,,,100,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/10/2000,,3/10/2000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-307,SPD405-307,'SPD405-307,,,"An Open Label, Randomized, Multicenter, Phase III, Comparator Controlled Parallel Group Study to Assess the Long-Term Safety and Efficacy of Lanthanum Carbonate in Chronic Renal Failure Patients Receiving Hemodialysis",SPD405-307 2yr compar.,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Open Label,,,"1,200",0,0,0,0,0,0,0.00%,110,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/7/1999,7/7/1999,7/7/1999,7/7/1999,,,,,,,,,,,,,,,,,,,,,,,,,,7/1/2004,,,,,,,,,,,,,,,,,,,8/1/2004,8/1/2004,9/15/2004,9/15/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-308,SPD405-308,'SPD405-308,,,"A Long Term, Open Label Extension Study of Protocols 
LAM-IV-302 and LAM-IV-205",SPD405-308 OL Extn,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Extension,,,77,0,0,0,0,0,0,0.00%,13,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/8/1999,10/8/1999,10/8/1999,10/8/1999,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-309,SPD405-309,'SPD405-309,,,"A Long Term, Open Label Extension Study of Protocols LAM-IV-301, LAM-IV-303, LAM-IV-307 and LAM-IV-308",SPD405-309 OL Extn,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Extension,,,93,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/20/2002,5/20/2002,5/20/2002,5/20/2002,,,,,1/1/2003,1/1/2003,,,,,,,,,,,,,,,,,5/31/2005,5/31/2005,5/31/2005,8/4/2005,,,,,,,,,,,,,,,,,,,8/23/2005,8/23/2005,12/1/2005,12/1/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-310,SPD405-310,'SPD405-310,,,"A multi-centre, open label, randomised, parallel group pilot study to assess the efficacy and safety of lanthanum carbonate and sevelamer hydrochloride in patients receiving haemodialysis for end stage renal disease",SPD405-310 sevelamer comp,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Comparator,,,48,0,0,0,0,0,0,0.00%,999,,,,,,,,,2004-001608-11,,,N,No,,,,COSMOS Inactive,,,8/9/2004,8/9/2004,8/9/2004,8/9/2004,,,,,,,,,,,,,,,,,,,,,,,3/2/2005,3/2/2005,3/2/2005,7/29/2005,,,,,,,,,,,,,,,,,,,8/22/2005,8/22/2005,12/6/2005,12/6/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-312,SPD405-312,'SPD405-312,,,"A Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis",SPD405-312 OL LT Extn,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,460,0,0,0,0,0,0,0.00%,60,,,Covance,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-313,SPD405-313,'SPD405-313,,,"A Multi-Centre, Open-Label Study Assessing the Efficacy and Tolerability of Lanthanum Carbonate in the Reduction of Serum Phosphate Levels in End Stage Renal Disease Patients Receiving Dialysis",SPD405-313 ESRD OL,III,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,456,5,0,0,0,0,0,1.10%,52,,,,Denise Dunkley,,,,,,,,N,No,,,,COSMOS Inactive,,,10/1/2003,10/1/2003,4/1/2004,4/1/2004,,,,,5/18/2004,5/18/2004,,,,,,,,,,,,,,,,,12/13/2005,12/13/2005,12/13/2005,6/13/2006,,,,,,,,,,,,,,,,,,,6/16/2006,6/16/2006,7/31/2006,7/31/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-314,SPD405-314,'SPD405-314,,,"A Multicentre, Open-Label, Two-Year Extension Study for ESRD Patients on Dialysis Who Participated Previously in Lanthanum Carbonate Protocols SPD405-309 and SPD405-313",SPD405-314 German Extn,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Open Label,,,35,9,9,0,0,0,0,25.71%,10,,,,,,,,,2005-005671-15,,,N,No,,,,COSMOS Inactive,,,5/25/2005,5/25/2005,12/14/2005,12/14/2005,,,,,9/18/2006,9/18/2006,,,11/28/2006,11/28/2006,,,,,,,,,,,,,12/29/2006,12/29/2006,12/29/2006,4/24/2007,,,,,,,,,,,,,,,,,,,4/25/2007,4/25/2007,5/10/2007,5/10/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-315,SPD405-315,'SPD405-315,,,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Efficacy and Safety of Lanthanum Carbonate for Reduction of Serum Phosphate Levels in Chronic Renal Failure Patients Receiving Haemodialysis.",SPD405-315 ESRD PCB,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Placebo-Controlled,,,61,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/26/2002,7/26/2002,7/26/2002,7/26/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-316,SPD405-316,'SPD405-316,,,SPD405-316,SPD405-316 Canceled,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-318,SPD405-318,'SPD405-318,,,SPD405-318,SPD405-318 DB PCB,III,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,150,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/15/2008,,2/19/2008,,,,,,6/17/2008,,,,6/30/2009,,,,,,,,,,,,,,8/25/2009,,8/25/2009,,,,,,,,,,,,,,,,,,,,,,12/18/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-319,SPD405-319,'SPD405-319,,,"A Prospective, Multicenter, Open-label, Randomized, Cross-over Study to Compare the Efficacy and Safety of Fosrenol® and Sevelamer Hydrochloride in Patients Receiving Hemodialysis for End Stage Renal Disease",SPD405-319 sevel. compar.,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,Comparator,,,214,183,350,0,188,0,51,85.51%,30,,,"Clinical Research Management, Harrison Clinical Research",Elizabeth Magee,,,"Antonia Coeshall, Karen Harmes","Carl Harmon, Gailee Gaither, Kathleen Walker, Kathy Gordon, Laura Brown, Lauri Pixley, Madalyn Reynolds, Mandi Humann, Michael Eppolito, Mimi Hinton, Robert Hickman, Tandee Scott, Tomas Marchertas",2006-004959-38,,,N,No,,,,COSMOS Inactive,,,5/10/2006,5/10/2006,8/28/2006,8/28/2006,,,,,2/7/2007,2/7/2007,,,3/21/2008,3/21/2008,,,,,,,,,,,,,7/3/2008,7/3/2008,7/3/2008,9/29/2008,,,,,,,,,,,,,,,,,,,10/6/2008,10/6/2008,11/12/2008,11/12/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-320,SPD405-320,'SPD405-320,,,Phase 3 Comparator-controlled study in CKD Stage 3 and 4,SPD405-320 CKD compar.,III,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,Comparator,,,308,0,0,0,0,0,0,0.00%,200,,,,Antonia Coeshall,,,Scharmen Confer,,,,,N,No,,,,COSMOS Inactive,,,6/12/2008,,7/25/2008,,,,,,12/22/2008,,,,2/14/2011,,,,,,,,,,,,,,6/6/2011,,6/6/2011,,,,,,,,,,,,,,,,,,,,8/10/2011,,9/21/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-321,SPD405-321,'SPD405-321,,,"A Phase III, open label, multicentre study to investigate the effect of FOSRENOL compared with Calcium Carbonate on bone health outcomes in CKD patients not on dialysis",SPD405-321 OL bone health,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,Comparator,,,60,0,0,0,0,0,0,0.00%,15,,,Premier Research,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/22/2009,,2/25/2009,,,,,,8/4/2009,,,,9/28/2010,,,,,,,,,,,,,,9/27/2011,,9/27/2011,,,,,,,,,,,,,,,,,,,,12/19/2011,,1/30/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-401,SPD405-401,'SPD405-401,,,"A Phase-IV, Open-Label, Multi-Center Trial Evaluating the Efficacy of Fosrenolâ Compared to Existing Therapy in Adults with End Stage Renal Disease Treated for Hyperphosphatemia.",SPD405-401 US binder,IV,Completed,Chronic Kidney Disease,,,Non-Registry,,Non-Interventional_CDO Support,Dose Conversion,,,"2,630",0,0,0,0,0,0,0.00%,500,,,Covance,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/1/2004,10/1/2004,11/1/2004,11/1/2004,,,,,1/10/2005,1/10/2005,,,8/19/2005,8/19/2005,,,,,,,,,,,,,12/13/2005,12/13/2005,12/13/2005,6/23/2006,,,,,,,,,,,,,,,,,,,7/5/2006,7/5/2006,7/26/2006,7/26/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-402,SPD405-402,'SPD405-402,,,"A Long-Term, Observational Study to Monitor Mortality, Bone-Related Adverse Events and the Safety of Subjects who were Recruited Into Study SPD405-309",SPD405-402 PAC observ.,IV,Completed,Chronic Kidney Disease,,,Non-Registry,,Non-Interventional_CDO Support,Long-Term,,,38,32,35,0,0,0,1,84.21%,24,14,,IQVIA,,,,Shelley Johnson,,,,,N,No,,,,COSMOS Inactive,,,4/6/2005,4/6/2005,5/18/2005,5/18/2005,,,,,8/23/2005,8/23/2005,,,11/27/2006,11/27/2006,,,,,,,,,,,,,8/23/2010,8/23/2010,8/23/2010,10/11/2010,,,,,,,,,,,,,,,,,,,10/18/2010,,11/22/2010,11/22/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-403,SPD405-403,'SPD405-403,,,"A Phase IV, Open Label, Multi-centre Trial Evaluating the Conversion from standard Phosphate Binder Therapy to Fosrenol in Chronic Kidney Disease Stage 5 patients on Haemodialysis. SPD405-403",SPD405-403 OL conversion,IV,Completed,Chronic Kidney Disease,,,Non-Registry,,Non-Interventional_CDO Support,Dose Conversion,,,760,72,112,53,48,0,26,9.47%,78,19,,ICON / MAPI / Paradigm,,,,"Antonia Coeshall, Scharmen Confer",,2006-003364-64,,,N,No,,,,COSMOS Inactive,,,7/21/2006,7/21/2006,9/18/2006,9/18/2006,,,,,5/22/2007,5/22/2007,,,11/20/2007,11/20/2007,,,,,,,,,,,,,12/5/2007,12/5/2007,12/5/2007,5/7/2008,,,,,,,,,,,,,,,,,,,6/5/2008,6/5/2008,5/30/2008,6/9/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-404,SPD405-404,'SPD405-404,,Fosrenol (Lanthanum Carbonate),"A Phase-IV, Long-Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with Lanthanum Carbonate (Fosrenol®)",405-404 PAC observ.,IV,Completed,Chronic Kidney Disease,Others,,Non-Registry,,Non-Interventional_CDO Support,PASS (Post Authorization Safety Study),,,"2,105","2,136",2369,0,0,0,1398,101.47%,200,,,ICON / MAPI / Paradigm,Shelley Johnson,"Jaya Vatsyayan, Robyn White",,Andrea Vergani,,,,,N,No,,,,COSMOS Inactive,,,10/20/2005,10/20/2005,12/5/2005,12/5/2005,,,4/25/2006,4/25/2006,4/25/2006,4/25/2006,,,7/17/2009,7/17/2009,,,7/16/2014,7/16/2014,,,,,,,,,,,,,,,,,,,,,10/14/2016,10/14/2016,,,,,,,,,,,,,,,,,,,,,,,3/31/2017,3/31/2017,,,,,,,,,,,,,,,3/31/2017,3/31/2017,,,,,,
SPD405-405,SPD405-405,'SPD405-405,,,SPD405-405,SPD405-405 w/ Vit D,IV,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,128,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-407,SPD405-407,'SPD405-407,,,"A Prospective, Multi-Center, Open-Label, Randomized, Crossover Study to Compare the Efficacy and Safety of Fosrenol and Sevelamer Hydrochloride in Patients Receiving Stable Hemodialysis for End-Stage Renal Disease (ESRD)",SPD405-407 OL x-over Cana,IV,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,300,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-501,SPD405-501,'SPD405-501,,,Value Diagnostic for Fosrenol in CKD and Fosrenol Cost Model,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-502,SPD405-502,'SPD405-502,,,"Use of Phosphate Binders in Patients with 
Chronic Kidney Disease--Cost Effectiveness Affinity Model for Fosrenol",Use of Phosphate Binders in Patients wit,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-503,SPD405-503,'SPD405-503,,,The Impact of Early Use of Phosphate Binders in Chronic Kidney Disease Patients:,The Impact of Early Use of Phosphate Bin,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-504,SPD405-504,'SPD405-504,,,Medication Utilization Patterns Associated With the Treatment of Hyperphosphatemia in Chronic Kidney Disease,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-505,SPD405-505,'SPD405-505,,,A Mixed Treatment Comparison of Sevelamer and Fosrenol in the Reduction of Phosphate Levels in Renal Dialysis Patients,A Mixed Treatment Comparison of Sevelame,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-506,SPD405-506,'SPD405-506,,,Association of lanthanum carbonate treatment strategies versus other treatment strategies with mortality and hospitalization in a large hemodialysis population,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-507,SPD405-507,'SPD405-507,,,Development of Cost-Effectiveness Models of Lanthanum Carbonate versus Sevelamer Hydrochloride in Patients Receiving Hemodialysis for ESRD,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-521,SPD405-521,'SPD405-521,,,EU Fosrenol Patient Satisfaction Survey,SPD405-521 OP Survey,IV,Completed,Chronic Kidney Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,150,0,0,0,0,0,0,0.00%,18,,,Kantar Health,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-601,SPD405-601,'SPD405-601,,,Bone and Mineral Metabolism Outcomes in Patients on Hemodialysis (Davita database analysis),Bone and Mineral Metabolism Outcomes in,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,"50,000",0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-602,SPD405-602,'SPD405-602,,,Epidemiology registry on evaluation & treatment optimization compliance with phosphate binders in CKD,Epidemiology registry on evaluation & tr,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,200,1,0,0,0,0,0,0.50%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-603,SPD405-603,'SPD405-603,,,Phosphate Reduction for “Normo-Phosphatemic” CKD Patients (FGF-23 study),Phosphate Reduction for “Normo-Phosphate,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-604,SPD405-604,'SPD405-604,,,Randomized trial on combined effects of dual blockade of the renin angiotensin system and phosphate binding in diabetic and non-diabetic patients with impaired renal function,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,80,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-605,SPD405-605,'SPD405-605,,,"Hyperphosphatemia, Pill Burden and Quality of Life in Patients with End-Stage Renal Disease","Hyperphosphatemia, Pill Burden and Quali",IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,275,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-606,SPD405-606,'SPD405-606,,,Calcium Binders and Vitamin D Prescribing: Compliance with K/DOQI Guidelines,Calcium Binders and Vitamin D Prescribin,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,250,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-607,SPD405-607,'SPD405-607,,,Association of serum phosphorus with outcomes in patients with moderate and advanced chronic kidney disease not yet on dialysis,Association of serum phosphorus with out,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,200,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-608,SPD405-608,'SPD405-608,,,The effects of Lanthanum Carbonate on coronary artery calcification and inflammation in patients with chronic kidney disease stage IV and V,The effects of Lanthanum Carbonate on co,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-609,SPD405-609,'SPD405-609,,,Cardiovascular disease in chronic kidney disease patients: A follow up study of bone mineral density and arterial structure and function in 91subjects,Cardiovascular disease in chronic kidney,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-610,SPD405-610,'SPD405-610,,,Pediatric normal concentration of FGF23 according to GFR determined by insulin clearance,Pediatric normal concentration of FGF23,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,200,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-611,SPD405-611,'SPD405-611,,,Retrospective registry of efficacy and safety of lanthanum carbonate in daily clinical practice (REFOS-1 study),,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,700,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-612,SPD405-612,'SPD405-612,,,Randomised Controlled trial of Lanthanum Carbonate vs Calcium Carbonate on Vascular Calcification and Arterial Stiffness in Haemodialysis Patients:  A Pilot Study,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,45,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-613,SPD405-613,'SPD405-613,,,Compliance to phosphate binders in the European hemodialysis population,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,480,0,0,0,0,0,0,0.00%,6,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-614,SPD405-614,'SPD405-614,,,"Compliance with Lanthanum regimen by chronic hemodialysis patients, and the effects of compliance on serum phosphate concentration",,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,50,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-615,SPD405-615,'SPD405-615,,,Efficacy of phosphate binding in dialysis patients: chewed vs. crushed lanthanum carbonate,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-616,SPD405-616,'SPD405-616,,,Molecularmechanisms involved into the pathogenesis and progression of vascular and ectopic calcification in uremia in vitro and in vivo studies.Role of Lanthanum Carbonate in prevention and treatment of vascular calcification in experimental models.,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,50,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-617,SPD405-617,'SPD405-617,,,"Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23
 in Patients with CKD 3 and 4",,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,9,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-624,SPD405-624,'SPD405-624,,,In-vivo Phosphate Binding Capacity and Cost-effectiveness of Lanthanum Carbonate,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-625,SPD405-625,'SPD405-625,,,PREPARE (PRE-dialysis Patients Record),,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,1,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-627,SPD405-627,'SPD405-627,,,CROSS-SECTIONAL OBSERVATIONAL STUDY TO EVALUATE VITAMIN K STATUS AND ITS POTENTIAL ROLE IN VERTEBRAL FRACTURES AND VASCULAR CALCIFICATIONS IN DIALYSED PATIENTS,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,397,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-628,SPD405-628,'SPD405-628,,,A Double-Blind Randomized Controlled Trial of Maintenance of Normal Serum Phosphorus in Chronic Kidney Disease,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,195,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-629,SPD405-629,'SPD405-629,,,Association of Serum Alkaline Phosphatase level with Outcomes in patients with moderate and advanced non-dialysis dependent CKD,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,"1,259",0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-630,SPD405-630,'SPD405-630,,,Fosrenol in the Outcomes of CKD,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,80,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-631,SPD405-631,'SPD405-631,,,Efficacy of phosphate binding in healthy volunteers: chewed vs. crushed lanthanum carbonate,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,15,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-632,SPD405-632,'SPD405-632,,,Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23) in Chronic Kidney Disease,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-633,SPD405-633,'SPD405-633,,,The Use of Lanthanum Carbonate for Management of Hyperphosphatemia in Peritoneal Dialysis Patients who Have Failed Previous Therapy with Calcium Carbonate and/or Sevelamer,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-634,SPD405-634,'SPD405-634,,,Is progression of arteriosclerosis in ESRD patients inhibited by nocturnal hemodialysis or renal transplantation?,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,160,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-635,SPD405-635,'SPD405-635,,,Prevalence And Progression Of Disturbances Of Bone Metabolism Through The Spectrum Of Diabetic Nephropathy In Predialysis And  Hemodialysis Phase,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-636,SPD405-636,'SPD405-636,,,Aortic calcification and atherosclerosis progression in uremic apoE-/- mice : Effect of lanthanum carbonate versus sevelamer versus low phosphate diet,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-637,SPD405-637,'SPD405-637,,,The Effects of Lanthanum Carbonate on the Complications of CKD (IST 2),Effects of Lanthanum Carbonate on CKT,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-638,SPD405-638,'SPD405-638,,,Lanthanum carbonate in ESRD: A phosphate binder to maintain vascular health?,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-639,SPD405-639,'SPD405-639,,,The Effects of Lanthanum Carbonate on Skeletal and Cardiac Morbidity in CKD,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-640,SPD405-640,'SPD405-640,,,The impact of combined lanthanum carbonate and calcitriol treatment on ectopic calcification and renal osteodystrophy in an established animal model of pediatric chronic kidney disease,animal model,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-641,SPD405-641,'SPD405-641,,,Morphological characterization of the growth plate in a rat model of chronic renal failure,rat model,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-642,SPD405-642,'SPD405-642,,,Treatment of Hyperphosphatemia with Lanthanum Carbonate: Effect on Vascular Calcifications,Effect on Vascular Calcifications,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-643,SPD405-643,'SPD405-643,,,Characterization of a rat model for investigating the efficacy of lanthanum carbonate as oxalate binder,rat model,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-644,SPD405-644,'SPD405-644,,,Comparative survival and vascular calcification in uremic rats treated with Lanthanum carbonate vs sevelamer vs dietary phosphate restriction,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,1,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-645,SPD405-645,'SPD405-645,,,Gastrointestinal calcium absorption after ingestion of non-calcium containing phosphate binders. Part II: Remnant kidney model,,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-646,SPD405-646,'SPD405-646,,,Evaluation of a Psycoeducational Program to Improve Adherence to Chronic Treatments in CKD Patients,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,160,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-647,SPD405-647,'SPD405-647,,,FGF-23 Reduction in Predialysis CKD,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-648,SPD405-648,'SPD405-648,,,Reduction in Cardiovascular Risk and CKD Progression with Lanthanum Carbonate in CKD Stages 3 & 4: A Randomized Placebo-Controlled Study,Cardiovascular Risk and CKD,IIIb,Study Withdrawn,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-649,SPD405-649,'SPD405-649,,,Cardiovascular Mortality: Study of Genetic and Functional Markers,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-650,SPD405-650,'SPD405-650,,,"The Importance of Phosphate in Patients with Chronic Kidney Disease, and the Role of Lanthanum in its Management",,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-651,SPD405-651,'SPD405-651,,,Longitudinal changes in bone and mineral metabolism and vascular calcification in dialysis and renal transplanted patients,,IIIb,Study Terminated,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,80,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-653,SPD405-653,'SPD405-653,,,"A Phase IV Randomized, Prospective Trial Evaluating the Influence of  2 Different Therapeutic Approaches  for  CKD-MBD  on the Progression of Vascular Calcifications",,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-655,SPD405-655,'SPD405-655,,,Fosrenol for the treatment of Calciphylaxis,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-656,SPD405-656,'SPD405-656,,,Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study,,IIIb,Completed,Chronic Kidney Disease,,,Non-Registry,,Interventional,,,,110,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD405-701,SPD405-701,'SPD405-701,,,Fosrenol Post-marketing surveillance study in patients with chronic renal failure and hyperphosphatemia requiring dialysis,German Fosrenol AWB,IV,Completed,Chronic Kidney Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,"1,000",528,0,0,0,0,0,52.80%,330,,,,,,,Paul Wilde,,,,,N,No,,,,COSMOS Inactive,,,1/2/2007,1/2/2007,2/13/2007,2/13/2007,,,,,5/7/2007,5/7/2007,,,10/19/2007,,,,,,,,,,,,,,2/28/2009,2/28/2009,2/28/2009,4/10/2009,,,,,,,,,,,,,,,,,,,4/20/2009,,5/26/2009,5/26/2009,,,,,,,,,,,7/20/2009,,,,,,,,,,,,,,,,,,,,,,,
SPD405-702,SPD405-702,'SPD405-702,,Fosrenol (Lanthanum Carbonate),"A multi-centre, observational study evaluating the effect of Lanthan Carbonate in patients previously treated with calcium-based phosphate binder therapy on serum phosphorus control and concomitant vitamin D therapy amd bone-related chemical parameters in end stage renal diseasepatients on haemodialysis",SPD405-702 German LOC study in ESRD,IV,Completed,Chronic Kidney Disease,Others,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,300,58,0,0,0,0,0,19.33%,30,,,Fgk Clinical Research,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/30/2009,4/30/2009,,,,,4/28/2010,4/28/2010,,,,,,,7/8/2011,7/8/2011,,,,,,,,,,,,,,,,,,,,,8/28/2012,8/28/2012,,,,,,,,,,,,,,,,,,,,,,,12/19/2012,12/19/2012,,,,,,,,,,,,,,,12/19/2012,12/19/2012,,,,,,
SPD405-703,SPD405-703,'SPD405-703,,Fosrenol (Lanthanum Carbonate),"A Proof of Concept, Phase 2a, Double-Blind, Parallel Group, Randomised, Placebo-Controlled Study to Assess  the Effect of Lanthanum Carbonate on intact FGF23 in Normo-Phophataemic Subjects with Stage 3 Chronic Kidney Disease",SPD405-703 FGF23 in CKD Stage 3 France,IIa,Completed,Chronic Kidney Disease,Others,,Non-Registry,,Interventional,Double-Blind,,,33,35,51,1,16,35,2,106.06%,1,1,,"Omnicare CR, Theorem Clinical Research",Paul Wilde,,,,,2009-016531-35,,,N,No,,,,COSMOS Inactive,,,,,6/9/2009,6/9/2009,,,,,12/21/2010,12/21/2010,,,,,,,12/27/2011,12/27/2011,,,,,,,,,,,,,,,,,,,,,5/24/2012,5/24/2012,,,,,,,,,,,,,,,,,,,,,,,9/6/2012,9/6/2012,,,,,,,,,,,,,,,9/6/2012,9/6/2012,,,,,,
SPD406-401,SPD406-401,'SPD406-401,,,SPD406-401,,IV,Study Withdrawn,,,,Non-Registry,,Non-Interventional_CDO Support,,,,300,0,0,0,0,0,0,0.00%,999,,,,,,,Paul Wilde,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD417-306,SPD417-306,'SPD417-306,,,"A Phase IIIb, Randomized, Double-Blind, Parallel-Group Study in Bipolar I Patients to Assess Efficacy and Safety of SPD417 Administered Once Daily vs. Twice-Daily in the Treatment of Manic Symptoms",SPD417-306 DB Rand,IIIb,Completed,Bipolar Disorder,,,Non-Registry,,Interventional,Marketing study,,,102,111,139,0,29,0,0,108.82%,12,,,Covance,,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,8/9/2004,8/9/2004,9/22/2004,9/22/2004,,,,,1/18/2005,1/18/2005,,,,,,,,,,,,,,,,,10/4/2005,10/4/2005,10/4/2005,12/19/2005,,,,,,,,,,,,,,,,,,,1/3/2006,1/3/2006,1/3/2006,1/3/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD417-307,SPD417-307,'SPD417-307,,,SPD417 - 307,SPD417-307 DB Ped,IIIb,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Efficacy,,,190,0,0,0,0,0,0,0.00%,30,,,,,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD417-308,SPD417-308,'SPD417-308,,,"A Phase IIIb, Open-label Observational Safety Study of SPD417 Used in Combination with Other Psychotropic Medications for the Treatment of Bipolar I Disorder",SPD417-308 OL Observation,IIIb,Completed,Bipolar Disorder,,,Non-Registry,,Interventional,Marketing study,,,50,0,0,0,0,0,0,0.00%,12,,,Covance,,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,10/14/2004,10/14/2004,12/8/2004,12/8/2004,,,,,3/8/2005,3/8/2005,,,,,,,,,,,,,,,,,10/19/2005,10/19/2005,10/19/2005,2/21/2006,,,,,,,,,,,,,,,,,,,11/9/2005,11/9/2005,3/7/2006,3/7/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD417-309,SPD417-309,'SPD417-309,,,SPD417-309,SPD417-309,IV,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Non-Interventional_CDO Support,Post Approval Commitment,,,342,0,0,0,0,0,0,0.00%,50,,,,,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD417-310,SPD417-310,'SPD417-310,,,SPD417 - 310,SPD417-310 OL Ped Extn,IIIb,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,,,,190,0,0,0,0,0,0,0.00%,30,,,IQVIA,Brooke Geibel,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD417-311,SPD417-311,'SPD417-311,,,"A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 years with Acute Manic or Mixed Bipolar I Disorder.",SPD417-311 OL Ped PAC,IV,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Non-Interventional_CDO Support,Adolescent,,,225,161,203,3,48,0,95,71.56%,40,,,PRA,Brooke Geibel,,,Alison McMorn,Carolina Otheguy,,,,N,No,,,,COSMOS Inactive,,,6/15/2011,3/23/2006,7/26/2011,,,,,,7/17/2006,7/17/2006,,,3/16/2007,3/22/2007,,,,,,,,,,,,,8/29/2013,,8/29/2013,,,,,,,,,,,,,,,,,,,,10/21/2013,,11/25/2013,,,,,,,,,,,,1/20/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD422-110,SPD422-110,'SPD422-110,,,"A phase I randomised double-blind, placebo controlled, four-period two by two way crossover, PD and PK study to investigates the effects of anagrelide (alone and in combination with acetylsalicylic acid) on platelet aggreagtion in healthy volunteers.",SPD422-110 HV PAC PD,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Post Approval Commitment,,,32,32,72,0,40,0,3,100.00%,1,,,Shire,,,,,,2007-004743-30,,,N,No,,,,COSMOS Inactive,,,6/15/2007,6/15/2007,8/29/2007,8/29/2007,,,,,1/22/2008,1/29/2008,,,2/19/2008,2/18/2008,,,,,,,,,,,,,3/18/2008,3/17/2008,3/18/2008,6/16/2008,,,,,,,,,,,,,,,,,,,6/26/2008,7/8/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-111,SPD422-111,'SPD422-111,,,"A Phase I, Randomized, Gender Stratified, Double-Blind, Placebo-and Positive-Controlled, Four Period Crossover Trial to Assess the Effect of Anagrelide Hydrochloride (HCl) on QT/QTc Interval in Healthy Men and Women",Xagrid TQT,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Crossover,,,60,60,120,0,60,60,0,100.00%,1,,,,"Anthony Robinson, Virginia Parks",Steve Troy,,,,,,,N,No,,,,COSMOS Inactive,,,1/31/2012,6/8/2011,1/4/2012,1/16/2012,,,,,4/11/2012,4/12/2012,,,6/20/2012,7/5/2012,,,,,,,,,,,,,7/20/2012,7/20/2012,7/20/2012,9/13/2012,,,,,,,,,,,,,,,,,,,10/30/2012,9/28/2012,11/9/2012,10/29/2012,,,,,,,,,,,6/6/2013,7/22/2013,,,,,,,,,,,,,,,,,,,,,,
SPD422-112,SPD422-112,'SPD422-112,,,SPD422-112 Chinese PK,SPD422-112 Chinese PK HV,I,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Healthy Volunteers,,,20,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Robert Homolka,,,,,N,No,,,,COSMOS Inactive,,,12/9/2015,,10/28/2016,,,,,,1/4/2017,,,,2/1/2017,,,,,,,,,,,,,,3/1/2017,,3/1/2017,,,,,,,,,,,,,,,,,,,,6/6/2017,,6/2/2017,,,,,,,,,,,,7/28/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD422-113,SPD422-113,'SPD422-113,,Xagrid (Anagrelide),"A Phase 1, Open-label, Single-sequence, Non-randomized, Crossover, Drug-Drug Interaction  Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (anagrelide) in Healthy Adult Subjects",DDI study between omeprazole &anagrelide,I,Completed,Essential Thrombocythemia,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,20,,,,,,,,1,,,PPD,Merri Carpenter,Debra Ennis,Patrick Martin,"Andreas Ivens, Joseph Murphy",Dustin Zahm,,Not Available,,N,No,,,,COSMOS Inactive,,4/10/2019,,,8/15/2018,8/15/2018,,,,,3/1/2019,3/1/2019,,,3/27/2019,3/27/2019,,,3/27/2019,3/27/2019,,,,,,,,,,,,,,,,,,,,,6/14/2019,6/14/2019,,,,,,,,,,,,,,,,,,,,,,,9/18/2019,9/18/2019,,,,,,,,,,,,,,,12/23/2019,,,,,,,
SPD422-203,SPD422-203,'SPD422-203,,,"A phase II, open label, multi centre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (=65 years) patients with essential thrombocythaemia.",SPD422-203 PAC PK Adlt,II,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Post Approval Commitment,,,24,23,0,0,1,0,0,95.83%,5,,,,"Geoff Brooks, Nicola Moore",,,Ruth Coll,,2004-004058-20,,,N,No,,,,COSMOS Inactive,,,2/23/2006,2/22/2006,12/22/2006,2/22/2006,,,,,10/25/2006,10/25/2006,,,2/15/2008,12/14/2007,,,,,,,,,,,,,3/14/2008,12/24/2007,3/14/2008,3/14/2008,,,,,,,,,,,,,,,,,,,5/16/2008,3/25/2008,6/23/2008,4/22/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-204,SPD422-204,'SPD422-204,,,Superceeded by the 110 study,SPD422-204 Xg Plat Aggreg,II,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Post Approval Commitment,,,12,0,0,0,0,0,0,0.00%,999,,,,Geoff Brooks,,,,,N/A,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-308,SPD422-308,'SPD422-308,,,"A phase 3, Open-Label, Single-Arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults Refractory to Current Cytoreductive Treatment.",SPD422-Adlt OL Japan,III,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Efficacy,,,50,53,62,0,10,0,10,106.00%,25,,,IQVIA,Tone Bjaaland,,Xinbin Qiu,"Paul Wilde, Rakuno Totsuka, Ruth Coll","Hanako Wada, Kaori Nozaki, Kimie Yamazaki, Maki Sakamoto, Mayumi Yamamoto, Saori Ichisawa, Takahiro Iwasa, Yoko Eguchi, Yuko Samiso",,,,N,No,,,,COSMOS Inactive,,,6/17/2010,6/17/2010,6/22/2010,6/22/2010,,,,,11/11/2010,11/11/2010,,,10/31/2011,11/14/2011,,,,,,,,,,,,,11/7/2012,10/25/2012,11/7/2012,11/30/2012,,,,,,,,,,,,,,,,,,,12/7/2012,12/6/2012,1/11/2013,1/11/2013,,,,,,,,,,,3/13/2013,3/22/2013,,,,,,,,,,,,,,,,,,,,,,
SPD422-309,SPD422-309,'SPD422-309,,,"A Phase 3, Multi-centre, Open-label, Extension Study to Investigate
the Long-term Safety of SPD422 in Japanese Adults with Essential
Thrombocythaemia",422-309 OL Safety Follow-up,IIIb,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Long-Term,,,41,41,41,0,0,0,9,100.00%,16,,,IQVIA,,Michael Malicsi,,,,,,,N,No,,,,COSMOS Inactive,,,12/14/2010,12/14/2010,5/31/2011,5/31/2011,,,,,11/10/2011,11/10/2011,,,10/25/2012,10/25/2012,,,,,,,,,,,,,5/1/2015,5/1/2015,5/1/2015,6/18/2015,,,,,,,,,,,,,,,,,,,,,8/7/2015,8/20/2015,,,,,,,,,,,9/25/2015,9/25/2015,,,,,,,,,,,,,,,,,,,,,,
SPD422-310,SPD422-310,'SPD422-310,,,"A Phase 3, Open-label, Single-arm Study Evaluating the Effect of Anagrelide Hydrochloride on Platelet Lowering and Safety in Chinese Adults with At-risk Essential Thrombocythaemia",SPD422 Adult OL China,IIIb,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Efficacy,,,60,0,0,0,0,0,0,0.00%,20,,,,,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,12/9/2015,,10/27/2016,,,,,,3/16/2017,,,,8/31/2017,,,,,,,,,,,,,,11/23/2017,,11/23/2017,,,,,,,,,,,,,,,,,,,,1/15/2018,,2/19/2018,,,,,,,,,,,,4/16/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD422-401,SPD422-401,'SPD422-401,,Xagrid (Anagrelide),"A non-interventional, post authorisation safety study, to continuously monitor safety and pregnancy outcomes in a cohort of at-risk Essential Thrombocythaemia (ET) subjects exposed to Xagrid compared to other conventional cytoreductive treatments.",422-401 PAC EXELS,IV,Completed,Essential Thrombocythemia,Others,,Non-Registry,,Non-Interventional_CDO Support,Post Approval Commitment,,,"3,500","2,977",3122,0,28,0,164,85.06%,200,2,,Covance,Teresa Urich,,,Michael Malicsi,"Alexandra Ponchier, Dina Quaresma, Elena Iovane, Fotini Christoulia, Hans Orum, Javier Dominguez, Jean-Paul Pirotte, Jorge Benita, Karen Crets, Kaye Wallington, Krystian Misztela, Lina Svensson, Marianna Bizzarri, Massimo Duranti, Monica Ortego, Ozlem Dinc, Paolo Battigello, Perpetua Rocha, Sophie Brussieux, Soren Richardt, Stijn Hayen, Tea Koskela, Vera Amoroso",N/A,,,N,No,,,,COSMOS Inactive,,,1/3/2005,1/3/2005,2/22/2005,2/22/2005,,,5/13/2005,5/13/2005,5/30/2005,5/30/2005,,,4/30/2009,4/30/2009,,,4/30/2014,4/30/2014,,,,,,,,,,,,,,,,,,,,,7/31/2014,7/31/2014,,,,,,,,,,,,,,,,,,,,,,,11/24/2014,11/24/2014,,,,,,,,,,,,,,,11/24/2014,11/24/2014,,,,,,
SPD422-403,SPD422-403,'SPD422-403,,Xagrid (Anagrelide),"A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.",422-403 COMET Rand OL Comparator,IIIb,Completed,Essential Thrombocythemia,Others,,Non-Registry,,Interventional,Post Approval Commitment,,,184,150,183,0,33,0,67,81.52%,50,,,Covance,Roy Edmonds,Dhanyatha Pasala,,Margo Jaffee,"Agata Skorupinska, Agnieszka Bennett, Aleksandar Sarac, Aleksandra Bozac, Anna Hudlerova, Anna Maria Caputo, Beatrix Horvath, Benjamen Varsano, Carol Austin, Daniela Esposito, Danijela Jelesijevic, Dina Quaresma, Dragoslav Jefic, Elena Depedro, Elena Iovane, Emanuela Restivo, Gabriela Kaloyanova, Guillermo Badenes, Hedvig Gaal, Igor Bogovic, Iren Koenova, Javier Dominguez, Jean-Paul Pirotte, Jovana Vlajkovic, Jovana Vujanovic, Katarzyna Drewnowska, Klara Kapcsos, Maria Arenas, Mariusz Luczynski, Marta Espada, Martina Hanouskova, Melita Kostic, Monica Ortego, Nicola Burridge, Peter Zelenay, Piergiorgio Galletti, Ricardo Melo, Sara Castanos, Sarie Gilooly, Sophie Brussieux, Tomasz Dziewiecki, Venelina Rasheva",2004-004061-15,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/25/2016,7/25/2016,,,,,,
SPD422-404,SPD422-404,'SPD422-404,,Xagrid (Anagrelide),"Multicentre Paediatric Disease Registry in Essential Thrombocythaemia
(ET)",Paediatric disease registry in ET,IV,Completed,Essential Thrombocythemia,Others,,Non-Registry,,Interventional,Adolescent,,,60,72,0,0,0,72,14,120.00%,30,,,Pharm-olam International,,"Dhanyatha Pasala, Michael Malicsi",,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/18/2016,8/18/2016,,,,,,
SPD422-601,SPD422-601,'SPD422-601,,,Spanish Biological Registry of Essential Thromobcythemia,Spanish Biological Registry of Essential,IIIb,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,,,,570,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-602,SPD422-602,'SPD422-602,,,The Effects of Hydroxyurea on Apoptosis and Cytotoxicity on Skin Cells in Vitro,,IIIb,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-603,SPD422-603,'SPD422-603,,,GATA1 Expression in Myeloproliferative Disorders and Possible Implications with Anagrelide activity,,IIIb,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,,,,200,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-610,SPD422-610,'SPD422-610,,,Study of the heterogeneity of essential thrombocytemia and idiopathic myelofibrosis and characterization of the molecular bases of JAK2 V617F non-mutated forms,,IIIb,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-612,SPD422-612,'SPD422-612,,,Skin Abnormalities Following Cytoreductive Therapy in MPD,,IIIb,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,,,,200,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-614,SPD422-614,'SPD422-614,,,"Patterns of morbidity and mortality in chronic myeloproliferative disorders (MPDs; essential thrombocytemia, polycythemia vera, and myelofibrosis)",,IIIb,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-701,SPD422-701,'SPD422-701,,,"Xagrid Post-marketing surveillance study
First-time treatment with xagrid in patients with essential thrombocythaemia (ET)",German Xagrid AWB,IV,Completed,Essential Thrombocythemia,,,Non-Registry,,Non-Interventional_CDO Support,,,,300,198,0,0,0,0,0,66.00%,100,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,10/3/2005,10/3/2005,,,9/1/2006,9/1/2006,,,,,,,,,,,,,2/19/2007,2/19/2007,2/19/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD422-702,SPD422-702,'SPD422-702,,Xagrid (Anagrelide),"A Phase 4, Observational Study to Explore How Different Treatment Regimens Affect Continuation with Treatment in the First 6 Months Following Initiation of XAGRID into Adult Patients' Essential Thrombocythemia Therapy.",SPD422-702 France Obs Xagrid (FOX Study),IV,Completed,Essential Thrombocythemia,Others,,Non-Registry,,Non-Interventional_CDO Support,,,,180,173,0,0,0,0,14,96.11%,60,3,,"Rcts, Rcts","Tone Bjaaland, Karen Harmes",,,"Paul Wilde, Ruth Coll","Julie Bisiaux, Karine Posada",,,,N,No,,,,COSMOS Inactive,,,7/9/2009,7/9/2009,11/26/2009,11/26/2009,,,9/13/2010,9/13/2010,9/13/2010,9/13/2010,,,4/27/2012,4/27/2012,,,10/27/2012,10/27/2012,,,,,,,,,,,,,,,,,,,,,1/24/2013,1/24/2013,,,,,,,,,,,,,,,,,,,,,,,6/7/2013,6/7/2013,,,,,,,,,,,,,,,11/7/2092,6/7/2013,,,,,,
SPD422-703,SPD422-703,'SPD422-703,,Xagrid (Anagrelide),"An Exploratory, Observational, Multi-Centre Study to Investigate the Impact of the Presence of JAK 2 (V617F) Mutation on Treatment Response in Patients with Essential Throbocythaemia Treated with XAGRID (anagrelide hydrocholoride).",422-703 Italian LOC Study,IV,Completed,Essential Thrombocythemia,Others,,Non-Registry,,Non-Interventional_CDO Support,,,,60,49,49,0,0,0,13,81.67%,11,,,PRA,"Sirpa Laukkanen, Paul Wilde",,,Paul Wilde,,,,,N,No,,,,COSMOS Inactive,,,2/20/2011,2/20/2011,2/23/2011,2/23/2011,,,9/13/2010,9/13/2010,7/19/2011,7/19/2011,,,8/31/2012,8/31/2012,,,9/6/2013,9/6/2013,,,,,,,,,,,,,,,,,,,,,11/6/2013,11/6/2013,,,,,,,,,,,,,,,,,,,,,,,2/28/2014,2/28/2014,,,,,,,,,,,,,,,2/28/2014,2/28/2014,,,,,,
SPD426-405,SPD426-405,'SPD426-405,,Proamatine (midodrine hydrochloride),"A Phase 4, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Clinical Benefit of Midodrine HCl in Male and Female Subjects with Symptomatic Orthostatic Hypotension",Withdrawal study,IV,Completed,Orthostatic Hypotension,Others,,Non-Registry,,Non-Interventional_CDO Support,Parallel Group,,,36,0,0,0,31,0,0,0.00%,25,,,"Drugdev, Ltd, Easthorn",,,,,,2012-005760-99,,,N,No,,,,COSMOS Inactive,,,3/22/2011,3/22/2011,5/24/2011,5/24/2011,,,5/3/2012,5/3/2012,5/31/2012,5/31/2012,,,9/25/2013,9/25/2013,,,11/4/2013,11/4/2013,,,,,,,,,,,,,,,,,,,,,3/13/2014,3/13/2014,,,,,,,,,,,,,,,,,,,,,,,5/9/2014,5/9/2014,,,,,,,,,,,,,,,5/9/2014,5/9/2014,,,,,,
SPD426-406,SPD426-406,'SPD426-406,,Proamatine (midodrine hydrochloride),Tilt Table Study,Tilt Table Study,IV,Completed,Orthostatic Hypotension,Others,,Non-Registry,,Non-Interventional_CDO Support,Double-Blind,,,18,0,0,0,5,0,0,0.00%,15,,,"Drugdev, Ltd, Easthorn",,,,,,,,,N,No,,,,COSMOS Inactive,,,5/24/2011,5/24/2011,6/24/2011,6/24/2011,,,5/3/2012,5/3/2012,5/31/2012,5/31/2012,,,6/12/2013,6/12/2013,,,6/16/2013,6/16/2013,,,,,,,,,,,,,,,,,,,,,10/11/2013,10/11/2013,,,,,,,,,,,,,,,,,,,,,,,3/25/2014,3/25/2014,,,,,,,,,,,,,,,3/25/2014,3/25/2014,,,,,,
SPD429-401,SPD429-401,'SPD429-401,,,SPD429-401,SPD429-401 Cancelled,IV,Study Withdrawn,Crohn's Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,40,0,0,0,0,0,0,0.00%,999,,,,Ken Eng,,,Mary Palmen,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD429-601,SPD429-601,'SPD429-601,,,CLINICAL AND IMMUNOGENETIC DETERMINANTS OF CORTICOSTEROID-FREE REMISSION IN PEDIATRIC ULCERATIVE COLITIS AND IBD-UNSPECIFIED,CORTICOSTEROID-FREE REMISSION IN UC,IIIb,Study Terminated,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,1,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD433-115,SPD433-115,'SPD433-115,,,"A Phase I, Pharmacokinetic Study in Healthy Volunteers to Assess the Bioequivalence of SPD433 Capsules Manufactured Using the Current SPD433 Manufacturing Process and Formulation and a New Process and Formulation Following a Single 300mg Dose",SPD433-115 Adlt HV BE,I,Completed,Epilepsy,,,Non-Registry,,Interventional,Bioequivalence,,,24,,,,,0,,,1,,,MDS,Brooke Geibel,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,9/30/2004,9/30/2004,10/26/2004,10/26/2004,,,,,12/3/2004,12/3/2004,,,12/3/2004,12/3/2004,,,,,,,,,,,,,12/26/2004,12/26/2004,12/26/2004,3/11/2005,,,,,,,,,,,,,,,,,,,2/18/2005,2/18/2005,7/1/2005,7/1/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD433-116,SPD433-116,'SPD433-116,,,A Phase I Single Oral Dose Pharmacokinetic Study in Healthy Volunteers to Assess the Bioequivalence of a 400mg SPD433 Capsule Manufactured Using a New Process and Formulation and 2 x 200mg SPD433 Capsules Manufactured Using the Current Process and Formulation,SPD433-116 Adlt HV BE,I,Completed,Epilepsy,,,Non-Registry,,Interventional,Bioequivalence,,,24,,,,,0,,,1,,,MDS,Brooke Geibel,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,9/30/2004,9/30/2004,10/26/2004,10/26/2004,,,,,12/10/2004,12/10/2004,,,12/10/2004,12/10/2004,,,,,,,,,,,,,12/28/2004,12/28/2004,12/28/2004,3/15/2005,,,,,,,,,,,,,,,,,,,2/11/2005,2/11/2005,3/25/2005,3/25/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD433-117,SPD433-117,'SPD433-117,,,"A Phase I, Randomized, Open-Label, Two-Period, Single Dose, Crossover Bioequivalence Study Of Two Oral Formulations Of 300mg SPD433 In Healthy Volunteers",SPD433-117 BE study,I,Completed,Epilepsy,,,Non-Registry,,Interventional,Bioequivalence,,,30,30,0,0,0,0,0,100.00%,1,,,PRA,Mary Corcoran,,,,,,,,N,No,,,,COSMOS Inactive,,,7/9/2009,7/9/2009,12/7/2009,12/7/2009,,,,,2/5/2010,2/5/2010,,,2/5/2010,2/5/2010,,,,,,,,,,,,,2/28/2010,2/28/2010,2/28/2010,4/5/2010,,,,,,,,,,,,,,,,,,,4/19/2010,4/19/2010,4/28/2010,4/28/2010,,,,,,,,,,,7/8/2010,7/8/2010,,,,,,,,,,,,,,,,,,,,,,
SPD435-601,SPD435-601,'SPD435-601,,,Immediate release vs. Long Acting Adderall in Adults Ages 18-55,Adult IR vs. XR compliance,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,58,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-101,SPD465-101,'SPD465-101,,,"A Phase I, Pharmacokinetic Study in Healthy Volunteers To Evaluate the Pharmacokinetic Profiles of Three Delayed-Release Bead Prototypes for SPD465 Compared to ADDERALL®",SPD465-101 PK,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,12,12,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/1/2002,10/1/2002,11/22/2002,11/22/2002,,,,,1/12/2003,1/12/2003,,,1/12/2003,1/12/2003,,,,,,,,,,,,,2/5/2003,2/5/2003,2/5/2003,,,,,,,,,,,,,,,,,,,,,,7/3/2003,7/3/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-102,SPD465-102,'SPD465-102,,,"A Phase 1, Pharmacokinetic Study in Healthy Volunteers to Evaluate the Pharmacokinetic Profiles of Three 30mg Delayed-Release Formulations for SPD465",SPD465-102 PK,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,20,20,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/1/2003,4/1/2003,5/15/2003,5/15/2003,,,,,6/26/2003,6/26/2003,,,6/26/2003,6/26/2003,,,,,,,,,,,,,7/27/2003,7/27/2003,7/27/2003,,,,,,,,,,,,,,,,,,,,,,9/5/2003,9/12/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-103,SPD465-103,'SPD465-103,,,A Phase I Pharmacokinetic Study In Healthy Adult Volunteers to Evaluate the Pharmacokinetic Profile of a 37.5mg SPD465 Product relative to an ADDERALL XR 25mg + Mixed Amphetamine Salts IR 12.5MG,SPD465-103 PK BE Adlt,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,20,20,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,10/1/2004,,11/2/2004,,,,,,12/13/2004,,,,12/13/2004,,,,,,,,,,,,,,12/20/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-104,SPD465-104,'SPD465-104,,,"A Single-Dose, Randomized, Two-Way Crossover, Bioequivalence Study to Compare a Single 37.5mg Capsule of SPD465 Manufactured at Shire Laboratories Inc. to a Single 37.5mg Capsule of SPD465 Manufactured at DSM Pharmaceuticals Inc. in Healthy Adult Subjects",SPD465-104 SD Rand x-over,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,1,,,,Lee Ann Shiveley,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-105,SPD465-105,'SPD465-105,,,"A Phase I Study to Evaluate the Pharmacokinetic Profile of SPD465 50mg Under Fed, Fasted, and Sprinkled Conditions in Healthy Adult Volunteers",SPD465-105 PK Adlt,I,Completed,ADHD,,,Non-Registry,,Interventional,Fed/Fasted,,,18,16,0,0,0,0,0,88.89%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/2/2004,8/2/2004,12/3/2004,12/3/2004,,,,,12/27/2004,12/27/2004,,,,,,,,,,,,,,,,,2/26/2005,2/26/2005,2/26/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-106,SPD465-106,'SPD465-106,,,"A Phase I, Open-Label, Single-Ascending Dose Study to Assess the Dose Proportionality, Safety, and Tolerability of SPD465 Administered at Doses of 12.5, 37.5, 50, and 75mg in Healthy Adult Volunteers",SPD465-106 OL SD Adlt,I,Completed,ADHD,,,Non-Registry,,Interventional,Multiple Dose,,,28,28,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/1/2004,11/1/2004,12/3/2004,12/3/2004,,,,,1/8/2005,1/8/2005,,,1/8/2005,1/8/2005,,,,,,,,,,,,,1/26/2005,1/26/2005,1/26/2005,6/29/2005,,,,,,,,,,,,,,,,,,,5/10/2005,5/10/2005,8/22/2005,8/22/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-107,SPD465-107,'SPD465-107,,,"An Open-label, Incomplete Block Randomization, Three-Period, Four-Treatment, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of SPD465 Administered at Steady State in Healthy Adult Subjects",SPD465-107 OL PK,I,Completed,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,20,,,,,0,,,1,,,"Aris Clinical, INC",,,,,,,,,N,No,,,,COSMOS Inactive,,,7/1/2005,7/1/2005,8/12/2005,8/12/2005,,,,,9/26/2005,9/26/2005,,,9/26/2005,9/26/2005,,,,,,,,,,,,,10/4/2005,10/4/2005,10/4/2005,1/13/2006,,,,,,,,,,,,,,,,,,,,,1/26/2006,1/26/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-108,SPD465-108,'SPD465-108,,,SPD465-108 Adol single dose PK study,SPD465-108 SD PK Adlsc,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Adolescent,,,999,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-109,SPD465-109,'SPD465-109,,,SPD465-109 Adol multidose PK study,SPD465-109 MulDose PK,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Adolescent,,,20,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-110,SPD465-110,'SPD465-110,,,"An Open-label, Incomplete Block Randomization, Three-Period, Four-Treatment, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of SPD465 Administered at Steady State in Healthy Adult Subjects",SPD465-110 OL Dose Escala,I,Completed,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,20,0,0,0,0,0,0,0.00%,1,,,"Aris Clinical, INC",,,,,,,,,N,No,,,,COSMOS Inactive,,,12/1/2004,12/1/2004,1/17/2005,1/17/2005,,,,,12/1/2005,12/1/2005,,,12/1/2005,12/1/2005,,,,,,,,,,,,,12/29/2005,12/29/2005,12/29/2005,2/24/2006,,,,,,,,,,,,,,,,,,,,,3/3/2006,3/3/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-201,SPD465-201,'SPD465-201,,,"A Phase II, Randomized, Double-blind, Multi-center, Placebo- and Active-controlled, Crossover Study of SPD465 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD465-201 DB Adlt x-over,II,Completed,ADHD,,,Non-Registry,,Interventional,Crossover,,,86,0,0,0,0,0,0,0.00%,4,,,IQVIA,Heather Golarz,,,,,,,,N,No,,,,COSMOS Inactive,,,1/15/2004,1/15/2004,2/13/2004,2/13/2004,,,,,7/10/2004,7/10/2004,,,10/30/2004,10/30/2004,,,,,,,,,,,,,11/20/2004,11/20/2004,11/20/2004,1/11/2005,,,,,,,,,,,,,,,,,,,1/17/2005,1/17/2005,7/22/2005,7/22/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-202,SPD465-202,'SPD465-202,,,"A Phase II, Randomized, Double-blind, Multi-center, Placebo- and Active-controlled, Crossover Study of SPD465 in Adolescents with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD465-202 DB Adlsc x-ove,II,Completed,ADHD,,,Non-Registry,,Interventional,Adolescent,,,84,0,0,0,0,0,0,0.00%,5,,,IQVIA,Heather Golarz,,,,,,,,N,No,,,,COSMOS Inactive,,,5/15/2004,5/15/2004,5/28/2004,5/28/2004,,,,,9/25/2004,9/25/2004,,,1/22/2005,1/22/2005,,,,,,,,,,,,,2/12/2005,2/12/2005,2/12/2005,4/7/2005,,,,,,,,,,,,,,,,,,,,,8/4/2005,8/4/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-203,SPD465-203,'SPD465-203,,,"A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD465-203 DB PCB x-over,II,Completed,ADHD,,,Non-Registry,,Interventional,Crossover,,,79,0,0,0,0,0,0,0.00%,4,,,IQVIA,Heather Golarz,,,,,,,,N,No,,,,COSMOS Inactive,,,8/4/2005,8/4/2005,8/24/2005,8/24/2005,,,,,11/5/2005,11/5/2005,,,12/15/2005,12/15/2005,,,,,,,,,,,,,1/6/2006,1/6/2006,1/6/2006,2/10/2006,,,,,,,,,,,,,,,,,,,2/16/2006,2/16/2006,3/31/2006,3/31/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-301,SPD465-301,'SPD465-301,,,"A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD465-301 DB PCB Paralle,III,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,274,280,0,0,0,0,0,102.19%,38,,,IQVIA,Heather Van Heusen,,,,,,,,N,No,,,,COSMOS Inactive,,,5/1/2004,5/1/2004,6/3/2004,6/3/2004,,,,,2/4/2005,2/4/2005,,,4/22/2005,4/22/2005,,,,,,,,,,,,,6/14/2005,6/14/2005,6/14/2005,9/7/2005,,,,,,,,,,,,,,,,,,,9/14/2005,9/14/2005,11/18/2005,11/18/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-302,SPD465-302,'SPD465-302,,,"A Phase III, Randomized, Double-blind, Multi-center, Placebo- controlled, Parallel-group, Safety and Efficacy Study of SPD465 with an Open-label Extension in Adolescents with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD465-302 DB Paralel OL,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Adolescent,,,250,0,0,0,0,0,0,0.00%,35,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-303,SPD465-303,'SPD465-303,,,"A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group, Forced Dose Titration, Safety and Efficacy Study of SPD465 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD465-303 DB Forced-Dose,III,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,412,437,0,0,0,0,0,106.07%,35,,,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/1/2005,2/1/2005,3/14/2005,3/14/2005,,,,,5/3/2005,5/3/2005,,,9/21/2005,9/21/2005,,,,,,,,,,,,,11/4/2005,11/4/2005,11/4/2005,1/6/2006,,,,,,,,,,,,,,,,,,,1/11/2006,1/11/2006,6/19/2006,6/19/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-304,SPD465-304,'SPD465-304,,,"A Phase III, Multi-center, 12-Month, Open-label, Safety Study of SPD465 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) (12-mo)",SPD465-304 OL 12-mo Adlt,III,Completed,ADHD,,,Non-Registry,,Interventional,Efficacy,,,505,501,0,0,0,0,0,99.21%,54,1,,IQVIA,Heather Van Heusen,,,,,,,,N,No,,,,COSMOS Inactive,,,1/4/2005,1/4/2005,2/9/2005,2/9/2005,,,,,3/7/2005,3/7/2005,,,11/2/2005,11/2/2005,,,,,,,,,,,,,11/7/2006,10/26/2006,11/7/2006,12/18/2006,,,,,,,,,,,,,,,,,,,1/4/2007,1/19/2007,2/27/2007,2/27/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-311,SPD465-311,'SPD465-311,,,A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment with SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults with Attention-Deficit Hyperactivity Disorder (ADHD),SPD465-311 Adlt Efficacy,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Crossover,,,171,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-312,SPD465-312,'SPD465-312,,,"A Phase IIIb, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Dose-Optimization, Safety and Efficacy Study of NRP104 in Adult Subjects aged 18-55 with Attention-Deficit/Hyperactivity Disorder (ADHD) and a comorbid history of Substance Use Disorder (SUD)",SPD465-312 DB Rand Adlt,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Crossover,,,300,0,0,0,0,0,0,0.00%,35,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/10/2008,,12/12/2008,,,,,,11/16/2009,,,,1/4/2010,,,,,,,,,,,,,,3/15/2010,,3/15/2010,,,,,,,,,,,,,,,,,,,,,,6/29/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-313,SPD465-313,'SPD465-313,,,SPD465-313 Driving Study,SPD465-313 Driving,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,46,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/13/2008,,6/16/2008,,,,,,11/16/2009,,,,6/25/2009,,,,,,,,,,,,,,8/13/2009,,8/13/2009,,,,,,,,,,,,,,,,,,,,,,11/25/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-315,SPD465-315,'SPD465-315,,,SPD465-315 Adults with hypertension,SPD465-315 Adlt hypertens,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD465-504,SPD465-504,'SPD465-504,,,Conjoint Survey - Adult ADHD Treatment Preferences,SPD564-504 Adult Txt Pref Survey,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,30,0,0,0,0,0,0,0.00%,1,,,ICON / MAPI / Paradigm,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD473-101,SPD473-101,'SPD473-101,,,SPD473-101,SPD473-101DMPK,I,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,Antonia Coeshall,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD473-203,SPD473-203,'SPD473-203,,,SPD473-203,SPD473-203 Rand DB PCB,II,Completed,ADHD,,,Non-Registry,,Interventional,Proof of Concept,,,220,0,0,0,0,0,0,0.00%,21,,,,Antonia Coeshall,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-101,SPD476-101,'SPD476-101,,,"A Phase I, Randomised, Open-Label, Single-Dose, Two-period, Cross-over, Pharmacoscintigraphic Pilot Study of SPD476 and Asacol® in Healthy Male Subjects",SPD476-101 Rand OL x-over,I,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,8,0,0,0,0,0,0,0.00%,1,,,,Mary Palmen,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-102,SPD476-102,'SPD476-102,,,"A Pharmacokinetic Study to Develop an IVIVC Evaluating the Bioavailability of Slow, Medium and Fast Releasing Formulations of SPD476 tablets Following a Single 1.2g Dose to Healthy Volunteers",SPD476-102 PK BA HV,I,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,48,48,0,0,0,0,3,100.00%,1,,,ICON / MAPI / Paradigm,Kirstin Lees,,,,,,,,N,No,,,,COSMOS Inactive,,,7/30/2004,7/30/2004,8/9/2004,8/9/2004,,,,,10/17/2004,10/17/2004,,,10/17/2004,10/17/2004,,,,,,,,,,,,,11/3/2004,11/3/2004,11/3/2004,1/4/2005,,,,,,,,,,,,,,,,,,,2/22/2005,2/22/2005,1/27/2005,1/27/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-103,SPD476-103,'SPD476-103,,,"A phase I, randomized, open-label, single-dose, two-period, cross-over study in healthy male and female volunteers to assess the effects of co-administration of SPD476 4.8g with food on the bioavailability of 5-aminosalicylic acid (5-ASA)",SPD476-103 Rand OL HV,I,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,34,34,0,0,0,0,2,100.00%,1,,,ICON / MAPI / Paradigm,Kirstin Lees,,,,,,,,N,No,,,,COSMOS Inactive,,,11/8/2004,11/8/2004,1/21/2005,1/21/2005,,,,,3/6/2005,3/6/2005,,,3/6/2005,3/6/2005,,,,,,,,,,,,,3/16/2005,3/16/2005,3/16/2005,5/6/2005,,,,,,,,,,,,,,,,,,,6/17/2005,6/17/2005,6/9/2005,6/9/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-104,SPD476-104,'SPD476-104,,,"A Bioequivalence Study Assessing the Pharmacokinetics Following Single-dose Administration of SPD476 manufactured at Owings Mills, MD, and Cosmo SpA, Italy, manufacturing sites","SPD476-104 HV, BE",I,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,Bioequivalence,,,120,0,0,0,0,0,0,0.00%,1,,,Shire,Michelle Swift,,,Anthony Robinson,,,,,N,No,,,,COSMOS Inactive,,,3/2/2007,3/2/2007,5/25/2007,5/25/2007,,,,,9/17/2007,9/17/2007,,,12/4/2007,12/4/2007,,,,,,,,,,,,,12/4/2007,12/4/2007,12/4/2007,4/2/2008,,,,,,,,,,,,,,,,,,,5/7/2008,5/7/2008,5/8/2008,5/8/2008,,,,,,,,,,,7/3/2008,7/3/2008,,,,,,,,,,,,,,,,,,,,,,
SPD476-105,SPD476-105,'SPD476-105,,,"A phase I, randomized, gender stratified, open-label, parallel-group, two-period, single and multiple-dose study in healthy male and female volunteers to assess the pharmacokinetic profile of 5-aminosalicylic acid (5-ASA) and N-Acetyl-5-aminosalicyli",SPD476-105 Rand OL HV,I,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,Healthy Volunteers,,,56,56,83,0,27,0,4,100.00%,1,,,,Kirstin Lees,,,,,,,,N,No,,,,COSMOS Inactive,,,10/26/2005,10/26/2005,12/1/2005,12/1/2005,,,,,1/3/2006,1/3/2006,,,1/7/2006,1/7/2006,,,,,,,,,,,,,1/26/2006,1/26/2006,1/26/2006,3/9/2006,,,,,,,,,,,,,,,,,,,3/27/2006,3/27/2006,4/12/2006,4/12/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-106,SPD476-106,'SPD476-106,,,"A Study to Characterize the Dose Linearity in Pharmacokinetics of 5-Amino-salicylic Acid (5-ASA) and Acetyl-5-ASA (Ac-5-ASA) for Three Single Doses of SPD476  (1.2g, 2.4g and 4.8g) and the Pharmacokinetic Profile of SPD476 (4.8g) in the Presence of Food in Healthy Subjects",SPD476-106 PK 3 SD,I,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,48,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/23/2005,12/23/2005,2/3/2006,2/3/2006,,,,,2/19/2006,2/19/2006,,,3/1/2006,3/1/2006,,,,,,,,,,,,,3/28/2006,3/28/2006,3/28/2006,6/9/2006,,,,,,,,,,,,,,,,,,,5/24/2006,5/24/2006,7/6/2006,7/6/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-107,SPD476-107,'SPD476-107,,,Pediatric Patient PK Study,SPD476-107 PK Ped,I,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,70,0,0,0,0,0,0,0.00%,14,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-108,SPD476-108,'SPD476-108,,,Diverticulitis Drug Interaction Study #1,SPD476-108 DDI,I,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,Drug Interaction,,,48,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-109,SPD476-109,'SPD476-109,,,"A Phase I, Age and Gender Stratified, Open Label, Parallel-Group, Single Dose Study Assessing the Pharmacokinetics of a Single 4.8g Oral Dose of SPD476 in Healthy Male and Female Subjects",SPD476-109 Elderly PK,I,Completed,Diverticulitis,,,Non-Registry,,Interventional,PK,,,72,0,0,0,0,0,0,0.00%,1,,,,,,,Anthony Robinson,,,,,N,No,,,,COSMOS Inactive,,,,6/22/2007,,9/7/2007,,,,,11/7/2007,11/7/2007,,,,12/4/2006,,,,,,,,,,,,,12/10/2007,12/10/2007,12/10/2007,6/30/2008,,,,,,,,,,,,,,,,,,,8/7/2008,8/7/2008,8/7/2008,8/7/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-110,SPD476-110,'SPD476-110,,,Diverticulitis Drug Interaction Study #2,SPD476-110 DDI,I,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,Drug Interaction,,,999,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-111,SPD476-111,'SPD476-111,,,"A Randomised, Double-Blind, Double-Dummy, Two-period, Crossover Pilot Study Exploring Plasma and Colonic/Rectal Mucosal Concentrations of 5-Aminosalicylic Acid (5-ASA) and Its Metabolite N-Acetyl-5-Aminosalicylic Acid (Ac-5-ASA) for Lialda® and Asacol® in Healthy Adult Male Subjects",SPD476-111 HV,I,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,Crossover,,,56,54,90,0,36,0,3,96.43%,1,,,Shire,,,Raymond Joseph,Kirstin Lees,,,,,N,No,,,,COSMOS Inactive,,,2/6/2008,2/28/2008,3/10/2008,3/14/2008,,,,,4/24/2008,4/24/2008,,,6/12/2008,6/12/2008,,,,,,,,,,,,,7/1/2008,7/1/2008,7/1/2008,8/29/2008,,,,,,,,,,,,,,,,,,,10/2/2008,10/6/2008,9/29/2008,10/8/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-112,SPD476-112,'SPD476-112,,Lialda (mesalamine),"A phase I, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX MESALAMINE Following Administration in Children/Adolescents With Ulcerative Colitis",476-112 PED PK,I,Completed,Ulcerative Colitis,Others,,Non-Registry,,Interventional,Safety,,,36,53,0,0,0,53,0,147.22%,20,,,,Heather Van Heusen,,,,,2011-000164-10,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-113,SPD476-113,'SPD476-113,,,BE study to confirm manufacturing transfer to DSM,SPD476-113 BE study,I,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,Bioequivalence,,,100,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/22/2010,,5/28/2010,,,,,,8/23/2010,,,,10/8/2010,,,,,,,,,,,,,,10/28/2010,,10/28/2010,,,,,,,,,,,,,,,,,,,,1/21/2011,,2/22/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-114,SPD476-114,'SPD476-114,,Lialda (mesalamine),"A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Amoxicillin Administered Alone and in Combination with MMX Mesalazine/Mesalamine in Healthy Adult Subjects",SPD476-114 DDI,I,Completed,Diverticulitis,Others,,Non-Registry,,Interventional,Bioequivalence,,,62,62,125,0,0,62,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-115,SPD476-115,'SPD476-115,,Lialda (mesalamine),"A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Ciprofloxacin XR Administered Alone and in Combination with MMX Mesalazine/Mesalamine in Healthy Adult Subjects",SPD476-115 DDI,I,Completed,Diverticulitis,Others,,Non-Registry,,Interventional,Bioequivalence,,,30,30,0,0,0,30,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-116,SPD476-116,'SPD476-116,,Lialda (mesalamine),"A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Metronidazole Administered Alone and in Combination with MMX Mesalazine/Mesalamine in Healthy Adult Subjects",SPD476-116 DDI,I,Completed,Diverticulitis,Others,,Non-Registry,,Interventional,Bioequivalence,,,30,30,0,0,0,30,0,100.00%,1,,,,,Mike Campbell,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-117,SPD476-117,'SPD476-117,,Lialda (mesalamine),"A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination with MMX Mesalazine/Mesalamine in Healthy Adult Subjects",SPD476-117 DDI study,I,Completed,Diverticulitis,Others,,Non-Registry,,Interventional,Crossover,,,40,44,0,0,0,44,0,110.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-118,SPD476-118,'SPD476-118,,,Scale BE study in HV  (fed),476-118 scale BE HV (fed),I,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,Bioequivalence,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,Mary Palmen,,,,,N,No,,,,COSMOS Inactive,,,6/12/2013,6/12/2013,2/4/2014,,,,,,4/24/2014,,,,5/29/2014,,,,,,,,,,,,,,6/18/2014,,6/18/2014,,,,,,,,,,,,,,,,,,,,9/23/2014,,9/19/2014,,,,,,,,,,,,11/14/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD476-119,SPD476-119,'SPD476-119,,,SPD476-119 scale BE in HV (fasted),476-119 scale BE HV (fasted),I,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,Bioequivalence,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/12/2013,6/12/2013,3/3/2014,,,,,,5/18/2014,,,,6/27/2014,,,,,,,,,,,,,,7/17/2014,,7/17/2014,,,,,,,,,,,,,,,,,,,,11/10/2014,,12/17/2014,,,,,,,,,,,,2/11/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD476-120,SPD476-120,'SPD476-120,,,"A Phase 1, Open-label, Randomized, 2-period Crossover Study Evaluating the Pharmacokinetic Profile of MMX Mesalamine in Healthy Chinese Adult Subjects After Administration of a Single Dose of  2.4 and 4.8g of SPD476",SPD476-120 PK China HV,I,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,Bioequivalence,,,40,0,0,0,0,0,0,0.00%,1,,,,Jeff Dragone,,Patrick Martin,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,11/18/2013,11/18/2013,3/4/2014,3/4/2014,,,,,8/22/2017,,,,9/5/2017,,,,,,,,,,,,,,10/3/2017,,10/3/2017,,,,,,,,,,,,,,,,,,,,1/8/2018,,1/4/2018,,,,,,,,,,,,3/1/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD476-202,SPD476-202,'SPD476-202,,,"A Phase II, Randomised, Multi-centre, Double-blind, Parallel Group, Dose-Ranging, Exploratory Study in Subjects with Mild to Moderate Ulcerative Colitis Treated with SPD476 (Mesalazine) Once Daily",SPD476-202 Rand DB DR,II,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,36,40,0,0,0,0,0,111.11%,9,,,Pharmanet,Mary Palmen,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-203,SPD476-203,'SPD476-203,,,"A Phase II, randomised, double-blind, multicentre, parallel group, placebo controlled proof of concept study to evaluate the safety and efficacy of SPD476 (mesalazine) 4.8g QD compared to placebo in the treatment of uncomplicated diverticulitis.",SPD476-203 Rand DB PCB,II,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,Proof of Concept,,,206,0,0,0,0,0,0,0.00%,40,,,,David Stephenson,,,Kirstin Lees,,,,,N,No,,,,COSMOS Inactive,,,7/23/2007,,8/20/2007,,,,,,12/27/2007,,,,7/28/2008,,,,,,,,,,,,,,9/22/2008,,9/22/2008,,,,,,,,,,,,,,,,,,,,12/22/2008,,2/16/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-204,SPD476-204,'SPD476-204,,,Crohn's Colitis Pilot Study,SPD476-204 Pilot,II,Study Withdrawn,Crohn's Colitis,,,Non-Registry,,Interventional,,,,100,0,0,0,0,0,0,0.00%,2,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-205,SPD476-205,'SPD476-205,,,"A Phase II, Randomised, Double-blind, Dose-Ranging, Placebo-Controlled Proof of Concept Study Evaluating the Safety and Efficacy of 4.8g SPD476 Versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis",SPD476-205 Rand DB DR,II,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,Proof of Concept,,,144,0,0,0,0,0,0,0.00%,30,,,,Alissa Sirbu,,,Kirstin Lees,,,,,N,No,,,,COSMOS Inactive,,,3/30/2007,,5/4/2007,,,,,,9/10/2007,,,,1/7/2008,,,,,,,,,,,,,,1/4/2010,,1/4/2010,,,,,,,,,,,,,,,,,,,,4/5/2010,,5/24/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-301,SPD476-301,'SPD476-301,,,"A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4g/day) versus SPD476 Given as a Single Dose (4.8g/day) in Subjects with Acute Mild to Moderate Ulcerative Colitis",SPD476-301 MATRx 1,III,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,Double-Blind,,,255,280,0,0,0,0,0,109.80%,50,,,,,,,Kirstin Lees,,2004-000733-12,,,N,No,,,,COSMOS Inactive,,,10/14/2002,10/14/2002,11/14/2002,11/14/2002,,,,,9/30/2003,9/30/2003,,,10/29/2004,10/29/2004,,,,,,,,,,,,,12/28/2004,12/28/2004,12/28/2004,4/12/2005,,,,,,,,,,,,,,,,,,,4/20/2005,4/20/2005,5/25/2005,5/25/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-302,SPD476-302,'SPD476-302,,,"A Phase III, Randomised, Multi-centre, Double-blind, Double dummy, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, with Reference to Asacol® 0.8g Three Times Daily, in Subjects with Acute, Mild to Moderate Ulcerative Colitis",SPD476-302 MATRx 2,III,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,340,342,0,0,0,0,0,100.59%,50,,,ICON / MAPI / Paradigm,David Stephenson,,,,,,,,N,No,,,,COSMOS Inactive,,,2/4/2003,2/4/2003,4/15/2003,4/15/2003,,,,,12/4/2003,12/4/2003,,,,,,,,,,,,,,,,,10/20/2004,10/20/2004,10/20/2004,2/10/2005,,,,,,,,,,,,,,,,,,,,,3/11/2005,3/11/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-303,SPD476-303,'SPD476-303,,,"A Phase III, Randomised, Multi-Centre, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs Twice Daily for the Maintenance of Ulcerative Colitis in Remission",SPD476-303 Rand OL Extn,III,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,Long-Term,,,480,455,0,0,0,0,0,94.79%,110,1,,IQVIA,Elise Hoyland,,,,,2004-000734-36,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-304,SPD476-304,'SPD476-304,,,"A Phase III, randomised, multi-centre, double-blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (QD) with Asacol 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",SPD476-304 Maint DB Comp,III,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,Comparator,,,826,796,472,3,67,416,103,96.37%,103,3,,ICON / MAPI / Paradigm,,,"Bassem Saleh, Michael Gallagher, Saleem Shariff","Mary Palmen, Karen Gallagher","Aneshni Nagan, Bianca Symes, Catalina Araus, Christer Hoeoeg, Daniel Ionescu, Eunok Kim, Fraenzi Furigo, Joana Figueiredo, Kamila Bimova, Laszlo Gyori, Maria Andrea Zumarraga, Marloes Blok, Martine Regoli, Michele Hummel, Padmini Ramesh, Pranjali Gaunker, Shek Hua Goh, Yadira Ramirez",2004-004184-29,,,N,No,,,,COSMOS Inactive,,,8/2/2004,8/2/2004,11/23/2004,11/23/2004,,,,,11/21/2007,4/18/2005,,,1/30/2009,3/6/2009,,,,,,,,,,,,,9/7/2009,9/10/2009,9/7/2009,11/9/2009,,,,,,,,,,,,,,,,,,,11/20/2009,11/13/2009,12/16/2009,12/16/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-310,SPD476-310,'SPD476-310,,,"Pediatric UC Study, SPD476-310 Ped, DB, Multiple-dose",This study was replaced with SPD476-319,IIIb,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,Post Approval Commitment,,,80,0,0,0,0,0,0,0.00%,30,,,,,,,Mary Palmen,,,,,N,No,,,,COSMOS Inactive,,,2/17/2012,,3/30/2012,,,,,,8/29/2012,,,,2/25/2015,,,,,,,,,,,,,,4/22/2015,,4/22/2015,,,,,,,,,,,,,,,,,,,,,,7/15/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-311,SPD476-311,'SPD476-311,,,Diverticulitis Acute Pivotal Study #1,SPD476-311 Pivotal Study,III,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,360,0,0,0,0,0,0,0.00%,60,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-312,SPD476-312,'SPD476-312,,,Diverticulitis Acute Pivotal Study #2,SPD476-312 Pivotal Study,III,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,360,0,0,0,0,0,0,0.00%,60,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-313,SPD476-313,'SPD476-313,,Lialda (mesalamine),"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis.","SPD476-313 Mult Dose, PCB",III,Completed,Diverticulitis,Others,,Non-Registry,,Interventional,Double-Blind,,,584,596,776,0,189,606,287,102.05%,110,,,ICON / MAPI / Paradigm,,,,,,2007-004895-37,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-314,SPD476-314,'SPD476-314,,Lialda (mesalamine),"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis.","SPD476-314 Mult Dose, PCB",III,Completed,Diverticulitis,Others,,Non-Registry,,Interventional,Double-Blind,,,584,612,736,0,140,610,245,104.79%,90,,,ICON / MAPI / Paradigm,,,,,,2007-004896-20,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-316,SPD476-316,'SPD476-316,,,Therapeutic Escalation Avoidance Pivotal Study #1,SPD476-316 TE Avoid.,III,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,Double-Blind,,,"1,000",0,0,0,0,0,0,0.00%,250,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-317,SPD476-317,'SPD476-317,,,Therapeutic Escalation Avoidance Pivotal Study #2,SPD476-317 TE Avoid.,III,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,100,0,0,0,0,0,0,0.00%,476,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/15/2009,,7/13/2009,,,,,,3/1/2010,,,,4/29/2011,,,,,,,,,,,,,,8/19/2011,,8/19/2011,,,,,,,,,,,,,,,,,,,,,,1/9/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-318,SPD476-318,'SPD476-318,,,Diverticulitis Follow-On HEOR Study,SPD476-318 HEOR Follow-On,III,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,"1,168",0,0,0,0,0,0,0.00%,180,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/4/2008,1/31/2008,3/10/2008,,,,,,5/23/2008,,,,12/22/2010,,,,,,,,,,,,,,6/21/2011,,6/21/2011,,,,,,,,,,,,,,,,,,,,9/13/2011,,10/4/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-319,SPD476-319,'SPD476-319,,Lialda (mesalamine),"A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX  Mesalamine/Mesalazine in Pediatric Subjects with Mild to Moderate Ulcerative Colitis, in both Acute and Maintenance Phases","SPD476-319 Ped, Rand, DB, PAC",III,Completed,Ulcerative Colitis,Others,,Non-Registry,Pediatric only (<18 yr),Interventional,Post Approval Commitment,,,128,107,,,,,,83.59%,48,,,Premier Research,Daisy Dillon,"Alicja Howley, Kevin Szwarc",,,,2013-001744-65,Not Available,,N,No,,,,COSMOS Inactive,30-Nov-18,11/28/2018,10/24/2012,10/24/2012,9/11/2013,9/11/2013,,,7/16/2014,7/16/2014,12/12/2014,12/12/2014,,,9/26/2018,9/26/2018,,,11/23/2018,11/23/2018,,,,,,,,,,,,,,,,,,,,,2/28/2019,2/28/2019,,,,,,,,,,,,,,,,,,,,,,,5/31/2019,5/31/2019,,,,,,,,,,,,,,,7/31/2019,,,,,,,
SPD476-401,SPD476-401,'SPD476-401,,,US Pharmacoeconomics,SPD476-401US PEcon,IV,Completed,Ulcerative Colitis,,,Non-Registry,,Non-Interventional_CDO Support,Pharmacoeconomics,,,300,0,0,0,0,0,0,0.00%,999,,,,Stephanie Read,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-402,SPD476-402,'SPD476-402,,,EU Pharmacoeconomics,SPD476-402 EU PEcon,IV,Completed,Ulcerative Colitis,,,Non-Registry,,Non-Interventional_CDO Support,Pharmacoeconomics,,,300,0,0,0,0,0,0,0.00%,999,,,,Stephanie Read,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-403,SPD476-403,'SPD476-403,,,SPD476-403,SPD476-403,IV,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-404,SPD476-404,'SPD476-404,,,"A phase IV, multi-center, open-label study to assess clinical recurrence related to compliance with treatment with MMX mesalamine  (SPD476) 2.4g/day given once daily for the maintenance of quiescent ulcerative colitis (UC)",SPD476-404 OL Compliance,IV,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,Maintenance,,,360,292,341,1,51,290,151,81.11%,60,,,ICON / MAPI / Paradigm,,,,,"Jessica Rieman, Lily Makannah, Mary Williamson, Susan Ginster",,,,N,No,,,,COSMOS Inactive,,,7/20/2006,7/20/2006,12/27/2006,12/27/2006,,,,,5/8/2007,5/8/2007,,,6/17/2008,6/17/2008,,,,,,,,,,,,,7/23/2009,,7/23/2009,8/26/2009,,,,,,,,,,,,,,,,,,,9/15/2009,10/5/2009,10/19/2009,10/19/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-405,SPD476-405,'SPD476-405,,,"MMX mesalamine  (SPD476) and mesalamine enema Study: A phase IV, randomized, multi-centre, open-label, parallel-group, pilot study assessing 4.8g QD MMX mesalamine (SPD476) for 8 weeks, combined with 4g Rowasa enema (or equivalent) for either 1 week or 4 weeks for the induction of remission in active mild to moderate left-sided UC",SPD476-405 SPEED,IV,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,114,0,0,0,0,0,0,0.00%,20,,,,Sonia Brinton,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-406,SPD476-406,'SPD476-406,,,"A Phase IV, Multi-center, Open-label, Eight Week Study to Assess Timing of Symptom Relief and Change in Symptom Severity in Patients Treated with MMX Mesalamine/MMX Mesalazine Given Once Daily for Mild to Moderate Ulcerative Colitis (UC)",SPD476-406 QUIC,IV,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,505,0,0,0,0,0,0,0.00%,125,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-409,SPD476-409,'SPD476-409,,Lialda (mesalamine),"A Phase 3b/4, Open-label, Multicenter Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase with 2.4g/day MMX Mesalamine/ Mesalazine Once Daily in Adult Subjects with Ulcerative Colitis",SPD476-409 MOMENTUM,IV,Completed,Ulcerative Colitis,Others,,Non-Registry,,Interventional,Maintenance,,,722,759,903,0,185,759,357,105.12%,100,,,ICON / MAPI / Paradigm,,,,Mary Palmen,"Aleksandra Dukaczewska, Bjorn Frijns, Vera Szilvasipohorala",2009-017044-13,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-410,SPD476-410,'SPD476-410,,,"Observational Diverticulitus Study
kl;",SPD476-410 DIVERT Registry,IV,Study Withdrawn,Diverticulitis,,,Non-Registry,,Non-Interventional_CDO Support,,,,"2,000",0,0,0,0,0,0,0.00%,100,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/25/2012,,9/4/2012,,,,,,3/26/2013,,,,4/1/2015,,,,,,,,,,,,,,4/6/2017,,4/6/2017,,,,,,,,,,,,,,,,,,,,5/22/2017,,6/26/2017,,,,,,,,,,,,8/21/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD476-500,SPD476-500,'SPD476-500,,,None,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-501,SPD476-501,'SPD476-501,,,Factors influencing survival of IBD patients after hospital admission - nationwide analysis in Scotland,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-502,SPD476-502,'SPD476-502,,,Economic model for mild-to-moderate ulcerative colitis,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-503,SPD476-503,'SPD476-503,,,The impact of adherence with 5-ASA therapy on health care utilization and costs among patients with UC in large manage care population,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-504,SPD476-504,'SPD476-504,,,Infliximab utilization model for the treatment of ulcerative colitis,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-505,SPD476-505,'SPD476-505,,,Modelling the cost effectiveness of Mezavant XL for the treatment of ulcerative colitis,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-506,SPD476-506,'SPD476-506,,,Early development pharmacoeconomic model for diverticulitis,,IIIb,Completed,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-507,SPD476-507,'SPD476-507,,,Patient preference,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-508,SPD476-508,'SPD476-508,,,PE Model adaptations,,IIIb,Completed,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-509,SPD476-509,'SPD476-509,,,DV prediction model,,IIIb,Completed,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-510,SPD476-510,'SPD476-510,,,Lialda adherence/resource use,Resource utilization,IIIb,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-511,SPD476-511,'SPD476-511,,,Cost of illness (EU) for DV,Cost of illness (EU) for DV,IIIb,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-512,SPD476-512,'SPD476-512,,,Cost of illness (US) for DV,Cost of illness (US) for DV,IIIb,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-513,SPD476-513,'SPD476-513,,,DV PE model,DV PE model,IIIb,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-514,SPD476-514,'SPD476-514,,,DV transition and recurrence db cr,DV transition and recurrence db,IIIb,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-515,SPD476-515,'SPD476-515,,,TBC,NA,IIIb,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-517,SPD476-517,'SPD476-517,,,EU (CA),EU (CA),IIIb,Study Withdrawn,Diverticulitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-518,SPD476-518,'SPD476-518,,,Compliance RU and cost model,RU and cost model,IIIb,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-601,SPD476-601,'SPD476-601,,,Prevention of CRC by administration of chemopreventive agents,Prevention of CRC,IIIb,Completed,Crohn's Colitis,,,Non-Registry,,Interventional,,,,50,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-602,SPD476-602,'SPD476-602,,,Randomized double blind placebo controlled trial on the efficacy and safety of once daily Lialda 4.8 grams for induction of remission in mild to moderate Crohn’s colitis.,,IIIb,Study Withdrawn,Crohn's Colitis,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-603,SPD476-603,'SPD476-603,,,Test-Treat strategy to prevent ulcerative colitis relapse: dose escalation and remission study,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,120,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-604,SPD476-604,'SPD476-604,,,"A phase IV, open-label study to assess MMX mesalamine in the maintenance of glucocorticosteroid induced remission in ulcerative colitis (UC)",,IV,Completed,Ulcerative Colitis,,,Non-Registry,,Non-Interventional_CDO Support,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-606,SPD476-606,'SPD476-606,,,The influence of aminosalicylate adherence on the risk of colorectal cancer in patients with ulcerative colitis,NA,IIIb,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-609,SPD476-609,'SPD476-609,,,The “Kane Score” for Determining Non-adherent Behaviour in Ulcerative Colitis,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,150,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-611,SPD476-611,'SPD476-611,,,Gastric emptying of solids in acute and chronic IBD and diverticulitis,,IIIb,Completed,Diverticulitis,,,Non-Registry,,Interventional,,,,80,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-613,SPD476-613,'SPD476-613,,,Microflora in IBD,Early Phase,IIIb,Study Withdrawn,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-614,SPD476-614,'SPD476-614,,,Effect of Patients’ Education on Adherence and Outcome in Ulcerative Colitis,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,182,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-615,SPD476-615,'SPD476-615,,,Mesalazine and NAPDH oxidases,,IIIb,Completed,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD476-617,SPD476-617,'SPD476-617,,,"Mesalamine in Irritable Bowel Syndrome
Investigator Sponsored Trial",Investigator Sponsored Trial,IIIb,Study Terminated,Ulcerative Colitis,,,Non-Registry,,Interventional,,,,69,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD477-404,SPD477-404,'SPD477-404,,,"An open-label, post-marketing safety study of Solaraze™ for the treatment of Actinic Keratosis in UK Primary Care Assessment (SPA Study)",SPD477-404 SPA,IV,Completed,Actinic keratosis,,,Non-Registry,,Non-Interventional_CDO Support,,,,500,17,37,0,4,0,1,3.40%,999,,,,,,,Paul Quinn,,,,,N,No,,,,COSMOS Inactive,,,,,6/25/2004,6/25/2004,,,,,12/1/2004,12/1/2004,,,,,,,,,,,,,,,,,2/23/2006,2/23/2006,2/23/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD483-101,SPD483-101,'SPD483-101,,,SPD483-101,NA,I,Study Withdrawn,,,,Non-Registry,,Interventional,Bioequivalence,,,20,20,0,0,0,0,0,100.00%,1,,,IQVIA,Raj Prasad,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD483-102,SPD483-102,'SPD483-102,,,SPD483-102,NA,I,Study Withdrawn,,,,Non-Registry,,Interventional,Dose Proportionaity,,,24,0,0,0,0,0,0,0.00%,999,,,,Jen Teti,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD483-103,SPD483-103,'SPD483-103,,,SPD483-103,,I,Study Withdrawn,,,,Non-Registry,,Interventional,Healthy Volunteers,,,20,0,0,0,0,0,0,0.00%,999,,,,Antonia Coeshall,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD483-301,SPD483-301,'SPD483-301,,,SPD483-301,NA,III,Study Withdrawn,,,,Non-Registry,,Interventional,Comparator,,,300,0,0,0,0,0,0,0.00%,999,,,,Jen Teti,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD483-302,SPD483-302,'SPD483-302,,,SPD483-302,NA,III,Study Withdrawn,,,,Non-Registry,,Interventional,Safety,,,300,0,0,0,0,0,0,0.00%,999,,,,Jen Teti,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-3xb,SPD485-3xb,'SPD485-3xb,,,"A Phase III placebo contolled, parallel group study to assess the efficacy and safety of MTS 9hour WT versus flexible WT in pediatric and adolescent subjects",Phase III PLO EU,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Safety,,,102,0,0,0,0,0,0,0.00%,15,,,,Antonia Coeshall,,,,,,,,N,No,,,,COSMOS Inactive,,,4/16/2009,,7/9/2009,,,,,,5/27/2010,,,,3/3/2011,,,,,,,,,,,,,,6/2/2011,,6/2/2011,,,,,,,,,,,,,,,,,,,,8/24/2011,,10/5/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-3xx,SPD485-3xx,'SPD485-3xx,,,Placebo Controlled Extended Wear Times in Adolescents aged 12-18 years.,SPD485-3xx Adlsc Efficacy,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,210,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/14/2007,,1/31/2008,,,,,,,,,,1/1/2009,,,,,,,,,,,,,,4/1/2009,,4/1/2009,,,,,,,,,,,,,,,,,,,,6/17/2009,,7/15/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-101,SPD485-101,'SPD485-101,,,A Phase I Study to Assess the Pharmacokinetics of Methylphenidate Transdermal System® (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD),SPD485-101 Ped PK x-over,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,24,24,34,0,10,0,1,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/10/2004,,3/10/2004,,,,,,4/20/2004,4/20/2004,,,5/9/2004,,,,,,,,,,,,,,5/9/2004,5/9/2004,5/9/2004,6/22/2004,,,,,,,,,,,,,,,,,,,8/6/2004,8/6/2004,8/20/2004,8/20/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-102,SPD485-102,'SPD485-102,,,A Phase I Study to Assess the Relative Bioavailability and Pharmacokinetics of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD),SPD485-102 Ped PL x-over,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,48,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/15/2004,8/15/2004,11/17/2004,11/17/2004,,,,,1/15/2004,1/15/2004,,,,,,,,,,,,,,,,,2/13/2004,2/13/2004,2/13/2004,3/15/2005,,,,,,,,,,,,,,,,,,,3/29/2005,3/29/2005,4/8/2005,4/8/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-105,SPD485-105,'SPD485-105,,,SPD485-105 - Bioequivalence,SPD485-105 BE,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/23/2009,,4/6/2009,,,,,,3/31/2009,,,,4/30/2009,,,,,,,,,,,,,,5/29/2009,,5/29/2009,,,,,,,,,,,,,,,,,,,,9/4/2009,,9/30/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-106,SPD485-106,'SPD485-106,,,"An Open-Label, Randomized Study of  the Pharmacokinetics of d-Methylphenidate and l-Methylphenidate After Single and Multiple Doses of Methylphenidate Transdermal System (MTS) or CONCERTA® Administered to Children and Adolescents Ages 6 to 17 Years with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD485-106 Ped Adlsc PK,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,72,71,84,0,9,0,7,98.61%,4,,,Shire,Mary Corcoran,,,"Alison McMorn, Antonia Coeshall",,,,,N,No,,,,COSMOS Inactive,,,7/11/2007,7/5/2007,8/27/2007,8/8/2007,,,,,11/16/2007,12/1/2007,,,6/21/2008,4/25/2008,,,,,,,,,,,,,7/27/2008,6/1/2008,7/27/2008,8/13/2008,,,,,,,,,,,,,,,,,,,8/28/2008,9/10/2008,9/11/2008,9/8/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-201,SPD485-201,'SPD485-201,,,"A Phase II, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Dose Optimization, Analog Classroom, Crossover Study, Designed to Assess the Time Course of Treatment Effect, Tolerability and Safety of Methylphenidate Transdermal System (MTS)",SPD485-201 Ped Classrm,II,Completed,ADHD,,,Non-Registry,,Interventional,Safety,,,85,93,125,0,32,0,14,109.41%,6,,,,Dan Sea,,,,,,,,N,No,,,,COSMOS Inactive,,,,3/10/2004,,6/24/2004,,,,,,,,,,,,,,,,,,,,,,,,2/1/2005,,3/4/2005,,,,,,,,,,,,,,,,,,,,,,4/4/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-302,SPD485-302,'SPD485-302,,,"A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of MTS vs Concerta in Pediatric Patients aged 6-12 years with ADHD.",SPD485-302 Ped Efficacy,III,Completed,ADHD,,,Non-Registry,,Interventional,Efficacy,,,300,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/10/2004,3/10/2004,6/24/2004,6/24/2004,,,,,8/23/2004,8/23/2004,,,2/23/2007,,,,,,,,,,,,,,1/29/2005,1/29/2005,1/29/2005,3/18/2005,,,,,,,,,,,,,,,,,,,3/21/2005,3/21/2005,3/21/2005,3/21/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-303,SPD485-303,'SPD485-303,,,"A Phase IIIb, Open-Label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD485-303 Ped Extn OL,III,Completed,ADHD,,,Non-Registry,,Interventional,Safety,,,376,0,0,0,0,0,0,0.00%,999,,,,,,"Liza Squires, Rich Civil, Timothy Whitaker",,,,,,N,No,,,,COSMOS Inactive,,,6/28/2004,,7/14/2004,,,,,,,,,,,,,,,,,,,,,,,,2/13/2006,,2/13/2006,,,,,,,,,,,,,,,,,,,,,,3/13/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-304,SPD485-304,'SPD485-304,,,"A Phase IIIb, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, 3-way cross-over, analog classroom study to assess the efficacy, duration of effect, tolerability and safety of 4- and 6-hour wear times of MTS in pediatric subjects aged 6-12 with ADHD",SPD485-304 Ped Classrm,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Crossover,,,128,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/4/2005,4/4/2005,,,,,5/31/2005,5/31/2005,,,2/23/2007,,,,,,,,,,,,,,11/12/2005,11/12/2005,11/12/2005,3/1/2006,,,,,,,,,,,,,,,,,,,3/17/2006,3/17/2006,9/1/2006,9/1/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-305,SPD485-305,'SPD485-305,,,"A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6–12 Previously Treated with Extended-Release Methylphenidate Product Abrupt cessation of oral MPH to MTS based on existing oral therapy.",SPD485-305 OL Ped,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Dose Conversion,,,171,0,0,0,0,0,0,0.00%,18,,,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/23/2005,2/23/2005,4/28/2005,4/28/2005,,,,,6/21/2005,6/21/2005,,,1/9/2006,1/9/2006,,,,,,,,,,,,,,,,3/31/2006,,,,,,,,,,,,,,,,,,,4/12/2006,4/12/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-306,SPD485-306,'SPD485-306,,,"A Phase IIIb, randomized, open-label, blinded-rater, multi-center, cross-over study to evaluate the efficacy, safety, use patterns, satisfaction and Quality of Life (QOL) of Methylphenidate Transdermal System (MTS)",SPD485-306 Ped &Adlsc O/L,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,140,0,0,0,0,0,0,0.00%,18,,,ICON / MAPI / Paradigm,Joanna Perrett,,,"Alison McMorn, Antonia Coeshall",,,,,N,No,,,,COSMOS Inactive,,,1/28/2009,,3/25/2009,,,,,,12/11/2009,,,,10/1/2010,,,,,,,,,,,,,,1/26/2011,,1/26/2011,,,,,,,,,,,,,,,,,,,,4/20/2011,,5/4/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-401,SPD485-401,'SPD485-401,,,SPD485-401,SPD485-401 Ped CET,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Community Effectiveness Trial (CET),,,"1,100",0,0,0,0,0,0,0.00%,200,,,,Michael McKay,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-403,SPD485-403,'SPD485-403,,,A Positron Emission Tomography Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy of single doses of Methylphenidate Transdermal System and multiple doses of Methylphenidate Transdermal System in Healthy Adults,SPD485-403 Adlt PK,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,PK,,,16,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-409,SPD485-409,'SPD485-409,,,"A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents aged 13-17 years with ADHD",SPD485-409 Adlsc Efficacy,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Adolescent,,,210,216,292,0,76,0,93,102.86%,32,,,I3 Research,,,,,"Beata Szewczyk, Janis Martin, Joan Krueger, Luis De La Cruz, Robert Trott, Scott Wood, William Vosburgh",,,,N,No,,,,COSMOS Inactive,,,10/6/2006,10/6/2006,4/30/2007,5/2/2007,,,,,7/6/2007,7/12/2007,,,3/14/2008,3/14/2008,,,,,,,,,,,,,5/9/2008,5/7/2008,5/9/2008,7/18/2008,,,,,,,,,,,,,,,,,,,8/11/2008,8/11/2008,9/5/2008,9/8/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-410,SPD485-410,'SPD485-410,,,"A Phase IIIb, Long-Term, Open-Label, Multi-Center Study Designed to Evaluate the Safety and Efficacy of Daytranaä Methylphenidate Transdermal System (MTS) in Adolescent Patients aged 13-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).",SPD485-410 Adlsc Extn OL,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Long-Term,,,185,164,164,0,0,0,77,88.65%,31,,,I3 Research,Lisa Politza,,,Alison McMorn,"Beata Szewczyk, Joan Krueger, Luis De La Cruz, Scott Wood",,,,N,No,,,,COSMOS Inactive,,,2/28/2007,2/28/2007,6/29/2007,6/29/2007,,,,,8/10/2007,8/10/2007,,,4/23/2008,4/23/2008,,,,,,,,,,,,,10/28/2008,10/28/2008,10/28/2008,12/22/2008,,,,,,,,,,,,,,,,,,,12/29/2008,12/29/2008,2/9/2009,2/9/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-411,SPD485-411,'SPD485-411,,,"A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients aged 6-12 with Attention Deficit/Hyperactivity Disorder (ADHD)/SPD485-411",SPD485-411 Derm PAC,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Open Label,,,300,342,352,0,43,0,58,114.00%,31,,,PRA,Brooke Geibel,,,Alison McMorn,"Mark Gurrieri, Michele Cronin",,,,N,No,,,,COSMOS Inactive,,,5/30/2006,5/30/2006,8/21/2006,8/21/2006,,,,,1/16/2007,1/16/2007,,,6/4/2007,6/4/2007,,,,,,,,,,,,,7/23/2007,7/23/2007,7/23/2007,10/31/2007,,,,,,,,,,,,,,,,,,,11/1/2007,11/1/2007,12/12/2007,12/12/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-501,SPD485-501,'SPD485-501,,,Quantifying the impact of illness burden and its relationship with treatment response,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-502,SPD485-502,'SPD485-502,,,Computing Reliable Change in ADHD Symptoms Using Regression-Based Change Scores,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-503,SPD485-503,'SPD485-503,,,Quantifying the impact of illness burden and its relationship with treatment response,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-504,SPD485-504,'SPD485-504,,,ADHD Pharmacy Budget Impact Model,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-505,SPD485-505,'SPD485-505,,,Methylphenidate delivery mechanisms for the treatment of ADHD: A study of parent’s preferences,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-506,SPD485-506,'SPD485-506,,,A qualitative investigation into the impact of childhood ADHD on the quality of life of children,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-507,SPD485-507,'SPD485-507,,,Cost effectiveness model for Daytrana,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-508,SPD485-508,'SPD485-508,,,ADHD and school exclusion,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-601,SPD485-601,'SPD485-601,,,"""Real world benefits of MPH: improving driving safety of young ADHD drivers with Daytrana""",Daytrana in young adult driving,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-602,SPD485-602,'SPD485-602,,,Open Label Study of Daytrana in Children with Comorbid Autism,,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-603,SPD485-603,'SPD485-603,,,Evaluation of the Safety and Efficacy of MTS in Former Stimulant Users with ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-604,SPD485-604,'SPD485-604,,,MTS in the Treatment of Adult ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,70,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-605,SPD485-605,'SPD485-605,,,Efficacy and safety/tolerability of MTS for Before-School Dysfunction in Children with ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-607,SPD485-607,'SPD485-607,,,"A Single-Center, Open-label Study of the Effect of Individualizing DaytranaTM Wear-Times on Sleep in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD)",,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD485-608,SPD485-608,'SPD485-608,,,"A Single-Center, Open-label Study of the Effect of Individualizing DaytranaTM Wear-Times on Sleep in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD)",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,50,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD487-101,SPD487-101,'SPD487-101,,,A Phase I Study to Assess the Relative Bioavailability and Pharmacokinetics of Three Pilot Formulations of ATS vs. Oral Administration of a 20mg ADDERALL XR® Capsule in Healthy Adult Volunteers Aged 18-55,,I,Study Withdrawn,,,,Non-Registry,,Interventional,First In Man (FIM),,,24,,,,,,,,1,,,,,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD487-102,SPD487-102,'SPD487-102,,,SPD487-102,,I,Study Withdrawn,,,,Non-Registry,,Interventional,,,,999,,,,,,,,999,,,,Dan Sea,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD487-103,SPD487-103,'SPD487-103,,,SPD487-103,NA,I,Study Withdrawn,,,,Non-Registry,,Interventional,,,,999,,,,,,,,999,,,,Dan Sea,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD487-104,SPD487-104,'SPD487-104,,,SPD487-104,NA,I,Study Withdrawn,,,,Non-Registry,,Interventional,,,,999,,,,,,,,999,,,,Dan Sea,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD488-401,SPD488-401,'SPD488-401,,,A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women with Excessive Facial Hair,SPD488-401 Adlt Non-inf,IV,Completed,Facial Hirsutism,,,Non-Registry,,Non-Interventional_CDO Support,,,,78,0,0,0,0,0,0,0.00%,999,,,,Chris Jones,,,,,2004-000726-78,,,N,No,,,,COSMOS Inactive,,,2/16/2004,2/16/2004,6/16/2004,6/16/2004,,,,,11/2/2004,11/2/2004,,,,,,,,,,,,,,,,,6/17/2005,6/17/2005,6/17/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD488-402,SPD488-402,'SPD488-402,,,"A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA® with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism)",SPD488-402 Rand OL,IV,Study Withdrawn,Facial Hirsutism,,,Non-Registry,,Non-Interventional_CDO Support,Randomized,,,200,0,0,0,0,0,0,0.00%,8,,,,Chris Jones,,,,,2006-002833-19,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD488-403,SPD488-403,'SPD488-403,,,SPD488-403,SPD488-403,IV,Study Withdrawn,Facial Hirsutism,,,Non-Registry,,Non-Interventional_CDO Support,,,,300,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xb,SPD489-1xb,'SPD489-1xb,,,Phase 1 Preference Study,SPD489-1Xb Pref Study,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,24,0,0,0,0,0,0,0.00%,1,,,,Mary Haffey,,,,,,,,N,No,,,,COSMOS Inactive,,,2/16/2012,,3/29/2012,,,,,,6/4/2012,,,,6/11/2012,,,,,,,,,,,,,,7/20/2012,,7/20/2012,,,,,,,,,,,,,,,,,,,,11/1/2012,,11/28/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xe,SPD489-1xe,'SPD489-1xe,,,PAC-RIM - China,SPD489-1xe PAC-RIM (China),I,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Healthy Volunteers,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/21/2012,,4/10/2012,,,,,,5/14/2013,,,,5/28/2013,,,,,,,,,,,,,,6/25/2013,,6/25/2013,,,,,,,,,,,,,,,,,,,,9/18/2013,,10/30/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xg,SPD489-1xg,'SPD489-1xg,,,Glucose Clamp Study,SPD489-1xg Adult Glucose Clamp Study,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xh,SPD489-1xh,'SPD489-1xh,,,PAC-RIM - Japan,SPD489-1xh PAC-RIM (Japan),I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/23/2011,,1/11/2012,,,,,,11/21/2012,,,,12/5/2012,,,,,,,,,,,,,,1/2/2013,,1/2/2013,,,,,,,,,,,,,,,,,,,,3/28/2013,,5/9/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xr,SPD489-1xr,'SPD489-1xr,,,Antipsychotic DDI #1,SPD489-1xr Antipsychotic DDI #1,I,Study Withdrawn,Schizophrenia,,,Non-Registry,,Interventional,Drug Interaction,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,Elise Hoyland,,,,,N,No,,,,COSMOS Inactive,,,12/20/2013,,1/31/2014,,,,,,4/9/2014,,,,5/7/2014,,,,,,,,,,,,,,6/4/2014,,6/4/2014,,,,,,,,,,,,,,,,,,,,9/9/2014,,9/5/2014,,,,,,,,,,,,10/31/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xs,SPD489-1xs,'SPD489-1xs,,,Antipsychotic DDI Study #2,SPD489-1xs Antipsychotic DDI Study #2,I,Study Withdrawn,Schizophrenia,,,Non-Registry,,Interventional,Drug Interaction,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,Mary Corcoran,,,,,N,No,,,,COSMOS Inactive,,,1/16/2014,,2/27/2014,,,,,,5/2/2014,,,,5/30/2014,,,,,,,,,,,,,,6/27/2014,,6/27/2014,,,,,,,,,,,,,,,,,,,,10/2/2014,,9/30/2014,,,,,,,,,,,,11/25/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xt,SPD489-1xt,'SPD489-1xt,,,Metabolic Study in BED Patients,Metabolic Study in BED Patients,I,Study Withdrawn,Binge Eating Disorder,,,Non-Registry,,Interventional,Double-Blind,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/18/2014,,4/1/2014,,,,,,6/6/2014,,,,7/4/2014,,,,,,,,,,,,,,8/1/2014,,8/1/2014,,,,,,,,,,,,,,,,,,,,11/6/2014,,11/4/2014,,,,,,,,,,,,12/30/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-1xu,SPD489-1xu,'SPD489-1xu,,,SPD489 Pilot Alternative Formulations BE study,SPD489-1xu Adult HV BE Alt.  Formulation,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,Nick Higgins,,,,,N,No,,,,COSMOS Inactive,,,9/1/2014,,10/13/2014,,,,,,12/16/2014,,,,12/30/2014,,,,,,,,,,,,,,1/13/2015,,1/13/2015,,,,,,,,,,,,,,,,,,,,4/20/2015,,4/16/2015,,,,,,,,,,,,6/11/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3xa,SPD489-3xa,'SPD489-3xa,,,Phase II Ped/Adol Randomized Withdrawl Study,SPD489-3xa Ped Rand WD,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Adolescent,,,116,0,0,0,0,0,0,0.00%,42,,,,"Cheryl Reburiano, Lisa Politza",,,Richard Sawyer,,,,,N,No,,,,COSMOS Inactive,,,2/2/2009,,3/2/2009,,,,,,10/27/2009,,,,9/21/2010,,,,,,,,,,,,,,11/9/2010,,11/9/2010,,,,,,,,,,,,,,,,,,,,1/13/2011,,2/24/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3xd,SPD489-3xd,'SPD489-3xd,,,Depression Augmentation Pivotal Study,SPD489-3xd Dep Pivotal,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,"1,200",0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/2/2010,,1/28/2011,,,,,,5/2/2011,,,,11/30/2012,,,,,,,,,,,,,,3/15/2013,,3/15/2013,,,,,,,,,,,,,,,,,,,,6/28/2013,,8/9/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3xe,SPD489-3xe,'SPD489-3xe,,,Depression Augmentation Pivotal Study,SPD489-3xe Dep Pivotal,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,"1,200",0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/2/2011,,3/28/2011,,,,,,8/2/2011,,,,3/2/2013,,,,,,,,,,,,,,6/15/2013,,6/15/2013,,,,,,,,,,,,,,,,,,,,9/28/2013,,11/9/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3xf,SPD489-3xf,'SPD489-3xf,,,Depression Augmentation Pivotal Study,SPD489-3xf Dep Pivotal,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,"1,200",0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/2/2011,,5/28/2011,,,,,,11/2/2011,,,,6/2/2013,,,,,,,,,,,,,,9/15/2013,,9/15/2013,,,,,,,,,,,,,,,,,,,,12/28/2013,,2/9/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3xg,SPD489-3xg,'SPD489-3xg,,,MDD Long Term OL Safety,SPD489-3xg Dep LT OL,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Safety,,,"1,000",0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/2/2011,,3/28/2011,,,,,,8/2/2011,,,,6/17/2013,,,,,,,,,,,,,,6/16/2014,,6/16/2014,,,,,,,,,,,,,,,,,,,,9/29/2014,,11/10/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3xh,SPD489-3xh,'SPD489-3xh,,,MDD EU LT Maintenance of Efficacy Study,SPD489-3xh EU Dep LTME,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,300,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/2/2013,,9/30/2013,,,,,,1/1/2014,,,,4/15/2015,,,,,,,,,,,,,,7/15/2015,,7/15/2015,,,,,,,,,,,,,,,,,,,,9/28/2015,,11/9/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3xi,SPD489-3xi,'SPD489-3xi,,,2-year open-label extension study,SPD489-3xi OL,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Adolescent,,,500,0,0,0,0,0,0,0.00%,80,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/31/2012,,12/7/2012,,,,,,7/19/2013,,,,10/30/2014,,,,,,,,,,,,,,10/27/2016,,10/27/2016,,,,,,,,,,,,,,,,,,,,12/7/2016,,1/3/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3yk,SPD489-3yk,'SPD489-3yk,,,12wk parallel,,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Double-Blind,,,940,0,0,0,0,0,0,0.00%,65,,,,"Celeste Ferreira-Cornwell, Joseph Gao, Sonia Brinton",Maria Gasior,,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,8/1/2012,,1/31/2013,,,,,,2/27/2015,,,,10/29/2015,,,,,,,,,,,,,,10/24/2017,,10/24/2017,,,,,,,,,,,,,,,,,,,,12/14/2017,,1/18/2018,,,,,,,,,,,,3/15/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3yo,SPD489-3yo,'SPD489-3yo,,,BED Neuroimaging,BED Neuroimaging,IV,Study Terminated,BED,,,Non-Registry,,Non-Interventional_CDO Support,,,,40,9,0,0,0,0,0,22.50%,5,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/31/2014,,1/30/2015,,,,,,5/29/2015,,,,11/20/2015,,,,,,,,,,,,,,2/23/2016,,2/23/2016,,,,,,,,,,,,,,,,,,,,4/13/2016,,5/18/2016,,,,,,,,,,,,7/13/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD489-3yp,SPD489-3yp,'SPD489-3yp,,,SPD489-3yp MDD Adlt Phase 3B Concept,489-3yp MDD Phase 3B,IIIb,Study Withdrawn,MDD,,,Non-Registry,,Interventional,,,,"1,034",0,0,0,0,0,0,0.00%,120,,,,Courtney Kirsch,,,Matthew Dauphin,,,,,N,No,,,,COSMOS Inactive,,,6/13/2014,,9/10/2014,,,,,,1/13/2015,,,,5/31/2016,,,,,,,,,,,,,,8/30/2016,,8/30/2016,,,,,,,,,,,,,,,,,,,,10/27/2016,,12/12/2016,,,,,,,,,,,,2/6/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD489-4xc,SPD489-4xc,'SPD489-4xc,,,Emotional Lability -Peds,Emotional Lability -Peds,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Randomized,,,150,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-4xe,SPD489-4xe,'SPD489-4xe,,,Lowest Effective Dose Concept,SPD489-4xe Ped LED,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Placebo-Controlled,,,130,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/2/2010,,7/14/2010,,,,,,10/8/2010,,,,2/28/2011,,,,,,,,,,,,,,3/28/2011,,3/28/2011,,,,,,,,,,,,,,,,,,,,5/6/2011,,6/2/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-4xr,SPD489-4xr,'SPD489-4xr,,,PRO#1,SPD489-4xr,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Adolescent,,,200,0,0,0,0,0,0,0.00%,60,,,,,,,Nick Higgins,,,,,N,No,,,,COSMOS Inactive,,,6/2/2014,,7/14/2014,,,,,,12/1/2014,,,,12/28/2015,,,,,,,,,,,,,,4/4/2016,,4/4/2016,,,,,,,,,,,,,,,,,,,,5/25/2016,,6/29/2016,,,,,,,,,,,,8/24/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD489-4xs,SPD489-4xs,'SPD489-4xs,,,PRO#2,SPD489-4xs,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Adolescent,,,200,0,0,0,0,0,0,0.00%,60,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/21/2016,,11/2/2016,,,,,,3/22/2017,,,,4/18/2018,,,,,,,,,,,,,,7/25/2018,,7/25/2018,,,,,,,,,,,,,,,,,,,,9/14/2018,,10/19/2018,,,,,,,,,,,,12/14/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD489-4xw,SPD489-4xw,'SPD489-4xw,,,SPD489-4xw 2 Year OL Study in Adults,SPD489-4xw 2 Year OL Study in Adults,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Long-Term,,,300,0,0,0,0,0,0,0.00%,55,,,,,,,Colleen Anderson,,,,,N,No,,,,COSMOS Inactive,,,4/2/2015,,5/14/2015,,,,,,12/15/2015,,,,6/20/2017,,,,,,,,,,,,,,6/18/2019,,6/18/2019,,,,,,,,,,,,,,,,,,,,8/15/2019,,9/19/2019,,,,,,,,,,,,11/14/2019,,,,,,,,,,,,,,,,,,,,,,,
SPD489-101,SPD489-101,'SPD489-101,,,"A Pharmacokinetic Study to Assess the Rate of Absorption and the Oral Bioavailability of two Dose Levels of NRP104 Capsules to Doses of the Reference Products, Dexedrine Spansules and Adderall XR Capsules Under Fasting Conditions",SPD489-101 PK,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioavailability (BA),,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/19/2003,3/19/2003,,,,,4/9/2004,4/9/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-102,SPD489-102,'SPD489-102,,,"A Single-Dose, 3-Treatment, 3-period, Crossover Pharmacokinetic Study to Assess Relative Bioavailability of NRP104 70 mg Capsules (1x70 mg) Under Fed State and Solution vs. Fasted State in Healthy Adult Volunteers",SPD489-102 PK Fed Fast,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,18,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/28/2004,10/28/2004,,,,,11/12/2004,11/12/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-103,SPD489-103,'SPD489-103,,,"A Single-Dose, 3-Treatment, 3-pd, Crossover PK Study to Assess Dose Proportionality of NRP104 30mg Capsules, 50mg Capsules, & 70mg Capsules in Children  6 to 12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD489-103 PK Dose Propor,I,Completed,ADHD,,,Non-Registry,,Interventional,Crossover,,,18,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/10/2004,8/10/2004,,,,,9/2/2004,9/2/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-104,SPD489-104,'SPD489-104,,,A Multiple-Dose Single-Arm Pharmacokinetics Study of NRP104 70 mg Capsules (1 x 70 mg) Following 7-Day Administration in Healthy Adult Volunteers Under Fasting Condition,SPD489-104 PK,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,11/3/2004,11/3/2004,,,,,11/12/2004,11/12/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-106,SPD489-106,'SPD489-106,,,"An Open-Label Study to Evaluate the Distribution, Metabolism and
Elimination of NRP-104 Radiolabeled with 14C and Administered as
an Oral Solution to Normal Healthy Subjects",SPD489-106 OL DME,I,Completed,ADHD,,,Non-Registry,,Interventional,Open Label,,,6,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/5/2005,4/5/2005,,,,,4/15/2005,4/15/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-109,SPD489-109,'SPD489-109,,,"An Open-label, Five-period, Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Lisdexamfetamine Dimesylate when Given as a Single-dose in Healthy Adult Subjects",SPD489-109 Dose Esc PK,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,20,20,52,0,32,0,11,100.00%,1,,,,,,,Robert Homolka,,,,,N,No,,,,COSMOS Inactive,,,5/17/2007,5/17/2007,6/27/2007,6/27/2007,,,,,8/7/2007,8/7/2007,,,8/7/2007,8/7/2007,,,,,,,,,,,,,8/28/2007,8/28/2007,8/28/2007,11/8/2007,,,,,,,,,,,,,,,,,,,10/29/2007,10/29/2007,12/27/2007,12/27/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-111,SPD489-111,'SPD489-111,,,"An Open-label, Two-Phase, Randomised Cross-over Study to Investigate Intranasal and Regional Absorption of Vyvanse™ in Healthy Volunteers",SPD489-111 rand x-over,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,18,18,23,0,2,0,0,100.00%,1,,,Shire,Mary Haffey,,,,,,,,N,No,,,,COSMOS Inactive,,,10/25/2007,10/26/2007,2/6/2008,1/31/2008,,,,,4/11/2008,4/11/2008,,,4/18/2008,4/25/2008,,,,,,,,,,,,,7/10/2008,7/14/2008,7/10/2008,9/16/2008,,,,,,,,,,,,,,,,,,,9/30/2008,10/16/2008,10/14/2008,10/29/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-112,SPD489-112,'SPD489-112,,,"A single-blind, randomized study of the comparative drug likeability and pharmacokinetics of VyvanseTM and Adderall XR(R) when administered as a solution",SPD489-112 PKPD PET HV,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,16,3,18,0,15,0,0,18.75%,1,,,Shire,,,,Mary Palmen,,,,,N,No,,,,COSMOS Inactive,,,6/22/2007,6/22/2007,9/17/2007,9/17/2007,,,,,1/10/2009,1/10/2009,,,2/7/2009,2/7/2009,,,,,,,,,,,,,3/31/2009,3/31/2009,3/31/2009,8/4/2009,,,,,,,,,,,,,,,,,,,8/5/2009,8/5/2009,8/5/2009,8/5/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-113,SPD489-113,'SPD489-113,,,"A Phase I, Open-Label, Randomized, Four Period Crossover Drug Interaction Study to Evaluate the Changes in Pharmacokinetic Profiles of VYVANSE and ADDERALL XR   When Each is Administered Alone and in Combination with the Proton Pump Inhibitor Omeprazole in Healthy Adult Volunteers","SPD489-113  PK, Interact",I,Completed,ADHD,,,Non-Registry,,Interventional,Drug Interaction,,,30,0,0,0,0,0,0,0.00%,1,,,Shire,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/22/2008,8/22/2008,8/28/2008,8/28/2008,,,,,9/23/2008,9/26/2008,,,9/23/2008,9/27/2008,,,,,,,,,,,,,10/15/2008,10/19/2008,10/15/2008,12/12/2008,,,,,,,,,,,,,,,,,,,1/1/2009,12/2/2008,2/16/2009,2/9/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-114,SPD489-114,'SPD489-114,,,Head to Head Psychometric Study with IR,SPD489-114 Adult HTH Psychometric Study,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,24,0,0,0,0,0,0,0.00%,1,,,,Mary Corcoran,,Patrick Martin,"Celeste Ferreira-Cornwell, Matthew Dauphin",,,,,N,No,,,,COSMOS Inactive,,,1/4/2011,,1/31/2011,,,,,,4/19/2011,,,,6/13/2011,,,,,,,,,,,,,,7/4/2011,,7/4/2011,,,,,,,,,,,,,,,,,,,,9/19/2011,,10/10/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-115,SPD489-115,'SPD489-115,,,"A Phase I, Randomized, Double Blind, Three-Period Crossover, Exploratory Study to Evaluate the Utility of a Standardized Computer Battery of Tests in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD489-115  Pilot Study of CDR battery,I,Completed,Bipolar Disorder,,,Non-Registry,,Interventional,Crossover,,,18,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/26/2009,6/26/2009,9/16/2009,9/16/2009,,,,,1/24/2010,1/24/2010,,,3/7/2010,3/7/2010,,,,,,,,,,,,,3/28/2010,3/28/2010,3/28/2010,7/16/2010,,,,,,,,,,,,,,,,,,,8/5/2010,8/5/2010,8/20/2010,8/20/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-116,SPD489-116,'SPD489-116,,,"A Phase I, Randomized, Double-blind, 2-period, Crossover, Placebo-controlled Study to Assess the Pharmacokinetics of a Single 50mg Oral Dose of Lisdexamfetamine Dimesylate in Health Elderly Male and Female Subjects",SPD489-116 Elderly PK,I,Completed,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,48,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/29/2010,4/29/2010,9/10/2010,9/27/2010,,,,,11/21/2010,11/21/2010,,,1/3/2011,1/13/2011,,,,,,,,,,,,,1/24/2011,1/24/2011,1/24/2011,4/21/2011,,,,,,,,,,,,,,,,,,,5/10/2011,5/10/2011,6/6/2011,5/26/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-117,SPD489-117,'SPD489-117,,,"A Phase 1, Open-Label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR®, Administered Alone and in Combination in Healthy Adult Volunteers",SPD489-117 SNRI DDI Study,I,Completed,ADHD,,,Non-Registry,,Interventional,Drug Interaction,,,72,0,0,0,0,0,0,0.00%,2,,,,,"Beverly Stanton, James Heinlein",,,,,,,N,No,,,,COSMOS Inactive,,,9/22/2010,9/22/2010,10/1/2010,10/18/2010,,,,,11/22/2010,11/16/2010,,,11/23/2010,11/23/2010,,,,,,,,,,,,,12/31/2010,12/31/2010,12/31/2010,2/28/2011,,,,,,,,,,,,,,,,,,,3/17/2011,3/17/2011,4/7/2011,4/7/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-118,SPD489-118,'SPD489-118,,,"A Phase 1, Randomized, Placebo controlled, Double-blind, Parallel Group, Exploratory Study of SPD489 to Investigate Changes in Metabolic Parameters in Overweight Adults Aged 18-45 with Elevated Fasting Blood Glucose",SPD489-118 Metabolic Study,I,Study Terminated,Metabolic,,,Non-Registry,,Interventional,,,,100,5,0,0,0,5,0,5.00%,1,,,,"Lyette Richards, Mary Haffey",,Patrick Martin,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,5/12/2010,5/12/2010,8/13/2010,7/16/2010,,,,,11/4/2010,11/18/2010,,,8/15/2011,1/18/2011,,,,,,,,,,,,,10/21/2011,3/1/2011,10/21/2011,6/1/2011,,,,,,,,,,,,,,,,,,,,,6/13/2011,6/16/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-119,SPD489-119,'SPD489-119,,,"A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending, Multiple Oral Doses of SPD489 (Lisdexamfetamine Dimesylate) in Clinically Stable Adults with Schizophrenia",SPD489-119 Schizophrenia PK,I,Completed,Schizophrenia,,,Non-Registry,,Interventional,,,,32,0,0,0,0,0,0,0.00%,2,,,,"Annette Stevenson, Kimberly McCormick",,,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,9/1/2011,9/1/2011,8/31/2011,9/1/2011,,,,,11/17/2011,11/15/2011,,,11/26/2011,12/11/2011,,,,,,,,,,,,,1/21/2012,1/12/2012,1/21/2012,2/23/2012,,,,,,,,,,,,,,,,,,,3/5/2012,3/2/2012,4/2/2012,4/3/2012,,,,,,,,,,,6/8/2012,6/12/2012,,,,,,,,,,,,,,,,,,,,,,
SPD489-120,SPD489-120,'SPD489-120,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 1, Single-dose, Open-label Study to Determine the Pharmacokinetic, Safety, and Tolerability Profiles of SPD489 (lisdexamfetamine dimesylate) in Subjects with Normal and Impaired Renal Function",489-120 Renal Study,I,Completed,ADHD,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,48,40,0,0,0,40,0,83.33%,6,,,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/30/2011,11/30/2011,2/26/2013,2/26/2013,,,5/8/2013,5/8/2013,,,,,10/3/2013,10/3/2013,,,10/7/2013,10/7/2013,,,,,,,,,,,,,,,,,,,,,3/6/2014,3/6/2014,,,,,,,,,,,,,,,,,,,,,,,4/22/2014,4/22/2014,,,,,,,,,,,,,,,4/22/2014,4/22/2014,,,,,,
SPD489-121,SPD489-121,'SPD489-121,,Vyvanse (Lisdexamfetamine dimesylate),Phase 1 Safety Tolerability and PK Study in Japanese and Caucasian Healthy Volunteers,SPD489-121 Japanese/Caucasian Safety PK,I,Completed,ADHD,NS,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,1,,West Coast Clinical Trials,"Bree Harlin, Jim Ermer, Nick Higgins",Lyette Richards,Patrick Martin,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,1/31/2011,1/31/2011,2/7/2012,2/7/2012,,,,,4/17/2012,4/17/2012,,,5/15/2012,5/15/2012,,,6/8/2012,6/8/2012,,,,,,,,,,,,,,,,,,,,,7/19/2012,7/19/2012,,,,,,,,,,,,,,,,,,,,,,,11/9/2012,11/9/2012,,,,,,,,,,,,,,,11/9/2012,11/9/2012,,,,,,
SPD489-122,SPD489-122,'SPD489-122,,,"A Phase 1, Open-label, Randomized, Two-period Crossover Drug Interaction Study Evaluating the Effect of SPD489 on the Pharmacokinetic Profiles of Various CYP Probe Substrates in the Cooperstown Cocktail when Given to Healthy Adult Subjects",SPD489-122 DDI Cocktail study,I,Completed,MDD,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Drug Interaction,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/5/2012,9/11/2012,11/16/2012,11/16/2012,,,,,1/18/2013,1/18/2013,,,1/18/2013,1/18/2013,,,,,,,,,,,,,1/28/2013,1/28/2013,1/28/2013,3/12/2013,,,,,,,,,,,,,,,,,,,6/6/2013,6/6/2013,5/23/2013,5/23/2013,,,,,,,,,,,9/5/2013,9/4/2013,,,,,,,,,,,,,,,,,,,,,,
SPD489-123,SPD489-123,'SPD489-123,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 1, Open-label, Randomized, 3-period Crossover Study Evaluating the Relative Bioavailability of SPD489 when the Contents are Emptied into a Soft Food and Orange Juice in Healthy Adult Subjects",489-123 Adult HV PK,I,Completed,ADHD,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Bioavailability (BA),,,30,30,70,0,0,30,0,100.00%,1,,,"Clinical Pharmacology of Miami, INC",,,,,,,,,N,No,,,,COSMOS Inactive,,,5/7/2013,5/7/2013,6/4/2013,6/4/2013,,,8/1/2013,8/1/2013,,,,,8/15/2013,8/15/2013,,,8/19/2013,8/19/2013,,,,,,,,,,,,,,,,,,,,,10/10/2013,10/10/2013,,,,,,,,,,,,,,,,,,,,,,,1/14/2014,1/14/2014,,,,,,,,,,,,,,,1/14/2014,1/14/2014,,,,,,
SPD489-124,SPD489-124,'SPD489-124,,Vyvanse (Lisdexamfetamine dimesylate),SPD489-124 Ascending dose pharmacokinetic study of chinese adolescents aged 12-18years,SPD489-124 BE China ADHD-Adlsc PK,I,Cancelled,,NS,Marketed Products,,Both pediatric and non-pediatric,Interventional,,,,12,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/14/2014,2/14/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/14/2014,2/14/2014,,,,,,
SPD489-125,SPD489-125,'SPD489-125,,,An Open-Label Sensory Evaluation of SPD489 (VYVANSE¿) in Healthy Panelists,SPD489-125 Palatability New Formulation,I,Completed,ADHD,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Healthy Volunteers,,,8,6,0,0,0,0,0,75.00%,1,,,,Heather Van Heusen,,,,,,,,N,No,,,,COSMOS Inactive,,,7/14/2014,7/14/2014,9/3/2014,9/3/2014,,,,,10/6/2014,10/6/2014,,,10/6/2014,10/6/2014,,,,,,,,,,,,,11/28/2014,10/23/2014,11/28/2014,3/6/2015,,,,,,,,,,,,,,,,,,,12/19/2014,12/15/2014,2/20/2015,2/12/2015,,,,,,,,,,,2/20/2015,2/12/2015,,,,,,,,,,,,,,,,,,,,,,
SPD489-149,SPD489-149,'SPD489-149,,,China PK Study,China PK SPD489,I,Cancelled,,,,,,Interventional,,,,20,,,,,,,,10,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-201,SPD489-201,'SPD489-201,,,"A Phase 2, Randomized, DB, PBO- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study with One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR®, or Placebo in Children Aged 6 to 12 Years with ADHD",NRP104.201 DB Ped Classroom Study,II,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,52,0,0,0,0,0,0,0.00%,4,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/12/2004,8/12/2004,,,,,9/30/2004,9/30/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-202,SPD489-202,'SPD489-202,,,Adult MDD,SPD489-202 Depression POC,II,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,400,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/13/2009,,5/7/2009,,,,,,7/30/2009,,,,2/28/2011,,,,,,,,,,,,,,3/20/2011,,3/20/2011,,,,,,,,,,,,,,,,,,,,5/8/2011,,6/5/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-203,SPD489-203,'SPD489-203,,,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Exploratory Study of LDX in Adults 18-55 years with Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant.",SPD489-203  MDD Augmentation Therapy,II,Completed,MDD,,,Non-Registry,,Interventional,Efficacy,,,252,270,386,0,165,200,44,107.14%,15,,,Syneos Health,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/27/2009,2/27/2009,5/5/2009,5/5/2009,,,,,7/29/2009,8/11/2009,,,4/23/2010,4/21/2010,,,,,,,,,,,,,8/3/2010,7/28/2010,8/3/2010,9/16/2010,,,,,,,,,,,,,,,,,,,9/23/2010,9/17/2010,10/28/2010,10/22/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-204,SPD489-204,'SPD489-204,,,"A Phase 2, Open-Label, Multi-Center study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18 to 55 with Prominent Negative Symptom Schizophrenia",SPD489-204 Negative Sx in Schizophrenia,II,Completed,Schizophrenia,,,Non-Registry,,Interventional,Cognitive,,,88,109,178,0,99,98,40,123.86%,12,28,,Syneos Health,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/15/2009,4/15/2009,6/10/2009,6/10/2009,,,,,10/5/2009,10/5/2009,,,10/18/2010,10/15/2010,,,,,,,,,,,,,1/21/2011,1/20/2011,1/21/2011,3/1/2011,,,,,,,,,,,,,,,,,,,3/10/2011,3/10/2011,4/15/2011,4/13/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-205,SPD489-205,'SPD489-205,,,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults with Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder",SPD489-205 EFI Impairment in Depression,II,Completed,MDD,,,Non-Registry,,Interventional,Efficacy,,,143,145,217,0,76,160,3,101.40%,32,,,Syneos Health,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/3/2009,6/3/2009,7/22/2009,7/22/2009,,,,,11/26/2009,11/27/2009,,,1/20/2011,1/20/2011,,,,,,,,,,,,,4/7/2011,4/11/2011,4/7/2011,5/19/2011,,,,,,,,,,,,,,,,,,,5/31/2011,5/31/2011,7/5/2011,7/5/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-206,SPD489-206,'SPD489-206,,,SPD489-206 ADHD and Obesity,SPD489-206 ADHD and Obesity,II,Study Withdrawn,ADHD and Obesity,,,Non-Registry,,Interventional,Double-Blind,,,70,0,0,0,0,0,0,0.00%,15,,,,John Pallante,,,,,,,,N,No,,,,COSMOS Inactive,,,7/28/2009,,12/23/2009,,,,,,6/7/2010,,,,3/31/2011,,,,,,,,,,,,,,7/7/2011,,7/7/2011,,,,,,,,,,,,,,,,,,,,8/23/2011,,9/20/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-207,SPD489-207,'SPD489-207,,,"A Phase 2, Randomized, Double-Blind, Single Center, Parallel Group, Placebo and Active Comparator, Controlled Study to Evaluate the Pharmacodynamic Profile of Single Doses of SPD489 in Healthy Adult Male Subjects Undergoing a Nocturnal Period of Acute Sleep Loss",SPD489-207 Adlt DB PD,II,Completed,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,135,0,0,0,0,0,0,0.00%,1,,,Shire,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/20/2009,3/2/2010,2/26/2010,3/3/2010,,,,,4/15/2010,4/26/2010,,,7/9/2010,7/8/2010,,,,,,,,,,,,,7/15/2010,7/10/2010,7/15/2010,8/17/2010,,,,,,,,,,,,,,,,,,,8/30/2010,8/30/2010,9/20/2010,9/9/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-208,SPD489-208,'SPD489-208,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55Years with Binge Eating Disorder",SPD489-208 Binge Eating Disorder,II,Completed,BED,NS,,Non-Registry,,Interventional,Proof of Concept,,,260,271,272,0,0,116,58,104.23%,31,,,Premier Research,,,John Morgan,,"Dana Jackson, John Osgood, June Jesunathadas, Nancy Mazzei, Paul Edwards, Rebekah De Vitry, Rita Aguilar, Rita Aguilar-Torres",,,,N,No,,,,COSMOS Inactive,,,11/11/2010,11/11/2010,2/18/2011,2/18/2011,,,,,5/25/2011,5/25/2011,,,11/4/2011,11/4/2011,,,1/30/2012,1/30/2012,,,,,,,,,,,,,,,,,,,,,3/19/2012,3/19/2012,,,,,,,,,,,,,,,,,,,,,,,6/21/2012,6/21/2012,,,,,,,,,,,,,,,6/21/2012,6/21/2012,,,,,,
SPD489-209,SPD489-209,'SPD489-209,,,"A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",489-209 MDD Exploratory DR,II,Completed,MDD,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,"1,134",852,2313,0,1111,852,449,75.13%,70,1,,ICON / MAPI / Paradigm,Erin Hartshaw,,,Courtney Kirsch,"Kultaran Sandhar, Regina Ingram, Tamara Pitcovsky",2011-003615-28,,,N,No,,,,COSMOS Inactive,,,6/15/2011,6/15/2011,8/5/2011,8/5/2011,,,,,11/8/2011,11/8/2011,,,9/24/2013,9/24/2013,,,,,,,,,,,,,1/13/2014,1/13/2014,1/13/2014,3/6/2014,,,,,,,,,,,,,,,,,,,3/31/2014,3/31/2014,6/30/2014,6/30/2014,,,,,,,,,,,9/12/2014,11/12/2014,,,,,,,,,,,,,,,,,,,,,,
SPD489-210,SPD489-210,'SPD489-210,,,NSS Phase 2 Exploratory Dose Ranging,NSS Phase 2 Exploratory Dose Ranging,II,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Randomized,,,425,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/20/2012,,8/30/2012,,,,,,12/28/2012,,,,12/12/2013,,,,,,,,,,,,,,3/20/2014,,3/20/2014,,,,,,,,,,,,,,,,,,,,5/5/2014,,6/9/2014,,,,,,,,,,,,8/4/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-211,SPD489-211,'SPD489-211,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention-deficit/Hyperactivity Disorder",489-211 OL Ped Pilot,II,Completed,ADHD,NS,,Non-Registry,Pediatric only (<18 yr),Interventional,Multi-Centre,,,,23,0,,0,0,5,,5,,,PPD,,Richard Sawyer,,,,,,,N,No,,,,COSMOS Inactive,,,7/28/2014,7/28/2014,10/6/2014,10/6/2014,,,4/15/2015,4/15/2015,6/26/2015,6/26/2015,,,4/29/2016,4/29/2016,,,6/30/2016,6/30/2016,,,,,,,,,,,,,,,,,,,,,10/10/2016,10/10/2016,,,,,,,,,,,,,,,,,,,,,,,2/15/2017,2/15/2017,,,,,,,,,,,,,,,2/15/2017,2/15/2017,,,,,,
SPD489-212,SPD489-212,'SPD489-212,,,A Study to Assess the Psychometric Properties of a Patient Reported Outcome (PRO) Measure in Adults Diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS),PRO Measure Study in CFS Patients,II,Cancelled,,,,,Non-pediatric only (>18 yr),Interventional,,,,120,,,,,,,,50,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-213,SPD489-213,'SPD489-213,,,SPD489+ SPD503 FDC 6-17 y/o ADHD,SPD489+ SPD503 FDC 6-17 y/o ADHD,II,Cancelled,,,,,,Interventional,,,,320,,,,,,,,45,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-301,SPD489-301,'SPD489-301,,,"A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD)",NRP104.301 DB PBO Ped,III,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,256,0,0,0,0,0,0,0.00%,64,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/18/2004,8/18/2004,,,,,10/28/2004,10/28/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-302,SPD489-302,'SPD489-302,,,"A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg
Per Day in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder
(ADHD)",NRP104.302 - Open-label 1 year safety,III,Completed,ADHD,,,Non-Registry,,Interventional,Open Label,,,200,0,0,0,0,0,0,0.00%,38,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/16/2004,8/16/2004,,,,,11/22/2004,11/22/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-303,SPD489-303,'SPD489-303,,,"A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD489-303 Adlt DB PCB,III,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,420,0,0,0,0,0,0,0.00%,48,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/3/2006,4/3/2006,,,,,6/6/2006,6/6/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/15/2006,11/15/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-304,SPD489-304,'SPD489-304,,,"A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults with Attention Deficit Hyperactivity Disorder (ADHD)",SPD489-304 Adlt OL LT,III,Completed,ADHD,,,Non-Registry,,Interventional,Open Label,,,349,0,0,0,0,0,0,0.00%,44,,,Chiltern,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/1/2006,3/1/2006,,4/22/2006,,,,,7/5/2006,7/5/2006,,,11/7/2006,11/7/2006,,,,,,,,,,,,,11/7/2007,11/16/2007,11/7/2007,2/28/2008,,,,,,,,,,,,,,,,,,,3/7/2008,3/7/2008,4/1/2008,4/1/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-305,SPD489-305,'SPD489-305,,,"A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in
Adolescents Aged 13-17 with Attention-Deficit/Hyperactivity
Disorder (ADHD)",SPD489-305 Adol PAC,III,Completed,ADHD,,,Non-Registry,,Interventional,Post Approval Commitment,,,300,314,409,0,95,0,49,104.67%,45,,,Premier Research,"Kurt Strittmatter, Michael McKay",,Bernard Brownstein,,"Agnes Olson, Amber Siptak, Barbara Komenda, Christine Jones, David Brockwell, David Mazzei, J Araujo, John Osgood, Keshica Butler, Kevin Kantor, Kristie Stewart, Larry Shailer, Lee Winakor, Nancy Mazzei, Susan Kimmel, Terri Self, Victor Smith",,,,N,No,,,,COSMOS Inactive,,,5/1/2008,5/1/2008,7/3/2008,7/3/2008,,,,,10/18/2008,10/18/2008,,,2/27/2009,3/2/2009,,,,,,,,,,,,,3/30/2009,4/1/2009,3/30/2009,5/21/2009,,,,,,,,,,,,,,,,,,,5/26/2009,5/29/2009,6/30/2009,6/24/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-306,SPD489-306,'SPD489-306,,,"A Phase III, Open-Label, Extension, Multi-center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in
Adolescents aged 13-17 with Attention-Deficit/Hyperactivity
Disorder (ADHD)",SPD489-306 OL Adol,III,Completed,ADHD,,,Non-Registry,,Interventional,Adolescent,,,300,54,0,0,2,267,113,18.00%,45,,,Premier Research,Theresa Sheehan,,Bernard Brownstein,,"Agnes Olson, Amber Siptak, Barbara Komenda, Christine Jones, David Brockwell, J Araujo, John Osgood, Keshica Butler, Kevin Kantor, Kristie Steward, Kristie Stewart, Larry Shailer, Lee Winakor, Nancy Mazzei, Paul Edwards, Rita Torres, Susan Kimmel, Terri Self, Victor Smith",,,,N,No,,,,COSMOS Inactive,,,5/20/2008,5/20/2008,6/30/2008,6/30/2008,,,,,11/13/2008,11/13/2008,,,4/1/2009,4/1/2009,,,,,,,,,,,,,3/31/2010,4/20/2010,3/31/2010,6/2/2010,,,,,,,,,,,,,,,,,,,6/9/2010,6/10/2010,6/30/2010,7/12/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-308,SPD489-308,'SPD489-308,,,SPD489-308,SPD489-308 Low Dose,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,240,0,0,0,0,0,0,0.00%,35,,,,Jen Teti,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-309,SPD489-309,'SPD489-309,,,SPD489-309,SPD489-309,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,300,0,0,0,0,0,0,0.00%,60,,,,Jen Teti,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-310,SPD489-310,'SPD489-310,,,"A Prospective, Open-Label, Multi-Center, Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse 20-70mg in Children aged 6-12 Diagnosed with ADHD",SPD489-310 OL Dose Op,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Efficacy,,,300,318,376,0,62,0,42,106.00%,35,,,,Rajesh Prasad,,Bernard Brownstein,,"Christy Dewees, Gale Faulkner, John Osgood, Katrina Reeves, Kevin Kantor, Nancy Mazzei, Robert Vanderpool, Sanqual Minger, Scott Boatwright, Scott Wilson, Susan Kimmel, Terri Self, Tim Murphy, William Vosburgh",,,,N,No,,,,COSMOS Inactive,,,1/4/2007,1/4/2007,4/2/2007,4/2/2007,,,,,7/6/2007,7/6/2007,,,10/12/2007,10/12/2007,,,,,,,,,,,,,12/11/2007,12/11/2007,12/11/2007,4/4/2008,,,,,,,,,,,,,,,,,,,4/29/2008,4/29/2008,5/16/2008,5/16/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-311,SPD489-311,'SPD489-311,,,"A Phase IIIb, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Dose-Optimization, Cross-Over, Analog Classroom Study to Assess the Time of Onset of Vyvanse in Pediatric Subjects aged 6-12 with Attention-Deficit/Hyperactivity Disorder",SPD489-311 DB Classrm x-o,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Efficacy,,,128,191,258,0,65,0,20,149.22%,9,,,Premier Research,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/4/2007,1/4/2007,3/27/2007,3/27/2007,,,,,6/27/2007,6/27/2007,,,9/24/2007,9/24/2007,,,,,,,,,,,,,11/3/2007,11/3/2007,11/3/2007,2/13/2008,,,,,,,,,,,,,,,,,,,3/4/2008,2/29/2008,5/14/2008,5/15/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-312,SPD489-312,'SPD489-312,,,Adult ADHD,SPD489-312 Adlt ADHD,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,240,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/20/2007,,1/30/2008,,,,,,5/9/2008,,,,6/25/2009,,,,,,,,,,,,,,9/19/2009,,9/19/2009,,,,,,,,,,,,,,,,,,,,12/1/2009,,1/18/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-313,SPD489-313,'SPD489-313,,,Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Major Depressive Disorder (MDD),SPD489-313 Adlt como MDD,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Randomized,,,200,0,0,0,0,0,0,0.00%,25,,,,Sonia Brinton,,,,,,,,N,No,,,,COSMOS Inactive,,,11/20/2007,,12/24/2007,,,,,,5/7/2008,,,,3/4/2009,,,,,,,,,,,,,,4/15/2009,,4/15/2009,,,,,,,,,,,,,,,,,,,,6/17/2009,,7/29/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-314,SPD489-314,'SPD489-314,,,Adult ADHD Driving Study,SPD489-314 Driving,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Randomized,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/14/2009,,10/14/2009,,,,,,,,,,11/15/2010,,,,,,,,,,,,,,2/14/2011,,2/14/2011,,,,,,,,,,,,,,,,,,,,4/15/2011,,5/27/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-315,SPD489-315,'SPD489-315,,,SPD489-315 Adults with hypertension,SPD489-315 Adlt hypertens,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Efficacy,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-316,SPD489-316,'SPD489-316,,,"A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)",SPD489-316 AWE,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,106,142,195,0,53,0,39,133.96%,5,,,Premier Research,,Maria Gasior,,,,,,,N,No,,,,COSMOS Inactive,,,2/14/2008,5/2/2008,3/27/2008,5/2/2008,,,,,8/14/2008,8/13/2008,,,11/10/2008,10/27/2008,,,,,,,,,,,,,12/22/2008,12/20/2008,12/22/2008,2/17/2009,,,,,,,,,,,,,,,,,,,2/26/2009,2/25/2009,4/7/2009,4/9/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-317,SPD489-317,'SPD489-317,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Reponse to Methylphenidate Therapy",SPD489-317 Rand DB Comparator,III,Completed,ADHD,NS,,Non-Registry,,Interventional,Adolescent,,,262,270,319,0,55,19,72,103.05%,60,1,,PRA,Alissa Sirbu,,,Nick Higgins,"Alicia Del Rey, Debora Parera, Iciar Caballero, Irene Soneira",2009-011745-94,,,N,No,,,,COSMOS Inactive,,,3/17/2009,3/17/2009,6/18/2009,6/18/2009,,,7/6/2010,7/6/2010,,,,,5/14/2012,5/14/2012,,,,,,,,,,,,,,,,,,,,,,,,,9/27/2012,9/27/2012,,,,,,,,,,,,,,,,,,,,,,,1/15/2013,1/15/2013,,,,,,,,,,,,,,,1/15/2013,1/15/2013,,,,,,
SPD489-318,SPD489-318,'SPD489-318,,,"A Phase IIIb, Randomised, Open-Label, Multi-Centre Study to Evaluate the Efficacy and Safety of Lisdexamfetamine Dimesylate  versus  Usual Treatment in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD489-318,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Adolescent,,,280,0,0,0,0,0,0,0.00%,54,,,,John Tobin,,,Nick Higgins,,,,,N,No,,,,COSMOS Inactive,,,7/10/2009,7/10/2009,4/30/2010,4/30/2010,,,,,8/17/2011,,,,2/7/2013,,,,,,,,,,,,,,5/2/2013,,5/2/2013,,,,,,,,,,,,,,,,,,,,6/12/2013,,7/9/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-319,SPD489-319,'SPD489-319,,,SPD489-319 Rand PCB Adult,SPD489-319 Rand PCB Adlt,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Randomized,,,150,0,0,0,0,0,0,0.00%,45,,,,,,,Nick Higgins,,,,,N,No,,,,COSMOS Inactive,,,3/17/2011,,4/28/2011,,,,,,4/18/2012,,,,10/29/2014,,,,,,,,,,,,,,3/18/2015,,3/18/2015,,,,,,,,,,,,,,,,,,,,5/12/2015,,5/19/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-320,SPD489-320,'SPD489-320,,,SPD489-320 NSS High and Low Vs. Placebo,SPD489-320 NSS High and Low Vs. Placebo,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Double-Blind,,,507,0,0,0,0,0,0,0.00%,70,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/5/2010,8/5/2010,10/21/2010,10/21/2010,,,,,1/27/2012,,,,8/9/2013,,,,,,,,,,,,,,2/24/2014,,2/24/2014,,,,,,,,,,,,,,,,,,,,4/16/2014,,5/21/2014,,,,,,,,,,,,7/16/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-321,SPD489-321,'SPD489-321,,,"A Phase 3b, Randomized, Double-blind, Multicenter, Placebo controlled, Dose optimization, Crossover, Analog Classroom, Safety and Efficacy Study of SPD489 in Adolescent Subjects Aged 13 17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD489-321 DB Classrm XO,IIIb,Study Terminated,ADHD,,,Non-Registry,,Interventional,Duration of Effect,,,156,0,1,0,0,0,0,0.00%,6,6,,Premier Research,,,John Morgan,,"David Brockwell, John Osgood, Nancy Mazzei, Rita Aguilar-Torres",,,,N,No,,,,COSMOS Inactive,,,10/29/2010,10/29/2010,12/7/2010,12/7/2010,,,,,5/20/2011,,,,11/11/2011,,,,,,,,,,,,,,12/23/2011,,12/23/2011,,,,,,,,,,,,,,,,,,,,2/14/2012,,3/20/2012,,,,,,,,,,,,5/15/2012,,,,,,,,,,,,,,,,,,,,,,,
SPD489-322,SPD489-322,'SPD489-322,,,"The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant",MDD Pivotal #1,III,Completed,MDD,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,"1,034",870,2196,0,953,870,168,84.14%,70,,,ICON / MAPI / Paradigm,Roy Edmonds,,,Courtney Kirsch,,2011-003018-17,,,N,No,,,,COSMOS Inactive,,,5/20/2011,5/20/2011,7/7/2011,7/7/2011,,,,,11/15/2011,11/15/2011,,,8/27/2013,8/27/2013,,,,,,,,,,,,,12/13/2013,12/17/2013,12/13/2013,1/28/2014,,,,,,,,,,,,,,,,,,,2/6/2014,2/6/2014,4/7/2014,4/7/2014,,,,,,,,,,,6/26/2014,6/26/2014,,,,,,,,,,,,,,,,,,,,,,
SPD489-323,SPD489-323,'SPD489-323,,,"The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant",MDD Pivotal #2,III,Completed,MDD,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,"1,034",823,1887,0,776,823,100,79.59%,70,,,ICON / MAPI / Paradigm,Erin Hartshaw,Fatos Bejta,,Courtney Kirsch,,2011-003006-25,,,N,No,,,,COSMOS Inactive,,,5/20/2011,5/20/2011,7/8/2011,7/8/2011,,,,,10/31/2011,10/31/2011,,,8/13/2013,8/13/2013,,,,,,,,,,,,,12/2/2013,12/3/2013,12/2/2013,1/15/2014,,,,,,,,,,,,,,,,,,,1/24/2014,2/6/2014,3/24/2014,3/24/2014,,,,,,,,,,,5/28/2014,6/3/2014,,,,,,,,,,,,,,,,,,,,,,
SPD489-324,SPD489-324,'SPD489-324,,,Adjunctive Treatment of MDD Pivotal #3,MDD Pivotal #3,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Efficacy,,,781,0,0,0,0,0,0,0.00%,60,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/6/2011,,8/16/2011,,,,,,2/22/2012,,,,10/14/2013,,,,,,,,,,,,,,2/10/2014,,2/10/2014,,,,,,,,,,,,,,,,,,,,4/2/2014,,5/7/2014,,,,,,,,,,,,7/2/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-325,SPD489-325,'SPD489-325,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD489-325 Rand PCB Ped,III,Completed,ADHD,NS,,Non-Registry,,Interventional,Adolescent,,,333,338,386,0,69,14,147,101.50%,70,5,,PRA,,,,,"Anja Puetz, Dagmar Pilz, Iciar Caballero, Irene Soneira, Sandra Jaepel, Satvinder Matharu, Scott Durston, Tom Lambrecht, Verena Molnar",2008-000679-90,,,N,No,,,,COSMOS Inactive,,,2/7/2008,2/7/2008,2/28/2008,2/28/2008,,,11/27/2008,11/27/2008,,,,,12/31/2010,12/31/2010,,,,,,,,,,,,,,,,,,,,,,,,,5/18/2011,5/18/2011,,,,,,,,,,,,,,,,,,,,,,,8/23/2011,8/23/2011,,,,,,,,,,,,,,,8/23/2011,8/23/2011,,,,,,
SPD489-326,SPD489-326,'SPD489-326,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase III, Double-Blind, Placebo-Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD489-326 Rand PCB Ped,III,Completed,ADHD,NS,,Non-Registry,,Interventional,Adolescent,,,232,274,257,0,13,15,186,118.10%,42,,,PRA,,,,,Amra Felic,2008-000720-10,,,N,No,,,,COSMOS Inactive,,,2/7/2008,2/7/2008,2/28/2008,2/28/2008,,,1/27/2009,1/27/2009,,,,,3/3/2011,3/3/2011,,,,,,,,,,,,,,,,,,,,,,,,,12/19/2011,12/19/2011,,,,,,,,,,,,,,,,,,,,,,,3/12/2012,3/12/2012,,,,,,,,,,,,,,,3/12/2012,3/12/2012,,,,,,
SPD489-327,SPD489-327,'SPD489-327,,,SPD489-327 ADHD study in adults 18-55 in EU,SPD489-327 Adlt EU,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Natural History,,,300,0,0,0,0,0,0,0.00%,35,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/16/2009,,5/20/2009,,,,,,9/15/2009,,,,7/1/2010,,,,,,,,,,,,,,8/19/2010,,8/19/2010,,,,,,,,,,,,,,,,,,,,10/25/2010,,12/6/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-328,SPD489-328,'SPD489-328,,,SPD489-328 ADHD open label study in adults 18-55 in EU,SPD489-328 OL Adlt EU,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Safety,,,240,0,0,0,0,0,0,0.00%,35,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/18/2009,,6/19/2009,,,,,,11/16/2009,,,,8/30/2010,,,,,,,,,,,,,,8/26/2011,,8/26/2011,,,,,,,,,,,,,,,,,,,,11/1/2011,,12/13/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-329,SPD489-329,'SPD489-329,,,"A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant",MDD LT OL Safety,III,Study Withdrawn,MDD,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Long-Term,,,"1,500","1,577",1,0,7,2,1270,105.13%,110,,,ICON / MAPI / Paradigm,,,,,,2011-003019-47,,,N,No,,,,COSMOS Inactive,,,5/20/2011,5/20/2011,7/12/2011,7/12/2011,,,,,2/27/2012,2/27/2012,,,1/30/2014,1/30/2014,,,,,,,,,,,,,3/20/2014,3/20/2014,3/20/2014,5/6/2014,,,,,,,,,,,,,,,,,,,5/14/2014,,8/22/2014,8/22/2014,,,,,,,,,,,11/10/2014,11/10/2014,,,,,,,,,,,,,,,,,,,,,,
SPD489-330,SPD489-330,'SPD489-330,,,"A Phase 3 multi-center, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of SPD489 as treatment for adults aged 18-65 with excessive daytime sleepiness associated with narcolepsy",489-330 EDS Assoc. w/Narcolepsy,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Forced-Dose,,,316,0,0,0,0,0,0,0.00%,65,,,,Patricia Donnelly,,,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,10/5/2011,11/4/2011,9/28/2012,,,,,,1/31/2013,,,,4/17/2014,,,,,,,,,,,,,,7/10/2014,,7/10/2014,,,,,,,,,,,,,,,,,,,,9/1/2014,,10/6/2014,,,,,,,,,,,,12/1/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-331,SPD489-331,'SPD489-331,,,"A Phase 3 multi-center, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of SPD489 as treatment for adults aged 18-65 with excessive daytime sleepiness associated with SWSD",489-331 EDS Assoc. w/SWSD,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Forced-Dose,,,525,0,0,0,0,0,0,0.00%,75,,,,Patricia Donnelly,,,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,10/5/2011,11/4/2011,9/28/2012,,,,,,1/31/2013,,,,7/3/2014,,,,,,,,,,,,,,9/11/2014,,9/11/2014,,,,,,,,,,,,,,,,,,,,11/3/2014,,12/8/2014,,,,,,,,,,,,2/2/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD489-332,SPD489-332,'SPD489-332,,,"A Phase 3 open-label, multi-center, safety and efficacy extension study of SPD489 as treatment for adults aged 18-65 with excessive daytime sleepiness associated with narcolepsy and SWSD",489-332 OL- EDS Assoc. w/Narc & SWSD,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Open Label,,,550,0,0,0,0,0,0,0.00%,75,,,,Patricia Donnelly,,,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,10/5/2011,11/4/2011,9/28/2012,,,,,,4/10/2013,,,,10/31/2017,,,,,,,,,,,,,,10/31/2018,,10/31/2018,,,,,,,,,,,,,,,,,,,,1/1/2019,,2/12/2019,,,,,,,,,,,,4/23/2019,,,,,,,,,,,,,,,,,,,,,,,
SPD489-333,SPD489-333,'SPD489-333,,,Adjunctive Treatment of MDD LTME,Adjunctive Treatment of MDD LTME,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Double-Blind,,,500,0,0,0,0,0,0,0.00%,90,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/30/2011,,1/10/2012,,,,,,6/8/2012,,,,6/11/2013,,,,,,,,,,,,,,12/16/2013,,12/16/2013,,,,,,,,,,,,,,,,,,,,2/5/2014,,3/12/2014,,,,,,,,,,,,5/7/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD489-334,SPD489-334,'SPD489-334,,,Adjunctive Treatment of MDD Active Comparator,Adjunctive Treatment of MDD Active Compa,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Comparator,,,"1,373",0,0,0,0,0,0,0.00%,75,,,,Elise Hoyland,,,,,,,,N,No,,,,COSMOS Inactive,,,6/29/2012,,8/9/2012,,,,,,4/19/2013,,,,4/17/2015,,,,,,,,,,,,,,8/21/2015,,8/21/2015,,,,,,,,,,,,,,,,,,,,10/13/2015,,11/17/2015,,,,,,,,,,,,1/12/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD489-335,SPD489-335,'SPD489-335,,,"A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults who have Persistent Predominant Negative Symptoms of Schizophrenia",NSS Phase 3 Study,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Double-Blind,,,261,0,1,0,0,0,1,0.00%,90,,,Syneos Health,,,,"Celeste Ferreira-Cornwell, Elise Hoyland","Keshica Butler, Kyle Reid",,,,N,No,,,,COSMOS Inactive,,,9/3/2012,7/24/2012,9/13/2012,9/7/2012,,,,,4/26/2013,,,,5/1/2014,,,,,,,,,,,,,,10/30/2014,,10/30/2014,,,,,,,,,,,,,,,,,,,,12/22/2014,,1/26/2015,,,,,,,,,,,,3/23/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD489-336,SPD489-336,'SPD489-336,,,"A Phase 3, Long-term, Open-label, Multicenter, 52-week, Flexible-dose Safety Study of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults who have Persistent Predominant Negative Symptoms of Schizophrenia",NSS Phase 3 OL study,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Long-Term,,,644,0,2,0,0,0,2,0.00%,120,,,Syneos Health,Lisa Knowles,,,Elise Hoyland,"Andrea Abbondanza, Angela Tabereaux, Blaise Mbunga-Mputu, Brandi Henley, Christopher Fromm, Clement Oguejiofor, Daniëlle Van Overbeek, Donna Keaton, Gloria Taylor, Holly Finefrock, Jennifer Thorne-Davis, Jennifer Zander, Katia Maurizi, Kimberly Warren, Kyle Reid, Marie-Laure Fuster, Nikolay Aleksandrov, Paule Marcotte, Phillip Sayo, Sachin Bhardwaj, Tomas Urbanek, Van Le",,,,N,No,,,,COSMOS Inactive,,,9/3/2012,7/24/2012,9/13/2012,9/7/2012,,,,,5/31/2013,,,,4/2/2015,,,,,,,,,,,,,,3/31/2016,,3/31/2016,,,,,,,,,,,,,,,,,,,,5/30/2016,,7/4/2016,,,,,,,,,,,,8/29/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD489-337,SPD489-337,'SPD489-337,,,NSS Phase 3 Relapse/Recurrance,NSS Phase 3 Relapse/Recurrance,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Double-Blind,,,400,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-338,SPD489-338,'SPD489-338,,,"A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 40mg, 100mg, or 160mg as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults who have Persistent Predominant Negative Symptoms of Schizophrenia",NSS Phase 3 Study 12weeks,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Double-Blind,,,380,0,4,0,4,0,0,0.00%,90,,,Syneos Health,,,,Elise Hoyland,,,,,N,No,,,,COSMOS Inactive,,,7/27/2012,7/27/2012,9/7/2012,9/7/2012,,,,,5/31/2013,,,,8/28/2014,,,,,,,,,,,,,,12/4/2014,,12/4/2014,,,,,,,,,,,,,,,,,,,,2/16/2015,,3/23/2015,,,,,,,,,,,,5/18/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD489-340,SPD489-340,'SPD489-340,,,EDS Differentiation Study,EDS Differentiation study,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,,,,185,0,0,0,0,0,0,0.00%,65,,,,Sonia Brinton,,,Celeste Ferreira-Cornwell,,,,,N,No,,,,COSMOS Inactive,,,1/31/2012,,8/31/2012,,,,,,1/31/2013,,,,6/20/2014,,,,,,,,,,,,,,12/4/2014,,12/4/2014,,,,,,,,,,,,,,,,,,,,1/28/2015,,3/4/2015,,,,,,,,,,,,4/29/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD489-341,SPD489-341,'SPD489-341,,,"A SPD489-341 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Elderly Patients with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",489-341 Elderly Safety Study,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Elderly,,,300,0,0,0,0,0,0,0.00%,50,,,ICON / MAPI / Paradigm,,,,Matthew Dauphin,,,,,N,No,,,,COSMOS Inactive,,,6/29/2012,,8/9/2012,,,,,,4/19/2013,,,,12/26/2014,,,,,,,,,,,,,,4/24/2015,,4/24/2015,,,,,,,,,,,,,,,,,,,,6/9/2015,,7/14/2015,,,,,,,,,,,,9/8/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD489-342,SPD489-342,'SPD489-342,,,"The SPD489-342 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Long Term Efficacy Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Historical Treatment with an Antidepressant.",489-342 LTE in Adults,III,Study Withdrawn,MDD,,,Non-Registry,,Interventional,Double-Blind,,,940,0,0,0,0,0,0,0.00%,70,,,,,,,Matthew Dauphin,,,,,N,No,,,,COSMOS Inactive,,,,,1/22/2013,,,,,,7/9/2013,,,,5/5/2015,,,,,,,,,,,,,,7/7/2015,,7/7/2015,,,,,,,,,,,,,,,,,,,,8/20/2015,,9/24/2015,,,,,,,,,,,,11/19/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD489-343,SPD489-343,'SPD489-343,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder",489-343 Binge Pivitol 1,III,Completed,Binge Eating Disorder,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,356,384,645,0,261,384,68,107.87%,62,,,Premier Research,,,,,,2012-003309-91,,,N,No,,,,COSMOS Inactive,,,8/6/2012,8/6/2012,8/30/2012,8/30/2012,,,11/26/2012,11/26/2012,12/18/2012,12/18/2012,,,6/19/2013,6/19/2013,,,9/19/2013,9/19/2013,,,,,,,,,,,,,,,,,,,,,11/8/2013,11/8/2013,,,,,,,,,,,,,,,,,,,,,,,2/24/2014,2/24/2014,,,,,,,,,,,,,,,2/24/2014,2/24/2014,,,,,,
SPD489-344,SPD489-344,'SPD489-344,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder",489-344 Binge Pivitol 2,III,Completed,Binge Eating Disorder,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,356,391,701,0,310,391,96,109.83%,60,,,Premier Research,,,,,,2012-003310-14,,,N,No,,,,COSMOS Inactive,,,8/16/2012,8/16/2012,8/30/2012,8/30/2012,,,11/26/2012,11/26/2012,12/15/2012,12/15/2012,,,6/20/2013,6/20/2013,,,9/13/2013,9/13/2013,,,,,,,,,,,,,,,,,,,,,11/5/2013,11/5/2013,,,,,,,,,,,,,,,,,,,,,,,3/26/2014,3/26/2014,,,,,,,,,,,,,,,3/26/2014,3/26/2014,,,,,,
SPD489-345,SPD489-345,'SPD489-345,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3 Multi-center, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder.",489-345 Binge Open Label Extension,III,Completed,Binge Eating Disorder,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Long-Term,,,530,614,115,0,12,614,234,115.85%,120,,,Premier Research,,Karen Hartman,,,,2012-003313-34,,,N,No,,,,COSMOS Inactive,,,7/31/2012,7/31/2012,8/13/2012,8/13/2012,,,8/21/2012,8/21/2012,8/30/2012,8/30/2012,,,10/31/2013,10/31/2013,,,10/21/2014,10/21/2014,,,,,,,,,,,,,,,,,,,,,12/31/2014,12/31/2014,,,,,,,,,,,,,,,,,,,,,,,3/23/2015,3/23/2015,,,,,,,,,,,,,,,3/23/2015,3/23/2015,,,,,,
SPD489-346,SPD489-346,'SPD489-346,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder",489-346 Binge LTME,III,Completed,Binge Eating Disorder,NS,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Efficacy,,,412,418,636,0,218,418,268,101.46%,50,,,Premier Research,,Calista Gauthier,,,,2012-004457-88,,,N,No,,,,COSMOS Inactive,,,9/14/2012,9/14/2012,12/21/2012,12/21/2012,,,1/27/2014,1/27/2014,2/12/2014,2/12/2014,,,7/10/2014,7/10/2014,,,3/31/2015,3/31/2015,,,,,,,,,,,,,,,,,,,,,6/15/2015,6/15/2015,,,,,,,,,,,,,,,,,,,,,,,10/7/2015,10/7/2015,,,,,,,,,,,,,,,10/7/2015,10/7/2015,,,,,,
SPD489-347,SPD489-347,'SPD489-347,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-dose Safety and Efficacy Study of SPD489 Compared with Placebo in Preschool Children Aged 4-5 Years with Attention-deficit/Hyperactivity Disorder",489-347 DB PCB Ped,III,Completed,ADHD,NS,,Non-Registry,Pediatric only (<18 yr),Interventional,Double-Blind,,,195,199,0,,0,0,49,102.05%,54,,,PPD,,"Diane Montross, Katherine Norton, Richard Sawyer, Steven Johnson Jr.",,,"Agnes Stevenson, Amanda Thomas, Bhavin Patel, Carl Wilson, Carmen Chrisman, Chelsi Pugliese, Elizabeth Bartels, Frances Reynolds, Heidi Kaiser, Isabelle St Clare, Jennifer Cislo, Kathleen Heverley, Kathleen Shirer, Kristen Meadows, Leslie Romanyshyn, Mark Picard, Nataliya Prudchenko, Richard Jensen, Riley Hurst, Shelly Ebel, Stephen Plummer, Susan Cox, Yadiel Kassa",,Not Available,,N,No,,,,COSMOS Inactive,19-Apr-19,9/30/2019,5/17/2017,5/17/2017,5/31/2017,5/31/2017,,,9/18/2017,9/18/2017,9/6/2017,9/6/2017,,,8/29/2018,8/29/2018,,,10/17/2018,10/17/2018,,,,,,,,,,,,,,,,,,,,,12/7/2018,12/7/2018,,,,,,,,,,,,,,,,,,,,,,,9/30/2019,9/30/2019,,,,,,,,,,,,,,,9/30/2019,9/30/2019,,,,,,
SPD489-348,SPD489-348,'SPD489-348,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder",489-348 Ped OL Extn,III,Completed,ADHD,NS,Marketed Products,Non-Registry,Pediatric only (<18 yr),Interventional,Multi-Centre,,,100,115,0,,0,0,46,115.00%,54,1,,Bracket,,Kevin Szwarc,,"Brooke Geibel, Steven Johnson Jr.","Amanda Thomas, Bhavin Patel, Folashade Adewale, Heidi Kaiser, Isabelle St Clare, Jason Hallman, Jennifer Cislo, Kellie Bemelmans, Kimberley McDonnell, Nataliya Prudchenko, Renuka Chawla, Riley Hurst, Sarah Lange, Shelly Ebel, Stephen Plummer, Yadiel Kassa",,,,N,No,,,,COSMOS Inactive,,,8/25/2014,8/25/2014,10/21/2014,10/21/2014,,,8/21/2015,8/21/2015,8/21/2015,8/21/2015,,,12/28/2018,12/28/2018,,,1/3/2020,1/3/2020,,,,,,,,,,,1/30/2020,1/30/2020,,,,,,,,,2/27/2020,2/27/2020,,,,,,,,,,,,,3/26/2020,3/26/2020,,,,,,,,,6/15/2020,6/15/2020,,,,,,,,,,,,,,,6/15/2020,6/15/2020,,,,,,
SPD489-349,SPD489-349,'SPD489-349,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3, Randomized, Double-blind, Multicenter, Parallel, Dose-optimization Study of SPD489 Compared with OROS-MPH (CONCERTA), in Adolescents Aged 6-17 Years with Attention-deficit/Hyperactivity Disorder",489-349 Chinese Comparator Study,III,Cancelled,,NS,Marketed Products,,,Interventional,,,,330,,,,,,,,20,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,3/17/2014,3/17/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/17/2014,3/17/2014,,,,,,
SPD489-401,SPD489-401,'SPD489-401,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase IV, Double-Blind, Multi-Center, Placebo Controlled, Randomized Withdrawal, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adults Aged 18-55 with ADHD",SPD489-401 Adlt Rand WD,IV,Completed,ADHD,NS,,Non-Registry,,Interventional,Efficacy,,,163,131,202,0,74,111,64,80.37%,40,4,,Premier Research,,,Bernard Brownstein,,"Amber Siptak, Barbara Komenda, David Brockwell, J Araujo, John Osgood, Kevin Kantor, Larry Shailer, Nancy Mazzei, Paul Edwards, Rita Torres, Scott Wilson, Susan Kimmel, Terri Self, Victor Smith",,,,N,No,,,,COSMOS Inactive,,,10/27/2008,10/27/2008,1/27/2009,1/27/2009,,,5/7/2009,5/7/2009,,,,,5/3/2010,5/3/2010,,,,,,,,,,,,,,,,,,,,,,,,,9/1/2010,9/1/2010,,,,,,,,,,,,,,,,,,,,,,,12/3/2010,12/3/2010,,,,,,,,,,,,,,,12/3/2010,12/3/2010,,,,,,
SPD489-402,SPD489-402,'SPD489-402,,,"Consortium for the Lifespan Examination of ADHD Registry (CLEAR)
Study: An International, Longitudinal, Observational Study of
Individuals with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD489-402 CLEAR,IV,Study Withdrawn,MDD,,,Non-Registry,,Non-Interventional_CDO Support,,,,"2,500",188,0,0,0,0,11,7.52%,250,,,I3 Innovus,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/5/2009,8/5/2009,3/22/2010,3/22/2010,,,,,8/20/2010,8/20/2010,,,6/29/2012,12/31/2012,,,,,,,,,,,,,6/23/2017,12/31/2012,6/23/2017,12/31/2012,,,,,,,,,,,,,,,,,,,8/4/2017,12/31/2012,9/8/2017,12/31/2012,,,,,,,,,,,11/3/2017,12/31/2012,,,,,,,,,,,,,,,,,,,,,,
SPD489-403,SPD489-403,'SPD489-403,,,"A Phase 4, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study Evaluating the Safety and Efficacy of SPD489 on Executive Function (Self-regulation) Behaviors in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) Reporting Clinically Significant Impairment of Real-world Executive Function Behavior",SPD489-403 Executive Function - Adlt PCB,IV,Completed,ADHD,,,Non-Registry,,Interventional,Randomized,,,160,201,201,0,46,163,32,125.63%,40,,,Chiltern,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/3/2010,2/3/2010,3/2/2010,3/9/2010,,,,,5/26/2010,5/26/2010,,,10/29/2010,9/7/2010,,,,,,,,,,,,,11/16/2010,11/16/2010,11/16/2010,1/5/2011,,,,,,,,,,,,,,,,,,,1/13/2011,1/13/2011,2/9/2011,2/8/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-404,SPD489-404,'SPD489-404,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 4, Open-Label, Multicentre, 2- Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)",489-404 Ped Adlsc OL Safety,IV,Completed,ADHD,NS,,Non-Registry,Pediatric only (<18 yr),Non-Interventional_CDO Support,PASS (Post Authorization Safety Study),,,300,314,348,0,34,0,123,104.67%,60,,,PRA,Lisa Politza,,,Brooke Geibel,"Alicia Del Rey, Aurelie Vincent, Beata Krzyzanowska, Bjorn Hansson, Blanka Felhazi, Cristina Molina, Daniela Phillips, Daniela Rodriguez Kobata, Debora Parera, Irene Ntim Acheampong, Jemmy Servaes, Katherine Crawford, Katja Scheinemann, Krisztina Kovacs, Lena Maria Bossmar, Libera Trotta, Olia Llopis Czemper, Olivia Gray, Patricia Jayne Piatek, Pradnya Sinalkar, Raluca Manea, Ravi Khatwa, Stefanie Stranner, Szymon Labus",2010-020951-30,,,N,No,,,,COSMOS Inactive,,,4/29/2010,4/29/2010,9/14/2010,9/14/2010,,,7/14/2011,7/14/2011,,,,,9/4/2012,9/4/2012,,,9/10/2014,9/10/2014,,,,,,,,,,,,,,,,,,,,,1/14/2015,1/14/2015,,,,,,,,,,,,,,,,,,,,,,,4/2/2015,4/2/2015,,,,,,,,,,,,,,,4/2/2015,4/2/2015,,,,,,
SPD489-405,SPD489-405,'SPD489-405,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (Vyvanse) Compared with OROS-MPH (Concerta) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)",489-405 Adlsc Comparator,IV,Completed,ADHD,NS,,Non-Registry,Pediatric only (<18 yr),Interventional,Randomized,,,456,464,628,0,164,464,84,101.75%,55,,,Premier Research,,Lisa Politza,,,"Dana Jackson, Deborah Plowman, Marjan Gunther, Robert Kennedy",,,,N,No,,,,COSMOS Inactive,,,10/20/2011,10/20/2011,12/28/2011,12/28/2011,,,4/25/2012,4/25/2012,,,,,11/26/2013,11/26/2013,,,1/22/2014,1/22/2014,,,,,,,,,,,,,,,,,,,,,7/10/2014,7/10/2014,,,,,,,,,,,,,,,,,,,,,,,10/16/2014,10/16/2014,,,,,,,,,,,,,,,10/16/2014,10/16/2014,,,,,,
SPD489-406,SPD489-406,'SPD489-406,,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration Safety and Efficacy Study of SPD489 (Vyvanse) Compared with OROS-MPH (Concerta) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)",489-406 Adlsc Forced-Dose Comparator,IV,Completed,ADHD,NS,,Non-Registry,Pediatric only (<18 yr),Interventional,Adolescent,,,542,559,788,0,228,559,90,103.14%,55,,,Premier Research,,Erin Van Winkle,,,,2011-005452-34,,,N,No,,,,COSMOS Inactive,,,10/20/2011,10/20/2011,12/28/2011,12/28/2011,,,6/4/2012,6/4/2012,,,,,4/3/2014,4/3/2014,,,5/14/2014,5/14/2014,,,,,,,,,,,,,,,,,,,,,7/11/2014,7/11/2014,,,,,,,,,,,,,,,,,,,,,,,11/26/2014,11/26/2014,,,,,,,,,,,,,,,11/26/2014,11/26/2014,,,,,,
SPD489-407,SPD489-407,'SPD489-407,,,"A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Exploratory Study of the Effects of SPD489 on Individualized Goal Achievement in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)",489-407 Mkt Stud Ped PCB,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,250,0,0,0,0,0,0,0.00%,50,,,PRA,Dan Sea,,,Ruth Coll,,,,,N,No,,,,COSMOS Inactive,,,4/23/2014,,6/12/2014,,,,,,10/29/2014,,,,5/11/2016,,,,,,,,,,,,,,8/3/2016,,8/3/2016,,,,,,,,,,,,,,,,,,,,9/23/2016,,10/27/2016,,,,,,,,,,,,12/8/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD489-408,SPD489-408,'SPD489-408,,,DriveCam - ADHD Subjects,SPD489-408 Driving Study,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Double-Blind,,,60,0,0,0,0,0,0,0.00%,10,,,,Patrick Deas,,,Brooke Geibel,,,,,N,No,,,,COSMOS Inactive,,,10/27/2014,,12/8/2014,,,,,,4/6/2015,,,,10/19/2015,,,,,,,,,,,,,,12/28/2015,,12/28/2015,,,,,,,,,,,,,,,,,,,,2/17/2016,,3/23/2016,,,,,,,,,,,,5/18/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD489-501,SPD489-501,'SPD489-501,,,Prevalence and Burden of ADHD in Adults,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-502,SPD489-502,'SPD489-502,,,"Current epidemiology, treatment patterns, and burden of ADHD",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-503,SPD489-503,'SPD489-503,,,Adult ADHD: impact of injuries on healthcare costs,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-504,SPD489-504,'SPD489-504,,,A comprehensive descriptive analysis of ADHD medication treatment patterns within the Texas Medicaid Program,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-505,SPD489-505,'SPD489-505,,,Daily average consumption and medication augmentation in patients with ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-506,SPD489-506,'SPD489-506,,,Prevalence and Burden of ADHD in Adults,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-507,SPD489-507,'SPD489-507,,,Experience of Living With ADHD Registry (ELAR),,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,"2,000",0,0,0,0,0,0,0.00%,5,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-508,SPD489-508,'SPD489-508,,,Sick Fund claims database analysis for ADHD in Germany,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-509,SPD489-509,'SPD489-509,,,ADHD Treatment  Patterns in Europe and Canada:  Development of Study Objectives and Data Collection Tools.,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-510,SPD489-510,'SPD489-510,,,"Attention-Deficit/Hyperactivity Disorder (ADHD): Administrative Prevalence, Treatment Patterns, Health Care Utilization, and Direct Medical Cost 2003 – 2008",Health Care Utilization,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-511,SPD489-511,'SPD489-511,,,Assessing the Impact of Children with ADHD on the Health and Well-Being of Their Families,Familial Impact Asssements,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-512,SPD489-512,'SPD489-512,,,Treatment Patterns in Attention Deficit Hyperactivity Disorder.  Analyses with the RAMQ Database,RAMQ Database,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-513,SPD489-513,'SPD489-513,,,Treatment patterns and health care resource utilization among patients taking lisdexamphetamine compared to other medications for attention deficit hyperactivity disorder,Treatment patterns/HC Utilization,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-514,SPD489-514,'SPD489-514,,,Tx differences of parents of children w/ADHD.  How do parents perceive benefits of Vyvanse?,Treatment perceptions Vyvanse,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-515,SPD489-515,'SPD489-515,,,Clinical Decision Making in ADHD,Clinical Decision Making in ADHD,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-516,SPD489-516,'SPD489-516,,,Epidemiology of ADHD Pharmacological Treatments in children & Adults in UK Primary Care,Epidemiology of ADHD,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-517,SPD489-517,'SPD489-517,,,Determine key determinants of adherence behavior and develop a predictive model,predictive model,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-518,SPD489-518,'SPD489-518,,,Psychometric Validation of the WFIRS,MeasureValidation,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-528,SPD489-528,'SPD489-528,,,To develop PRO in adolescent ADHD & to validate the PRO instrument in an observational setting,SPD489-528 Adol PRO Dev,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Adolescent,,,168,0,0,0,0,0,0,0.00%,13,,,United BioSource Corporation,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-531,SPD489-531,'SPD489-531,,,Qualitative interviews with adult ADHD and BED patients to understand their experiences with ADHD and BED and treatment (LDX vs. AXR),SPD489-531 Adult LDXvAXR FGs,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,80,0,0,0,0,0,0,0.00%,6,,,Health Research Associates,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-601,SPD489-601,'SPD489-601,,,Increasing ADHD Awareness in China,ADHD awareness in China,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-602,SPD489-602,'SPD489-602,,,Effects of Vyvanse on driving performance of Young Adults with ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-603,SPD489-603,'SPD489-603,,,Genetics and Clinical Features of Substance Abuse Disorders in Europe,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,413,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-604,SPD489-604,'SPD489-604,,,Healthy Lifestyle in Adults with ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,100,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-605,SPD489-605,'SPD489-605,,,Efficacy and Duration of Effect of Open Treatment in Adult ADHD Patients Treated with Lisdexamfetamine Dimesylate –LDX (Vyvanse),,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-606,SPD489-606,'SPD489-606,,,Prevention of Adolescent Substance Use with LDX Treatment of ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-607,SPD489-607,'SPD489-607,,,Lis-dexamphetamine (LDX/SPD489) as a treatment for smoking cessation in nicotine dependent individuals with ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,32,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-608,SPD489-608,'SPD489-608,,,"An Open-label, dose-optimization study testing the duration of action and generalizability of LDX in pediatric subjects 6-12 with ADHD in a Summer Treatment Program (STP)",SPD489-608,IIIb,Completed,ADHD,,,Non-Registry,Pediatric only (<18 yr),Interventional,,,,28,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-609,SPD489-609,'SPD489-609,,,Simultaneous Treatment with LDX and Fluoxetine for ADHD Comorbid with Major Depression,,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-610,SPD489-610,'SPD489-610,,,Double-Blind Study of Vyvanse on Sleep in Children 6-12 Years w/ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-611,SPD489-611,'SPD489-611,,,In-Depth Cardiovascular Study of LDX in Healthy and Treated Hypertensive Adults with ADHD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-612,SPD489-612,'SPD489-612,,,The Effect of Vyvanse on Brain Hemodynamics and Reading,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,28,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-614,SPD489-614,'SPD489-614,,,An Epidemiological Study of ADHD and its Impairments Among French Children,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,"1,000",0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-615,SPD489-615,'SPD489-615,,,The International Collaboration on ADHD and Substance Abuse (ICASA) European ADHD in Substance Abuse Disorders Prevalence Study,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,500,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-625,SPD489-625,'SPD489-625,,,"Effects of Vyvanse on the Behavioral, Academic, and Psychosocial Functioning of College Students with ADHD",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,25,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-626,SPD489-626,'SPD489-626,,,"Psychostimulant Treatment of TBI-Related Attention Deficits:
fMRI Analysis of Neural Mechanisms of Response",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-628,SPD489-628,'SPD489-628,,,"USE OF LISDEXAMFETAMINE DIMESYLATE IN TREATMENT OF CHRONIC FATIGUE SYNDROME: IS CHRONIC FATIGUE SYNDROME RELATED TO ADHD? A DOUBLE BLIND, PLACEBO CONTROLLED STUDY",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,26,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-630,SPD489-630,'SPD489-630,,,Evaluation of Pharmacokinetics and Profile of Clinical Response of Acute and Subacute Lisdexamfetamine (Vyvanse) Treatment in Adults with ADHD,Evaluation of Pharmacokinetics,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-632,SPD489-632,'SPD489-632,,,Effects of Lisdexamfetamine on Bradyphrenia in Multiple Sclerosis,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-633,SPD489-633,'SPD489-633,,,Lisdexamfetamine in Binge Eating Disorder,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-634,SPD489-634,'SPD489-634,,,Adjunctive Lisdexamfetamine in Bipolar Depression,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-636,SPD489-636,'SPD489-636,,,Does Pharmacological Treatment of ADHD in Adults Enhance Parenting?,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,70,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-638,SPD489-638,'SPD489-638,,,Evaluation of Pharmacokinetics and Profile of Clinical Response of Acute and Subacute Lisdexamfetamine (Vyvanse) vs. Mixed Amphetamine Salts XR (MAS XR) Treatment in Adults with ADHD,,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,50,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-640,SPD489-640,'SPD489-640,,,Vyvanse and glucose intolerance in childhood obesity,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-642,SPD489-642,'SPD489-642,,,A Magnetic Resonance Spectroscopy and fMRI Study of the Effects of Lisdexamfetamine on Bipolar Depression,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-644,SPD489-644,'SPD489-644,,,Vyvanse treatment of residual symptoms and cognitive impairment in SSRI/SNRI treated depression.,,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-645,SPD489-645,'SPD489-645,,,Testing the Validity of Emotional Symptoms in Adult ADHD: Proposal for Analyses of Archival Data,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,363,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-647,SPD489-647,'SPD489-647,,,To Evaluate the Efficacy and Safety of Vyvanse for the Treatment of ADHD in Euthymic Adults with Bipolar I/II Disorder,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-648,SPD489-648,'SPD489-648,,,"Endophenotype Study of ADHD: the interaction of clinical, neuropsychological, genetic and environmental factors",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,150,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-649,SPD489-649,'SPD489-649,,,ADHD in the elderly study,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-650,SPD489-650,'SPD489-650,,,Menopause Attention and Memory: A Role for Vyvanse,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-801,SPD489-801,'SPD489-801,,,Identify meaningful and objective endpoints for a RCT of Vyvanse,SPD489-801 RWOutcomes,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,35,0,0,0,0,0,0,0.00%,2,,,United BioSource Corporation,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-802,SPD489-802,'SPD489-802,,,IR/ER Adult ADHD Focus Groups - Understand the participants’ preferences that underlie their ADHD treatment choices for immediate-release (IR) and extended-release (ER) prescription stimulants.,SPD489-802 IR/ER Adult FGs,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,75,0,0,0,0,0,0,0.00%,5,,,United BioSource Corporation,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-810,SPD489-810,'SPD489-810,,,Adult ADHD Stimulant Misuse Internet Survey,SPD489-810 Stim Misuse,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,"10,000",0,0,0,0,0,0,0.00%,1,,,Inflexxion,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-814,SPD489-814,'SPD489-814,,,EU Baseline Stimulant Misuse Survey,SPD489-814 EU Stim Misuse,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,"22,000",0,0,0,0,0,0,0.00%,5,,,Rti International,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-820,SPD489-820,'SPD489-820,,,"To obtain prevalence and characteristics of BED, MDD, and ADHD in a representative sample of US adults.  Pediatric ADHD prevalence, according to caregiver self-report, will also be captured.",SPD489-820 Validate Survey,IV,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,"27,719",0,0,0,0,0,0,0.00%,1,,,Kantar Health,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-A01,SPD489-A01,'SPD489-A01,,,"A Single-Blind, Placebo- and Active-Controlled, Single-Dose Escalation Study of NRP104 (up to 150 mg) to Evaluate Safety, Tolerability, and Abuse Liability in Healthy Adult Volunteers with Histories of Stimulant Abuse",SPD489-A01 PBO,I,Completed,ADHD,,,Non-Registry,,Interventional,Single Dose,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,2/10/2005,2/10/2005,,,,,6/27/2005,6/27/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-A02,SPD489-A02,'SPD489-A02,,,"A Double-Blind, Placebo and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV administered NRP104 25mg and 50mg in Healthy Adult Volunteers with Histories of Stimulant
Abuse",SPD489-A02 DB PK PD,II,Completed,ADHD,,,Non-Registry,,Interventional,Crossover,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,5/27/2005,,,,,,9/27/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD489-A03,SPD489-A03,'SPD489-A03,,,"A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy
Adult Volunteers with Histories of Stimulant Abuse",SPD489-A03 DB PBO Xover,I,Completed,ADHD,,,Non-Registry,,Interventional,Placebo-Controlled,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,9/23/2005,9/23/2005,,,,,12/22/2005,12/22/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-301,SPD490-301,'SPD490-301,,,"An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease who are Pre-Dialysis or Require Peritoneal Dialysis or Haemodialysis",SPD490-301 Dynepo Infrequent Dosing Stud,IIIb,Completed,Anemia,,,Non-Registry,,Interventional,Efficacy,,,416,407,528,0,220,0,0,97.84%,78,,,ICON / MAPI / Paradigm,Kate Chapman,,,Mary Palmen,,2006-002052-15,,,N,No,,,,COSMOS Inactive,,,7/6/2006,7/6/2006,7/6/2006,7/6/2006,,,,,11/22/2006,11/22/2006,,,6/30/2008,8/1/2008,,,,,,,,,,,,,9/2/2008,9/10/2008,9/2/2008,12/12/2008,,,,,,,,,,,,,,,,,,,,,1/21/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-302,SPD490-302,'SPD490-302,,,"Safety and efficacy of HMR4396 for the management of anemia in pediatric subjects with chronic renal failure (predialysis, hemodialysis, peritoneal dialysis) Paediatric",SPD490-302 Ped,IIIb,Completed,Anemia,,,Non-Registry,,Interventional,Open Label,,,130,0,0,0,0,0,0,0.00%,30,,,ICON / MAPI / Paradigm,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-401,SPD490-401,'SPD490-401,,,SPD490-401,SPD490-401 Anemia,IV,Study Withdrawn,Anemia,,,Non-Registry,,Non-Interventional_CDO Support,,,,80,0,0,0,0,0,0,0.00%,999,,,,Mary Palmen,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-402,SPD490-402,'SPD490-402,,,"An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease.",SPD490-402 Dynepo Long-Term Safety Study,IV,Completed,Anemia,,,Non-Registry,,Non-Interventional_CDO Support,Efficacy,,,416,0,0,0,0,0,0,0.00%,53,,,ICON / MAPI / Paradigm,Kate Chapman,,,Mary Palmen,"Anthony Kershaw, Camille Kia, Eva Jaks, Linda Liberte, Lorenzo Majerini, Nuria Badia",2007-000054-31,,,N,No,,,,COSMOS Inactive,,,10/18/2006,10/18/2006,2/16/2007,2/16/2007,,,,,6/6/2007,6/6/2007,,,12/29/2008,8/1/2008,,,,,,,,,,,,,9/30/2008,9/30/2008,9/30/2008,1/19/2009,,,,,,,,,,,,,,,,,,,,,2/27/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-403,SPD490-403,'SPD490-403,,,SPD490-403,SPD490-403 Anemia,IV,Study Withdrawn,Anemia,,,Non-Registry,,Non-Interventional_CDO Support,,,,100,0,0,0,0,0,0,0.00%,999,,,,Mary Palmen,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-404,SPD490-404,'SPD490-404,,,"A Non-Interventional, Post-Authorisation Study to Assess Adverse Events and Drug Utilisation Among Chronic Kidney Disease Patients Treated With Dynepo",SPD490-404 Non-interven,IV,Study Terminated,Anemia,,,Non-Registry,,Non-Interventional_CDO Support,Safety,,,"1,500",0,0,0,0,0,0,0.00%,300,,,ICON / MAPI / Paradigm,Alissa Sirbu,,,Mary Palmen,"Lorraine Oregan, Sebastian Scharf",,,,N,No,,,,COSMOS Inactive,,,2/1/2008,2/1/2008,2/1/2008,2/1/2008,,,,,4/25/2008,4/25/2008,,,5/28/2008,5/28/2008,,,,,,,,,,,,,8/8/2008,8/8/2008,8/8/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-601,SPD490-601,'SPD490-601,,,The effect of Erythropoietin Delta (Dynepo) on autonomic dysfunction in non-dialysed patients with anaemia of renal failure.,Autonomic dysfunction in renal failure,IIIb,Study Withdrawn,Chronic Renal Failure,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-602,SPD490-602,'SPD490-602,,,Effect of Dynepo on Endothelial Damage Induced by Inflammation,,IIIb,Completed,Chronic Renal Failure,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-603,SPD490-603,'SPD490-603,,,WINDOW OF DETECTION AND IDENTIFICATION FOLLOWING DOPING WITH DYNEPO,,IIIb,Completed,Chronic Renal Failure,,,Non-Registry,,Interventional,,,,6,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD490-701,SPD490-701,'SPD490-701,,,Dynepo Post-marketing surveillance study in patients with chronic renal failure requiring dialysis or not requiring dialysis.,German Dynepo AWB,IV,Completed,Chronic Renal Failure,,,Non-Registry,,Non-Interventional_CDO Support,,,,"1,250","1,085",0,0,0,0,0,86.80%,250,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/20/2006,10/20/2006,12/1/2006,12/1/2006,,,,,3/19/2007,3/19/2007,,,8/31/2007,,,,,,,,,,,,,,10/8/2008,10/8/2008,10/8/2008,11/18/2008,,,,,,,,,,,,,,,,,,,11/26/2008,,1/1/2009,12/31/2008,,,,,,,,,,,2/24/2009,,,,,,,,,,,,,,,,,,,,,,,
SPD491-101,SPD491-101,'SPD491-101,,,"Single dose, placebo controlled, cross-over study in healthy subjects to assess the safety, local tolerabnce and pharmacokinetic profile of a transdermal gel of meptazinol (SPD491) versus a placebo and versus intravenous meptazinol",SPD491-101FIM PK,I,Completed,Epilepsy,,,Non-Registry,,Interventional,Crossover,,,10,0,0,0,8,0,0,0.00%,1,,,,,,,,Geoff Brooks,2006-005507-33,,,N,No,,,,COSMOS Inactive,,,9/1/2006,9/1/2006,10/13/2006,10/13/2006,,,,,2/6/2007,2/6/2007,,,2/6/2007,2/6/2007,,,,,,,,,,,,,2/11/2007,2/11/2007,2/11/2007,6/21/2007,,,,,,,,,,,,,,,,,,,7/5/2007,7/5/2007,7/5/2007,7/5/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD491-102,SPD491-102,'SPD491-102,,,SPD491-102,,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,PKPD,,,50,0,0,0,0,,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-101,SPD493-101,'SPD493-101,,,"An Open-Label, Randomized, Single-Dose, Three-Period, Crossover, Relative Bioavailability Study to Compare the Pharmacokinetics of Controlled Release and Immediate Release SPD493 Tablets",SPD493-101 BA CRF#1,I,Completed,Bipolar Disorder,,,Non-Registry,,Interventional,Bioavailability (BA),,,24,999,0,0,0,0,0,4162.50%,1,,,Shire,,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,3/16/2007,3/16/2007,6/8/2007,6/8/2007,,,,,10/8/2007,10/8/2007,,,10/8/2007,10/8/2007,,,,,,,,,,,,,10/29/2007,10/26/2007,10/29/2007,1/8/2008,,,,,,,,,,,,,,,,,,,1/29/2008,,2/20/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-102,SPD493-102,'SPD493-102,,,"A Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Valrocemide (Administered Once Daily or Every 12 Hours) in Healthy Adult Male Volunteers",SPD493 Max Tolerated Dose,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,PK,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/22/2007,2/22/2007,6/15/2007,6/15/2007,,,,,11/27/2007,,,,3/27/2008,,,,,,,,,,,,,,4/13/2008,,4/13/2008,,,,,,,,,,,,,,,,,,,,7/23/2008,,8/13/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-103,SPD493-103,'SPD493-103,,,"An Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetic Profiles and Assess the Safety and Tolerability of Valrocemide and Lamotrigine (Lamictal) Administered Alone and in Combination to Healthy Adult Male Volunteers",Lamotrigine Interaction,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Healthy Volunteers,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/22/2007,2/22/2007,6/15/2007,6/15/2007,,,,,12/4/2007,,,,1/8/2008,,,,,,,,,,,,,,1/25/2008,,1/25/2008,,,,,,,,,,,,,,,,,,,,5/8/2008,,5/30/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-104,SPD493-104,'SPD493-104,,,Bioavailability #2,SPD493-104 BA CRF #2,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Bioavailability (BA),,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/27/2008,,7/17/2008,,,,,,11/6/2008,,,,11/6/2008,,,,,,,,,,,,,,12/3/2008,,12/3/2008,,,,,,,,,,,,,,,,,,,,3/4/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-105,SPD493-105,'SPD493-105,,,Food Effect,SPD493-105 Food Inx.,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Food Effect,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/31/2008,,3/26/2008,,,,,,7/16/2008,,,,7/16/2008,,,,,,,,,,,,,,8/6/2008,,8/6/2008,,,,,,,,,,,,,,,,,,,,11/5/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-106,SPD493-106,'SPD493-106,,,Dose Proportionality,SPD49Dose Proportionality,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Bioavailability (BA),,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/22/2008,,8/13/2008,,,,,,11/6/2008,,,,11/6/2008,,,,,,,,,,,,,,12/3/2008,,12/3/2008,,,,,,,,,,,,,,,,,,,,3/4/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-107,SPD493-107,'SPD493-107,,,QT Study,Thorough ECG Trial,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Safety,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/17/2008,,9/10/2008,,,,,,1/5/2009,,,,1/5/2009,,,,,,,,,,,,,,1/28/2009,,1/28/2009,,,,,,,,,,,,,,,,,,,,4/22/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-115,SPD493-115,'SPD493-115,,,Broad based CYP-450 Inhibitor,SPD493-115 P450 Inhibitor,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/28/2008,,4/24/2008,,,,,,8/14/2008,,,,8/14/2008,,,,,,,,,,,,,,8/27/2008,,8/27/2008,,,,,,,,,,,,,,,,,,,,11/26/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-118,SPD493-118,'SPD493-118,,,PGP Inhibitor,SPD493-118 PGP Inhibitor,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/28/2008,,4/24/2008,,,,,,8/14/2008,,,,8/14/2008,,,,,,,,,,,,,,8/27/2008,,8/27/2008,,,,,,,,,,,,,,,,,,,,11/26/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-119,SPD493-119,'SPD493-119,,,CYP-450 Inducer,SPD493-119 P450 Inducer,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/28/2008,,4/24/2008,,,,,,8/13/2008,,,,8/13/2008,,,,,,,,,,,,,,9/3/2008,,9/3/2008,,,,,,,,,,,,,,,,,,,,12/3/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-121,SPD493-121,'SPD493-121,,,Hormonal Contraceptives,Oral Contraceptive Inx.,I,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/17/2008,,9/10/2008,,,,,,1/1/2009,,,,1/1/2009,,,,,,,,,,,,,,3/25/2009,,3/25/2009,,,,,,,,,,,,,,,,,,,,6/24/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD493-201,SPD493-201,'SPD493-201,,,Proof of Concept,SPD493 Proof of Concept,II,Study Withdrawn,Bipolar Disorder,,,Non-Registry,,Interventional,Proof of Concept,,,300,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/5/2008,,6/30/2008,,,,,,10/22/2008,,,,8/21/2009,,,,,,,,,,,,,,10/16/2009,,10/16/2009,,,,,,,,,,,,,,,,,,,,2/5/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD494-201,SPD494-201,'SPD494-201,,,SPD494-201,,II,Study Withdrawn,,,,Non-Registry,,Interventional,Crossover,,,100,0,0,0,0,,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD494-301,SPD494-301,'SPD494-301,,,SPD494-301,,IIIb,Study Withdrawn,,,,Non-Registry,,Interventional,Comparator,,,400,0,0,0,0,,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD494-xxx,SPD494-xxx,'SPD494-xxx,,,SPD494-xxx Joint Development with Duramed,SPD494-xxx Joint Dev.,x,Study Withdrawn,,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,Kimberly Farrand,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD495-xxx,SPD495-xxx,'SPD495-xxx,,,SPD495-xxx Joint Development with Duramed,SPD495-xxx Joint Dev.,x,Study Terminated,,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD500-101,SPD500-101,'SPD500-101,,,SPD500-101,SPD500-101 FIM PK,I,Study Withdrawn,ARF following Bypass,,,Non-Registry,,Interventional,PK,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,Geoff Brooks,,,,,N,No,,,,COSMOS Inactive,,,1/26/2010,,,,,,,,6/30/2010,,,,,,,,,,,,,,,,,,9/21/2010,,9/21/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD500-201,SPD500-201,'SPD500-201,,,SPD500-201,SPD500-102 DR POC,II,Study Withdrawn,ARF following Bypass,,,Non-Registry,,Interventional,Dose-Ranging,,,720,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/15/2010,,,,,,,,5/19/2011,,,,,,,,,,,,,,,,,,1/25/2012,,1/25/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD500-301,SPD500-301,'SPD500-301,,,SPD500-301,SPD500-301 PIII Efficacy,III,Study Withdrawn,ARF following Bypass,,,Non-Registry,,Interventional,,,,360,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/4/2012,,,,,,,,12/6/2012,,,,,,,,,,,,,,,,,,8/28/2013,,8/28/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD500-302,SPD500-302,'SPD500-302,,,SPD500-302,SPD500-302 PIII Efficacy,III,Study Withdrawn,ARF following Bypass,,,Non-Registry,,Interventional,,,,360,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/4/2012,,,,,,,,12/6/2012,,,,,,,,,,,,,,,,,,8/28/2013,,8/28/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-3xa,SPD503-3xa,'SPD503-3xa,,,SPD503-3xa,SPD503-3xa DB PCB Comparator,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Comparator,,,333,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/24/2009,,8/27/2009,,,,,,8/16/2010,,,,7/18/2011,,,,,,,,,,,,,,12/2/2011,,12/2/2011,,,,,,,,,,,,,,,,,,,,2/7/2012,,3/20/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-3xb,SPD503-3xb,'SPD503-3xb,,,SPD503-3xb,SPD503-3xb ADHD w/ x,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,250,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-101,SPD503-101,'SPD503-101,,,A Pharmacokinetic Study to Assess the Bioavailability of Three Guanfacine Hydrochloride Extended-Release Test Formulations Compared to the Marketed Product TENEX® Following a Single 1mg Dose,SPD503-101 FormSelect,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,12,12,16,0,4,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-102,SPD503-102,'SPD503-102,,,"A Phase I, Double-blind, Placebo-controlled, Randomized Safety Study of SPD503 in Young Healthy Adult Volunteers Aged 19-24",SPD503-102 AbruptCess,I,Completed,ADHD,,,Non-Registry,,Interventional,Abrupt Cessation,,,45,,,,,0,,,1,,,Shire,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,4/15/2004,4/15/2004,5/10/2004,5/10/2004,,,,,6/9/2004,6/9/2004,,,7/21/2004,7/21/2004,,,,,,,,,,,,,9/6/2004,9/6/2004,9/6/2004,11/19/2004,,,,,,,,,,,,,,,,,,,11/24/2004,11/24/2004,5/17/2005,5/17/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-103,SPD503-103,'SPD503-103,,,"A Phase I, Pharmacokinetic Study in Healthy Volunteers to Assess the Bioequivalence of SPD503 2mg and 4mg Tablets Manufactured at PII and SUMI Following a Single Dose Each of 2mg and 4mg",SPD503-103 BE,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,36,,,,,0,,,1,,,"Aris Clinical, INC",,,,,,,,,N,No,,,,COSMOS Inactive,,,10/28/2003,10/28/2003,12/8/2003,12/8/2003,,,,,1/4/2004,1/4/2004,,,1/18/2004,1/18/2004,,,,,,,,,,,,,1/30/2004,1/30/2004,1/30/2004,3/25/2004,,,,,,,,,,,,,,,,,,,6/1/2004,6/1/2004,3/21/2005,3/21/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-104,SPD503-104,'SPD503-104,,,A Phase I Study to investigate the Effect of Food on the Pharmacokinetics of SPD503 in Healthy Volunteers,SPD503-104 Fd Eff,I,Completed,ADHD,,,Non-Registry,,Interventional,Food Effect,,,48,,,,,0,,,1,,,IQVIA,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,8/24/2004,8/24/2004,9/29/2004,9/29/2004,,,,,11/5/2004,11/5/2004,,,11/18/2004,11/18/2004,,,,,,,,,,,,,12/15/2004,12/15/2004,12/15/2004,3/16/2005,,,,,,,,,,,,,,,,,,,3/18/2005,3/18/2005,6/24/2005,6/24/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-106,SPD503-106,'SPD503-106,,,"A Phase I, Open-Label, Single-Sequence, Crossover Study to Evaluate the Effect of Ketoconazole on the Pharmacokinetics of SPD503 in Healthy Adult Subjects",SPD503-106 3A4Inhib Intrx,I,Completed,ADHD,,,Non-Registry,,Interventional,Drug Interaction,,,20,,,,,0,,,1,,,IQVIA,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,5/25/2004,5/25/2004,6/9/2004,6/9/2004,,,,,7/8/2004,7/8/2004,,,7/8/2004,7/8/2004,,,,,,,,,,,,,7/22/2004,7/22/2004,7/22/2004,10/8/2004,,,,,,,,,,,,,,,,,,,,,2/11/2005,2/11/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-107,SPD503-107,'SPD503-107,,,A Phase I Study to Assess the Pharmacokinetics of SPD503 Administered to Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD),SPD503-107 Ped PK SD/Mult,I,Completed,ADHD,,,Non-Registry,,Interventional,PK,,,28,0,0,0,0,0,0,0.00%,1,,,IQVIA,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,8/17/2004,8/17/2004,8/25/2004,8/25/2004,,,,,11/20/2004,11/20/2004,,,11/20/2004,11/20/2004,,,,,,,,,,,,,12/27/2004,12/27/2004,12/27/2004,3/2/2005,,,,,,,,,,,,,,,,,,,3/24/2005,3/24/2005,9/9/2005,9/9/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-108,SPD503-108,'SPD503-108,,,"A Phase I, Open-label, Single-Sequence, Crossover Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of SPD503 in Healthy Adult Subjects",SPD503-108 3A4Induc Intrx,I,Completed,ADHD,,,Non-Registry,,Interventional,Drug Interaction,,,20,,,,,0,,,1,,,IQVIA,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,6/24/2004,6/24/2004,7/13/2004,7/13/2004,,,,,8/13/2004,8/13/2004,,,8/13/2004,8/13/2004,,,,,,,,,,,,,9/1/2004,9/1/2004,9/1/2004,10/25/2004,,,,,,,,,,,,,,,,,,,11/30/2004,11/30/2004,7/18/2005,7/18/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-109,SPD503-109,'SPD503-109,,,"A Phase I, Pharmacokinetic Study in Heathly Volunteers to Assess the Bioequivalence of SPD503 2mg and 4mg Tablets Manufactured at PII and SUMI Following a Single Dose Each of 2mg and 4mg",SPD503-109 BE,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,52,,,,,0,,,1,,,IQVIA,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,5/27/2004,5/27/2004,6/9/2004,6/9/2004,,,,,6/30/2004,6/30/2004,,,6/30/2004,6/30/2004,,,,,,,,,,,,,8/2/2004,8/2/2004,8/2/2004,10/18/2004,,,,,,,,,,,,,,,,,,,12/8/2004,12/8/2004,5/24/2005,5/24/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-110,SPD503-110,'SPD503-110,,,"A Phase I, Pharmacokinetic Study to Investigate the Bioequivalence of SPD503 2.5mg Tablets",SPD503-110 BE 2.5mg dose,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,48,,,,,0,,,1,,,IQVIA,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,10/19/2004,10/19/2004,10/27/2004,10/27/2004,,,,,11/30/2004,11/30/2004,,,11/30/2004,11/30/2004,,,,,,,,,,,,,12/19/2004,12/19/2004,12/19/2004,3/4/2005,,,,,,,,,,,,,,,,,,,3/11/2005,3/11/2005,5/24/2005,5/24/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-111,SPD503-111,'SPD503-111,,,SPD503-111,SPD503-111,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,36,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-112,SPD503-112,'SPD503-112,,,"A Phase I, Non-Randomized, Single-Blind, Double-Dummy, Placebo- and Positive-Controlled, Single-Sequence, Three Period Crossover Trial to Assess the Effect of Guanfacine Hydrochloride on Ventricular Repolarization in Healthy Men and Women",SPD503-112 tQT PAC,I,Completed,ADHD,,,Non-Registry,,Interventional,Post Approval Commitment,,,48,83,0,0,0,0,0,172.92%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-113,SPD503-113,'SPD503-113,,,"A Study of the Safety, Tolerability and Steady-State Pharmacokinetics of SPD503 in Adolescents Ages 13 to 17 Years with Attention-Deficit Hyperactivity Disorder",SPD503-113 DR Adlsc PK,I,Completed,ADHD,,,Non-Registry,,Interventional,Post Approval Commitment,,,30,31,42,0,11,0,5,103.33%,2,,,Shire,Mary Corcoran,,Patrick Martin,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,9/28/2007,9/28/2007,11/27/2007,1/10/2008,,,,,5/11/2008,5/11/2008,,,6/29/2008,6/29/2008,,,,,,,,,,,,,8/9/2008,8/9/2008,8/9/2008,11/21/2008,,,,,,,,,,,,,,,,,,,11/28/2008,12/17/2008,12/17/2008,12/18/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-114,SPD503-114,'SPD503-114,,,"A Phase I, Open-Label, Randomized, Three-Period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and Concerta, Administered Alone and in Combination in Healthy Volunteers",SPD503-114 Methylphen,I,Completed,ADHD,,,Non-Registry,,Interventional,Potential PAC Study,,,42,38,0,0,0,0,0,90.48%,1,,,Shire,,,,,"Adriana Gutierrez, Ana Afanador, Ana Llabres, Anna Stolberg, Cinzia Giansante, David Mills, Erika Konczer, Geva Shtein, Henry Grant, Laura Johnston, Lisa Tyndall, Marcela Chiriboga, Olga Lozano-Solarska, Patricia Boykin, Przemyslaw Wziatek, Sabine Laus, Sara Derballa, Steffi Gabler, Victoria Garcia, Yuwen (jill) Tan",,,,N,No,,,,COSMOS Inactive,,,11/13/2008,11/13/2008,2/26/2009,2/26/2009,,,,,6/15/2009,6/15/2009,,,6/15/2009,6/15/2009,,,,,,,,,,,,,7/2/2009,7/2/2009,7/2/2009,9/8/2009,,,,,,,,,,,,,,,,,,,10/13/2009,10/16/2009,10/15/2009,10/9/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-115,SPD503-115,'SPD503-115,,,"A Phase I, Open-Label, Randomized, Three-Period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and Vyvanse, Administered Alone and in Combination in Healthy Volunteers",SPD503-115 Amphetamine,I,Completed,ADHD,,,Non-Registry,,Interventional,Potential PAC Study,,,42,42,0,0,0,0,0,100.00%,1,,,Shire,Beverly Stanton,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,11/13/2008,11/13/2008,4/9/2009,4/9/2009,,,,,7/13/2009,7/13/2009,,,7/13/2009,7/13/2009,,,,,,,,,,,,,7/30/2009,7/30/2009,7/30/2009,9/30/2009,,,,,,,,,,,,,,,,,,,11/6/2009,11/6/2009,11/10/2009,10/27/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-116,SPD503-116,'SPD503-116,,,SPD503-116,SPD503-116 IVIVC,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/19/2008,,,,,,,,2/20/2009,,,,,,,,,,,,,,,,,,6/19/2009,,6/19/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-117,SPD503-117,'SPD503-117,,,SPD503-117,SPD503-117 Valpro PAC,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Post Approval Commitment,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-118,SPD503-118,'SPD503-118,,,SPD503-118,SPD503-118 GXRvGIR PK,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/15/2008,,,,,,,,9/15/2008,,,,,,,,,,,,,,,,,,1/15/2009,,1/15/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-119,SPD503-119,'SPD503-119,,,"A Phase I, Randomized, Open-Label, Two-Period, Single Dose, Crossover Bioequivalence Study Of Two Oral Formulations Of 2mg SPD503 In Healthy Volunteers",SPD503-119 2mg BE,I,Completed,ADHD,,,Non-Registry,,Interventional,,,,60,60,0,0,0,0,0,100.00%,1,,,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/12/2009,7/9/2009,10/8/2009,10/14/2009,,,,,12/1/2009,12/1/2009,,,12/11/2009,12/7/2009,,,,,,,,,,,,,12/10/2009,12/10/2009,12/10/2009,1/22/2010,,,,,,,,,,,,,,,,,,,2/8/2010,2/8/2010,2/18/2010,2/26/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-120,SPD503-120,'SPD503-120,,,"A Phase I, Randomized, Open-Label, Two-Period, Single Dose, Crossover Bioequivalence Study Of Two Oral Formulations Of 4mg SPD503 In Healthy Volunteers",SPD503-120 4mg BE study,I,Completed,ADHD,,,Non-Registry,,Interventional,,,,60,0,0,0,0,0,0,0.00%,1,,,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/11/2009,7/9/2009,11/5/2009,11/3/2009,,,,,1/5/2010,1/5/2010,,,1/19/2010,1/19/2010,,,,,,,,,,,,,1/22/2010,1/22/2010,1/22/2010,3/2/2010,,,,,,,,,,,,,,,,,,,3/17/2010,3/18/2010,3/29/2010,4/1/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-121,SPD503-121,'SPD503-121,,,"A Phas 1, Randomized Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of SPD503 in Japanese and Caucasian Healthy Adult Subjects",SPD489-121 Japanese/Caucasian Safety PK,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,Ronald Budhram,,Patrick Martin,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,11/30/2011,11/30/2011,2/17/2012,,,,,,4/16/2012,,,,4/30/2012,,,,,,,,,,,,,,5/29/2012,,5/29/2012,,,,,,,,,,,,,,,,,,,,7/19/2012,,8/8/2012,,,,,,,,,,,,10/4/2012,,,,,,,,,,,,,,,,,,,,,,,
SPD503-122,SPD503-122,'SPD503-122,,,"A phase 1, randomized, open-label, 3-period crossover, study to determine the pharmacokinetic profile of guanfacine in healthy Chinese adults after dosing with 1, 2, 4, 6, 7, and 8 mg of SPD503.",SPD503-122 PK HV  Chinese Subjects,I,Cancelled,,,,,Non-pediatric only (>18 yr),Interventional,,,,30,,,,,,,,1,,,TBD,,,Patrick Martin,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-205,SPD503-205,'SPD503-205,,,"A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 with Attention Deficit Hyperactivity Disorder (ADHD)",SPD503-205 SafetyCoadmin,II,Completed,ADHD,,,Non-Registry,,Interventional,Coadministration,,,75,75,0,0,0,0,12,100.00%,17,,,PPD,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/1/2004,6/1/2004,6/30/2004,6/30/2004,,,,,8/10/2004,8/10/2004,,,,,,,,,,,,,,,,,12/27/2004,12/27/2004,12/27/2004,3/18/2005,,,,,,,,,,,,,,,,,,,,,4/24/2006,4/24/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-206,SPD503-206,'SPD503-206,,,"A Phase II Study of Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",SPD503-206 Cog/Sleep,II,Completed,ADHD,,,Non-Registry,,Interventional,Safety,,,187,0,0,0,0,0,0,0.00%,10,,,IQVIA,Kimberly Fiske,,,,,,,,N,No,,,,COSMOS Inactive,,,3/14/2005,3/14/2005,4/4/2005,4/4/2005,,,,,6/8/2005,6/8/2005,,,8/13/2005,8/13/2005,,,,,,,,,,,,,10/5/2005,10/5/2005,10/5/2005,11/23/2005,,,,,,,,,,,,,,,,,,,12/2/2005,12/2/2005,2/14/2006,2/14/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-207,SPD503-207,'SPD503-207,,,"A Phase 2, Double-Blind, PBO Controlled, Dose Range Finding Study of Intuniv in Adults with ADHD",SPD503-207 DB PCB DR,II,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,268,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/4/2011,,6/14/2011,,,,,,9/15/2011,,,,4/19/2012,,,,,,,,,,,,,,6/28/2012,,6/28/2012,,,,,,,,,,,,,,,,,,,,8/20/2012,,9/24/2012,,,,,,,,,,,,11/19/2012,,,,,,,,,,,,,,,,,,,,,,,
SPD503-208,SPD503-208,'SPD503-208,,,Phase II Signal finding study in Autism,Signal finding study in autism,II,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Randomized,,,128,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/11/2011,,9/5/2011,,,,,,1/9/2012,,,,9/9/2013,,,,,,,,,,,,,,12/30/2013,,12/30/2013,,,,,,,,,,,,,,,,,,,,3/7/2014,,4/4/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-209,SPD503-209,'SPD503-209,,,"Phase II,  double blind, multicentre, parallel group signal finding versus intuniv",GCW Signal finding in pediatric OCD,II,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Placebo-Controlled,,,128,0,0,0,0,0,0,0.00%,25,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/11/2011,,9/5/2011,,,,,,1/9/2012,,,,10/29/2012,,,,,,,,,,,,,,2/18/2013,,2/18/2013,,,,,,,,,,,,,,,,,,,,4/26/2013,,5/24/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-210,SPD503-210,'SPD503-210,,,A Phase II multicentre double blind signal finding study in pediatric GAD/SAD and SoP,503-210 Exploratory GAD/SAD and SoP,II,Completed,ADHD,,,Non-Registry,Pediatric only (<18 yr),Interventional,Double-Blind,,,80,83,135,0,52,83,31,103.75%,25,,,ICON / MAPI / Paradigm,Theresa Fritz,,Theresa Cole,Alison McMorn,"Cheryl Fedak, Marifi Dinoso, Melanie Walker, Stacey Porter, Syed Ali, Theresa Dries",,,,N,No,,,,COSMOS Inactive,,,8/3/2011,9/7/2011,9/13/2011,9/20/2011,,,,,12/15/2011,1/19/2012,,,5/21/2013,3/27/2013,,,,,,,,,,,,,7/4/2013,7/1/2013,7/4/2013,8/29/2013,,,,,,,,,,,,,,,,,,,9/9/2013,9/9/2013,10/11/2013,10/22/2013,,,,,,,,,,,12/10/2013,12/10/2013,,,,,,,,,,,,,,,,,,,,,,
SPD503-301,SPD503-301,'SPD503-301,,,"A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 with Attention Deficit Hyperactivity Disorder (ADHD)",SPD503-301 Eff/Safety,III,Completed,ADHD,,,Non-Registry,,Interventional,Placebo-Controlled,,,280,345,0,0,0,0,130,123.21%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-302,SPD503-302,'SPD503-302,,,SPD503-302,SPD503-302,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,200,,,,,0,,,35,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-303,SPD503-303,'SPD503-303,,,"A Phase III, Open-Label Study of SPD503 in Children and Adolescents (aged 6-17) with Attention Deficit Hyperactivity Disorder",SPD503-303 OL Extn 301,III,Completed,ADHD,,,Non-Registry,,Interventional,Open Label,,,240,3,0,0,0,3,0,1.25%,45,,,,Jessica Kardish,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/24/2003,12/3/2002,,,,,3/10/2003,3/10/2003,,,,,,,,,,,,,,,,,7/21/2005,7/21/2005,7/21/2005,9/13/2005,,,,,,,,,,,,,,,,,,,,,3/30/2006,3/30/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-304,SPD503-304,'SPD503-304,,,"A phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled safety and efficacy study of SPD503 in children and adolescents aged 6 17 with Attention Deficit Hyperactivity Disorder (ADHD)",SPD503-304 Eff/Safety,III,Completed,ADHD,,,Non-Registry,,Interventional,Placebo-Controlled,,,300,0,0,0,0,0,0,0.00%,51,,,,Jessica Kardish,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-305,SPD503-305,'SPD503-305,,,"A Phase III, Open-Label Study of SPD503 in Children and Adolescents Aged 6-17 with Attention Deficit Hyperactivity Disorder (ADHD)",SPD503-305 OL Extn205/304,III,Completed,ADHD,,,Non-Registry,,Interventional,Open Label,,,257,263,263,0,0,0,198,102.33%,48,4,,PPD,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,5/14/2004,5/14/2004,,,,,6/10/2004,6/10/2004,,,,,,,,,,,,,,,,,1/27/2007,1/27/2007,1/27/2007,3/26/2007,,,,,,,,,,,,,,,,,,,,,7/19/2007,7/19/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-306,SPD503-306,'SPD503-306,,,SPD503-306,SPD503-306,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,300,,,,,0,,,55,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-307,SPD503-307,'SPD503-307,,,"A Double-Blind, Randomized, Multi-Center, Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 in Children Aged 6-12 with Symptoms of Oppositionality and a Diagnosis of Attention-Deficit/Hyperactivity Disorder",SPD503-307 ADHD w/opp,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,210,0,0,0,0,0,0,0.00%,35,,,Parexel,Kara Grannis,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,5/17/2006,5/17/2006,10/13/2006,10/13/2006,,,,,12/12/2006,12/12/2006,,,10/9/2007,10/9/2007,,,,,,,,,,,,,12/4/2007,12/4/2007,12/4/2007,3/17/2008,,,,,,,,,,,,,,,,,,,3/25/2008,3/19/2008,5/2/2008,4/30/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-308,SPD503-308,'SPD503-308,,,SPD503-308,SPD503-308,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,999,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-310,SPD503-310,'SPD503-310,,,SPD503-310,SPD503-310,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,999,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-311,SPD503-311,'SPD503-311,,,SPD503-311,SPD503-311,IIIb,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,999,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-312,SPD503-312,'SPD503-312,,Intuniv (guanfacine hydrochloride),SPD503-312,503-312 Adlsc PAC,III,Completed,ADHD,Others,,Non-Registry,Pediatric only (<18 yr),Interventional,Potential PAC Study,,,310,52,52,0,52,52,52,16.77%,53,,,Chiltern,Gail Rynkowski,,,John Tobin,,2011-002221-21,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-313,SPD503-313,'SPD503-313,,,"A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Pediatrics Aged 6-17 with a Diagnosis of Attention-Deficit/Hyperactivity Disorder",SPD503-313 Coadmin PAC,III,Completed,ADHD,,,Non-Registry,,Interventional,Potential PAC Study,,,441,439,535,0,148,0,74,99.55%,50,,,Chiltern,Kara Grannis,,,Dan Sea,"Carly Repass, Depew Susan, Jennell Marler, Joyce Gillespie, Judy Gillespie, Kristin O'Brien, Patrick Farley, Vickie Bland",,,,N,No,,,,COSMOS Inactive,,,9/28/2007,9/28/2007,1/22/2008,1/22/2008,,,,,10/1/2008,10/1/2008,,,9/15/2009,,,,,,,,,,,,,,11/23/2009,,11/23/2009,1/29/2010,,,,,,,,,,,,,,,,,,,2/5/2010,,3/5/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-314,SPD503-314,'SPD503-314,,,SPD503-314,SPD503-314 DB Rand Once Daily Dosing Ped,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,333,340,440,0,100,36,97,102.10%,45,4,,PRA,Gail Rynkowski,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,7/10/2009,7/10/2009,8/27/2009,8/27/2009,,,,,12/1/2009,12/1/2009,,,6/30/2010,6/30/2010,,,,,,,,,,,,,9/9/2010,9/10/2010,9/9/2010,10/11/2010,,,,,,,,,,,,,,,,,,,10/14/2010,10/15/2010,11/16/2010,11/15/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-315,SPD503-315,'SPD503-315,,Intuniv (guanfacine hydrochloride),"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder",503-315 Maintenance of Efficacy PAC,III,Completed,ADHD,Others,,Non-Registry,Pediatric only (<18 yr),Interventional,Double-Blind,,,510,525,637,0,115,0,380,102.94%,72,,,PRA,Holly Edgar,,,Dan Sea,"Birgit Luechtenborg, Cornelia Magin, Daniela Rodriguez Kobata, Kenyarda Anderson, Laura Cation, Lies Bosman, Penny Frequin, Pradnya Sinalkar, Rosario Lorente, Silvio Serani, Steffen Rauchfuss",2009-018161-12,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-316,SPD503-316,'SPD503-316,,Intuniv (guanfacine hydrochloride),"A Phase 3, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Reference, Dose-Optimisation Efficacy and safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6 to 17 with Attention-Deficit/Hyperactivuty Disorder",503-316 Ped Adlsc DB Rand,III,Completed,ADHD,Others,,Non-Registry,Pediatric only (<18 yr),Interventional,Comparator,,,252,341,405,0,66,0,66,135.32%,50,,,PRA,,"Kristy Fusco, Philip Canton, Robert Allnutt, Sarah Marshall",,,"Alicia Sanchezcaro, Anne-Julie Eve, Bernd Martin, Birgit Luechtenborg, Celio Azinheiro Marques, Eliane Tchingambu, Ion David, Irene Soneira, Lucia Zapico, Luella Reese, Olivia Mountcastle, Steffen Rauchfuss, Suzanne Kochanski, Ursula Kothe",2010-018579-12,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-318,SPD503-318,'SPD503-318,,Intuniv (guanfacine hydrochloride),"A Phase 3, open-label, multicentre, protocol to provide access to guanfacine hydrochloride extended release in subjects with ADHD who participated in Study SPD503-315 or SPD503-316",SPD503-318 ADHD OL Ped & Adlsc LT Safety,III,Completed,ADHD,Others,,Non-Registry,Pediatric only (<18 yr),Interventional,PASS (Post Authorization Safety Study),,,250,215,215,0,0,85,82,86.00%,92,,,PRA,Robert Pavia,,,Dan Sea,"Adriana Canitano, Alban Cipriano, Alexandru Pahontu, Alicia Sanchezcaro, Ana Heredero, Andrea Kraft, Ann Monfils, Anna Kacprzyk, Barbara De Gregorio Morales, Beata Krzyzanowska, Bernd Martin, Bernhard Greve, Birgit Luechtenborg, Boguslawa Raciborska, Brigitte Dapoz, Calin Claudiu Caluser, Carl Whittaker, Carmen Alvarez, Christiane Roentgen, Daniela Phillips, Elisa Campostrini, Elizabeth Covell, Elke Goetz, Franklin Otu, Irene Soneira, Jemmy Servaes, Jennifer Gauld, Joo Sung Muller, Katja Scheinemann, Lenu Paulose, Lies Bosman, Marco Kuik, Marie Soderblom, Mariusz Kwiatkowski, Marlie Leerssen, Monica Zapardiel Pena, Nataliya Ivankova, Natalyia Shkuratova, Olena Sazanova, Olivia Gray, Olivia To, Rachel Radcliffe, Ravi Khatwa, Rosario Berruezo Ortuno, Ruud Van Engelen, Sandra Jaepel, Scott Durston, Silvio Serani, Sonia Gil Morales, Szymon Labus, Vanessa Fantuz",2011-004668-31,,,N,No,,,,COSMOS Inactive,,9/15/2015,7/5/2011,7/5/2011,9/28/2011,9/28/2011,,,3/20/2012,3/20/2012,4/2/2012,4/2/2012,,,9/4/2013,9/4/2013,,,9/15/2015,9/15/2015,,,,,,,,,,,,,,,,,,,,,11/9/2015,11/9/2015,,,,,,,,,,,,,,,,,,,,,,,4/12/2016,4/12/2016,,,,,,,,,,,,,,,4/12/2016,4/12/2016,,,,,,
SPD503-319,SPD503-319,'SPD503-319,,,"A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose-optimizing Study Evaluating the Efficacy, Safety and Tolerability of Once-daily dosing with SPD503 in Children and Adolescents Aged 6-17 with ADHD",503-319 Ph3 China Study,III,Cancelled,,,,,Pediatric only (<18 yr),Interventional,,,,338,,,,,,,,20,,,TBD,,,,Bryan Dirks,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-401,SPD503-401,'SPD503-401,,Intuniv (guanfacine hydrochloride),"A Phase 4, Multicenter, 2-part Study Composed of a 1-Year
Randomized, Double-blind, Parallel-group, Placebo-controlled,
Active-comparator, Dose-optimization Evaluation followed by a
1-Year Open-label Evaluation to Assess the Safety and Efficacy of
Guanfacine Hydrochloride Prolonged-release (SPD503) in Children
and Adolescents aged 6 to 17 Years with Attentiondeficit/
Hyperactivity Disorder","SPD503-401 Ped & Adlsc, Safety, OL",IV,Recruiting,(ADHD) Attention-deficit hyperactivity disorder,Others,Marketed Products,,Pediatric only (<18 yr),Interventional,Treatment,Prospective,Cohort,288,105,163,,50,105,42,36.46%,65,43,,IQVIA,,Dianne DeLucia,,,,,,,,,,,,Medidata CTMS (Pharma),,,2/6/2017,2/6/2017,2/8/2018,2/8/2018,,,9/18/2019,9/18/2019,10/28/2019,10/28/2019,,,3/23/2022,,,,4/8/2024,,,,,,,,,,,,5/6/2024,,,,,,,,,,5/20/2024,,,,,,,,,,,,,,6/4/2024,,,,,,,,,,8/5/2024,,,,,,,,,,,,,,,,8/30/2024,,,,,,,
SPD503-402,SPD503-402,'SPD503-402,,,SPD503-402,SPD503-402,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,,,,,0,,,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-501,SPD503-501,'SPD503-501,,,"A retrospective study of the characteristics, incremental resource use and cost of patients with complex ADHD",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-601,SPD503-601,'SPD503-601,,,"A Randomized, Single-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents with Autism and Comorbid ADHD",Study of Guanfacine ER with ADHD,IIIb,All Activities Closed,,,,,,Interventional,,,,1,,,,,,,,1,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-602,SPD503-602,'SPD503-602,,,AN OPEN-LABEL PILOT STUDY OF GUANFACINE EXTENDED RELEASE FOR IMPULSIVE AGGRESSION IN ADHD CHILDREN WITH AND WITHOUT PTSD,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-604,SPD503-604,'SPD503-604,,,Study to Demonstrate that Guanfacine Strengthens Network Connectivity in Rat Prefrontal Cortex,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-606,SPD503-606,'SPD503-606,,,Electrophysiological Effects of Guanfacine Extended-Release (GXR) on Inhibitory Control in Children with Attention Deficit/Hyperactivity Disorder (ADHD),,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-607,SPD503-607,'SPD503-607,,,"Sustained-Release Guanfacine, Language-Based Learning and ADHD",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-608,SPD503-608,'SPD503-608,,,"GXR in Non-Predatory Aggression: A Double-Blind, Placebo Controlled Study",,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,42,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-609,SPD503-609,'SPD503-609,,,Testing the Validity of Emotional Symptoms in Youth with ADHD: Proposal for Analyses of Archival Data,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-610,SPD503-610,'SPD503-610,,,The effect of guanfacine extended-release on ADHD-associated insomnia,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-611,SPD503-611,'SPD503-611,,,Guanfacine in Children with Tourette Syndrome,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,42,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-612,SPD503-612,'SPD503-612,,,Effect of extended release guanfacine on working memory in children,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-613,SPD503-613,'SPD503-613,,,Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents with ADHD: an fMRI Study of Brain Activation Pre and Post Treatment,,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD503-801,SPD503-801,'SPD503-801,,,SPD503-801 Growth and Maturation,SPD503-801 Growth/Maturation,IIIb,Completed,ADHD,,,Non-Registry,,Interventional,,,,"9,000",0,0,0,0,0,0,0.00%,1,,,United BioSource Corporation,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-2xd,SPD535-2xd,'SPD535-2xd,,,Knee Replacement,SPD535-2xd Knee Replacement,II,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Proof of Concept,,,156,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/28/2011,,7/18/2011,,,,,,11/15/2011,,,,12/25/2012,,,,,,,,,,,,,,4/16/2013,,4/16/2013,,,,,,,,,,,,,,,,,,,,5/27/2013,,6/21/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-2xe,SPD535-2xe,'SPD535-2xe,,,Phase II Carotid Endarterectomy,SPD535-2xe Carotid Endarterectomy,II,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Proof of Concept,,,200,0,0,0,0,0,0,0.00%,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/28/2011,,7/18/2011,,,,,,11/15/2011,,,,8/21/2012,,,,,,,,,,,,,,11/13/2012,,11/13/2012,,,,,,,,,,,,,,,,,,,,12/24/2012,,1/18/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-2xf,SPD535-2xf,'SPD535-2xf,,,Phase II Inflammatory Modulation,SPD535-2xf Inflammatory Modulation,II,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Proof of Concept,,,100,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/28/2011,,7/18/2011,,,,,,10/14/2011,,,,10/12/2012,,,,,,,,,,,,,,1/4/2013,,1/4/2013,,,,,,,,,,,,,,,,,,,,2/14/2013,,3/13/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-2xg,SPD535-2xg,'SPD535-2xg,,,SPD535 in Sickle Cell Disease,SPD535-2xg Sickle Cell Disease,IIa,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Proof of Concept,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-101,SPD535-101,'SPD535-101,,,"A Phase 1, Randomised, PKPD, SAD study in healthy volunteers",SPD535-101 SAD,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,First In Man (FIM),,,24,23,30,0,7,0,0,95.83%,1,,,Shire,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/17/2008,11/17/2008,7/9/2009,7/9/2009,,,,,8/31/2009,8/31/2009,,,11/10/2009,11/10/2009,,,,,,,,,,,,,11/24/2009,11/24/2009,11/24/2009,12/22/2009,,,,,,,,,,,,,,,,,,,1/6/2010,1/6/2010,2/5/2010,2/5/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-102,SPD535-102,'SPD535-102,,,"A Phase 1, Randomised, PKPD MAD study in healthy volunteers",SPD535-102 MAD,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Healthy Volunteers,,,84,79,193,0,0,0,0,94.05%,1,,,,"Jeff Dragone, Rachael Grose-Hodge",,,Geoff Brooks,,,,,N,No,,,,COSMOS Inactive,,,7/3/2008,11/17/2008,8/21/2009,8/21/2009,,,,,10/22/2009,10/22/2009,,,5/13/2010,5/13/2010,,,,,,,,,,,,,7/25/2010,7/25/2010,7/25/2010,9/28/2010,,,,,,,,,,,,,,,,,,,10/5/2010,10/5/2010,10/29/2010,12/3/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-103,SPD535-103,'SPD535-103,,,Badimon Chamber,Badimon Chamber,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,PK,,,12,15,37,0,0,0,0,125.00%,1,,,,"Jeff Dragone, Rachael Grose-Hodge",Richard Abbott,,Geoff Brooks,,,,,N,No,,,,COSMOS Inactive,,,11/6/2009,11/6/2009,2/26/2010,5/18/2010,,,,,8/18/2010,8/18/2010,,,10/25/2010,10/25/2010,,,,,,,,,,,,,1/28/2011,1/28/2011,1/28/2011,3/9/2011,,,,,,,,,,,,,,,,,,,3/21/2011,3/21/2011,7/1/2011,7/1/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-104,SPD535-104,'SPD535-104,,,PK/PD in dialysis single dose,PK/PD in dialysis single dose,I,Completed,ESRD,,,Non-Registry,,Interventional,Single Dose,,,12,12,15,0,0,12,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/14/2009,10/14/2009,12/10/2009,12/10/2009,,,,,3/24/2010,3/24/2010,,,6/6/2010,6/8/2010,,,,,,,,,,,,,7/3/2010,7/3/2010,7/3/2010,8/4/2010,,,,,,,,,,,,,,,,,,,8/11/2010,8/19/2010,9/10/2010,9/10/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-105,SPD535-105,'SPD535-105,,,PK/PD in dialysis multi-dose,PK/PD in dialysis multiple dose,I,Completed,ESRD,,,Non-Registry,,Interventional,Pharmacodynamic,,,24,16,18,0,0,16,0,66.67%,1,,,,,Richard Abbott,,,,,,,N,No,,,,COSMOS Inactive,,,10/17/2009,10/17/2009,6/21/2010,6/21/2010,,,,,8/23/2010,8/23/2010,,,12/3/2010,12/3/2010,,,,,,,,,,,,,12/28/2010,12/28/2010,12/28/2010,2/9/2011,,,,,,,,,,,,,,,,,,,3/1/2011,3/1/2011,3/8/2011,3/8/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-106,SPD535-106,'SPD535-106,,,Comparative Bioavailability,Comparative BA,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Bioavailability (BA),,,18,18,38,0,0,0,0,100.00%,1,,,,Jeff Long,Richard Abbott,,Geoff Brooks,,,,,N,No,,,,COSMOS Inactive,,,11/23/2009,11/23/2009,9/15/2010,9/15/2010,,,,,1/18/2011,1/18/2011,,,1/19/2011,1/19/2011,,,,,,,,,,,,,2/21/2011,2/21/2011,2/21/2011,3/29/2011,,,,,,,,,,,,,,,,,,,4/13/2011,4/13/2011,5/5/2011,5/5/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-107,SPD535-107,'SPD535-107,,,Dose Optimization Study,SPD535-107 Dose Optimization Study,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Dose-Ranging,,,30,0,0,0,0,0,0,0.00%,1,,,,Jeff Dragone,,,,,,,,N,No,,,,COSMOS Inactive,,,5/31/2010,5/20/2010,10/27/2010,9/2/2010,,,,,1/6/2011,1/6/2011,,,1/19/2011,1/19/2011,,,,,,,,,,,,,4/27/2011,4/27/2011,4/27/2011,5/31/2011,,,,,,,,,,,,,,,,,,,6/13/2011,6/13/2011,7/7/2011,7/1/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-108,SPD535-108,'SPD535-108,,,Drug-Drug Interation study Heparin,SPD535-108 Drug-Drug Interation Heparin,I,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Drug Interaction,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/15/2015,,6/16/2015,,,,,,7/8/2015,,,,7/22/2015,,,,,,,,,,,,,,8/31/2015,,8/31/2015,,,,,,,,,,,,,,,,,,,,10/16/2015,,11/17/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-109,SPD535-109,'SPD535-109,,,Drug-Drug Interaction study Aspirin,SPD535-109 Drug-Drug Interation Aspirin,I,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Drug Interaction,,,36,0,0,0,0,0,0,0.00%,1,,,,"Rachael Grose-Hodge, Ronald Budhram",,,Scharmen Confer,,,,,N,No,,,,COSMOS Inactive,,,9/21/2011,,8/6/2014,,,,,,11/19/2014,,,,11/21/2014,,,,,,,,,,,,,,12/12/2014,,12/12/2014,,,,,,,,,,,,,,,,,,,,,,3/30/2015,,,,,,,,,,,,5/25/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD535-110,SPD535-110,'SPD535-110,,,Exploratory evaluation of biomarkers,SPD535-110 Exploratory Biomarker,I,Study Terminated,Essential Thrombocythemia,,,Non-Registry,,Interventional,Multiple Dose,,,40,0,0,0,0,0,0,0.00%,1,,,,,Jeff Long,,,,,,,N,No,,,,COSMOS Inactive,,,2/2/2011,5/19/2011,7/1/2011,7/12/2011,,,,,9/8/2011,9/8/2011,,,10/7/2011,,,,,,,,,,,,,,10/20/2011,10/20/2011,10/20/2011,,,,,,,,,,,,,,,,,,,,1/30/2012,,2/10/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-111,SPD535-111,'SPD535-111,,,Phase I Elderly PK Study,SPD535-111 Age/Gender PK,I,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Healthy Volunteers,,,48,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/5/2015,,6/16/2015,,,,,,7/16/2015,,,,7/30/2015,,,,,,,,,,,,,,9/9/2015,,9/9/2015,,,,,,,,,,,,,,,,,,,,12/3/2015,,1/4/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-112,SPD535-112,'SPD535-112,,,Japanese Bridging Study,SPD535-112 Japanese Bridging,I,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Healthy Volunteers,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/19/2015,,6/30/2015,,,,,,7/28/2015,,,,8/11/2015,,,,,,,,,,,,,,9/21/2015,,9/21/2015,,,,,,,,,,,,,,,,,,,,12/15/2015,,1/14/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-113,SPD535-113,'SPD535-113,,,ADME Study,SPD535-113 ADME,I,Completed,Essential Thrombocythemia,,,Non-Registry,,Interventional,Drug Metabolism Pharmacokinetics (DMPK),,,8,8,22,0,0,8,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/13/2011,7/13/2011,3/30/2012,3/28/2012,,,,,7/18/2012,7/18/2012,,,7/18/2012,7/18/2012,,,,,,,,,,,,,7/30/2012,7/30/2012,7/30/2012,9/13/2012,,,,,,,,,,,,,,,,,,,9/20/2012,9/20/2012,10/12/2012,10/9/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-114,SPD535-114,'SPD535-114,,,"A Phase I, Single Center, Open-label Study to Investigate the Effect a Dose Titration Regimen of SSP-1009G has on Platelet Response in Healthy Subjects",Effect of SSP-1009G on Platelet Response,I,Study Withdrawn,ARF following Bypass,,,Non-Registry,,Interventional,,,,40,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/31/2012,,9/20/2012,,,,,,11/23/2012,,,,12/7/2012,,,,,,,,,,,,,,3/15/2013,,3/15/2013,,,,,,,,,,,,,,,,,,,,6/13/2013,,6/24/2013,,,,,,,,,,,,8/19/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD535-201,SPD535-201,'SPD535-201,,,"A Randomized, Double-blind, Ph II study of SPD535 in dialysis patients with End Stage Renal Disease",Phase 2 fistula maturation POC study,II,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Double-Blind,,,310,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/9/2011,,4/29/2011,,,,,,8/11/2011,,,,7/12/2012,,,,,,,,,,,,,,12/27/2012,,12/27/2012,,,,,,,,,,,,,,,,,,,,2/25/2013,,4/1/2013,,,,,,,,,,,,5/27/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD535-202,SPD535-202,'SPD535-202,,,Phase II Fistula/Graft Maintenance,Phase 2 vascular access maintenance,II,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Proof of Concept,,,800,0,0,0,0,0,0,0.00%,100,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/18/2011,,9/7/2011,,,,,,12/5/2011,,,,12/2/2013,,,,,,,,,,,,,,11/23/2015,,11/23/2015,,,,,,,,,,,,,,,,,,,,1/1/2016,,1/28/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD535-206,SPD535-206,'SPD535-206,,,"A Phase 2, Multicenter, Randomized, Placebo-Controlled, Single-Blind Study to Investigate the Effects of Platelet Lowering by SSP-1009G on the Patency of Arteriovenous Grafts in Subjects with End Stage Renal Disease",SPD535-206 graft flow and maintenance,II,Study Withdrawn,ESRD,,,Non-Registry,,Interventional,Double-Blind,,,156,2,2,0,0,0,0,1.28%,70,,,Clinical Research Management,Sharon Morriss,,,Scharmen Confer,"Diane Bedor, Jessica Moskey, Tandee Scott",,,,N,No,,,,COSMOS Inactive,,,3/23/2012,3/23/2012,5/11/2012,5/11/2012,,,,,10/16/2012,,,,7/23/2013,,,,,,,,,,,,,,7/22/2014,,7/22/2014,,,,,,,,,,,,,,,,,,,,10/2/2014,,11/6/2014,,,,,,,,,,,,1/1/2015,1/1/2049,,,,,,,,,,,,,,,,,,,,,,
SPD535-207,SPD535-207,'SPD535-207,,,"A randomized, single blind phase 2 study to evaluate safety and tolerability and characterize the pharmacodynamic and biomarker response profile of Rafigrelide in sickle cell disease","study to evaluate the safety, tolerabili",II,Study Withdrawn,Essential Thrombocythemia,,,Non-Registry,,Interventional,Randomized,,,20,0,0,0,0,0,0,0.00%,1,,,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/15/2013,2/15/2013,5/10/2013,5/10/2013,,,,,8/30/2013,,,,2/14/2014,,,,,,,,,,,,,,5/9/2014,,5/9/2014,,,,,,,,,,,,,,,,,,,,7/1/2014,,8/5/2014,,,,,,,,,,,,9/30/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD538-xxx,SPD538-xxx,'SPD538-xxx,,,SPD538-xxx Joint Development with Alba,SPD538-xxx Joint Dev.,x,Study Terminated,Reduction of Scarring,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD541-101,SPD541-101,'SPD541-101,,,"Phase i randomised, single dose study in healthy volunteers to investigate the PK, bioavailability, safety and tolerance of SSP1053 compared to currently available formulations of meptazinol and placebo.",SPD541 FIM,I,Study Terminated,Pain,,,Non-Registry,,Interventional,Crossover,,,48,23,56,0,33,0,0,47.92%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/6/2009,2/11/2009,2/12/2009,2/11/2009,,,,,4/15/2009,4/15/2009,,,6/27/2009,5/14/2009,,,,,,,,,,,,,6/29/2009,5/16/2009,6/29/2009,7/30/2009,,,,,,,,,,,,,,,,,,,8/17/2009,8/13/2009,9/4/2009,8/27/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD541-102,SPD541-102,'SPD541-102,,,"A Randomised, Double Blind, Placebo-Controlled, Crossover Phase I study to Investigate the Pharmacokinetics and Therapeutic Effects of IV meptazinol (meptid) vs comparator in a pain model setting in Healthy Volunteers.",Meptazinol (IV) vs active comparator,I,Completed,Pain,,,Non-Registry,,Interventional,,,,20,20,0,0,0,0,0,100.00%,1,,,,,,,Geoff Brooks,,,,,N,No,,,,COSMOS Inactive,,,3/4/2009,3/4/2009,5/14/2009,3/18/2009,,,,,7/27/2009,7/27/2009,,,11/16/2009,11/4/2009,,,,,,,,,,,,,12/2/2009,12/2/2009,12/2/2009,1/25/2010,,,,,,,,,,,,,,,,,,,2/26/2010,4/15/2010,4/6/2010,4/16/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD543-xxx,SPD543-xxx,'SPD543-xxx,,,SPD543-xxx acquisition Feb 2009,SPD543-xxx acquisition Feb 2009,x,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,John Tobin,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD544-1xa,SPD544-1xa,'SPD544-1xa,,,A Phase I study to investigate the bioequivalence of Equasym 60mg od with Equasym 30mg bid,Bioequivalence study for higher strength,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD544-4xa,SPD544-4xa,'SPD544-4xa,,,A Phase IV study to investigate the effect of long acting methylphenidate on academic performance,Ped Executive function study,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/24/2009,,6/19/2009,,,,,,11/27/2009,,,,6/25/2010,,,,,,,,,,,,,,9/24/2010,,9/24/2010,,,,,,,,,,,,,,,,,,,,12/16/2010,,1/27/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD544-4xb,SPD544-4xb,'SPD544-4xb,,,"A Phase IV, randomized, multi-centre, parallel group study designed to evaluate the efficacy and safety of Equasym and Medikinet in subjects aged 6 to 17 years with ADHD.",SPD544-4xb Rand ped comparator,IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/4/2010,,3/18/2010,,,,,,7/23/2010,,,,7/22/2011,,,,,,,,,,,,,,9/2/2011,,9/2/2011,,,,,,,,,,,,,,,,,,,,10/13/2011,,11/9/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD544-101,SPD544-101,'SPD544-101,,,SPD544-101 A ~Phase I study to investigate the bioequivalence of Equasym 60mg OD with Equasym 30mg bid,Higher strength BE,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,28,28,71,0,43,28,1,100.00%,1,,,,Kerry Dennis,,Patrick Martin,"Antonia Coeshall, John Tobin",,,,,N,No,,,,COSMOS Inactive,,,5/27/2010,5/28/2010,6/30/2010,7/8/2010,,,,,9/20/2010,9/20/2010,,,9/24/2010,9/24/2010,,,,,,,,,,,,,10/2/2010,10/2/2010,10/2/2010,11/22/2010,,,,,,,,,,,,,,,,,,,1/12/2011,1/12/2011,1/12/2011,1/12/2011,,,,,,,,,,,3/9/2011,4/7/2011,,,,,,,,,,,,,,,,,,,,,,
SPD544-102,SPD544-102,'SPD544-102,,,Staedy state relative bioavailability study of methylphenidate Metadate CD 30mg capsule vs Ritalin LA 30mg capsule in healthy volunteers of both gendser under fasting conditions,Metadate Mexican BE study,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioequivalence,,,26,26,30,0,4,26,2,100.00%,1,,,Parexel,"Jeff Dragone, Kerry Dennis",,,John Tobin,,,,,N,No,,,,COSMOS Inactive,,,1/12/2011,1/12/2011,7/28/2011,1/31/2011,,,,,12/1/2011,12/1/2011,,,12/1/2011,12/1/2011,,,,,,,,,,,,,12/22/2011,12/22/2011,12/22/2011,1/16/2012,,,,,,,,,,,,,,,,,,,1/13/2012,1/19/2012,1/27/2012,3/6/2012,,,,,,,,,,,7/6/2012,6/6/2012,,,,,,,,,,,,,,,,,,,,,,
SPD544-701,SPD544-701,'SPD544-701,,,"A Phase IV Multi-centre, non-interventional observational study evaluating Quasym LP in chidren and adolescents aged 6-17 years","SPD544-701 Ped, adlsc obs",IV,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,400,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD544-xxx,SPD544-xxx,'SPD544-xxx,,,SPD544-xxx acquisition Feb 2009,SPD544-xxx acquisition Feb 2009,x,Study Withdrawn,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-1xd,SPD545-1xd,'SPD545-1xd,,,"open-label, randomized, 4-period crossover study, SSP-1104A administered to 3 specific sites in the GI (upper small intestine, lower small intestine, colon) and 1 standard oral administration",SPD545-1xd Site of absorption,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,,,,12,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Antonia Coeshall,,,,,N,No,,,,COSMOS Inactive,,,6/17/2011,,8/12/2011,,,,,,10/24/2011,,,,12/2/2011,,,,,,,,,,,,,,12/30/2011,,12/30/2011,,,,,,,,,,,,,,,,,,,,3/26/2012,,4/25/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-1xe,SPD545-1xe,'SPD545-1xe,,,Phase I double blind cross sover study to investiage gut motility,SPD545-1xe Gut motility,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,,,,12,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Antonia Coeshall,,,,,N,No,,,,COSMOS Inactive,,,2/16/2011,,4/15/2011,,,,,,6/27/2011,,,,7/14/2011,,,,,,,,,,,,,,8/25/2011,,8/25/2011,,,,,,,,,,,,,,,,,,,,1/26/2012,,2/27/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-3xa,SPD545-3xa,'SPD545-3xa,,,"A Phase III, Randomized, multi-center study to investigate the efficacy and safety of SPD545 in patients with chronic LBP.",SPD545-3xa Chronic Low Back Pain,III,Study Withdrawn,Pain,,,Non-Registry,,Interventional,,,,300,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/30/2012,,5/11/2012,,,,,,10/19/2012,,,,7/26/2013,,,,,,,,,,,,,,10/18/2013,,10/18/2013,,,,,,,,,,,,,,,,,,,,12/26/2013,,1/23/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-3xb,SPD545-3xb,'SPD545-3xb,,,"A Phase III, multi-center, randomized study to assess the efficacy and safety of SPD545 in  chronic LBP.",SPD545-3xb Chronic Low Back Pain,III,Study Withdrawn,Pain,,,Non-Registry,,Interventional,,,,300,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/23/2012,,5/4/2012,,,,,,10/12/2012,,,,7/19/2013,,,,,,,,,,,,,,10/11/2013,,10/11/2013,,,,,,,,,,,,,,,,,,,,12/19/2013,,1/16/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-3xc,SPD545-3xc,'SPD545-3xc,,,"A Phase III, Randomized, Multi-center study to investigate the efficacy and safety of SPD545 in chronic OA.",SPD545-3xc,III,Study Withdrawn,Pain,,,Non-Registry,,Interventional,,,,300,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/23/2012,,5/4/2012,,,,,,10/12/2012,,,,7/19/2013,,,,,,,,,,,,,,10/11/2013,,10/11/2013,,,,,,,,,,,,,,,,,,,,12/19/2013,,1/16/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-3xd,SPD545-3xd,'SPD545-3xd,,,"A Phase III, Randomized, Multi-center study to Investigate the Efficacy and safety of SPD545 in chronic LTS",SPD545-3xd Long Term Safety,III,Study Withdrawn,Pain,,,Non-Registry,,Interventional,,,,300,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/23/2012,,5/4/2012,,,,,,10/12/2012,,,,7/19/2013,,,,,,,,,,,,,,10/11/2013,,10/11/2013,,,,,,,,,,,,,,,,,,,,12/19/2013,,1/16/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-101,SPD545-101,'SPD545-101,,,SPD545-101 SAD,SPD545-1xa SAD study,I,Completed,Pain,,,Non-Registry,,Interventional,First In Man (FIM),,,56,56,191,0,135,56,0,100.00%,1,,,Clinical Development & Support Services Ltd,"Antonia Coeshall, Kerry Dennis, Richard Abbott",,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,9/24/2010,9/22/2010,11/29/2010,11/29/2010,,,,,2/3/2011,2/3/2011,,,5/10/2011,5/10/2011,,,,,,,,,,,,,5/11/2011,5/11/2011,5/11/2011,6/23/2011,,,,,,,,,,,,,,,,,,,7/19/2011,7/19/2011,8/3/2011,7/27/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-102,SPD545-102,'SPD545-102,,,SPD545-102 MAD,SPD545-1xb MAD study,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Healthy Volunteers,,,48,0,0,0,0,0,0,0.00%,1,,,,Antonia Coeshall,,,,,,,,N,No,,,,COSMOS Inactive,,,11/30/2010,10/1/2010,2/8/2011,,,,,,5/3/2011,,,,7/5/2011,,,,,,,,,,,,,,7/13/2011,,7/13/2011,,,,,,,,,,,,,,,,,,,,9/5/2011,,9/28/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD545-103,SPD545-103,'SPD545-103,,,SPD545-103 Intranasal Abuse Liability,SPD545-1xb IN/IV PK study,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Healthy Volunteers,,,18,0,0,0,0,0,0,0.00%,1,,,,Antonia Coeshall,,,,,,,,N,No,,,,COSMOS Inactive,,,2/25/2011,,3/25/2011,,,,,,6/6/2011,,,,8/1/2011,,,,,,,,,,,,,,9/9/2011,,9/9/2011,,,,,,,,,,,,,,,,,,,,12/9/2011,,12/20/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-1xg,SPD547-1xg,'SPD547-1xg,,,"A Single Center, Open Label Randomized relative Bioavailability Study- this study was merged with the food effect study- no work done on 1xg, prior to cancellation",SPD547-1xg Relative Bioavailability,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,18,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/21/2010,,12/6/2010,,,,,,2/15/2011,,,,2/15/2011,,,,,,,,,,,,,,2/26/2011,,2/26/2011,,,,,,,,,,,,,,,,,,,,5/17/2011,,6/7/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-3xa,SPD547-3xa,'SPD547-3xa,,,"A Phase III, Multi-Center, Randomized, Efficacy and Safety Study of SPD547 in Children with ADHD.",SPD547-3xa Child Piv 1 Efficacy,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,352,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/3/2011,,12/20/2011,,,,,,5/7/2012,,,,1/14/2013,,,,,,,,,,,,,,3/18/2013,,3/18/2013,,,,,,,,,,,,,,,,,,,,5/8/2013,,6/12/2013,,,,,,,,,,,,8/7/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD547-3xb,SPD547-3xb,'SPD547-3xb,,,"A Phase III, Multi-center, Randomized, Efficacy and Safety Study of SPD547 in Children with ADHD",SPD547-3xb Child Piv 2 Efficacy,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,176,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/3/2011,,12/20/2011,,,,,,5/7/2012,,,,9/24/2012,,,,,,,,,,,,,,11/26/2012,,11/26/2012,,,,,,,,,,,,,,,,,,,,1/16/2013,,2/20/2013,,,,,,,,,,,,4/17/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD547-3xc,SPD547-3xc,'SPD547-3xc,,,"A Phase III, Multi-Center, Randomized, Efficacy and Safety Study of SPD547 in Adolescents with ADHD.",SPD547-3xc Adolescent Piv 1 Efficacy,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,532,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/3/2011,,12/20/2011,,,,,,5/7/2012,,,,8/19/2013,,,,,,,,,,,,,,12/2/2013,,12/2/2013,,,,,,,,,,,,,,,,,,,,1/22/2014,,2/26/2014,,,,,,,,,,,,4/23/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD547-3xd,SPD547-3xd,'SPD547-3xd,,,"A Phase III, Multi-center study to assess the LTS of SPD547 in children and adolescents with ADHD",SPD547-3xd Child & Adol LTS,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,650,0,0,0,0,0,0,0.00%,135,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/3/2011,,12/20/2011,,,,,,5/7/2012,,,,1/6/2014,,,,,,,,,,,,,,1/5/2015,,1/5/2015,,,,,,,,,,,,,,,,,,,,2/25/2015,,4/1/2015,,,,,,,,,,,,5/27/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD547-3xe,SPD547-3xe,'SPD547-3xe,,,"A Phase III, Randomized, Multicenter, efficacy and safety study of SPD547 and active comparitor in children and adolescents with ADHD",SPD547-3xe Active Comparitor Study,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,300,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/3/2011,,6/21/2011,,,,,,10/17/2011,,,,12/10/2012,,,,,,,,,,,,,,4/29/2013,,4/29/2013,,,,,,,,,,,,,,,,,,,,6/19/2013,,7/24/2013,,,,,,,,,,,,9/18/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD547-3xf,SPD547-3xf,'SPD547-3xf,,,"A Phase III, Multi-center, Long Term Mainentance of Efficacy study in Children and Adolescents with ADHD",SPD547-3xf EU LTME Study,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,300,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/3/2011,,12/20/2011,,,,,,4/16/2012,,,,6/22/2013,,,,,,,,,,,,,,4/5/2014,,4/5/2014,,,,,,,,,,,,,,,,,,,,5/27/2014,,7/1/2014,,,,,,,,,,,,8/26/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD547-101,SPD547-101,'SPD547-101,,,"A Single Center,Randomized,  Double Blind, Placebo Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of SPD547 in Healthy Volunteers",SPD547-101 SAD Study,I,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,88,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/3/2010,2/3/2010,7/9/2010,7/9/2010,,,,,10/4/2010,10/4/2010,,,2/21/2011,2/21/2011,,,,,,,,,,,,,2/24/2011,2/24/2011,2/24/2011,6/16/2011,,,,,,,,,,,,,,,,,,,,,7/22/2011,7/26/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-102,SPD547-102,'SPD547-102,,,"A Single Center,Randomized,  Double Blind, Placebo Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of SPD547 in Healthy Volunteers",SPD547-102 MAD Study,I,Completed,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,84,0,0,0,0,0,0,0.00%,1,,,,"Jennifer Fetterolf, Kimberly Minger",,,,,,,,N,No,,,,COSMOS Inactive,,,5/12/2010,5/12/2010,10/7/2010,10/7/2010,,,,,11/4/2010,11/4/2010,,,2/3/2011,2/3/2011,,,,,,,,,,,,,2/19/2011,2/19/2011,2/19/2011,8/5/2011,,,,,,,,,,,,,,,,,,,,,9/20/2011,9/16/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-103,SPD547-103,'SPD547-103,,,Tenex Cmax Study,SPD547-103 Tenex Cmax Study,I,Completed,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/6/2010,9/29/2010,11/16/2010,11/19/2010,,,,,1/26/2011,1/19/2011,,,1/27/2011,1/19/2011,,,,,,,,,,,,,2/22/2011,2/22/2011,2/22/2011,3/28/2011,,,,,,,,,,,,,,,,,,,4/14/2011,4/11/2011,6/1/2011,5/27/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-104,SPD547-104,'SPD547-104,,,"A Single Center, Randomized, Open label Two Period Crossover Ketoconazole Drug Interaction Study",SPD547-104 DDI,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,18,0,0,0,0,0,0,0.00%,1,,,,Alexis Gomez,,Patrick Martin,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,9/23/2010,9/29/2010,3/25/2011,,,,,,5/25/2011,,,,5/25/2011,,,,,,,,,,,,,,6/14/2011,,6/14/2011,,,,,,,,,,,,,,,,,,,,8/2/2011,,9/14/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-105,SPD547-105,'SPD547-105,,,"A Single Center, Open Label, Randomized, Two period Crossover  Phase 1 Food Effect and Relative Bioavailability Study of SPD547",SPD547-105 Food Effect/Relative BA Study,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,12,0,0,0,0,0,0,0.00%,1,,,,Heather Van Heusen,Phillip Wang,Patrick Martin,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,1/18/2011,,4/14/2011,,,,,,7/12/2011,,,,7/12/2011,,,,,,,,,,,,,,7/29/2011,,7/29/2011,,,,,,,,,,,,,,,,,,,,9/19/2011,,10/18/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-106,SPD547-106,'SPD547-106,,,"A Multi-Center, Open-Label, Pediatric Pharmacokinetic Bridging Study",SPD547-106 Ped PK Bridging,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Safety,,,16,0,0,0,0,0,0,0.00%,2,,,,Lyette Richards,Phillip Wang,Patrick Martin,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,11/10/2010,11/3/2010,3/4/2011,,,,,,6/8/2011,,,,7/22/2011,,,,,,,,,,,,,,7/26/2011,,7/26/2011,,,,,,,,,,,,,,,,,,,,9/12/2011,,10/7/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD547-107,SPD547-107,'SPD547-107,,,A Single Center ADME Study in Healthy Adults,SPD547-107 ADME Study,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,,,,8,0,0,0,0,0,0,0.00%,1,,,,,Phillip Wang,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD548-1xc,SPD548-1xc,'SPD548-1xc,,,SPD548-1XC  Phase I IN/IV study,IN/IV study,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Double-Blind,,,12,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Antonia Coeshall,,,,,N,No,,,,COSMOS Inactive,,,8/16/2013,,9/27/2013,,,,,,11/27/2013,,,,12/25/2013,,,,,,,,,,,,,,1/22/2014,,1/22/2014,,,,,,,,,,,,,,,,,,,,4/17/2014,,5/19/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD548-1xd,SPD548-1xd,'SPD548-1xd,,,site of absorption,SPD548-1xd site of absorption,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Healthy Volunteers,,,18,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Antonia Coeshall,,,,,N,No,,,,COSMOS Inactive,,,7/4/2011,,8/22/2011,,,,,,11/1/2011,,,,1/9/2012,,,,,,,,,,,,,,2/20/2012,,2/20/2012,,,,,,,,,,,,,,,,,,,,5/15/2012,,6/14/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD548-1xe,SPD548-1xe,'SPD548-1xe,,,Phase I relative bioavailability,SPD548-1xe relative bioavailability,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Bioavailability (BA),,,24,0,0,0,0,0,0,0.00%,1,,,,"Antonia Coeshall, Kerry Dennis",,,,,,,,N,No,,,,COSMOS Inactive,,,11/5/2012,,12/17/2012,,,,,,2/15/2013,,,,3/1/2013,,,,,,,,,,,,,,3/15/2013,,3/15/2013,,,,,,,,,,,,,,,,,,,,6/10/2013,,7/10/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD548-1xf,SPD548-1xf,'SPD548-1xf,,,Phase I neurocognition study,SPD545-1xf PK/PD study,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Cognitive,,,24,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Antonia Coeshall,,,,,N,No,,,,COSMOS Inactive,,,4/11/2012,,6/19/2012,,,,,,9/7/2012,,,,10/19/2012,,,,,,,,,,,,,,11/30/2012,,11/30/2012,,,,,,,,,,,,,,,,,,,,3/6/2013,,3/27/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD548-1xg,SPD548-1xg,'SPD548-1xg,,,SPD548-1xg Abuse liability 1,SPD548-1xg Abuse liability 1,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Pilot,,,20,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,,,,,,N,No,,,,COSMOS Inactive,,,4/20/2012,,7/19/2012,,,,,,10/9/2012,,,,3/4/2013,,,,,,,,,,,,,,4/15/2013,,4/15/2013,,,,,,,,,,,,,,,,,,,,6/26/2013,,7/17/2013,,,,,,,,,,,,9/11/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD548-2xa,SPD548-2xa,'SPD548-2xa,,,A Phase II multicenter dose optimisation study to investigate the efficacy and safety of SPD548 versus placebo and active comparator in patients with chronic OA pain,SPD548-2xa Dose Optimised 3 arm,II,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Comparator,,,150,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/10/2013,,6/5/2013,,,,,,9/18/2013,,,,3/19/2014,,,,,,,,,,,,,,4/30/2014,,4/30/2014,,,,,,,,,,,,,,,,,,,,7/8/2014,,8/5/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD548-2xb,SPD548-2xb,'SPD548-2xb,,,"A Phase II, double blind fixed dose dose ranging effiacy and safety study in patients with chronic OA pain",SPD548-2xb Fixed Dose 5 arm,II,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Double-Blind,,,250,0,0,0,0,0,0,0.00%,32,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/10/2013,,6/5/2013,,,,,,9/18/2013,,,,3/19/2014,,,,,,,,,,,,,,4/30/2014,,4/30/2014,,,,,,,,,,,,,,,,,,,,7/8/2014,,8/5/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD548-101,SPD548-101,'SPD548-101,,,SAD,SPD548-101 SAD,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Double-Blind,,,104,0,0,0,0,0,0,0.00%,1,,,,"Antonia Coeshall, Kerry Dennis",,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,1/12/2011,1/12/2011,11/22/2011,,,,,,2/23/2012,,,,8/9/2012,,,,,,,,,,,,,,8/18/2012,,8/18/2012,,,,,,,,,,,,,,,,,,,,11/22/2012,,11/20/2012,,,,,,,,,,,,1/15/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD548-102,SPD548-102,'SPD548-102,,,MAD,SPD548-102 MAD,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,,,,48,0,0,0,0,0,0,0.00%,1,,,,"Alison McMorn, Antonia Coeshall, Kerry Dennis",,,,,,,,N,No,,,,COSMOS Inactive,,,4/27/2011,,12/9/2011,,,,,,2/24/2012,,,,6/15/2012,,,,,,,,,,,,,,6/28/2012,,6/28/2012,,,,,,,,,,,,,,,,,,,,8/29/2012,,9/19/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD549-1xc,SPD549-1xc,'SPD549-1xc,,,SPD549-ixc IN/IV,SPD549-1xc IN/IV,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Healthy Volunteers,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/22/2013,,5/3/2013,,,,,,7/31/2013,,,,9/25/2013,,,,,,,,,,,,,,11/6/2013,,11/6/2013,,,,,,,,,,,,,,,,,,,,2/11/2014,,2/7/2014,,,,,,,,,,,,4/4/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD549-1xd,SPD549-1xd,'SPD549-1xd,,,SPD549-1xd PK_PD,SPD549-1xd PK_PD,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,PKPD,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/18/2012,,7/18/2012,,,,,,10/4/2012,,,,1/24/2013,,,,,,,,,,,,,,3/7/2013,,3/7/2013,,,,,,,,,,,,,,,,,,,,6/12/2013,,6/10/2013,,,,,,,,,,,,8/5/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD549-1xe,SPD549-1xe,'SPD549-1xe,,,SPD549-1xe abuse liability 1,SPD549-1xe abuse liability 1,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Pilot,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/18/2012,,7/26/2012,,,,,,10/14/2012,,,,3/29/2013,,,,,,,,,,,,,,5/10/2013,,5/10/2013,,,,,,,,,,,,,,,,,,,,8/15/2013,,8/13/2013,,,,,,,,,,,,10/8/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD549-2xa,SPD549-2xa,'SPD549-2xa,,,"A Phase II, dose optimised, placebo and active comparator effiacay and safety study in patients with chronic OA pain",SPD549-2xa Dose opt plo and Active,II,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Comparator,,,150,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/22/2013,,4/19/2013,,,,,,8/2/2013,,,,1/31/2014,,,,,,,,,,,,,,3/14/2014,,3/14/2014,,,,,,,,,,,,,,,,,,,,5/22/2014,,6/19/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD549-2xb,SPD549-2xb,'SPD549-2xb,,,"A Phase II, Fixed dose, 5 arm adaptive design placebo controlled efficacy and safety study in patients with chronic OA pain",SPD549-2xb Adlt,II,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Safety,,,250,0,0,0,0,0,0,0.00%,32,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,2/22/2013,,4/19/2013,,,,,,8/2/2013,,,,1/31/2014,,,,,,,,,,,,,,3/14/2014,,3/14/2014,,,,,,,,,,,,,,,,,,,,5/22/2014,,6/19/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD549-101,SPD549-101,'SPD549-101,,,SPD549-101 SAD study,SPD549-101 SAD,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Healthy Volunteers,,,104,0,0,0,0,0,0,0.00%,1,,,,"Antonia Coeshall, Kerry Dennis",,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,7/25/2011,7/13/2011,12/23/2011,,,,,,3/15/2012,,,,8/31/2012,,,,,,,,,,,,,,9/9/2012,,9/9/2012,,,,,,,,,,,,,,,,,,,,12/13/2012,,12/11/2012,,,,,,,,,,,,2/5/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD549-102,SPD549-102,'SPD549-102,,,SPD549-102 MAD study,SPD549-102 MAD,I,Study Withdrawn,Pain,,,Non-Registry,,Interventional,Healthy Volunteers,,,60,0,0,0,0,0,0,0.00%,1,,,,"Antonia Coeshall, Kerry Dennis",,,,,,,,N,No,,,,COSMOS Inactive,,,10/31/2011,,3/19/2012,,,,,,5/31/2012,,,,8/23/2012,,,,,,,,,,,,,,9/13/2012,,9/13/2012,,,,,,,,,,,,,,,,,,,,11/14/2012,,12/5/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD550-501,SPD550-501,'SPD550-501,,,Decision model for SPD550 in Celiac Disease,,IIIb,Completed,Celiac,,,Non-Registry,,Interventional,,,,1,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD550-xxx,SPD550-xxx,'SPD550-xxx,,,SPD550-xxx Joint Development with ...,SPD550-xxx Joint Dev.,x,Study Withdrawn,Celiac,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD551-001,SPD551-001,'SPD551-001,,,"A Phase 0, Single Center, In-vitro Study on the Cellular Mechanisms and Potential Efficacy of Mesalamine on Biopsies Taken From Subjects Who Have Been Diagnosed With Coeliac Disease and Refractory Coeliac Disease",A Phase 0 in vitro Study,0,Completed,Celiac,,,Non-Registry,,Non-Interventional_CDO Support,Pilot,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,Mary Palmen,,,,,N,No,,,,COSMOS Inactive,,,2/9/2011,2/9/2011,5/11/2011,5/11/2011,,,,,12/6/2011,12/6/2011,,,7/31/2012,8/16/2012,,,,,,,,,,,,,7/31/2012,8/16/2012,7/31/2012,11/29/2012,,,,,,,,,,,,,,,,,,,12/6/2012,12/18/2012,12/20/2012,12/18/2012,,,,,,,,,,,1/31/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD551-101,SPD551-101,'SPD551-101,,,Bioavailability Study,Bioavailability Study,I,Study Withdrawn,Celiac,,,Non-Registry,,Interventional,Bioavailability (BA),,,45,0,0,0,0,0,0,0.00%,1,,,,Anthony Robinson,,,Mary Palmen,,,,,N,No,,,,COSMOS Inactive,,,,,4/11/2011,,,,,,7/1/2011,,,,7/5/2011,,,,,,,,,,,,,,7/22/2011,,7/22/2011,,,,,,,,,,,,,,,,,,,,10/25/2011,,10/31/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD551-102,SPD551-102,'SPD551-102,,,Dose Proportionality,Dose Proportionality,I,Study Withdrawn,Celiac,,,Non-Registry,,Interventional,Randomized,,,12,0,0,0,0,0,0,0.00%,1,,,,"Anthony Robinson, Mary Palmen",,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/24/2011,,,,,,2/2/2012,,,,2/2/2012,,,,,,,,,,,,,,3/1/2012,,3/1/2012,,,,,,,,,,,,,,,,,,,,6/4/2012,,6/14/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD551-103,SPD551-103,'SPD551-103,,,Food Effect,Food Effect,I,Study Withdrawn,Celiac,,,Non-Registry,,Interventional,Forced-Dose,,,35,0,0,0,0,0,0,0.00%,1,,,,"Anthony Robinson, Mary Palmen",,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/24/2011,,,,,,2/8/2012,,,,2/8/2012,,,,,,,,,,,,,,2/22/2012,,2/22/2012,,,,,,,,,,,,,,,,,,,,5/25/2012,,6/6/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD553-101,SPD553-101,'SPD553-101,,,Guanfacine Carrierwave SAD Study,1228R SAD,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Tolerability,,,48,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/22/2010,9/22/2010,6/29/2011,,,,,,8/19/2011,,,,9/30/2011,,,,,,,,,,,,,,10/7/2011,,10/7/2011,,,,,,,,,,,,,,,,,,,,12/13/2011,,12/27/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD553-102,SPD553-102,'SPD553-102,,,1228R MAD,1228R MAD,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Multiple Dose,,,10,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/2/2011,,4/13/2011,,,,,,7/1/2011,,,,9/9/2011,,,,,,,,,,,,,,9/26/2011,,9/26/2011,,,,,,,,,,,,,,,,,,,,11/25/2011,,12/20/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD554-2xg,SPD554-2xg,'SPD554-2xg,,,SPD554-2xg Dose Range Finding Study,SPD554-2xg DRF Study,II,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Dose-Ranging,,,740,0,0,0,0,0,0,0.00%,62,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/2/2012,,12/14/2012,,,,,,4/1/2013,,,,10/30/2013,,,,,,,,,,,,,,3/12/2014,,3/12/2014,,,,,,,,,,,,,,,,,,,,4/29/2014,,6/3/2014,,,,,,,,,,,,8/13/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD554-3xa,SPD554-3xa,'SPD554-3xa,,,SPD554-3xa Child Piv 1 Efficacy ADHD,SPD554-3xa ADHD Child Piv 1 Efficacy,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,352,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/3/2015,,12/15/2015,,,,,,5/3/2016,,,,12/13/2016,,,,,,,,,,,,,,2/14/2017,,2/14/2017,,,,,,,,,,,,,,,,,,,,4/6/2017,,5/11/2017,,,,,,,,,,,,7/6/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD554-3xb,SPD554-3xb,'SPD554-3xb,,,Flexible Dose Short Term Efficacy and Safety in Children 6-12 with ADHD,SPD554-3xb ADHD Child Piv 2 Efficacy,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,176,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/3/2015,,12/15/2015,,,,,,5/3/2016,,,,8/23/2016,,,,,,,,,,,,,,10/25/2016,,10/25/2016,,,,,,,,,,,,,,,,,,,,12/15/2016,,1/19/2017,,,,,,,,,,,,3/16/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD554-3xc,SPD554-3xc,'SPD554-3xc,,,Fixed Dose Short Term Safety and Efficacy in Adolescents with ADHD,SPD554-3xc ADHD Adolescent Piv Efficacy,III,Study Withdrawn,ADHD,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Adolescent,,,532,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/24/2012,,1/11/2013,,,,,,5/30/2013,,,,8/7/2014,,,,,,,,,,,,,,11/20/2014,,11/20/2014,,,,,,,,,,,,,,,,,,,,1/12/2015,,2/16/2015,,,,,,,,,,,,4/13/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD554-3xd,SPD554-3xd,'SPD554-3xd,,,"Long Term, OL, Safety in Children and Adolescents with ADHD",SPD554-3xd ADHD LTS Child and Adol,III,Study Withdrawn,ADHD,,,Non-Registry,Both Pediatric & Non-pediatric,Interventional,Adolescent,,,500,0,0,0,0,0,0,0.00%,90,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/3/2015,,12/15/2015,,,,,,5/3/2016,,,,2/14/2017,,,,,,,,,,,,,,2/12/2018,,2/12/2018,,,,,,,,,,,,,,,,,,,,4/4/2018,,5/9/2018,,,,,,,,,,,,7/4/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD554-3xh,SPD554-3xh,'SPD554-3xh,,,"Fixed Dose, Short Term Efficacy and Safety in Adults with ADHD",SPD554-3xe ADHD Adult Piv Efficacy,III,Study Withdrawn,ADHD,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Double-Blind,,,532,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/15/2014,,10/27/2014,,,,,,3/2/2015,,,,5/9/2016,,,,,,,,,,,,,,7/11/2016,,7/11/2016,,,,,,,,,,,,,,,,,,,,8/31/2016,,10/5/2016,,,,,,,,,,,,11/30/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD554-3xi,SPD554-3xi,'SPD554-3xi,,,Long-Term Open Label Safety in Adults with ADHD,SPD554-3xi ADHD LTS Adult,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Long-Term,,,300,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/15/2014,,10/27/2014,,,,,,5/5/2015,,,,7/12/2016,,,,,,,,,,,,,,7/10/2017,,7/10/2017,,,,,,,,,,,,,,,,,,,,8/30/2017,,10/4/2017,,,,,,,,,,,,11/29/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD554-4xb,SPD554-4xb,'SPD554-4xb,,,LTME in Children and Adolescents,SPD554-4xb ADHD Child LTME,III,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Potential PAC Study,,,510,0,0,0,0,0,0,0.00%,50,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/3/2020,,4/14/2020,,,,,,9/1/2020,,,,7/6/2021,,,,,,,,,,,,,,4/5/2022,,4/5/2022,,,,,,,,,,,,,,,,,,,,5/26/2022,,6/30/2022,,,,,,,,,,,,8/25/2022,,,,,,,,,,,,,,,,,,,,,,,
SPD554-001,SPD554-001,'SPD554-001,,,"A Phase 0, exploratory, open-label, two-period, randomized, cross-over microdose study to investigate the relative bioavailability of a single dose of orally-administered SSP-1871R (a guanfacine prodrug) and guanfacine hydrochloride (HCL)",SSP-1871 Microdose,0,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Bioavailability (BA),,,12,0,0,0,0,0,0,0.00%,1,,,,Anthony Robinson,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,11/3/2010,11/3/2010,1/7/2011,1/7/2011,,,,,3/24/2011,3/24/2011,,,3/25/2011,3/25/2011,,,,,,,,,,,,,4/1/2011,3/31/2011,4/1/2011,5/23/2011,,,,,,,,,,,,,,,,,,,4/14/2011,4/14/2011,6/28/2011,6/22/2011,,,,,,,,,,,8/25/2011,9/14/2011,,,,,,,,,,,,,,,,,,,,,,
SPD554-101,SPD554-101,'SPD554-101,,,Guanfacine Carriewave SAD,1871R SAD,I,Completed,ADHD,,,Non-Registry,,Interventional,First In Man (FIM),,,48,0,0,0,0,0,0,0.00%,1,,,,"Anthony Robinson, Bree Harlin",,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,2/2/2011,2/1/2011,5/23/2011,5/23/2011,,,,,7/26/2011,7/26/2011,,,10/11/2011,10/11/2011,,,,,,,,,,,,,10/14/2011,10/14/2011,10/14/2011,11/15/2011,,,,,,,,,,,,,,,,,,,12/8/2011,12/8/2011,1/5/2012,1/5/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD554-102,SPD554-102,'SPD554-102,,,1871R MAD,1871R MAD,I,Completed,ADHD,,,Non-Registry,,Interventional,First In Man (FIM),,,10,0,0,0,0,0,0,0.00%,1,,,,Anthony Robinson,,,Amy Manley,Bree Harlin,,,,N,No,,,,COSMOS Inactive,,,3/1/2011,2/24/2011,6/3/2011,6/8/2011,,,,,11/4/2011,11/4/2011,,,2/8/2012,2/8/2012,,,,,,,,,,,,,2/24/2012,2/24/2012,2/24/2012,3/27/2012,,,,,,,,,,,,,,,,,,,4/12/2012,4/16/2012,5/3/2012,4/25/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD554-103,SPD554-103,'SPD554-103,,,"A Single Center, Randomized, Open label Two Period Crossover Ketoconazole Drug Interaction Study",SPD554-103 DDI Ketoconazole,I,Completed,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,18,0,0,0,0,0,0,0.00%,1,,,,Kimberly Minger,"James Heinlein, Paul Gretz",,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,8/25/2011,8/25/2011,10/19/2011,10/12/2011,,,,,12/6/2011,12/6/2011,,,12/6/2011,12/6/2011,,,,,,,,,,,,,12/19/2011,12/19/2011,12/19/2011,1/27/2012,,,,,,,,,,,,,,,,,,,2/13/2012,2/13/2012,3/8/2012,3/8/2012,,,,,,,,,,,5/15/2012,,,,,,,,,,,,,,,,,,,,,,,
SPD554-104,SPD554-104,'SPD554-104,,,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effect of SSP-1871 on the Pharmacodynamics and Pharmacokinetics of Ethanol in Healthy Adult Subjects",SPD554-104 Alcohol Interaction Study,I,Completed,ADHD,,,Non-Registry,,Interventional,Cognitive,,,28,31,0,0,0,31,0,110.71%,1,,,PRA,Floris Hoppener,,,Amy Manley,Bill Richardson,,,,N,No,,,,COSMOS Inactive,,,2/28/2012,3/2/2012,4/9/2012,4/12/2012,,,,,5/22/2012,5/22/2012,,,5/28/2012,6/14/2012,,,,,,,,,,,,,7/9/2012,7/7/2012,7/9/2012,8/23/2012,,,,,,,,,,,,,,,,,,,9/11/2012,9/13/2012,10/9/2012,10/2/2012,,,,,,,,,,,11/27/2012,,,,,,,,,,,,,,,,,,,,,,,
SPD554-105,SPD554-105,'SPD554-105,,,"A Single Center, Open Label, Randomized, Two period Crossover  Phase 1 Food Effect and Relative Bioavailability Study of SPD554",SPD554-105 BA,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioavailability (BA),,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/26/2011,10/26/2011,12/7/2011,12/14/2011,,,,,2/15/2012,2/15/2012,,,2/15/2012,2/15/2012,,,,,,,,,,,,,3/3/2012,3/3/2012,3/3/2012,4/3/2012,,,,,,,,,,,,,,,,,,,4/24/2012,4/30/2012,5/14/2012,5/14/2012,,,,,,,,,,,7/9/2012,7/16/2012,,,,,,,,,,,,,,,,,,,,,,
SPD554-106,SPD554-106,'SPD554-106,,,"A Multi-Center, Open-label, Pediatric Pharmacokinetic Bridging Study",SPD554-106 Ped PK Bridging,I,Completed,ADHD,,,Non-Registry,,Interventional,Open Label,,,20,20,35,0,0,0,0,100.00%,2,,,,,Suzanne Elliott,,,,,,,N,No,,,,COSMOS Inactive,,,8/26/2011,8/26/2011,11/17/2011,11/17/2011,,,,,2/17/2012,2/17/2012,,,7/19/2012,2/18/2012,,,,,,,,,,,,,7/26/2012,2/21/2012,7/26/2012,4/16/2012,,,,,,,,,,,,,,,,,,,4/30/2012,4/30/2012,5/28/2012,5/28/2012,,,,,,,,,,,7/25/2012,7/25/2012,,,,,,,,,,,,,,,,,,,,,,
SPD554-107,SPD554-107,'SPD554-107,,,ADME,ADME,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioavailability (BA),,,10,0,0,0,0,0,0,0.00%,1,,,,Kimberly Minger,"James Heinlein, Paul Gretz",,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,9/22/2011,9/22/2011,11/11/2011,11/11/2011,,,,,1/12/2012,1/12/2012,,,1/12/2012,1/12/2012,,,,,,,,,,,,,1/20/2012,1/20/2012,1/20/2012,2/28/2012,,,,,,,,,,,,,,,,,,,3/21/2012,3/21/2012,4/11/2012,4/9/2012,,,,,,,,,,,1/11/2013,1/11/2013,,,,,,,,,,,,,,,,,,,,,,
SPD554-108,SPD554-108,'SPD554-108,,,An unblinded 4-arm crossover site of absorption study,Site of Absorption Study,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioavailability (BA),,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/28/2011,7/28/2011,9/16/2011,9/22/2011,,,,,11/8/2011,11/8/2011,,,1/17/2012,1/17/2012,,,,,,,,,,,,,1/20/2012,1/20/2012,1/20/2012,2/24/2012,,,,,,,,,,,,,,,,,,,3/19/2012,3/19/2012,4/6/2012,4/4/2012,,,,,,,,,,,7/11/2012,7/10/2012,,,,,,,,,,,,,,,,,,,,,,
SPD554-109,SPD554-109,'SPD554-109,,,"A Single Center, Randomized, Open label Two Period Crossover P450 Inducer Drug Interaction Study",DDI P450 Inducer,I,Completed,ADHD,,,Non-Registry,,Interventional,Drug Interaction,,,18,21,0,0,0,21,0,116.67%,1,,,,Lyette Richards,,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,2/28/2012,2/29/2012,4/10/2012,4/10/2012,,,,,6/13/2012,6/13/2012,,,6/13/2012,6/13/2012,,,,,,,,,,,,,7/8/2012,7/8/2012,7/8/2012,8/21/2012,,,,,,,,,,,,,,,,,,,9/13/2012,9/12/2012,10/3/2012,10/3/2012,,,,,,,,,,,1/29/2013,2/4/2013,,,,,,,,,,,,,,,,,,,,,,
SPD554-110,SPD554-110,'SPD554-110,,,"A Single Center, Open Label, Randomized, Two period Crossover  Phase 1 Food Effect and Relative Bioavailability Study of Pediatric SPD554",SPD554-110 BA,I,Completed,ADHD,,,Non-Registry,,Interventional,Bioavailability (BA),,,20,0,0,0,0,0,0,0.00%,1,,,,Jennifer Fetterolf,,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,2/28/2012,2/28/2012,4/24/2012,4/24/2012,,,,,6/26/2012,6/27/2012,,,7/17/2012,7/17/2012,,,,,,,,,,,,,8/2/2012,8/2/2012,8/2/2012,9/6/2012,,,,,,,,,,,,,,,,,,,9/27/2012,9/27/2012,10/18/2012,10/18/2012,,,,,,,,,,,12/27/2012,12/27/2012,,,,,,,,,,,,,,,,,,,,,,
SPD554-111,SPD554-111,'SPD554-111,,,An unblinded multiple-dose pharmacokinetic bridging study of Japanese and non-Japanese healthy volunteers,SPD554-111 Japanese PK Bridging Study,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,7/18/2014,,9/12/2014,,,,,,11/26/2014,,,,12/24/2014,,,,,,,,,,,,,,1/21/2015,,1/21/2015,,,,,,,,,,,,,,,,,,,,3/11/2015,,4/3/2015,,,,,,,,,,,,5/29/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD554-112,SPD554-112,'SPD554-112,,,"A Phase I Open Label Single Dose Study Comparing the Safety, Tolerability and Pharmacokinetics of Healthy Adult Normal Subjects with Elderly Subjects",SPD554-112 Age/Gender PK Study,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,48,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/18/2014,,5/30/2014,,,,,,8/4/2014,,,,9/1/2014,,,,,,,,,,,,,,9/29/2014,,9/29/2014,,,,,,,,,,,,,,,,,,,,12/5/2014,,12/31/2014,,,,,,,,,,,,2/25/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD554-201,SPD554-201,'SPD554-201,,,"Fixed Dose, Dose Range Finding in Adults with ADHD",SPD554-201 ADHD Adult DRF,II,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Double-Blind,,,400,0,0,0,0,0,0,0.00%,45,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/9/2012,,12/21/2012,,,,,,4/26/2013,,,,3/21/2014,,,,,,,,,,,,,,5/23/2014,,5/23/2014,,,,,,,,,,,,,,,,,,,,7/15/2014,,8/19/2014,,,,,,,,,,,,10/14/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD554-203,SPD554-203,'SPD554-203,,,SPD554-203 VMS POC Study,SPD554-203 VMS POC Study,II,Study Withdrawn,VMS,,,Non-Registry,,Interventional,Proof of Concept,,,80,0,0,0,0,0,0,0.00%,15,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/2/2012,10/9/2012,12/17/2012,,,,,,5/6/2013,,,,8/26/2013,,,,,,,,,,,,,,2/3/2014,,2/3/2014,,,,,,,,,,,,,,,,,,,,3/28/2014,,5/2/2014,,,,,,,,,,,,6/27/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD554-204,SPD554-204,'SPD554-204,,,"A Phase 2, Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Multicenter,
Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of SPD554 in Children Aged 4-12 Years with Symptoms of Hyperactivity and Behavioral Noncompliance Associated with Autism Spectrum Disorder",SPD554-204 Autism DR,II,Study Withdrawn,ASD,,,Non-Registry,,Interventional,Double-Blind,,,216,0,0,0,0,0,0,0.00%,45,,,Premier Research,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/15/2012,11/15/2012,1/18/2013,1/18/2013,,,,,9/9/2013,,,,8/25/2014,,,,,,,,,,,,,,12/1/2014,,12/1/2014,,,,,,,,,,,,,,,,,,,,1/21/2015,,2/25/2015,,,,,,,,,,,,4/22/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD554-205,SPD554-205,'SPD554-205,,,"A Long-Term, Open Label, Extension Study of Safety and Tolerability of SPD554 in Autistic Children",SPD554-205 Autism Phase 2 LTS,II,Study Withdrawn,ASD,,,Non-Registry,,Interventional,Long-Term,,,204,0,0,0,0,0,0,0.00%,45,,,Premier Research,"Joan Sandberg, Sonia Brinton",,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,1/16/2013,1/16/2013,2/27/2013,3/5/2013,,,,,9/23/2013,,,,8/29/2014,,,,,,,,,,,,,,8/27/2015,,8/27/2015,,,,,,,,,,,,,,,,,,,,10/19/2015,,11/23/2015,,,,,,,,,,,,1/18/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD555-103,SPD555-103,'SPD555-103,,,"Evaluation of pharmacokinetics, safety and tolerability of a single dose of prucalopride, in subjects with moderate and severe hepatic impairment, in comparison with healthy subjects",Prucalopride in hepatic impairment,I,Completed,Chronic Constipation,,,Non-Registry,,Interventional,,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/3/2009,12/3/2009,,,,,7/14/2010,7/14/2010,,,2/14/2011,2/5/2011,,,,,,,,,,,,,2/20/2011,2/20/2011,2/20/2011,4/11/2011,,,,,,,,,,,,,,,,,,,6/2/2011,4/29/2011,5/31/2011,5/4/2011,,,,,,,,,,,6/29/2011,,,,,,,,,,,,,,,,,,,,,,,
SPD555-104,SPD555-104,'SPD555-104,,Motegrity (Prucalopride),"A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] prucalopride succinate Following a Single Oral Dose in Healthy Subjects",555-104 ADME,I,Completed,Chronic Constipation,Others,,Non-Registry,,Interventional,Healthy Volunteers,,,6,6,0,0,0,0,0,100.00%,1,,,Covance,,Laura Epelbaum,,,,,,,N,No,,,,COSMOS Inactive,,,,,2/7/2013,2/7/2013,,,3/18/2013,3/18/2013,4/11/2013,4/11/2013,,,4/11/2013,4/11/2013,,,4/28/2013,4/28/2013,,,,,,,,,,,,,,,,,,,,,12/4/2013,12/4/2013,,,,,,,,,,,,,,,,,,,,,,,7/1/2014,7/1/2014,,,,,,,,,,,,,,,7/1/2014,7/1/2014,,,,,,
SPD555-301,SPD555-301,'SPD555-301,,Motegrity (Prucalopride),"A 12-week, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of prucalopride in subjects with chronic non-cancer pain suffering from opioid induced constipation",SPD555-301 OIC Rand DB,III,Completed,Opioid-Induced Constipation,Others,,Non-Registry,,Interventional,,,,510,0,0,0,0,0,0,0.00%,52,,,"Omnicare CR, Theorem Clinical Research",,,,,,2009-015652-20,,,N,No,,,,COSMOS Inactive,,,,,,,,,4/23/2010,4/23/2010,6/2/2010,6/2/2010,,,5/9/2012,5/9/2012,,,8/8/2012,8/8/2012,,,,,,,,,,,,,,,,,,,,,9/26/2012,9/26/2012,,,,,,,,,,,,,9/26/2012,9/26/2012,,,,,,,,,2/6/2013,2/6/2013,,,,,,,,,,,,,,,2/6/2013,2/6/2013,,,,,,
SPD555-302,SPD555-302,'SPD555-302,,Motegrity (Prucalopride),"A 12-week, randomised, double-blind, placebo-controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipation",555-302 MALE Adlt Rand DB PCB,III,Completed,Chronic Constipation,Others,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,360,374,553,0,179,0,56,103.89%,98,,,"INC Research, Syneos Health",Cheryl Fisher,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/30/2010,3/30/2010,,,9/23/2010,9/23/2010,10/8/2010,10/8/2010,,,6/28/2013,6/28/2013,,,10/25/2013,10/25/2013,,,,,,,,,,,,,,,,,,,,,12/6/2013,12/6/2013,,,,,,,,,,,,,,,,,,,,,,,3/27/2014,3/27/2014,,,,,,,,,,,,,,,3/27/2014,3/27/2014,,,,,,
SPD555-303,SPD555-303,'SPD555-303,,Motegrity (Prucalopride),"Trial consisting of an 8-week double-blind placebo-controlled part to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in paediatric subjects with functional constipation, aged =6 months to <18 years, followed by a 16-week open-label comparator (PEG) controlled part, to document safety and tolerability up to 24 weeks",SPD555-303 FC paediatrics,III,Completed,Functional Constipation,Others,,Non-Registry,,Interventional,,,,210,218,305,0,89,0,46,103.81%,45,,,PRA,Cheryl Fisher,,,Mary Palmen,,,,,N,No,,,,COSMOS Inactive,,,,,1/27/2011,1/27/2011,,,4/28/2011,4/28/2011,4/28/2011,4/28/2011,,,9/6/2012,9/6/2012,,,3/1/2013,3/1/2013,,,,,,,,,,,,,,,,,,,,,5/3/2013,5/3/2013,,,,,,,,,,,,,,,,,,,,,,,8/23/2013,8/23/2013,,,,,,,,,,,,,,,8/23/2013,8/23/2013,,,,,,
SPD555-304,SPD555-304,'SPD555-304,,,TBD (OIC in cancer patients),SPD555-304 (OIC in cancer patients),III,Study Withdrawn,Opioid-Induced Constipation,,,Non-Registry,,Interventional,,,,384,0,0,0,0,0,0,0.00%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,8/17/2011,,9/21/2011,,,,,,1/4/2012,,,,10/17/2012,,,,,,,,,,,,,,2/20/2013,,2/20/2013,,,,,,,,,,,,,,,,,,,,3/1/2013,,4/5/2013,,,,,,,,,,,,5/31/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD555-305,SPD555-305,'SPD555-305,,,"4-week open-label trial to evaluate the efficacy, safety and tolerability of prucalopride in paediatric patients from 2 years to less than 18 years of age with opiod-induced constipation as a result of chronic opioid use",OIC in paediatrics,III,Study Withdrawn,Opioid-Induced Constipation,,,Non-Registry,,Interventional,,,,34,0,0,0,0,0,0,0.00%,999,,,,Jannie Ausma,,,Marina Cools,,,,,N,No,,,,COSMOS Inactive,,,9/28/2010,9/28/2010,12/5/2012,,,,,,4/23/2013,,,,11/15/2014,,,,,,,,,,,,,,12/31/2014,,12/31/2014,,,,,,,,,,,,,,,,,,,,2/19/2015,,3/26/2015,,,,,,,,,,,,5/21/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD555-306,SPD555-306,'SPD555-306,,,TBD (OIC in cancer patients LTFU),SPD555-306 (OIC in cancer patients LTFU),III,Study Withdrawn,Opioid-Induced Constipation,,,Non-Registry,,Interventional,,,,384,0,0,0,0,0,0,0.00%,999,,,,Marina Cools,,,,,,,,N,No,,,,COSMOS Inactive,,,8/17/2011,,9/21/2011,,,,,,4/18/2012,,,,1/16/2013,,,,,,,,,,,,,,12/31/2013,,12/31/2013,,,,,,,,,,,,,,,,,,,,3/3/2014,,4/7/2014,,,,,,,,,,,,6/2/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD555-307,SPD555-307,'SPD555-307,,,A 5-Year Follow-up Study of Growth and Sexual Maturation of Paediatric Subjects with Functional Constipation Who Participated in Study M0001-C303,Long-term follow-up of SPD555-303,III,Study Withdrawn,Functional Constipation,,,Non-Registry,,Interventional,,,,210,0,0,0,0,0,0,0.00%,40,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD555-401,SPD555-401,'SPD555-401,,Motegrity (Prucalopride),"A randomised, double-blind, placebo-controlled trial to evaluate the efficacy, quality of life, safety and tolerability of long-term treatment (24 weeks) with prucalopride in subjects aged >= 18 years with chronic constipation",555-401 Ran Dbl Blind Placebo Trial,IV,Completed,Chronic Constipation,Others,,Non-Registry,,Non-Interventional_CDO Support,,,,360,364,469,0,105,0,103,101.11%,54,,,PRA,"Cheryl Fisher, Marina Cools",,,,,2011-000670-62,,,N,No,,,,COSMOS Inactive,,,,,1/10/2010,1/10/2010,,,6/10/2011,6/10/2011,6/10/2011,6/10/2011,,,7/2/2012,7/2/2012,,,12/26/2012,12/26/2012,,,,,,,,,,,,,,,,,,,,,2/26/2013,2/26/2013,,,,,,,,,,,,,2/26/2013,2/26/2013,,,,,,,,,10/17/2013,10/17/2013,,,,,,,,,,,,,,,10/17/2013,10/17/2013,,,,,,
SPD555-402,SPD555-402,'SPD555-402,,,A non-interventional phase 4 study to evaluate the characteristics of patients on Resolor® prescriptions and their treatment satisfaction.,SPD555-402 NIS,IV,Study Withdrawn,Chronic Constipation,,,Non-Registry,,Non-Interventional_CDO Support,,,,"2,000",0,0,0,0,0,0,0.00%,160,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/1/2011,,9/15/2011,,,,,,1/2/2012,,,,6/1/2013,,,,,,,,,,,,,,9/10/2012,,9/10/2012,,,,,,,,,,,,,,,,,,,,9/1/2014,,8/28/2014,,,,,,,,,,,,10/23/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD555-403,SPD555-403,'SPD555-403,,Motegrity (Prucalopride),"An open-label, randomized, single-dose, crossover, reader-blinded study to investigate the effect of prucalopride and polyethylene glycol on colon motility with intra-luminal manometry in subjects with chronic constipation",555-403 Mechanistic Study vs. PEG,IV,Completed,Chronic Constipation,Others,,Non-Registry,,Non-Interventional_CDO Support,Comparator,,,12,13,0,0,0,0,0,108.33%,3,,,Sgs Belgium,,,,,,2012-002495-13,,,N,No,,,,COSMOS Inactive,,,,,7/2/2012,7/2/2012,,,1/18/2013,1/18/2013,3/20/2013,3/20/2013,,,11/27/2013,11/27/2013,,,11/27/2013,11/27/2013,,,,,,,,,,,,,,,,,,,,,4/8/2014,4/8/2014,,,,,,,,,,,,,,,,,,,,,,,6/27/2014,6/27/2014,,,,,,,,,,,,,,,4/10/2012,4/10/2012,,,,,,
SPD555-404,SPD555-404,'SPD555-404,,,"An open-label, randomized, single-dose, crossover, reader-blinded study to investigate the effect of prucalopride and linaclotide on colon motility with intra-luminal manometry in subjects with chronic constipation",Mechanistic Study Versus Linaclotide,IV,Study Withdrawn,Functional Constipation,,,Non-Registry,,Non-Interventional_CDO Support,Single Dose,,,12,0,0,0,0,0,0,0.00%,3,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/22/2014,,4/7/2014,,,,,,6/23/2014,,,,12/22/2014,,,,,,,,,,,,,,1/16/2015,,1/16/2015,,,,,,,,,,,,,,,,,,,,3/3/2015,,4/7/2015,,,,,,,,,,,,6/2/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD555-405,SPD555-405,'SPD555-405,,,"A randomized, double-blind, placebo-controlled trial to evaluate the differences in efficacy, quality of life, safety and tolerability of prucalopride in subjects with chronic constipation and an inadequate response to optimized  laxatives",SPD555-405 Laxatives non-responder,IV,Study Withdrawn,Chronic Constipation,,,Non-Registry,,Non-Interventional_CDO Support,Randomized,,,300,0,0,0,0,0,0,0.00%,80,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/20/2012,,8/31/2012,,,,,,4/1/2013,,,,2/28/2014,,,,,,,,,,,,,,10/31/2014,,10/31/2014,,,,,,,,,,,,,,,,,,,,12/22/2014,,1/26/2015,,,,,,,,,,,,3/23/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD557-101,SPD557-101,'SPD557-101,,,"A Phase 1, Open-Label, Randomized, 2-Period Crossover Drug Interaction Study in Healthy Adult Volunteers to Evaluate the Effect of the Proton Pump Inhibitor Omeprazole on the Pharmacokinetics of SPD557",SPD557-101 DDI with the PPI Omeprazole,I,Completed,GERD,,,Non-Registry,,Interventional,Drug Interaction,,,42,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/1/2011,4/6/2011,5/13/2011,6/1/2011,,,,,9/8/2011,8/31/2011,,,9/16/2011,9/16/2011,,,,,,,,,,,,,9/23/2011,9/23/2011,9/23/2011,10/27/2011,,,,,,,,,,,,,,,,,,,12/14/2011,12/15/2011,12/7/2011,12/8/2011,,,,,,,,,,,2/1/2012,1/27/2012,,,,,,,,,,,,,,,,,,,,,,
SPD557-102,SPD557-102,'SPD557-102,,,tQTc,tQTC,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,Healthy Volunteers,,,40,0,0,0,0,0,0,0.00%,1,,,,Ronald Budhram,,,,,,,,N,No,,,,COSMOS Inactive,,,11/20/2012,11/20/2012,7/19/2013,,,,,,9/20/2013,,,,9/30/2013,,,,,,,,,,,,,,11/11/2013,,11/11/2013,,,,,,,,,,,,,,,,,,,,2/13/2014,,2/17/2014,,,,,,,,,,,,4/14/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD557-103,SPD557-103,'SPD557-103,,,DDI rifampicin,DDI rifampicin,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,Drug Interaction,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/10/2014,,5/21/2014,,,,,,7/24/2014,,,,8/15/2014,,,,,,,,,,,,,,8/30/2014,,8/30/2014,,,,,,,,,,,,,,,,,,,,12/4/2014,,12/2/2014,,,,,,,,,,,,1/27/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD557-104,SPD557-104,'SPD557-104,,,DDI warfarin,DDI warfarin,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,Drug Interaction,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/25/2014,,11/5/2014,,,,,,2/4/2015,,,,3/5/2015,,,,,,,,,,,,,,3/20/2015,,3/20/2015,,,,,,,,,,,,,,,,,,,,6/24/2015,,6/22/2015,,,,,,,,,,,,8/17/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD557-105,SPD557-105,'SPD557-105,,,GI Transporter Interaction,SPD557-105 PK GI Transporter Interaction,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,PK,,,36,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/25/2014,,11/5/2014,,,,,,2/4/2015,,,,3/5/2015,,,,,,,,,,,,,,3/20/2015,,3/20/2015,,,,,,,,,,,,,,,,,,,,6/24/2015,,6/22/2015,,,,,,,,,,,,8/17/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD557-106,SPD557-106,'SPD557-106,,,Renal impairment,Renal impairment,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/16/2014,,6/26/2014,,,,,,8/29/2014,,,,4/10/2015,,,,,,,,,,,,,,4/25/2015,,4/25/2015,,,,,,,,,,,,,,,,,,,,7/30/2015,,7/28/2015,,,,,,,,,,,,9/22/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD557-107,SPD557-107,'SPD557-107,,,ADME,ADME,I,Completed,GERD,,,Non-Registry,,Interventional,Healthy Volunteers,,,12,0,0,0,0,0,0,0.00%,1,,,,Ronald Budhram,,,,,,,,N,No,,,,COSMOS Inactive,,,9/28/2012,9/28/2012,12/27/2012,12/27/2012,,,,,3/26/2013,3/26/2013,,,3/26/2013,3/26/2013,,,,,,,,,,,,,4/5/2013,4/5/2013,4/5/2013,8/7/2013,,,,,,,,,,,,,,,,,,,10/17/2013,10/30/2013,10/17/2013,10/18/2013,,,,,,,,,,,12/20/2013,12/18/2013,,,,,,,,,,,,,,,,,,,,,,
SPD557-108,SPD557-108,'SPD557-108,,,Hepatic impairment,Hepatic impairment,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,PK,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/25/2014,,6/5/2014,,,,,,8/8/2014,,,,3/20/2015,,,,,,,,,,,,,,4/4/2015,,4/4/2015,,,,,,,,,,,,,,,,,,,,7/9/2015,,7/7/2015,,,,,,,,,,,,9/1/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD557-109,SPD557-109,'SPD557-109,,,Elderly,Elderly,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,PK,,,100,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/28/2014,,7/8/2014,,,,,,9/18/2014,,,,1/27/2015,,,,,,,,,,,,,,2/24/2015,,2/24/2015,,,,,,,,,,,,,,,,,,,,6/1/2015,,5/28/2015,,,,,,,,,,,,7/23/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD557-110,SPD557-110,'SPD557-110,,,New Formulation Scintigraphy Study,SPD557-110 PKPD New Scintigraphy Study,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,PKPD,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/7/2013,,7/18/2013,,,,,,9/20/2013,,,,11/1/2013,,,,,,,,,,,,,,12/13/2013,,12/13/2013,,,,,,,,,,,,,,,,,,,,3/20/2014,,3/18/2014,,,,,,,,,,,,5/13/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD557-111,SPD557-111,'SPD557-111,,,New Formulation PK/PD,New Formulation PK/PD,I,Study Withdrawn,GERD,,,Non-Registry,,Interventional,Healthy Volunteers,,,12,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/9/2013,,1/17/2014,,,,,,3/24/2014,,,,3/28/2014,,,,,,,,,,,,,,4/18/2014,,4/18/2014,,,,,,,,,,,,,,,,,,,,7/24/2014,,7/22/2014,,,,,,,,,,,,9/16/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD557-202,SPD557-202,'SPD557-202,,,"An explorative, Rand, PCB, DB, parallel-group trial, to evaluate the PD effect of M0003 on reflux parameters in subjects with gastroesophageal reflux disease and with persistent symptoms despite taking a stable dose of proton pomp inhiboitrs.",SPD557 rand PCB DB PD effect,IIa,Completed,GERD,,,Non-Registry,,Interventional,,,,90,106,44,0,13,66,0,117.78%,15,,,,"An Rykx, Kristel Vermeire",,,Sophie Dedrie,,2010-021397-12,,,N,No,,,,COSMOS Inactive,,,,,8/20/2010,8/20/2010,,,,,12/23/2010,12/23/2010,,,3/23/2012,5/3/2012,,,,,,,,,,,,,5/17/2012,5/29/2012,5/17/2012,8/14/2012,,,,,,,,,,,,,,,,,,,8/23/2012,8/20/2012,9/14/2012,9/14/2012,,,,,,,,,,,11/8/2012,11/8/2012,,,,,,,,,,,,,,,,,,,,,,
SPD557-206,SPD557-206,'SPD557-206,,,"A dose-finding & efficacy study of a novel selective 5HT4 receptor agonist, SSP-002358  co-administered with a proton pump inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) who have incomplete symptomatic response to PPI therapy",SP-002358 dose-finding and efficacy,II,Completed,GERD,,,Non-Registry,,Interventional,Double-Blind,,,460,480,1283,0,803,480,65,104.35%,100,,,ICON / MAPI / Paradigm,"Mohsan Malik, Tone Bjaaland",,,Karen Harmes,"Lorand Domahidy, Lukasz Luszczyna, Stephanie Beblavy, Vincent Wajcberg",2011-004388-62,,,N,No,,,,COSMOS Inactive,,,6/28/2011,6/28/2011,12/13/2011,12/12/2011,,,,,3/28/2012,3/28/2012,,,3/7/2013,3/7/2013,,,,,,,,,,,,,5/9/2013,5/14/2013,5/9/2013,6/20/2013,,,,,,,,,,,,,,,,,,,6/28/2013,6/28/2013,8/1/2013,7/17/2013,,,,,,,,,,,9/25/2013,9/24/2013,,,,,,,,,,,,,,,,,,,,,,
SPD557-301,SPD557-301,'SPD557-301,,,"A phase 3, double-blind, randomised,placebo controlled study to compare the saftey and efficacy of treatment with SPD557 in subjects with persistent symptoms of regurgitation while on proton pump inhibitor therapy.",,III,Study Withdrawn,GERD,,,Non-Registry,,Interventional,Double-Blind,,,"1,000",0,0,0,0,0,0,0.00%,100,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/29/2013,,9/9/2013,,,,,,6/19/2014,,,,12/3/2014,,,,,,,,,,,,,,2/25/2015,,2/25/2015,,,,,,,,,,,,,,,,,,,,4/17/2015,,5/22/2015,,,,,,,,,,,,7/17/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD559-101,SPD559-101,'SPD559-101,,,"A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Oral Doses of SSP-002388X in Healthy Adult Subjects",SPD559-101 FIM,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,First In Man (FIM),,,40,0,0,0,0,0,0,0.00%,1,,,,Mary Corcoran,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,12/26/2012,12/5/2012,3/1/2013,2/28/2013,,,,,8/25/2013,,,,11/1/2013,,,,,,,,,,,,,,11/3/2013,,11/3/2013,,,,,,,,,,,,,,,,,,,,2/6/2014,,2/4/2014,,,,,,,,,,,,4/1/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD559-102,SPD559-102,'SPD559-102,,,"A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to
Assess the Safety, Tolerability, and Pharmacokinetics of Multiple, Ascending, Oral Doses of SSP-002388X in Healthy Adult Subjects",SPD559-102 MAD,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,72,0,0,0,0,0,0,0.00%,1,,,,"Janice Rowe, Mary Corcoran",,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,12/26/2012,12/5/2012,4/10/2013,4/10/2013,,,,,10/10/2013,,,,1/5/2014,,,,,,,,,,,,,,1/20/2014,,1/20/2014,,,,,,,,,,,,,,,,,,,,4/25/2014,,4/23/2014,,,,,,,,,,,,6/18/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD559-103,SPD559-103,'SPD559-103,,,SPECT study,SPD559-103 SPECT,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,16,0,0,0,0,0,0,0.00%,1,,,,,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,3/8/2013,2/26/2013,8/13/2013,,,,,,10/16/2013,,,,2/5/2014,,,,,,,,,,,,,,2/14/2014,,2/14/2014,,,,,,,,,,,,,,,,,,,,5/22/2014,,5/20/2014,,,,,,,,,,,,7/15/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD559-104,SPD559-104,'SPD559-104,,,Site of Absorption,SPD559-104 Site of Absorption,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,30,0,0,0,0,0,0,0.00%,1,,,,,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,10/25/2013,,12/6/2013,,,,,,2/12/2014,,,,3/12/2014,,,,,,,,,,,,,,3/19/2014,,3/19/2014,,,,,,,,,,,,,,,,,,,,6/24/2014,,6/20/2014,,,,,,,,,,,,8/15/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD559-105,SPD559-105,'SPD559-105,,,Relative Bioavailability,SPD559-105 Relative BA,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Bioavailability (BA),,,30,0,0,0,0,0,0,0.00%,1,,,,,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,1/31/2014,,3/14/2014,,,,,,5/19/2014,,,,6/2/2014,,,,,,,,,,,,,,6/9/2014,,6/9/2014,,,,,,,,,,,,,,,,,,,,9/12/2014,,9/10/2014,,,,,,,,,,,,11/5/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD559-106,SPD559-106,'SPD559-106,,,Pediatric PK,SPD559-106 Ped PK,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,2,,,,Mary Corcoran,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,4/25/2014,,6/6/2014,,,,,,8/11/2014,,,,9/22/2014,,,,,,,,,,,,,,9/24/2014,,9/24/2014,,,,,,,,,,,,,,,,,,,,12/30/2014,,12/26/2014,,,,,,,,,,,,2/20/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD559-107,SPD559-107,'SPD559-107,,,Preliminary Abuse Liability,SPD559-107 Preliminary Abuse Liability,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,30,0,0,0,0,0,0,0.00%,1,,,,Mary Corcoran,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,4/17/2015,,5/29/2015,,,,,,8/5/2015,,,,9/2/2015,,,,,,,,,,,,,,9/6/2015,,9/6/2015,,,,,,,,,,,,,,,,,,,,12/10/2015,,12/8/2015,,,,,,,,,,,,2/2/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD559-108,SPD559-108,'SPD559-108,,,SPD559-108 Age/Gender,SPD559-108 Age/Gender,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Elderly,,,40,0,0,0,0,0,0,0.00%,1,,,,Mary Corcoran,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,1/17/2014,,2/28/2014,,,,,,5/5/2014,,,,6/2/2014,,,,,,,,,,,,,,6/30/2014,,6/30/2014,,,,,,,,,,,,,,,,,,,,10/3/2014,,10/1/2014,,,,,,,,,,,,11/26/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD559-109,SPD559-109,'SPD559-109,,,SPD559-1xc DDI,SPD559-109 DDI,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Drug Interaction,,,40,0,0,0,0,0,0,0.00%,1,,,,Mary Corcoran,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,4/17/2015,,5/29/2015,,,,,,8/3/2015,,,,8/31/2015,,,,,,,,,,,,,,9/28/2015,,9/28/2015,,,,,,,,,,,,,,,,,,,,1/1/2016,,12/30/2015,,,,,,,,,,,,2/24/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD559-201,SPD559-201,'SPD559-201,,,SPD559 Adult Proof of Concept,SPD559-201 Adlt POC,IIa,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Proof of Concept,,,135,0,0,0,0,0,0,0.00%,30,,,,,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,2/13/2014,,3/27/2014,,,,,,8/14/2014,,,,12/29/2014,,,,,,,,,,,,,,3/2/2015,,3/2/2015,,,,,,,,,,,,,,,,,,,,4/22/2015,,5/27/2015,,,,,,,,,,,,7/22/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD601-101,SPD601-101,'SPD601-101,,,"Open-Label, Phase I Study, to Assess Potential Safety, Tolerability and Pharmacokinetic Differences Between Single, Ascending, IV and PO Doses of  Galantamine Hydrobromide in Healthy Adult Volunteers",SPD601 IV study,I,Study Withdrawn,Alzheimer's Disease,,,Non-Registry,,Interventional,Safety,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/24/2012,,6/5/2012,,,,,,11/14/2012,,,,11/14/2012,,,,,,,,,,,,,,12/5/2012,,12/5/2012,,,,,,,,,,,,,,,,,,,,2/4/2013,,2/22/2013,,,,,,,,,,,,4/19/2013,,,,,,,,,,,,,,,,,,,,,,,
SPD602-1xa,SPD602-1xa,'SPD602-1xa,,,A Study of Food Effects on FBS0701 Absorption in Healthy Volunteers,SPD602-1xa Adlt,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD602-1xb,SPD602-1xb,'SPD602-1xb,,,A Mass Balance Study using 14[C] Radio-labeled FBS0701 in Healthy Volunteers,SPD602-1xb Adlt,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,6,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD602-1xc,SPD602-1xc,'SPD602-1xc,,,"(A Phase 1, Single-Center, Randomized, Single-Dose, Placebo and Positive-Controlled, 3-Period Crossover Thorough QT/QTc Study  to Evaluate the Effect of FBS0701 on Cardiac Repolarization in Healthy Male and Female Subjects) (AKA THOROUGH QT STUDY)",SPD602-1xc Adlt,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,39,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD602-1xi,SPD602-1xi,'SPD602-1xi,,,Phase I Japanese Study with 7 day treatmetn,,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,26,0,0,0,0,0,0,0.00%,9,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/30/2014,,9/10/2014,,,,,,11/15/2014,,,,9/15/2015,,,,,,,,,,,,,,9/22/2015,,9/22/2015,,,,,,,,,,,,,,,,,,,,12/28/2015,,12/24/2015,,,,,,,,,,,,2/18/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD602-1xm,SPD602-1xm,'SPD602-1xm,,,DDI Study with Methotrexate,602-1xm DDI with Methotrexate,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/3/2015,,5/7/2015,,,,,,6/24/2015,,,,7/8/2015,,,,,,,,,,,,,,7/20/2015,,7/20/2015,,,,,,,,,,,,,,,,,,,,10/23/2015,,10/21/2015,,,,,,,,,,,,12/16/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD602-1xn,SPD602-1xn,'SPD602-1xn,,,DDI Study with Metformin,SPD602-1xn DDI with Metformin,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,5/7/2015,,6/17/2015,,,,,,8/4/2015,,,,8/18/2015,,,,,,,,,,,,,,8/28/2015,,8/28/2015,,,,,,,,,,,,,,,,,,,,12/3/2015,,12/1/2015,,,,,,,,,,,,1/26/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD602-2xa,SPD602-2xa,'SPD602-2xa,,,Japanese Phase 2/3 combination,Jap Ph2/3 3 doses to 2 doses,II,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,52,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/10/2014,,4/21/2014,,,,,,9/8/2014,,,,10/12/2017,,,,,,,,,,,,,,11/15/2018,,11/15/2018,,,,,,,,,,,,,,,,,,,,1/7/2019,,2/11/2019,,,,,,,,,,,,4/8/2019,,,,,,,,,,,,,,,,,,,,,,,
SPD602-2xb,SPD602-2xb,'SPD602-2xb,,,Phase 2 Japan study with 75 enrolled,Jap Ph2 75 ppl,II,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,75,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/28/2013,,5/9/2013,,,,,,1/16/2014,,,,8/17/2015,,,,,,,,,,,,,,2/1/2016,,2/1/2016,,,,,,,,,,,,,,,,,,,,3/23/2016,,4/27/2016,,,,,,,,,,,,6/22/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD602-2xd,SPD602-2xd,'SPD602-2xd,,,Myelodysplastic Syndrome (MDS) Study,MDS Study,II,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Safety,,,200,0,0,0,0,0,0,0.00%,75,,,,Sharon Morriss,,,Alissa Sirbu,,,,,N,No,,,,COSMOS Inactive,,,10/12/2015,,12/7/2015,,,,,,5/27/2016,,,,8/25/2017,,,,,,,,,,,,,,7/27/2018,,7/27/2018,,,,,,,,,,,,,,,,,,,,8/31/2018,,9/21/2018,,,,,,,,,,,,11/16/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD602-2xf,SPD602-2xf,'SPD602-2xf,,,"Study to assess a single PK dose, and the safety, efficacy and acceptability of BID dosing of deferitazole in a 2 – 5 year old pediatric population using a sachet formulation.",Pediatric PK and chronic,IIa,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,8,0,0,0,0,0,0,0.00%,6,,,,Nigel Payne,,,,,,,,N,No,,,,COSMOS Inactive,,,7/1/2014,,1/12/2016,,,,,,5/31/2016,,,,5/30/2017,,,,,,,,,,,,,,5/1/2018,,5/1/2018,,,,,,,,,,,,,,,,,,,,6/11/2018,,7/2/2018,,,,,,,,,,,,8/13/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD602-3xa,SPD602-3xa,'SPD602-3xa,,,"A Phase 3, Randomized, Open Label, Multi-Center Study to Assess the Safety and Efficacy of SPD602 in the Treatment of Transfusional Iron Overload in Patients Requiring Chelation Therapy, with a Long Term Safety Extension",SPD602-3xa Ped,III,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,500,0,0,0,0,0,0,0.00%,125,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,3/20/2014,,10/14/2014,,,,,,3/13/2015,,,,12/18/2015,,,,,,,,,,,,,,11/18/2016,,11/18/2016,,,,,,,,,,,,,,,,,,,,12/23/2016,,1/13/2017,,,,,,,,,,,,3/10/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD602-3xb,SPD602-3xb,'SPD602-3xb,,,"A Phase 3, Randomized, Open Label, Multi-Center Comparator Study to Assess the Safety and Efficacy of FBS0701 versus ?? in the Treatment of Transfusional Iron Overload in Chelation Naïve Patients with",SPD602-3xb Adlt,III,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,465,0,0,0,0,0,0,0.00%,100,,,,Amy Harman,,,,,,,,N,No,,,,COSMOS Inactive,,,3/20/2014,,5/1/2014,,,,,,9/25/2014,,,,7/2/2015,,,,,,,,,,,,,,6/2/2016,,6/2/2016,,,,,,,,,,,,,,,,,,,,7/25/2016,,8/29/2016,,,,,,,,,,,,10/24/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD602-3xc,SPD602-3xc,'SPD602-3xc,,,Bthal Comparator trial with Exjade,BThal Study,III,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Comparator,,,516,0,0,0,0,0,0,0.00%,90,,,,,,,Alissa Sirbu,,,,,N,No,,,,COSMOS Inactive,,,11/16/2015,,1/11/2016,,,,,,5/27/2016,,,,5/12/2017,,,,,,,,,,,,,,4/13/2018,,4/13/2018,,,,,,,,,,,,,,,,,,,,5/18/2018,,6/8/2018,,,,,,,,,,,,8/3/2018,,,,,,,,,,,,,,,,,,,,,,,
SPD602-3xd,SPD602-3xd,'SPD602-3xd,,,Treatment of Iron Overload in subjects with Myelodysplastic Syndrom,,III,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,200,0,0,0,0,0,0,0.00%,63,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/19/2013,,1/30/2014,,,,,,9/11/2014,,,,8/13/2015,,,,,,,,,,,,,,7/14/2016,,7/14/2016,,,,,,,,,,,,,,,,,,,,9/5/2016,,10/10/2016,,,,,,,,,,,,12/5/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD602-3xe,SPD602-3xe,'SPD602-3xe,,,Japan MDS study with 150 subjects and 20 sites,,III,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,175,0,0,0,0,0,0,0.00%,20,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,11/13/2014,,12/25/2014,,,,,,8/27/2015,,,,10/29/2018,,,,,,,,,,,,,,9/30/2019,,9/30/2019,,,,,,,,,,,,,,,,,,,,11/20/2019,,12/25/2019,,,,,,,,,,,,2/19/2020,,,,,,,,,,,,,,,,,,,,,,,
SPD602-3xf,SPD602-3xf,'SPD602-3xf,,,Phase 3 Pediatric study,Pediatric study,III,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,100,0,0,0,0,0,0,0.00%,44,,,,,,,Alissa Sirbu,,,,,N,No,,,,COSMOS Inactive,,,3/1/2016,,6/20/2017,,,,,,11/10/2017,,,,7/13/2018,,,,,,,,,,,,,,6/14/2019,,6/14/2019,,,,,,,,,,,,,,,,,,,,7/23/2019,,8/13/2019,,,,,,,,,,,,10/8/2019,,,,,,,,,,,,,,,,,,,,,,,
SPD602-3xg,SPD602-3xg,'SPD602-3xg,,,DiNa Salt Long Term Safety Extension Study,DiNa Long Term Safety Extension Study,III,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Long-Term,,,900,0,0,0,0,0,0,0.00%,190,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD602-102,SPD602-102,'SPD602-102,,,"A Dose-Escalation Placebo-Controlled, Phase 1 Study in Healthy Human Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701",SPD602-102 Adlt,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,,,,31,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,9/13/2011,9/13/2011,,,1/31/2012,1/31/2012,,,,,,,,,,,,,2/4/2012,2/4/2012,2/4/2012,3/28/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD602-103,SPD602-103,'SPD602-103,,,"A Phase 1b, Open Label, Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetic Equivalency of  Two Formulations of FBS0701",SPD602-103 Adlt,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,,,,20,0,0,0,0,0,0,0.00%,1,,,,Rachael Grose-Hodge,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,4/17/2012,4/17/2012,,,4/17/2012,4/17/2012,,,,,,,,,,,,,5/5/2012,5/5/2012,5/5/2012,8/1/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD602-104,SPD602-104,'SPD602-104,,,"A Phase 1, Open-label, Single Dose Study of the Pharmacokinetics, Safety and Tolerability of SSP-004184 (FBS0701) in Subjects with Normal and Impaired Renal Function.",602-104 Renal Impairment Study,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Open Label,,,72,66,0,0,0,66,0,91.67%,2,,,,"Kimberly Minger, Ravi Duvvuri",,,"Antonia Coeshall, Jessica Kardish",,,,,N,No,,,,COSMOS Inactive,,,8/14/2012,8/14/2012,10/8/2012,10/8/2012,,,,,11/14/2012,11/14/2012,,,3/6/2013,3/6/2013,,,,,,,,,,,,,3/13/2013,3/10/2013,3/13/2013,5/8/2013,,,,,,,,,,,,,,,,,,,9/13/2013,9/6/2013,9/27/2013,9/18/2013,,,,,,,,,,,3/10/2014,3/10/2014,,,,,,,,,,,,,,,,,,,,,,
SPD602-105,SPD602-105,'SPD602-105,,,"A Phase 1, Open-label, Single Dose Study of the Pharmacokinetics, Safety and Tolerability of SSP-004184 in Subjects with Normal and Hepatic Impairment",602-105 Hep I Study,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Hepatic Impairment,,,48,43,0,0,0,43,0,89.58%,1,,,,"Dawn Harper, Ravi Duvvuri",,,"Antonia Coeshall, Jessica Kardish",,,,,N,No,,,,COSMOS Inactive,,,8/14/2012,8/14/2012,10/8/2012,10/8/2012,,,,,12/3/2012,12/4/2012,,,3/25/2013,3/25/2013,,,,,,,,,,,,,3/29/2013,3/29/2013,3/29/2013,5/24/2013,,,,,,,,,,,,,,,,,,,9/6/2013,9/6/2013,9/9/2013,9/4/2013,,,,,,,,,,,3/28/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD602-106,SPD602-106,'SPD602-106,,,"A Phase 1, Randomized, Double-blind, Parallel, Placebo-controlled Study to Evaluate the  Pharmacokinetics, Safety and Tolerability of Single Doses of SSP-004184 (FBS0701) in Japanese and Caucasian Healthy Adult Subjects",602-106 Japanese Bridging Study,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Double-Blind,,,36,36,0,0,0,36,0,100.00%,1,,,Discover Clinical Research LLC,Ravi Duvvuri,,,"Antonia Coeshall, Jessica Kardish",,,,,N,No,,,,COSMOS Inactive,,,7/16/2012,7/16/2012,8/31/2012,9/5/2012,,,,,11/28/2012,11/28/2012,,,1/22/2013,1/22/2013,,,,,,,,,,,,,1/31/2013,1/28/2013,1/31/2013,4/16/2013,,,,,,,,,,,,,,,,,,,,,8/14/2013,8/13/2013,,,,,,,,,,,1/28/2014,1/28/2014,,,,,,,,,,,,,,,,,,,,,,
SPD602-107,SPD602-107,'SPD602-107,,,Phase 1 taste panel for peds,phase 1 taste panel,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Healthy Volunteers,,,18,10,0,0,0,10,0,55.56%,1,,,,Jennifer Fetterolf,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,9/25/2012,9/25/2012,11/5/2012,11/5/2012,,,,,11/27/2012,11/27/2012,,,11/27/2012,11/27/2012,,,,,,,,,,,,,11/27/2012,11/27/2012,11/27/2012,1/11/2013,,,,,,,,,,,,,,,,,,,1/22/2013,1/22/2013,2/22/2013,2/14/2013,,,,,,,,,,,4/11/2013,4/11/2013,,,,,,,,,,,,,,,,,,,,,,
SPD602-108,SPD602-108,'SPD602-108,,,SPD602-108 Food Effect Study,Food Effect Study,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Food Effect,,,28,0,0,0,0,0,0,0.00%,1,,,,Jennifer Fetterolf,,,,,,,,N,No,,,,COSMOS Inactive,,,12/17/2012,12/18/2012,1/9/2015,,,,,,2/16/2015,,,,3/2/2015,,,,,,,,,,,,,,3/24/2015,,3/24/2015,,,,,,,,,,,,,,,,,,,,6/29/2015,,6/25/2015,,,,,,,,,,,,8/20/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD602-109,SPD602-109,'SPD602-109,,,SPD602-109 ADME Study,602-109 ADME Study,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,PK,,,6,6,24,0,18,6,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,12/17/2012,12/18/2012,3/11/2013,3/11/2013,,,,,5/22/2013,5/22/2013,,,5/22/2013,5/22/2013,,,,,,,,,,,,,6/3/2013,5/29/2013,6/3/2013,8/22/2013,,,,,,,,,,,,,,,,,,,1/7/2014,1/7/2014,10/11/2013,11/27/2013,,,,,,,,,,,3/14/2014,3/11/2014,,,,,,,,,,,,,,,,,,,,,,
SPD602-110,SPD602-110,'SPD602-110,,,tQTc Study,602-110 tQTc Study,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,PK,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,9/17/2015,,10/21/2015,,,,,,12/21/2015,,,,1/4/2016,,,,,,,,,,,,,,1/11/2016,,1/11/2016,,,,,,,,,,,,,,,,,,,,3/18/2016,,4/13/2016,,,,,,,,,,,,6/8/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD602-111,SPD602-111,'SPD602-111,,,"A Phase 1, Open-label, Randomised, Relative Bioavailability Study Comparing the Pharmacokinetics of the SPD602 Mg and DiNa Salts  Administered to Healthy Adult Subjects",602-111 Relative BA,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Bioavailability (BA),,,10,28,0,0,0,28,0,280.00%,1,,,PRA,,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,4/23/2013,4/23/2013,6/24/2013,6/27/2013,,,,,8/20/2013,8/20/2013,,,8/20/2013,8/21/2013,,,,,,,,,,,,,9/9/2013,9/7/2013,9/9/2013,10/18/2013,,,,,,,,,,,,,,,,,,,12/5/2013,10/15/2013,12/3/2013,11/26/2013,,,,,,,,,,,6/26/2014,6/25/2014,,,,,,,,,,,,,,,,,,,,,,
SPD602-112,SPD602-112,'SPD602-112,,,Relative BA (Mg capsules vs DiNa tablets vs DiNa sachet),Relative BA (Mg capsules vs DiNa tablets,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Bioavailability (BA),,,24,0,0,0,0,0,0,0.00%,1,1,,,"Kimberly Minger, Ronald Budhram",,,Alissa Sirbu,,,,,N,No,,,,COSMOS Inactive,,,10/22/2013,10/22/2013,1/10/2014,1/17/2014,,,,,2/28/2014,,,,2/28/2014,,,,,,,,,,,,,,3/19/2014,,3/19/2014,,,,,,,,,,,,,,,,,,,,6/11/2014,,6/13/2014,,,,,,,,,,,,8/8/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD602-113,SPD602-113,'SPD602-113,,,Pilot Food Effect Study,602-113 Pilot Fd Eff,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Crossover,,,8,9,0,0,0,9,1,112.50%,1,,,PRA,Janice Rowe,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,4/23/2013,4/23/2013,6/24/2013,6/27/2013,,,,,9/6/2013,9/6/2013,,,9/6/2013,9/13/2013,,,,,,,,,,,,,9/19/2013,9/20/2013,9/19/2013,10/22/2013,,,,,,,,,,,,,,,,,,,10/29/2013,10/29/2013,12/5/2013,11/27/2013,,,,,,,,,,,8/25/2014,9/3/2014,,,,,,,,,,,,,,,,,,,,,,
SPD602-114,SPD602-114,'SPD602-114,,,DDI Study with simvastatin,602-114 DDI with Simvastatin,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Drug Interaction,,,30,30,0,0,0,30,0,100.00%,1,,,PRA,,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,8/27/2013,8/27/2013,10/17/2013,10/24/2013,,,,,12/3/2013,12/3/2013,,,12/3/2013,12/3/2013,,,,,,,,,,,,,12/13/2013,12/13/2013,12/13/2013,2/7/2014,,,,,,,,,,,,,,,,,,,3/27/2014,4/25/2014,3/25/2014,4/7/2014,,,,,,,,,,,9/9/2014,9/12/2014,,,,,,,,,,,,,,,,,,,,,,
SPD602-115,SPD602-115,'SPD602-115,,,DDI Study with Ritonovir,602-115 DDI with Ritonovir,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,2/6/2015,,3/19/2015,,,,,,5/10/2015,,,,5/22/2015,,,,,,,,,,,,,,6/3/2015,,6/3/2015,,,,,,,,,,,,,,,,,,,,9/8/2015,,9/4/2015,,,,,,,,,,,,10/30/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD602-116,SPD602-116,'SPD602-116,,,DDI Study with Probenacid,602-116 DDI with Probenacid,I,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Drug Interaction,,,24,0,0,0,0,0,0,0.00%,1,,,,,,,Jessica Kardish,,,,,N,No,,,,COSMOS Inactive,,,3/6/2015,,3/27/2015,,,,,,5/13/2015,,,,5/27/2015,,,,,,,,,,,,,,6/8/2015,,6/8/2015,,,,,,,,,,,,,,,,,,,,9/11/2015,,9/9/2015,,,,,,,,,,,,11/4/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD602-117,SPD602-117,'SPD602-117,,,"A Phase 1, Randomized, Open-label, Crossover Study To Evaluate the Pharmacokinetic Interaction Between SSP-004184 (FBS0701) and Midazolam in Healthy Study Subjects",602-117 DDI with midazolam,I,Completed,Iron Chelation,,,Non-Registry,,Interventional,Drug Interaction,,,30,30,0,0,0,30,0,100.00%,1,,,PRA,,,,"Antonia Coeshall, Jessica Kardish",,,,,N,No,,,,COSMOS Inactive,,,8/27/2013,8/27/2013,10/29/2013,10/29/2013,,,,,12/12/2013,12/12/2013,,,12/22/2013,12/22/2013,,,,,,,,,,,,,12/27/2013,12/27/2013,12/27/2013,2/14/2014,,,,,,,,,,,,,,,,,,,4/25/2014,4/25/2014,4/30/2014,4/30/2014,,,,,,,,,,,9/22/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD602-201,SPD602-201,'SPD602-201,,,"A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, with a 72 Week Extension",602-201 Adlt,II,Completed,Iron Chelation,,,Non-Registry,,Interventional,,,,51,51,51,0,11,0,16,100.00%,9,,,ICON / MAPI / Paradigm,,,,,,2010-019645-25,,,N,No,,,,COSMOS Inactive,,,5/25/2010,5/25/2010,5/25/2010,5/25/2010,,,,,9/2/2010,9/2/2010,,,2/10/2011,11/24/2010,,,,,,,,,,,,,12/12/2012,12/13/2012,12/12/2012,2/12/2013,,,,,,,,,,,,,,,,,,,2/19/2013,2/19/2013,3/26/2013,3/26/2013,,,,,,,,,,,8/7/2013,8/3/2013,,,,,,,,,,,,,,,,,,,,,,
SPD602-202,SPD602-202,'SPD602-202,,,"A Phase 2 Open Label, Multi-Center Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy, and Tolerability of  SSP-004184 (FBS0701) in a Pediatric Population with Transfusional Iron Overload","602-202 Ped OL Mult dose, SD PK",II,Study Terminated,Iron Chelation,,,Non-Registry,,Interventional,,,,30,30,32,0,14,0,16,100.00%,7,9,,ICON / MAPI / Paradigm,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/12/2011,4/12/2011,,,,,9/13/2011,9/13/2011,,,1/31/2014,1/31/2014,,,,,,,,,,,,,5/13/2014,5/13/2014,5/13/2014,8/5/2014,,,,,,,,,,,,,,,,,,,,,11/26/2014,,,,,,,,,,,,4/6/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD602-203,SPD602-203,'SPD602-203,,,"A Phase 2, 24 wk randomized, open label, multi center study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of two FBS0701 doses in treatment of chronic iron overload requiring chelation therapy",602-203 Adlt Rand OL,II,Study Terminated,Iron Chelation,,,Non-Registry,,Interventional,,,,50,32,64,4,65,6,27,64.00%,9,20,,ICON / MAPI / Paradigm,,,,,,,,,N,No,,,,COSMOS Inactive,,,10/31/2011,10/31/2011,12/12/2011,12/12/2011,,,,,10/23/2012,10/23/2012,,,2/24/2014,2/24/2014,,,,,,,,,,,,,4/18/2014,4/18/2014,4/18/2014,8/27/2014,,,,,,,,,,,,,,,,,,,,,12/15/2014,,,,,,,,,,,,4/14/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD602-204,SPD602-204,'SPD602-204,,,"A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory
Study to Assess Liver Iron Concentration Measured by FerriScan® (R2)
Magnetic Resonance Imaging in beta-thalassemia Subjects Administered
SPD602 (SSP-004184AQ) or Exjade® (deferasirox) for Treatment of
Chronic Transfusional Iron Overload",602-204 Adlt OL Comparator,II,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Comparator,,,50,0,0,0,0,0,0,0.00%,43,28,,ICON / MAPI / Paradigm,,,,,,2013-000743-33,,,N,No,,,,COSMOS Inactive,,,4/15/2013,4/15/2013,6/6/2013,6/6/2013,,,,,11/20/2014,,,,4/20/2015,,,,,,,,,,,,,,10/5/2015,,10/5/2015,,,,,,,,,,,,,,,,,,,,11/10/2015,,11/24/2015,,,,,,,,,,,,1/19/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD602-205,SPD602-205,'SPD602-205,,,Sickle Cell Disease (SCD) Study,SCD Study,II,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,Comparator,,,150,0,0,0,0,0,0,0.00%,35,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,7/10/2013,10/23/2013,1/11/2016,,,,,,5/27/2016,,,,6/22/2018,,,,,,,,,,,,,,5/24/2019,,5/24/2019,,,,,,,,,,,,,,,,,,,,6/28/2019,,7/19/2019,,,,,,,,,,,,9/13/2019,,,,,,,,,,,,,,,,,,,,,,,
SPD602-301,SPD602-301,'SPD602-301,,,"A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)",602-301 Ped Adlsc Adlt multi-centre OL,III,Study Terminated,Iron Chelation,,,Non-Registry,,Interventional,Adolescent,,,"1,500",30,30,0,0,30,0,2.00%,140,,,IQVIA,,"Kuo-Mei Chen, Svetlana Garafola",,,,2011-006322-25,,,N,No,,,,COSMOS Inactive,,,5/1/2012,5/1/2012,5/1/2012,5/1/2012,,,,,8/21/2012,8/21/2012,,,1/13/2014,1/13/2014,,,,,,,,,,,,,5/12/2014,5/12/2014,5/12/2014,8/28/2014,,,,,,,,,,,,,,,,,,,,,2/27/2015,,,,,,,,,,,,5/20/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD602-401,SPD602-401,'SPD602-401,,,Phase 2 study with 2 BID 602 doses and exjade,Phase 4 studies with exjade,II,Study Withdrawn,Iron Chelation,,,Non-Registry,,Interventional,,,,80,0,0,0,0,0,0,0.00%,36,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/9/2013,,1/22/2013,,,,,,6/25/2013,,,,9/24/2013,,,,,,,,,,,,,,3/11/2014,,3/11/2014,,,,,,,,,,,,,,,,,,,,4/17/2014,,5/1/2014,,,,,,,,,,,,6/26/2014,,,,,,,,,,,,,,,,,,,,,,,
SPD604-101,SPD604-101,'SPD604-101,,,SPD601-101 SAD-MAD,604-101 SAD-MAD,I,Study Withdrawn,,,,Non-Registry,,Interventional,Healthy Volunteers,,,60,0,0,0,0,0,0,0.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,6/20/2014,,8/1/2014,,,,,,10/6/2014,,,,12/29/2014,,,,,,,,,,,,,,1/26/2015,,1/26/2015,,,,,,,,,,,,,,,,,,,,5/1/2015,,4/29/2015,,,,,,,,,,,,6/24/2015,,,,,,,,,,,,,,,,,,,,,,,
SPD605-1xa,SPD605-1xa,'SPD605-1xa,,,SPD605-1xa antibiotic DDI,605-1xa antibiotic DDI,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Crossover,,,24,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,2/24/2017,,4/7/2017,,,,,,6/14/2017,,,,6/28/2017,,,,,,,,,,,,,,7/26/2017,,7/26/2017,,,,,,,,,,,,,,,,,,,,10/31/2017,,10/27/2017,,,,,,,,,,,,12/22/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD605-1xb,SPD605-1xb,'SPD605-1xb,,,SPD605-1xb ADME study,605-1xb ADME,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,6,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,3/21/2017,,5/2/2017,,,,,,7/7/2017,,,,7/10/2017,,,,,,,,,,,,,,7/28/2017,,7/28/2017,,,,,,,,,,,,,,,,,,,,11/2/2017,,10/31/2017,,,,,,,,,,,,12/26/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD605-1xc,SPD605-1xc,'SPD605-1xc,,,SPD605-1xc Intellisite study,SPD605-1xc intellisite,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,12,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,2/18/2015,,4/21/2015,,,,,,6/24/2015,,,,8/5/2015,,,,,,,,,,,,,,9/2/2015,,9/2/2015,,,,,,,,,,,,,,,,,,,,12/8/2015,,12/4/2015,,,,,,,,,,,,1/29/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD605-1xh,SPD605-1xh,'SPD605-1xh,,,SPD605-1xh Ped PK,605-1xd Ped PK,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,PK,,,20,0,0,0,0,0,0,0.00%,2,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/18/2016,,3/4/2016,,,,,,5/11/2016,,,,8/17/2016,,,,,,,,,,,,,,9/14/2016,,9/14/2016,,,,,,,,,,,,,,,,,,,,12/20/2016,,12/16/2016,,,,,,,,,,,,2/10/2017,,,,,,,,,,,,,,,,,,,,,,,
SPD605-101,SPD605-101,'SPD605-101,,,SPD605 SAD study,605-101 FIM,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,First In Man (FIM),,,24,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,2/20/2015,,4/10/2015,,,,,,7/31/2015,,,,8/28/2015,,,,,,,,,,,,,,9/4/2015,,9/4/2015,,,,,,,,,,,,,,,,,,,,12/10/2015,,12/8/2015,,,,,,,,,,,,2/2/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD605-102,SPD605-102,'SPD605-102,,,SPD605-102,605-102 MAD,I,Study Withdrawn,ADHD,,,Non-Registry,,Interventional,Healthy Volunteers,,,48,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,Dan Sea,,,,,N,No,,,,COSMOS Inactive,,,7/24/2015,,9/25/2015,,,,,,11/30/2015,,,,1/25/2016,,,,,,,,,,,,,,2/12/2016,,2/12/2016,,,,,,,,,,,,,,,,,,,,5/19/2016,,5/17/2016,,,,,,,,,,,,7/12/2016,,,,,,,,,,,,,,,,,,,,,,,
SPD606-301,SPD606-301,'SPD606-301,,,"Phase 3, multi-center, randomized, double-masked, and PBO controlled study evaluating the efficacy of SAR1118 ophthalmic solution compared to placebo in subjects with dry eye (OPUS-1)",OPUS-1 SARcode 1118-KCS-200,III,Completed,Dry eye,,,Non-Registry,,Interventional,Double-Blind,,,588,0,0,0,0,0,0,0.00%,20,,,,,,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,5/27/2011,5/27/2011,5/27/2011,5/27/2011,,,,,9/14/2011,9/14/2011,,,1/21/2012,1/21/2012,,,,,,,,,,,,,4/16/2012,4/16/2012,4/16/2012,5/9/2012,,,,,,,,,,,,,,,,,,,5/11/2012,5/11/2012,9/27/2013,10/1/2013,,,,,,,,,,,12/2/2013,12/2/2013,,,,,,,,,,,,,,,,,,,,,,
SPD606-302,SPD606-302,'SPD606-302,,Xiidra (lifitegrast opthalmic solution),"Phase 3, multicenter, randomized, double-masked, and pbo controlled study evaluating the efficacy of Lifitegrast ophthalmic solution compared with placebo in subjects with dry eye currently using artificial tears",OPUS-2 SARcode 1118-DRY-300,III,Completed,Dry eye,Others,,Non-Registry,,Interventional,Double-Blind,,,700,0,0,0,0,0,0,0.00%,20,,,,,,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/11/2014,3/11/2014,,,,,,
SPD606-303,SPD606-303,'SPD606-303,,Xiidra (lifitegrast opthalmic solution),"Phase 3, Multicenter, Double-Masked, PBO-Controlled Study Evaluating the Safety of Lifitegrast Ophthalmic Solution in Subjects with Dry Eye",SONATA SARcode 1118-DRY-400,III,Completed,Dry eye,Others,,Non-Registry,,Interventional,Tolerability,,,300,0,0,0,0,0,0,0.00%,15,,,,,,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD624-1xa,SPD624-1xa,'SPD624-1xa,,,"A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects with Severe Hemophilia B",SPD624-1xa OL SAD,I,Study Withdrawn,Hemophilia B,,,Non-Registry,,Interventional,Single Dose,,,18,0,0,0,0,0,0,0.00%,10,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SPD754-201,SPD754-201,'SPD754-201,,,SPD754,,II,Legacy,,,,Non-Registry,,Interventional,,,,32,0,0,0,0,,0,0.00%,89,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SSP1074A-101,SSP1074A-101,'SSP1074A-101,,,"A Phase I, 5-Period, Randomised, Double-Blind Crossover Study to Investigate the Pharmacokinetics and Therapeutic Effects of Oxycodone Compared to Morphine and  Placebo in Healthy Volunteers",SSP1074A-101 oxycodone cold pain model,I,Completed,Pain,,,Non-Registry,,Interventional,Crossover,,,20,0,0,0,0,0,0,0.00%,1,,,,Kerry Dennis,,,"Alison McMorn, Antonia Coeshall",,,,,N,No,,,,COSMOS Inactive,,,9/9/2009,9/4/2009,4/2/2010,4/8/2010,,,,,6/14/2010,6/14/2010,,,6/21/2010,6/25/2010,,,,,,,,,,,,,7/23/2010,7/23/2010,7/23/2010,9/15/2010,,,,,,,,,,,,,,,,,,,10/12/2010,10/26/2010,11/16/2010,11/8/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SSP1104R-001,SSP1104R-001,'SSP1104R-001,,,"A Phase I, Single Oral Micro-Dose,  Pharmacokinetic Study in Healthy Male Subjects",SSP1104R-0xa microdose,0,Completed,Pain,,,Non-Registry,,Interventional,Crossover,,,12,12,45,0,33,12,0,100.00%,1,,,,Kerry Dennis,,,Alison McMorn,,,,,N,No,,,,COSMOS Inactive,,,11/26/2009,11/6/2009,2/17/2010,2/17/2010,,,,,4/20/2010,4/20/2010,,,4/20/2010,4/20/2010,,,,,,,,,,,,,4/30/2010,4/27/2010,4/30/2010,6/10/2010,,,,,,,,,,,,,,,,,,,5/31/2010,5/5/2010,5/26/2010,7/16/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SSP-1228-001,SSP-1228-001,'SSP-1228-001,,,"Phase 0, Single Oral Dose Microdosing Study of SSP1228  in Healthy Adult Volunteers",SSP-1228-001 Microdose,0,Completed,ADHD,,,Non-Registry,Non-pediatric only (>18 yr),Non-Interventional_CDO Support,Healthy Volunteers,,,12,0,0,0,0,0,0,0.00%,1,,,Covance,Anthony Robinson,,,Amy Manley,,,,,N,No,,,,COSMOS Inactive,,,3/17/2010,3/17/2010,6/15/2010,6/15/2010,,,,,8/3/2010,8/3/2010,,,8/3/2010,8/3/2010,,,,,,,,,,,,,8/12/2010,8/12/2010,8/12/2010,9/28/2010,,,,,,,,,,,,,,,,,,,8/26/2010,8/26/2010,10/19/2010,10/19/2010,,,,,,,,,,,12/16/2010,12/16/2010,,,,,,,,,,,,,,,,,,,,,,
SSP-1252-001,SSP-1252-001,'SSP-1252-001,,,"A Phase 0, Single Oral Doses Microdosing Study in Healthy Adult Volunteers",SSP-1252-001 Microdose,0,Completed,ADHD,,,Non-Registry,,Non-Interventional_CDO Support,Crossover,,,12,12,0,0,0,0,0,100.00%,1,,,Aptuit INC,Mary Haffey,,,,,,,,N,No,,,,COSMOS Inactive,,,10/29/2009,10/22/2009,12/7/2009,12/11/2009,,,,,2/9/2010,2/9/2010,,,2/9/2010,2/9/2010,,,,,,,,,,,,,2/19/2010,2/19/2010,2/19/2010,3/17/2010,,,,,,,,,,,,,,,,,,,4/2/2010,3/4/2010,4/7/2010,4/13/2010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-073-1501,TAK-073-1501,'TAK-073-1501,,TAK-073 Hunter Gene Therapy,"An Open-label, Multi-center, First-in-Human Study of TAK-073, an Adeno Associated Virus Serotype 8 Vector Expressing Iduronate-2-Sulfatase, to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adult Subjects with Mucopolysaccharidosis Type II",First in patient trial in Hunter Syndrom,I/II,Withdrawn,Hunter Syndrome treatment of somatic symptoms,RGH,,,,Interventional,,,,8,,,,,,,,10,,,PPD,,Olivia Sahnas,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,1/6/2021,1/6/2021,2/26/2021,2/26/2021,,,12/8/2025,,12/8/2025,,,,12/8/2025,,,,2/15/2029,,,,,,,,,,,,3/15/2029,,,,,,,,,,3/30/2029,,,,,,,,,,,,,,,,,,,,,,,,7/16/2029,,,,,,,,,,,,,,,,7/16/2029,,,,,,,
TAK-073-2001,TAK-073-2001,'TAK-073-2001,,TAK-073 Hunter Gene Therapy,Hunter Syndrom long-term safety follow up,Hunter Syndrom longterm safety follow up,I/II,Cancelled,Hunter Syndrome treatment of somatic symptoms,RGH,,,,Interventional,,,,15,,,,,,,,5,,,TBD,,Olivia Sahnas,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-073-2002,TAK-073-2002,'TAK-073-2002,,TAK-073 Hunter Gene Therapy,Hunter Syndrome Natural History/Control Study (TBD),Hunter Syndrome Natural History,N/A,Cancelled,Hunter Syndrome treatment of somatic symptoms,RGH,,,Both pediatric and non-pediatric,Interventional,,,,20,,,,,,,,15,,,TBD,,,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,11/30/2025,,1/30/2026,,,,7/29/2026,,7/29/2026,,,,7/29/2026,,,,8/31/2027,,,,,,,,,,,,10/5/2027,,,,,,,,,,10/19/2027,,,,,,,,,,,,,,,,,,,,,,,,1/25/2028,,,,,,,,,,,,,,,,1/25/2028,,,,,,,
TAK-079-1006,TAK-079-1006,'TAK-079-1006,,Mezagitamab (TAK-079),TBD,TAK-079-1006 TBD,I,Planned,,RGH,RGH,,Non-pediatric only (>18 yr),,Treatment,,,12,,,,,,,,12,,,TBD,,Rachel Mccomb,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,1/17/2022,,,,,,7/26/2022,,,,4/28/2023,,,,1/29/2026,,,,,,,,,,,,3/26/2026,,,,,,,,,,4/2/2026,,,,,,,,,,,,,,4/23/2026,,,,,,,,,,8/13/2026,,,,,,,,,,,,,,,,8/13/2026,,,,,,,
TAK-330-2001,TAK-330-2001,'TAK-330-2001,,TAK-330 Prothromplex,TAK-330 Prothromplex Phase 2/3 PDT,TAK-330 Phase 2/3 Study,II/III,Planned,,Plasma Derived Therapy,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/30/2021,6/30/2021,8/8/2022,,,,8/11/2022,,8/12/2022,,,,8/15/2022,,,,12/11/2024,,,,,,,,,,,,12/12/2024,,,,,,,,,,12/13/2024,,,,,,,,,,,,,,12/16/2024,,,,,,,,,,12/17/2024,,,,,,,,,,,,,,,,12/17/2024,,,,,,,
TAK-330-3001,TAK-330-3001,'TAK-330-3001,,TAK-330 Prothromplex,"A Phase 3, Prospective, Randomized, Open Label, Multicentre Trial to Assess the Efficacy and Safety of Prothromplex Total, a Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Factor Xa Inhibitor Induced Anticoagulation in Patients Requiring Urgent Surgery/Invasive Procedure",TAK-330 Phase 3 Study,III,Planned,,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Interventional,Treatment,,,250,,,,,,,,47,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/30/2021,6/30/2021,8/2/2021,,,,2/2/2022,,2/3/2022,,,,12/7/2022,,,,1/11/2023,,,,,,,,,,,,3/30/2023,,,,,,,,,,4/10/2023,,,,,,,,,,,,,,6/8/2023,,,,,,,,,,7/20/2023,,,,,,,,,,,,,,,,12/17/2024,,,,,,,
TAK-555-3010,TAK-555-3010,'TAK-555-3010,,Motegrity (Prucalopride),"TBD: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Determine the Efficacy and Safety of 2 Different Prucalopride Doses Administered Orally for 12 Weeks to Children and Adolescents, Aged 6 Months to <18 Years, who Fulfill Modified Rome IV Criteria for Child/Adolescent Functional Constipation",Phase 3 Prucalopride-Pediatrics,III,Recruiting,Delay in progression of atherosclerosis with Type 2 diabetes,Others,Marketed Products,,Pediatric only (<18 yr),Interventional,Treatment,,,255,,,,,,,,50,,,IQVIA,,"Paula Boutwell, Tangela Williams",Andre Gabriel,,,N/A,,,,,,,,Medidata CTMS (Pharma),,,8/30/2019,8/30/2019,10/21/2020,10/21/2020,,,6/25/2021,6/25/2021,7/13/2021,,,,11/1/2024,,,,11/19/2025,,,,,,,,,,,,1/14/2026,,,,,,,,,,1/28/2026,,,,,,,,,,,,,,3/27/2026,,,,,,,,,,5/19/2026,,,,,,,,,,,,,,,,5/19/2026,,,,,,,
TAK-555-4006,TAK-555-4006,'TAK-555-4006,,,"A Breast Milk Study in Lactating Women who have been Prescribed Therapeutic Doses of Motgrity (prucalopride) for Chronic Idiopathic Constipation to Evaluate Prucalopride Concentrations in Breast Mild and Breast Milk Composition, and to Collect Incidental Safety Data from the Nursing Infant",Prucalopride Lactation Study,IV,Not Yet Recruiting,,,Marketed Products,,Both pediatric and non-pediatric,Observational,,,,12,,,,,,,,999,,,TBD,,Paula Boutwell,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-555-5001,TAK-555-5001,'TAK-555-5001,,,Prucalopride Pregnancy Exposure Study: A VAMPSS Post-Marketing Surveillance Study of Prucalopride Safety in Pregnancy,Prucalopride Pregnancy Study (VAMPSS),IV,Study Terminated,Chronic Constipation,,,Non-Registry,,Non-Intervention_Other Support,,,,616,,,,,,,,999,,,,Lynn Sanders,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/31/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/20/2026,,,,,,,,,,,,2/10/2027,,,,,,,,,,,,,,,,,,,,,,,
TAK-577-3001,TAK-577-3001,'TAK-577-3001,,Vonvendi (von Willebrand factor (recombinant)),"A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD)",rVWF Pediatric Prophylaxis Study,III,Planned,Von Willebrand Disease,RGH,,,Pediatric only (<18 yr),Interventional,,,,19,,,,,,,,55,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,3/27/2020,3/27/2020,9/30/2021,,,,9/30/2022,,12/30/2022,,,,12/30/2024,,,,12/25/2025,,,,,,,,,,,,2/9/2026,,,,,,,,,,2/16/2026,,,,,,,,,,,,,,,,,,,,,,,,5/12/2026,,,,,,,,,,,,,,,,12/3/2027,,,,,,,
TAK-577-3002,TAK-577-3002,'TAK-577-3002,,Vonvendi (von Willebrand factor (recombinant)),"A clinical study to evaluate the efficacy, safety and pharmacokinetics of rVWF with or without ADVATE in the treatment of bleeding episodes in Chinese subjects diagnosed with von Willebrand Disease",Vonvendi China PAC Study,III,Concept,Support - Rare Diseases,RGH,,,,Interventional,,,,8,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,12/31/2024,,,,,,9/30/2025,,,,2/1/2027,,,,1/31/2028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/31/2028,,,,,,,,,,,,,,,,7/31/2028,,,,,,,
TAK-620-1019,TAK-620-1019,'TAK-620-1019,'SHP620-119,maribavir (TAK-620),"A Phase 1, Open-label, Randomized,  Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Subjects","A Phase 1, Open-label, Randomized, Cross",I,Study Terminated,CMV Treatment,RGH,RGH,Non-Registry,Non-pediatric only (>18 yr),Interventional,Food Effect,,,38,,,,,,,,1,,Shire,PPD,Andrew Putney,,Katarina Ilic,"Martha Fournier, Obi Umeh","Merri Carpenter, Sophie Fitzhugh",,,,N,No,,,,COSMOS Inactive,,,6/25/2019,6/25/2019,7/24/2019,7/24/2019,,,10/18/2019,10/18/2019,11/15/2019,11/15/2019,,,,,,,11/25/2019,11/25/2019,,,,,,,,,,,3/3/2020,3/3/2020,,,,,,,,,,,,,,,,,,,,,,,3/17/2020,3/17/2020,,,,,,,,,6/23/2020,6/23/2020,,,,,,,,,,,,,,,6/23/2020,6/23/2020,,,,,,
TAK-620-1020,TAK-620-1020,'TAK-620-1020,,maribavir (TAK-620),"A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Subjects Compared with Matched, Healthy, Non-Hispanic, Caucasian Subjects and to Assess Dose-Proportionality of 3 Doses of Maribavir in the Japanese Subjects",TAK-620-1020 Japanese Bridging Study,I,Reported,Supportive treatment in surgery,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,Treatment,Other,Case-Crossover,24,24,0,,0,0,0,100.00%,1,1,,TBD,,Erin Hefner,Katarina Ilic,,,,,Approved,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,2/13/2020,2/13/2020,4/8/2020,4/8/2020,,,8/7/2020,8/7/2020,8/20/2020,8/20/2020,,,11/6/2020,11/6/2020,,,11/11/2020,11/11/2020,,,,,,,,,,,12/15/2021,12/15/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/5/2021,3/5/2021,,,,,,,,,,,,,,,12/15/2021,12/15/2021,,,,,,
TAK-620-1021,TAK-620-1021,'TAK-620-1021,,maribavir (TAK-620),An Open-Label Sensory Evaluation of Maribavir in Healthy Panelists,SHP620-118 Taste Assessment,I,Planned,Post-Transplant CMV,RGH,,,,Interventional,,,,25,6,6,,,,,24.00%,1,,,TBD,,Rhett Behrje,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,1/12/2021,1/12/2021,,,4/21/2021,4/21/2021,4/21/2021,4/21/2021,,,10/25/2021,,,,11/8/2021,,,,,,,,,,,,12/6/2021,,,,,,,,,,,,,,,,,,,,,,,,1/3/2022,,,,,,,,,,3/14/2022,,,,,,,,,,,,,,,,3/14/2022,,,,,,,
TAK-620-1022,TAK-620-1022,'TAK-620-1022,,maribavir (TAK-620),Drug-drug interaction trial of Maribavir vs Statins in Healthy Adults,DDI with Statins,I,Planned,Post-Transplant CMV,RGH,,,,Interventional,,,,64,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,3/18/2022,,4/29/2022,,,,,,7/1/2022,,,,9/2/2022,,,,10/28/2022,,,,,,,,,,,,12/9/2022,,,,,,,,,,12/23/2022,,,,,,,,,,,,,,2/3/2023,,,,,,,,,,3/31/2023,,,,,,,,,,,,,,,,4/28/2023,,,,,,,
TAK-620-1023,TAK-620-1023,'TAK-620-1023,,maribavir (TAK-620),"A Phase 1, Open label, Randomized, Three-period, Three-treatment Crossover Study Comparing the Relative Bioavailability of Three Tablet  Formulations of Maribavir in Healthy Adults",3 Period cross-over rBA in HV,I,Cancelled,Post-Transplant CMV,RGH,,,,Interventional,,,,36,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-620-1024,TAK-620-1024,'TAK-620-1024,,maribavir (TAK-620),"Pediatric dose formulation relative bioavailability, drug-drug interaction and food effect trial of Maribavir in Healthy Adults","Pediatric dose form rBA, DDi, and FE",I,Planned,Post-Transplant CMV,RGH,,,Non-pediatric only (>18 yr),Interventional,,,,64,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,8/5/2022,,9/16/2022,,,,,,3/7/2023,,,,5/30/2023,,,,7/11/2023,,,,,,,,,,,,8/22/2023,,,,,,,,,,9/5/2023,,,,,,,,,,,,,,10/17/2023,,,,,,,,,,12/12/2023,,,,,,,,,,,,,,,,1/9/2024,,,,,,,
TAK-620-2004,TAK-620-2004,'TAK-620-2004,,maribavir (TAK-620),": A Phase 2, open-label, single-arm, study to evaluate the safety and tolerability, pharmacokinetics, and efficacy of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents from birth to less than 18 years of age who have received a hematopoietic stem cell transplant (HSCT)",Pediatric phase 2,II,Planned,Post-Transplant CMV,RGH,,,,Interventional,,,,80,,,,,,,,40,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,,,9/30/2021,,,,,,3/31/2022,,,,9/30/2024,,,,12/31/2024,,,,,,,,,,,,1/15/2025,,,,,,,,,,,,,,,,,,,,,,,,2/14/2025,,,,,,,,,,5/15/2025,,,,,,,,,,,,,,,,5/15/2025,,,,,,,
TAK-633-1001,TAK-633-1001,'TAK-633-1001,,Gattex (teduglutide),"A Randomized, Two-treatment, Two-period, Crossover study to Evaluate BA of Teduglutide Administered by SC injection from the approved vial and a proposed new pen injector in Healthy Volunteers",Evaluate BA of Teduglutide,I,Not Yet Recruiting,Short bowel syndrome,GI,Marketed Products,,Non-pediatric only (>18 yr),Interventional,,,,64,0,127,,0,0,0,0.00%,1,1,,Celerion,,Anne Crissey,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,9/14/2020,9/14/2020,,,4/19/2021,4/19/2021,5/13/2021,5/13/2021,,,7/2/2021,7/2/2021,,,7/16/2021,,,,,,,,,,,,8/20/2021,,,,,,,,,,9/3/2021,,,,,,,,,,,,,,,,,,,,,,,,11/5/2021,,,,,,,,,,,,,,,,11/5/2021,,,,,,,
TAK-633-1501,TAK-633-1501,'TAK-633-1501,,,"A Randomized, Two-treatment, Two-period, Crossover study to Evaluate BA of Teduglutide Administered by SC injection from the approved vial and a proposed new pen injector in Healthy Volunteers",Evaluate BA of Teduglutide,I/II,Study Withdrawn,Short Bowel Syndrome,,,Non-Registry,,Interventional,,,,999,0,0,0,0,0,0,0.00%,999,,,Study Withdrawn,,,,,,,,,N,No,,,,COSMOS Inactive,,,1/1/2049,,1/1/2049,,1/1/2049,,,,1/1/2049,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,1/1/2049,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
TAK-633-3009,TAK-633-3009,'TAK-633-3009,,Gattex (teduglutide),"TAK-633-3009 An Open-label, 24-Week, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetic of 0.05 mg/kg/day SC Teduglutide in the Treatment of Chinese Adult Subjects with Short Bowel Syndrome (SBS) who are Dependent on Parenteral Nutrition (PN)",TAK-633-3009 24W Chinese Adult Study,III,Planned,,GI,,,,Interventional,,,,13,,,,,,,,2,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,6/28/2024,,,,1/27/2025,,5/26/2025,,,,9/28/2026,,,,4/29/2027,,,,,,,,,,,,6/14/2027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/24/2027,,,,,,,,,,,,,,,,12/24/2027,,,,,,,
TAK-660-403,TAK-660-403,'TAK-660-403,,Adynovate (Antihemophilic Factor (Recombinant) PEGylated),"Evaluation of long-term safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, rurioctocog alfa pegol) in patients with haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)",TAK-660-403_PASS,IV,Recruiting,Sjogren's syndrom,RGH,Real World Evidence,,Both pediatric and non-pediatric,Observational,Other,Prospective,Other,200,33,1,,0,0,,16.50%,40,33,,IQVIA,,Ali Aslan,,,,EUPAS35698 - NCT04158934,,,,,,,,Medidata CTMS (Pharma),,,11/26/2018,11/26/2018,4/17/2020,4/17/2020,,,7/9/2020,7/9/2020,7/9/2020,7/9/2020,,,1/21/2022,,,,10/18/2028,,,,,,,,,,,,11/15/2028,,,,,,,,,,11/22/2028,,,,,,,,,,,,,,1/12/2029,,,,,,,,,,3/12/2029,,,,,,,,,,,,,,,,3/12/2029,,,,,,,
TAK-664-3001,TAK-664-3001,'TAK-664-3001,,CUVITRU,"A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Efficacy, and Safety and Tolerability of IGSC, 20% Immune Globulin Subcutaneous (Human) (IGSC), 20% in Japanese Subjects with Primary Immunodeficiency Diseases",TAK-664-3001 Japan PID,III,Recruitment Complete,Support - Plasma Derived Therapy,Plasma Derived Therapy,PDT,,Both pediatric and non-pediatric,Interventional,,,,16,15,20,3,4,,1,93.75%,8,,,IQVIA,,Tetsuharu Hori,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,9/28/2019,9/28/2019,,,,,8/11/2020,8/11/2020,,,2/18/2021,2/18/2021,,,1/27/2022,,,,,,,,,,,,,,,,,,,,,,4/27/2022,,,,,,,,,,,,,,,,,,,,,,,,9/30/2022,,,,,,,,,,,,,,,,9/30/2022,,,,,,,
TAK-665-4003,TAK-665-4003,'TAK-665-4003,,Elaprase (idursulfase),"An open-label, multicenter, phase 4 study to assess the effects of prophylactic and therapeutic immune tolerizing regimens in 2 groups of MPS II patients receiving Elaprase who are at risk for developing persistent neutralizing antibodies",ELAPRASE Immune Tolerizing Study,IV,Planned,Hunter Syndrome treatment of somatic symptoms,RGH,Marketed Products,,,Interventional,,,,10,,,,,,,,10,,,PPD,,"Kerri Whyte, Christy Saulters",,,,,,,,,,,,Medidata CTMS (Pharma),,,,,6/30/2021,,,,,,2/15/2022,,,,2/13/2024,,,,7/7/2026,,,,,,,,,,,,9/1/2026,,,,,,,,,,9/29/2026,,,,,,,,,,,,,,,,,,,,,,,,2/16/2027,,,,,,,,,,,,,,,,2/16/2027,,,,,,,
TAK-667-4001,TAK-667-4001,'TAK-667-4001,,Firazyr (Icatibant),TBD,Firazyr China PAC Study,III,Concept,Hereditary Angioedema,RGH,Marketed Products,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,1/30/2022,,,,,,10/30/2022,,,,2/28/2024,,,,5/30/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/30/2024,,,,,,,,,,,,,,,,11/30/2024,,,,,,,
TAK-669-3001,TAK-669-3001,'TAK-669-3001,,VPRIV (velaglucerase alfa),TBD,Vpriv China PAC Study,III,Planned,Gaucher's,RGH,Marketed Products,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,10/29/2021,,,,,,8/23/2022,,,,10/30/2023,,,,11/29/2024,,,,,,,,,,,,12/24/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/24/2025,,,,,,,,,,,,,,,,3/28/2024,,,,,,,
TAK-670-3002,TAK-670-3002,'TAK-670-3002,"'SHP670-302, TAK-883-3001",GLASSIA,"A Prospective, Randomized, Double-Blind, Parallel Group Study to
Evaluate the Safety and Efficacy of ARALAST NP 60 mg/kg and
120 mg/kg for Alpha-1 Proteinase Inhibitor (A1PI) Augmentation
Therapy in Subjects with A1PI Deficiency and Chronic Obstructive
Pulmonary Disease-Emphysema (COPD-E)",ARALAST NP Alpha-1 Lung Density COPD-E S,IIIb,Study Withdrawn,Alpha-1 antitrypsin deficiency,Plasma Derived Therapy,PDT,Non-Registry,Non-pediatric only (>18 yr),Interventional,Randomized,,,142,,,,,,,,70,,,IQVIA,Salvador Dominguez,,,,,,Not Available,,N,No,,,,COSMOS Inactive,12-Sep-25,,8/30/2019,4/24/2020,10/15/2019,4/24/2020,3/1/2021,,,,3/29/2021,,3/8/2021,,9/15/2023,,,,,,,,,,,,,,9/12/2025,,9/12/2025,,,,,,,,,,,,,,,,,,,,1/10/2026,,1/10/2026,,,,,,,,,,,,3/26/2026,,,,,,,,,,,,,,,,,,1/15/2020,,1/15/2020,,,
TAK-670-3003,TAK-670-3003,'TAK-670-3003,,,Aralast PMC Efficacy study,Aralast PMC Efficacy study,IIIb,Concept,,,,,Non-pediatric only (>18 yr),Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-670-4001,TAK-670-4001,'TAK-670-4001,,GLASSIA,Glassia Post Marketing Commitment Human Factors Evaluation - Usability Study,TAK-670-4001 Human Factors Evaluation,N/A,Planned,Alpha1-Antitrypsin Deficient Emphysema,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Observational,,,,50,,,,,,,,5,,,TBD,,Frederick Houghton,,,,,,,,,,,,Medidata CTMS (Pharma),,,6/17/2022,,6/17/2022,,,,6/20/2022,,6/20/2022,,,,10/7/2022,,,,10/7/2022,,,,,,,,,,,,10/7/2022,,,,,,,,,,10/7/2022,,,,,,,,,,,,,,,,,,,,,,,,10/31/2022,,,,,,,,,,,,,,,,10/31/2022,,,,,,,
TAK-672-3001,TAK-672-3001,'TAK-672-3001,,Obizur (antihemophilic factor [recombinant] porcine sequence),TBD,TBD - Japanese Registration Trial,III,Planned,,RGH,,,,Observational,,,,5,0,1,,0,0,,0.00%,5,,,IQVIA,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-672-3002,TAK-672-3002,'TAK-672-3002,,Obizur (antihemophilic factor [recombinant] porcine sequence),"A multicenter clinical trial to Evaluate the Efficacy, Safety, and Dosing of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672), in the Treatment of Serious BEs in Chinese Subjects with Acquired Hemophilia A (AHA)",TAK-672-3002,III,Planned,,RGH,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,12/31/2024,,,,,,9/30/2025,,,,2/1/2027,,,,1/31/2028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/31/2028,,,,,,,,,,,,,,,,7/31/2028,,,,,,,
TAK-675-3001,TAK-675-3001,'TAK-675-3001,,Replagal (agalsidase alfa),"An Open label Study to Evaluate the Safety , Efficacy and Pharmacokinetics of Replagal in Treatment naive Chinese Subjects with Fabry Disease",Replagal China PAC Study,III,Not Yet Recruiting,Fabry's,RGH,,,,Interventional,,,,24,,,,,,,,999,,,IQVIA,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,8/27/2020,8/27/2020,3/30/2021,3/30/2021,,,,,12/31/2021,,,,3/31/2023,,,,3/29/2024,,,,,,,,,,,,4/30/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/30/2024,,,,,,,,,,,,,,,,12/28/2023,,,,,,,
TAK-675-4010,TAK-675-4010,'TAK-675-4010,,,A retrospective study to assess the effect of treatment change in Fabry patients switching from migalastat (Galafold) to agalsidase alfa (Replagal) therapy,Migalastat to agalsidase alfa switch,IV,Not Yet Recruiting,,,Real World Evidence,,Both pediatric and non-pediatric,Observational,,Retrospective,Cohort,30,,,,,,,,14,,,IQVIA,,Derek Bell,Lade Ayodele,,,,,Not yet submitted,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-686-1001,TAK-686-1001,'TAK-686-1001,,TAK-686,Huntington's disease phase 1 study,Huntington's disease phase 1 study,I,Planned,(HD) Huntington's Disease,NS,Early NS,,,Interventional,,,,999,,,,,,,,999,,,PPD,,Annette Stevenson,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,8/30/2019,8/30/2019,5/14/2022,,,,9/16/2022,,6/29/2022,,,,3/6/2024,,,,2/28/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/23/2025,,,,,,,,,,,,,,,,,,10/3/2025,,,,,,,,5/5/2021,,,,,,,
TAK-686-1501,TAK-686-1501,'TAK-686-1501,,,"An Open-Label Phase 1/2 Study to Evaluate Safety, Tolerability, and Pharmacodynamics of TAK-686 Administered by MRI-guided Convection-Enhanced Delivery into Caudate Nucleus + Putamen and Putamen + Thalamus in Early Manifest Huntington's Disease Patients",Huntington Disease study,I/II,All Activities Closed,,,,,,Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-686-3001,TAK-686-3001,'TAK-686-3001,,TAK-686,Long Term Safety follow-up (2-5yrs) trial for all patients dosed with TAK-686,Ph. 2/3 Study for Huntington�s Disease,III,Planned,(HD) Huntington's Disease,NS,,,Pediatric only (<18 yr),Interventional,,,,999,,,,,,,,999,,,TBD,,,,,,,,,,,NA,De-Risk,,Medidata CTMS (Pharma),,,10/29/2025,,5/7/2026,,,,10/23/2026,,10/23/2026,,,,5/24/2028,,,,5/22/2030,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/12/2030,,,,,,,,,,1/28/2031,,,,,,,,11/3/2025,,,,,,,
TAK-721-1003,TAK-721-1003,'TAK-721-1003,,budesonide (TAK-721),"Randomized, Open-Label, Single-Dose, Two-Period, Two-Way Crossover Evaluation of the Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Subjects",Food Effect of BOS,I,Planned,Eosinophilic Esophagitis,GI,,,Non-pediatric only (>18 yr),Interventional,,,,20,,,,,,,,1,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,9/14/2020,9/14/2020,3/25/2022,,,,,,5/24/2022,,,,5/24/2022,,,,5/31/2022,,,,,,,,,,,,7/12/2022,,,,,,,,,,7/26/2022,,,,,,,,,,,,,,9/6/2022,,,,,,,,,,10/25/2022,,,,,,,,,,,,,,,,10/25/2022,,,,,,,
TAK-721-3004,TAK-721-3004,'TAK-721-3004,,budesonide (TAK-721),"Budesonide Oral Suspension (BOS) in Pediatrics (2 to 10 Years of Age, Inclusive) with Eosinophilic Esophagitis: A Phase 3 Open-Label Study in the United States",TAK-721-3004 Open-label Pediatric Study,III,Planned,Eosinophilic Esophagitis,GI,Gastroenterology,,Pediatric only (<18 yr),Interventional,,,,80,,,,,,,,30,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,9/29/2020,9/29/2020,3/24/2023,,,,,,10/16/2023,,,,3/27/2025,,,,4/23/2026,,,,,,,,,,,,6/4/2026,,,,,,,,,,6/18/2026,,,,,,,,,,,,,,7/30/2026,,,,,,,,,,9/24/2026,,,,,,,,,,,,,,,,5/3/2028,,,,,,,
TAK-721-4001,TAK-721-4001,'TAK-721-4001,,,"Real-World Evidence on Comorbidities, Outcomes, and Healthcare Resource Utilization Associated with EoE",Natural History of EoE,N/A,Study Terminated,Eosinophilic Esophagitis (EoE),,,Non-Registry,,Non-Intervention_Other Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,Lynn Sanders,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/15/2019,8/15/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/15/2020,,,,,,,,,,,,6/26/2020,,,,,,,,,,,,,,,,,,,,,,,
TAK-721-4002,TAK-721-4002,'TAK-721-4002,,,Diagnostic Journey and Disease Progression of Eosinopphilic Esophagitis,EoE Diagnostic Journey,N/A,Study Terminated,Eosinophilic Esophagitis (EoE),,,Non-Registry,,Non-Intervention_Other Support,,,,999,0,0,0,0,0,0,0.00%,999,,,,Lynn Sanders,,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/15/2019,10/15/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/20/2020,,,,,,,,,,,,5/15/2020,,,,,,,,,,,,,,,,,,,,,,,
TAK-721-4003,TAK-721-4003,'TAK-721-4003,,budesonide (TAK-721),N/A,Adolescent postmarketing placeholder,IV,Planned,Eosinophilic Esophagitis,GI,,,Pediatric only (<18 yr),Interventional,,,,50,,,,,,,,25,,,TBD,,,,,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,10/13/2022,,12/30/2022,,,,,,6/26/2023,,,,4/25/2024,,,,5/22/2025,,,,,,,,,,,,7/3/2025,,,,,,,,,,7/17/2025,,,,,,,,,,,,,,8/28/2025,,,,,,,,,,10/23/2025,,,,,,,,,,,,,,,,10/23/2025,,,,,,,
TAK-743-1001,TAK-743-1001,'TAK-743-1001,'TAK-765-1001,,"An Open-label, Phase 1, Single Ascending Dose (SAD) Study to Investigate Safety and Tolerability of Intravitreal Lanadelumab in Adult Subjects with Diabetic Macular Edema (DME)",TAK-743 FIH DME,I,Study Withdrawn,Hereditary Angioedema,,,Non-Registry,Non-pediatric only (>18 yr),Interventional,,,,27,,,,,,,,15,,,,Scott Cope,,,,,,,,N,No,,,,COSMOS Inactive,,,1/1/2049,,1/1/2049,,1/1/2049,,,,1/1/2049,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,,,,,,,,,,1/1/2049,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
TAK-743-1002,TAK-743-1002,'TAK-743-1002,,Takhzyro (Lanadelumab),"A phase 1b, randomized, double-blind, single and repeat dosing study to evaluate the safety, pharmacokinetics, and pharmacodynamics of lanadelumab when added to standard-of-care in subjects hospitalized with COVID-19 pneumonia.",TAK-743-1002 Phase Ib COVID19,I,Study Terminated,Hereditary Angioedema,RGH,,Non-Registry,,Interventional,,,,25,,,,,,,,8,,,IQVIA,Annette Stevenson,,,Ian Shempp,,,,,N,No,,,,COSMOS Inactive,,,,,5/25/2020,5/25/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/7/2020,10/7/2020,,,,,,
TAK-743-1003,TAK-743-1003,'TAK-743-1003,,Takhzyro (Lanadelumab),"TAK-743-1003 Safety, tolerability and PK trial using intravenous formulation in Healthy Volunteers","TAK-743-1003 S&T, PK IV trial",I,Reported,Renal Fibrosis associated with CKD,RGH,RGH,,Non-pediatric only (>18 yr),Interventional,Treatment,,,12,12,32,,0,0,0,100.00%,1,,,Celerion,,Annette Stevenson,,,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,7/22/2020,7/22/2020,,,8/10/2020,8/10/2020,8/17/2020,8/17/2020,,,8/27/2020,8/27/2020,,,12/16/2020,12/16/2020,,,,,,,,,,,1/26/2021,1/26/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/12/2021,5/12/2021,,,,,,,,,,,,,,,5/12/2021,5/12/2021,,,,,,
TAK-743-3001,TAK-743-3001,'TAK-743-3001,,Takhzyro (Lanadelumab),An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH),TAK743-3001,III,Recruiting,(BMA) Bradykinin-mediated angioedema,RGH,RGH,,Both pediatric and non-pediatric,Interventional,Prevention,,,75,9,,,,,4,12.00%,60,37,,IQVIA,,Tanya Annunziata,,Ming Yu,,,,,,,NA,Advance,,Medidata CTMS (Pharma),,,,,1/20/2020,1/20/2020,,,,,2/5/2021,2/5/2021,,,9/30/2022,,,,4/14/2023,,,,,,,,,,,,6/9/2023,,,,,,,,,,7/27/2023,,,,,,,,,,,,,,7/27/2023,,,,,,,,,,9/21/2023,,,,,,,,,,,,,,,,9/21/2023,,,,,,,
TAK-743-3002,TAK-743-3002,'TAK-743-3002,,,"Addressing ARDS in COVID-19 with Kallikrein Inhibition. An adaptive phase 2/3, randomized, double-blind, parallel-group controlled study assessing efficacy and safety of lanadelumab compared to placebo when added to standard-of-care in hospitalized patients with COVID-19 pneumonia",TAK-743 COVID-19 pneumonia,II/III,Cancelled,,,,,Non-pediatric only (>18 yr),Interventional,,,,481,,,,,,,,25,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-748-3001,TAK-748-3001,'TAK-748-3001,,,Still to be adjusted - Phase III TAK748,Phase III of TAK748,III,Concept,,,RGH,,,Interventional,,,,120,,,,,,,,65,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-748-3002,TAK-748-3002,'TAK-748-3002,,,TBD,FIX Phase III,III,Concept,,,RGH,,,Interventional,,,,55,,,,,,,,50,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-748-3003,TAK-748-3003,'TAK-748-3003,,,TBD - Extention study,Extention study,IIIb,Concept,,,RGH,,Non-pediatric only (>18 yr),Interventional,,,,21,,,,,,,,21,,,TBD,,Emily Skelton,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-755-3002,TAK-755-3002,'TAK-755-3002,,TAK-755,"A phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also know as BAX930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)",TAK-755 Continuation study,IIIb,Recruiting,Congenital Thrombotic Thrombotocytopenic Purpura,RGH,RGH,,Both pediatric and non-pediatric,Interventional,Prevention,,,88,3,3,,,,,3.41%,40,,,IQVIA,,Emily Skelton,"Cecilia Marquez, Nirjhar Chatterjee, Nisha Jain",,,,,,,,Wave 1,Advance,,Medidata CTMS (Pharma),,,2/19/2020,2/19/2020,7/13/2020,7/13/2020,,,,,4/14/2021,4/14/2021,,,7/3/2023,,,,8/27/2026,,,,,,,,,,,,12/28/2026,,,,,,,,,,1/12/2027,,,,,,,,,,,,,,3/1/2027,,,,,,,,,,1/22/2027,,,,,,,,,,,,,,,,3/1/2027,,,,,,,
TAK-755-3004,TAK-755-3004,'TAK-755-3004,,TAK-755,"A Phase 3, multicenter, randomized placebo controlled study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate efficacy and safety of rADAMTS-13 (SHP655)",TAK-755-3004,III,Planned,Immune-mediated Thrombotic Thrombotocytopenic Purpura,RGH,,,,Interventional,,,,999,,,,,,,,999,,,IQVIA,,Suman Raj,,,,,,,,,Wave 2,Advance,,Medidata CTMS (Pharma),,,1/21/2022,,2/20/2022,,,,,,3/31/2022,,,,7/31/2024,,,,12/31/2024,,,,,,,,,,,,,,,,,,,,,,1/28/2025,,,,,,,,,,,,,,3/25/2025,,,,,,,,,,5/24/2025,,,,,,,,,,,,,,,,5/24/2025,,,,,,,
TAK-765-1001,TAK-765-1001,'TAK-765-1001,,,"An Open-label, Phase 1, Single Ascending Dose (SAD) Study to Investigate Safety and Tolerability of Intravitreal Lanadelumab in Adult Subjects with Diabetic Macular Edema (DME)",TAK-765 FIH DME,I,Planned,,,,,Non-pediatric only (>18 yr),Interventional,,,,38,,,,,,,,15,,,TBD,,,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TAK-771-1001,TAK-771-1001,'TAK-771-1001,,HYQVIA,SHP671 HyQ (CIDP-4) Dose Ramp-up,SHP671 CIDP Dose Ramp-up Ph1,I,Recruiting,Restenosis prevention in Peripheral Arterial Disease,Plasma Derived Therapy,PDT,,Non-pediatric only (>18 yr),Interventional,,,,48,25,0,,0,0,3,52.08%,1,1,,PPD,,Debra Ennis,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,2/5/2020,2/5/2020,,,10/6/2020,10/6/2020,11/4/2020,11/4/2020,,,7/20/2021,,,,1/5/2022,,,,,,,,,,,,2/2/2022,,,,,,,,,,2/16/2022,,,,,,,,,,,,,,3/2/2022,,,,,,,,,,4/13/2022,,,,,,,,,,,,,,,,4/13/2022,,,,,,,
TAK-881-1001,TAK-881-1001,'TAK-881-1001,,TAK-881 Facilitated 20 percent,TAK-881,TAK-881,I,Planned,Replacement for Daxas oral,Plasma Derived Therapy,,,Non-pediatric only (>18 yr),Interventional,,,,24,,,,,,,,1,,,TBD,,Debra Ennis,,,,,,,,,,,,Medidata CTMS (Pharma),,,,,3/25/2021,3/25/2021,,,9/27/2021,,10/15/2021,,,,1/21/2022,,,,4/15/2022,,,,,,,,,,,,5/6/2022,,,,,,,,,,2/18/2022,,,,,,,,,,,,,,5/13/2022,,,,,,,,,,8/26/2022,,,,,,,,,,,,,,,,8/26/2022,,,,,,,
TAK-883-3001,TAK-883-3001,'TAK-883-3001,'TAK-670-3002,TAK-883 Aralast,"A Prospective, Randomized, Double-Blind, Parallel Group Study to
Evaluate the Safety and Efficacy of ARALAST NP 60 mg/kg and
120 mg/kg for Alpha-1 Proteinase Inhibitor (A1PI) Augmentation
Therapy in Subjects with A1PI Deficiency and Chronic Obstructive
Pulmonary Disease-Emphysema (COPD-E)",ARALAST NP Alpha-1 Lung Density COPD-E S,IIIb,Study Withdrawn,Alpha-1 antitrypsin deficiency,Plasma Derived Therapy,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Randomized,,,142,,,,,,,,70,,,IQVIA,Salvador Dominguez,,,,,,Not Available,,N,No,,,,COSMOS Inactive,12-Sep-25,,1/1/2049,,4/24/2020,4/24/2020,3/1/2021,,,,3/29/2021,,3/8/2021,,9/15/2023,,,,,,,,,,,,,,9/12/2025,,9/12/2025,,,,,,,,,,,,,,,,,,,,1/10/2026,,1/10/2026,,,,,,,,,,,,3/26/2026,,,,,,,,,,,,,,,,,,1/1/2049,,1/1/2049,,,
TAK-888-2001,TAK-888-2001,'TAK-888-2001,,CoVIg-19,"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",Tx with Anti-Coronavirus Ig (ITAC),III,Study Withdrawn,,Plasma Derived Therapy,,Non-Registry,,Interventional,,,,500,,,,,,,,30,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,4/15/2020,4/15/2020,7/13/2020,7/13/2020,,,10/8/2020,10/8/2020,10/8/2020,10/8/2020,,,2/10/2021,2/10/2021,,,3/10/2021,3/10/2021,,,,,,,,,,,3/28/2021,3/28/2021,,,,,,,,,3/31/2021,3/28/2021,,,,,,,,,,,,,,,,,,,,,,,6/30/2021,,,,,,,,,,,,,,,,6/30/2021,,,,,,,
TED-C11-011,TED-C11-011,'TED-C11-011,,,NPS Legacy Study,NPS Legacy Study,x,Completed,Short Bowel Syndrome,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,"(NPS) National Pharmaceutical Services, Inc",,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TED-C13-003,TED-C13-003,'TED-C13-003,,Gattex (teduglutide),"A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year through 17 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support",12W Pediatric,III,Completed,Short Bowel Syndrome,GI,,Non-Registry,Pediatric only (<18 yr),Interventional,PASS (Post Authorization Safety Study),,,42,42,0,0,0,0,0,100.00%,19,,"(NPS) National Pharmaceutical Services, Inc",Psi,,Chantal Letourneau,,,,2013-004588-30,,,N,No,,,,COSMOS Inactive,,,5/15/2013,5/15/2013,7/3/2013,7/3/2013,,,11/14/2013,11/14/2013,12/15/2013,12/15/2013,,,9/15/2014,9/15/2014,,,1/9/2015,1/9/2015,,,,,,,,,,,2/5/2015,2/5/2015,,,,,,,,,2/12/2015,2/12/2015,,,,,,,,,,,,,3/10/2015,3/10/2015,,,,,,,,,6/18/2015,6/18/2015,,,,,,,,,,,,,,,6/18/2015,6/18/2015,,,,,,
TED-C14-004,TED-C14-004,'TED-C14-004,,Gattex (teduglutide),"A 4-Stage Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects with PN-dependent Short Bowel Syndrome",24W Japanese Adult Bridging,III,Completed,Short Bowel Syndrome,GI,,Non-Registry,Non-pediatric only (>18 yr),Interventional,Open Label,,,10,11,13,0,2,0,2,110.00%,5,,"(NPS) National Pharmaceutical Services, Inc",EPS,,"Asif Talat, Laura McCarthy, Linda Morgan, Maria Ponsillo, Nader Youssef",,,,,,,N,No,,,,COSMOS Inactive,,,3/11/2014,3/11/2014,8/11/2014,8/11/2014,,,12/18/2014,12/18/2014,3/10/2015,3/10/2015,,,10/7/2015,10/7/2015,,,11/5/2018,11/5/2018,,,,,,,,,,,,,,,,,,,,,12/12/2018,12/12/2018,,,,,,,,,,,,,,,,,,,,,,,12/31/2018,12/31/2018,,,,,,,,,,,,,,,12/31/2018,,,,,,,
TED-C14-006,TED-C14-006,'TED-C14-006,,Gattex (teduglutide),"A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years With Short Bowel Syndrome who are Dependent on Parenteral Support",24W Global Pediatric,III,Completed,Short Bowel Syndrome,GI,,Non-Registry,Pediatric only (<18 yr),Interventional,PKPD,,,34,59,71,0,12,0,0,173.53%,27,,"(NPS) National Pharmaceutical Services, Inc",IQVIA,,Lauren Dinsmore,,,,2015-002252-27,,,N,No,,,,COSMOS Inactive,,8/18/2017,11/3/2014,11/3/2014,3/12/2015,3/12/2015,,,6/2/2016,6/2/2016,6/23/2016,6/23/2016,,,12/30/2016,12/30/2016,,,7/28/2017,7/28/2017,,,,,,,,,,,10/20/2017,10/20/2017,,,,,,,,,10/27/2017,10/27/2017,,,,,,,,,,,,,10/30/2017,10/30/2017,,,,,,,,,2/21/2018,2/21/2018,,,,,,,,,,,,,,,2/21/2018,2/21/2018,,,,,,
TED-R13-002,TED-R13-002,'TED-R13-002,,Gattex (teduglutide),"A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome",SBS Registry,IV,Recruiting,Short bowel syndrome,GI,Marketed Products,,Both pediatric and non-pediatric,Observational,Other,Other,Cohort,"1,310","1,712",0,,0,682,,130.69%,166,115,,IQVIA,,"Bridgette Goodwin, Ali Aslan","Adam Plewa, Kamran Iqbal, Elisabeth Genestin",Justin Klaff,,,,Approved,,,NA,Advance,,Medidata CTMS (Pharma),,,,,10/28/2013,10/28/2013,,,,,6/23/2014,6/23/2014,,,6/25/2021,,,,5/26/2031,,,,,,,,,,,,12/31/2031,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/30/2032,,,,,,,,,,,,,,,,4/30/2032,,,,,,,
TKT NH001,TKT NH001,'TKT NH001,,,The Natural History of Mucopolysaccharidosis II (MPS II),TKT NH001 - MPS II,0,Completed,Hunter Syndrome,,,Non-Registry,,Non-Interventional_CDO Support,,,,999,0,0,0,0,0,0,0.00%,999,,Shire HGT,PPD,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,5/7/2002,5/7/2002,,,,,10/1/2002,10/1/2002,,,,,,,,,,,,,,,,,4/25/2005,4/25/2005,4/25/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT5S001,TKT5S001,'TKT5S001,,,A Clinical Trial of Replagal Enzyme Replacement Therapy on Children aged < 18 years with Fabry Disease,TKT55001 - Children <18,III,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,13,13,0,0,0,0,0,100.00%,5,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,7/8/2003,7/8/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT001,TKT001,'TKT001,,,"A Phase I Open-label Single dose, dose escalation safety study to evaluate the safety of a-galactosidase A produced by transfected human fibroblasts in patients with Fabry disease","TKT001 - OL, Safety",I,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,10,0,0,0,0,0,1.00%,999,,,PPD,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,1/11/1996,1/11/1996,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT003,TKT003,'TKT003,,,"A Phase II Randomized, double-blind, placebo controlled study to evaluate safety and efficacy of DRX005B over 24 weeks",TKT003- DB Placebo Safety,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,26,27,0,0,0,0,2.60%,999,,,"Ockham Development Group, INC",,,,,,,,,N,No,,,,COSMOS Inactive,,,,,7/20/1998,7/20/1998,,,,,12/12/1998,12/12/1998,,,3/29/1999,3/29/1999,,,,,,,,,,,,,9/2/1999,9/2/1999,9/2/1999,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT005,TKT005,'TKT005,,,"A Phase II Randomized, double-blind, placebo controlled study to continue to evaluate safety and efficacy of Replagal","TKT005 - Randomized, DB, Placebo Safety",II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,15,0,0,0,0,0,1.50%,999,,,Applied Analytical Industries International,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/31/1998,8/31/1998,,,,,7/15/1999,7/15/1999,,,9/9/1999,9/9/1999,,,,,,,,,,,,,3/3/2000,3/3/2000,3/3/2000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT006,TKT006,'TKT006,,,A Phase II Open-label maintenance study for patients completing TKT003 to evaluate long term safety and efficacy of Replagal,TKT006 - OL Long Term Safety,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,25,0,0,0,0,0,2.50%,999,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/16/1999,4/16/1999,,,,,6/21/1999,6/21/1999,,,8/31/1999,8/31/1999,,,,,,,,,,,,,9/1/2000,9/1/2000,9/1/2000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT007,TKT007,'TKT007,,,A Phase II Open-label maintenance study for patients completing TKT005 to evaluate long-term safety and efficacy of Replagal,"TKT007 - OL, Maintenance",II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,15,0,0,0,0,0,1.50%,999,,Shire HGT,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/22/1999,12/22/1999,,,,,2/7/2000,2/7/2000,,,3/19/2000,3/19/2000,,,,,,,,,,,,,1/25/2000,1/25/2000,1/25/2000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT008,TKT008,'TKT008,,,"A Phase I/II, Randomized, Double Blind, Placebo Controlled, Multiple Dose, Dose Escalation, Safety and Clinical Activity Study of Iduronate-2-Sulfatase Replacement Therapy in Patients with Mucopolysaccharidosis (MPS) II",TKT008 - DB Placebo,II,Completed,Hunter Syndrome,,,Non-Registry,,Interventional,,,,999,12,0,0,0,0,0,1.20%,999,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,4/6/2001,4/6/2001,,,,,4/23/2001,4/23/2001,,,10/8/2001,10/8/2001,,,,,,,,,,,,,3/26/2002,3/26/2002,3/26/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT010,TKT010,'TKT010,,,"A Phase III Randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of Replagal over 24 weeks","TKT010 - Rnadomized, DB, Placebo",III,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,74,80,0,0,0,0,0,108.11%,10,,Shire HGT,"Clinical Studies Management Group, INC, Inveresk Research",,,,,,,,,N,No,,,,COSMOS Inactive,,,,,1/31/2000,1/31/2000,,,,,4/12/2000,4/12/2000,,,1/11/2002,1/11/2002,,,,,,,,,,,,,7/2/2002,7/2/2002,7/2/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT011,TKT011,'TKT011,,,A Phase II Open-label maintenance study for patients completing TKT006 to evaluate long-term safety of Replagal and to collect data on sentinel clinical events,"TKT011 -OL, Maintenance Long Term Safety",II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,24,24,0,0,0,0,0,100.00%,1,,Shire HGT,PRA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,5/12/2000,5/12/2000,,,,,8/8/2000,8/8/2000,,,9/8/2000,9/8/2000,,,,,,,,,,,,,8/29/2003,8/29/2003,8/29/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT013,TKT013,'TKT013,,,"A Phase III Open-label maintenance study for 1 patient, who completed TKT006 and German patients who completed TKT010 to evaluate long term safety and efficacy of Replagal in patients from TKT006 (1) TKT010.","TKT013 - OL, Maintenance safety",III,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,10,10,0,0,0,0,0,100.00%,1,,Shire HGT,Pharmanet,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,7/13/2000,7/13/2000,,,,,12/7/2000,12/7/2000,,,1/11/2002,1/11/2002,,,,,,,,,,,,,2/18/2002,2/18/2002,2/18/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT014,TKT014,'TKT014,,,A Phase II Open label safety and efficacy trial in female patients,TKT014 - OL Female,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,15,15,0,0,0,0,0,100.00%,1,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,9/26/2000,9/26/2000,,,,,10/27/2000,10/27/2000,,,9/6/2001,9/6/2001,,,,,,,,,,,,,1/30/2002,1/30/2002,1/30/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT015,TKT015,'TKT015,,,A Phase III Open-label maintenance study for patients completing TKT010 to evaluate long term safety and efficacy of Replagal in patients who completed TKT010,TKT015 - OL Maintenance -pat comp TKT010,III,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,67,67,0,0,0,0,0,100.00%,9,,,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/30/2000,8/30/2000,,,,,10/11/2000,10/11/2000,,,7/16/2002,7/16/2002,,,,,,,,,,,,,9/2/2003,9/2/2003,9/2/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT018,TKT018,'TKT018,,,An Open-Label Maintenance Clinical Study of Iduronate-2-Sulfatase Replacement Therapy in Patients with MPS II,TKT018 - OL MPS II,II,Completed,Hunter Syndrome,,,Non-Registry,,Interventional,,,,999,12,0,0,0,0,0,1.20%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,6/16/2003,6/16/2003,,,,,10/8/2001,10/8/2001,,,3/26/2002,3/26/2002,,,,,,,,,,,,,3/6/2007,3/6/2007,3/6/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT019,TKT019,'TKT019,,,A Safety and Pharmacokinetic Study of Replagal Enzyme Replacement Therapy in Patients with Fabry Disease,TKT019- PK Enzyme Replacement,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,999,21,0,0,0,0,0,2.10%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/20/2001,12/20/2001,,,,,5/6/2002,5/6/2002,,,3/20/2003,3/20/2003,,,,,,,,,,,,,9/4/2003,9/4/2003,9/4/2003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT020,TKT020,'TKT020,,,A Pharmacokinetic Study in Normal Healthy Adult Volunteers Comparing Replagalâ„¢ Produced From Agalsidase Alfa Bulks Manufactured at Two Different Facilities,TKT020 - PK Healthy Adjults,I,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,42,42,0,0,0,0,0,100.00%,3,,,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/22/2002,8/22/2002,,,,,10/21/2002,10/21/2002,,,11/6/2002,11/6/2002,,,,,,,,,,,,,12/5/2002,12/5/2002,12/5/2002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT023,TKT023,'TKT023,,,Replagal Enzyme Replacement Therapy in Children  Fabry Disease,TKT023 - Enzyme Rep - Children,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,25,24,0,0,0,0,0,96.00%,4,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,8/1/2003,8/1/2003,,,,,8/12/2002,8/12/2002,,,5/3/2004,5/3/2004,,,,,,,,,,,,,10/22/2004,10/22/2004,10/22/2004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT024,TKT024,'TKT024,,,"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients with MPS II",TKT-024 - DB Placebo MPS II,III,Completed,Hunter Syndrome,,,Non-Registry,,Interventional,,,,999,96,0,0,0,0,0,9.61%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/22/2013,12/22/2013,,,,,9/15/2003,9/15/2003,,,3/3/2003,3/3/2003,,,,,,,,,,,,,3/16/2005,3/16/2005,3/16/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT024EXT,TKT024EXT,'TKT024EXT,,,An open-label extension of Study TKT024 evaluating long-term safety and clinical outcomes in Hunter syndrome patients receiving iduronate-2-sulfatase enzyme replacement therapy,TKT-024 - OL ext - No Comparator,III,Completed,Hunter Syndrome,,,Non-Registry,,Interventional,,,,999,77,0,0,0,0,0,7.71%,999,,,Pharmanet,,,,,,2004-002743-27,,,N,No,,,,COSMOS Inactive,,,,,7/26/2006,7/26/2006,,,,,9/13/2004,9/13/2004,,,3/22/2005,3/22/2005,,,,,,,,,,,,,1/31/2008,1/31/2008,1/31/2008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT025,TKT025,'TKT025,,,A Phase I/II Safety Study of DRX008A Glucocerebrosidase Replacement Therapy in Patients with Type 1 Gaucher Disease,TKT025 - Safety,II,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,999,12,0,0,0,0,0,1.20%,999,,,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/11/2005,3/11/2005,,,,,4/28/2004,4/28/2004,,,7/22/2004,7/22/2004,,,,,,,,,,,,,5/3/2005,5/3/2005,5/3/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT025 Ext,TKT025 Ext,'TKT025 Ext,,,An Open-Label Extension of Study TKT025 Evaluating Long Term Safety in Patients with Type 1 Gaucher Disease Receiving DRX008A Enzyme Replacement Therapy,TKT025 EXT - OL ext,x,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,999,10,0,0,0,0,0,1.00%,999,,Shire HGT,IQVIA,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/8/2008,12/8/2008,,,,,2/3/2005,2/3/2005,,,5/10/2005,5/10/2005,,,,,,,,,,,,,12/23/2011,12/23/2011,12/23/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT027,TKT027,'TKT027,,,A Phase I-II Pharmacokinetic/Pharmocodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients with Fabry Disease,TKT027 - PK/PD alternate dose,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,20,21,0,0,0,0,0,105.00%,4,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/20/2001,12/20/2001,,,,,8/2/2004,8/2/2004,,,1/30/2005,1/30/2005,,,,,,,,,,,,,5/27/2005,5/27/2005,5/27/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT028,TKT028,'TKT028,,,"A Multi-center, Open Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease",TKT028 - SO to Access Altntve dosing,IV,Completed,Fabry Disease,,,Non-Registry,,Non-Interventional_CDO Support,,,,44,44,0,0,0,0,0,100.00%,12,,Shire HGT,,,,,,,2007-005543-22,,,N,No,,,,COSMOS Inactive,,,,,9/5/2007,9/5/2007,,,,,1/20/2009,1/20/2009,,,6/22/2011,6/22/2011,,,,,,,,,,,,,6/5/2012,6/5/2012,6/5/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT029,TKT029,'TKT029,,,An Open-Label Clinical Trial of Replagal Enzyme Replacement Therapy in Children with Fabry Disease who have Completed Study TKT023,TKT029 - Open Label No Comparator,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,17,17,0,0,0,0,0,100.00%,14,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,3/3/2008,3/3/2008,,,,,6/10/2004,6/10/2004,,,7/12/2005,7/12/2005,,,,,,,,,,,,,6/15/2011,6/15/2011,6/15/2011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT030,TKT030,'TKT030,,,An Open Label Six-month Maintenance Clinical Trial of Replagal Enzyme Replacement Therapy in Patients with Fabry Disease Who Have Completed TKT027,TKT030 -OL -6 mo maintenance -pat TKT027,II,Completed,Fabry Disease,,,Non-Registry,,Interventional,,,,20,4,0,0,0,0,0,20.00%,1,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,10/26/2004,10/26/2004,,,,,12/20/2004,12/20/2004,,,6/14/2005,6/14/2005,,,,,,,,,,,,,10/3/2005,10/3/2005,10/3/2005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT031NPU,TKT031NPU,'TKT031NPU,,,Idursulfase Named-Patient Use: Alternative Access to Treatment for Select MPS II Patients,TKT-031 NPU - Alternative Access,III,Completed,Hunter Syndrome,,,Non-Registry,,Interventional,,,,2,2,0,0,0,0,0,100.00%,999,,Shire HGT,Pharmanet,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,12/21/2006,12/21/2006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT032,TKT032,'TKT032,,,"A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-ActivatedÂ® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease","TKT032 -Randomized, DB, Parallel -type 1",III,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,25,25,39,0,0,0,0,100.00%,999,,Shire HGT,,,,,,,,,,N,No,,,,COSMOS Inactive,,,,,6/22/2007,6/22/2007,,,,,1/11/2007,1/11/2007,,,3/12/2008,3/12/2008,,,,,,,,,,,,,4/2/2009,4/2/2009,4/2/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TKT034,TKT034,'TKT034,,,A Multicenter Open-Label Study of Gene-ActivatedÂ® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Previously Treated Patients with Type 1 Gaucher Disease,TKT034 - OL,III,Completed,Gaucher's Disease,,,Non-Registry,,Interventional,,,,40,40,0,0,0,0,0,100.00%,20,,Shire HGT,,,,,,,2006-006304-11,,,N,No,,,,COSMOS Inactive,,,,,10/19/2007,10/19/2007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_001,DEN-001,'DEN-001,,TAK-003,Rapid Seroincidence and Syndromic Surveillance for Dengue and Norovirus in Latin America,DEN-001,0,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,"2,000",,,,,,,,4,,,TBD,,Morgan McNamara,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,4/23/2014,4/23/2014,4/23/2014,4/23/2014,,,3/31/2015,4/13/2015,3/31/2015,4/13/2015,,,3/31/2016,3/31/2016,,,12/31/2016,12/31/2016,,,,,,,,,,,1/31/2017,1/31/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/31/2017,3/17/2017,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_002,DEN-002,'DEN-002,,TAK-003,Dengue as a cause of non-malarial febrile illness in Southwestern Uganda,DEN-002,0,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,"1,200",,,,,,,,3,,,TBD,,Morgan McNamara,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,2/28/2017,2/28/2017,2/28/2017,2/28/2017,,,11/1/2017,11/1/2017,11/1/2017,11/1/2017,,,6/1/2018,7/18/2018,,,6/1/2018,7/18/2018,,,,,,,,,,,4/30/2019,10/25/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/1/2019,2/14/2020,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_003,DEN-003,'DEN-003,,TAK-003,Identifying the determinants of short and long-term immunity in a dengue virus immune cohort,DEN-003,0,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,240,,,,,,,,2,,,TBD,,"Anne Crissey, DIane Pohl, Morgan McNamara",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,8/16/2016,7/18/2016,8/16/2016,7/18/2016,,,9/1/2017,11/28/2017,9/1/2017,11/28/2017,,,3/29/2019,,,,3/29/2019,,,,,,,,,,,,6/28/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/29/2019,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_005,DEN-005,'DEN-005,,,The association between prior exposure to Dengue Tetravalent Vaccine (Live Attenuated) (TDV) and dengue hospitalization: a matched case-control post-licensure safety study.,DEN-005,IV,Cancelled,Prevention of Dengue virus infection,,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,,,,Medidata CTMS (VBU),,,7/31/2021,,7/31/2021,,,,1/31/2022,,1/31/2022,,,,7/31/2022,,,,7/31/2025,,,,,,,,,,,,10/31/2025,,,,,,,,,,11/30/2025,,,,,,,,,,,,,,,,,,,,,,,,1/31/2026,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_006,DEN-006,'DEN-006,,,"Effectiveness of Dengue Tetravalent Vaccine (Live Attenuated) (TDV) against outpatient, symptomatic virologically confirmed dengue: a test-negative case-control study.",DEN-006,IV,Cancelled,Prevention of Dengue virus infection,,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,,,,Medidata CTMS (VBU),,,7/31/2021,,7/31/2021,,,,1/31/2022,,1/31/2022,,,,7/31/2022,,,,7/31/2025,,,,,,,,,,,,10/31/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/31/2026,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_101,DEN-101,'DEN-101,,,"A Double-blind Randomized, Placebo-controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers",DEN-101,I,Reported,Prevention of Dengue virus infection,,Vaccine,,,,Prevention,,,72,,,,,,,,1,,,DMID-CROMS Pharmacovigilance Group,,Andre Campos,,,,,,,,,,,,Medidata CTMS (VBU),,,9/1/2009,9/1/2009,11/1/2009,11/1/2009,,,6/7/2010,6/7/2010,6/7/2010,6/7/2010,,,7/11/2011,7/11/2011,,,4/12/2012,4/12/2012,,,,,,,,,,,12/4/2012,12/4/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/14/2013,6/14/2013,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_102,DEN-102,'DEN-102,,,"A Phase I, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults",DEN-102,I,Reported,Prevention of Dengue virus infection,,Vaccine,,,,Prevention,,,112,,,,,,,,1,,,IQVIA,,"Andre Campos, Seloni Sodha",,,,,,,,,,,,Medidata CTMS (VBU),,,8/1/2009,2/11/2010,10/1/2009,2/11/2010,,,10/11/2010,10/11/2010,10/11/2010,10/11/2010,,,11/10/2010,11/10/2010,,,11/9/2011,11/9/2011,,,,,,,,,,,5/1/2013,5/1/2013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/7/2013,10/7/2013,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_103,DEN-103,'DEN-103,,TAK-003,"A Phase 1b, Partial-blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Using Needle or Needle-free PharmaJet® Injector in Healthy Adults",DEN-103,I,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,96,,,,,,,,2,,,TBD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/1/2016,3/1/2016,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_104,DEN-104,'DEN-104,,,"A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 – 45 Years",DEN-104,I,Reported,Prevention of Dengue virus infection,,Vaccine,,,,Prevention,,,144,,,,,,,,3,,,TBD,,"Andre Campos, Seloni Sodha",,Athanasia Papadimitriou,,,,,,,,,,Medidata CTMS (VBU),,,9/25/2011,9/25/2011,9/25/2011,9/25/2011,,,1/23/2012,1/23/2012,2/1/2012,2/1/2012,,,8/26/2013,8/26/2013,,,1/6/2014,1/6/2014,,,,,,,,,,,3/1/2014,3/1/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/16/2015,4/16/2015,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_105,DEN-105,'DEN-105,,TAK-003,Impact of Subcutaneous versus Intramuscular Administration of Inviragen’s Live Attenuated Dengue Vaccine on Safety and Immunogenicity,DEN-105,I,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,80,,,,,,,,1,,,SUNY Upstate Medical University,,"Andre Campos, Jennifer Kilbury, Kim Grill, Seloni Sodha","Harshini Turner, Vincent Mwangi","Athanasia Papadimitriou, Derek Wallace",,,,,,,,,,Medidata CTMS (VBU),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/1/2015,12/1/2015,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_106,DEN-106,'DEN-106,,TAK-003,"A Randomized, Double Blind, Phase 2 Study to assess the Safety and Immunogenicity of Three Formulations of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults",DEN-106,IIa,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,"1,000",,,,,,,,7,,,IQVIA,,"Ana Sekine, Andre Campos, Debbie Mendoza, Glaucia Santina, Seloni Sodha",Harshini Turner,"Athanasia Papadimitriou, Derek Wallace",,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/4/2016,1/4/2016,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_108,DEN-108,'DEN-108,,TAK-003,"A Phase II, Double-blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Single Dose of Takeda's Tetravalent Dengue Vaccine (TDV) Candidate in Healthy Adults",DEN-108,IIa,Cancelled,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,60,,,,,,,,1,,,PPD,,"Andre Campos, Jennifer Kilbury, Seloni Sodha","Harshini Turner, Vincent Mwangi",Derek Wallace,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,12/19/2013,12/19/2013,,,,,7/2/2018,,7/2/2018,,,,8/27/2018,,,,2/23/2019,,,,,,,,,,,,7/5/2019,,,,,,,,,,7/29/2019,,,,,,,,,,,,,,,,,,,,,,,,11/22/2019,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_109,DEN-109,'DEN-109,,TAK-003,Study Specific Setting,DEN-109,IIa,Cancelled,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,90,,,,,,,,1,,,PPD,,"Andre Campos, DIane Pohl, Jennifer Kilbury, Marian Weijs, Seloni Sodha","Harshini Turner, Vincent Mwangi",Derek Wallace,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,9/10/2018,,11/12/2018,,,,5/4/2020,,5/4/2020,,,,9/7/2020,,,,6/19/2021,,,,,,,,,,,,10/19/2021,,,,,,,,,,11/19/2021,,,,,,,,,,,,,,,,,,,,,,,,3/15/2022,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_110,DEN-110,'DEN-110,,TAK-003,Long term immuno persistence in subjects from parent studies DEN-101 and 104,DEN-110,IIa,Cancelled,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,30,,,,,,,,,,,PPD,,Andre Campos,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,6/30/2016,,9/30/2016,,,,1/31/2017,,1/31/2017,,,,2/28/2017,,,,3/31/2017,,,,,,,,,,,,5/31/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/20/2017,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_203-2,DEN-203-2,'DEN-203-2,,TAK-003,"A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 – 45 Years",DEN-203,IIa,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,360,,,,,,,,8,,,Chiltern,,"Andre Campos, Jennifer Kilbury, Seloni Sodha",Vincent Mwangi,"Athanasia Papadimitriou, Derek Wallace, Yanee Hutagalung",,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,6/16/2011,6/16/2011,8/26/2011,8/26/2011,,,1/11/2012,1/11/2012,1/11/2012,1/11/2012,,,4/1/2013,4/1/2013,,,4/1/2016,4/1/2016,,,,,,,,,,,12/30/2016,12/30/2016,,,,,,,,,12/30/2016,12/30/2016,,,,,,,,,,,,,3/10/2017,3/10/2017,,,,,,,,,8/1/2017,8/1/2017,,,,,,,,,,,,,,,8/1/2017,8/1/2017,,,,,,
VV_DEN_204,DEN-204,'DEN-204,,TAK-003,"A Phase II, double-blind, controlled trial to assess the Safety and Immunogenicity of different schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in healthy subjects aged between 2 and <18 years and living in dengue endemic countries in Asia and Latin America",DEN-204,IIa,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,Non-Registry,,,Prevention,,,"1,800","1,778",0,,2,1800,0,98.78%,3,,,IQVIA,,"Debbie Mendoza, Glaucia Santina, Seloni Sodha","Suely Tuboi, Yanee Hutagalung","Derek Wallace, Pedro Garbes, Vianney Tricou",,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,3/13/2014,3/13/2014,3/13/2014,3/13/2014,,,12/5/2014,12/5/2014,12/5/2014,12/5/2014,,,2/13/2015,2/13/2015,,,9/13/2016,9/13/2016,,,,,,,2/18/2019,2/18/2019,,,12/30/2016,12/30/2016,,,,,,,8/1/2019,8/1/2019,5/9/2017,5/9/2017,,,,,,,8/19/2019,8/19/2019,,,,,9/11/2017,9/11/2017,,,,,,,9/16/2019,9/16/2019,11/30/2017,11/30/2017,,,,,,,6/15/2020,6/15/2020,,,,,,,11/23/2020,11/23/2020,,,,,,
VV_DEN_205,DEN-205,'DEN-205,,TAK-003,"A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine with two Different Serotype 2 Potencies in an Adult Population in Singapore",DEN-205,IIa,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,400,351,0,,0,0,29,87.75%,3,,,PPD,,"Hannah Woo, Kai Fern Chan, Seloni Sodha",Yanee Hutagalung,"Derek Wallace, Vianney Tricou",,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,9/17/2014,9/17/2014,1/25/2015,1/25/2015,,,6/3/2015,6/3/2015,6/8/2015,6/8/2015,,,8/29/2016,8/29/2016,,,9/18/2017,9/18/2017,,,,,,,,,,,1/11/2018,1/11/2018,,,,,,,,,3/5/2018,3/5/2018,,,,,,,,,,,,,7/6/2018,7/6/2018,,,,,,,,,10/10/2018,10/10/2018,,,,,,,,,,,,,,,1/14/2024,,,,,,,
VV_DEN_208,DEN-208,'DEN-208,,TAK-003,,DEN-208,IIIa,Cancelled,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,3/3/2016,,5/10/2016,,,,7/15/2016,,7/15/2016,,,,10/15/2016,,,,4/15/2017,,,,,,,,,,,,8/21/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/15/2017,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_209,DEN-209,'DEN-209,,TAK-003,Study Specific Setting,DEN-209,IIa,Withdrawn,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,300,,,,,,,,6,,,PPD,,"Andre Campos, Hannah Woo, Kai Fern Chan, Seloni Sodha",,Vianney Tricou,,Not applicable,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,8/15/2016,6/27/2016,8/29/2016,8/29/2016,,,5/14/2021,,5/14/2021,,,,9/13/2021,,,,7/8/2022,,,,,,,,,,,,8/9/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/26/2022,,,,,,,,,,,,,,,,,,,,,,,
VV_DEN_210,DEN-210,'DEN-210,,TAK-003,An open-label Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses to Safety of Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naive and Dengue-Immune Healthy Adults,DEN-210,II,Recruitment Complete,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,44,32,0,,149,0,0,72.73%,2,,,IQVIA,,"Anne Crissey, DIane Pohl, Jennifer Kilbury, Marian Weijs",Vincent Mwangi,Derek Wallace,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,5/2/2018,5/2/2018,5/2/2018,5/2/2018,,,12/28/2018,12/28/2018,12/28/2018,12/28/2018,,,2/27/2020,2/27/2020,,,3/1/2021,3/1/2021,,,,,,,,,,,9/30/2021,,,,,,,,,,,,,,,,,,11/11/2021,,,,,,,,,,,,,,1/5/2022,,4/26/2022,,,,,,,,,,,,,,,,4/26/2022,,,,,,,
VV_DEN_301,DEN-301,'DEN-301,,TAK-003,"Phase III, Double-Blind, Randomized, Placebo-Controlled, Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 – 16 Years Old",DEN-301,IIIa,Recruitment Complete,Prevention of Dengue virus infection,Vaccine,Vaccine,,Pediatric only (<18 yr),Interventional,Prevention,,,"20,100","20,100",23418,,3318,20100,357,100.00%,26,26,,PPD,,"Andre Campos, Debbie Mendoza, Glaucia Santina, Harald Pfaar, Jennifer Kilbury, Joyce Garcia, Kai Fern Chan, lorenzo bertelli, Marian Weijs, PATRICIA PEREZ, Seloni Sodha, Silvia Lucini, Supornpan Sriwongsitanont","Suely Tuboi, Yanee Hutagalung","Derek Wallace, Ian Escudero, Pedro Garbes, Shibadas Biswal",,2018-003979-34,,Approved,,,Wave 1,NA,,Medidata CTMS (VBU),,,9/29/2014,9/29/2014,12/17/2014,12/17/2014,,,9/7/2016,9/7/2016,9/7/2016,9/7/2016,,,3/31/2017,3/31/2017,,,,,,,,,,,8/13/2024,,,,,,,,,,,,12/4/2024,,,,,,,,,,2/4/2025,,,,,,,,,,,,,,4/24/2025,,,,,,,,,,8/14/2025,,,,,,,,8/14/2025,,,,,,,
VV_DEN_302,DEN-302,'DEN-302,,TAK-003,Registration study in India,DEN-302,II,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,300,,,,,,,,3,,,PPD,,"Andre Campos, Debbie Mendoza, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,11/25/2019,,4/30/2020,4/30/2020,,,6/15/2022,,6/15/2022,,,,12/12/2022,,,,7/7/2023,,,,,,,,,,,,2/16/2024,,,,,,,,,,3/15/2024,,,,,,,,,,,,,,5/24/2024,,,,,,,,,,9/25/2024,,,,,,,,,,,,,,,,9/25/2024,,,,,,,
VV_DEN_303,DEN-303,'DEN-303,,TAK-003,Persistence in Adolescents & Adults,DEN-303,III,Not Yet Recruiting,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,600,261,366,,105,149,,43.50%,10,10,,PPD,,"Aline Prates, Andre Campos, Debbie Mendoza",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,1/28/2019,1/28/2019,3/4/2019,3/4/2019,,,9/5/2019,9/5/2019,11/12/2019,11/12/2019,,,3/2/2020,3/2/2020,,,1/16/2023,,,,,,,,,,,,5/22/2023,,,,,,,,,,6/12/2023,,,,,,,,,,,,,,7/3/2023,,,,,,,,,,12/4/2023,,,,,,,,,,,,,,,,12/4/2023,,,,,,,
VV_DEN_304,DEN-304,'DEN-304,,TAK-003,Lot-to-lot Consistency of 3 Lots of TDV in Non-Endemic Country(ies) for Dengue,DEN-304,III,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,924,4,1007,,85,,111,0.43%,14,1,,PPD,,"Jennifer Kilbury, Morgan McNamara, Seloni Sodha",,Athanasia Papadimitriou,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,2/17/2016,2/17/2016,7/18/2017,7/18/2017,,,2/12/2018,2/12/2018,2/12/2018,2/12/2018,,,3/8/2018,3/8/2018,,,1/14/2019,1/14/2019,,,,,,,,,,,5/22/2019,5/22/2019,,,,,,,,,5/31/2019,5/31/2019,,,,,,,,,,,,,7/22/2019,7/22/2019,,,,,,,,,6/5/2020,6/5/2020,,,,,,,,,,,,,,,7/1/2021,7/1/2021,,,,,,
VV_DEN_305,DEN-305,'DEN-305,,TAK-003,"A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever
YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects
Aged 18 to 60 years in Non-Endemic Country(ies)",DEN-305,III,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,900,900,0,,0,0,160,100.00%,11,,,PPD,,"Anne Crissey, Jennifer Kilbury, Morgan McNamara, Seloni Sodha",Vincent Mwangi,Vianney Tricou,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,2/17/2016,2/17/2016,12/19/2016,12/19/2016,,,2/28/2018,2/28/2018,2/28/2018,2/28/2018,,,3/27/2018,3/27/2018,,,5/13/2019,5/13/2019,,,,,,,,,,,11/4/2019,11/4/2019,,,,,,,,,12/2/2019,12/2/2019,,,,,,,,,,,,,12/18/2019,12/18/2019,,,,,,,,,6/30/2020,6/30/2020,,,,,,,,,,,,,,,6/30/2020,6/30/2020,,,,,,
VV_DEN_306,DEN-306,'DEN-306,,TAK-003,Immuno bridging infants,DEN-306,IIIa,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,200,,,,,,,,,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,3/17/2022,,6/9/2022,,,,2/15/2023,,2/15/2023,,,,4/12/2023,,,,3/27/2026,,,,,,,,,,,,8/7/2026,,,,,,,,,,9/3/2026,,,,,,,,,,,,,,11/12/2026,,,,,,,,,,3/17/2027,,,,,,,,,,,,,,,,3/17/2027,,,,,,,
VV_DEN_307,DEN-307,'DEN-307,,TAK-003,End of shelf life,DEN-307,IIIa,Recruitment Complete,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,200,203,0,,25,0,,101.50%,,,,IQVIA,,"Andre Campos, Marian Weijs, Seloni Sodha, Sonja Moua",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,2/15/2018,2/15/2018,6/21/2018,6/21/2018,,,3/28/2019,3/28/2019,3/28/2019,3/28/2019,,,5/31/2019,5/31/2019,,,3/13/2020,3/13/2020,,,,,,,,,,,12/15/2020,12/15/2020,,,,,,,,,10/30/2020,10/30/2020,,,,,,,,,,,,,9/3/2020,9/3/2020,,,,,,,,,5/27/2021,5/27/2021,,,,,,,,,,,,,,,5/27/2021,5/27/2021,,,,,,
VV_DEN_308,DEN-308,'DEN-308,,TAK-003,Co-administration with HPV,DEN-308,IIIa,Recruitment Complete,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,614,614,618,,4,614,2,100.00%,3,4,,IQVIA,,"Andre Campos, Kai Fern Chan, Seloni Sodha, Debbie Mendoza",,,,NA,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,7/9/2018,7/9/2018,12/20/2019,12/20/2019,,,8/15/2020,8/15/2020,5/17/2021,5/17/2021,,,7/22/2021,,,,7/29/2022,,,,,,,,,,,,8/29/2022,,,,,,,,,,5/16/2022,,,,,,,,9/19/2022,,,,,,5/31/2022,,,,,,,,9/27/2022,,1/22/2023,,,,,,,,,,,,,,,,1/22/2023,,,,,,,
VV_DEN_309,DEN-309,'DEN-309,,TAK-003,Phase 3 specific setting (Japan),DEN-309,IIIa,Cancelled,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,250,,,,,,,,,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,11/2/2022,,1/25/2023,,,,4/19/2023,,4/19/2023,,,,6/29/2023,,,,6/3/2024,,,,,,,,,,,,10/14/2024,,,,,,,,,,11/11/2024,,,,,,,,,,,,,,1/20/2025,,,,,,,,,,2/28/2025,,,,,,,,,,,,,,,,2/28/2025,,,,,,,
VV_DEN_310,DEN-310,'DEN-310,,TAK-003,Phase 3 specific setting (China),DEN-310,IIIa,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,900,,,,,,,,,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,7/8/2022,,10/6/2022,,,,6/15/2023,,6/15/2023,,,,9/8/2023,,,,6/28/2024,,,,,,,,,,,,11/8/2024,,,,,,,,,,12/6/2024,,,,,,,,,,,,,,2/14/2025,,,,,,,,,,5/30/2025,,,,,,,,,,,,,,,,5/30/2025,,,,,,,
VV_DEN_311,DEN-311,'DEN-311,,TAK-003,Immunogenicity and Safety of TDV Administered with Tdap in Children and Adolescents,DEN-311,IIIa,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,"1,200",,,,,,,,8,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,11/12/2020,11/12/2020,2/10/2021,,,,10/19/2021,,10/19/2021,,,,2/15/2022,,,,12/6/2022,,,,,,,,,,,,5/2/2023,,,,,,,,,,5/30/2023,,,,,,,,,,,,,,8/8/2023,,,,,,,,,,11/21/2023,,,,,,,,,,,,,,,,11/21/2023,,,,,,,
VV_DEN_312,DEN-312,'DEN-312,,TAK-003,"A Randomized, Double-Blind, Phase 3 Trial to Demonstrate the Non-inferiority of the
Dengue Tetravalent Vaccine (New Process) Versus the Dengue Tetravalent Vaccine (Current
Process) when Administered as a 2-Dose Schedule in Healthy Subjects Aged 18 to 60 Years",DEN-312,IIIa,Suspended,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,470,,,,,,,,,,,PPD,,"Andre Campos, Ilaria Albieri, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,3/22/2022,,6/29/2022,,,,11/16/2022,,11/16/2022,,,,2/8/2023,,,,11/22/2023,,,,,,,,,,,,5/1/2024,,,,,,,,,,5/28/2024,,,,,,,,,,,,,,8/6/2024,,,,,,,,,,11/12/2024,,,,,,,,,,,,,,,,11/12/2024,,,,,,,
VV_DEN_313,DEN-313,'DEN-313,,TAK-003,"An open label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years",DEN-313,II,Recruitment Complete,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,200,392,0,,0,0,16,196.00%,2,2,,PPD,,"Aline Prates, Debbie Mendoza, Silvia Lucini",Suely Tuboi,"Ian Escudero, Pedro Garbes, Shibadas Biswal, Yanee Hutagalung",,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,7/1/2016,7/1/2016,7/1/2016,7/1/2016,,,4/3/2017,4/3/2017,4/3/2017,4/3/2017,,,6/2/2017,6/2/2017,,,9/29/2020,9/29/2020,,,,,,,,,,,2/25/2021,2/25/2021,,,,,,,,,5/9/2019,5/9/2019,,,,,,,5/5/2021,5/5/2021,,,,,,,,,,,,,7/13/2021,7/13/2021,11/19/2021,,,,,,,,,,,,,,,,11/19/2021,,,,,,,
VV_DEN_314,DEN-314,'DEN-314,,TAK-003,"A Phase III, observer-blinded, randomized trial to investigate the immunogenicity and safety of the co-administration of TDV and inactivated hepatitis A vaccine in healthy subjects aged 18 to 60 years from non-endemic areas",DEN-314,IIIa,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,Non-pediatric only (>18 yr),,Prevention,,,900,899,0,,0,0,121,99.89%,10,,,PPD,,"Kai Fern Chan, Seloni Sodha",,Athanasia Papadimitriou,,2017-001071-23,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,2/17/2016,2/17/2016,8/31/2016,8/31/2016,,,5/16/2018,5/16/2018,5/16/2018,5/16/2018,,,8/30/2018,8/30/2018,,,7/9/2019,7/9/2019,,,,,,,,,,,10/2/2019,10/2/2019,,,,,,,,,10/28/2019,10/28/2019,,,,,,,,,,,,,11/18/2019,11/18/2019,,,,,,,,,6/3/2020,6/3/2020,,,,,,,,,,,,,,,7/9/2020,7/9/2020,,,,,,
VV_DEN_315,DEN-315,'DEN-315,,TAK-003,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate
the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent
Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic
Area(s) for Dengue",DEN-315,III,Reported,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,400,400,0,,0,0,9,100.00%,5,1,,PPD,,"Aline Prates, PATRICIA PEREZ, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,2/22/2016,2/22/2016,10/28/2016,10/28/2016,,,12/14/2017,12/14/2017,12/14/2017,12/14/2017,,,4/8/2018,4/8/2018,,,1/26/2019,1/26/2019,,,,,,,,,,,5/8/2019,5/8/2019,,,,,,,,,5/31/2019,5/31/2019,,,,,,,,,,,,,6/17/2019,6/17/2019,,,,,,,,,11/21/2019,11/21/2019,,,,,,,,,,,,,,,6/3/2020,6/3/2020,,,,,,
VV_DEN_316,DEN-316,'DEN-316,,TAK-003,Infants Co-Admin MMR,DEN-316,IIIa,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,625,,,,,,,,,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,4/16/2024,,7/9/2024,,,,3/18/2025,,3/18/2025,,,,7/15/2025,,,,5/5/2026,,,,,,,,,,,,9/14/2026,,,,,,,,,,10/19/2026,,,,,,,,,,,,,,12/28/2026,,,,,,,,,,4/9/2027,,,,,,,,,,,,,,,,4/9/2027,,,,,,,
VV_DEN_317,DEN-317,'DEN-317,,TAK-003,Infants Co-Admin Penta,DEN-317,III,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,875,,,,,,,,,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,4/16/2024,,7/9/2024,,,,3/18/2025,,3/18/2025,,,,7/15/2025,,,,5/5/2026,,,,,,,,,,,,9/14/2026,,,,,,,,,,10/12/2026,,,,,,,,,,,,,,12/21/2026,,,,,,,,,,4/5/2027,,,,,,,,,,,,,,,,4/5/2027,,,,,,,
VV_DEN_318,DEN-318,'DEN-318,,TAK-003,Infants Co-Admin YF,DEN-318,III,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,875,,,,,,,,,,,PPD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,4/16/2024,,7/9/2024,,,,3/18/2025,,3/18/2025,,,,7/15/2025,,,,5/5/2026,,,,,,,,,,,,9/14/2026,,,,,,,,,,10/12/2026,,,,,,,,,,,,,,12/21/2026,,,,,,,,,,4/5/2027,,,,,,,,,,,,,,,,4/5/2027,,,,,,,
VV_DEN_319,DEN-319,'DEN-319,,TAK-003,Co-administration of TDV with routine vaccines in infants 2 to less than 6 months of age,DEN-319,IIIa,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,900,,,,,,,,,,,TBD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,11/16/2027,,2/8/2028,,,,10/17/2028,,10/17/2028,,,,2/13/2029,,,,12/4/2029,,,,,,,,,,,,4/16/2030,,,,,,,,,,6/4/2030,,,,,,,,,,,,,,8/13/2030,,,,,,,,,,11/25/2030,,,,,,,,,,,,,,,,11/25/2030,,,,,,,
VV_DEN_320,DEN-320,'DEN-320,,TAK-003,Efficacy in subjects 2-<6 months,DEN-320,IIIa,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,"10,500",,,,,,,,,,,TBD,,"Andre Campos, Seloni Sodha",,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,2/26/2030,,5/21/2030,,,,1/28/2031,,1/28/2031,,,,8/18/2031,,,,6/7/2032,,,,,,,,,,,,10/15/2032,,,,,,,,,,11/12/2032,,,,,,,,,,,,,,1/21/2033,,,,,,,,,,5/6/2033,,,,,,,,,,,,,,,,5/6/2033,,,,,,,
VV_DEN_321,DEN-321,'DEN-321,,TAK-003,Elderly 60yr+ randomized double blind placebo control descriptive safety & immunogenicity,DEN-321,IIIb,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,750,,,,,,,,,,,TBD,,Marian Weijs,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,3/11/2022,,6/9/2022,,,,2/15/2023,,2/15/2023,,,,6/14/2023,,,,4/19/2024,,,,,,,,,,,,8/28/2024,,,,,,,,,,9/25/2024,,,,,,,,,,,,,,12/4/2024,,,,,,,,,,3/19/2025,,,,,,,,,,,,,,,,3/19/2025,,,,,,,
VV_DEN_322,DEN-322,'DEN-322,,TAK-003,TDV Reformulation Manufacturing Support Study (MDV),DEN-322,IIIb,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,530,,,,,,,,,,,TBD,,Marian Weijs,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,5/4/2022,,8/3/2022,,,,4/11/2023,,4/12/2023,,,,8/30/2023,,,,6/19/2024,,,,,,,,,,,,11/12/2024,,,,,,,,,,12/10/2024,,,,,,,,,,,,,,2/18/2025,,,,,,,,,,6/3/2025,,,,,,,,,,,,,,,,6/3/2025,,,,,,,
VV_DEN_401,DEN-401,'DEN-401,,TAK-003,The association between prior exposure to Dengue Tetravalent Vaccine (Live Attenuated) (TDV) and dengue hospitalization: a matched case-control post-licensure safety study.,DEN-401,IV,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,11/30/2024,,11/30/2024,,,,4/30/2025,,4/30/2025,,,,10/31/2025,,,,10/31/2028,,,,,,,,,,,,1/31/2029,,,,,,,,,,2/28/2029,,,,,,,,,,,,,,,,,,,,,,,,4/30/2029,,,,,,,,,,,,,,,,4/30/2029,,,,,,,
VV_DEN_402,DEN-402,'DEN-402,,TAK-003,"Effectiveness of Dengue Tetravalent Vaccine (Live Attenuated) (TDV) against outpatient, symptomatic virologically confirmed dengue: a test-negative case-control study.",DEN-402,IV,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,11/30/2024,,11/30/2024,,,,4/30/2025,,4/30/2025,,,,10/31/2025,,,,10/31/2028,,,,,,,,,,,,1/31/2029,,,,,,,,,,2/28/2029,,,,,,,,,,,,,,,,,,,,,,,,4/30/2029,,,,,,,,,,,,,,,,4/30/2029,,,,,,,
VV_DEN_403,DEN-403,'DEN-403,,TAK-003,"Pregnancy-registry study, post-licensure.",DEN-403,IV,Planned,Prevention of Dengue virus infection,Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,450,,,TBD,,Morgan McNamara,,,,,,,,,Wave 1,NA,,Medidata CTMS (VBU),,,10/31/2022,,10/31/2022,,,,3/31/2023,,3/31/2023,,,,10/2/2023,,,,9/30/2026,,,,,,,,,,,,12/31/2026,,,,,,,,,,1/29/2027,,,,,,,,,,,,,,,,,,,,,,,,3/31/2027,,,,,,,,,,,,,,,,3/31/2027,,,,,,,
VV_EPI_001,EPI-001,'EPI-001,,TAK-214,Active Surveillance for Medically-Attended Acute Gastroenteritis (MAAGE) and Norovirus Infection in a Managed Care Population,EPI-001,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"3,500",,,,,,,,1,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,5/14/2013,5/14/2013,5/14/2013,5/14/2013,,,3/15/2014,3/15/2014,3/15/2014,3/15/2014,,,11/13/2017,11/13/2017,,,12/13/2017,11/13/2017,,,,,,,,,,,1/31/2018,1/31/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/30/2019,11/5/2020,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_002,EPI-002,'EPI-002,,TAK-214,Community and hospital burden of norovirus disease in children,EPI-002,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"2,750",,,,,,,,9,6,,Assign Group,,"Manuela Viana, Morgan McNamara",,"Kerim Chitour, Margarita Riera, Pedro Garbes",,NA,,,,,NA,,,Medidata CTMS (VBU),,,4/30/2013,4/30/2013,9/26/2013,9/26/2013,,,11/24/2014,11/24/2014,11/24/2014,11/24/2014,,,3/31/2017,3/17/2017,,,4/30/2017,3/31/2017,,,,,,,,,,,8/31/2018,8/31/2018,,,,,,,,,9/14/2018,9/28/2018,,,,,,,,,,,,,,,,,,,,,,,10/30/2019,3/2/2020,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_003A,EPI-003A,'EPI-003A,,TAK-214,"Norovirus acute gastroenteritis among international travelers from the United States, Switzerland and Germany (Norovirus Travel Study)",EPI-003A,0,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"2,152",,,,,,,,5,2,,Assign Group,,Morgan McNamara,,"Kerim Chitour, Lisa Lindsay",,NA,,,,,NA,,,Medidata CTMS (VBU),,,9/27/2013,9/27/2013,9/27/2013,9/27/2013,,,3/6/2015,3/6/2015,3/6/2015,3/6/2015,,,3/31/2017,4/22/2017,,,7/31/2017,7/7/2017,,,,,,,,,,,10/9/2019,12/13/2019,,,,,,,,,2/17/2020,2/17/2020,,,,,,,,,,,,,,,,,,,,,,,5/31/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_003B,EPI-003B,'EPI-003B,,TAK-214,Norovirus acute gastroenteritis among international travelers on cruise ships,EPI-003B,0,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,600,,,,,,,,2,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,7/2/2013,7/2/2013,12/31/2018,,,,3/22/2019,,3/31/2019,,,,3/31/2020,,,,4/30/2020,,,,,,,,,,,,7/31/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/31/2020,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_004,EPI-004,'EPI-004,,TAK-214,Norovirus epidemiology study 004 (Mathematical modeling),EPI-004,0,Withdrawn,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,0,,,,,,,,1,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,9/15/2013,9/15/2013,9/15/2013,9/15/2013,,,3/22/2018,,3/31/2018,,,,3/31/2020,,,,3/31/2020,,,,,,,,,,,,4/30/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/31/2020,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_005,EPI-005,'EPI-005,,,Burden of norovirus disease in children in the USA,EPI-005,0,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,,,,Medidata CTMS (VBU),,,6/16/2016,,7/1/2016,,,,9/22/2016,,10/1/2016,,,,10/1/2017,,,,1/1/2018,,,,,,,,,,,,4/1/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/1/2018,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_006,EPI-006,'EPI-006,,TAK-214,Burden of norovirus disease in children in the EU,EPI-006,0,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"3,000",,,,,,,,5,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,12/30/2019,,12/31/2019,,,,3/31/2020,,3/31/2020,,,,3/31/2022,,,,4/30/2022,,,,,,,,,,,,7/31/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/31/2022,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_007,EPI-007,'EPI-007,,,Burden of Norovirus disease in children and the elderly in Japan (Okitama study),EPI-007,0,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,"1,050",,,,,,,,1,,,TBD,,Morgan McNamara,,Munehide Kano,,,,,,,,,,Medidata CTMS (VBU),,,3/31/2015,3/31/2015,6/30/2018,,,,1/1/2019,,1/1/2019,,,,12/31/2019,,,,12/31/2019,,,,,,,,,,,,3/31/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/30/2020,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_008,EPI-008,'EPI-008,,TAK-214,"Norovirus (NoV) Associated Gastroenteritis in a Pediatric Population from Cali, Colombia",EPI-008,0,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,400,,,,,,,,2,,,TBD,,Morgan McNamara,,Leyla Hernandez-Donoso,,,,,,,NA,,,Medidata CTMS (VBU),,,5/31/2014,5/31/2014,5/31/2014,5/31/2014,,,3/12/2015,3/12/2015,3/12/2015,3/12/2015,,,3/15/2016,3/15/2016,,,4/15/2016,3/23/2016,,,,,,,,,,,6/30/2016,6/30/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/2/2016,12/2/2016,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_009,EPI-009,'EPI-009,,TAK-214,Burden of Norovirus disease among the elderly in the European Union,EPI-009,0,Withdrawn,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,300",,,,,,,,3,,,TBD,,Morgan McNamara,,Margarita Riera,,N/A,,,,,NA,,,Medidata CTMS (VBU),,,9/18/2014,9/18/2014,12/4/2014,12/4/2014,,,6/30/2019,,6/30/2019,,,,6/30/2020,,,,7/31/2020,,,,,,,,,,,,9/30/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/31/2020,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_010,EPI-010,'EPI-010,,,Sandai study. Burden of Norovirus disease among the elderly living in long term care facilities in Japan.,EPI-010,0,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,497,,,,,,,,2,,,TBD,,Morgan McNamara,,Munehide Kano,,,,,,,,,,Medidata CTMS (VBU),,,3/20/2015,3/20/2015,9/28/2018,,,,1/1/2019,,1/1/2019,,,,12/31/2019,,,,6/30/2020,,,,,,,,,,,,7/31/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/30/2020,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_011,EPI-011,'EPI-011,,,Osaka retrospective study - Community Dwelling,EPI-011,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,"5,000",,,,,,,,1,,,Mediscience Planning Inc.,,Morgan McNamara,,Munehide Kano,,,,,,,,,,Medidata CTMS (VBU),,,6/30/2015,6/30/2015,9/16/2015,9/16/2015,,,3/31/2016,1/16/2016,3/31/2016,1/16/2016,,,3/31/2017,3/31/2017,,,3/31/2017,3/31/2017,,,,,,,,,,,3/31/2017,3/31/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/31/2017,5/30/2017,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_012,EPI-012,'EPI-012,,TAK-214,Norovirus disease in Germany. A method- mix study to assess epidemiology and action processes,EPI-012,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"2,000",,,,,,,,1,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,6/30/2015,6/30/2015,6/30/2015,6/30/2015,,,11/1/2016,11/1/2016,11/1/2016,11/1/2016,,,3/30/2018,3/30/2018,,,3/30/2018,3/30/2018,,,,,,,,,,,4/30/2018,4/30/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/31/2018,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_013,EPI-013,'EPI-013,,,Burden of disease of norovirus gastroenteritis among hospitalized patients in Germany,EPI-013,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,0,,,,,,,,1,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,,,,Medidata CTMS (VBU),,,7/1/2013,7/1/2013,7/1/2013,7/1/2013,,,2/15/2014,2/15/2014,2/15/2014,2/15/2014,,,12/31/2014,12/31/2014,,,1/15/2015,1/15/2015,,,,,,,,,,,1/31/2015,1/31/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/31/2015,10/16/2015,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_014,EPI-014,'EPI-014,,TAK-214,Norovirus disease in the UK population: Identifying the potential impact of a vaccine,EPI-014,0,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,0,,,,,,,,110,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,1/31/2019,,1/31/2019,,,,3/31/2019,,3/31/2019,,,,3/31/2021,,,,4/30/2021,,,,,,,,,,,,5/31/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/31/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_015,EPI-015,'EPI-015,,TAK-214,Early Bird Study (Immunologic and Genetic Markers of Protection to Norovirus),EPI-015,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,100,,,,,,,,1,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,3/1/2013,3/1/2013,3/1/2013,3/1/2013,,,4/30/2013,4/30/2013,4/30/2013,4/30/2013,,,12/30/2016,5/9/2017,,,12/31/2016,5/9/2017,,,,,,,,,,,6/1/2017,6/1/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/31/2017,1/3/2018,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_016,EPI-016,'EPI-016,,TAK-214,Strain surveillance EU - Koopmans Study,EPI-016,0,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,0,,,,,,,,25,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,1/31/2020,,1/31/2020,,,,4/30/2020,,4/30/2020,,,,4/30/2021,,,,4/30/2022,,,,,,,,,,,,4/30/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/31/2022,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_017,EPI-017,'EPI-017,,TAK-214,Disease Burden of Norovirus in Children in Malawi,EPI-017,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,242",,,,,,,,2,,,TBD,,Morgan McNamara,,Thomas Verstraeten,,,,,,,NA,,,Medidata CTMS (VBU),,,12/5/2014,12/5/2014,7/23/2015,7/23/2015,,,10/31/2015,10/31/2015,10/31/2015,10/31/2015,,,10/31/2016,10/31/2016,,,12/31/2016,12/30/2016,,,,,,,,,,,4/30/2017,4/30/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/30/2018,8/29/2018,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_018,EPI-018,'EPI-018,,TAK-214,Seroprevalence of Norovirus antibodies in Chilean infants,EPI-018,0,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,495,,,,,,,,1,,,TBD,,Morgan McNamara,,Margarita Riera,,,,,,,NA,,,Medidata CTMS (VBU),,,1/26/2015,1/26/2015,1/26/2015,1/26/2015,,,5/31/2015,5/31/2015,6/30/2015,5/31/2015,,,8/31/2015,7/31/2015,,,8/31/2015,7/31/2015,,,,,,,,,,,6/30/2016,6/30/2016,,,,,,,,,7/9/2016,7/9/2016,,,,,,,,,,,,,,,,,,,,,,,8/31/2017,8/9/2017,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_020,EPI-020,'EPI-020,,TAK-214,Burden of Norovirus disease among families from a semirural low-mid socioeconomic county (Colina) in a middle-high income country (Chile),EPI-020,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,30,,,,,,,,1,,,TBD,,Morgan McNamara,,Leyla Hernandez-Donoso,,N/A,,,,,NA,,,Medidata CTMS (VBU),,,12/7/2015,12/7/2015,12/7/2015,12/7/2015,,,3/30/2016,4/11/2016,3/31/2016,4/11/2016,,,8/15/2016,7/18/2016,,,8/15/2018,8/15/2018,,,,,,,,,,,8/30/2018,8/30/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/30/2018,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_024,EPI-024,'EPI-024,,TAK-214,Role of Human Calicivirus in acute Diarrhea in children < 5 years old assisting to outpatient health clinic in Buenos Aires: A cross sectional study,EPI-024,0,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,330,,,,,,,,1,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,11/30/2016,11/21/2016,11/30/2016,11/21/2016,,,3/1/2018,3/1/2018,3/1/2018,3/1/2018,,,4/29/2021,,,,4/30/2021,,,,,,,,,,,,5/31/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/30/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_025,EPI-025,'EPI-025,,TAK-214,Norovirus Laboratory Surveillance in Germany,EPI-025,0,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,240,,,,,,,,1,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,10/29/2016,10/29/2016,10/29/2016,10/29/2016,,,1/1/2017,1/1/2018,1/1/2017,1/1/2018,,,4/30/2021,,,,4/30/2021,,,,,,,,,,,,6/30/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/30/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_026,EPI-026,'EPI-026,,TAK-214,"The epidemiology of Norovirus in a pediatric population in a peri-urban area of Lima, Peru",EPI-026,0,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,800,,,,,,,,2,1,,IQVIA,,"Anne Crissey, Ilaria Albieri, Morgan McNamara",,,,,,,,,NA,,,Medidata CTMS (VBU),,,12/22/2017,2/26/2018,3/30/2018,2/26/2018,,,2/26/2019,3/15/2019,2/26/2019,3/15/2019,,,10/31/2019,10/31/2019,,,4/30/2020,4/8/2020,,,,,,,,,,,1/29/2021,1/29/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/31/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_027,EPI-027,'EPI-027,,TAK-214,Secondary household transmission of norovirus and implications for the indirect effects of pediatric norovirus vaccines. (PI. Sylvia Becker-Dreps),EPI-027,0,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,2/18/2019,2/18/2019,,,,,8/1/2019,8/1/2019,,,11/30/2021,,,,12/31/2021,,,,,,,,,,,,3/31/2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/30/2022,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_028,EPI-028,'EPI-028,,TAK-214,Global Pediatric Norovirus Surveillance Network (NoroSurv) to Monitor Global Norovirus Strain Distribution in Children < 5 years of Age. PI. Jan Vinje.,EPI-028,0,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,4/1/2019,2/18/2019,,,,,5/31/2020,,,,5/31/2023,,,,5/31/2023,,,,,,,,,,,,6/30/2023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/30/2023,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_029,EPI-029,'EPI-029,,TAK-214,"Prospective cohort study pre-Phase III (NOR-335) North America, Latin America, Japan",EPI-029,0,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,9/30/2023,,,,,,12/31/2023,,,,12/31/2024,,,,12/31/2024,,,,,,,,,,,,3/31/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/30/2025,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_030,EPI-030,'EPI-030,,TAK-214,Additional analyses MAAGE/CAAGE (using EPI-001 Kaiser P.),EPI-030,0,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,10/1/2021,,,,,,1/1/2022,,,,1/1/2023,,,,1/1/2023,,,,,,,,,,,,3/1/2023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/1/2023,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_031,EPI-031,'EPI-031,,TAK-214,"Collaboration birth cohort study (PREVAIL), Cincinnati",EPI-031,0,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,4/1/2023,,,,,,7/1/2023,,,,7/1/2024,,,,7/1/2024,,,,,,,,,,,,9/1/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/1/2024,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_032,EPI-032,'EPI-032,,TAK-214,Additional analyses APPETITE study Alberta.,EPI-032,0,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,4/1/2023,,,,,,7/1/2023,,,,7/1/2024,,,,7/1/2024,,,,,,,,,,,,9/1/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/1/2024,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_033,EPI-033,'EPI-033,,TAK-214,Additional analyses existing datasets Latin America,EPI-033,0,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,4/1/2023,,,,,,7/1/2023,,,,7/1/2024,,,,7/1/2024,,,,,,,,,,,,9/1/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/1/2024,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_034,EPI-034,'EPI-034,,TAK-214,Additional analyses existing datasets Japan (IISR),EPI-034,0,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,4/1/2023,,,,,,7/1/2023,,,,7/1/2024,,,,7/1/2024,,,,,,,,,,,,9/1/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/1/2024,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_035,EPI-035,'EPI-035,,TAK-214,Laboratory-based surveillance for  GII.4  in MAAGE (IISR),EPI-035,0,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,1,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,,,6/30/2023,,,,,,9/30/2023,,,,9/30/2027,,,,9/30/2027,,,,,,,,,,,,11/30/2027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/30/2028,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI_036,EPI-036,'EPI-036,,TAK-214,EPIDEMIOLOGICAL STUDY TO ESTIMATE THE INCIDENCE AND PREVALENCE OF NOROVIRUS IN CHILDREN UNDER TWO YEARS OF AGE IN PANAMA,EPI-036,0,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,480,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,7/22/2019,7/22/2019,7/22/2019,7/22/2019,,,11/30/2019,1/6/2020,11/30/2019,1/6/2020,,,3/31/2020,3/31/2020,,,9/30/2020,9/30/2020,,,,,,,,,,,5/31/2021,,,,,,,,,,6/15/2021,,,,,,,,,,,,,,,,,,,,,,,,6/30/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_EPI-021,EPI-021,'EPI-021,,TAK-214,Population-Based Surveillance for Pathogens Associated With Acute Gastroenteritis Among U.S. Military Basic Trainees,EPI-021,0,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,1,,,TBD,,Morgan McNamara,,John Weil,,,,,,,NA,,,Medidata CTMS (VBU),,,2/29/2016,2/29/2016,2/29/2016,2/29/2016,,,7/31/2016,7/31/2016,7/31/2016,7/31/2016,,,7/31/2019,,,,8/30/2019,,,,,,,,,,,,9/30/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/31/2019,,,,,,,,,,,,,,,,,,,,,,,
VV_IPV_101,IPV-101,'IPV-101,,,"A Randomized, Observer-Blind, Controlled Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses of a Stand-alone Trivalent, Inactivated Poliomyelitis Vaccine from Sabin Strains in Healthy Infants, with a Safety and Tolerability Lead-in in Healthy Toddlers",IPV-101,I,Cancelled,Prevention of infectious disease caused by polio virus,,Vaccine,,,,Prevention,,,300,,,,,,,,3,,,TBD,,lorenzo bertelli,,,,,,,,,,,,Medidata CTMS (VBU),,,7/11/2016,7/11/2016,11/25/2016,,,,4/30/2017,,4/30/2017,,,,8/31/2017,,,,3/1/2019,,,,,,,,,,,,4/12/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8/23/2019,,,,,,,,,,,,,,,,,,,,,,,
VV_IPV_102,IPV-102,'IPV-102,,TAK-195,"A Randomized, Observer-Blind, Controlled Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses of a Stand-alone Trivalent, Inactivated Poliomyelitis Vaccine from Sabin Strains in Healthy Infants, with a Safety and Tolerability Lead-in in Healthy Toddlers",IPV-102,I,Reported,Prevention of infectious disease caused by polio virus,Vaccine,Vaccine,,,,Prevention,,,340,,,,,,,,3,4,,PRA Health Sciences,,"Ilaria Albieri, lorenzo bertelli, Marian Weijs",Pedro Garbes,Jakob Cramer,,,,,,,,,,Medidata CTMS (VBU),,,7/11/2016,7/11/2016,11/25/2016,11/23/2016,,,5/26/2017,6/7/2017,5/26/2017,6/7/2017,,,12/26/2017,12/28/2017,,,6/29/2018,6/29/2018,,,,,,,,,,,12/14/2018,12/14/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/8/2019,11/18/2019,,,,,,,,,,,,,,,,,,,,,,
VV_IPV_301,IPV-301,'IPV-301,,TAK-195,"A Randomized, Observer-Blind, Controlled Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Stand-alone Trivalent, Inactivated Poliomyelitis Vaccine from Sabin Strains Compared with Standard Salk-based Inactivated Poliomyelitis Vaccine in Healthy Infants in sub-Saharan Africa",IPV-301,III,Cancelled,Prevention of infectious disease caused by polio virus,Vaccine,Vaccine,,,,Prevention,,,350,,,,,,,,6,,,PRA Health Sciences,,"lorenzo bertelli, Marian Weijs",,,,,,,,,,,,Medidata CTMS (VBU),,,10/1/2016,,5/1/2018,,,,1/7/2019,,1/7/2019,,,,2/7/2019,,,,8/7/2020,,,,,,,,,,,,9/7/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/8/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_IPV_302,IPV-302,'IPV-302,,TAK-195,"A Randomized, Observer-Blind, Controlled Phase 3 Trial to Evaluate the Safety, Tolerability, and immunologic Non-Inferiority of a Stand-alone Trivalent, Inactivated Poliomyelitis Vaccine from Sabin Strains Compared with Standard Salk-based Inactivated Poliomyelitis Vaccine in Healthy Infants",IPV-302,III,Cancelled,Prevention of infectious disease caused by polio virus,Vaccine,Vaccine,,,,Prevention,,,"1,020",,,,,,,,5,,,PRA Health Sciences,,"lorenzo bertelli, Marian Weijs",,,,,,,,,,,,Medidata CTMS (VBU),,,10/1/2016,,5/1/2018,,,,10/1/2018,,10/1/2018,,,,11/1/2018,,,,5/1/2020,,,,,,,,,,,,7/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/1/2020,,,,,,,,,,,,,,,,,,,,,,,
VV_IPV_303,IPV-303,'IPV-303,,TAK-195,"A Randomized, Observer-Blind, Controlled Phase 3 Trial to Evaluate the Safety, Tolerability, and Lot-to-Lot Consistency of a Stand-alone Trivalent, Inactivated Poliomyelitis Vaccine from Sabin Strains Compared with Standard Salk-based Inactivated Poliomyelitis Vaccine in Healthy Infants",IPV-303,III,Cancelled,Prevention of infectious disease caused by polio virus,Vaccine,Vaccine,,,,Prevention,,,"1,125",,,,,,,,5,,,PRA Health Sciences,,"lorenzo bertelli, Marian Weijs",,,,,,,,,,,,Medidata CTMS (VBU),,,4/1/2017,,6/1/2018,,,,11/1/2018,,11/1/2018,,,,1/7/2019,,,,7/1/2020,,,,,,,,,,,,9/12/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/30/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_IPV_305,IPV-305,'IPV-305,,TAK-195,,IPV-305,IIIa,Cancelled,Prevention of infectious disease caused by polio virus,Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,,,,,,,,,,,,,Medidata CTMS (VBU),,,11/29/2019,,11/29/2019,,,,11/29/2019,,11/29/2019,,,,11/29/2019,,,,11/29/2019,,,,,,,,,,,,11/29/2019,,,,,,,,,,11/29/2019,,,,,,,,,,,,,,,,,,,,,,,,11/29/2019,,,,,,,,,,,,,,,,,,,,,,,
VV_IPV_306,IPV-306,'IPV-306,,TAK-195,,IPV-306,IIIa,Cancelled,Prevention of infectious disease caused by polio virus,Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,,,,,,,,,,,,,Medidata CTMS (VBU),,,11/29/2019,,11/29/2019,,,,11/29/2019,,11/29/2019,,,,11/29/2019,,,,11/29/2019,,,,,,,,,,,,11/29/2019,,,,,,,,,,11/29/2019,,,,,,,,,,,,,,,,,,,,,,,,11/29/2019,,,,,,,,,,,,,,,,,,,,,,,
VV_LV01_101,LV01-101,'LV01-101,,,"Phase 1 Dose Escalation, Safety and Immunogenicity Study of Intranasal Norwalk VLP Vaccine with Adjuvant (MPL) and Excipients (Chitosan, Mannitol and Sucrose)",LV01-101,I,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,28,,,,,,,,1,,,"DP Clinical, Inc.",,Julie Cordova,,,,,,,,,,,,Medidata CTMS (VBU),,,3/6/2007,3/6/2007,3/6/2007,3/6/2007,,,4/9/2007,4/9/2007,4/23/2007,4/23/2007,,,5/15/2008,5/15/2008,,,10/7/2008,10/7/2008,,,,,,,,,,,10/12/2009,10/12/2009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/24/2010,3/24/2010,,,,,,,,,,,,,,,,,,,,,,
VV_LV01_102,LV01-102,'LV01-102,,,"Phase 1, Randomized Double blind Placebo-Controlled Phase 1,Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-like Particle Vaccine (Norwalk VLP Antigen, MPL, chitosan, mannitol and sucrose) compared to Adjuvant/Excipients (MPL,chitosan,mannitol, and sucrose) and to Placebo (empty device)",LV01-102,I,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,61,,,,,,,,4,,,"DP Clinical, Inc.",,Julie Cordova,,,,,,,,,,,,Medidata CTMS (VBU),,,8/6/2008,8/6/2008,8/6/2008,8/6/2008,,,11/17/2008,11/17/2008,11/24/2008,11/24/2008,,,3/19/2009,3/19/2009,,,10/13/2009,10/13/2009,,,,,,,,,,,9/10/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/9/2011,2/9/2011,,,,,,,,,,,,,,,,,,,,,,
VV_LV01_103,LV01-103,'LV01-103,,,"Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety and Efficacy Study in Healthy Adults of Intranasal Norwalk Virus-like Particle Vaccine in Experimental Human Norwalk Virus Infection",LV01-103,I,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,90,,,,,,,,4,,,"DP Clinical, Inc.",,Julie Cordova,,,,,,,,,,,,Medidata CTMS (VBU),,,1/12/2009,1/12/2009,1/12/2009,1/12/2009,,,8/4/2009,8/4/2009,8/9/2009,8/9/2009,,,1/20/2010,1/20/2010,,,8/18/2010,8/18/2010,,,,,,,,,,,9/10/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/24/2015,6/24/2015,,,,,,,,,,,,,,,,,,,,,,
VV_LV03_104,LV03-104,'LV03-104,,,"Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide (AlOH) in Adults",LV03-104,I,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,102,,,,,,,,3,,,"DP Clinical, Inc.",,Julie Cordova,,,,,,,,,,,,Medidata CTMS (VBU),,,2/23/2010,2/23/2010,2/23/2010,2/23/2010,,,9/3/2010,9/3/2010,9/15/2010,9/15/2010,,,12/12/2011,12/12/2011,,,1/9/2013,1/9/2013,,,,,,,,,,,9/10/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/21/2015,5/21/2015,,,,,,,,,,,,,,,,,,,,,,
VV_LV03_105,LV03-105,'LV03-105,,,"Phase I - II, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity and Efficacy trial in Healthy Adults of Norovirus IM Bivalent VLP Vaccine in Experimental Human Norovirus GII.4 Disease",LV03-105,I,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,132,,,,,,,,5,,,"DP Clinical, Inc.",,"Georgios Foteinos, Julie Cordova",,,,,,,,,,,,Medidata CTMS (VBU),,,1/26/2012,1/26/2012,1/26/2012,1/26/2012,,,2/17/2012,2/17/2012,2/19/2012,2/19/2012,,,2/23/2012,2/23/2012,,,2/24/2012,2/24/2012,,,,,,,,,,,3/2/2012,3/2/2012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/15/2015,9/10/2015,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_107,NOR-107,'NOR-107,,TAK-214,"Phase II, Dosage and Adjuvant Justification, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Adults",NOR-107,IIa,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,420,,,,,,,,2,,,IQVIA,,"Georgios Foteinos, Harald Pfaar",,"Frank Baehner, Jakob Cramer, Jim Sherwood, Kerim Chitour",,2015-000252-18,,,,,NA,,,Medidata CTMS (VBU),,,10/10/2013,10/10/2013,10/10/2013,10/10/2013,,,3/28/2014,3/28/2014,3/28/2014,3/28/2014,,,5/22/2014,5/22/2014,,,6/24/2015,6/19/2015,,,,,,,,,,,8/26/2015,8/17/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11/30/2016,12/2/2016,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_110,NOR-110,'NOR-110,,,"An Open-Label, Long Term Immunogenicity Follow-up Trial of Subjects who have Previously Received an Intramuscular Injection of Norovirus GI/GII.4 Bivalent Virus Like Particle vaccine in selected clinical trials",NOR-110,II,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,"1,067",,,,,,,,15,,,IQVIA,,"Georgios Foteinos, Harald Pfaar",,,,,,,,,,,,Medidata CTMS (VBU),,,10/7/2016,,11/30/2016,,,,2/17/2017,,2/17/2017,,,,7/17/2017,,,,7/17/2022,,,,,,,,,,,,10/17/2022,,,,,,,,,,9/26/2016,,,,,,,,,,,,,,,,,,,,,,,,1/17/2023,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_201,NOR-201,'NOR-201,,TAK-214,"Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Adults",NOR-201,II,Reported,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,450,,,,,,,,10,,,IQVIA,,"Georgios Foteinos, Jennifer Kilbury","Vincent Mwangi, Ximena Calvo","Frank Baehner, Jakob Cramer",,,,,,,NA,,,Medidata CTMS (VBU),,,12/13/2013,12/13/2013,1/28/2014,1/28/2014,,,5/15/2014,5/15/2014,5/15/2014,5/15/2014,,,7/2/2014,7/2/2014,,,1/11/2016,1/14/2016,,,,,,,,,,,1/29/2016,2/1/2016,,,,,,,,,3/14/2016,3/14/2016,,,,,,,,,,,,,,,,,,,,,,,11/7/2016,12/20/2016,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_202,NOR-202,'NOR-202,,TAK-214,"Phase II, Dose Finding, Age Step Down, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine in Children, Toddlers and Infants",NOR-202,IIa,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,840,840,0,,59,840,0,100.00%,12,,,IQVIA,,"Aline Prates, Ana Sekine, Georgios Foteinos, Manuela Viana",Paul Mendelman,"Jim Sherwood, Kerim Chitour, Pedro Garbes",,2014-000778-20,,,,,NA,,,Medidata CTMS (VBU),,,12/3/2013,12/3/2013,3/10/2014,3/10/2014,,,6/23/2015,6/23/2015,6/23/2015,6/23/2015,,,7/25/2017,7/25/2017,,,6/20/2018,6/20/2018,,,,,,,,,,,8/30/2018,8/30/2018,,,,,,,,,9/18/2018,9/18/2018,,,,,,,,,,,,,5/8/2019,5/8/2019,,,,,,,,,2/26/2020,2/26/2020,,,,,,,,,,,,,,,4/26/2020,,,,,,,
VV_NOR_204,NOR-204,'NOR-204,,TAK-214,"Phase II, Dosage and Adjuvant Confirmation, Age Step down, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Older Adults",NOR-204,IIa,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,325,320,0,,0,0,11,98.46%,10,,,PPD,,"Anne Crissey, Georgios Foteinos, Harald Pfaar, lorenzo bertelli","Vincent Mwangi, Ximena Calvo","Frank Baehner, Jakob Cramer, Jim Sherwood, Nancy Bouveret Le Cam, Sudhir Bansod",,NA,,,,,NA,,,Medidata CTMS (VBU),,,6/26/2014,6/26/2014,7/29/2014,7/29/2014,,,2/1/2016,2/1/2016,2/1/2016,2/1/2016,,,9/2/2016,9/2/2016,,,9/29/2017,9/29/2017,,,,,,,,,,,2/5/2018,2/5/2018,,,,,,,,,3/1/2018,3/1/2018,,,,,,,,,,,,,,,,,,,,,,,10/22/2018,10/22/2018,,,,,,,,,,,,,,,10/22/2018,10/22/2018,,,,,,
VV_NOR_206,NOR-206,'NOR-206,,TAK-214,"A Phase II Partially-Blinded, Randomized Placebo-Controlled Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine when administered with or without Routine infant Vaccines",NOR-206,IIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,800",,,,,,,,12,,,IQVIA,,"Anne Crissey, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,3/30/2022,,6/30/2022,,,,1/30/2023,,1/30/2023,,,,6/29/2023,,,,6/21/2024,,,,,,,,,,,,9/7/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/18/2025,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_207,NOR-207,'NOR-207,,TAK-214,"Phase II, Uncontrolled, Open Label Trial to Evaluate the Long Term Safety and Immunogenicity of the Norovirus VLP Vaccine in Infants who Participated in Trial NOR-206 with and without a Booster Dose",NOR-207,IIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,800",,,,,,,,12,,,IQVIA,,"Anne Crissey, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,2/28/2023,,5/28/2023,,,,11/28/2023,,11/28/2023,,,,4/26/2024,,,,10/23/2027,,,,,,,,,,,,1/9/2028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/21/2028,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_208,NOR-208,'NOR-208,,TAK-214,"Phase II, Randomized, Placebo Controlled, Blinded, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine In Healthy Adolescents",NOR-208,IIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,250",,,,,,,,10,,,IQVIA,,"Georgios Foteinos, Harald Pfaar",Vincent Mwangi,"Frank Baehner, Jakob Cramer, Jim Sherwood",,,,,,,NA,,,Medidata CTMS (VBU),,,4/30/2022,,7/30/2022,,,,1/30/2023,,1/30/2023,,,,5/30/2023,,,,11/29/2023,,,,,,,,,,,,2/15/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/27/2024,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_210,NOR-210,'NOR-210,,TAK-214,"Phase II, Open label, Safety and Immunogenicity Study of Bivalent Norovirus Vaccine to generate High Titer Positive Control Serum",NOR-210,IIa,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,50,50,0,,0,0,2,100.00%,1,,,PPD,,"Georgios Foteinos, Jennifer Kilbury, lorenzo bertelli",Vincent Mwangi,"Frank Baehner, Jakob Cramer, Jim Sherwood, Sudhir Bansod",,,,,,,NA,,,Medidata CTMS (VBU),,,12/1/2014,12/17/2014,1/12/2015,1/19/2015,,,3/3/2015,2/26/2015,2/26/2015,2/26/2015,,,3/9/2015,2/27/2015,,,9/9/2015,9/11/2015,,,,,,,,,,,10/27/2015,10/29/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9/30/2016,9/26/2016,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_211,NOR-211,'NOR-211,,TAK-214,"Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years",NOR-211,IIb,Completed,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"4,176","4,758",0,,751,0,0,113.94%,1,,,IQVIA,,"Anne Crissey, Georgios Foteinos, Sonja Moua",,Jim Sherwood,,,,,,,NA,,,Medidata CTMS (VBU),,,6/24/2015,6/24/2015,7/27/2015,7/27/2015,,,6/14/2016,6/14/2016,6/14/2016,6/14/2016,,,4/26/2018,4/26/2018,,,6/16/2018,6/16/2018,,,,,,,,,,,8/8/2018,8/8/2018,,,,,,,,,8/31/2018,8/31/2018,,,,,,,,,,,,,7/7/2019,7/7/2019,,,,,,,,,3/3/2020,,,,,,,,,,,,,,,,3/3/2020,,,,,,,
VV_NOR_212,NOR-212,'NOR-212,,TAK-214,"A phase 2b, double-blind, randomized, multi-site, placebo-controlled trial to evaluate the efficacy, safety and immunogenicity of intramuscular TAK-214 Norovirus vaccine in healthy children 6 Months of age at initial vaccination.",NOR-212,IIb,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"2,000",,,,,,,,1,,,IQVIA,,"Ana Sekine, Anne Crissey, Marian Weijs",,,,,,,,,NA,,,Medidata CTMS (VBU),,,11/14/2019,,3/23/2020,,,,8/25/2021,,3/18/2023,,,,11/3/2022,,,,,,,,,,,,11/20/2024,,,,6/24/2023,,2/8/2024,,,,,,2/2/2025,,7/15/2023,,2/22/2024,,,,,,2/16/2025,,,,,,8/5/2023,,3/21/2024,,,,,,3/16/2025,,10/28/2023,,6/13/2024,,,,,,6/8/2025,,,,,,,,6/8/2025,,,,,,,
VV_NOR_213,NOR-213,'NOR-213,,TAK-214,"An Open-Label, Long Term Immunogenicity Follow-up Trial of Subjects who have Previously Received an Intramuscular Injection of Norovirus GI/GII.4 Bivalent Virus Like Particle vaccine in selected clinical trials",NOR-213,II,Recruitment Complete,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,597,540,0,,2,0,0,90.45%,12,,,IQVIA,,"Anne Crissey, Georgios Foteinos, Sonja Moua","Seetha Meyer, Zenaida Mojares",Seetha Meyer,,2016-004288-37,,,,,NA,,,Medidata CTMS (VBU),,,9/28/2016,9/28/2016,11/2/2016,11/2/2016,,,2/21/2017,2/21/2017,2/21/2017,2/21/2017,,,8/13/2018,8/13/2018,,,10/26/2021,,,,,,,,,,,,1/28/2022,1/14/2020,,,,,,,,,3/1/2022,,,,,,,,,,,,,,3/8/2022,,,,,,,,,,3/29/2022,,,,,,,,,,,,,,,,3/29/2022,,,,,,,
VV_NOR_214,NOR-214,'NOR-214,,TAK-214,,NOR-214,IIb,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,IQVIA,,Anne Crissey,,,,,,,,,NA,,,Medidata CTMS (VBU),,,6/19/2017,,5/15/2018,,,,7/24/2018,,7/24/2018,,,,7/24/2018,,,,7/24/2018,,,,,,,,,,,,10/26/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/6/2019,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_223,NOR-223,'NOR-223,,TAK-214,,NOR-223,II,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,300,,,,,,,,,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,7/17/2016,,10/17/2016,,,,4/26/2017,,4/26/2017,,,,5/31/2017,,,,11/30/2017,,,,,,,,,,,,1/29/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/29/2018,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_303,NOR-303,'NOR-303,,TAK-214,"Phase 3, Double-blind, Randomized, Placebo-controlled trial to determine the Efficacy, Safety, and Immunogenicity of Norovirus Bivalent GI.1/GII.4 VLP Vaccine in Healthy Adults ≥ 18 years",NOR-303,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"6,600",,,,,,,,60,,,IQVIA,,"Georgios Foteinos, Jennifer Kilbury, lorenzo bertelli","Paul Mendelman, Vincent Mwangi, Ximena Calvo","Frank Baehner, Jim Sherwood",,,,,,,NA,,,Medidata CTMS (VBU),,,12/1/2017,,3/2/2019,,,,9/2/2019,,9/2/2019,,,,6/28/2020,,,,9/8/2020,,,,,,,,,,,,11/25/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/7/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_304,NOR-304,'NOR-304,,TAK-214,"A Phase III, Randomized, Multi-Center, Double Blind, Placebo-Controlled Trial to Compare the Safety and Immunogenicity of Three Consecutive Manufacturing Lots of the Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",NOR-304,IIIa,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"2,100",,,,,,,,3,,,IQVIA,,"Eva Ammon, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,5/26/2022,,7/27/2024,,,,11/24/2024,,11/24/2024,,,,7/22/2025,,,,2/15/2026,,,,,,,,,,,,3/15/2026,,,,,,,,,,3/29/2026,,,,,,,,,,,,,,4/26/2026,,,,,,,,,,7/5/2026,,,,,,,,,,,,,,,,7/5/2026,,,,,,,
VV_NOR_306,NOR-306,'NOR-306,,TAK-214,"Phase III, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Administered Alone or Concomitantly with Influenza and Zostavax in Older Adults (include also frail Older Adults)",NOR-306,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,750",,,,,,,,12,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,4/30/2022,,7/30/2022,,,,1/30/2023,,1/30/2023,,,,9/27/2023,,,,3/28/2024,,,,,,,,,,,,6/14/2024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/25/2024,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_307,NOR-307,'NOR-307,,TAK-214,A Phase III Randomized Controlled Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Administered alone or Concomitantly with Travel Vaccines in Healthy Children and Adolescents,NOR-307,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,650",,,,,,,,10,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,1/30/2020,,4/30/2020,,,,10/30/2020,,10/30/2020,,,,2/27/2021,,,,9/26/2021,,,,,,,,,,,,12/25/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/25/2022,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_308,NOR-308,'NOR-308,,TAK-214,Safety / Immunogenicity in Immunocompromised Subjects,NOR-308,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,,,,,,,,,,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,6/20/2026,,9/20/2026,,,,3/20/2027,,3/20/2027,,,,12/15/2027,,,,12/9/2028,,,,,,,,,,,,2/25/2029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/8/2029,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_309,NOR-309,'NOR-309,,TAK-214,"Phase III, Safety and Immunogenicity Trial, Concomitant Administration (Various Schedules) and Non-Interference with Routine Vaccinations in Infants",NOR-309,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,980",,,,,,,,6,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,7/3/2023,,10/3/2023,,,,4/3/2024,,4/3/2024,,,,9/30/2024,,,,10/28/2025,,,,,,,,,,,,1/14/2026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/27/2026,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_310,NOR-310,'NOR-310,,TAK-214,"Safety-Immuno, Concomitant Vaccination, follow-up extension study, 11 months, infants",NOR-310,IIIb,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"2,000",,,,,,,,12,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,2/1/2021,,9/29/2025,,,,3/29/2025,,3/29/2025,,,,9/25/2025,,,,9/4/2029,,,,,,,,,,,,11/21/2029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/3/2030,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_311,NOR-311,'NOR-311,,TAK-214,"Phase III, Safety and Immunogenicity Trial, Persistence and Concomitant Use with Routine Vaccinations in Infants (Developing Countries – Expanded Program on Immunization (EPI)-World Health Organization (WHO) Schedule)",NOR-311,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,300,,,,,,,,2,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,7/3/2023,,10/3/2023,,,,4/3/2024,,4/3/2024,,,,6/2/2024,,,,6/30/2025,,,,,,,,,,,,9/16/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/27/2026,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_312,NOR-312,'NOR-312,,TAK-214,"Phase III, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Administered Concomitantly with MMR+Varicella, or DTaP and Pneumococcal Vaccines in Children",NOR-312,IIIa,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,250",,,,,,,,6,,,IQVIA,,"Eva Ammon, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,4/27/2022,,7/27/2024,,,,11/24/2024,,1/27/2025,,,,9/24/2025,,,,4/20/2026,,,,,,,,,,,,7/3/2026,,,,,,,,,,7/17/2026,,,,,,,,,,,,,,8/14/2026,,,,,,,,,,12/4/2026,,,,,,,,,,,,,,,,12/4/2026,,,,,,,
VV_NOR_315,NOR-315,'NOR-315,,TAK-214,"A Phase III, Double Blind, Randomized, Multi-Site, Placebo Controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Infants Co-administered with Routine Infant Vaccines",NOR-315,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"8,000",,,,,,,,10,,,IQVIA,,"Ana Sekine, Georgios Foteinos",,"Frank Baehner, Jim Sherwood, Pedro Garbes",,,,,,,NA,,,Medidata CTMS (VBU),,,7/3/2023,,10/3/2023,,,,4/3/2024,,4/3/2024,,,,9/30/2024,,,,9/30/2025,,,,,,,,,,,,12/17/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/29/2026,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_316,NOR-316,'NOR-316,,TAK-214,"Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Long Term Safety and Immunogenicity of the Bivalent Norovirus VLP Vaccine in Adults with Booster Doses at Various Time Points",NOR-316,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,600,,,,,,,,6,,,IQVIA,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,4/30/2022,,7/30/2022,,,,1/30/2023,,1/30/2023,,,,3/31/2023,,,,4/3/2028,,,,,,,,,,,,6/20/2028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/31/2028,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_317,NOR-317,'NOR-317,,TAK-214,"Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, long term safety and immunogenicity of the bivalent Norovirus VLP Vaccine in Older Adults with Booster doses at various time points",NOR-317,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,600,,,,,,,,6,,,IQVIA,,Morgan McNamara,,,,,,,,,NA,,,Medidata CTMS (VBU),,,4/30/2022,,8/30/2022,,,,1/30/2023,,1/30/2023,,,,5/22/2023,,,,5/25/2028,,,,,,,,,,,,8/11/2028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/22/2028,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_318,NOR-318,'NOR-318,,TAK-214,"Phase III, Randomized, Double-Blind, Safety and Long Term Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Infants and Children with and without booster",NOR-318,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,000",,,,,,,,6,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,7/3/2023,,10/3/2023,,,,4/3/2024,,4/3/2024,,,,10/30/2024,,,,11/3/2029,,,,,,,,,,,,1/20/2030,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/2/2030,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_319,NOR-319,'NOR-319,,TAK-214,Phase III Randomized Controlled Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Administered alone or Concomitantly with Travel and Influenza Vaccines in Adults,NOR-319,IIIa,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,860",,,,,,,,12,,,IQVIA,,"Eva Ammon, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,5/28/2022,,7/27/2024,,,,11/24/2024,,11/24/2024,,,,5/23/2025,,,,11/19/2025,,,,,,,,,,,,2/1/2026,,,,,,,,,,2/15/2026,,,,,,,,,,,,,,3/15/2026,,,,,,,,,,7/5/2026,,,,,,,,,,,,,,,,7/5/2026,,,,,,,
VV_NOR_322,NOR-322,'NOR-322,,,Phase III Randomized Double-Blind Immunogenicity and Safety Trial comparing Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine manufactured according to two Different Aluminum Hydroxide Adsorption Approaches,NOR-322,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,440,,,,,,,,2,,,IQVIA,,Georgios Foteinos,,,,,,,,,,,,Medidata CTMS (VBU),,,8/17/2016,,11/17/2016,,,,3/17/2017,,3/17/2017,,,,4/7/2017,,,,10/7/2017,,,,,,,,,,,,12/6/2017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/4/2018,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_326,NOR-326,'NOR-326,,TAK-214,Observational LFTU of NOR-303,NOR-326,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"6,600",,,,,,,,3,,,IQVIA,,"Anne Crissey, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,1/4/2017,,3/2/2019,,,,9/2/2019,,9/2/2019,,,,6/28/2020,,,,3/28/2021,,,,,,,,,,,,3/28/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/27/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_327,NOR-327,'NOR-327,,TAK-214,"Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Caucasian and Asian Subjects: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multinational, Parallel-Group Trial in Healthy Adults Aged 18 - <60 Years",NOR-327,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,780,,,,,,,,6,,,IQVIA,,Georgios Foteinos,,,,,,,,,NA,,,Medidata CTMS (VBU),,,12/27/2024,,2/27/2025,,,,10/27/2025,,10/27/2025,,,,1/25/2026,,,,7/27/2026,,,,,,,,,,,,10/13/2026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/23/2027,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_328,NOR-328,'NOR-328,,,Effectiveness in older adults,NOR-328,IIIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",,Vaccine,,,,Prevention,,,,,,,,,,,,,,IQVIA,,Georgios Foteinos,,,,,,,,,,,,Medidata CTMS (VBU),,,2/1/2022,,5/8/2022,,,,11/8/2022,,11/8/2022,,,,5/1/2024,,,,4/26/2025,,,,,,,,,,,,7/13/2025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12/16/2025,,,,,,,,,,,,,,,,,,,,,,,
VV_NOR_334,NOR-334,'NOR-334,,TAK-214,,NOR-334,IIIa,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,000",,,,,,,,,,,TBD,,"Eva Ammon, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,4/27/2022,,7/27/2024,,,,11/24/2024,,1/27/2025,,,,9/24/2025,,,,4/20/2026,,,,,,,,,,,,7/3/2026,,,,,,,,,,7/17/2026,,,,,,,,,,,,,,8/14/2026,,,,,,,,,,12/4/2026,,,,,,,,,,,,,,,,12/4/2026,,,,,,,
VV_NOR_335,NOR-335,'NOR-335,,TAK-214,,NOR-335,IIIa,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"5,600",,,,,,,,,,,TBD,,"Eva Ammon, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,4/30/2023,,7/27/2024,,,,11/24/2024,,1/27/2025,,,,9/24/2025,,,,10/12/2027,,,,,,,,10/12/2027,,,,6/29/2026,,12/30/2026,,,,,,12/25/2027,,7/13/2026,,1/13/2027,,,,,,1/8/2028,,,,,,9/7/2026,,2/10/2027,,,,,,2/5/2028,,11/6/2026,,5/5/2027,,,,,,4/29/2028,,,,,,,,4/29/2028,,,,,,,
VV_NOR_336,NOR-336,'NOR-336,,TAK-214,,NOR-336,IIIb,Planned,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,"1,000",,,,,,,,,,,TBD,,"Eva Ammon, Georgios Foteinos",,,,,,,,,NA,,,Medidata CTMS (VBU),,,5/28/2022,,7/27/2024,,,,11/24/2024,,11/24/2024,,,,7/22/2025,,,,1/18/2026,,,,,,,,,,,,4/2/2026,,,,,,,,,,4/16/2026,,,,,,,,,,,,,,5/14/2026,,,,,,,,,,9/3/2026,,,,,,,,,,,,,,,,9/3/2026,,,,,,,
VV_NOR-222,NOR-222,'NOR-222,,TAK-214,Phase III Randomized Double-Blind Immunogenicity and Safety Trial comparing Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine manufactured according to two Different Aluminum Hydroxide Adsorption Approaches,NOR-222,IIa,Cancelled,"Prevention of AGE caused by norovirus, at risk over 5 years old",Vaccine,Vaccine,,,,Prevention,,,270,,,,,,,,,,,TBD,,"Aline Prates, Georgios Foteinos, PATRICIA PEREZ",,,,,,,,,NA,,,Medidata CTMS (VBU),,,6/29/2015,6/29/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VV_ZIK_101,ZIK-101,'ZIK-101,,TAK-426,"Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adults",ZIK-101,I,Recruiting,Prevention of Zika Virus,Vaccine,Vaccine,,,,Prevention,,,240,271,894,,623,271,20,112.92%,9,8,,PRA Health Sciences,,"Aline Prates, Harald Pfaar, Sonja Moua",,,,NA,,,,,Wave 2,NA,,Medidata CTMS (VBU),,,12/19/2016,12/19/2016,1/29/2017,1/29/2017,,,11/13/2017,11/13/2017,11/27/2017,11/27/2017,,,10/26/2018,10/26/2018,,,12/28/2018,12/28/2018,11/21/2019,11/21/2019,,,,,11/24/2020,11/24/2020,,,5/28/2019,5/28/2019,3/11/2020,3/11/2020,,,,,6/14/2021,6/14/2021,6/28/2019,6/28/2019,9/23/2020,9/23/2020,,,,,7/14/2021,,,,,,6/28/2019,6/28/2019,4/23/2020,4/23/2020,,,,,6/28/2021,,1/31/2020,1/31/2020,1/21/2021,1/21/2021,,,,,9/10/2021,,,,,,,,9/10/2021,,,,,,,
VV_ZIK_102,ZIK-102,'ZIK-102,,,,ZIK-102,I,Cancelled,Prevention of Zika Virus,,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Harald Pfaar,,,,,,,,,,,,Medidata CTMS (VBU),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VV_ZIK_201,ZIK-201,'ZIK-201,,TAK-426,Safety and Immunogenicity Study of Two-Dose Priming and Single-Dose Booster PIZV (TAK-426) Vaccination in Healthy Subjects Aged 9 to 65 Years,ZIK-201,II,Planned,Prevention of Zika Virus,Vaccine,Vaccine,,,,Prevention,,,648,,,,,,,,12,,,TBD,,"Aline Prates, Anne Crissey, Bangalore Kamala, Harald Pfaar, Sonja Moua",,,,,,,,,Wave 2,NA,,Medidata CTMS (VBU),,,4/26/2018,4/26/2018,9/27/2021,,,,7/27/2022,,8/14/2022,,,,4/24/2023,,,,6/19/2023,,,,,,,,5/14/2024,,,,8/14/2023,,,,,,,,7/9/2024,,10/9/2023,,,,,,,,9/3/2024,,,,,,10/30/2023,,,,,,,,,,,,,,,,,,12/1/2024,,,,,,,,12/1/2024,,,,,,,
VV_ZIK_202,ZIK-202,'ZIK-202,,TAK-426,,ZIK-202,IIa,Cancelled,Prevention of Zika Virus,Vaccine,Vaccine,,,,Prevention,,,50,,,,,,,,,,,TBD,,Harald Pfaar,,,,,,,,,Wave 2,NA,,Medidata CTMS (VBU),,,,,6/26/2020,,,,,,3/26/2021,,,,5/26/2021,,,,7/11/2023,,,,,,,,,,,,10/11/2023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/11/2024,,,,,,,,,,,,,,,,,,,,,,,
VV_ZIK_301,ZIK-301,'ZIK-301,,TAK-426,,ZIK-301,III,Planned,Prevention of Zika Virus,Vaccine,Vaccine,,,,Prevention,,,"3,600",,,,,,,,,,,TBD,,Harald Pfaar,,,,,,,,,Wave 2,NA,,Medidata CTMS (VBU),,,3/15/2023,,6/13/2023,,,,3/21/2024,,4/4/2024,,,,7/3/2024,,,,1/27/2025,,8/25/2025,,1/24/2026,,,,,,,,3/26/2025,,10/20/2025,,3/21/2026,,,,,,5/21/2025,,12/15/2025,,5/16/2026,,,,,,,,,,5/21/2025,,,,,,,,5/16/2026,,7/28/2025,,,,,,,,8/13/2026,,,,,,,,8/13/2026,,,,,,,
VV_ZIK_302,ZIK-302,'ZIK-302,,,,ZIK-302,IIIa,Cancelled,Prevention of Zika Virus,,Vaccine,,,,Prevention,,,"1,500",,,,,,,,,,,TBD,,Harald Pfaar,,,,,,,,,,,,Medidata CTMS (VBU),,,2/6/2017,,1/1/2019,,,,2/6/2017,,12/1/2019,,,,1/1/2020,,,,7/1/2020,,,,,,,,,,,,10/1/2020,,,,,,,,,,3/13/2017,,,,,,,,,,,,,,,,,,,,,,,,3/1/2021,,,,,,,,,,,,,,,,,,,,,,,
VV_Zik_epi_001A,Zik-epi-001A,'Zik-epi-001A,,,Zika Virus Natural History Study to Support the TAK-426 pathway to licensure- retrospective study. A Research Collaboration with AFRIMS Bangkok,Zik-epi-001A,0,Planned,Prevention of Zika Virus,,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,,,,Medidata CTMS (VBU),,,4/1/2021,,4/1/2021,,,,5/1/2021,,5/1/2021,,,,10/31/2021,,,,11/30/2021,,,,,,,,,,,,12/31/2021,,,,,,,,,,1/31/2022,,,,,,,,,,,,,,,,,,,,,,,,3/31/2022,,,,,,,,,,,,,,,,,,,,,,,
VV_Zik_epi_001B,Zik-epi-001B,'Zik-epi-001B,,,ZIKV Natural History Study to Support the TAK-426 Pathway to Licensure - Prospective Study. A Research Collaboration with AFRIMS Bangkok,Zik-epi-001B,0,Planned,Prevention of Zika Virus,,Vaccine,,,,Prevention,,,,,,,,,,,,,,TBD,,Morgan McNamara,,,,,,,,,,,,Medidata CTMS (VBU),,,4/1/2021,,4/1/2021,,,,5/1/2021,,5/1/2021,,,,10/31/2022,,,,11/30/2022,,,,,,,,,,,,12/31/2022,,,,,,,,,,1/31/2023,,,,,,,,,,,,,,,,,,,,,,,,3/31/2023,,,,,,,,,,,,,,,,,,,,,,,
